-DOCSTART- (31109313)

Transformation NN O O
of NN O O
chronic NN O O
lymphocytic NN O O
leukaemia NN O O
( NN O O
CLL NN O O
) NN O O
to NN O O
diffuse NN O O
large NN O O
B-cell NN O O
lymphoma NN O O
( NN O O
DLCBL NN O O
) NN O O
type NN O O
Richter NN O O
's NN O O
syndrome NN O O
( NN O O
RS NN O O
) NN O O
carries NN O O
a NN O O
dismal NN O O
prognosis NN O O
. NN O O

Standard-of-care NN O O
chemoimmunotherapy NN O O
for NN O O
de NN O O
novo NN O O
RS NN O O
is NN O O
inadequate NN O O
with NN O O
median NN O O
survival NN O O
of NN O O
less NN O O
than NN O O
one NN O O
year NN O O
. NN O O

Patients NN O O
are NN O O
frequently NN O O
elderly NN O O
or NN O O
have NN O O
co-morbidities NN O O
limiting NN O O
dose-intense NN O O
chemotherapy NN O O
. NN O O

Treatment NN O O
of NN O O
relapsed/refractory NN O O
( NN O O
R/R NN O O
) NN O O
RS NN O O
and NN O O
RS NN O O
emerging NN O O
after NN O O
CLL-directed NN O O
therapy NN O O
represent NN O O
urgent NN O O
unmet NN O O
clinical NN O O
needs NN O O
. NN O O

Agents NN O O
targeting NN O O
Bruton NN O O
's NN O O
tyrosine NN O O
kinase NN O O
( NN O O
BTK NN O O
) NN O O
deliver NN O O
improved NN O O
outcomes NN O O
for NN O O
patients NN O O
with NN O O
high-risk NN O O
CLL NN O O
and NN O O
expand NN O O
effective NN O O
treatments NN O O
to NN O O
frailer NN O O
patients NN O O
. NN O O

Acalabrutinib NN O O
is NN O O
an NN O O
oral NN O O
, NN O O
second-generation NN O O
BTK NN O O
inhibitor NN O O
with NN O O
a NN O O
favourable NN O O
toxicity NN O O
profile NN O O
and NN O O
demonstrated NN O O
activity NN O O
in NN O O
CLL NN O O
and NN O O
B-cell NN O O
lymphomas NN O O
. NN O O

Combination NN O O
of NN O O
acalabrutinib NN O O
with NN O O
standard-of-care NN O O
CHOP-R NN O O
chemoimmunotherapy NN O O
offers NN O O
a NN O O
sound NN O O
rationale NN O O
to NN O O
test NN O O
in NN O O
a NN O O
prospective NN O O
trial NN O O
for NN O O
de NN O O
novo NN O O
RS NN O O
. NN O O

The NN O O
prospective NN O O
multicentre NN O O
STELLAR NN O O
study NN O O
is NN O O
designed NN O O
in NN O O
two NN O O
elements NN O O
, NN O O
consisting NN O O
of NN O O
a NN O O
randomised NN O O
study NN O O
to NN O O
evaluate NN O O
the NN O O
safety NN O O
and NN O O
activity NN O O
of NN O O
CHOP-R NN O O
chemoimmunotherapy NN O O
in NN O O
combination NN O O
with NN O O
acalabrutinib NN O O
in NN O O
newly NN O O
diagnosed NN O O
RS NN O O
and NN O O
single-arm NN O O
studies NN O O
of NN O O
novel NN O O
agents NN O O
for NN O O
other NN O O
RS NN O O
patient NN O O
cohorts NN O O
. NN O O

Eligible NN O O
patients NN O O
with NN O O
newly NN O O
diagnosed NN O O
DLBCL-type NN O O
RS NN O O
are NN O O
randomised NN O O
between NN O O
six NN O O
cycles NN O O
of NN O O
CHOP-R NN O O
therapy NN O O
and NN O O
six NN O O
cycles NN O O
CHOP-R NN O O
plus NN O O
acalabrutinib NN O O
, NN O O
followed NN O O
by NN O O
acalabrutinib NN O O
maintenance NN O O
. NN O O

The NN O O
primary NN O O
endpoint NN O O
of NN O O
the NN O O
randomised NN O O
component NN O O
is NN O O
progression NN O O
free NN O O
survival NN O O
( NN O O
PFS NN O O
) NN O O
. NN O O

Cohort NN O O
1 NN O O
enrols NN O O
RS NN O O
patients NN O O
with NN O O
progressive NN O O
disease NN O O
following NN O O
chemoimmunotherapy NN O O
for NN O O
acalabrutinib NN O O
monotherapy NN O O
. NN O O

Patients NN O O
with NN O O
RS NN O O
diagnosed NN O O
while NN O O
on NN O O
ibrutinib NN O O
may NN O O
enrol NN O O
in NN O O
Cohort NN O O
2 NN O O
, NN O O
a NN O O
single-arm NN O O
study NN O O
of NN O O
CHOP-R NN O O
plus NN O O
acalabrutinib NN O O
. NN O O

The NN O O
primary NN O O
endpoint NN O O
for NN O O
the NN O O
single-arm NN O O
studies NN O O
is NN O O
overall NN O O
response NN O O
rate NN O O
( NN O O
ORR NN O O
) NN O O
. NN O O

Secondary NN O O
endpoints NN O O
for NN O O
all NN O O
cohorts NN O O
are NN O O
overall NN O O
survival NN O O
( NN O O
OS NN O O
) NN O O
, NN O O
quality NN O O
of NN O O
life NN O O
and NN O O
proportion NN O O
of NN O O
patients NN O O
proceeding NN O O
to NN O O
stem NN O O
cell NN O O
transplantation NN O O
. NN O O

The NN O O
study NN O O
will NN O O
be NN O O
accompanied NN O O
by NN O O
exploratory NN O O
analysis NN O O
of NN O O
the NN O O
mutational NN O O
landscape NN O O
of NN O O
RS NN O O
and NN O O
the NN O O
relationship NN O O
between NN O O
dynamic NN O O
changes NN O O
in NN O O
sequential NN O O
circulating NN O O
tumour NN O O
DNA NN O O
samples NN O O
and NN O O
clinical NN O O
outcomes NN O O
. NN O O

The NN O O
STELLAR NN O O
randomised NN O O
trial NN O O
evaluates NN O O
the NN O O
role NN O O
of NN O O
CHOP-R NN O O
plus NN O O
acalabrutinib NN O O
in NN O O
newly NN O O
diagnosed NN O O
RS NN O O
patients NN O O
. NN O O

The NN O O
single-arm NN O O
platform NN O O
studies NN O O
enable NN O O
the NN O O
incorporation NN O O
of NN O O
promising NN O O
novel NN O O
therapies NN O O
into NN O O
the NN O O
protocol NN O O
. NN O O

The NN O O
STELLAR NN O O
study NN O O
has NN O O
potential NN O O
to NN O O
identify NN O O
novel NN O O
biomarkers NN O O
of NN O O
treatment NN O O
response NN O O
in NN O O
this NN O O
high-risk NN O O
malignancy NN O O
. NN O O

EudraCT NN O O
: NN O O
2017 NN O O
- NN O O
004401 NN O O
- NN O O
40 NN O O
, NN O O
registered NN O O
on NN O O
the NN O O
31-Oct-2017 NN O O
. NN O O

IRSCTN NN O O
: NN O O
https://www.isrctn.com/ISRCTN52839057 NN O O
, NN O O
registered NN O O
on NN O O
the NN O O
04-Mar-2019 NN O O
. NN O O

ClinicalTrials.gov NN O O
: NN O O
NCT03899337 NN O O
, NN O O
registered NN O O
on NN O O
02-April-2019 NN O O
. NN O O



-DOCSTART- (30827782)

Supraflex NN O O
is NN O O
a NN O O
sirolimus-eluting NN O O
stent NN O O
with NN O O
a NN O O
biodegradable NN O O
polymer NN O O
coating NN O O
and NN O O
ultra-thin NN O O
struts NN O O
. NN O O

We NN O O
aimed NN O O
to NN O O
compare NN O O
Supraflex NN O O
with NN O O
the NN O O
standard NN O O
of NN O O
care NN O O
, NN O O
Xience NN O O
, NN O O
an NN O O
everolimus-eluting NN O O
stent NN O O
with NN O O
a NN O O
durable NN O O
polymer NN O O
coating NN O O
, NN O O
regarding NN O O
clinical NN O O
outcomes NN O O
with NN O O
a NN O O
randomised NN O O
trial NN O O
in NN O O
an NN O O
all-comer NN O O
population NN O O
. NN O O

We NN O O
did NN O O
a NN O O
prospective NN O O
, NN O O
randomised NN O O
, NN O O
single-blind NN O O
, NN O O
multicentre NN O O
study NN O O
( NN O O
TALENT NN O O
) NN O O
across NN O O
23 NN O O
centres NN O O
in NN O O
Europe NN O O
( NN O O
the NN O O
Netherlands NN O O
, NN O O
Poland NN O O
, NN O O
the NN O O
UK NN O O
, NN O O
Spain NN O O
, NN O O
Bulgaria NN O O
, NN O O
Hungary NN O O
, NN O O
and NN O O
Italy NN O O
) NN O O
. NN O O

Eligible NN O O
participants NN O O
were NN O O
aged NN O O
18 NN O O
years NN O O
or NN O O
older NN O O
, NN O O
had NN O O
one NN O O
or NN O O
more NN O O
coronary NN O O
artery NN O O
stenosis NN O O
of NN O O
50 NN O O
% NN O O
or NN O O
greater NN O O
in NN O O
a NN O O
native NN O O
coronary NN O O
artery NN O O
, NN O O
saphenous NN O O
venous NN O O
graft NN O O
, NN O O
or NN O O
arterial NN O O
bypass NN O O
conduit NN O O
, NN O O
and NN O O
had NN O O
a NN O O
reference NN O O
vessel NN O O
diameter NN O O
of NN O O
2·25 NN O O
- NN O O
4·50 NN O O
mm NN O O
. NN O O

Patients NN O O
underwent NN O O
percutaneous NN O O
coronary NN O O
intervention NN O O
in NN O O
an NN O O
all-comer NN O O
manner NN O O
. NN O O

We NN O O
randomly NN O O
assigned NN O O
patients NN O O
( NN O O
1:1 NN O O
) NN O O
to NN O O
implantation NN O O
of NN O O
either NN O O
a NN O O
sirolimus-eluting NN O O
stent NN O O
with NN O O
a NN O O
biodegradable NN O O
polymer NN O O
coating NN O O
and NN O O
ultra-thin NN O O
struts NN O O
( NN O O
Supraflex NN O O
) NN O O
or NN O O
an NN O O
everolimus-eluting NN O O
stent NN O O
with NN O O
a NN O O
durable NN O O
polymer NN O O
coating NN O O
( NN O O
Xience NN O O
) NN O O
. NN O O

Randomisation NN O O
was NN O O
done NN O O
by NN O O
local NN O O
investigators NN O O
by NN O O
use NN O O
of NN O O
a NN O O
web-based NN O O
software NN O O
with NN O O
random NN O O
blocks NN O O
according NN O O
to NN O O
centre NN O O
. NN O O

The NN O O
primary NN O O
endpoint NN O O
was NN O O
a NN O O
non-inferiority NN O O
comparison NN O O
of NN O O
a NN O O
device-oriented NN O O
composite NN O O
endpoint-cardiac NN O O
death NN O O
, NN O O
target-vessel NN O O
myocardial NN O O
infarction NN O O
, NN O O
or NN O O
clinically NN O O
indicated NN O O
target NN O O
lesion NN O O
revascularisation-between NN O O
groups NN O O
at NN O O
12 NN O O
months NN O O
after NN O O
the NN O O
procedure NN O O
, NN O O
assessed NN O O
in NN O O
an NN O O
intention-to-treat NN O O
population NN O O
. NN O O

On NN O O
assumption NN O O
of NN O O
1-year NN O O
composite NN O O
endpoint NN O O
prevalence NN O O
of NN O O
8·3 NN O O
% NN O O
, NN O O
a NN O O
margin NN O O
of NN O O
4·0 NN O O
% NN O O
was NN O O
defined NN O O
for NN O O
non-inferiority NN O O
of NN O O
the NN O O
Supraflex NN O O
group NN O O
compared NN O O
with NN O O
the NN O O
Xience NN O O
group NN O O
. NN O O

This NN O O
trial NN O O
is NN O O
registered NN O O
with NN O O
ClinicalTrials.gov NN O O
, NN O O
number NN O O
NCT02870140 NN O O
. NN O O

Between NN O O
Oct NN O O
21 NN O O
, NN O O
2016 NN O O
, NN O O
and NN O O
July NN O O
3 NN O O
, NN O O
2017 NN O O
, NN O O
1435 NN O O
patients NN O O
with NN O O
1046 NN O O
lesions NN O O
were NN O O
randomly NN O O
assigned NN O O
to NN O O
Supraflex NN O O
, NN O O
of NN O O
whom NN O O
720 NN O O
received NN O O
the NN O O
index NN O O
procedure NN O O
, NN O O
and NN O O
715 NN O O
patients NN O O
with NN O O
1030 NN O O
lesions NN O O
were NN O O
assigned NN O O
to NN O O
Xience NN O O
, NN O O
all NN O O
receiving NN O O
the NN O O
index NN O O
procedure NN O O
. NN O O

At NN O O
12 NN O O
months NN O O
, NN O O
the NN O O
primary NN O O
endpoint NN O O
had NN O O
occurred NN O O
in NN O O
35 NN O O
patients NN O O
( NN O O
4·9 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
Supraflex NN O O
group NN O O
and NN O O
in NN O O
37 NN O O
patients NN O O
( NN O O
5·3 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
Xience NN O O
group NN O O
( NN O O
absolute NN O O
difference NN O O
-0·3 NN O O
% NN O O
[ NN O O
one-sided NN O O
95 NN O O
% NN O O
upper NN O O
confidence NN O O
bound NN O O
1·6 NN O O
% NN O O
] NN O O
, NN O O
p NN O O
< NN O O
0·0001 NN O O
) NN O O
. NN O O

Definite NN O O
or NN O O
probable NN O O
stent NN O O
thrombosis NN O O
prevalence NN O O
, NN O O
a NN O O
safety NN O O
indicator NN O O
, NN O O
was NN O O
low NN O O
in NN O O
both NN O O
groups NN O O
and NN O O
did NN O O
not NN O O
differ NN O O
between NN O O
them NN O O
. NN O O

The NN O O
Supraflex NN O O
stent NN O O
was NN O O
non-inferior NN O O
to NN O O
the NN O O
Xience NN O O
stent NN O O
for NN O O
a NN O O
device-oriented NN O O
composite NN O O
clinical NN O O
endpoint NN O O
at NN O O
12 NN O O
months NN O O
in NN O O
an NN O O
all-comer NN O O
population NN O O
. NN O O

Supraflex NN O O
seems NN O O
a NN O O
safe NN O O
and NN O O
effective NN O O
alternative NN O O
drug-eluting NN O O
stent NN O O
to NN O O
other NN O O
stents NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O

European NN O O
Cardiovascular NN O O
Research NN O O
Institute NN O O
. NN O O



-DOCSTART- (30920602)

The NN O O
Framingham NN O O
Risk NN O O
Score NN O O
( NN O O
FRS NN O O
) NN O O
is NN O O
a NN O O
valid NN O O
method NN O O
for NN O O
predicting NN O O
the NN O O
10-year NN O O
risk NN O O
of NN O O
developing NN O O
cardiovascular NN O O
disease NN O O
. NN O O

Higher NN O O
FRS NN O O
is NN O O
reported NN O O
in NN O O
patients NN O O
with NN O O
early-stage NN O O
breast NN O O
cancer NN O O
who NN O O
are NN O O
overweight NN O O
than NN O O
in NN O O
healthy NN O O
, NN O O
age-matched NN O O
women NN O O
, NN O O
but NN O O
whether NN O O
exercise NN O O
reduces NN O O
FRS NN O O
in NN O O
this NN O O
patient NN O O
population NN O O
is NN O O
unclear NN O O
. NN O O

To NN O O
examine NN O O
the NN O O
effects NN O O
of NN O O
a NN O O
16-week NN O O
aerobic NN O O
and NN O O
resistance NN O O
exercise NN O O
intervention NN O O
on NN O O
the NN O O
FRS NN O O
in NN O O
women NN O O
with NN O O
early-stage NN O O
breast NN O O
cancer NN O O
and NN O O
with NN O O
overweight NN O O
condition NN O O
or NN O O
obesity NN O O
. NN O O

This NN O O
single-center NN O O
, NN O O
prospective NN O O
randomized NN O O
clinical NN O O
trial NN O O
included NN O O
100 NN O O
women NN O O
with NN O O
stage NN O O
I NN O O
to NN O O
III NN O O
breast NN O O
cancer NN O O
who NN O O
were NN O O
sedentary NN O O
, NN O O
with NN O O
overweight NN O O
condition NN O O
or NN O O
obesity NN O O
( NN O O
body NN O O
mass NN O O
index NN O O
of NN O O
≥25.0 NN O O
or NN O O
body NN O O
fat NN O O
of NN O O
≥30 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
completed NN O O
cancer NN O O
treatment NN O O
within NN O O
6 NN O O
months NN O O
prior NN O O
to NN O O
enrollment NN O O
. NN O O

Participants NN O O
were NN O O
randomized NN O O
to NN O O
either NN O O
the NN O O
usual NN O O
care NN O O
or NN O O
exercise NN O O
group NN O O
. NN O O

Differences NN O O
in NN O O
mean NN O O
changes NN O O
for NN O O
outcomes NN O O
were NN O O
evaluated NN O O
using NN O O
mixed-model NN O O
repeated-measures NN O O
analyses NN O O
. NN O O

Data NN O O
were NN O O
collected NN O O
from NN O O
August NN O O
1 NN O O
, NN O O
2012 NN O O
, NN O O
through NN O O
July NN O O
1 NN O O
, NN O O
2017 NN O O
. NN O O

Data NN O O
analysis NN O O
, NN O O
which NN O O
followed NN O O
the NN O O
intention-to-treat NN O O
approach NN O O
, NN O O
was NN O O
performed NN O O
from NN O O
May NN O O
24 NN O O
to NN O O
October NN O O
2 NN O O
, NN O O
2018 NN O O
. NN O O

The NN O O
exercise NN O O
group NN O O
underwent NN O O
supervised NN O O
aerobic NN O O
and NN O O
resistance NN O O
exercise NN O O
sessions NN O O
thrice NN O O
weekly NN O O
for NN O O
16 NN O O
weeks NN O O
. NN O O

The NN O O
FRS NN O O
was NN O O
calculated NN O O
for NN O O
each NN O O
participant NN O O
using NN O O
preset NN O O
points NN O O
for NN O O
each NN O O
of NN O O
the NN O O
6 NN O O
FRS NN O O
categories NN O O
: NN O O
age NN O O
, NN O O
systolic NN O O
blood NN O O
pressure NN O O
, NN O O
high-density NN O O
lipoprotein NN O O
cholesterol NN O O
, NN O O
low-density NN O O
lipoprotein NN O O
cholesterol NN O O
, NN O O
diabetes NN O O
presence NN O O
, NN O O
and NN O O
smoking NN O O
status NN O O
. NN O O

In NN O O
total NN O O
, NN O O
100 NN O O
women NN O O
were NN O O
randomized NN O O
to NN O O
either NN O O
the NN O O
exercise NN O O
group NN O O
( NN O O
n NN O O
= NN O O
50 NN O O
) NN O O
or NN O O
usual NN O O
care NN O O
group NN O O
( NN O O
n NN O O
= NN O O
50 NN O O
) NN O O
. NN O O

Of NN O O
these NN O O
women NN O O
, NN O O
55 NN O O
( NN O O
55 NN O O
% NN O O
) NN O O
were NN O O
of NN O O
Hispanic NN O O
white NN O O
race/ethnicity NN O O
and NN O O
the NN O O
mean NN O O
( NN O O
SD NN O O
) NN O O
age NN O O
was NN O O
53.5 NN O O
( NN O O
10.4 NN O O
) NN O O
years NN O O
. NN O O

The NN O O
mean NN O O
( NN O O
SD NN O O
) NN O O
total NN O O
FRS NN O O
scores NN O O
postintervention NN O O
were NN O O
2.0 NN O O
( NN O O
1.5 NN O O
) NN O O
in NN O O
the NN O O
exercise NN O O
group NN O O
and NN O O
13.0 NN O O
( NN O O
3.0 NN O O
) NN O O
in NN O O
the NN O O
usual NN O O
care NN O O
group NN O O
. NN O O

The NN O O
postintervention NN O O
FRS NN O O
was NN O O
significantly NN O O
reduced NN O O
in NN O O
the NN O O
exercise NN O O
group NN O O
compared NN O O
with NN O O
the NN O O
usual NN O O
care NN O O
group NN O O
( NN O O
mean NN O O
, NN O O
-9.5 NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
-13.0 NN O O
to NN O O
-6.0 NN O O
) NN O O
, NN O O
which NN O O
corresponds NN O O
to NN O O
an NN O O
11 NN O O
% NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
-15.0 NN O O
to NN O O
-5.0 NN O O
) NN O O
decrease NN O O
on NN O O
the NN O O
FRS-predicted NN O O
10-year NN O O
risk NN O O
of NN O O
developing NN O O
cardiovascular NN O O
disease NN O O
. NN O O

A NN O O
16-week NN O O
supervised NN O O
aerobic NN O O
and NN O O
resistance NN O O
exercise NN O O
intervention NN O O
appeared NN O O
to NN O O
reduce NN O O
the NN O O
FRS-predicted NN O O
10-year NN O O
risk NN O O
of NN O O
cardiovascular NN O O
disease NN O O
in NN O O
women NN O O
with NN O O
early-stage NN O O
breast NN O O
cancer NN O O
with NN O O
overweight NN O O
condition NN O O
or NN O O
obesity NN O O
. NN O O

ClinicalTrials.gov NN O O
identifier NN O O
: NN O O
NCT01140282 NN O O
. NN O O



-DOCSTART- (31182135)

Neurological NN O O
injuries NN O O
remain NN O O
the NN O O
leading NN O O
cause NN O O
of NN O O
death NN O O
in NN O O
comatose NN O O
patients NN O O
resuscitated NN O O
from NN O O
out-of-hospital NN O O
cardiac NN O O
arrest NN O O
( NN O O
OHCA NN O O
) NN O O
. NN O O

Adequate NN O O
blood NN O O
pressure NN O O
is NN O O
of NN O O
paramount NN O O
importance NN O O
to NN O O
optimize NN O O
cerebral NN O O
perfusion NN O O
and NN O O
to NN O O
minimize NN O O
secondary NN O O
brain NN O O
injury NN O O
. NN O O

Markers NN O O
measuring NN O O
global NN O O
cerebral NN O O
ischemia NN O O
caused NN O O
by NN O O
cardiac NN O O
arrest NN O O
and NN O O
consecutive NN O O
resuscitation NN O O
and NN O O
reflecting NN O O
the NN O O
metabolic NN O O
variations NN O O
after NN O O
successful NN O O
resuscitation NN O O
are NN O O
needed NN O O
to NN O O
assist NN O O
a NN O O
more NN O O
individualized NN O O
post-resuscitation NN O O
care NN O O
. NN O O

Currently NN O O
, NN O O
no NN O O
technique NN O O
is NN O O
available NN O O
for NN O O
bedside NN O O
evaluation NN O O
of NN O O
global NN O O
cerebral NN O O
energy NN O O
state NN O O
, NN O O
and NN O O
until NN O O
now NN O O
blood NN O O
pressure NN O O
targets NN O O
have NN O O
been NN O O
based NN O O
on NN O O
limited NN O O
clinical NN O O
evidence NN O O
. NN O O

Recent NN O O
experimental NN O O
and NN O O
clinical NN O O
studies NN O O
indicate NN O O
that NN O O
it NN O O
might NN O O
be NN O O
possible NN O O
to NN O O
evaluate NN O O
cerebral NN O O
oxidative NN O O
metabolism NN O O
from NN O O
measuring NN O O
the NN O O
lactate-to-pyruvate NN O O
( NN O O
LP NN O O
) NN O O
ratio NN O O
of NN O O
the NN O O
draining NN O O
venous NN O O
blood NN O O
. NN O O

In NN O O
this NN O O
study NN O O
, NN O O
jugular NN O O
bulb NN O O
microdialysis NN O O
and NN O O
immediate NN O O
bedside NN O O
biochemical NN O O
analysis NN O O
are NN O O
introduced NN O O
as NN O O
new NN O O
diagnostic NN O O
tools NN O O
to NN O O
evaluate NN O O
the NN O O
effect NN O O
of NN O O
higher NN O O
mean NN O O
arterial NN O O
blood NN O O
pressure NN O O
on NN O O
global NN O O
cerebral NN O O
metabolism NN O O
and NN O O
the NN O O
degree NN O O
of NN O O
cellular NN O O
damage NN O O
after NN O O
OHCA NN O O
. NN O O

This NN O O
is NN O O
a NN O O
single-center NN O O
, NN O O
randomized NN O O
, NN O O
double-blinded NN O O
, NN O O
superiority NN O O
trial NN O O
. NN O O

Sixty NN O O
unconscious NN O O
patients NN O O
with NN O O
sustained NN O O
return NN O O
of NN O O
spontaneous NN O O
circulation NN O O
after NN O O
OHCA NN O O
will NN O O
be NN O O
randomly NN O O
assigned NN O O
in NN O O
a NN O O
one-to-one NN O O
fashion NN O O
to NN O O
low NN O O
( NN O O
63 NN O O
mm NN O O
Hg NN O O
) NN O O
or NN O O
high NN O O
( NN O O
77 NN O O
mm NN O O
Hg NN O O
) NN O O
mean NN O O
arterial NN O O
blood NN O O
pressure NN O O
target NN O O
. NN O O

The NN O O
primary NN O O
end-point NN O O
will NN O O
be NN O O
a NN O O
difference NN O O
in NN O O
mean NN O O
LP NN O O
ratio NN O O
within NN O O
48 NN O O
h NN O O
between NN O O
blood NN O O
pressure NN O O
groups NN O O
. NN O O

Secondary NN O O
end-points NN O O
are NN O O
( NN O O
1 NN O O
) NN O O
association NN O O
between NN O O
LP NN O O
ratio NN O O
and NN O O
all-cause NN O O
intensive NN O O
care NN O O
unit NN O O
( NN O O
ICU NN O O
) NN O O
mortality NN O O
and NN O O
( NN O O
2 NN O O
) NN O O
association NN O O
between NN O O
LP NN O O
ratio NN O O
and NN O O
survival NN O O
to NN O O
hospital NN O O
discharge NN O O
with NN O O
poor NN O O
neurological NN O O
function NN O O
. NN O O

Markers NN O O
measuring NN O O
cerebral NN O O
ischemia NN O O
caused NN O O
by NN O O
cardiac NN O O
arrest NN O O
and NN O O
consecutive NN O O
resuscitation NN O O
and NN O O
reflecting NN O O
the NN O O
metabolic NN O O
changes NN O O
after NN O O
successful NN O O
resuscitation NN O O
are NN O O
urgently NN O O
needed NN O O
to NN O O
enable NN O O
a NN O O
more NN O O
personalized NN O O
post-resuscitation NN O O
care NN O O
and NN O O
prognostication NN O O
. NN O O

Jugular NN O O
bulb NN O O
microdialysis NN O O
may NN O O
provide NN O O
a NN O O
reliable NN O O
global NN O O
estimate NN O O
of NN O O
cerebral NN O O
metabolic NN O O
state NN O O
and NN O O
can NN O O
be NN O O
implemented NN O O
as NN O O
an NN O O
entirely NN O O
new NN O O
and NN O O
less NN O O
invasive NN O O
diagnostic NN O O
tool NN O O
for NN O O
ICU NN O O
patients NN O O
after NN O O
OHCA NN O O
and NN O O
has NN O O
implications NN O O
for NN O O
early NN O O
prognosis NN O O
and NN O O
treatment NN O O
. NN O O

ClinicalTrials.gov NN O O
( NN O O
ClinicalTrials.gov NN O O
Identifier NN O O
: NN O O
NCT03095742 NN O O
) NN O O
. NN O O

Registered NN O O
March NN O O
30 NN O O
, NN O O
2017 NN O O
. NN O O



-DOCSTART- (30906694)

The NN O O
current NN O O
randomized NN O O
controlled NN O O
trial NN O O
tested NN O O
whether NN O O
there NN O O
was NN O O
benefit NN O O
to NN O O
providing NN O O
an NN O O
online NN O O
gambling NN O O
intervention NN O O
and NN O O
a NN O O
separate NN O O
self-help NN O O
mental NN O O
health NN O O
intervention NN O O
for NN O O
anxiety NN O O
and NN O O
depression NN O O
( NN O O
i.e. NN O O
MoodGYM NN O O
) NN O O
( NN O O
G NN O O
+ NN O O
MH NN O O
) NN O O
, NN O O
compared NN O O
to NN O O
only NN O O
a NN O O
gambling NN O O
intervention NN O O
( NN O O
G NN O O
only NN O O
) NN O O
among NN O O
people NN O O
with NN O O
co-occurring NN O O
gambling NN O O
problems NN O O
and NN O O
mental NN O O
health NN O O
distress NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
of NN O O
interest NN O O
was NN O O
improvement NN O O
in NN O O
gambling NN O O
outcomes NN O O
. NN O O

Secondary NN O O
analyses NN O O
also NN O O
tested NN O O
for NN O O
the NN O O
impact NN O O
of NN O O
the NN O O
combined NN O O
intervention NN O O
on NN O O
depression NN O O
and NN O O
anxiety NN O O
outcomes NN O O
. NN O O

Participants NN O O
who NN O O
were NN O O
concerned NN O O
about NN O O
their NN O O
gambling NN O O
were NN O O
recruited NN O O
to NN O O
help NN O O
evaluate NN O O
an NN O O
online NN O O
intervention NN O O
for NN O O
gamblers NN O O
. NN O O

Those NN O O
who NN O O
met NN O O
criteria NN O O
for NN O O
problem NN O O
gambling NN O O
were NN O O
randomized NN O O
to NN O O
receive NN O O
either NN O O
the NN O O
G NN O O
only NN O O
or NN O O
the NN O O
G NN O O
+ NN O O
MH NN O O
intervention NN O O
. NN O O

Participants NN O O
were NN O O
also NN O O
assessed NN O O
for NN O O
current NN O O
mental NN O O
health NN O O
distress NN O O
at NN O O
baseline NN O O
, NN O O
with NN O O
three NN O O
quarters NN O O
( NN O O
n NN O O
= NN O O
214 NN O O
) NN O O
reporting NN O O
significant NN O O
current NN O O
distress NN O O
and NN O O
form NN O O
the NN O O
sample NN O O
for NN O O
this NN O O
study NN O O
. NN O O

Participants NN O O
were NN O O
followed-up NN O O
at NN O O
3- NN O O
and NN O O
6-months NN O O
to NN O O
assess NN O O
changes NN O O
in NN O O
gambling NN O O
status NN O O
, NN O O
and NN O O
improvements NN O O
in NN O O
depression NN O O
and NN O O
anxiety NN O O
. NN O O

Follow-up NN O O
rates NN O O
were NN O O
poor NN O O
( NN O O
47 NN O O
% NN O O
completed NN O O
at NN O O
least NN O O
one NN O O
follow-up NN O O
) NN O O
. NN O O

While NN O O
there NN O O
were NN O O
significant NN O O
reductions NN O O
in NN O O
gambling NN O O
outcomes NN O O
, NN O O
as NN O O
well NN O O
as NN O O
on NN O O
measures NN O O
of NN O O
current NN O O
depression NN O O
and NN O O
anxiety NN O O
, NN O O
there NN O O
was NN O O
no NN O O
significant NN O O
difference NN O O
in NN O O
outcomes NN O O
between NN O O
participants NN O O
receiving NN O O
the NN O O
G NN O O
only NN O O
versus NN O O
the NN O O
G NN O O
+ NN O O
MH NN O O
intervention NN O O
. NN O O

There NN O O
does NN O O
not NN O O
appear NN O O
to NN O O
be NN O O
a NN O O
benefit NN O O
to NN O O
providing NN O O
access NN O O
to NN O O
an NN O O
additional NN O O
online NN O O
mental NN O O
health NN O O
intervention NN O O
to NN O O
our NN O O
online NN O O
gambling NN O O
intervention NN O O
, NN O O
at NN O O
least NN O O
among NN O O
participants NN O O
who NN O O
are NN O O
concerned NN O O
about NN O O
their NN O O
gambling NN O O
. NN O O

Trial NN O O
registration NN O O
: NN O O
ClinicalTrials.govNCT02800096 NN O O
; NN O O
Registration NN O O
date NN O O
: NN O O
June NN O O
14 NN O O
, NN O O
2016 NN O O
. NN O O



-DOCSTART- (30865632)

Seasonal NN O O
malaria NN O O
chemoprevention NN O O
( NN O O
SMC NN O O
) NN O O
is NN O O
recommended NN O O
in NN O O
the NN O O
Sahel NN O O
region NN O O
of NN O O
Africa NN O O
for NN O O
children NN O O
under NN O O
5 NN O O
years NN O O
of NN O O
age NN O O
, NN O O
for NN O O
up NN O O
to NN O O
4 NN O O
months NN O O
of NN O O
the NN O O
year NN O O
. NN O O

It NN O O
may NN O O
be NN O O
appropriate NN O O
to NN O O
include NN O O
older NN O O
children NN O O
, NN O O
and NN O O
to NN O O
provide NN O O
protection NN O O
for NN O O
more NN O O
than NN O O
4 NN O O
months NN O O
. NN O O

We NN O O
evaluated NN O O
the NN O O
effectiveness NN O O
of NN O O
SMC NN O O
using NN O O
sulfadoxine-pyrimethamine NN O O
plus NN O O
amodiaquine NN O O
given NN O O
over NN O O
5 NN O O
months NN O O
to NN O O
children NN O O
under NN O O
10 NN O O
years NN O O
of NN O O
age NN O O
in NN O O
Saraya NN O O
district NN O O
in NN O O
south-east NN O O
Senegal NN O O
in NN O O
2011 NN O O
. NN O O

Twenty-four NN O O
villages NN O O
, NN O O
including NN O O
2,301 NN O O
children NN O O
aged NN O O
3 NN O O
- NN O O
59 NN O O
months NN O O
and NN O O
2,245 NN O O
aged NN O O
5 NN O O
- NN O O
9 NN O O
years NN O O
, NN O O
were NN O O
randomised NN O O
to NN O O
receive NN O O
SMC NN O O
with NN O O
community NN O O
case NN O O
management NN O O
( NN O O
CCM NN O O
) NN O O
( NN O O
SMC NN O O
villages NN O O
) NN O O
or NN O O
CCM NN O O
alone NN O O
( NN O O
control NN O O
villages NN O O
) NN O O
. NN O O

In NN O O
all NN O O
villages NN O O
, NN O O
community NN O O
health NN O O
workers NN O O
( NN O O
CHWs NN O O
) NN O O
were NN O O
trained NN O O
to NN O O
treat NN O O
malaria NN O O
cases NN O O
with NN O O
artemisinin NN O O
combination NN O O
therapy NN O O
after NN O O
testing NN O O
with NN O O
a NN O O
rapid NN O O
diagnostic NN O O
test NN O O
( NN O O
RDT NN O O
) NN O O
. NN O O

In NN O O
SMC NN O O
villages NN O O
, NN O O
CHWs NN O O
administered NN O O
SMC NN O O
to NN O O
children NN O O
aged NN O O
3 NN O O
months NN O O
to NN O O
9 NN O O
years NN O O
once NN O O
a NN O O
month NN O O
for NN O O
5 NN O O
months NN O O
. NN O O

The NN O O
study NN O O
was NN O O
conducted NN O O
from NN O O
27 NN O O
July NN O O
to NN O O
31 NN O O
December NN O O
2011 NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
was NN O O
malaria NN O O
( NN O O
fever NN O O
or NN O O
history NN O O
of NN O O
fever NN O O
with NN O O
a NN O O
positive NN O O
RDT NN O O
) NN O O
. NN O O

The NN O O
prevalence NN O O
of NN O O
anaemia NN O O
and NN O O
parasitaemia NN O O
was NN O O
measured NN O O
in NN O O
a NN O O
survey NN O O
at NN O O
the NN O O
end NN O O
of NN O O
the NN O O
transmission NN O O
season NN O O
. NN O O

Molecular NN O O
markers NN O O
associated NN O O
with NN O O
resistance NN O O
to NN O O
SMC NN O O
drugs NN O O
were NN O O
analysed NN O O
in NN O O
samples NN O O
from NN O O
incident NN O O
malaria NN O O
cases NN O O
and NN O O
from NN O O
children NN O O
with NN O O
parasitaemia NN O O
in NN O O
the NN O O
survey NN O O
. NN O O

SMC NN O O
was NN O O
well NN O O
tolerated NN O O
with NN O O
no NN O O
serious NN O O
adverse NN O O
reactions NN O O
. NN O O

There NN O O
were NN O O
1,472 NN O O
RDT-confirmed NN O O
malaria NN O O
cases NN O O
in NN O O
the NN O O
control NN O O
villages NN O O
and NN O O
270 NN O O
in NN O O
the NN O O
SMC NN O O
villages NN O O
. NN O O

Among NN O O
children NN O O
under NN O O
5 NN O O
years NN O O
of NN O O
age NN O O
, NN O O
the NN O O
rate NN O O
difference NN O O
was NN O O
110.8/1,000/month NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
64.7 NN O O
, NN O O
156.8 NN O O
; NN O O
p NN O O
< NN O O
0.001 NN O O
) NN O O
and NN O O
among NN O O
children NN O O
5 NN O O
- NN O O
9 NN O O
years NN O O
of NN O O
age NN O O
, NN O O
101.3/1,000/month NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
66.7 NN O O
, NN O O
136.0 NN O O
; NN O O
p NN O O
< NN O O
0.001 NN O O
) NN O O
. NN O O

The NN O O
mean NN O O
haemoglobin NN O O
concentration NN O O
at NN O O
the NN O O
end NN O O
of NN O O
the NN O O
transmission NN O O
season NN O O
was NN O O
higher NN O O
in NN O O
SMC NN O O
than NN O O
control NN O O
villages NN O O
, NN O O
by NN O O
6.5 NN O O
g/l NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
2.0 NN O O
, NN O O
11 NN O O
; NN O O
p NN O O
= NN O O
0.007 NN O O
) NN O O
among NN O O
children NN O O
under NN O O
5 NN O O
years NN O O
of NN O O
age NN O O
, NN O O
and NN O O
by NN O O
5.2 NN O O
g/l NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
0.4 NN O O
, NN O O
9.9 NN O O
; NN O O
p NN O O
= NN O O
0.035 NN O O
) NN O O
among NN O O
children NN O O
5 NN O O
- NN O O
9 NN O O
years NN O O
of NN O O
age NN O O
. NN O O

The NN O O
prevalence NN O O
of NN O O
parasitaemia NN O O
was NN O O
18 NN O O
% NN O O
in NN O O
children NN O O
under NN O O
5 NN O O
years NN O O
of NN O O
age NN O O
and NN O O
25 NN O O
% NN O O
in NN O O
children NN O O
5 NN O O
- NN O O
9 NN O O
years NN O O
of NN O O
age NN O O
in NN O O
the NN O O
control NN O O
villages NN O O
, NN O O
and NN O O
5.7 NN O O
% NN O O
and NN O O
5.8 NN O O
% NN O O
, NN O O
respectively NN O O
, NN O O
in NN O O
these NN O O
2 NN O O
age NN O O
groups NN O O
in NN O O
the NN O O
SMC NN O O
villages NN O O
, NN O O
with NN O O
prevalence NN O O
differences NN O O
of NN O O
12.5 NN O O
% NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
6.8 NN O O
% NN O O
, NN O O
18.2 NN O O
% NN O O
; NN O O
p NN O O
< NN O O
0.001 NN O O
) NN O O
in NN O O
children NN O O
under NN O O
5 NN O O
years NN O O
of NN O O
age NN O O
and NN O O
19.3 NN O O
% NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
8.3 NN O O
% NN O O
, NN O O
30.2 NN O O
% NN O O
; NN O O
p NN O O
< NN O O
0.001 NN O O
) NN O O
in NN O O
children NN O O
5 NN O O
- NN O O
9 NN O O
years NN O O
of NN O O
age NN O O
. NN O O

The NN O O
pfdhps-540E NN O O
mutation NN O O
associated NN O O
with NN O O
clinical NN O O
resistance NN O O
to NN O O
sulfadoxine-pyrimethamine NN O O
was NN O O
found NN O O
in NN O O
0.8 NN O O
% NN O O
of NN O O
samples NN O O
from NN O O
malaria NN O O
cases NN O O
but NN O O
not NN O O
in NN O O
the NN O O
final NN O O
survey NN O O
. NN O O

Twelve NN O O
children NN O O
died NN O O
in NN O O
the NN O O
control NN O O
group NN O O
and NN O O
14 NN O O
in NN O O
the NN O O
SMC NN O O
group NN O O
, NN O O
a NN O O
rate NN O O
difference NN O O
of NN O O
0.096/1,000 NN O O
child-months NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
0.99 NN O O
, NN O O
1.18 NN O O
; NN O O
p NN O O
= NN O O
0.895 NN O O
) NN O O
. NN O O

Limitations NN O O
of NN O O
this NN O O
study NN O O
include NN O O
that NN O O
we NN O O
were NN O O
not NN O O
able NN O O
to NN O O
obtain NN O O
blood NN O O
smears NN O O
for NN O O
microscopy NN O O
for NN O O
all NN O O
suspected NN O O
malaria NN O O
cases NN O O
, NN O O
such NN O O
that NN O O
we NN O O
had NN O O
to NN O O
rely NN O O
on NN O O
RDTs NN O O
for NN O O
confirmation NN O O
, NN O O
which NN O O
may NN O O
have NN O O
included NN O O
false NN O O
positives NN O O
. NN O O

In NN O O
this NN O O
study NN O O
SMC NN O O
for NN O O
children NN O O
under NN O O
10 NN O O
years NN O O
of NN O O
age NN O O
given NN O O
over NN O O
5 NN O O
months NN O O
was NN O O
feasible NN O O
, NN O O
well NN O O
tolerated NN O O
, NN O O
and NN O O
effective NN O O
in NN O O
preventing NN O O
malaria NN O O
episodes NN O O
, NN O O
and NN O O
reduced NN O O
the NN O O
prevalence NN O O
of NN O O
parasitaemia NN O O
and NN O O
anaemia NN O O
. NN O O

SMC NN O O
with NN O O
CCM NN O O
achieved NN O O
high NN O O
coverage NN O O
and NN O O
ensured NN O O
children NN O O
with NN O O
malaria NN O O
were NN O O
promptly NN O O
treated NN O O
with NN O O
artemether-lumefantrine NN O O
. NN O O

www.clinicaltrials.gov NN O O
NCT01449045 NN O O
. NN O O



-DOCSTART- (30635252)

Nepalese NN O O
infants NN O O
receive NN O O
ten-valent NN O O
pneumococcal NN O O
conjugate NN O O
vaccine NN O O
( NN O O
PCV10 NN O O
) NN O O
with NN O O
a NN O O
1 NN O O
month NN O O
interval NN O O
between NN O O
priming NN O O
doses NN O O
for NN O O
programmatic NN O O
reasons NN O O
. NN O O

We NN O O
aimed NN O O
to NN O O
investigate NN O O
whether NN O O
immune NN O O
responses NN O O
to NN O O
PCV10 NN O O
serotypes NN O O
were NN O O
non-inferior NN O O
if NN O O
the NN O O
second NN O O
priming NN O O
dose NN O O
of NN O O
PCV10 NN O O
was NN O O
delivered NN O O
at NN O O
a NN O O
1 NN O O
month NN O O
interval NN O O
as NN O O
opposed NN O O
to NN O O
a NN O O
2 NN O O
month NN O O
interval NN O O
. NN O O

We NN O O
did NN O O
an NN O O
open-label NN O O
, NN O O
randomised NN O O
, NN O O
parallel NN O O
group NN O O
trial NN O O
in NN O O
healthy NN O O
Nepalese NN O O
infants NN O O
aged NN O O
40 NN O O
- NN O O
60 NN O O
days NN O O
at NN O O
Patan NN O O
Hospital NN O O
, NN O O
Kathmandu NN O O
, NN O O
Nepal NN O O
. NN O O

Children NN O O
were NN O O
eligible NN O O
for NN O O
inclusion NN O O
if NN O O
they NN O O
were NN O O
healthy NN O O
, NN O O
were NN O O
born NN O O
at NN O O
more NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
37 NN O O
weeks NN O O
' NN O O
gestation NN O O
, NN O O
were NN O O
residing NN O O
in NN O O
Kathmandu NN O O
, NN O O
and NN O O
had NN O O
not NN O O
had NN O O
any NN O O
previous NN O O
vaccinations NN O O
other NN O O
than NN O O
BCG NN O O
, NN O O
and NN O O
oral NN O O
polio NN O O
vaccine NN O O
. NN O O

Participants NN O O
were NN O O
randomly NN O O
assigned NN O O
( NN O O
1:1 NN O O
) NN O O
by NN O O
means NN O O
of NN O O
a NN O O
computer-generated NN O O
list NN O O
with NN O O
randomly NN O O
varying NN O O
permuted NN O O
block NN O O
sizes NN O O
accessed NN O O
through NN O O
a NN O O
validated NN O O
web-based NN O O
interface NN O O
, NN O O
to NN O O
receive NN O O
PCV10 NN O O
either NN O O
at NN O O
6 NN O O
weeks NN O O
and NN O O
10 NN O O
weeks NN O O
of NN O O
age NN O O
( NN O O
6 NN O O
+ NN O O
10 NN O O
group NN O O
) NN O O
or NN O O
at NN O O
6 NN O O
weeks NN O O
and NN O O
14 NN O O
weeks NN O O
of NN O O
age NN O O
( NN O O
6 NN O O
+ NN O O
14 NN O O
group NN O O
) NN O O
, NN O O
with NN O O
both NN O O
groups NN O O
receiving NN O O
a NN O O
booster NN O O
at NN O O
9 NN O O
months NN O O
of NN O O
age NN O O
. NN O O

Laboratory NN O O
staff NN O O
, NN O O
masked NN O O
to NN O O
study NN O O
intervention NN O O
, NN O O
analysed NN O O
serum NN O O
samples NN O O
for NN O O
antibodies NN O O
against NN O O
PCV10 NN O O
serotypes NN O O
by NN O O
ELISA NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
was NN O O
to NN O O
determine NN O O
whether NN O O
the NN O O
6 NN O O
+ NN O O
10 NN O O
schedule NN O O
was NN O O
non-inferior NN O O
to NN O O
the NN O O
6 NN O O
+ NN O O
14 NN O O
schedule NN O O
at NN O O
9 NN O O
months NN O O
of NN O O
age NN O O
, NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
the NN O O
proportion NN O O
of NN O O
infants NN O O
with NN O O
serotype-specific NN O O
IgG NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
0·35 NN O O
μg/mL. NN O O
Non-inferiority NN O O
was NN O O
established NN O O
with NN O O
a NN O O
10 NN O O
% NN O O
margin NN O O
, NN O O
and NN O O
the NN O O
primary NN O O
endpoint NN O O
was NN O O
measured NN O O
in NN O O
a NN O O
modified NN O O
intention-to-treat NN O O
population NN O O
, NN O O
which NN O O
included NN O O
only NN O O
participants NN O O
who NN O O
successfully NN O O
had NN O O
a NN O O
blood NN O O
sample NN O O
collected NN O O
. NN O O

This NN O O
trial NN O O
is NN O O
registered NN O O
at NN O O
ClinicalTrials.gov NN O O
, NN O O
number NN O O
NCT02385513 NN O O
. NN O O

Between NN O O
Aug NN O O
21 NN O O
, NN O O
2015 NN O O
, NN O O
and NN O O
April NN O O
4 NN O O
, NN O O
2016 NN O O
, NN O O
304 NN O O
Nepalese NN O O
children NN O O
were NN O O
randomly NN O O
assigned NN O O
to NN O O
either NN O O
the NN O O
6 NN O O
+ NN O O
10 NN O O
group NN O O
( NN O O
n=152 NN O O
) NN O O
or NN O O
the NN O O
6 NN O O
+ NN O O
14 NN O O
group NN O O
( NN O O
n=152 NN O O
) NN O O
. NN O O

At NN O O
9 NN O O
months NN O O
of NN O O
age NN O O
, NN O O
the NN O O
6 NN O O
+ NN O O
10 NN O O
schedule NN O O
was NN O O
non-inferior NN O O
for NN O O
serotype NN O O
5 NN O O
( NN O O
79 NN O O
[ NN O O
55·2 NN O O
% NN O O
] NN O O
of NN O O
143 NN O O
vs NN O O
78 NN O O
[ NN O O
53·4 NN O O
% NN O O
] NN O O
of NN O O
146 NN O O
, NN O O
difference NN O O
1·82 NN O O
% NN O O
[ NN O O
95 NN O O
% NN O O
CI NN O O
-9·6 NN O O
to NN O O
13·25 NN O O
] NN O O
, NN O O
p=0·021 NN O O
) NN O O
, NN O O
serotype NN O O
9V NN O O
( NN O O
66 NN O O
[ NN O O
46·1 NN O O
% NN O O
] NN O O
of NN O O
143 NN O O
vs NN O O
55 NN O O
[ NN O O
37·6 NN O O
% NN O O
] NN O O
of NN O O
146 NN O O
, NN O O
difference NN O O
8·48 NN O O
% NN O O
[ NN O O
-2·84 NN O O
to NN O O
19·8 NN O O
] NN O O
, NN O O
p=0·001 NN O O
) NN O O
, NN O O
serotype NN O O
14 NN O O
( NN O O
110 NN O O
[ NN O O
77·4 NN O O
% NN O O
] NN O O
of NN O O
142 NN O O
vs NN O O
110 NN O O
[ NN O O
74·8 NN O O
% NN O O
] NN O O
of NN O O
147 NN O O
, NN O O
difference NN O O
2·63 NN O O
% NN O O
[ NN O O
-7·27 NN O O
to NN O O
12·54 NN O O
] NN O O
, NN O O
p=0·006 NN O O
) NN O O
, NN O O
and NN O O
serotype NN O O
19F NN O O
( NN O O
135 NN O O
[ NN O O
95 NN O O
% NN O O
] NN O O
of NN O O
142 NN O O
vs NN O O
146 NN O O
[ NN O O
100 NN O O
% NN O O
] NN O O
of NN O O
146 NN O O
, NN O O
difference NN O O
-4·92 NN O O
% NN O O
[ NN O O
-9·86 NN O O
to NN O O
0 NN O O
] NN O O
, NN O O
p=0·022 NN O O
) NN O O
. NN O O

At NN O O
the NN O O
same NN O O
timepoint NN O O
, NN O O
non-inferiority NN O O
was NN O O
not NN O O
shown NN O O
for NN O O
serotype NN O O
1 NN O O
( NN O O
36 NN O O
[ NN O O
25·1 NN O O
% NN O O
] NN O O
of NN O O
143 NN O O
vs NN O O
42 NN O O
[ NN O O
28·5 NN O O
% NN O O
] NN O O
of NN O O
147 NN O O
, NN O O
difference NN O O
-3·39 NN O O
% NN O O
[ NN O O
95 NN O O
% NN O O
CI NN O O
-13·56 NN O O
to NN O O
6·77 NN O O
] NN O O
, NN O O
p=0·102 NN O O
) NN O O
, NN O O
serotype NN O O
4 NN O O
( NN O O
70 NN O O
[ NN O O
48·9 NN O O
% NN O O
] NN O O
of NN O O
143 NN O O
vs NN O O
87 NN O O
[ NN O O
59·1 NN O O
% NN O O
] NN O O
of NN O O
147 NN O O
, NN O O
difference NN O O
-10·23 NN O O
% NN O O
[ NN O O
-21·64 NN O O
to NN O O
1·18 NN O O
] NN O O
, NN O O
p=0·516 NN O O
) NN O O
, NN O O
serotype NN O O
6B NN O O
( NN O O
96 NN O O
[ NN O O
67·1 NN O O
% NN O O
] NN O O
of NN O O
143 NN O O
vs NN O O
114 NN O O
[ NN O O
77·5 NN O O
% NN O O
] NN O O
of NN O O
147 NN O O
, NN O O
difference NN O O
-10·41 NN O O
% NN O O
[ NN O O
-20·65 NN O O
to NN O O
-0·18 NN O O
] NN O O
, NN O O
p=0·532 NN O O
) NN O O
, NN O O
serotype NN O O
7F NN O O
( NN O O
99 NN O O
[ NN O O
69·2 NN O O
% NN O O
] NN O O
of NN O O
143 NN O O
vs NN O O
109 NN O O
[ NN O O
74·1 NN O O
% NN O O
] NN O O
of NN O O
147 NN O O
, NN O O
difference NN O O
-4·91 NN O O
% NN O O
[ NN O O
-15·26 NN O O
to NN O O
5·42 NN O O
] NN O O
, NN O O
p=0·168 NN O O
) NN O O
, NN O O
serotype NN O O
18C NN O O
( NN O O
89 NN O O
[ NN O O
62·2 NN O O
% NN O O
] NN O O
of NN O O
143 NN O O
vs NN O O
114 NN O O
[ NN O O
77·5 NN O O
% NN O O
] NN O O
of NN O O
147 NN O O
, NN O O
difference NN O O
-15·31 NN O O
% NN O O
[ NN O O
-25·78 NN O O
to NN O O
-4·83 NN O O
] NN O O
, NN O O
p=0·840 NN O O
) NN O O
, NN O O
and NN O O
serotype NN O O
23F NN O O
( NN O O
37 NN O O
[ NN O O
25·8 NN O O
% NN O O
] NN O O
of NN O O
143 NN O O
vs NN O O
41 NN O O
[ NN O O
27·8 NN O O
% NN O O
] NN O O
of NN O O
147 NN O O
, NN O O
difference NN O O
-2·01 NN O O
% NN O O
[ NN O O
-12·19 NN O O
to NN O O
8·16 NN O O
] NN O O
, NN O O
p=0·062 NN O O
) NN O O
. NN O O

After NN O O
the NN O O
booster NN O O
dose NN O O
, NN O O
at NN O O
10 NN O O
months NN O O
of NN O O
age NN O O
, NN O O
there NN O O
were NN O O
no NN O O
significant NN O O
differences NN O O
in NN O O
immunogenicity NN O O
( NN O O
proportion NN O O
of NN O O
children NN O O
with NN O O
antibody NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
0.35 NN O O
μg/mL NN O O
) NN O O
for NN O O
any NN O O
of NN O O
the NN O O
ten NN O O
serotypes NN O O
, NN O O
when NN O O
comparing NN O O
the NN O O
two NN O O
schedules NN O O
. NN O O

Serious NN O O
adverse NN O O
events NN O O
occurred NN O O
in NN O O
32 NN O O
participants NN O O
, NN O O
11 NN O O
( NN O O
7 NN O O
% NN O O
) NN O O
of NN O O
152 NN O O
in NN O O
the NN O O
6 NN O O
+ NN O O
10 NN O O
group NN O O
and NN O O
21 NN O O
( NN O O
14 NN O O
% NN O O
) NN O O
of NN O O
152 NN O O
in NN O O
the NN O O
6 NN O O
+ NN O O
14 NN O O
group NN O O
. NN O O

The NN O O
6 NN O O
week NN O O
, NN O O
14 NN O O
week NN O O
, NN O O
and NN O O
9 NN O O
month NN O O
schedule NN O O
should NN O O
be NN O O
implemented NN O O
where NN O O
possible NN O O
. NN O O

However NN O O
, NN O O
post-booster NN O O
responses NN O O
, NN O O
which NN O O
are NN O O
thought NN O O
to NN O O
drive NN O O
herd NN O O
immunity NN O O
, NN O O
were NN O O
similar NN O O
in NN O O
the NN O O
two NN O O
schedules NN O O
. NN O O

Therefore NN O O
, NN O O
the NN O O
6 NN O O
week NN O O
, NN O O
10 NN O O
week NN O O
, NN O O
and NN O O
9 NN O O
month NN O O
schedule NN O O
is NN O O
an NN O O
alternative NN O O
that NN O O
can NN O O
be NN O O
used NN O O
when NN O O
logistically NN O O
necessary NN O O
, NN O O
and NN O O
is NN O O
expected NN O O
to NN O O
provide NN O O
herd NN O O
protection NN O O
. NN O O

Gavi NN O O
, NN O O
the NN O O
Vaccine NN O O
Alliance NN O O
. NN O O



-DOCSTART- (31135850)

Laparoscopic NN O O
distal NN O O
gastrectomy NN O O
is NN O O
accepted NN O O
as NN O O
a NN O O
more NN O O
effective NN O O
approach NN O O
to NN O O
conventional NN O O
open NN O O
distal NN O O
gastrectomy NN O O
for NN O O
early-stage NN O O
gastric NN O O
cancer NN O O
. NN O O

However NN O O
, NN O O
efficacy NN O O
for NN O O
locally NN O O
advanced NN O O
gastric NN O O
cancer NN O O
remains NN O O
uncertain NN O O
. NN O O

To NN O O
compare NN O O
3-year NN O O
disease-free NN O O
survival NN O O
for NN O O
patients NN O O
with NN O O
locally NN O O
advanced NN O O
gastric NN O O
cancer NN O O
after NN O O
laparoscopic NN O O
distal NN O O
gastrectomy NN O O
or NN O O
open NN O O
distal NN O O
gastrectomy NN O O
. NN O O

The NN O O
study NN O O
was NN O O
a NN O O
noninferiority NN O O
, NN O O
open-label NN O O
, NN O O
randomized NN O O
clinical NN O O
trial NN O O
at NN O O
14 NN O O
centers NN O O
in NN O O
China NN O O
. NN O O

A NN O O
total NN O O
of NN O O
1056 NN O O
eligible NN O O
patients NN O O
with NN O O
clinical NN O O
stage NN O O
T2 NN O O
, NN O O
T3 NN O O
, NN O O
or NN O O
T4a NN O O
gastric NN O O
cancer NN O O
without NN O O
bulky NN O O
nodes NN O O
or NN O O
distant NN O O
metastases NN O O
were NN O O
enrolled NN O O
from NN O O
September NN O O
2012 NN O O
to NN O O
December NN O O
2014 NN O O
. NN O O

Final NN O O
follow-up NN O O
was NN O O
on NN O O
December NN O O
31 NN O O
, NN O O
2017 NN O O
. NN O O

Participants NN O O
were NN O O
randomized NN O O
in NN O O
a NN O O
1:1 NN O O
ratio NN O O
after NN O O
stratification NN O O
by NN O O
site NN O O
, NN O O
age NN O O
, NN O O
cancer NN O O
stage NN O O
, NN O O
and NN O O
histology NN O O
to NN O O
undergo NN O O
either NN O O
laparoscopic NN O O
distal NN O O
gastrectomy NN O O
( NN O O
n NN O O
= NN O O
528 NN O O
) NN O O
or NN O O
open NN O O
distal NN O O
gastrectomy NN O O
( NN O O
n NN O O
= NN O O
528 NN O O
) NN O O
with NN O O
D2 NN O O
lymphadenectomy NN O O
. NN O O

The NN O O
primary NN O O
end NN O O
point NN O O
was NN O O
3-year NN O O
disease-free NN O O
survival NN O O
with NN O O
a NN O O
noninferiority NN O O
margin NN O O
of NN O O
-10 NN O O
% NN O O
to NN O O
compare NN O O
laparoscopic NN O O
distal NN O O
gastrectomy NN O O
with NN O O
open NN O O
distal NN O O
gastrectomy NN O O
. NN O O

Secondary NN O O
end NN O O
points NN O O
of NN O O
3-year NN O O
overall NN O O
survival NN O O
and NN O O
recurrence NN O O
patterns NN O O
were NN O O
tested NN O O
for NN O O
superiority NN O O
. NN O O

Among NN O O
1056 NN O O
patients NN O O
, NN O O
1039 NN O O
( NN O O
98.4 NN O O
% NN O O
; NN O O
mean NN O O
age NN O O
, NN O O
56.2 NN O O
years NN O O
; NN O O
313 NN O O
[ NN O O
30.1 NN O O
% NN O O
] NN O O
women NN O O
) NN O O
had NN O O
surgery NN O O
( NN O O
laparoscopic NN O O
distal NN O O
gastrectomy NN O O
[ NN O O
n=519 NN O O
] NN O O
vs NN O O
open NN O O
distal NN O O
gastrectomy NN O O
[ NN O O
n=520 NN O O
] NN O O
) NN O O
, NN O O
and NN O O
999 NN O O
( NN O O
94.6 NN O O
% NN O O
) NN O O
completed NN O O
the NN O O
study NN O O
. NN O O

Three-year NN O O
disease-free NN O O
survival NN O O
rate NN O O
was NN O O
76.5 NN O O
% NN O O
in NN O O
the NN O O
laparoscopic NN O O
distal NN O O
gastrectomy NN O O
group NN O O
and NN O O
77.8 NN O O
% NN O O
in NN O O
the NN O O
open NN O O
distal NN O O
gastrectomy NN O O
group NN O O
, NN O O
absolute NN O O
difference NN O O
of NN O O
-1.3 NN O O
% NN O O
and NN O O
a NN O O
1-sided NN O O
97.5 NN O O
% NN O O
CI NN O O
of NN O O
-6.5 NN O O
% NN O O
to NN O O
∞ NN O O
, NN O O
not NN O O
crossing NN O O
the NN O O
prespecified NN O O
noninferiority NN O O
margin NN O O
. NN O O

Three-year NN O O
overall NN O O
survival NN O O
rate NN O O
( NN O O
laparoscopic NN O O
distal NN O O
gastrectomy NN O O
vs NN O O
open NN O O
distal NN O O
gastrectomy NN O O
: NN O O
83.1 NN O O
% NN O O
vs NN O O
85.2 NN O O
% NN O O
; NN O O
adjusted NN O O
hazard NN O O
ratio NN O O
, NN O O
1.19 NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
0.87 NN O O
to NN O O
1.64 NN O O
; NN O O
P NN O O
= NN O O
.28 NN O O
) NN O O
and NN O O
cumulative NN O O
incidence NN O O
of NN O O
recurrence NN O O
over NN O O
the NN O O
3-year NN O O
period NN O O
( NN O O
laparoscopic NN O O
distal NN O O
gastrectomy NN O O
vs NN O O
open NN O O
distal NN O O
gastrectomy NN O O
: NN O O
18.8 NN O O
% NN O O
vs NN O O
16.5 NN O O
% NN O O
; NN O O
subhazard NN O O
ratio NN O O
, NN O O
1.15 NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
0.86 NN O O
to NN O O
1.54 NN O O
; NN O O
P NN O O
= NN O O
.35 NN O O
) NN O O
did NN O O
not NN O O
significantly NN O O
differ NN O O
between NN O O
laparoscopic NN O O
distal NN O O
gastrectomy NN O O
and NN O O
open NN O O
distal NN O O
gastrectomy NN O O
groups NN O O
. NN O O

Among NN O O
patients NN O O
with NN O O
a NN O O
preoperative NN O O
clinical NN O O
stage NN O O
indicating NN O O
locally NN O O
advanced NN O O
gastric NN O O
cancer NN O O
, NN O O
laparoscopic NN O O
distal NN O O
gastrectomy NN O O
, NN O O
compared NN O O
with NN O O
open NN O O
distal NN O O
gastrectomy NN O O
, NN O O
did NN O O
not NN O O
result NN O O
in NN O O
inferior NN O O
disease-free NN O O
survival NN O O
at NN O O
3 NN O O
years NN O O
. NN O O

ClinicalTrials.gov NN O O
Identifier NN O O
: NN O O
NCT01609309 NN O O
. NN O O



-DOCSTART- (31076468)

To NN O O
evaluate NN O O
the NN O O
safety NN O O
and NN O O
efficacy NN O O
of NN O O
removing NN O O
blood NN O O
stasis NN O O
( NN O O
RBS NN O O
) NN O O
herbal NN O O
medicine NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
acute NN O O
intracerebral NN O O
haemorrhage NN O O
( NN O O
AICH NN O O
) NN O O
within NN O O
a NN O O
6-hour NN O O
time NN O O
window NN O O
. NN O O

A NN O O
randomised NN O O
, NN O O
multicentre NN O O
, NN O O
double-blind NN O O
, NN O O
placebo-controlled NN O O
study NN O O
performed NN O O
in NN O O
14 NN O O
hospitals NN O O
in NN O O
China NN O O
. NN O O

Patients NN O O
with NN O O
AICH NN O O
were NN O O
randomly NN O O
assigned NN O O
to NN O O
receive NN O O
a NN O O
placebo NN O O
, NN O O
the NN O O
ICH-1 NN O O
( NN O O
Intracerebral NN O O
Haemorrhage NN O O
) NN O O
formula NN O O
( NN O O
eight NN O O
herbs NN O O
, NN O O
including NN O O
the NN O O
RBS NN O O
herbs NN O O
and NN O O
) NN O O
or NN O O
the NN O O
ICH-2 NN O O
formula NN O O
( NN O O
six NN O O
herbs NN O O
without NN O O
the NN O O
RBS NN O O
herbs NN O O
and NN O O
) NN O O
within NN O O
6 NN O O
hours NN O O
of NN O O
ICH NN O O
onset NN O O
. NN O O

The NN O O
primary NN O O
safety NN O O
outcome NN O O
was NN O O
the NN O O
incidence NN O O
of NN O O
haematoma NN O O
enlargement NN O O
at NN O O
24 NN O O
hours NN O O
and NN O O
at NN O O
10 NN O O
days NN O O
after NN O O
treatment NN O O
. NN O O

The NN O O
secondary NN O O
outcome NN O O
was NN O O
the NN O O
incidence NN O O
of NN O O
poor NN O O
prognosis NN O O
( NN O O
mortality NN O O
or NN O O
modified NN O O
Rankin NN O O
Scale NN O O
score NN O O
≥5 NN O O
) NN O O
assessed NN O O
at NN O O
90 NN O O
days NN O O
after NN O O
symptom NN O O
onset NN O O
. NN O O

A NN O O
total NN O O
of NN O O
324 NN O O
subjects NN O O
were NN O O
randomised NN O O
between NN O O
October NN O O
2013 NN O O
and NN O O
May NN O O
2016 NN O O
: NN O O
105 NN O O
patients NN O O
received NN O O
placebo NN O O
; NN O O
108 NN O O
patients NN O O
received NN O O
the NN O O
ICH-1 NN O O
formula NN O O
; NN O O
and NN O O
111 NN O O
patients NN O O
received NN O O
the NN O O
ICH-2 NN O O
formula NN O O
. NN O O

The NN O O
incidence NN O O
of NN O O
haematoma NN O O
enlargement NN O O
at NN O O
24 NN O O
hours NN O O
was NN O O
7.8 NN O O
% NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
, NN O O
12.3 NN O O
% NN O O
in NN O O
the NN O O
ICH-1 NN O O
group NN O O
and NN O O
7.5 NN O O
% NN O O
in NN O O
the NN O O
ICH-2 NN O O
group NN O O
; NN O O
the NN O O
incidence NN O O
of NN O O
haematoma NN O O
enlargement NN O O
on NN O O
day NN O O
10 NN O O
was NN O O
1.1 NN O O
% NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
, NN O O
1.1 NN O O
% NN O O
in NN O O
the NN O O
ICH-1 NN O O
group NN O O
, NN O O
and NN O O
3.1 NN O O
% NN O O
in NN O O
the NN O O
ICH-2 NN O O
group NN O O
, NN O O
with NN O O
no NN O O
significant NN O O
differences NN O O
among NN O O
the NN O O
groups NN O O
( NN O O
P>0.05 NN O O
) NN O O
. NN O O

The NN O O
mortality NN O O
rates NN O O
were NN O O
3.8 NN O O
% NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
, NN O O
2.8 NN O O
% NN O O
in NN O O
the NN O O
ICH-1 NN O O
group NN O O
, NN O O
and NN O O
0.9 NN O O
% NN O O
in NN O O
the NN O O
ICH-2 NN O O
group NN O O
; NN O O
the NN O O
incidences NN O O
of NN O O
poor NN O O
prognosis NN O O
were NN O O
7.1 NN O O
% NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
, NN O O
6.0 NN O O
% NN O O
in NN O O
the NN O O
ICH-1 NN O O
group NN O O
and NN O O
4.8 NN O O
% NN O O
in NN O O
the NN O O
ICH-2 NN O O
group NN O O
at NN O O
3 NN O O
months NN O O
, NN O O
with NN O O
no NN O O
significant NN O O
differences NN O O
among NN O O
the NN O O
groups NN O O
( NN O O
p>0.05 NN O O
) NN O O
. NN O O

However NN O O
, NN O O
the NN O O
overall NN O O
frequency NN O O
of NN O O
treatment-emergent NN O O
adverse NN O O
events NN O O
in NN O O
the NN O O
ICH-1 NN O O
group NN O O
( NN O O
12.1 NN O O
% NN O O
) NN O O
was NN O O
higher NN O O
among NN O O
the NN O O
three NN O O
groups NN O O
( NN O O
5.8 NN O O
% NN O O
and NN O O
2.8 NN O O
% NN O O
, NN O O
respectively NN O O
, NN O O
p NN O O
0.05 NN O O
) NN O O
. NN O O

All NN O O
three NN O O
cases NN O O
of NN O O
serious NN O O
adverse NN O O
events NN O O
were NN O O
in NN O O
the NN O O
ICH-1 NN O O
group NN O O
. NN O O

Ultra-early NN O O
administration NN O O
of NN O O
ICH-1 NN O O
formula NN O O
for NN O O
AICH NN O O
patients NN O O
did NN O O
not NN O O
exert NN O O
significant NN O O
beneficial NN O O
effects NN O O
on NN O O
clinical NN O O
outcomes NN O O
but NN O O
increased NN O O
the NN O O
risk NN O O
of NN O O
bleeding NN O O
, NN O O
which NN O O
probably NN O O
resulted NN O O
from NN O O
the NN O O
inclusion NN O O
of NN O O
RBS NN O O
herbal NN O O
medicines NN O O
in NN O O
ICH-1 NN O O
. NN O O

NCT01918722 NN O O
. NN O O



-DOCSTART- (30772908)

Abnormal NN O O
peripheral NN O O
perfusion NN O O
after NN O O
septic NN O O
shock NN O O
resuscitation NN O O
has NN O O
been NN O O
associated NN O O
with NN O O
organ NN O O
dysfunction NN O O
and NN O O
mortality NN O O
. NN O O

The NN O O
potential NN O O
role NN O O
of NN O O
the NN O O
clinical NN O O
assessment NN O O
of NN O O
peripheral NN O O
perfusion NN O O
as NN O O
a NN O O
target NN O O
during NN O O
resuscitation NN O O
in NN O O
early NN O O
septic NN O O
shock NN O O
has NN O O
not NN O O
been NN O O
established NN O O
. NN O O

To NN O O
determine NN O O
if NN O O
a NN O O
peripheral NN O O
perfusion-targeted NN O O
resuscitation NN O O
during NN O O
early NN O O
septic NN O O
shock NN O O
in NN O O
adults NN O O
is NN O O
more NN O O
effective NN O O
than NN O O
a NN O O
lactate NN O O
level-targeted NN O O
resuscitation NN O O
for NN O O
reducing NN O O
mortality NN O O
. NN O O

Multicenter NN O O
, NN O O
randomized NN O O
trial NN O O
conducted NN O O
at NN O O
28 NN O O
intensive NN O O
care NN O O
units NN O O
in NN O O
5 NN O O
countries NN O O
. NN O O

Four-hundred NN O O
twenty-four NN O O
patients NN O O
with NN O O
septic NN O O
shock NN O O
were NN O O
included NN O O
between NN O O
March NN O O
2017 NN O O
and NN O O
March NN O O
2018 NN O O
. NN O O

The NN O O
last NN O O
date NN O O
of NN O O
follow-up NN O O
was NN O O
June NN O O
12 NN O O
, NN O O
2018 NN O O
. NN O O

Patients NN O O
were NN O O
randomized NN O O
to NN O O
a NN O O
step-by-step NN O O
resuscitation NN O O
protocol NN O O
aimed NN O O
at NN O O
either NN O O
normalizing NN O O
capillary NN O O
refill NN O O
time NN O O
( NN O O
n NN O O
= NN O O
212 NN O O
) NN O O
or NN O O
normalizing NN O O
or NN O O
decreasing NN O O
lactate NN O O
levels NN O O
at NN O O
rates NN O O
greater NN O O
than NN O O
20 NN O O
% NN O O
per NN O O
2 NN O O
hours NN O O
( NN O O
n NN O O
= NN O O
212 NN O O
) NN O O
, NN O O
during NN O O
an NN O O
8-hour NN O O
intervention NN O O
period NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
was NN O O
all-cause NN O O
mortality NN O O
at NN O O
28 NN O O
days NN O O
. NN O O

Secondary NN O O
outcomes NN O O
were NN O O
organ NN O O
dysfunction NN O O
at NN O O
72 NN O O
hours NN O O
after NN O O
randomization NN O O
, NN O O
as NN O O
assessed NN O O
by NN O O
Sequential NN O O
Organ NN O O
Failure NN O O
Assessment NN O O
( NN O O
SOFA NN O O
) NN O O
score NN O O
( NN O O
range NN O O
, NN O O
0 NN O O
[ NN O O
best NN O O
] NN O O
to NN O O
24 NN O O
[ NN O O
worst NN O O
] NN O O
) NN O O
; NN O O
death NN O O
within NN O O
90 NN O O
days NN O O
; NN O O
mechanical NN O O
ventilation- NN O O
, NN O O
renal NN O O
replacement NN O O
therapy- NN O O
, NN O O
and NN O O
vasopressor-free NN O O
days NN O O
within NN O O
28 NN O O
days NN O O
; NN O O
intensive NN O O
care NN O O
unit NN O O
and NN O O
hospital NN O O
length NN O O
of NN O O
stay NN O O
. NN O O

Among NN O O
424 NN O O
patients NN O O
randomized NN O O
( NN O O
mean NN O O
age NN O O
, NN O O
63 NN O O
years NN O O
; NN O O
226 NN O O
[ NN O O
53 NN O O
% NN O O
] NN O O
women NN O O
) NN O O
, NN O O
416 NN O O
( NN O O
98 NN O O
% NN O O
) NN O O
completed NN O O
the NN O O
trial NN O O
. NN O O

By NN O O
day NN O O
28 NN O O
, NN O O
74 NN O O
patients NN O O
( NN O O
34.9 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
peripheral NN O O
perfusion NN O O
group NN O O
and NN O O
92 NN O O
patients NN O O
( NN O O
43.4 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
lactate NN O O
group NN O O
had NN O O
died NN O O
( NN O O
hazard NN O O
ratio NN O O
, NN O O
0.75 NN O O
[ NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
0.55 NN O O
to NN O O
1.02 NN O O
] NN O O
; NN O O
P NN O O
= NN O O
.06 NN O O
; NN O O
risk NN O O
difference NN O O
, NN O O
-8.5 NN O O
% NN O O
[ NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
-18.2 NN O O
% NN O O
to NN O O
1.2 NN O O
% NN O O
] NN O O
) NN O O
. NN O O

Peripheral NN O O
perfusion-targeted NN O O
resuscitation NN O O
was NN O O
associated NN O O
with NN O O
less NN O O
organ NN O O
dysfunction NN O O
at NN O O
72 NN O O
hours NN O O
( NN O O
mean NN O O
SOFA NN O O
score NN O O
, NN O O
5.6 NN O O
[ NN O O
SD NN O O
, NN O O
4.3 NN O O
] NN O O
vs NN O O
6.6 NN O O
[ NN O O
SD NN O O
, NN O O
4.7 NN O O
] NN O O
; NN O O
mean NN O O
difference NN O O
, NN O O
-1.00 NN O O
[ NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
-1.97 NN O O
to NN O O
-0.02 NN O O
] NN O O
; NN O O
P NN O O
= NN O O
.045 NN O O
) NN O O
. NN O O

There NN O O
were NN O O
no NN O O
significant NN O O
differences NN O O
in NN O O
the NN O O
other NN O O
6 NN O O
secondary NN O O
outcomes NN O O
. NN O O

No NN O O
protocol-related NN O O
serious NN O O
adverse NN O O
reactions NN O O
were NN O O
confirmed NN O O
. NN O O

Among NN O O
patients NN O O
with NN O O
septic NN O O
shock NN O O
, NN O O
a NN O O
resuscitation NN O O
strategy NN O O
targeting NN O O
normalization NN O O
of NN O O
capillary NN O O
refill NN O O
time NN O O
, NN O O
compared NN O O
with NN O O
a NN O O
strategy NN O O
targeting NN O O
serum NN O O
lactate NN O O
levels NN O O
, NN O O
did NN O O
not NN O O
reduce NN O O
all-cause NN O O
28-day NN O O
mortality NN O O
. NN O O

ClinicalTrials.gov NN O O
Identifier NN O O
: NN O O
NCT03078712 NN O O
. NN O O



-DOCSTART- (30680237)

In NN O O
order NN O O
to NN O O
investigate NN O O
the NN O O
efficacy NN O O
and NN O O
safety NN O O
of NN O O
Afalaza NN O O
in NN O O
men NN O O
with NN O O
benign NN O O
prostatic NN O O
hyperplasia NN O O
( NN O O
BPH NN O O
) NN O O
at NN O O
risk NN O O
of NN O O
progression NN O O
, NN O O
this NN O O
multicenter NN O O
, NN O O
double-blind NN O O
, NN O O
placebo-controlled NN O O
, NN O O
randomized NN O O
clinical NN O O
trial NN O O
was NN O O
performed NN O O
. NN O O

Derived NN O O
by NN O O
technological NN O O
treatment NN O O
of NN O O
antibodies NN O O
to NN O O
prostate-specific NN O O
antigen NN O O
( NN O O
PSA NN O O
) NN O O
and NN O O
endothelial NN O O
nitric NN O O
oxide NN O O
synthase NN O O
( NN O O
eNOs NN O O
) NN O O
, NN O O
Afalaza NN O O
was NN O O
previously NN O O
proved NN O O
to NN O O
modulate NN O O
its NN O O
molecular NN O O
targets NN O O
. NN O O

The NN O O
mechanism NN O O
of NN O O
action NN O O
of NN O O
the NN O O
drug NN O O
is NN O O
associated NN O O
with NN O O
the NN O O
modulating NN O O
effect NN O O
of NN O O
the NN O O
antibiodies NN O O
( NN O O
RA-Abs NN O O
) NN O O
on NN O O
the NN O O
molecular NN O O
targets NN O O
( NN O O
PSA NN O O
and NN O O
eNOS NN O O
) NN O O
by NN O O
way NN O O
of NN O O
conformational NN O O
changes NN O O
. NN O O

A NN O O
total NN O O
of NN O O
49 NN O O
patients NN O O
aged NN O O
45 NN O O
- NN O O
60 NN O O
years NN O O
with NN O O
BPH NN O O
and NN O O
moderate NN O O
lower NN O O
urinary NN O O
tract NN O O
symptoms NN O O
( NN O O
LUTS NN O O
) NN O O
, NN O O
total NN O O
prostate NN O O
volume NN O O
( NN O O
TPV NN O O
) NN O O
≥30 NN O O
cm NN O O
, NN O O
Qmax NN O O
10 NN O O
- NN O O
15 NN O O
ml/s NN O O
, NN O O
and NN O O
serum NN O O
PSA<4 NN O O
ng/ml NN O O
were NN O O
randomly NN O O
assigned NN O O
to NN O O
receive NN O O
either NN O O
Afalaza NN O O
( NN O O
n NN O O
= NN O O
125 NN O O
) NN O O
or NN O O
placebo NN O O
( NN O O
n NN O O
= NN O O
124 NN O O
) NN O O
for NN O O
12 NN O O
months NN O O
. NN O O

Changes NN O O
in NN O O
BPH/LUTS NN O O
symptoms NN O O
( NN O O
according NN O O
to NN O O
the NN O O
International NN O O
Prostate NN O O
Symptom NN O O
Score NN O O
) NN O O
, NN O O
Qmax NN O O
, NN O O
TPV NN O O
, NN O O
PSA NN O O
, NN O O
BPH NN O O
clinical NN O O
progression NN O O
, NN O O
occurrence NN O O
of NN O O
acure NN O O
urinary NN O O
retention NN O O
( NN O O
AUR NN O O
) NN O O
events NN O O
or NN O O
BPH-related NN O O
surgery NN O O
were NN O O
estimated NN O O
as NN O O
the NN O O
study NN O O
endpoints NN O O
. NN O O

IPSS NN O O
mean NN O O
change NN O O
was NN O O
-3.7 NN O O
±3.0 NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
-4.3 NN O O
to NN O O
-3.2 NN O O
) NN O O
after NN O O
12 NN O O
months NN O O
of NN O O
Afalaza NN O O
( NN O O
vs. NN O O
-2.9 NN O O
±2.4 NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
-3.3 NN O O
to NN O O
-2.4 NN O O
in NN O O
placebo NN O O
; NN O O
р NN O O
= NN O O
0.02 NN O O
) NN O O
. NN O O

Qmax NN O O
growth NN O O
was NN O O
2.5 NN O O
±4.3 NN O O
ml/s NN O O
( NN O O
vs. NN O O
1.4 NN O O
±3.3 NN O O
in NN O O
placebo NN O O
; NN O O
p NN O O
= NN O O
0.049 NN O O
) NN O O
, NN O O
TPV NN O O
reduced NN O O
by NN O O
11.8 NN O O
±16.0 NN O O
% NN O O
( NN O O
vs. NN O O
6.5 NN O O
±14.7 NN O O
% NN O O
; NN O O
p NN O O
= NN O O
0.01 NN O O
, NN O O
and NN O O
PSA NN O O
remained NN O O
unchanged NN O O
. NN O O

Afalaza NN O O
therapy NN O O
resulted NN O O
in NN O O
a NN O O
significant NN O O
decrease NN O O
in NN O O
the NN O O
total NN O O
sum NN O O
of NN O O
BPH NN O O
progression NN O O
symptoms NN O O
( NN O O
p NN O O
= NN O O
0.01 NN O O
) NN O O
. NN O O

The NN O O
maximum NN O O
effect NN O O
of NN O O
Afalaza NN O O
was NN O O
registered NN O O
after NN O O
12 NN O O
months NN O O
without NN O O
a NN O O
tendency NN O O
to NN O O
form NN O O
a NN O O
' NN O O
plateau NN O O
' NN O O
. NN O O

During NN O O
the NN O O
study NN O O
, NN O O
no NN O O
patients NN O O
experienced NN O O
AUR NN O O
or NN O O
BPH-related NN O O
surgery NN O O
. NN O O

A NN O O
12-month NN O O
course NN O O
of NN O O
Afalaza NN O O
therapy NN O O
is NN O O
effective NN O O
and NN O O
safe NN O O
for NN O O
patients NN O O
with NN O O
BPH NN O O
. NN O O

The NN O O
results NN O O
of NN O O
end NN O O
points NN O O
measurements NN O O
revealed NN O O
asignificant NN O O
advantage NN O O
of NN O O
Afalaza NN O O
compared NN O O
to NN O O
placebo NN O O
in NN O O
the NN O O
overall NN O O
symptoms NN O O
benefit NN O O
and NN O O
a NN O O
decline NN O O
in NN O O
the NN O O
risk NN O O
of NN O O
BPH NN O O
progression NN O O
. NN O O

ClinicalTrials.gov NN O O
: NN O O
NCT01716104 NN O O
. NN O O



-DOCSTART- (30870102)

We NN O O
compared NN O O
two NN O O
treatments NN O O
for NN O O
depression NN O O
and/ NN O O
or NN O O
anxiety NN O O
in NN O O
chronic NN O O
moderate NN O O
to NN O O
severe NN O O
traumatic NN O O
brain NN O O
injury NN O O
( NN O O
TBI NN O O
) NN O O
( NN O O
Clinicaltrials.gov NN O O
NCT02061553 NN O O
) NN O O
. NN O O

Fifty-nine NN O O
participants NN O O
were NN O O
randomized NN O O
2:1 NN O O
to NN O O
a NN O O
single NN O O
session NN O O
of NN O O
Behavioural NN O O
Activation NN O O
followed NN O O
by NN O O
8 NN O O
weeks NN O O
of NN O O
daily NN O O
SMS NN O O
( NN O O
text NN O O
) NN O O
messages NN O O
in NN O O
the NN O O
form NN O O
of NN O O
implementation NN O O
intentions NN O O
supporting NN O O
individualized NN O O
goals NN O O
for NN O O
increased NN O O
rewarding/ NN O O
meaningful NN O O
activities NN O O
( NN O O
INT NN O O
) NN O O
, NN O O
or NN O O
a NN O O
single NN O O
( NN O O
attention NN O O
control NN O O
) NN O O
session NN O O
focused NN O O
on NN O O
the NN O O
importance NN O O
of NN O O
motivation NN O O
followed NN O O
by NN O O
8 NN O O
weeks NN O O
of NN O O
motivational NN O O
SMS NN O O
messages NN O O
( NN O O
MOT NN O O
) NN O O
. NN O O

Both NN O O
conditions NN O O
resulted NN O O
in NN O O
modestly NN O O
improved NN O O
emotional NN O O
status NN O O
. NN O O

The NN O O
INT NN O O
condition NN O O
led NN O O
to NN O O
more NN O O
exposure NN O O
to NN O O
environmental NN O O
reward NN O O
and NN O O
greater NN O O
productivity NN O O
. NN O O

Gains NN O O
in NN O O
both NN O O
conditions NN O O
were NN O O
of NN O O
questionable NN O O
clinical NN O O
significance NN O O
but NN O O
suggested NN O O
different NN O O
mechanisms NN O O
of NN O O
action NN O O
, NN O O
which NN O O
should NN O O
be NN O O
confirmed NN O O
by NN O O
further NN O O
research NN O O
. NN O O

The NN O O
delivery NN O O
of NN O O
frequent NN O O
text NN O O
messages NN O O
proved NN O O
to NN O O
be NN O O
a NN O O
very NN O O
feasible NN O O
means NN O O
of NN O O
supporting NN O O
treatment NN O O
in NN O O
this NN O O
population NN O O
. NN O O



-DOCSTART- (30556832)

Limited NN O O
evidence NN O O
supports NN O O
mobile NN O O
phone-delivered NN O O
cessation NN O O
interventions NN O O
for NN O O
socioeconomically NN O O
disadvantaged NN O O
individuals NN O O
. NN O O

To NN O O
assess NN O O
the NN O O
efficacy NN O O
of NN O O
mobile NN O O
phone-delivered NN O O
cessation NN O O
interventions NN O O
targeted NN O O
to NN O O
smokers NN O O
at NN O O
neighborhood NN O O
sites NN O O
serving NN O O
racial/ethnic NN O O
minority NN O O
and NN O O
socioeconomically NN O O
disadvantaged NN O O
individuals NN O O
. NN O O

This NN O O
group-randomized NN O O
clinical NN O O
trial NN O O
with NN O O
neighborhood NN O O
site NN O O
serving NN O O
as NN O O
the NN O O
sampling NN O O
unit NN O O
compared NN O O
smoking NN O O
cessation NN O O
interventions NN O O
that NN O O
included NN O O
( NN O O
1 NN O O
) NN O O
nicotine NN O O
replacement NN O O
therapy NN O O
( NN O O
NRT NN O O
) NN O O
, NN O O
( NN O O
2 NN O O
) NN O O
NRT NN O O
plus NN O O
text NN O O
messaging NN O O
, NN O O
and NN O O
( NN O O
3 NN O O
) NN O O
NRT NN O O
plus NN O O
text NN O O
messaging NN O O
plus NN O O
proactive NN O O
counseling NN O O
via NN O O
mobile NN O O
phone NN O O
. NN O O

Recruitment NN O O
took NN O O
place NN O O
at NN O O
churches NN O O
, NN O O
public NN O O
housing NN O O
complexes NN O O
, NN O O
and NN O O
community NN O O
centers NN O O
located NN O O
throughout NN O O
the NN O O
Houston NN O O
, NN O O
Texas NN O O
, NN O O
area NN O O
. NN O O

A NN O O
total NN O O
of NN O O
624 NN O O
current NN O O
cigarette NN O O
smokers NN O O
18 NN O O
years NN O O
or NN O O
older NN O O
were NN O O
enrolled NN O O
at NN O O
neighborhood NN O O
sites NN O O
from NN O O
August NN O O
13 NN O O
, NN O O
2011 NN O O
, NN O O
through NN O O
December NN O O
12 NN O O
, NN O O
2014 NN O O
. NN O O

Final NN O O
follow-up NN O O
was NN O O
completed NN O O
on NN O O
June NN O O
12 NN O O
, NN O O
2015 NN O O
, NN O O
and NN O O
data NN O O
were NN O O
analyzed NN O O
from NN O O
August NN O O
17 NN O O
, NN O O
2017 NN O O
, NN O O
through NN O O
May NN O O
10 NN O O
, NN O O
2018 NN O O
, NN O O
based NN O O
on NN O O
intention NN O O
to NN O O
treat NN O O
. NN O O

Nicotine NN O O
replacement NN O O
therapy NN O O
consisted NN O O
of NN O O
transdermal NN O O
nicotine NN O O
patches NN O O
; NN O O
NRT NN O O
plus NN O O
text NN O O
messages NN O O
, NN O O
transdermal NN O O
nicotine NN O O
patches NN O O
and NN O O
individually NN O O
tailored NN O O
mobile NN O O
phone NN O O
text NN O O
messages NN O O
; NN O O
and NN O O
NRT NN O O
plus NN O O
text NN O O
plus NN O O
call NN O O
, NN O O
transdermal NN O O
patches NN O O
, NN O O
individually NN O O
tailored NN O O
mobile NN O O
phone NN O O
text NN O O
messages NN O O
, NN O O
and NN O O
proactive NN O O
counseling NN O O
via NN O O
mobile NN O O
phone NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
was NN O O
smoking NN O O
abstinence NN O O
at NN O O
6 NN O O
months NN O O
, NN O O
defined NN O O
as NN O O
( NN O O
1 NN O O
) NN O O
biochemically NN O O
verified NN O O
smoking NN O O
abstinence NN O O
( NN O O
calculated NN O O
among NN O O
a NN O O
subgroup NN O O
of NN O O
377 NN O O
participants NN O O
) NN O O
as NN O O
determined NN O O
by NN O O
saliva NN O O
cotinine NN O O
level NN O O
; NN O O
and NN O O
( NN O O
2 NN O O
) NN O O
self-reported NN O O
30-day NN O O
abstinence NN O O
( NN O O
calculated NN O O
among NN O O
all NN O O
624 NN O O
participants NN O O
) NN O O
. NN O O

The NN O O
study NN O O
sample NN O O
included NN O O
624 NN O O
current NN O O
cigarette NN O O
smokers NN O O
( NN O O
50.6 NN O O
% NN O O
female NN O O
; NN O O
mean NN O O
[ NN O O
SD NN O O
] NN O O
age NN O O
, NN O O
45.8 NN O O
[ NN O O
12.8 NN O O
] NN O O
years NN O O
) NN O O
. NN O O

Among NN O O
the NN O O
377 NN O O
participants NN O O
eligible NN O O
for NN O O
biochemical NN O O
verification NN O O
, NN O O
127 NN O O
self-reported NN O O
30-day NN O O
abstinence NN O O
and NN O O
were NN O O
asked NN O O
to NN O O
provide NN O O
saliva NN O O
samples NN O O
. NN O O

Of NN O O
these NN O O
, NN O O
98 NN O O
samples NN O O
were NN O O
returned NN O O
( NN O O
participants NN O O
who NN O O
did NN O O
not NN O O
return NN O O
samples NN O O
were NN O O
coded NN O O
as NN O O
smoking NN O O
) NN O O
. NN O O

Biochemically NN O O
verified NN O O
abstinence NN O O
rates NN O O
were NN O O
12.0 NN O O
% NN O O
for NN O O
NRT NN O O
, NN O O
12.0 NN O O
% NN O O
for NN O O
NRT NN O O
plus NN O O
text NN O O
, NN O O
and NN O O
25.5 NN O O
% NN O O
for NN O O
NRT NN O O
plus NN O O
text NN O O
plus NN O O
call NN O O
. NN O O

Participants NN O O
in NN O O
the NN O O
NRT NN O O
plus NN O O
text NN O O
plus NN O O
call NN O O
group NN O O
were NN O O
2.11 NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
1.00 NN O O
- NN O O
4.48 NN O O
) NN O O
times NN O O
more NN O O
likely NN O O
to NN O O
be NN O O
biochemically NN O O
verified NN O O
as NN O O
abstinent NN O O
compared NN O O
with NN O O
the NN O O
NRT NN O O
group NN O O
. NN O O

No NN O O
differences NN O O
in NN O O
biochemically NN O O
verified NN O O
abstinence NN O O
between NN O O
the NN O O
NRT NN O O
plus NN O O
text NN O O
group NN O O
and NN O O
the NN O O
NRT NN O O
group NN O O
were NN O O
observed NN O O
. NN O O

Similar NN O O
associations NN O O
were NN O O
observed NN O O
with NN O O
the NN O O
self-report NN O O
cessation NN O O
outcomes NN O O
. NN O O

Findings NN O O
indicate NN O O
that NN O O
assignment NN O O
to NN O O
an NN O O
intervention NN O O
consisting NN O O
of NN O O
text NN O O
messaging NN O O
alone NN O O
may NN O O
not NN O O
increase NN O O
cessation NN O O
rates NN O O
for NN O O
socioeconomically NN O O
disadvantaged NN O O
smokers NN O O
. NN O O

However NN O O
, NN O O
text NN O O
messaging NN O O
plus NN O O
proactive NN O O
counseling NN O O
may NN O O
be NN O O
an NN O O
efficacious NN O O
option NN O O
. NN O O

ClinicalTrials.gov NN O O
identifier NN O O
: NN O O
NCT00948129 NN O O
. NN O O



-DOCSTART- (30541572)

Proprietary NN O O
spearmint NN O O
extract NN O O
( NN O O
PSE NN O O
) NN O O
containing NN O O
a NN O O
minimum NN O O
14.5 NN O O
% NN O O
rosmarinic NN O O
acid NN O O
and NN O O
24 NN O O
% NN O O
total NN O O
phenolic NN O O
content NN O O
, NN O O
has NN O O
evinced NN O O
positive NN O O
effects NN O O
on NN O O
cognition NN O O
in NN O O
individuals NN O O
aged NN O O
50 NN O O
- NN O O
70 NN O O
with NN O O
memory NN O O
impairment NN O O
after NN O O
chronic NN O O
supplementation NN O O
. NN O O

To NN O O
address NN O O
the NN O O
growing NN O O
interest NN O O
in NN O O
connecting NN O O
mental NN O O
and NN O O
physical NN O O
performance NN O O
, NN O O
the NN O O
present NN O O
study NN O O
examined NN O O
whether NN O O
the NN O O
nootropic NN O O
effects NN O O
of NN O O
PSE NN O O
translate NN O O
into NN O O
changes NN O O
in NN O O
reactive NN O O
agility NN O O
following NN O O
daily NN O O
supplementation NN O O
with NN O O
PSE NN O O
. NN O O

Utilizing NN O O
a NN O O
randomized NN O O
, NN O O
double-blind NN O O
, NN O O
placebo-controlled NN O O
, NN O O
parallel NN O O
design NN O O
, NN O O
healthy NN O O
, NN O O
recreationally-active NN O O
men NN O O
and NN O O
women NN O O
( NN O O
n NN O O
= NN O O
142 NN O O
) NN O O
received NN O O
900 NN O O
mg NN O O
of NN O O
PSE NN O O
or NN O O
placebo NN O O
( NN O O
PLA NN O O
) NN O O
daily NN O O
for NN O O
90 NN O O
days NN O O
. NN O O

Reactive NN O O
agility NN O O
, NN O O
our NN O O
primary NN O O
outcome NN O O
, NN O O
was NN O O
determined NN O O
by NN O O
measuring NN O O
the NN O O
number NN O O
of NN O O
hits NN O O
and NN O O
average NN O O
reaction NN O O
time NN O O
( NN O O
ART NN O O
) NN O O
on NN O O
a NN O O
Makoto NN O O
Arena NN O O
II NN O O
, NN O O
a NN O O
360 NN O O
audio-visual NN O O
device NN O O
that NN O O
measures NN O O
stationary NN O O
, NN O O
lateral NN O O
, NN O O
and NN O O
multi-directional NN O O
active NN O O
choice NN O O
reaction NN O O
performance NN O O
. NN O O

Safety NN O O
was NN O O
evaluated NN O O
using NN O O
complete NN O O
blood NN O O
count NN O O
, NN O O
comprehensive NN O O
metabolic NN O O
panel NN O O
, NN O O
and NN O O
blood NN O O
lipids NN O O
. NN O O

Measurements NN O O
were NN O O
evaluated NN O O
on NN O O
days NN O O
7 NN O O
, NN O O
30 NN O O
, NN O O
and NN O O
90 NN O O
of NN O O
supplementation NN O O
. NN O O

An NN O O
overall NN O O
treatment NN O O
effect NN O O
( NN O O
p NN O O
= NN O O
0.019 NN O O
) NN O O
was NN O O
evident NN O O
for NN O O
increased NN O O
hits NN O O
with NN O O
PSE NN O O
on NN O O
the NN O O
stationary NN O O
test NN O O
with NN O O
footplates NN O O
, NN O O
with NN O O
between NN O O
group NN O O
differences NN O O
at NN O O
Day NN O O
30 NN O O
( NN O O
PSE NN O O
vs. NN O O
PLA NN O O
: NN O O
28.96 NN O O
± NN O O
2.08 NN O O
vs. NN O O
28.09 NN O O
± NN O O
1.92 NN O O
hits NN O O
; NN O O
p NN O O
= NN O O
0.040 NN O O
) NN O O
and NN O O
Day NN O O
90 NN O O
( NN O O
PSE NN O O
vs. NN O O
PLA NN O O
: NN O O
28.42 NN O O
± NN O O
2.54 NN O O
vs. NN O O
27.02 NN O O
± NN O O
3.55 NN O O
hits NN O O
; NN O O
p NN O O
= NN O O
0.002 NN O O
) NN O O
. NN O O

On NN O O
the NN O O
same NN O O
task NN O O
, NN O O
ART NN O O
improved NN O O
( NN O O
treatment NN O O
effect NN O O
, NN O O
p NN O O
= NN O O
0.036 NN O O
) NN O O
with NN O O
PSE NN O O
at NN O O
Day NN O O
7 NN O O
( NN O O
PSE NN O O
vs. NN O O
PLA NN O O
: NN O O
0.5896 NN O O
± NN O O
0.060 NN O O
vs. NN O O
0.6141 NN O O
± NN O O
0.073 NN O O
s NN O O
; NN O O
p NN O O
= NN O O
0.049 NN O O
) NN O O
and NN O O
Day NN O O
30 NN O O
( NN O O
PSE NN O O
vs. NN O O
PLA NN O O
: NN O O
0.5811 NN O O
± NN O O
0.068 NN O O
vs. NN O O
0.6033 NN O O
± NN O O
0.055 NN O O
s NN O O
; NN O O
p NN O O
= NN O O
0.049 NN O O
) NN O O
. NN O O

PSE NN O O
also NN O O
significantly NN O O
increased NN O O
hits NN O O
( NN O O
treatment NN O O
effect NN O O
, NN O O
p NN O O
= NN O O
0.020 NN O O
) NN O O
at NN O O
Day NN O O
30 NN O O
( NN O O
PSE NN O O
vs. NN O O
PLA NN O O
: NN O O
19.25 NN O O
± NN O O
1.84 NN O O
vs. NN O O
18.45 NN O O
± NN O O
1.48 NN O O
hits NN O O
; NN O O
p NN O O
= NN O O
0.007 NN O O
) NN O O
and NN O O
Day NN O O
90 NN O O
( NN O O
PSE NN O O
vs. NN O O
PLA NN O O
: NN O O
19.39 NN O O
± NN O O
1.90 NN O O
vs. NN O O
18.66 NN O O
± NN O O
1.64 NN O O
hits NN O O
; NN O O
p NN O O
= NN O O
0.026 NN O O
) NN O O
for NN O O
the NN O O
multi-directional NN O O
test NN O O
with NN O O
footplates NN O O
. NN O O

Significant NN O O
differences NN O O
were NN O O
not NN O O
observed NN O O
in NN O O
the NN O O
remaining NN O O
Makoto NN O O
tests NN O O
. NN O O

PSE NN O O
was NN O O
well NN O O
tolerated NN O O
as NN O O
evidenced NN O O
by NN O O
no NN O O
effects NN O O
observed NN O O
in NN O O
the NN O O
blood NN O O
safety NN O O
panels NN O O
. NN O O

The NN O O
findings NN O O
of NN O O
the NN O O
current NN O O
study NN O O
demonstrate NN O O
that NN O O
consumption NN O O
of NN O O
900 NN O O
mg NN O O
of NN O O
PSE NN O O
improved NN O O
specific NN O O
measures NN O O
of NN O O
reactive NN O O
agility NN O O
in NN O O
a NN O O
young NN O O
, NN O O
active NN O O
population NN O O
. NN O O

clinicaltrials.gov NN O O
, NN O O
NCT02518165 NN O O
. NN O O

Registered NN O O
August NN O O
7 NN O O
, NN O O
2015 NN O O
- NN O O
retrospectively NN O O
registered NN O O
. NN O O



-DOCSTART- (30771559)

Improving NN O O
children NN O O
's NN O O
tap NN O O
water NN O O
intake NN O O
and NN O O
reducing NN O O
sugar-sweetened NN O O
beverage NN O O
( NN O O
SSB NN O O
) NN O O
consumption NN O O
is NN O O
beneficial NN O O
for NN O O
health NN O O
and NN O O
health NN O O
equity NN O O
, NN O O
particularly NN O O
in NN O O
low-income NN O O
communities NN O O
and NN O O
communities NN O O
of NN O O
color NN O O
. NN O O

Existing NN O O
community NN O O
level NN O O
interventions NN O O
to NN O O
improve NN O O
the NN O O
intake NN O O
of NN O O
tap NN O O
water NN O O
have NN O O
predominantly NN O O
occurred NN O O
in NN O O
schools NN O O
and NN O O
have NN O O
focused NN O O
on NN O O
promoting NN O O
water NN O O
consumption NN O O
in NN O O
cafeterias NN O O
during NN O O
lunch NN O O
or NN O O
snack NN O O
periods NN O O
. NN O O

The NN O O
" NN O O
Hydrate NN O O
Philly NN O O
" NN O O
intervention NN O O
was NN O O
developed NN O O
to NN O O
target NN O O
multiple NN O O
environmental NN O O
and NN O O
social NN O O
factors NN O O
to NN O O
improve NN O O
tap NN O O
water NN O O
consumption NN O O
in NN O O
community NN O O
recreation NN O O
centers NN O O
in NN O O
low-income NN O O
communities NN O O
: NN O O
replacing NN O O
old NN O O
and NN O O
unappealing NN O O
water NN O O
fountains NN O O
with NN O O
appealing NN O O
water-bottle-filling NN O O
" NN O O
hydration NN O O
stations NN O O
" NN O O
, NN O O
conducting NN O O
water NN O O
safety NN O O
testing NN O O
and NN O O
publicizing NN O O
results NN O O
, NN O O
disseminating NN O O
reusable NN O O
water NN O O
bottles NN O O
, NN O O
promoting NN O O
tap NN O O
water NN O O
, NN O O
and NN O O
discouraging NN O O
SSB NN O O
consumption NN O O
. NN O O

Efficacy NN O O
of NN O O
the NN O O
intervention NN O O
will NN O O
be NN O O
tested NN O O
through NN O O
a NN O O
group-randomized NN O O
controlled NN O O
trial NN O O
( NN O O
n NN O O
= NN O O
28 NN O O
centers NN O O
) NN O O
of NN O O
the NN O O
intervention NN O O
's NN O O
impact NN O O
on NN O O
center-level NN O O
water NN O O
fountain/station NN O O
use NN O O
as NN O O
measured NN O O
by NN O O
flow NN O O
meters NN O O
during NN O O
a NN O O
youth NN O O
summer NN O O
camp NN O O
program NN O O
primarily NN O O
for NN O O
children NN O O
aged NN O O
6 NN O O
- NN O O
12 NN O O
years NN O O
. NN O O

Intervention NN O O
impact NN O O
on NN O O
the NN O O
primary NN O O
outcome NN O O
( NN O O
use NN O O
of NN O O
drinking NN O O
water NN O O
sources NN O O
) NN O O
will NN O O
be NN O O
examined NN O O
with NN O O
a NN O O
difference-in-differences NN O O
approach NN O O
using NN O O
an NN O O
ordinary NN O O
least NN O O
squares NN O O
regression NN O O
model NN O O
for NN O O
analysis NN O O
at NN O O
the NN O O
center NN O O
level NN O O
. NN O O

Secondary NN O O
outcomes NN O O
include NN O O
SSBs NN O O
brought NN O O
to NN O O
summer NN O O
camp NN O O
, NN O O
reusable NN O O
and NN O O
single-use NN O O
bottled NN O O
water NN O O
use NN O O
, NN O O
program NN O O
trash NN O O
, NN O O
and NN O O
recreation NN O O
center NN O O
staff NN O O
SSB NN O O
consumption NN O O
. NN O O

Multilevel NN O O
approaches NN O O
are NN O O
needed NN O O
to NN O O
increase NN O O
tap NN O O
water NN O O
intake NN O O
and NN O O
decrease NN O O
SSB NN O O
consumption NN O O
among NN O O
low-income NN O O
and NN O O
minority NN O O
youth NN O O
beyond NN O O
school NN O O
and NN O O
meal NN O O
settings NN O O
. NN O O

The NN O O
current NN O O
study NN O O
describes NN O O
the NN O O
Hydrate NN O O
Philly NN O O
intervention NN O O
, NN O O
the NN O O
study NN O O
design NN O O
, NN O O
and NN O O
baseline NN O O
characteristics NN O O
of NN O O
recreation NN O O
centers NN O O
participating NN O O
in NN O O
the NN O O
study NN O O
. NN O O

ClinicalTrials.gov NN O O
Registration NN O O
: NN O O
# NN O O
NCT03637465 NN O O
. NN O O



-DOCSTART- (31248392)

Sexual NN O O
violence NN O O
against NN O O
adolescents NN O O
is NN O O
prevalent NN O O
worldwide NN O O
and NN O O
results NN O O
in NN O O
significant NN O O
physical NN O O
and NN O O
mental NN O O
injuries NN O O
as NN O O
well NN O O
as NN O O
loss NN O O
of NN O O
economic NN O O
and NN O O
personal NN O O
potential NN O O
. NN O O

Urban NN O O
informal NN O O
settlements NN O O
such NN O O
as NN O O
those NN O O
around NN O O
Nairobi NN O O
, NN O O
Kenya NN O O
have NN O O
been NN O O
shown NN O O
to NN O O
have NN O O
especially NN O O
high NN O O
incidences NN O O
of NN O O
violence NN O O
. NN O O

Research NN O O
has NN O O
shown NN O O
that NN O O
empowerment NN O O
interventions NN O O
for NN O O
female NN O O
adolescents NN O O
can NN O O
reduce NN O O
sexual NN O O
assault NN O O
. NN O O

However NN O O
, NN O O
these NN O O
interventions NN O O
have NN O O
had NN O O
limited NN O O
testing NN O O
in NN O O
urban NN O O
informal NN O O
settlements NN O O
, NN O O
with NN O O
young NN O O
adolescents NN O O
, NN O O
or NN O O
in NN O O
coordination NN O O
with NN O O
complementary NN O O
programs NN O O
for NN O O
male NN O O
adolescents NN O O
. NN O O

This NN O O
study NN O O
was NN O O
a NN O O
two-arm NN O O
, NN O O
parallel NN O O
, NN O O
cluster-randomized NN O O
trial NN O O
testing NN O O
a NN O O
combination NN O O
of NN O O
a NN O O
previously-tested NN O O
girls NN O O
' NN O O
intervention NN O O
, NN O O
IMPower NN O O
, NN O O
and NN O O
a NN O O
newly NN O O
revised NN O O
boys NN O O
' NN O O
intervention NN O O
, NN O O
Source NN O O
of NN O O
Strength NN O O
. NN O O

Clusters NN O O
were NN O O
defined NN O O
as NN O O
schools NN O O
within NN O O
the NN O O
informal NN O O
settlements NN O O
; NN O O
participants NN O O
were NN O O
adolescent NN O O
girls NN O O
and NN O O
boys NN O O
in NN O O
class NN O O
6 NN O O
, NN O O
generally NN O O
between NN O O
the NN O O
ages NN O O
of NN O O
10 NN O O
- NN O O
14 NN O O
at NN O O
baseline NN O O
. NN O O

Data NN O O
collection NN O O
began NN O O
in NN O O
January NN O O
2016 NN O O
and NN O O
continued NN O O
through NN O O
December NN O O
2018 NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
was NN O O
the NN O O
change NN O O
in NN O O
incidence NN O O
of NN O O
self-reported NN O O
sexual NN O O
assault NN O O
among NN O O
girls NN O O
from NN O O
baseline NN O O
, NN O O
compared NN O O
to NN O O
a NN O O
life NN O O
skills NN O O
standard NN O O
of NN O O
care NN O O
intervention NN O O
. NN O O

Secondary NN O O
outcomes NN O O
included NN O O
experiences NN O O
of NN O O
physical NN O O
and NN O O
emotional NN O O
violence NN O O
, NN O O
as NN O O
well NN O O
as NN O O
determining NN O O
the NN O O
effects NN O O
of NN O O
the NN O O
intervention NN O O
on NN O O
self-efficacy NN O O
, NN O O
self-esteem NN O O
, NN O O
and NN O O
gender NN O O
attitudes NN O O
and NN O O
beliefs NN O O
, NN O O
and NN O O
how NN O O
those NN O O
effects NN O O
led NN O O
to NN O O
changes NN O O
in NN O O
experience NN O O
of NN O O
sexual NN O O
assault NN O O
. NN O O

For NN O O
the NN O O
primary NN O O
outcome NN O O
and NN O O
several NN O O
of NN O O
the NN O O
secondary NN O O
outcomes NN O O
, NN O O
we NN O O
used NN O O
an NN O O
intention NN O O
to NN O O
treat NN O O
estimand NN O O
. NN O O

This NN O O
was NN O O
the NN O O
first NN O O
randomized NN O O
controlled NN O O
trial NN O O
with NN O O
longitudinal NN O O
follow-up NN O O
of NN O O
an NN O O
empowerment NN O O
self-defense NN O O
approach NN O O
to NN O O
violence NN O O
prevention NN O O
for NN O O
adolescents NN O O
in NN O O
informal NN O O
settlements NN O O
. NN O O

The NN O O
large NN O O
size NN O O
and NN O O
rigorous NN O O
design NN O O
supported NN O O
analysis NN O O
to NN O O
understand NN O O
multiple NN O O
subgroup NN O O
experiences NN O O
in NN O O
the NN O O
hypothesized NN O O
reduction NN O O
in NN O O
sexual NN O O
assault NN O O
. NN O O

The NN O O
study NN O O
was NN O O
also NN O O
unique NN O O
in NN O O
its NN O O
focus NN O O
on NN O O
young NN O O
( NN O O
10 NN O O
- NN O O
14 NN O O
years NN O O
of NN O O
age NN O O
) NN O O
adolescents NN O O
and NN O O
in NN O O
engaging NN O O
both NN O O
boys NN O O
and NN O O
girls NN O O
in NN O O
separate NN O O
but NN O O
coordinated NN O O
curriculums NN O O
. NN O O

The NN O O
focus NN O O
on NN O O
a NN O O
highly NN O O
vulnerable NN O O
and NN O O
understudied NN O O
population NN O O
will NN O O
make NN O O
it NN O O
a NN O O
significant NN O O
contribution NN O O
to NN O O
the NN O O
literature NN O O
on NN O O
violence NN O O
prevention NN O O
. NN O O

Clinical NN O O
Trials.gov NN O O
# NN O O
NCT02771132 NN O O
. NN O O

Version NN O O
3.1 NN O O
registered NN O O
May NN O O
2017 NN O O
, NN O O
first NN O O
participant NN O O
enrolled NN O O
January NN O O
2017 NN O O
. NN O O

Retrospectively NN O O
registered NN O O
. NN O O



-DOCSTART- (30541492)

Childhood NN O O
abuse NN O O
related NN O O
posttraumatic NN O O
stress NN O O
disorder NN O O
( NN O O
CA-PTSD NN O O
) NN O O
is NN O O
associated NN O O
with NN O O
a NN O O
high NN O O
burden NN O O
of NN O O
disease NN O O
and NN O O
with NN O O
treatment NN O O
response NN O O
rates NN O O
that NN O O
leave NN O O
room NN O O
for NN O O
improvement NN O O
. NN O O

One NN O O
of NN O O
the NN O O
treatments NN O O
for NN O O
PTSD NN O O
, NN O O
prolonged NN O O
exposure NN O O
( NN O O
PE NN O O
) NN O O
, NN O O
is NN O O
effective NN O O
but NN O O
has NN O O
high NN O O
drop-out NN O O
rates NN O O
and NN O O
remission NN O O
rates NN O O
are NN O O
relatively NN O O
low NN O O
. NN O O

An NN O O
intensified NN O O
form NN O O
of NN O O
PE NN O O
( NN O O
iPE NN O O
) NN O O
was NN O O
associated NN O O
with NN O O
good NN O O
response NN O O
and NN O O
low NN O O
drop-out NN O O
rates NN O O
in NN O O
PTSD NN O O
and NN O O
has NN O O
not NN O O
yet NN O O
been NN O O
tested NN O O
in NN O O
a NN O O
controlled NN O O
trial NN O O
in NN O O
CA-PTSD NN O O
. NN O O

Phase-based NN O O
treatment NN O O
( NN O O
PBT NN O O
) NN O O
, NN O O
in NN O O
which NN O O
PE NN O O
is NN O O
preceded NN O O
by NN O O
skills NN O O
training NN O O
may NN O O
improve NN O O
overall NN O O
outcomes NN O O
in NN O O
this NN O O
population NN O O
. NN O O

We NN O O
will NN O O
assess NN O O
the NN O O
effectiveness NN O O
and NN O O
cost-effectiveness NN O O
of NN O O
standard NN O O
PE NN O O
, NN O O
iPE NN O O
and NN O O
PBT NN O O
in NN O O
patients NN O O
with NN O O
CA-PTSD NN O O
. NN O O

Multi-center NN O O
randomized NN O O
controlled NN O O
trial NN O O
. NN O O

Treatment NN O O
conditions NN O O
are NN O O
: NN O O
prolonged NN O O
exposure NN O O
( NN O O
PE NN O O
; NN O O
maximum NN O O
of NN O O
16 NN O O
sessions NN O O
in NN O O
16 NN O O
weeks NN O O
) NN O O
; NN O O
intensified NN O O
PE NN O O
( NN O O
iPE NN O O
; NN O O
maximum NN O O
of NN O O
12 NN O O
sessions NN O O
in NN O O
four NN O O
weeks NN O O
and NN O O
two NN O O
booster NN O O
sessions NN O O
) NN O O
; NN O O
phase-based NN O O
treatment NN O O
( NN O O
PBT NN O O
; NN O O
maximum NN O O
of NN O O
eight NN O O
sessions NN O O
skills NN O O
training NN O O
followed NN O O
by NN O O
eight NN O O
sessions NN O O
PE NN O O
in NN O O
16 NN O O
weeks NN O O
) NN O O
. NN O O

Clinician-rated NN O O
PTSD NN O O
symptom NN O O
severity NN O O
. NN O O

loss NN O O
of NN O O
PTSD NN O O
diagnosis NN O O
, NN O O
self-reported NN O O
PTSD NN O O
symptom NN O O
severity NN O O
, NN O O
comorbid NN O O
symptom NN O O
severity NN O O
and NN O O
quality NN O O
of NN O O
life NN O O
. NN O O

Moreover NN O O
, NN O O
we NN O O
will NN O O
examine NN O O
cost-effectiveness NN O O
and NN O O
moderators NN O O
and NN O O
mediators NN O O
of NN O O
treatment NN O O
outcome NN O O
. NN O O

adults NN O O
with NN O O
CA-PTSD NN O O
( NN O O
N NN O O
= NN O O
150 NN O O
) NN O O
. NN O O

Assessments NN O O
in NN O O
weeks NN O O
0 NN O O
, NN O O
4 NN O O
, NN O O
8 NN O O
, NN O O
16 NN O O
, NN O O
26 NN O O
and NN O O
52 NN O O
. NN O O

Given NN O O
that NN O O
no NN O O
consensus NN O O
yet NN O O
exists NN O O
about NN O O
the NN O O
treatment NN O O
guidelines NN O O
for NN O O
patients NN O O
with NN O O
CA-PTSD NN O O
, NN O O
the NN O O
present NN O O
study NN O O
may NN O O
have NN O O
important NN O O
implications NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
CA-PTSD NN O O
. NN O O

Registered NN O O
at NN O O
C.C.M.O. NN O O
on NN O O
Sept NN O O
7 NN O O
, NN O O
2016 NN O O
( NN O O
NL57984.058.16 NN O O
) NN O O
; NN O O
retrospectively NN O O
registered NN O O
at NN O O
June NN O O
21 NN O O
, NN O O
2017 NN O O
at NN O O
clinicaltrials.gov NN O O
identifier NN O O
: NN O O
NCT03194113 NN O O
. NN O O



-DOCSTART- (30591073)

Despite NN O O
the NN O O
high NN O O
prevalence NN O O
of NN O O
insomnia NN O O
in NN O O
patients NN O O
with NN O O
advanced NN O O
cancer NN O O
, NN O O
there NN O O
are NN O O
no NN O O
randomized NN O O
controlled NN O O
trials NN O O
on NN O O
pharmacological NN O O
interventions NN O O
for NN O O
insomnia NN O O
in NN O O
this NN O O
group NN O O
of NN O O
patients NN O O
. NN O O

A NN O O
variety NN O O
of NN O O
pharmacological NN O O
agents NN O O
is NN O O
recommended NN O O
to NN O O
manage NN O O
sleep NN O O
disturbance NN O O
for NN O O
insomnia NN O O
in NN O O
the NN O O
general NN O O
population NN O O
, NN O O
but NN O O
their NN O O
efficacy NN O O
and NN O O
safety NN O O
in NN O O
adults NN O O
with NN O O
advanced NN O O
cancer NN O O
are NN O O
not NN O O
established NN O O
. NN O O

Thus NN O O
, NN O O
there NN O O
is NN O O
a NN O O
need NN O O
to NN O O
evaluate NN O O
the NN O O
effectiveness NN O O
of NN O O
medications NN O O
for NN O O
insomnia NN O O
in NN O O
order NN O O
to NN O O
improve NN O O
the NN O O
evidence NN O O
in NN O O
patients NN O O
with NN O O
advanced NN O O
cancer NN O O
. NN O O

One NN O O
of NN O O
the NN O O
most NN O O
used NN O O
sleep NN O O
medications NN O O
at NN O O
present NN O O
in NN O O
patients NN O O
with NN O O
cancer NN O O
is NN O O
zopiclone NN O O
. NN O O

This NN O O
is NN O O
a NN O O
randomized NN O O
, NN O O
double-blind NN O O
, NN O O
placebo-controlled NN O O
, NN O O
parallel-group NN O O
, NN O O
multicenter NN O O
trial NN O O
. NN O O

A NN O O
total NN O O
of NN O O
100 NN O O
patients NN O O
with NN O O
metastatic NN O O
cancer NN O O
who NN O O
report NN O O
insomnia NN O O
will NN O O
be NN O O
randomly NN O O
allocated NN O O
to NN O O
zopiclone NN O O
or NN O O
placebo NN O O
. NN O O

The NN O O
treatment NN O O
duration NN O O
with NN O O
zopiclone/placebo NN O O
is NN O O
6 NN O O
consecutive NN O O
nights NN O O
. NN O O

The NN O O
primary NN O O
endpoint NN O O
is NN O O
patient-reported NN O O
sleep NN O O
quality NN O O
during NN O O
the NN O O
final NN O O
study NN O O
night NN O O
( NN O O
night NN O O
6 NN O O
) NN O O
assessed NN O O
on NN O O
a NN O O
numerical NN O O
rating NN O O
scale NN O O
of NN O O
0 NN O O
- NN O O
10 NN O O
, NN O O
where NN O O
0 NN O O
= NN O O
Best NN O O
sleep NN O O
and NN O O
10 NN O O
= NN O O
Worst NN O O
possible NN O O
sleep NN O O
. NN O O

Secondary NN O O
endpoints NN O O
include NN O O
the NN O O
mean NN O O
patient-reported NN O O
total NN O O
sleep NN O O
time NN O O
and NN O O
sleep NN O O
onset NN O O
latency NN O O
during NN O O
the NN O O
final NN O O
study NN O O
night NN O O
( NN O O
night NN O O
6 NN O O
) NN O O
. NN O O

Results NN O O
from NN O O
this NN O O
study NN O O
on NN O O
treatment NN O O
of NN O O
insomnia NN O O
in NN O O
advanced NN O O
cancer NN O O
will NN O O
contribute NN O O
to NN O O
clinical NN O O
decision-making NN O O
and NN O O
improve NN O O
the NN O O
treatment NN O O
of NN O O
sleep NN O O
disturbance NN O O
in NN O O
this NN O O
patient NN O O
cohort NN O O
. NN O O

ClinicalTrials.gov NN O O
, NN O O
NCT02807922 NN O O
. NN O O

Registered NN O O
on NN O O
21 NN O O
June NN O O
2016 NN O O
. NN O O



-DOCSTART- (31399071)

Young NN O O
gay NN O O
and NN O O
bisexual NN O O
men NN O O
disproportionately NN O O
experience NN O O
depression NN O O
, NN O O
anxiety NN O O
, NN O O
and NN O O
substance NN O O
use NN O O
problems NN O O
and NN O O
are NN O O
among NN O O
the NN O O
highest NN O O
risk NN O O
group NN O O
for NN O O
HIV NN O O
infection NN O O
in NN O O
the NN O O
U.S. NN O O
Diverse NN O O
methods NN O O
locate NN O O
the NN O O
source NN O O
of NN O O
these NN O O
health NN O O
disparities NN O O
in NN O O
young NN O O
gay NN O O
and NN O O
bisexual NN O O
men NN O O
's NN O O
exposure NN O O
to NN O O
minority NN O O
stress NN O O
. NN O O

In NN O O
fact NN O O
, NN O O
minority NN O O
stress NN O O
, NN O O
psychiatric NN O O
morbidity NN O O
, NN O O
substance NN O O
use NN O O
, NN O O
and NN O O
HIV NN O O
risk NN O O
fuel NN O O
each NN O O
other NN O O
, NN O O
forming NN O O
a NN O O
synergistic NN O O
threat NN O O
to NN O O
young NN O O
gay NN O O
and NN O O
bisexual NN O O
men NN O O
's NN O O
health NN O O
. NN O O

Yet NN O O
no NN O O
known NN O O
intervention NN O O
addresses NN O O
minority NN O O
stress NN O O
to NN O O
improve NN O O
mental NN O O
health NN O O
, NN O O
substance NN O O
use NN O O
problems NN O O
, NN O O
or NN O O
their NN O O
joint NN O O
impact NN O O
on NN O O
HIV NN O O
risk NN O O
in NN O O
this NN O O
population NN O O
. NN O O

This NN O O
paper NN O O
describes NN O O
the NN O O
design NN O O
of NN O O
a NN O O
study NN O O
to NN O O
test NN O O
the NN O O
efficacy NN O O
of NN O O
such NN O O
an NN O O
intervention NN O O
, NN O O
called NN O O
ESTEEM NN O O
( NN O O
Effective NN O O
Skills NN O O
to NN O O
Empower NN O O
Effective NN O O
Men NN O O
) NN O O
, NN O O
a NN O O
10-session NN O O
skills-building NN O O
intervention NN O O
designed NN O O
to NN O O
reduce NN O O
young NN O O
gay NN O O
and NN O O
bisexual NN O O
men NN O O
's NN O O
co-occurring NN O O
health NN O O
risks NN O O
by NN O O
addressing NN O O
the NN O O
underlying NN O O
cognitive NN O O
, NN O O
affective NN O O
, NN O O
and NN O O
behavioral NN O O
pathways NN O O
through NN O O
which NN O O
minority NN O O
stress NN O O
impairs NN O O
health NN O O
. NN O O

This NN O O
study NN O O
, NN O O
funded NN O O
by NN O O
the NN O O
National NN O O
Institute NN O O
of NN O O
Mental NN O O
Health NN O O
, NN O O
is NN O O
a NN O O
three-arm NN O O
randomized NN O O
controlled NN O O
trial NN O O
to NN O O
examine NN O O
( NN O O
1 NN O O
) NN O O
the NN O O
efficacy NN O O
of NN O O
ESTEEM NN O O
compared NN O O
to NN O O
community NN O O
mental NN O O
health NN O O
treatment NN O O
and NN O O
HIV NN O O
counseling NN O O
and NN O O
testing NN O O
and NN O O
( NN O O
2 NN O O
) NN O O
whether NN O O
ESTEEM NN O O
works NN O O
through NN O O
its NN O O
hypothesized NN O O
cognitive NN O O
, NN O O
affective NN O O
, NN O O
and NN O O
behavioral NN O O
minority NN O O
stress NN O O
processes NN O O
. NN O O

Our NN O O
primary NN O O
outcome NN O O
, NN O O
measured NN O O
8 NN O O
months NN O O
after NN O O
baseline NN O O
, NN O O
is NN O O
condomless NN O O
anal NN O O
sex NN O O
in NN O O
the NN O O
absence NN O O
of NN O O
PrEP NN O O
or NN O O
known NN O O
undetectable NN O O
viral NN O O
load NN O O
of NN O O
HIV+ NN O O
primary NN O O
partners NN O O
. NN O O

Secondary NN O O
outcomes NN O O
include NN O O
depression NN O O
, NN O O
anxiety NN O O
, NN O O
substance NN O O
use NN O O
, NN O O
sexual NN O O
compulsivity NN O O
, NN O O
and NN O O
PrEP NN O O
uptake NN O O
, NN O O
also NN O O
measured NN O O
8 NN O O
months NN O O
after NN O O
baseline NN O O
. NN O O

Delivering NN O O
specific NN O O
stand-alone NN O O
treatments NN O O
for NN O O
specific NN O O
mental NN O O
, NN O O
behavioral NN O O
, NN O O
and NN O O
sexual NN O O
health NN O O
problems NN O O
represents NN O O
the NN O O
current NN O O
state NN O O
of NN O O
evidence-based NN O O
practice NN O O
. NN O O

However NN O O
, NN O O
dissemination NN O O
and NN O O
implementation NN O O
of NN O O
this NN O O
one NN O O
treatment-one NN O O
problem NN O O
approach NN O O
has NN O O
not NN O O
been NN O O
ideal NN O O
. NN O O

A NN O O
single NN O O
intervention NN O O
that NN O O
reduces NN O O
young NN O O
gay NN O O
and NN O O
bisexual NN O O
men NN O O
's NN O O
depression NN O O
, NN O O
anxiety NN O O
, NN O O
substance NN O O
use NN O O
, NN O O
and NN O O
HIV NN O O
risk NN O O
by NN O O
reducing NN O O
the NN O O
common NN O O
minority NN O O
stress NN O O
pathways NN O O
across NN O O
these NN O O
problems NN O O
would NN O O
represent NN O O
an NN O O
efficient NN O O
, NN O O
cost-effective NN O O
alternative NN O O
to NN O O
currently NN O O
isolated NN O O
approaches NN O O
, NN O O
and NN O O
holds NN O O
great NN O O
promise NN O O
for NN O O
reducing NN O O
sexual NN O O
orientation NN O O
health NN O O
disparities NN O O
among NN O O
young NN O O
men NN O O
. NN O O

Registered NN O O
October NN O O
10 NN O O
, NN O O
2016 NN O O
to NN O O
ClinicalTrials.gov NN O O
Identifier NN O O
: NN O O
NCT02929069 NN O O
. NN O O



-DOCSTART- (31408652)

Peroral NN O O
endoscopic NN O O
myotomy NN O O
( NN O O
POEM NN O O
) NN O O
has NN O O
become NN O O
the NN O O
mainstay NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
achalasia NN O O
at NN O O
many NN O O
institutions NN O O
around NN O O
the NN O O
world NN O O
since NN O O
its NN O O
inception NN O O
in NN O O
2008 NN O O
. NN O O

POEM NN O O
can NN O O
be NN O O
performed NN O O
using NN O O
either NN O O
the NN O O
anterior NN O O
or NN O O
the NN O O
posterior NN O O
approach NN O O
. NN O O

The NN O O
primary NN O O
aim NN O O
of NN O O
this NN O O
study NN O O
was NN O O
to NN O O
compare NN O O
the NN O O
efficacy NN O O
of NN O O
the NN O O
anterior NN O O
and NN O O
posterior NN O O
approaches NN O O
at NN O O
1year NN O O
after NN O O
POEM NN O O
. NN O O

This NN O O
is NN O O
a NN O O
single-blinded NN O O
, NN O O
randomized NN O O
, NN O O
non-inferiority NN O O
international NN O O
clinical NN O O
trial NN O O
. NN O O

Eligible NN O O
participants NN O O
were NN O O
adult NN O O
patients NN O O
with NN O O
a NN O O
confirmed NN O O
diagnosis NN O O
of NN O O
achalasia NN O O
via NN O O
high-resolution NN O O
esophageal NN O O
manometry NN O O
. NN O O

Patients NN O O
were NN O O
randomly NN O O
allocated NN O O
with NN O O
a NN O O
1:1 NN O O
ratio NN O O
to NN O O
receive NN O O
POEM NN O O
with NN O O
anterior NN O O
or NN O O
posterior NN O O
approach NN O O
. NN O O

The NN O O
primary NN O O
aim NN O O
was NN O O
to NN O O
compare NN O O
the NN O O
rate NN O O
of NN O O
clinical NN O O
success NN O O
( NN O O
Eckardt NN O O
score NN O O
<3 NN O O
) NN O O
of NN O O
anterior NN O O
and NN O O
posterior NN O O
approaches NN O O
at NN O O
1 NN O O
year NN O O
. NN O O

A NN O O
total NN O O
of NN O O
150 NN O O
patients NN O O
were NN O O
randomized NN O O
to NN O O
receive NN O O
either NN O O
anterior NN O O
( NN O O
n= NN O O
73 NN O O
) NN O O
or NN O O
posterior NN O O
( NN O O
n= NN O O
77 NN O O
) NN O O
POEM NN O O
. NN O O

A NN O O
total NN O O
of NN O O
148 NN O O
patients NN O O
received NN O O
the NN O O
POEM NN O O
treatment NN O O
and NN O O
a NN O O
total NN O O
of NN O O
138 NN O O
patients NN O O
completed NN O O
the NN O O
1-year NN O O
follow-up NN O O
and NN O O
were NN O O
included NN O O
in NN O O
the NN O O
primary NN O O
efficacy NN O O
analysis NN O O
. NN O O

Technical NN O O
success NN O O
was NN O O
achieved NN O O
in NN O O
71 NN O O
( NN O O
97.3 NN O O
% NN O O
) NN O O
patients NN O O
in NN O O
the NN O O
anterior NN O O
group NN O O
versus NN O O
77 NN O O
( NN O O
100 NN O O
% NN O O
) NN O O
patients NN O O
in NN O O
the NN O O
posterior NN O O
group NN O O
( NN O O
p=0.23 NN O O
) NN O O
. NN O O

The NN O O
median NN O O
( NN O O
interquartile NN O O
range NN O O
) NN O O
length NN O O
of NN O O
hospital NN O O
stay NN O O
after NN O O
the NN O O
procedure NN O O
was NN O O
2 NN O O
( NN O O
1 NN O O
- NN O O
3 NN O O
) NN O O
days NN O O
for NN O O
both NN O O
groups NN O O
. NN O O

Adverse NN O O
events NN O O
occurred NN O O
in NN O O
a NN O O
total NN O O
of NN O O
15 NN O O
( NN O O
10 NN O O
% NN O O
) NN O O
patients NN O O
( NN O O
8 NN O O
patients NN O O
( NN O O
11 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
anterior NN O O
group NN O O
and NN O O
7 NN O O
patients NN O O
( NN O O
9 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
posterior NN O O
group NN O O
; NN O O
p=0.703 NN O O
) NN O O
. NN O O

Clinical NN O O
success NN O O
was NN O O
achieved NN O O
in NN O O
90 NN O O
% NN O O
of NN O O
patients NN O O
in NN O O
the NN O O
anterior NN O O
group NN O O
and NN O O
89 NN O O
% NN O O
of NN O O
patients NN O O
in NN O O
the NN O O
posterior NN O O
group NN O O
. NN O O

Abnormal NN O O
esophageal NN O O
acid NN O O
exposure NN O O
was NN O O
detected NN O O
in NN O O
29 NN O O
out NN O O
of NN O O
59 NN O O
( NN O O
49 NN O O
% NN O O
) NN O O
and NN O O
25 NN O O
out NN O O
of NN O O
60 NN O O
( NN O O
42 NN O O
% NN O O
) NN O O
patients NN O O
in NN O O
the NN O O
anterior NN O O
and NN O O
posterior NN O O
groups NN O O
, NN O O
respectively NN O O
, NN O O
( NN O O
p=0.67 NN O O
) NN O O
. NN O O

GERDQ NN O O
scores NN O O
were NN O O
also NN O O
not NN O O
significantly NN O O
different NN O O
between NN O O
the NN O O
study NN O O
groups NN O O
. NN O O

In NN O O
both NN O O
groups NN O O
, NN O O
quality NN O O
of NN O O
life NN O O
improved NN O O
after NN O O
POEM NN O O
for NN O O
all NN O O
SF-36 NN O O
measures NN O O
and NN O O
was NN O O
similar NN O O
between NN O O
both NN O O
groups NN O O
. NN O O

Posterior NN O O
myotomy NN O O
during NN O O
POEM NN O O
was NN O O
not NN O O
inferior NN O O
to NN O O
anterior NN O O
myotomy NN O O
in NN O O
terms NN O O
of NN O O
efficacy NN O O
and NN O O
safety NN O O
in NN O O
the NN O O
treatment NN O O
of NN O O
patients NN O O
with NN O O
achalasia NN O O
. NN O O

( NN O O
NCT02454335 NN O O
) NN O O
. NN O O



-DOCSTART- (30940189)

The NN O O
benefit NN O O
of NN O O
systemic NN O O
treatments NN O O
in NN O O
esophageal NN O O
squamous NN O O
cell NN O O
carcinoma NN O O
( NN O O
ESCC NN O O
) NN O O
which NN O O
has NN O O
progressed NN O O
after NN O O
chemotherapy NN O O
is NN O O
still NN O O
uncertain NN O O
and NN O O
optimal NN O O
regimens NN O O
based NN O O
on NN O O
randomized NN O O
trials NN O O
have NN O O
not NN O O
yet NN O O
been NN O O
established NN O O
. NN O O

We NN O O
aimed NN O O
to NN O O
compare NN O O
the NN O O
efficacy NN O O
of NN O O
irinotecan NN O O
plus NN O O
S-1 NN O O
with NN O O
S-1 NN O O
monotherapy NN O O
in NN O O
recurrent NN O O
or NN O O
metastatic NN O O
ESCC NN O O
patients NN O O
who NN O O
had NN O O
resistance NN O O
to NN O O
platinum- NN O O
or NN O O
taxane-based NN O O
chemotherapy NN O O
. NN O O

We NN O O
conducted NN O O
a NN O O
prospective NN O O
randomized NN O O
, NN O O
multicenter NN O O
, NN O O
open-label NN O O
, NN O O
phase NN O O
3 NN O O
trial NN O O
in NN O O
15 NN O O
centers NN O O
across NN O O
China NN O O
. NN O O

Eligible NN O O
patients NN O O
were NN O O
adults NN O O
with NN O O
histologically NN O O
confirmed NN O O
recurrent NN O O
or NN O O
metastatic NN O O
ESCC NN O O
, NN O O
and NN O O
were NN O O
randomly NN O O
assigned NN O O
( NN O O
ratio NN O O
, NN O O
1:1 NN O O
) NN O O
to NN O O
receive NN O O
either NN O O
irinotecan NN O O
plus NN O O
S-1 NN O O
( NN O O
intravenous NN O O
infusion NN O O
of NN O O
irinotecan NN O O
[ NN O O
160 NN O O
mg/m NN O O
] NN O O
on NN O O
day NN O O
1 NN O O
and NN O O
oral NN O O
S-1 NN O O
[ NN O O
80 NN O O
- NN O O
120 NN O O
mg NN O O
] NN O O
on NN O O
days NN O O
1 NN O O
- NN O O
10 NN O O
, NN O O
repeated NN O O
every NN O O
14 NN O O
days NN O O
) NN O O
or NN O O
oral NN O O
S-1 NN O O
monotherapy NN O O
( NN O O
80 NN O O
- NN O O
120 NN O O
mg/day NN O O
on NN O O
days NN O O
1 NN O O
- NN O O
14 NN O O
, NN O O
repeated NN O O
every NN O O
21 NN O O
days NN O O
) NN O O
using NN O O
a NN O O
central NN O O
computerized NN O O
minimization NN O O
procedure NN O O
. NN O O

The NN O O
primary NN O O
endpoint NN O O
was NN O O
progression-free NN O O
survival NN O O
( NN O O
PFS NN O O
) NN O O
. NN O O

Between NN O O
December NN O O
23 NN O O
, NN O O
2014 NN O O
and NN O O
July NN O O
25 NN O O
, NN O O
2016 NN O O
, NN O O
we NN O O
screened NN O O
148 NN O O
patients NN O O
and NN O O
randomly NN O O
assigned NN O O
123 NN O O
patients NN O O
to NN O O
receive NN O O
either NN O O
irinotecan NN O O
plus NN O O
S-1 NN O O
regimen NN O O
( NN O O
n NN O O
= NN O O
61 NN O O
) NN O O
or NN O O
S-1 NN O O
monotherapy NN O O
( NN O O
n NN O O
= NN O O
62 NN O O
) NN O O
. NN O O

After NN O O
a NN O O
median NN O O
follow-up NN O O
of NN O O
29.2 NN O O
months NN O O
( NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
[ NN O O
CI NN O O
] NN O O
17.5 NN O O
- NN O O
40.9 NN O O
months NN O O
) NN O O
, NN O O
the NN O O
median NN O O
PFS NN O O
was NN O O
significantly NN O O
longer NN O O
in NN O O
the NN O O
irinotecan NN O O
plus NN O O
S-1 NN O O
group NN O O
than NN O O
in NN O O
the NN O O
S-1 NN O O
monotherapy NN O O
group NN O O
( NN O O
3.8 NN O O
months NN O O
[ NN O O
95 NN O O
% NN O O
CI NN O O
2.9 NN O O
- NN O O
4.3 NN O O
months NN O O
] NN O O
vs. NN O O
1.7 NN O O
months NN O O
[ NN O O
95 NN O O
% NN O O
CI NN O O
1.4 NN O O
- NN O O
2.7 NN O O
months NN O O
] NN O O
, NN O O
hazard NN O O
ratio NN O O
= NN O O
0.58 NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
0.38 NN O O
- NN O O
0.86 NN O O
, NN O O
P NN O O
= NN O O
0.006 NN O O
) NN O O
. NN O O

The NN O O
objective NN O O
response NN O O
rates NN O O
were NN O O
24.6 NN O O
% NN O O
in NN O O
the NN O O
irinotecan NN O O
plus NN O O
S-1 NN O O
group NN O O
and NN O O
9.7 NN O O
% NN O O
in NN O O
the NN O O
S-1 NN O O
monotherapy NN O O
group NN O O
( NN O O
P NN O O
= NN O O
0.002 NN O O
) NN O O
. NN O O

The NN O O
patients NN O O
in NN O O
the NN O O
irinotecan NN O O
plus NN O O
S-1 NN O O
group NN O O
presented NN O O
with NN O O
increased NN O O
rates NN O O
of NN O O
grade NN O O
3 NN O O
- NN O O
4 NN O O
leukopenia NN O O
( NN O O
16.4 NN O O
% NN O O
vs. NN O O
0 NN O O
% NN O O
) NN O O
, NN O O
neutropenia NN O O
( NN O O
14.8 NN O O
% NN O O
vs. NN O O
1.6 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
nausea NN O O
( NN O O
4.9 NN O O
% NN O O
vs. NN O O
0 NN O O
% NN O O
) NN O O
. NN O O

No NN O O
significant NN O O
difference NN O O
in NN O O
grade NN O O
3 NN O O
- NN O O
4 NN O O
diarrhea NN O O
and NN O O
no NN O O
treatment-related NN O O
deaths NN O O
were NN O O
observed NN O O
in NN O O
both NN O O
groups NN O O
. NN O O

The NN O O
combination NN O O
of NN O O
irinotecan NN O O
with NN O O
S-1 NN O O
was NN O O
similarly NN O O
tolerable NN O O
but NN O O
significantly NN O O
prolonged NN O O
PFS NN O O
compared NN O O
to NN O O
S-1 NN O O
monotherapy NN O O
as NN O O
a NN O O
second- NN O O
or NN O O
third-line NN O O
treatment NN O O
in NN O O
patients NN O O
with NN O O
recurrent NN O O
or NN O O
metastatic NN O O
ESCC NN O O
. NN O O

Clinical NN O O
Trial NN O O
Registration NN O O
NCT02319187 NN O O
. NN O O

Registered NN O O
on NN O O
December NN O O
9 NN O O
, NN O O
2014 NN O O
. NN O O



-DOCSTART- (30843421)

To NN O O
evaluate NN O O
the NN O O
efficacy NN O O
of NN O O
electroacupuncture NN O O
( NN O O
EA NN O O
) NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
anxiety NN O O
and NN O O
depression NN O O
in NN O O
unmarried NN O O
patients NN O O
with NN O O
polycystic NN O O
ovarian NN O O
syndrome NN O O
( NN O O
PCOS NN O O
) NN O O
by NN O O
secondary NN O O
analysis NN O O
of NN O O
a NN O O
randomised NN O O
controlled NN O O
trial NN O O
. NN O O

A NN O O
prospective NN O O
pilot NN O O
randomised NN O O
controlled NN O O
trial NN O O
of NN O O
unmarried NN O O
women NN O O
with NN O O
PCOS NN O O
was NN O O
conducted NN O O
from NN O O
November NN O O
2012 NN O O
to NN O O
March NN O O
2016 NN O O
. NN O O

Participants NN O O
were NN O O
assigned NN O O
to NN O O
the NN O O
acupuncture NN O O
group NN O O
( NN O O
receiving NN O O
EA NN O O
for NN O O
16 NN O O
weeks NN O O
) NN O O
or NN O O
the NN O O
control NN O O
group NN O O
( NN O O
receiving NN O O
sham NN O O
acupuncture NN O O
for NN O O
16 NN O O
weeks NN O O
) NN O O
, NN O O
with NN O O
27 NN O O
patients NN O O
in NN O O
each NN O O
group NN O O
. NN O O

The NN O O
pre-specified NN O O
primary NN O O
outcomes NN O O
and NN O O
all NN O O
secondary NN O O
outcomes NN O O
, NN O O
with NN O O
the NN O O
exception NN O O
of NN O O
serum NN O O
levels NN O O
of NN O O
neurotransmitters NN O O
including NN O O
norepinephrine NN O O
( NN O O
NE NN O O
) NN O O
, NN O O
epinephrine NN O O
( NN O O
AD NN O O
) NN O O
, NN O O
serotonin NN O O
( NN O O
5-HT NN O O
) NN O O
and NN O O
γ-aminobutyric NN O O
acid NN O O
( NN O O
GABA NN O O
) NN O O
, NN O O
will NN O O
be NN O O
reported NN O O
separately NN O O
. NN O O

Additional NN O O
outcome NN O O
measures NN O O
selected NN O O
for NN O O
this NN O O
secondary NN O O
analysis NN O O
included NN O O
anxiety NN O O
and NN O O
depression NN O O
scale NN O O
scores NN O O
( NN O O
Zung-SAS NN O O
and NN O O
Zung-SDS NN O O
) NN O O
, NN O O
36-Item NN O O
Short NN O O
Form NN O O
( NN O O
SF-36 NN O O
) NN O O
scale NN O O
scores NN O O
, NN O O
PCOS NN O O
Quality NN O O
of NN O O
Life NN O O
( NN O O
PCOSQOL NN O O
) NN O O
scale NN O O
scores NN O O
and NN O O
Chinese NN O O
Quality NN O O
of NN O O
Life NN O O
( NN O O
CHQOL NN O O
) NN O O
scale NN O O
scores NN O O
. NN O O

After NN O O
the16-week NN O O
intervention NN O O
, NN O O
an NN O O
increase NN O O
in NN O O
serum NN O O
NE NN O O
and NN O O
reduction NN O O
in NN O O
5-HT NN O O
were NN O O
observed NN O O
in NN O O
the NN O O
acupuncture NN O O
group NN O O
( NN O O
P=0.028 NN O O
and NN O O
P=0.023 NN O O
, NN O O
respectively NN O O
) NN O O
. NN O O

The NN O O
serum NN O O
level NN O O
of NN O O
GABA NN O O
decreased NN O O
in NN O O
both NN O O
groups NN O O
after NN O O
the NN O O
interventions NN O O
( NN O O
both NN O O
P<0.001 NN O O
) NN O O
. NN O O

However NN O O
, NN O O
there NN O O
were NN O O
no NN O O
significant NN O O
differences NN O O
between NN O O
the NN O O
two NN O O
groups NN O O
in NN O O
the NN O O
levels NN O O
of NN O O
any NN O O
neurotransmitters NN O O
( NN O O
p>0.05 NN O O
) NN O O
. NN O O

After NN O O
EA NN O O
treatment NN O O
, NN O O
SAS NN O O
and NN O O
SDS NN O O
scores NN O O
were NN O O
decreased NN O O
in NN O O
the NN O O
acupuncture NN O O
group NN O O
( NN O O
P=0.007 NN O O
and NN O O
P=0.027 NN O O
, NN O O
respectively NN O O
) NN O O
and NN O O
were NN O O
lower NN O O
than NN O O
those NN O O
of NN O O
the NN O O
control NN O O
group NN O O
( NN O O
P=0.003 NN O O
and NN O O
P=0.004 NN O O
, NN O O
respectively NN O O
) NN O O
. NN O O

The NN O O
SF-36 NN O O
domain NN O O
scores NN O O
for NN O O
mental NN O O
health NN O O
, NN O O
vitality NN O O
, NN O O
social NN O O
functioning NN O O
, NN O O
general NN O O
health NN O O
and NN O O
health NN O O
transition NN O O
, NN O O
the NN O O
total NN O O
CHQOL NN O O
scores NN O O
, NN O O
and NN O O
the NN O O
infertility NN O O
problems NN O O
and NN O O
body NN O O
hair NN O O
domains NN O O
of NN O O
the NN O O
PCOSQOL NN O O
improved NN O O
significantly NN O O
after NN O O
EA NN O O
( NN O O
P<0.05 NN O O
) NN O O
. NN O O

EA NN O O
appears NN O O
to NN O O
improve NN O O
symptoms NN O O
of NN O O
anxiety/depression NN O O
and NN O O
quality NN O O
of NN O O
life NN O O
in NN O O
PCOS NN O O
patients NN O O
and NN O O
may NN O O
influence NN O O
serum NN O O
levels NN O O
of NN O O
NE NN O O
and NN O O
5-HT NN O O
. NN O O

These NN O O
findings NN O O
should NN O O
be NN O O
interpreted NN O O
with NN O O
caution NN O O
, NN O O
given NN O O
the NN O O
secondary NN O O
nature NN O O
of NN O O
the NN O O
outcome NN O O
measures NN O O
reported NN O O
herein NN O O
. NN O O

NCT01812161 NN O O
; NN O O
ChiCTR-TRC-12002529 NN O O
. NN O O



-DOCSTART- (30586136)

Localization NN O O
of NN O O
small NN O O
lung NN O O
nodules NN O O
are NN O O
challenging NN O O
because NN O O
of NN O O
the NN O O
difficulty NN O O
of NN O O
nodule NN O O
recognition NN O O
during NN O O
video-assisted NN O O
thoracoscopic NN O O
surgery NN O O
. NN O O

Using NN O O
3-dimensional NN O O
( NN O O
3-D NN O O
) NN O O
printing NN O O
technology NN O O
, NN O O
a NN O O
navigational NN O O
template NN O O
was NN O O
recently NN O O
created NN O O
to NN O O
assist NN O O
percutaneous NN O O
lung NN O O
nodule NN O O
localization NN O O
; NN O O
however NN O O
, NN O O
the NN O O
efficacy NN O O
and NN O O
safety NN O O
of NN O O
this NN O O
template NN O O
have NN O O
not NN O O
yet NN O O
been NN O O
evaluated NN O O
. NN O O

To NN O O
assess NN O O
the NN O O
noninferiority NN O O
of NN O O
the NN O O
efficacy NN O O
and NN O O
safety NN O O
of NN O O
a NN O O
3-D-printed NN O O
navigational NN O O
template NN O O
guide NN O O
for NN O O
localizing NN O O
small NN O O
peripheral NN O O
lung NN O O
nodules NN O O
. NN O O

This NN O O
noninferiority NN O O
randomized NN O O
clinical NN O O
trial NN O O
conducted NN O O
between NN O O
October NN O O
2016 NN O O
and NN O O
October NN O O
2017 NN O O
at NN O O
Shanghai NN O O
Pulmonary NN O O
Hospital NN O O
, NN O O
Shanghai NN O O
, NN O O
China NN O O
, NN O O
compared NN O O
the NN O O
safety NN O O
and NN O O
precision NN O O
of NN O O
lung NN O O
nodule NN O O
localization NN O O
using NN O O
a NN O O
template-guided NN O O
approach NN O O
vs NN O O
the NN O O
conventional NN O O
computed NN O O
tomography NN O O
(CT)-guided NN O O
approach NN O O
. NN O O

In NN O O
total NN O O
, NN O O
213 NN O O
surgical NN O O
candidates NN O O
with NN O O
small NN O O
peripheral NN O O
lung NN O O
nodules NN O O
( NN O O
< NN O O
2 NN O O
cm NN O O
) NN O O
were NN O O
recruited NN O O
to NN O O
undergo NN O O
either NN O O
CT- NN O O
or NN O O
template-guided NN O O
lung NN O O
nodule NN O O
localization NN O O
. NN O O

An NN O O
intention-to-treat NN O O
analysis NN O O
was NN O O
conducted NN O O
. NN O O

Percutaneous NN O O
lung NN O O
nodule NN O O
localization NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
was NN O O
the NN O O
accuracy NN O O
of NN O O
lung NN O O
nodule NN O O
localization NN O O
( NN O O
localizer NN O O
deviation NN O O
) NN O O
, NN O O
and NN O O
secondary NN O O
outcomes NN O O
were NN O O
procedural NN O O
duration NN O O
, NN O O
radiation NN O O
dosage NN O O
, NN O O
and NN O O
complication NN O O
rate NN O O
. NN O O

Of NN O O
the NN O O
200 NN O O
patients NN O O
randomized NN O O
at NN O O
a NN O O
ratio NN O O
of NN O O
1:1 NN O O
to NN O O
the NN O O
template- NN O O
and NN O O
CT-guided NN O O
groups NN O O
, NN O O
most NN O O
were NN O O
women NN O O
( NN O O
147 NN O O
vs NN O O
53 NN O O
) NN O O
, NN O O
body NN O O
mass NN O O
index NN O O
ranged NN O O
from NN O O
15.4 NN O O
to NN O O
37.3 NN O O
, NN O O
the NN O O
mean NN O O
( NN O O
SD NN O O
) NN O O
nodule NN O O
size NN O O
was NN O O
9.7 NN O O
( NN O O
2.9 NN O O
) NN O O
mm NN O O
, NN O O
and NN O O
the NN O O
mean NN O O
distance NN O O
between NN O O
the NN O O
outer NN O O
edge NN O O
of NN O O
target NN O O
nodule NN O O
and NN O O
the NN O O
pleura NN O O
was NN O O
7.8 NN O O
( NN O O
range NN O O
, NN O O
0.0 NN O O
- NN O O
43.9 NN O O
) NN O O
mm NN O O
. NN O O

In NN O O
total NN O O
, NN O O
190 NN O O
patients NN O O
underwent NN O O
either NN O O
CT- NN O O
or NN O O
template-guided NN O O
lung NN O O
nodule NN O O
localization NN O O
and NN O O
subsequent NN O O
surgery NN O O
. NN O O

Among NN O O
these NN O O
patients NN O O
, NN O O
localizer NN O O
deviation NN O O
did NN O O
not NN O O
significantly NN O O
differ NN O O
between NN O O
the NN O O
template- NN O O
and NN O O
CT-guided NN O O
groups NN O O
( NN O O
mean NN O O
[ NN O O
SD NN O O
] NN O O
, NN O O
8.7 NN O O
[ NN O O
6.9 NN O O
] NN O O
vs NN O O
9.6 NN O O
[ NN O O
5.8 NN O O
] NN O O
mm NN O O
; NN O O
P NN O O
= NN O O
.36 NN O O
) NN O O
. NN O O

The NN O O
mean NN O O
( NN O O
SD NN O O
) NN O O
procedural NN O O
durations NN O O
were NN O O
7.4 NN O O
( NN O O
3.2 NN O O
) NN O O
minutes NN O O
for NN O O
the NN O O
template-guided NN O O
group NN O O
and NN O O
9.5 NN O O
( NN O O
3.6 NN O O
) NN O O
minutes NN O O
for NN O O
the NN O O
CT-guided NN O O
group NN O O
( NN O O
P NN O O
< NN O O
.001 NN O O
) NN O O
. NN O O

The NN O O
mean NN O O
( NN O O
SD NN O O
) NN O O
radiation NN O O
dose NN O O
was NN O O
229 NN O O
( NN O O
65 NN O O
) NN O O
mGy NN O O
× NN O O
cm NN O O
in NN O O
the NN O O
template-guided NN O O
group NN O O
and NN O O
313 NN O O
( NN O O
84 NN O O
) NN O O
mGy NN O O
× NN O O
cm NN O O
in NN O O
CT-guided NN O O
group NN O O
( NN O O
P NN O O
< NN O O
.001 NN O O
) NN O O
. NN O O

The NN O O
use NN O O
of NN O O
the NN O O
3-D-printed NN O O
navigational NN O O
template NN O O
for NN O O
localization NN O O
of NN O O
small NN O O
peripheral NN O O
lung NN O O
nodules NN O O
showed NN O O
efficacy NN O O
and NN O O
safety NN O O
that NN O O
were NN O O
not NN O O
substantially NN O O
worse NN O O
than NN O O
those NN O O
for NN O O
the NN O O
CT-guided NN O O
approach NN O O
while NN O O
significantly NN O O
simplifying NN O O
the NN O O
localization NN O O
procedure NN O O
and NN O O
decreasing NN O O
patient NN O O
radiation NN O O
exposure NN O O
. NN O O

ClinicalTrials.gov NN O O
identifier NN O O
: NN O O
NCT02952261 NN O O
. NN O O



-DOCSTART- (31397866)

Rotator NN O O
cuff NN O O
disorders NN O O
remain NN O O
the NN O O
most NN O O
common NN O O
cause NN O O
of NN O O
shoulder NN O O
pain NN O O
and NN O O
are NN O O
among NN O O
the NN O O
most NN O O
common NN O O
reasons NN O O
for NN O O
patients NN O O
to NN O O
seek NN O O
care NN O O
in NN O O
primary NN O O
and NN O O
specialty NN O O
settings NN O O
. NN O O

Although NN O O
operative NN O O
and NN O O
nonoperative NN O O
treatments NN O O
are NN O O
offered NN O O
to NN O O
patients NN O O
with NN O O
atraumatic NN O O
rotator NN O O
cuff NN O O
tears NN O O
, NN O O
there NN O O
is NN O O
a NN O O
lack NN O O
of NN O O
evidence NN O O
to NN O O
support NN O O
operative NN O O
vs NN O O
nonoperative NN O O
treatment NN O O
. NN O O

This NN O O
paucity NN O O
of NN O O
evidence NN O O
has NN O O
been NN O O
highlighted NN O O
by NN O O
several NN O O
professional NN O O
agencies NN O O
and NN O O
experts NN O O
. NN O O

To NN O O
perform NN O O
a NN O O
pragmatic NN O O
randomized NN O O
clinical NN O O
trial NN O O
, NN O O
the NN O O
Arthroscopic NN O O
Rotator NN O O
Cuff NN O O
trial NN O O
, NN O O
comparing NN O O
pain NN O O
and NN O O
functional NN O O
outcomes NN O O
in NN O O
patients NN O O
undergoing NN O O
operative NN O O
vs NN O O
nonoperative NN O O
treatment NN O O
for NN O O
atraumatic NN O O
rotator NN O O
cuff NN O O
tears NN O O
, NN O O
and NN O O
assessing NN O O
heterogeneity NN O O
of NN O O
treatment NN O O
effects NN O O
by NN O O
age NN O O
and NN O O
tear NN O O
size NN O O
. NN O O

Trial NN O O
protocol NN O O
of NN O O
the NN O O
Arthroscopic NN O O
Rotator NN O O
Cuff NN O O
trial NN O O
. NN O O

This NN O O
pragmatic NN O O
randomized NN O O
clinical NN O O
trial NN O O
of NN O O
an NN O O
estimated NN O O
700 NN O O
patients NN O O
is NN O O
adequately NN O O
powered NN O O
to NN O O
accomplish NN O O
its NN O O
aims NN O O
with NN O O
488 NN O O
patients NN O O
. NN O O

Primary NN O O
analysis NN O O
will NN O O
be NN O O
conducted NN O O
on NN O O
an NN O O
intent-to-treat NN O O
population NN O O
in NN O O
the NN O O
context NN O O
of NN O O
a NN O O
mixed NN O O
model NN O O
. NN O O

The NN O O
multicenter NN O O
trial NN O O
started NN O O
recruitment NN O O
in NN O O
2018 NN O O
with NN O O
a NN O O
1-year NN O O
follow-up NN O O
duration NN O O
. NN O O

Patients NN O O
aged NN O O
50 NN O O
years NN O O
or NN O O
older NN O O
to NN O O
younger NN O O
than NN O O
85 NN O O
years NN O O
with NN O O
magnetic NN O O
resonance NN O O
imaging-confirmed NN O O
atraumatic NN O O
rotator NN O O
cuff NN O O
tears NN O O
that NN O O
are NN O O
suitable NN O O
for NN O O
either NN O O
operative NN O O
or NN O O
nonoperative NN O O
treatment NN O O
will NN O O
be NN O O
enrolled NN O O
. NN O O

Block NN O O
randomization NN O O
will NN O O
be NN O O
performed NN O O
and NN O O
stratified NN O O
by NN O O
site NN O O
, NN O O
age NN O O
, NN O O
and NN O O
tear NN O O
size NN O O
. NN O O

Nonoperative NN O O
treatment NN O O
consists NN O O
of NN O O
an NN O O
approximately NN O O
3-month NN O O
standardized NN O O
physical NN O O
therapy NN O O
program NN O O
, NN O O
whereas NN O O
operative NN O O
treatment NN O O
consists NN O O
of NN O O
rotator NN O O
cuff NN O O
surgery NN O O
followed NN O O
by NN O O
approximately NN O O
4 NN O O
months NN O O
of NN O O
postoperative NN O O
rehabilitation NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
is NN O O
patient-reported NN O O
Shoulder NN O O
Pain NN O O
and NN O O
Disability NN O O
Index NN O O
score NN O O
, NN O O
and NN O O
the NN O O
secondary NN O O
outcome NN O O
is NN O O
American NN O O
Shoulder NN O O
and NN O O
Elbow NN O O
Surgeons NN O O
Standardized NN O O
Shoulder NN O O
Form NN O O
score NN O O
measured NN O O
at NN O O
1 NN O O
year NN O O
of NN O O
follow-up NN O O
. NN O O

The NN O O
Arthroscopic NN O O
Rotator NN O O
Cuff NN O O
trial NN O O
is NN O O
ongoing NN O O
, NN O O
and NN O O
12 NN O O
sites NN O O
with NN O O
more NN O O
than NN O O
40 NN O O
physicians NN O O
are NN O O
currently NN O O
recruiting NN O O
patients NN O O
. NN O O

Although NN O O
there NN O O
is NN O O
variation NN O O
by NN O O
site NN O O
, NN O O
as NN O O
of NN O O
May NN O O
2 NN O O
, NN O O
2019 NN O O
, NN O O
13 NN O O
% NN O O
of NN O O
all NN O O
patients NN O O
screened NN O O
( NN O O
787 NN O O
of NN O O
6293 NN O O
) NN O O
were NN O O
eligible NN O O
for NN O O
the NN O O
trial NN O O
, NN O O
and NN O O
9 NN O O
% NN O O
of NN O O
eligible NN O O
patients NN O O
( NN O O
74 NN O O
of NN O O
787 NN O O
) NN O O
were NN O O
recruited NN O O
. NN O O

Results NN O O
of NN O O
this NN O O
study NN O O
may NN O O
help NN O O
patients NN O O
, NN O O
clinicians NN O O
, NN O O
and NN O O
policy NN O O
makers NN O O
assess NN O O
the NN O O
comparative NN O O
effectiveness NN O O
of NN O O
operative NN O O
vs NN O O
nonoperative NN O O
treatment NN O O
for NN O O
atraumatic NN O O
rotator NN O O
cuff NN O O
tears NN O O
. NN O O

ClinicalTrials.gov NN O O
identifier NN O O
: NN O O
NCT03295994 NN O O
. NN O O



-DOCSTART- (30763425)

Hypofractionated NN O O
radiotherapy NN O O
( NN O O
HRT NN O O
) NN O O
would NN O O
be NN O O
more NN O O
convenient NN O O
for NN O O
men NN O O
with NN O O
low-risk NN O O
prostate NN O O
cancer NN O O
and NN O O
cost NN O O
less NN O O
than NN O O
conventional NN O O
radiotherapy NN O O
( NN O O
CRT NN O O
) NN O O
as NN O O
long NN O O
as NN O O
HRT NN O O
is NN O O
noninferior NN O O
to NN O O
CRT NN O O
in NN O O
terms NN O O
of NN O O
survival NN O O
and NN O O
quality NN O O
of NN O O
life NN O O
( NN O O
QOL NN O O
) NN O O
is NN O O
not NN O O
found NN O O
to NN O O
be NN O O
worse NN O O
. NN O O

To NN O O
assess NN O O
differences NN O O
in NN O O
QOL NN O O
between NN O O
men NN O O
with NN O O
low-risk NN O O
prostate NN O O
cancer NN O O
who NN O O
are NN O O
treated NN O O
with NN O O
HRT NN O O
vs NN O O
CRT NN O O
. NN O O

In NN O O
this NN O O
phase NN O O
3 NN O O
randomized NN O O
clinical NN O O
trial NN O O
, NN O O
men NN O O
with NN O O
low-risk NN O O
prostate NN O O
cancer NN O O
were NN O O
enrolled NN O O
from NN O O
sites NN O O
within NN O O
the NN O O
National NN O O
Cancer NN O O
Institute NN O O
's NN O O
National NN O O
Clinical NN O O
Trials NN O O
Network NN O O
in NN O O
the NN O O
United NN O O
States NN O O
, NN O O
Canada NN O O
, NN O O
and NN O O
Switzerland NN O O
. NN O O

Random NN O O
assignment NN O O
to NN O O
CRT NN O O
( NN O O
73.8 NN O O
Gy NN O O
in NN O O
41 NN O O
fractions NN O O
over NN O O
8.2 NN O O
weeks NN O O
) NN O O
or NN O O
to NN O O
HRT NN O O
( NN O O
70 NN O O
Gy NN O O
in NN O O
28 NN O O
fractions NN O O
over NN O O
5.6 NN O O
weeks NN O O
) NN O O
. NN O O

Quality NN O O
of NN O O
life NN O O
was NN O O
assessed NN O O
using NN O O
the NN O O
Expanded NN O O
Prostate NN O O
Index NN O O
Composite NN O O
questionnaire NN O O
measuring NN O O
bowel NN O O
, NN O O
urinary NN O O
, NN O O
sexual NN O O
, NN O O
and NN O O
hormonal NN O O
domains NN O O
; NN O O
the NN O O
25-item NN O O
Hopkins NN O O
Symptom NN O O
Checklist NN O O
measuring NN O O
anxiety NN O O
and NN O O
depression NN O O
; NN O O
and NN O O
the NN O O
EuroQol-5 NN O O
Dimension NN O O
questionnaire NN O O
measuring NN O O
global NN O O
QOL NN O O
. NN O O

All NN O O
data NN O O
were NN O O
collected NN O O
at NN O O
baseline NN O O
and NN O O
6 NN O O
, NN O O
12 NN O O
, NN O O
24 NN O O
, NN O O
and NN O O
60 NN O O
months NN O O
. NN O O

Change NN O O
scores NN O O
were NN O O
compared NN O O
between NN O O
treatment NN O O
arms NN O O
using NN O O
the NN O O
Wilcoxon NN O O
signed NN O O
rank NN O O
test NN O O
. NN O O

A NN O O
significance NN O O
level NN O O
of NN O O
.0125 NN O O
to NN O O
adjust NN O O
for NN O O
multiple NN O O
comparisons NN O O
was NN O O
used NN O O
for NN O O
an NN O O
overall NN O O
2-sided NN O O
type NN O O
1 NN O O
error NN O O
of NN O O
.05 NN O O
. NN O O

Clinical NN O O
significance NN O O
was NN O O
determined NN O O
for NN O O
the NN O O
Expanded NN O O
Prostate NN O O
Index NN O O
Composite NN O O
change NN O O
scores NN O O
by NN O O
an NN O O
effect NN O O
size NN O O
of NN O O
0.5 NN O O
. NN O O

Of NN O O
1092 NN O O
patients NN O O
analyzable NN O O
for NN O O
the NN O O
primary NN O O
end NN O O
point NN O O
, NN O O
962 NN O O
( NN O O
mean NN O O
[ NN O O
SD NN O O
] NN O O
age NN O O
, NN O O
66.6 NN O O
[ NN O O
7.4 NN O O
] NN O O
years NN O O
) NN O O
consented NN O O
to NN O O
the NN O O
QOL NN O O
component NN O O
. NN O O

No NN O O
statistically NN O O
significant NN O O
differences NN O O
with NN O O
regard NN O O
to NN O O
baseline NN O O
characteristics NN O O
nor NN O O
any NN O O
of NN O O
the NN O O
QOL NN O O
baseline NN O O
domains NN O O
were NN O O
measured NN O O
between NN O O
arms NN O O
. NN O O

There NN O O
were NN O O
no NN O O
differences NN O O
in NN O O
change NN O O
score NN O O
between NN O O
arms NN O O
with NN O O
respect NN O O
to NN O O
any NN O O
of NN O O
the NN O O
Expanded NN O O
Prostate NN O O
Index NN O O
Composite NN O O
questionnaire NN O O
domain NN O O
scores NN O O
except NN O O
at NN O O
12 NN O O
months NN O O
when NN O O
the NN O O
HRT NN O O
arm NN O O
had NN O O
a NN O O
larger NN O O
decline NN O O
than NN O O
the NN O O
CRT NN O O
arm NN O O
in NN O O
the NN O O
bowel NN O O
domain NN O O
( NN O O
mean NN O O
score NN O O
, NN O O
-7.5 NN O O
vs NN O O
-3.7 NN O O
, NN O O
respectively NN O O
; NN O O
P<.001 NN O O
) NN O O
, NN O O
but NN O O
it NN O O
did NN O O
not NN O O
reach NN O O
clinical NN O O
significance NN O O
( NN O O
effect NN O O
size NN O O
= NN O O
0.29 NN O O
) NN O O
. NN O O

There NN O O
were NN O O
no NN O O
differences NN O O
between NN O O
arms NN O O
at NN O O
any NN O O
time NN O O
point NN O O
for NN O O
the NN O O
Hopkins NN O O
Symptom NN O O
Checklist NN O O
nor NN O O
EuroQol-5 NN O O
Dimension NN O O
questionnaire NN O O
. NN O O

Treatment NN O O
with NN O O
HRT NN O O
is NN O O
noninferior NN O O
to NN O O
CRT NN O O
in NN O O
men NN O O
with NN O O
low-risk NN O O
prostate NN O O
cancer NN O O
in NN O O
terms NN O O
of NN O O
disease-free NN O O
survival NN O O
and NN O O
, NN O O
as NN O O
shown NN O O
in NN O O
the NN O O
present NN O O
study NN O O
, NN O O
in NN O O
prostate NN O O
cancer-specific NN O O
( NN O O
eg NN O O
, NN O O
bowel NN O O
, NN O O
bladder NN O O
, NN O O
sexual NN O O
) NN O O
and NN O O
general NN O O
QOL NN O O
, NN O O
as NN O O
well NN O O
as NN O O
in NN O O
anxiety NN O O
and NN O O
depression NN O O
. NN O O

This NN O O
study NN O O
provides NN O O
evidence NN O O
to NN O O
affirm NN O O
that NN O O
HRT NN O O
is NN O O
a NN O O
practice NN O O
standard NN O O
for NN O O
men NN O O
with NN O O
low-risk NN O O
prostate NN O O
cancer NN O O
. NN O O

ClinicalTrials.gov NN O O
identifier NN O O
: NN O O
NCT00331773 NN O O
. NN O O



-DOCSTART- (31253237)

Female NN O O
veterans NN O O
smoke NN O O
cigarettes NN O O
at NN O O
high NN O O
rates NN O O
compared NN O O
with NN O O
both NN O O
male NN O O
veterans NN O O
and NN O O
nonveteran NN O O
women NN O O
. NN O O

Proactive NN O O
outreach NN O O
to NN O O
smokers NN O O
may NN O O
reduce NN O O
gender NN O O
disparities NN O O
in NN O O
cessation NN O O
care NN O O
. NN O O

The NN O O
objectives NN O O
of NN O O
this NN O O
study NN O O
were NN O O
to NN O O
compare NN O O
baseline NN O O
experiences NN O O
with NN O O
VA NN O O
smoking NN O O
cessation NN O O
care NN O O
for NN O O
men NN O O
and NN O O
women NN O O
and NN O O
to NN O O
assess NN O O
for NN O O
gender NN O O
differences NN O O
in NN O O
response NN O O
to NN O O
a NN O O
proactive NN O O
outreach NN O O
intervention NN O O
. NN O O

We NN O O
conducted NN O O
a NN O O
post NN O O
hoc NN O O
subgroup NN O O
analysis NN O O
of NN O O
a NN O O
pragmatic NN O O
, NN O O
multisite NN O O
randomized NN O O
, NN O O
controlled NN O O
trial NN O O
comparing NN O O
proactive NN O O
outreach NN O O
with NN O O
usual NN O O
care NN O O
( NN O O
UC NN O O
) NN O O
. NN O O

Baseline NN O O
experiences NN O O
included NN O O
physician NN O O
advice NN O O
to NN O O
quit NN O O
, NN O O
satisfaction NN O O
with NN O O
care NN O O
, NN O O
and NN O O
past-year NN O O
treatment NN O O
use NN O O
. NN O O

At NN O O
the NN O O
1-year NN O O
follow-up NN O O
, NN O O
treatment NN O O
use NN O O
, NN O O
quit NN O O
attempts NN O O
, NN O O
and NN O O
6-month NN O O
prolonged NN O O
abstinence NN O O
for NN O O
women NN O O
and NN O O
men NN O O
randomized NN O O
to NN O O
proactive NN O O
outreach NN O O
versus NN O O
UC NN O O
were NN O O
compared NN O O
using NN O O
logistic NN O O
regression NN O O
. NN O O

Baseline NN O O
and NN O O
follow-up NN O O
surveys NN O O
were NN O O
returned NN O O
by NN O O
138 NN O O
women NN O O
and NN O O
2,516 NN O O
men NN O O
. NN O O

At NN O O
baseline NN O O
, NN O O
women NN O O
were NN O O
less NN O O
likely NN O O
than NN O O
men NN O O
to NN O O
report NN O O
being NN O O
very NN O O
or NN O O
somewhat NN O O
satisfied NN O O
with NN O O
the NN O O
process NN O O
of NN O O
obtaining NN O O
smoking NN O O
cessation NN O O
medications NN O O
in NN O O
the NN O O
VA NN O O
( NN O O
47 NN O O
% NN O O
of NN O O
women NN O O
vs. NN O O
62 NN O O
% NN O O
of NN O O
men NN O O
) NN O O
, NN O O
but NN O O
no NN O O
less NN O O
likely NN O O
to NN O O
report NN O O
having NN O O
used NN O O
cessation NN O O
medications NN O O
from NN O O
the NN O O
VA NN O O
in NN O O
the NN O O
past NN O O
year NN O O
( NN O O
39 NN O O
% NN O O
of NN O O
women NN O O
vs. NN O O
34 NN O O
% NN O O
of NN O O
men NN O O
) NN O O
. NN O O

After NN O O
the NN O O
intervention NN O O
, NN O O
phone NN O O
counseling NN O O
and NN O O
combined NN O O
therapy NN O O
increased NN O O
among NN O O
both NN O O
women NN O O
and NN O O
men NN O O
in NN O O
proactive NN O O
outreach NN O O
as NN O O
compared NN O O
with NN O O
UC NN O O
. NN O O

At NN O O
the NN O O
1-year NN O O
follow-up NN O O
, NN O O
men NN O O
in NN O O
proactive NN O O
outreach NN O O
were NN O O
significantly NN O O
more NN O O
likely NN O O
to NN O O
report NN O O
prolonged NN O O
abstinence NN O O
than NN O O
those NN O O
in NN O O
UC NN O O
( NN O O
odds NN O O
ratio NN O O
, NN O O
1.65 NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
1.28 NN O O
- NN O O
2.14 NN O O
) NN O O
; NN O O
results NN O O
for NN O O
women NN O O
were NN O O
in NN O O
the NN O O
same NN O O
direction NN O O
but NN O O
not NN O O
statistically NN O O
significant NN O O
( NN O O
odds NN O O
ratio NN O O
, NN O O
1.39 NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
0.48 NN O O
- NN O O
3.99 NN O O
) NN O O
. NN O O

Satisfaction NN O O
with NN O O
cessation NN O O
care NN O O
in NN O O
VA NN O O
remains NN O O
low NN O O
. NN O O

Proactive NN O O
outreach NN O O
to NN O O
smokers NN O O
was NN O O
associated NN O O
with NN O O
an NN O O
increased NN O O
use NN O O
of NN O O
cessation NN O O
therapies NN O O
, NN O O
and NN O O
increased NN O O
odds NN O O
of NN O O
achieving NN O O
prolonged NN O O
abstinence NN O O
. NN O O

A NN O O
subgroup NN O O
analysis NN O O
by NN O O
gender NN O O
did NN O O
not NN O O
reveal NN O O
significant NN O O
differences NN O O
in NN O O
the NN O O
treatment NN O O
effect NN O O
. NN O O



-DOCSTART- (31388790)

Laparoscopic NN O O
totally NN O O
extraperitoneal NN O O
inguinal NN O O
hernia NN O O
repair NN O O
( NN O O
TEP NN O O
) NN O O
can NN O O
be NN O O
performed NN O O
using NN O O
either NN O O
telescopic NN O O
( NN O O
TD NN O O
) NN O O
or NN O O
balloon NN O O
dissection NN O O
( NN O O
BD NN O O
) NN O O
. NN O O

The NN O O
use NN O O
of NN O O
a NN O O
disposable NN O O
balloon NN O O
dissector NN O O
increases NN O O
the NN O O
cost NN O O
of NN O O
TEP NN O O
. NN O O

However NN O O
, NN O O
it NN O O
remains NN O O
unclear NN O O
whether NN O O
BD NN O O
saves NN O O
enough NN O O
time NN O O
to NN O O
justify NN O O
its NN O O
cost NN O O
. NN O O

We NN O O
hypothesized NN O O
that NN O O
BD NN O O
would NN O O
consistently NN O O
save NN O O
15 NN O O
min NN O O
in NN O O
operative NN O O
time NN O O
. NN O O

To NN O O
test NN O O
this NN O O
hypothesis NN O O
, NN O O
we NN O O
designed NN O O
a NN O O
registry-based NN O O
randomized NN O O
controlled NN O O
trial NN O O
( NN O O
RB-RCT NN O O
) NN O O
embedded NN O O
into NN O O
the NN O O
Americas NN O O
Hernia NN O O
Society NN O O
Quality NN O O
Collaborative NN O O
. NN O O

A NN O O
single-blinded NN O O
, NN O O
parallel NN O O
, NN O O
RB-RCT NN O O
was NN O O
conducted NN O O
. NN O O

Adults NN O O
with NN O O
inguinal NN O O
hernias NN O O
presenting NN O O
for NN O O
elective NN O O
repair NN O O
were NN O O
screened NN O O
. NN O O

Patients NN O O
with NN O O
unilateral NN O O
hernias NN O O
deemed NN O O
fit NN O O
to NN O O
undergo NN O O
TEP NN O O
were NN O O
eligible NN O O
; NN O O
those NN O O
with NN O O
bilateral NN O O
hernias NN O O
( NN O O
BIH NN O O
) NN O O
or NN O O
undergoing NN O O
open NN O O
repair NN O O
were NN O O
excluded NN O O
. NN O O

Individuals NN O O
were NN O O
randomized NN O O
to NN O O
TD NN O O
or NN O O
BD NN O O
with NN O O
a NN O O
disposable NN O O
device NN O O
. NN O O

TEP NN O O
was NN O O
performed NN O O
with NN O O
synthetic NN O O
mesh NN O O
and NN O O
tacks NN O O
. NN O O

Subjects NN O O
were NN O O
blinded NN O O
and NN O O
followed NN O O
up NN O O
for NN O O
30 NN O O
day NN O O
. NN O O

Main NN O O
outcome NN O O
was NN O O
operative NN O O
time NN O O
. NN O O

207 NN O O
patients NN O O
were NN O O
screened NN O O
: NN O O
166 NN O O
were NN O O
excluded NN O O
and NN O O
41 NN O O
were NN O O
randomized NN O O
( NN O O
21 NN O O
BD NN O O
, NN O O
20 NN O O
TD NN O O
) NN O O
. NN O O

One NN O O
patient NN O O
( NN O O
TD NN O O
group NN O O
) NN O O
was NN O O
excluded NN O O
due NN O O
to NN O O
the NN O O
incidental NN O O
finding NN O O
of NN O O
BIH NN O O
. NN O O

40 NN O O
patients NN O O
were NN O O
analyzed NN O O
( NN O O
median NN O O
age NN O O
56 NN O O
, NN O O
median NN O O
BMI NN O O
26 NN O O
kg/m NN O O
, NN O O
98 NN O O
% NN O O
males NN O O
) NN O O
. NN O O

Hernias NN O O
were NN O O
72 NN O O
% NN O O
indirect NN O O
, NN O O
17 NN O O
% NN O O
direct NN O O
, NN O O
10 NN O O
% NN O O
pantaloon NN O O
, NN O O
and NN O O
8 NN O O
% NN O O
recurrent NN O O
. NN O O

Other NN O O
than NN O O
obesity NN O O
( NN O O
26.5 NN O O
% NN O O
vs. NN O O
0 NN O O
, NN O O
p NN O O
= NN O O
0.018 NN O O
) NN O O
, NN O O
there NN O O
were NN O O
no NN O O
baseline NN O O
differences NN O O
between NN O O
the NN O O
groups NN O O
. NN O O

Median NN O O
operative NN O O
times NN O O
were NN O O
similar NN O O
( NN O O
TD NN O O
43 NN O O
min NN O O
, NN O O
IQR NN O O
33 NN O O
- NN O O
63 NN O O
; NN O O
BD NN O O
46 NN O O
min NN O O
, NN O O
IQR NN O O
35 NN O O
- NN O O
90 NN O O
, NN O O
p NN O O
= NN O O
0.490 NN O O
) NN O O
. NN O O

There NN O O
were NN O O
2 NN O O
seromas NN O O
and NN O O
2 NN O O
hematomas NN O O
in NN O O
the NN O O
BD NN O O
group NN O O
, NN O O
and NN O O
none NN O O
in NN O O
the NN O O
TD NN O O
( NN O O
p NN O O
= NN O O
0.108 NN O O
) NN O O
. NN O O

BD NN O O
does NN O O
not NN O O
consistently NN O O
result NN O O
in NN O O
15-min NN O O
time NN O O
saving NN O O
during NN O O
TEP NN O O
. NN O O

Use NN O O
of NN O O
a NN O O
disposable NN O O
balloon NN O O
dissector NN O O
can NN O O
be NN O O
deferred NN O O
in NN O O
the NN O O
experienced NN O O
hands NN O O
. NN O O

ClinicalTrials.gov NN O O
( NN O O
NCT03276871 NN O O
) NN O O
. NN O O



-DOCSTART- (31178155)

In NN O O
2013 NN O O
, NN O O
the NN O O
interim NN O O
analysis NN O O
of NN O O
the NN O O
Protocol NN O O
for NN O O
Herceptin NN O O
as NN O O
Adjuvant NN O O
therapy NN O O
with NN O O
Reduced NN O O
Exposure NN O O
( NN O O
PHARE NN O O
) NN O O
trial NN O O
could NN O O
not NN O O
show NN O O
that NN O O
6 NN O O
months NN O O
of NN O O
adjuvant NN O O
trastuzumab NN O O
was NN O O
non-inferior NN O O
to NN O O
12 NN O O
months NN O O
. NN O O

Here NN O O
, NN O O
we NN O O
report NN O O
the NN O O
planned NN O O
final NN O O
analysis NN O O
based NN O O
on NN O O
the NN O O
prespecified NN O O
number NN O O
of NN O O
occurring NN O O
events NN O O
. NN O O

PHARE NN O O
is NN O O
an NN O O
open-label NN O O
, NN O O
phase NN O O
3 NN O O
, NN O O
non-inferiority NN O O
randomised NN O O
trial NN O O
of NN O O
patients NN O O
with NN O O
HER2-positive NN O O
early NN O O
breast NN O O
cancer NN O O
comparing NN O O
6 NN O O
months NN O O
versus NN O O
12 NN O O
months NN O O
of NN O O
trastuzumab NN O O
treatment NN O O
concomitant NN O O
with NN O O
or NN O O
following NN O O
standard NN O O
neoadjuvant NN O O
or NN O O
adjuvant NN O O
chemotherapy NN O O
. NN O O

The NN O O
study NN O O
was NN O O
undertaken NN O O
in NN O O
156 NN O O
centres NN O O
in NN O O
France NN O O
. NN O O

Eligible NN O O
patients NN O O
were NN O O
women NN O O
aged NN O O
18 NN O O
years NN O O
or NN O O
older NN O O
with NN O O
non-metastatic NN O O
, NN O O
operable NN O O
, NN O O
histologically NN O O
confirmed NN O O
adenocarcinoma NN O O
of NN O O
the NN O O
breast NN O O
and NN O O
either NN O O
positive NN O O
axillary NN O O
nodes NN O O
or NN O O
negative NN O O
axillary NN O O
nodes NN O O
but NN O O
a NN O O
tumour NN O O
of NN O O
at NN O O
least NN O O
10 NN O O
mm NN O O
. NN O O

Participants NN O O
must NN O O
have NN O O
received NN O O
at NN O O
least NN O O
four NN O O
cycles NN O O
of NN O O
a NN O O
chemotherapy NN O O
for NN O O
this NN O O
breast NN O O
cancer NN O O
and NN O O
have NN O O
started NN O O
receiving NN O O
adjuvant NN O O
trastuzumab-treatment NN O O
. NN O O

Eligible NN O O
patients NN O O
were NN O O
randomly NN O O
assigned NN O O
to NN O O
either NN O O
6 NN O O
months NN O O
or NN O O
12 NN O O
months NN O O
of NN O O
trastuzumab NN O O
therapy NN O O
duration NN O O
between NN O O
the NN O O
third NN O O
and NN O O
sixth NN O O
months NN O O
of NN O O
adjuvant NN O O
trastuzumab NN O O
. NN O O

The NN O O
randomisation NN O O
was NN O O
stratified NN O O
by NN O O
concomitant NN O O
or NN O O
sequential NN O O
treatment NN O O
with NN O O
chemotherapy NN O O
, NN O O
oestrogen NN O O
receptor NN O O
status NN O O
, NN O O
and NN O O
centre NN O O
. NN O O

The NN O O
primary NN O O
objective NN O O
was NN O O
non-inferiority NN O O
in NN O O
the NN O O
intention-to-treat NN O O
population NN O O
in NN O O
the NN O O
6-month NN O O
group NN O O
in NN O O
terms NN O O
of NN O O
disease-free NN O O
survival NN O O
with NN O O
a NN O O
prespecified NN O O
hazard NN O O
margin NN O O
of NN O O
1·15 NN O O
. NN O O

This NN O O
trial NN O O
is NN O O
registered NN O O
with NN O O
ClinicalTrials.gov NN O O
, NN O O
number NN O O
NCT00381901 NN O O
. NN O O

3384 NN O O
patients NN O O
were NN O O
enrolled NN O O
and NN O O
randomly NN O O
assigned NN O O
to NN O O
either NN O O
12 NN O O
months NN O O
( NN O O
n=1691 NN O O
) NN O O
or NN O O
6 NN O O
months NN O O
( NN O O
n=1693 NN O O
) NN O O
of NN O O
adjuvant NN O O
trastuzumab NN O O
. NN O O

One NN O O
patient NN O O
in NN O O
the NN O O
12-month NN O O
group NN O O
and NN O O
three NN O O
patients NN O O
in NN O O
the NN O O
6-month NN O O
group NN O O
were NN O O
excluded NN O O
, NN O O
so NN O O
1690 NN O O
patients NN O O
in NN O O
each NN O O
group NN O O
were NN O O
included NN O O
in NN O O
the NN O O
intention-to-treat NN O O
analysis NN O O
. NN O O

At NN O O
a NN O O
median NN O O
follow-up NN O O
of NN O O
7·5 NN O O
years NN O O
( NN O O
IQR NN O O
5·3 NN O O
- NN O O
8·8 NN O O
) NN O O
, NN O O
704 NN O O
events NN O O
relevant NN O O
to NN O O
disease-free NN O O
survival NN O O
were NN O O
observed NN O O
( NN O O
345 NN O O
[ NN O O
20·4 NN O O
% NN O O
] NN O O
in NN O O
the NN O O
12-month NN O O
group NN O O
and NN O O
359 NN O O
[ NN O O
21·2 NN O O
% NN O O
] NN O O
in NN O O
the NN O O
6-month NN O O
group NN O O
) NN O O
. NN O O

The NN O O
adjusted NN O O
hazard NN O O
ratio NN O O
for NN O O
disease-free NN O O
survival NN O O
in NN O O
the NN O O
12-month NN O O
group NN O O
versus NN O O
the NN O O
6-month NN O O
group NN O O
was NN O O
1·08 NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
0·93 NN O O
- NN O O
1·25 NN O O
; NN O O
p=0·39 NN O O
) NN O O
. NN O O

The NN O O
non-inferiority NN O O
margin NN O O
was NN O O
included NN O O
in NN O O
the NN O O
95 NN O O
% NN O O
CI NN O O
. NN O O

No NN O O
differences NN O O
in NN O O
effects NN O O
pertaining NN O O
to NN O O
trastuzumab NN O O
duration NN O O
were NN O O
found NN O O
in NN O O
any NN O O
of NN O O
the NN O O
subgroups NN O O
. NN O O

After NN O O
the NN O O
completion NN O O
of NN O O
trastuzumab NN O O
treatment NN O O
, NN O O
rare NN O O
adverse NN O O
events NN O O
occurred NN O O
over NN O O
time NN O O
and NN O O
the NN O O
safety NN O O
analysis NN O O
remained NN O O
similar NN O O
to NN O O
the NN O O
previously NN O O
published NN O O
report NN O O
. NN O O

In NN O O
particular NN O O
, NN O O
we NN O O
found NN O O
no NN O O
change NN O O
in NN O O
the NN O O
cardiac NN O O
safety NN O O
comparison NN O O
, NN O O
and NN O O
only NN O O
three NN O O
additional NN O O
cases NN O O
in NN O O
which NN O O
the NN O O
left NN O O
ventricular NN O O
ejection NN O O
fraction NN O O
decreased NN O O
to NN O O
less NN O O
than NN O O
50 NN O O
% NN O O
have NN O O
been NN O O
reported NN O O
in NN O O
the NN O O
12-month NN O O
group NN O O
. NN O O

The NN O O
PHARE NN O O
study NN O O
did NN O O
not NN O O
show NN O O
the NN O O
non-inferiority NN O O
of NN O O
6 NN O O
months NN O O
versus NN O O
12 NN O O
months NN O O
of NN O O
adjuvant NN O O
trastuzumab NN O O
. NN O O

Hence NN O O
, NN O O
adjuvant NN O O
trastuzumab NN O O
standard NN O O
duration NN O O
should NN O O
remain NN O O
12 NN O O
months NN O O
. NN O O

The NN O O
French NN O O
National NN O O
Cancer NN O O
Institute NN O O
. NN O O



-DOCSTART- (30851062)

The NN O O
aim NN O O
of NN O O
this NN O O
study NN O O
was NN O O
to NN O O
evaluate NN O O
the NN O O
efficacy NN O O
and NN O O
safety NN O O
of NN O O
evolocumab NN O O
with NN O O
background NN O O
atorvastatin NN O O
in NN O O
Chinese NN O O
patients NN O O
with NN O O
type NN O O
2 NN O O
diabetes NN O O
mellitus NN O O
( NN O O
T2DM NN O O
) NN O O
and NN O O
hyperlipidaemia NN O O
or NN O O
mixed NN O O
dyslipidaemia NN O O
. NN O O

This NN O O
is NN O O
a NN O O
pre-specified NN O O
analysis NN O O
of NN O O
patients NN O O
in NN O O
the NN O O
BERSON NN O O
study NN O O
( NN O O
ClinicalTrials.gov NN O O
, NN O O
NCT02662569 NN O O
) NN O O
in NN O O
China NN O O
. NN O O

Patients NN O O
initiated NN O O
background NN O O
atorvastatin NN O O
20 NN O O
mg/d NN O O
, NN O O
after NN O O
which NN O O
they NN O O
were NN O O
randomized NN O O
2:2:1:1 NN O O
to NN O O
evolocumab NN O O
140 NN O O
mg NN O O
every NN O O
2 NN O O
weeks NN O O
( NN O O
Q2W NN O O
) NN O O
or NN O O
420 NN O O
mg NN O O
monthly NN O O
( NN O O
QM NN O O
) NN O O
or NN O O
to NN O O
placebo NN O O
Q2W NN O O
or NN O O
QM NN O O
. NN O O

Co-primary NN O O
endpoints NN O O
were NN O O
percentage NN O O
change NN O O
in NN O O
LDL NN O O
cholesterol NN O O
( NN O O
LDL-C NN O O
) NN O O
from NN O O
baseline NN O O
to NN O O
week NN O O
12 NN O O
and NN O O
from NN O O
baseline NN O O
to NN O O
the NN O O
mean NN O O
of NN O O
weeks NN O O
10 NN O O
and NN O O
12 NN O O
. NN O O

Additional NN O O
endpoints NN O O
included NN O O
atherogenic NN O O
lipids NN O O
, NN O O
glycaemic NN O O
measures NN O O
and NN O O
adverse NN O O
events NN O O
( NN O O
AEs NN O O
) NN O O
. NN O O

Among NN O O
453 NN O O
patients NN O O
randomized NN O O
in NN O O
China NN O O
, NN O O
451 NN O O
received NN O O
at NN O O
least NN O O
one NN O O
dose NN O O
of NN O O
study NN O O
drug NN O O
( NN O O
evolocumab NN O O
or NN O O
placebo NN O O
) NN O O
. NN O O

Evolocumab NN O O
significantly NN O O
reduced NN O O
LDL-C NN O O
compared NN O O
with NN O O
placebo NN O O
at NN O O
week NN O O
12 NN O O
( NN O O
Q2W NN O O
, NN O O
-85.0 NN O O
% NN O O
; NN O O
QM NN O O
, NN O O
-74.8 NN O O
% NN O O
) NN O O
and NN O O
at NN O O
the NN O O
mean NN O O
of NN O O
weeks NN O O
10 NN O O
and NN O O
12 NN O O
( NN O O
Q2W NN O O
, NN O O
-80.4 NN O O
% NN O O
; NN O O
QM NN O O
, NN O O
-81.0 NN O O
% NN O O
) NN O O
( NN O O
adjusted NN O O
P NN O O
< NN O O
0.0001 NN O O
for NN O O
all NN O O
) NN O O
when NN O O
administered NN O O
with NN O O
background NN O O
atorvastatin NN O O
. NN O O

Non-HDL-C NN O O
, NN O O
ApoB100 NN O O
, NN O O
total NN O O
cholesterol NN O O
, NN O O
Lp(a NN O O
) NN O O
, NN O O
triglycerides NN O O
, NN O O
HDL-C NN O O
and NN O O
VLDL-C NN O O
significantly NN O O
improved NN O O
with NN O O
evolocumab NN O O
vs NN O O
placebo NN O O
. NN O O

No NN O O
new NN O O
safety NN O O
findings NN O O
were NN O O
observed NN O O
with NN O O
evolocumab NN O O
. NN O O

The NN O O
incidence NN O O
of NN O O
diabetes NN O O
AEs NN O O
was NN O O
higher NN O O
with NN O O
evolocumab NN O O
compared NN O O
with NN O O
placebo NN O O
. NN O O

There NN O O
were NN O O
no NN O O
differences NN O O
over NN O O
time NN O O
between NN O O
evolocumab NN O O
and NN O O
placebo NN O O
in NN O O
measures NN O O
of NN O O
glycaemic NN O O
control NN O O
. NN O O

In NN O O
patients NN O O
in NN O O
China NN O O
with NN O O
T2DM NN O O
and NN O O
hyperlipidaemia NN O O
or NN O O
mixed NN O O
dyslipidaemia NN O O
receiving NN O O
background NN O O
atorvastatin NN O O
, NN O O
evolocumab NN O O
significantly NN O O
reduced NN O O
LDL-C NN O O
and NN O O
other NN O O
atherogenic NN O O
lipids NN O O
, NN O O
was NN O O
well NN O O
tolerated NN O O
, NN O O
and NN O O
had NN O O
no NN O O
notable NN O O
impact NN O O
on NN O O
glycaemic NN O O
measures NN O O
. NN O O



-DOCSTART- (30792945)

We NN O O
investigated NN O O
electronic NN O O
health NN O O
record NN O O
( NN O O
EHR NN O O
) NN O O
access NN O O
as NN O O
an NN O O
indicator NN O O
of NN O O
cardiovascular NN O O
health NN O O
promotion NN O O
by NN O O
patients NN O O
in NN O O
their NN O O
social NN O O
networks NN O O
, NN O O
by NN O O
identifying NN O O
individuals NN O O
who NN O O
viewed NN O O
their NN O O
coronary NN O O
heart NN O O
disease NN O O
( NN O O
CHD NN O O
) NN O O
risk NN O O
information NN O O
in NN O O
the NN O O
EHR NN O O
and NN O O
shared NN O O
this NN O O
information NN O O
in NN O O
their NN O O
social NN O O
networks NN O O
among NN O O
various NN O O
spheres NN O O
of NN O O
influence NN O O
. NN O O

In NN O O
a NN O O
secondary NN O O
analysis NN O O
of NN O O
the NN O O
Myocardial NN O O
Infarction NN O O
Genes NN O O
trial NN O O
, NN O O
Olmsted NN O O
County NN O O
MN NN O O
residents NN O O
( NN O O
2013 NN O O
- NN O O
2015 NN O O
; NN O O
n NN O O
= NN O O
203 NN O O
; NN O O
whites NN O O
, NN O O
ages NN O O
45 NN O O
- NN O O
65 NN O O
years NN O O
) NN O O
at NN O O
intermediate NN O O
CHD NN O O
risk NN O O
were NN O O
randomized NN O O
to NN O O
receive NN O O
their NN O O
conventional NN O O
risk NN O O
score NN O O
( NN O O
CRS NN O O
; NN O O
based NN O O
on NN O O
traditional NN O O
risk NN O O
factors NN O O
) NN O O
alone NN O O
or NN O O
also NN O O
their NN O O
genetic NN O O
risk NN O O
score NN O O
( NN O O
GRS NN O O
; NN O O
based NN O O
on NN O O
28 NN O O
genomic NN O O
variants NN O O
) NN O O
. NN O O

We NN O O
assessed NN O O
self-reported NN O O
and NN O O
objectively NN O O
quantified NN O O
EHR NN O O
access NN O O
via NN O O
a NN O O
patient NN O O
portal NN O O
at NN O O
three NN O O
and NN O O
six NN O O
months NN O O
after NN O O
risk NN O O
disclosure NN O O
, NN O O
and NN O O
determined NN O O
whether NN O O
this NN O O
differed NN O O
by NN O O
GRS NN O O
disclosure NN O O
. NN O O

Data NN O O
were NN O O
analyzed NN O O
using NN O O
logistic NN O O
regression NN O O
and NN O O
adjusted NN O O
for NN O O
sociodemographic NN O O
characteristics NN O O
, NN O O
family NN O O
history NN O O
, NN O O
and NN O O
baseline NN O O
CRS/GRS NN O O
. NN O O

Self-reported NN O O
EHR NN O O
access NN O O
to NN O O
view NN O O
CHD NN O O
risk NN O O
information NN O O
was NN O O
associated NN O O
with NN O O
a NN O O
high NN O O
frequency NN O O
of NN O O
objectively NN O O
quantified NN O O
EHR NN O O
access NN O O
( NN O O
71(10 NN O O
) NN O O
versus NN O O
37(5 NN O O
) NN O O
logins NN O O
; NN O O
= NN O O
0.0025 NN O O
) NN O O
and NN O O
a NN O O
high NN O O
likelihood NN O O
of NN O O
encouraging NN O O
others NN O O
to NN O O
be NN O O
screened NN O O
for NN O O
their NN O O
CHD NN O O
risk NN O O
( NN O O
OR NN O O
2.936 NN O O
, NN O O
CI NN O O
1.443 NN O O
- NN O O
5.973 NN O O
, NN O O
= NN O O
0.0030 NN O O
) NN O O
, NN O O
compared NN O O
to NN O O
the NN O O
absence NN O O
of NN O O
self-reported NN O O
EHR NN O O
access NN O O
to NN O O
view NN O O
CHD NN O O
risk NN O O
information NN O O
. NN O O

We NN O O
thereby NN O O
used NN O O
EHR NN O O
access NN O O
trends NN O O
to NN O O
identify NN O O
individuals NN O O
who NN O O
may NN O O
function NN O O
as NN O O
disseminators NN O O
of NN O O
CHD NN O O
risk NN O O
information NN O O
in NN O O
social NN O O
networks NN O O
, NN O O
compared NN O O
to NN O O
individuals NN O O
on NN O O
the NN O O
periphery NN O O
of NN O O
their NN O O
social NN O O
networks NN O O
who NN O O
did NN O O
not NN O O
exhibit NN O O
this NN O O
behavior NN O O
. NN O O

Partnering NN O O
with NN O O
such NN O O
individuals NN O O
could NN O O
amplify NN O O
CHD NN O O
health NN O O
promotion NN O O
. NN O O
: NN O O
Myocardial NN O O
Infarction NN O O
Genes NN O O
( NN O O
MI-GENES NN O O
) NN O O
Study NN O O
, NN O O
NCT01936675 NN O O
, NN O O
https://clinicaltrials.gov/ct2/show/NCT01936675 NN O O
. NN O O



-DOCSTART- (30487231)

To NN O O
evaluate NN O O
the NN O O
efficacy NN O O
and NN O O
safety NN O O
of NN O O
inclisiran NN O O
by NN O O
diabetes NN O O
status NN O O
. NN O O

ORION-1 NN O O
( NN O O
ClinicalTrials.gov NN O O
, NN O O
NCT02597127 NN O O
) NN O O
randomized NN O O
501 NN O O
subjects NN O O
with NN O O
atherosclerotic NN O O
cardiovascular NN O O
disease NN O O
( NN O O
ASCVD NN O O
) NN O O
or NN O O
ASCVD NN O O
risk NN O O
equivalents NN O O
and NN O O
high NN O O
LDL NN O O
cholesterol NN O O
( NN O O
LDL-C NN O O
) NN O O
, NN O O
despite NN O O
maximally NN O O
tolerated NN O O
LDL-C-lowering NN O O
therapies NN O O
, NN O O
to NN O O
one NN O O
or NN O O
two NN O O
doses NN O O
of NN O O
placebo NN O O
or NN O O
inclisiran NN O O
. NN O O

Levels NN O O
of NN O O
lipids NN O O
and NN O O
proprotein NN O O
convertase NN O O
subtilisin/kexin NN O O
type NN O O
9 NN O O
( NN O O
PCSK9 NN O O
) NN O O
at NN O O
baseline NN O O
and NN O O
day NN O O
180 NN O O
were NN O O
compared NN O O
. NN O O

Inclisiran NN O O
was NN O O
associated NN O O
with NN O O
marked NN O O
declines NN O O
in NN O O
LDL-C NN O O
( NN O O
median NN O O
-28 NN O O
% NN O O
to NN O O
-52 NN O O
% NN O O
, NN O O
< NN O O
0.0001 NN O O
and NN O O
-28 NN O O
% NN O O
to NN O O
-55 NN O O
% NN O O
, NN O O
< NN O O
0.005 NN O O
for NN O O
all NN O O
doses NN O O
in NN O O
the NN O O
without- NN O O
and NN O O
with-diabetes NN O O
groups NN O O
, NN O O
respectively NN O O
) NN O O
and NN O O
PCSK9 NN O O
. NN O O

The NN O O
inclisiran-treated NN O O
groups NN O O
also NN O O
had NN O O
lower NN O O
apolipoprotein NN O O
B NN O O
, NN O O
non-HDL NN O O
cholesterol NN O O
, NN O O
and NN O O
lipoprotein(a NN O O
) NN O O
but NN O O
higher NN O O
HDL NN O O
cholesterol NN O O
. NN O O

Inclisiran NN O O
had NN O O
an NN O O
adverse NN O O
profile NN O O
similar NN O O
to NN O O
that NN O O
of NN O O
placebo NN O O
, NN O O
and NN O O
adverse NN O O
events NN O O
were NN O O
proportionally NN O O
balanced NN O O
in NN O O
the NN O O
baseline NN O O
with- NN O O
and NN O O
without-diabetes NN O O
groups NN O O
. NN O O

PCSK9-targeted NN O O
siRNA-driven NN O O
strategies NN O O
may NN O O
provide NN O O
a NN O O
novel NN O O
therapeutic NN O O
option NN O O
for NN O O
managing NN O O
dyslipidemia NN O O
in NN O O
the NN O O
presence NN O O
and NN O O
absence NN O O
of NN O O
diabetes NN O O
. NN O O



-DOCSTART- (30856652)

Hashimoto NN O O
disease NN O O
is NN O O
a NN O O
chronic NN O O
autoimmune NN O O
thyroiditis NN O O
. NN O O

Despite NN O O
adequate NN O O
hormone NN O O
substitution NN O O
, NN O O
some NN O O
patients NN O O
have NN O O
persistent NN O O
symptoms NN O O
that NN O O
may NN O O
be NN O O
the NN O O
result NN O O
of NN O O
immunologic NN O O
pathophysiology NN O O
. NN O O

To NN O O
determine NN O O
whether NN O O
thyroidectomy NN O O
improves NN O O
symptoms NN O O
in NN O O
patients NN O O
with NN O O
Hashimoto NN O O
thyroiditis NN O O
who NN O O
still NN O O
have NN O O
symptoms NN O O
despite NN O O
having NN O O
normal NN O O
thyroid NN O O
gland NN O O
function NN O O
while NN O O
receiving NN O O
medical NN O O
therapy NN O O
. NN O O

Randomized NN O O
trial NN O O
. NN O O

( NN O O
ClinicalTrials.gov NN O O
: NN O O
NCT02319538 NN O O
) NN O O
. NN O O

Secondary NN O O
care NN O O
hospital NN O O
in NN O O
Norway NN O O
. NN O O

150 NN O O
patients NN O O
aged NN O O
18 NN O O
to NN O O
79 NN O O
years NN O O
with NN O O
persistent NN O O
Hashimoto-related NN O O
symptoms NN O O
despite NN O O
euthyroid NN O O
status NN O O
while NN O O
receiving NN O O
hormone NN O O
replacement NN O O
therapy NN O O
and NN O O
with NN O O
serum NN O O
antithyroid NN O O
peroxidase NN O O
( NN O O
anti-TPO NN O O
) NN O O
antibody NN O O
titers NN O O
greater NN O O
than NN O O
1000 NN O O
IU/mL. NN O O
Total NN O O
thyroidectomy NN O O
or NN O O
medical NN O O
management NN O O
with NN O O
hormone NN O O
substitution NN O O
to NN O O
secure NN O O
euthyroid NN O O
status NN O O
in NN O O
both NN O O
groups NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
was NN O O
general NN O O
health NN O O
score NN O O
on NN O O
the NN O O
Short NN O O
Form-36 NN O O
Health NN O O
Survey NN O O
( NN O O
SF-36 NN O O
) NN O O
at NN O O
18 NN O O
months NN O O
. NN O O

Secondary NN O O
outcomes NN O O
were NN O O
adverse NN O O
effects NN O O
of NN O O
surgery NN O O
, NN O O
the NN O O
other NN O O
7 NN O O
SF-36 NN O O
subscores NN O O
, NN O O
fatigue NN O O
questionnaire NN O O
scores NN O O
, NN O O
and NN O O
serum NN O O
anti-TPO NN O O
antibody NN O O
titers NN O O
at NN O O
6 NN O O
, NN O O
12 NN O O
, NN O O
and NN O O
18 NN O O
months NN O O
. NN O O

During NN O O
follow-up NN O O
, NN O O
only NN O O
the NN O O
surgical NN O O
group NN O O
demonstrated NN O O
improvement NN O O
: NN O O
Mean NN O O
general NN O O
health NN O O
score NN O O
increased NN O O
from NN O O
38 NN O O
to NN O O
64 NN O O
points NN O O
, NN O O
for NN O O
a NN O O
between-group NN O O
difference NN O O
of NN O O
29 NN O O
points NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
22 NN O O
to NN O O
35 NN O O
points NN O O
) NN O O
at NN O O
18 NN O O
months NN O O
. NN O O

Fatigue NN O O
score NN O O
decreased NN O O
from NN O O
23 NN O O
to NN O O
14 NN O O
points NN O O
, NN O O
for NN O O
a NN O O
between-group NN O O
difference NN O O
of NN O O
9.3 NN O O
points NN O O
( NN O O
CI NN O O
, NN O O
7.4 NN O O
to NN O O
11.2 NN O O
points NN O O
) NN O O
. NN O O

Chronic NN O O
fatigue NN O O
frequency NN O O
decreased NN O O
from NN O O
82 NN O O
% NN O O
to NN O O
35 NN O O
% NN O O
, NN O O
for NN O O
a NN O O
between-group NN O O
difference NN O O
of NN O O
39 NN O O
percentage NN O O
points NN O O
( NN O O
CI NN O O
, NN O O
23 NN O O
to NN O O
53 NN O O
percentage NN O O
points NN O O
) NN O O
. NN O O

Median NN O O
serum NN O O
anti-TPO NN O O
antibody NN O O
titers NN O O
decreased NN O O
from NN O O
2232 NN O O
to NN O O
152 NN O O
IU/mL NN O O
, NN O O
for NN O O
a NN O O
between-group NN O O
difference NN O O
of NN O O
1148 NN O O
IU/mL NN O O
( NN O O
CI NN O O
, NN O O
1080 NN O O
to NN O O
1304 NN O O
IU/mL NN O O
) NN O O
. NN O O

In NN O O
multivariable NN O O
regression NN O O
analyses NN O O
, NN O O
the NN O O
adjusted NN O O
treatment NN O O
effects NN O O
remained NN O O
similar NN O O
to NN O O
the NN O O
unadjusted NN O O
effects NN O O
. NN O O

Results NN O O
are NN O O
applicable NN O O
only NN O O
to NN O O
a NN O O
subgroup NN O O
of NN O O
patients NN O O
with NN O O
Hashimoto NN O O
disease NN O O
, NN O O
and NN O O
follow-up NN O O
was NN O O
limited NN O O
to NN O O
18 NN O O
months NN O O
. NN O O

Total NN O O
thyroidectomy NN O O
improved NN O O
health-related NN O O
quality NN O O
of NN O O
life NN O O
and NN O O
fatigue NN O O
, NN O O
whereas NN O O
medical NN O O
therapy NN O O
did NN O O
not NN O O
. NN O O

This NN O O
improvement NN O O
, NN O O
along NN O O
with NN O O
concomitant NN O O
elimination NN O O
of NN O O
serum NN O O
anti-TPO NN O O
antibodies NN O O
, NN O O
may NN O O
elucidate NN O O
disease NN O O
mechanisms NN O O
. NN O O

Telemark NN O O
Hospital NN O O
. NN O O



-DOCSTART- (31036412)

To NN O O
assess NN O O
the NN O O
efficacy NN O O
of NN O O
water-soluble NN O O
dietary NN O O
fiber NN O O
, NN O O
glucomannan NN O O
supplementation NN O O
, NN O O
on NN O O
the NN O O
body NN O O
mass NN O O
index NN O O
( NN O O
BMI NN O O
) NN O O
in NN O O
children NN O O
with NN O O
overweight NN O O
or NN O O
obesity NN O O
. NN O O

In NN O O
this NN O O
randomized NN O O
, NN O O
double-blind NN O O
, NN O O
placebo-controlled NN O O
trial NN O O
, NN O O
we NN O O
enrolled NN O O
96 NN O O
children NN O O
aged NN O O
6 NN O O
- NN O O
17 NN O O
years NN O O
with NN O O
overweight NN O O
or NN O O
obesity NN O O
based NN O O
on NN O O
the NN O O
World NN O O
Health NN O O
Organization NN O O
growth NN O O
criteria NN O O
( NN O O
> NN O O
+ NN O O
1 NN O O
SD NN O O
or NN O O
> NN O O
+ NN O O
2 NN O O
SD NN O O
, NN O O
respectively NN O O
) NN O O
. NN O O

Participants NN O O
were NN O O
assigned NN O O
to NN O O
receive NN O O
glucomannan NN O O
or NN O O
placebo NN O O
( NN O O
maltodextrin NN O O
) NN O O
, NN O O
both NN O O
at NN O O
a NN O O
dose NN O O
of NN O O
3 NN O O
g/d NN O O
for NN O O
12 NN O O
weeks NN O O
and NN O O
were NN O O
followed NN O O
up NN O O
for NN O O
the NN O O
next NN O O
12 NN O O
weeks NN O O
. NN O O

Concomitant NN O O
care NN O O
included NN O O
dietary NN O O
and NN O O
lifestyle NN O O
advice NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
was NN O O
the NN O O
difference NN O O
in NN O O
the NN O O
BMI-for-age NN O O
z NN O O
score NN O O
change NN O O
between NN O O
the NN O O
groups NN O O
at NN O O
12 NN O O
weeks NN O O
. NN O O

Compared NN O O
with NN O O
the NN O O
placebo NN O O
, NN O O
glucomannan NN O O
had NN O O
no NN O O
effect NN O O
on NN O O
the NN O O
BMI-for-age NN O O
z NN O O
score NN O O
at NN O O
12 NN O O
weeks NN O O
( NN O O
mean NN O O
difference NN O O
: NN O O
0.0 NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
-0.1 NN O O
to NN O O
0.1 NN O O
) NN O O
. NN O O

Compared NN O O
with NN O O
the NN O O
placebo NN O O
, NN O O
the NN O O
glucomannan NN O O
group NN O O
had NN O O
lower NN O O
total NN O O
and NN O O
low-density NN O O
lipoprotein NN O O
cholesterol NN O O
concentrations NN O O
at NN O O
12 NN O O
weeks NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
the NN O O
blood NN O O
pressure NN O O
was NN O O
greater NN O O
at NN O O
12 NN O O
weeks NN O O
( NN O O
systolic NN O O
) NN O O
and NN O O
at NN O O
24 NN O O
weeks NN O O
( NN O O
diastolic NN O O
) NN O O
in NN O O
the NN O O
glucomannan NN O O
group NN O O
. NN O O

No NN O O
differences NN O O
between NN O O
the NN O O
groups NN O O
in NN O O
adverse NN O O
events NN O O
and NN O O
other NN O O
secondary NN O O
outcomes NN O O
were NN O O
observed NN O O
. NN O O

Glucomannan NN O O
supplementation NN O O
compared NN O O
with NN O O
placebo NN O O
had NN O O
no NN O O
effect NN O O
on NN O O
weight NN O O
reduction NN O O
in NN O O
children NN O O
with NN O O
overweight NN O O
and NN O O
obesity NN O O
. NN O O

ClinicalTrials.govNCT02280772 NN O O
. NN O O



-DOCSTART- (31277659)

Bronchoscopic NN O O
cryobiopsy NN O O
is NN O O
a NN O O
new NN O O
method NN O O
of NN O O
bronchoscopic NN O O
tissue NN O O
sampling NN O O
in NN O O
interstitial NN O O
lung NN O O
disease NN O O
. NN O O

In NN O O
case NN O O
of NN O O
transbronchial NN O O
biopsies NN O O
, NN O O
the NN O O
resultant NN O O
tissue NN O O
samples NN O O
are NN O O
of NN O O
high NN O O
quality NN O O
, NN O O
and NN O O
the NN O O
lung NN O O
parenchyma NN O O
seen NN O O
in NN O O
the NN O O
samples NN O O
is NN O O
adequate NN O O
for NN O O
a NN O O
histological NN O O
diagnosis NN O O
in NN O O
most NN O O
cases NN O O
. NN O O

Bleeding NN O O
after NN O O
transbronchial NN O O
biopsy NN O O
is NN O O
the NN O O
most NN O O
important NN O O
procedure- NN O O
associated NN O O
complication NN O O
and NN O O
may NN O O
be NN O O
life NN O O
threatening NN O O
. NN O O

This NN O O
study NN O O
addresses NN O O
the NN O O
risk NN O O
of NN O O
bleeding NN O O
of NN O O
transbronchial NN O O
cryobiopsy NN O O
. NN O O

In NN O O
this NN O O
prospective NN O O
, NN O O
randomized NN O O
, NN O O
controlled NN O O
multicentre NN O O
study NN O O
359 NN O O
patients NN O O
with NN O O
interstitial NN O O
lung NN O O
disease NN O O
requiring NN O O
diagnostic NN O O
bronchoscopic NN O O
tissue NN O O
sampling NN O O
were NN O O
included NN O O
. NN O O

Both NN O O
conventional NN O O
transbronchial NN O O
forceps NN O O
biopsy NN O O
and NN O O
transbronchial NN O O
cryobiopsy NN O O
were NN O O
undertaken NN O O
in NN O O
each NN O O
patient NN O O
. NN O O

The NN O O
sequence NN O O
of NN O O
the NN O O
procedures NN O O
was NN O O
randomized NN O O
. NN O O

Bleeding NN O O
severity NN O O
was NN O O
evaluated NN O O
semi-quantitatively NN O O
as NN O O
" NN O O
no NN O O
bleeding NN O O
" NN O O
, NN O O
" NN O O
mild NN O O
" NN O O
( NN O O
suction NN O O
alone NN O O
) NN O O
, NN O O
" NN O O
moderate NN O O
" NN O O
( NN O O
additional NN O O
intervention NN O O
) NN O O
or NN O O
" NN O O
severe NN O O
" NN O O
( NN O O
prolonged NN O O
monitoring NN O O
necessary NN O O
or NN O O
fatal NN O O
outcome NN O O
) NN O O
, NN O O
for NN O O
each NN O O
intervention NN O O
. NN O O

In NN O O
359 NN O O
patients NN O O
atotal NN O O
of NN O O
1160 NN O O
cryobiopsies NN O O
and NN O O
1302 NN O O
forceps NN O O
biopsies NN O O
were NN O O
performed NN O O
. NN O O

Bleeding NN O O
was NN O O
observed NN O O
after NN O O
forceps NN O O
biopsy NN O O
in NN O O
173 NN O O
patients NN O O
( NN O O
48.2 NN O O
% NN O O
) NN O O
and NN O O
after NN O O
cryobiopsy NN O O
in NN O O
261 NN O O
patients NN O O
( NN O O
72.7 NN O O
% NN O O
) NN O O
. NN O O

Bleeding NN O O
was NN O O
significantly NN O O
greater NN O O
in NN O O
the NN O O
cryobiopsy NN O O
group NN O O
( NN O O
cryobiopsy/forceps NN O O
biopsy NN O O
: NN O O
no NN O O
bleeding NN O O
27.3%/51.8 NN O O
% NN O O
; NN O O
mild NN O O
56.5%/44.0 NN O O
% NN O O
; NN O O
moderate NN O O
15.0%/4.2 NN O O
% NN O O
; NN O O
severe NN O O
1.2%/0 NN O O
% NN O O
; NN O O
p NN O O
< NN O O
0.001 NN O O
) NN O O
. NN O O

The NN O O
rate NN O O
of NN O O
clinically NN O O
relevant NN O O
bleeding NN O O
( NN O O
moderate NN O O
or NN O O
severe NN O O
) NN O O
was NN O O
higher NN O O
after NN O O
the NN O O
cryobiopsy NN O O
procedures NN O O
compared NN O O
to NN O O
the NN O O
forceps NN O O
biopsies NN O O
( NN O O
16.2 NN O O
% NN O O
vs. NN O O
4.2 NN O O
% NN O O
, NN O O
p NN O O
< NN O O
0.05 NN O O
) NN O O
. NN O O

No NN O O
fatal NN O O
bleeding NN O O
complications NN O O
occurred NN O O
. NN O O

Compared NN O O
to NN O O
transbronchial NN O O
forceps NN O O
biopsy NN O O
, NN O O
transbronchial NN O O
cryobiopsy NN O O
was NN O O
associated NN O O
with NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
bleeding NN O O
which NN O O
is NN O O
of NN O O
clinical NN O O
relevance NN O O
. NN O O

Therefore NN O O
training NN O O
and NN O O
additional NN O O
precautions NN O O
for NN O O
bleeding NN O O
control NN O O
should NN O O
be NN O O
considered NN O O
. NN O O

The NN O O
study NN O O
was NN O O
registered NN O O
with NN O O
clinicaltrials.gov NN O O
( NN O O
NCT01894113 NN O O
) NN O O
. NN O O



-DOCSTART- (31187344)

Unhealthy NN O O
alcohol NN O O
use NN O O
has NN O O
adverse NN O O
effects NN O O
on NN O O
HIV NN O O
treatment NN O O
. NN O O

Screening NN O O
, NN O O
brief NN O O
intervention NN O O
, NN O O
and NN O O
referral NN O O
to NN O O
treatment NN O O
( NN O O
SBIRT NN O O
) NN O O
has NN O O
some NN O O
evidence NN O O
of NN O O
efficacy NN O O
but NN O O
may NN O O
not NN O O
be NN O O
sufficient NN O O
for NN O O
those NN O O
with NN O O
low NN O O
motivation NN O O
or NN O O
comorbid NN O O
substance NN O O
use NN O O
. NN O O

To NN O O
examine NN O O
the NN O O
effectiveness NN O O
of NN O O
motivational NN O O
interviewing NN O O
( NN O O
MI NN O O
) NN O O
and NN O O
emailed NN O O
feedback NN O O
( NN O O
EF NN O O
) NN O O
among NN O O
primary NN O O
care NN O O
HIV-positive NN O O
patients NN O O
, NN O O
compared NN O O
with NN O O
treatment NN O O
as NN O O
usual NN O O
care NN O O
( NN O O
UC NN O O
) NN O O
only NN O O
, NN O O
which NN O O
included NN O O
SBIRT NN O O
. NN O O

Randomized NN O O
clinical NN O O
trial NN O O
. NN O O

Six NN O O
hundred NN O O
fourteen NN O O
adult NN O O
HIV-positive NN O O
patients NN O O
in NN O O
Kaiser NN O O
Permanente NN O O
Northern NN O O
California NN O O
who NN O O
reported NN O O
prior-year NN O O
unhealthy NN O O
alcohol NN O O
use NN O O
. NN O O

Participants NN O O
were NN O O
randomized NN O O
to NN O O
either NN O O
three NN O O
sessions NN O O
of NN O O
MI NN O O
( NN O O
one NN O O
in NN O O
person NN O O
and NN O O
two NN O O
by NN O O
phone NN O O
) NN O O
, NN O O
information NN O O
regarding NN O O
alcohol NN O O
risks NN O O
via NN O O
EF NN O O
through NN O O
a NN O O
patient NN O O
portal NN O O
, NN O O
or NN O O
UC NN O O
alone NN O O
. NN O O

MI NN O O
and NN O O
EF NN O O
participants NN O O
who NN O O
reported NN O O
unhealthy NN O O
alcohol NN O O
use NN O O
at NN O O
6 NN O O
months NN O O
were NN O O
offered NN O O
additional NN O O
MI NN O O
and NN O O
EF NN O O
treatment NN O O
, NN O O
respectively NN O O
. NN O O

Participant-reported NN O O
unhealthy NN O O
alcohol NN O O
use NN O O
( NN O O
defined NN O O
as NN O O
≥ NN O O
4/≥ NN O O
5 NN O O
drinks NN O O
per NN O O
day NN O O
for NN O O
women/men NN O O
) NN O O
, NN O O
alcohol NN O O
problems NN O O
at NN O O
12 NN O O
months NN O O
, NN O O
based NN O O
on NN O O
blinded NN O O
telephone NN O O
interviews NN O O
. NN O O

Secondary NN O O
outcomes NN O O
included NN O O
drug NN O O
use NN O O
and NN O O
antiretroviral NN O O
( NN O O
ART NN O O
) NN O O
adherence NN O O
. NN O O

At NN O O
12 NN O O
months NN O O
, NN O O
there NN O O
were NN O O
no NN O O
overall NN O O
group NN O O
differences NN O O
, NN O O
but NN O O
in NN O O
all NN O O
three NN O O
arms NN O O
, NN O O
there NN O O
were NN O O
declines NN O O
in NN O O
unhealthy NN O O
alcohol NN O O
use NN O O
and NN O O
alcohol-related NN O O
problems NN O O
( NN O O
p NN O O
< NN O O
0.001 NN O O
) NN O O
. NN O O

Participants NN O O
reporting NN O O
low NN O O
motivation NN O O
to NN O O
reduce NN O O
drinking NN O O
at NN O O
baseline NN O O
were NN O O
less NN O O
likely NN O O
to NN O O
report NN O O
unhealthy NN O O
alcohol NN O O
use NN O O
if NN O O
they NN O O
received NN O O
MI NN O O
vs. NN O O
EF NN O O
and NN O O
UC NN O O
( NN O O
p NN O O
= NN O O
0.013 NN O O
) NN O O
. NN O O

At NN O O
6 NN O O
months NN O O
, NN O O
reported NN O O
illegal NN O O
drug NN O O
use/misuse NN O O
of NN O O
prescription NN O O
drugs NN O O
other NN O O
than NN O O
marijuana NN O O
was NN O O
lower NN O O
in NN O O
the NN O O
MI NN O O
arm NN O O
than NN O O
EF NN O O
or NN O O
UC NN O O
( NN O O
p NN O O
= NN O O
0.012 NN O O
) NN O O
. NN O O

There NN O O
were NN O O
no NN O O
differences NN O O
in NN O O
ART NN O O
adherence NN O O
between NN O O
groups NN O O
. NN O O

In NN O O
a NN O O
randomized NN O O
trial NN O O
of NN O O
HIV-positive NN O O
patients NN O O
using NN O O
two NN O O
behavioral NN O O
interventions NN O O
compared NN O O
with NN O O
SBIRT NN O O
alone NN O O
, NN O O
participants NN O O
in NN O O
all NN O O
three NN O O
conditions NN O O
reduced NN O O
unhealthy NN O O
alcohol NN O O
use NN O O
. NN O O

MI NN O O
may NN O O
provide NN O O
added NN O O
benefit NN O O
for NN O O
patients NN O O
with NN O O
low NN O O
motivation NN O O
or NN O O
who NN O O
report NN O O
illegal NN O O
drug NN O O
use/misuse NN O O
of NN O O
prescription NN O O
drugs NN O O
. NN O O

NCT01671501 NN O O
( NN O O
ClinicalTrials.gov NN O O
) NN O O
. NN O O



-DOCSTART- (30744610)

The NN O O
World NN O O
Health NN O O
Organization NN O O
( NN O O
WHO NN O O
) NN O O
has NN O O
included NN O O
comorbidity NN O O
between NN O O
depression NN O O
and NN O O
a NN O O
chronic NN O O
disease NN O O
among NN O O
the NN O O
10 NN O O
leading NN O O
global NN O O
health NN O O
priorities NN O O
. NN O O

Although NN O O
there NN O O
is NN O O
a NN O O
high NN O O
prevalence NN O O
of NN O O
multimorbidity NN O O
, NN O O
health NN O O
care NN O O
systems NN O O
are NN O O
mainly NN O O
designed NN O O
for NN O O
the NN O O
management NN O O
of NN O O
individual NN O O
diseases NN O O
. NN O O

Given NN O O
the NN O O
difficulty NN O O
in NN O O
delivering NN O O
face-to-face NN O O
psychological NN O O
treatments NN O O
, NN O O
alternative NN O O
models NN O O
of NN O O
treatment NN O O
delivery NN O O
have NN O O
been NN O O
proposed NN O O
, NN O O
emphasizing NN O O
the NN O O
role NN O O
of NN O O
technologies NN O O
such NN O O
as NN O O
the NN O O
Internet NN O O
. NN O O

The NN O O
aim NN O O
of NN O O
this NN O O
study NN O O
is NN O O
to NN O O
assess NN O O
the NN O O
efficacy NN O O
in NN O O
Primary NN O O
Care NN O O
( NN O O
PC NN O O
) NN O O
of NN O O
a NN O O
blended NN O O
low-intensity NN O O
psychological NN O O
intervention NN O O
applied NN O O
using NN O O
information NN O O
and NN O O
communication NN O O
technologies NN O O
( NN O O
ICTs NN O O
) NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
multimorbidity NN O O
in NN O O
PC NN O O
( NN O O
depression NN O O
and NN O O
type NN O O
2 NN O O
diabetes/low NN O O
back NN O O
pain NN O O
) NN O O
by NN O O
means NN O O
of NN O O
a NN O O
randomized NN O O
controlled NN O O
trial NN O O
( NN O O
RCT NN O O
) NN O O
. NN O O

Our NN O O
main NN O O
hypothesis NN O O
is NN O O
that NN O O
improved NN O O
usual NN O O
care NN O O
combined NN O O
with NN O O
psychological NN O O
therapy NN O O
applied NN O O
using NN O O
ICTs NN O O
will NN O O
be NN O O
more NN O O
efficacious NN O O
for NN O O
improvement NN O O
in NN O O
the NN O O
symptomatology NN O O
of NN O O
multimorbidity NN O O
, NN O O
compared NN O O
to NN O O
a NN O O
group NN O O
with NN O O
only NN O O
improved NN O O
treatment NN O O
as NN O O
usual NN O O
six NN O O
months NN O O
after NN O O
the NN O O
end NN O O
of NN O O
treatment NN O O
. NN O O

A NN O O
protocol NN O O
has NN O O
been NN O O
designed NN O O
combining NN O O
a NN O O
face-to-face NN O O
intervention NN O O
with NN O O
a NN O O
supporting NN O O
online NN O O
programme NN O O
that NN O O
will NN O O
be NN O O
tested NN O O
by NN O O
an NN O O
RCT NN O O
conducted NN O O
in NN O O
three NN O O
different NN O O
regions NN O O
( NN O O
Andalusia NN O O
, NN O O
Aragon NN O O
and NN O O
the NN O O
Balearic NN O O
Islands NN O O
) NN O O
. NN O O

The NN O O
RCT NN O O
will NN O O
evaluate NN O O
three NN O O
hundred NN O O
participants NN O O
diagnosed NN O O
with NN O O
depression NN O O
and NN O O
type NN O O
2 NN O O
diabetes/low NN O O
back NN O O
pain NN O O
. NN O O

Four NN O O
highly NN O O
experienced NN O O
research NN O O
groups NN O O
specializing NN O O
in NN O O
clinical NN O O
psychology NN O O
are NN O O
involved NN O O
in NN O O
this NN O O
trial NN O O
, NN O O
and NN O O
there NN O O
will NN O O
be NN O O
ample NN O O
possibilities NN O O
for NN O O
translation NN O O
and NN O O
transfer NN O O
to NN O O
usual NN O O
clinical NN O O
practice NN O O
. NN O O

This NN O O
clinical NN O O
trial NN O O
will NN O O
lead NN O O
to NN O O
improvement NN O O
in NN O O
financial NN O O
sustainability NN O O
, NN O O
maximizing NN O O
the NN O O
use NN O O
of NN O O
resources NN O O
and NN O O
responding NN O O
to NN O O
principles NN O O
of NN O O
efficiency NN O O
and NN O O
effectiveness NN O O
. NN O O

Furthermore NN O O
, NN O O
based NN O O
on NN O O
the NN O O
evaluation NN O O
of NN O O
the NN O O
feasibility NN O O
of NN O O
implementing NN O O
this NN O O
intervention NN O O
in NN O O
primary NN O O
care NN O O
facilities NN O O
, NN O O
we NN O O
expect NN O O
to NN O O
be NN O O
able NN O O
to NN O O
suggest NN O O
the NN O O
intervention NN O O
for NN O O
incorporation NN O O
into NN O O
public NN O O
policy NN O O
. NN O O

In NN O O
conclusion NN O O
, NN O O
positive NN O O
results NN O O
of NN O O
this NN O O
study NN O O
could NN O O
have NN O O
a NN O O
significant NN O O
impact NN O O
on NN O O
one NN O O
of NN O O
the NN O O
most NN O O
important NN O O
health-related NN O O
problems NN O O
, NN O O
multimorbidity NN O O
. NN O O

ClinicalTrials.gov NN O O
, NN O O
NCT03426709 NN O O
. NN O O

Registered NN O O
retrospectively NN O O
on NN O O
08 NN O O
February NN O O
2018 NN O O
. NN O O



-DOCSTART- (30659041)

Despite NN O O
antiretroviral NN O O
therapy NN O O
( NN O O
ART NN O O
) NN O O
, NN O O
people NN O O
living NN O O
with NN O O
HIV NN O O
have NN O O
higher NN O O
rates NN O O
of NN O O
non-infectious NN O O
chronic NN O O
diseases NN O O
. NN O O

These NN O O
conditions NN O O
are NN O O
driven NN O O
by NN O O
relatively NN O O
high NN O O
levels NN O O
of NN O O
inflammation NN O O
persisting NN O O
on NN O O
ART NN O O
compared NN O O
with NN O O
uninfected NN O O
individuals NN O O
. NN O O

Chronic NN O O
inflammation NN O O
also NN O O
contributes NN O O
to NN O O
HIV NN O O
persistence NN O O
during NN O O
ART NN O O
. NN O O

Cannabis NN O O
when NN O O
taken NN O O
orally NN O O
may NN O O
represent NN O O
a NN O O
way NN O O
to NN O O
reduce NN O O
inflammation NN O O
and NN O O
strengthen NN O O
immune NN O O
responses NN O O
. NN O O

Before NN O O
planning NN O O
large NN O O
interventional NN O O
studies NN O O
, NN O O
it NN O O
is NN O O
important NN O O
to NN O O
ensure NN O O
that NN O O
cannabis NN O O
taken NN O O
orally NN O O
is NN O O
safe NN O O
and NN O O
well NN O O
tolerated NN O O
in NN O O
people NN O O
living NN O O
with NN O O
HIV NN O O
. NN O O

We NN O O
propose NN O O
to NN O O
conduct NN O O
a NN O O
pilot NN O O
randomised NN O O
trial NN O O
to NN O O
examine NN O O
the NN O O
safety NN O O
and NN O O
tolerability NN O O
of NN O O
cannabis NN O O
oils NN O O
containing NN O O
tetrahydrocannabinol NN O O
( NN O O
THC NN O O
) NN O O
and NN O O
cannabidiol NN O O
( NN O O
CBD NN O O
) NN O O
consumed NN O O
orally NN O O
in NN O O
people NN O O
living NN O O
with NN O O
HIV NN O O
. NN O O

We NN O O
will NN O O
also NN O O
measure NN O O
inflammatory NN O O
markers NN O O
, NN O O
markers NN O O
of NN O O
HIV NN O O
persistence NN O O
in NN O O
peripheral NN O O
blood NN O O
cells NN O O
and NN O O
changes NN O O
in NN O O
the NN O O
gastrointestinal NN O O
microbiome NN O O
. NN O O

Twenty-six NN O O
people NN O O
living NN O O
with NN O O
HIV NN O O
having NN O O
undetectable NN O O
viral NN O O
load NN O O
for NN O O
at NN O O
least NN O O
3 NN O O
years NN O O
will NN O O
be NN O O
randomised NN O O
to NN O O
receive NN O O
TN-TC11LM NN O O
( NN O O
THC NN O O
: NN O O
CBD NN O O
in NN O O
1:1 NN O O
ratio NN O O
) NN O O
or NN O O
TN-TC19LM NN O O
( NN O O
THC NN O O
: NN O O
CBD NN O O
in NN O O
1:9 NN O O
ratio NN O O
) NN O O
capsules NN O O
daily NN O O
for NN O O
12 NN O O
weeks NN O O
. NN O O

Safety NN O O
and NN O O
tolerability NN O O
of NN O O
these NN O O
capsules NN O O
will NN O O
be NN O O
assessed NN O O
through NN O O
haematological NN O O
, NN O O
hepatic NN O O
and NN O O
renal NN O O
blood NN O O
tests NN O O
, NN O O
face-to-face NN O O
interviews NN O O
and NN O O
questionnaires NN O O
. NN O O

Proportions NN O O
of NN O O
participants NN O O
without NN O O
any NN O O
signs NN O O
of NN O O
significant NN O O
toxicity NN O O
( NN O O
grades NN O O
0 NN O O
- NN O O
2 NN O O
scores NN O O
on NN O O
the NN O O
WHO NN O O
toxicity NN O O
scale NN O O
) NN O O
and NN O O
who NN O O
complete NN O O
the NN O O
study NN O O
, NN O O
as NN O O
well NN O O
as NN O O
scores NN O O
on NN O O
quality NN O O
of NN O O
life NN O O
and NN O O
mood NN O O
will NN O O
be NN O O
examined NN O O
using NN O O
descriptive NN O O
statistics NN O O
. NN O O

The NN O O
effects NN O O
on NN O O
inflammatory NN O O
markers NN O O
, NN O O
markers NN O O
of NN O O
peripheral NN O O
blood NN O O
reservoir NN O O
size NN O O
and NN O O
effect NN O O
on NN O O
the NN O O
composition NN O O
of NN O O
the NN O O
gastrointestinal NN O O
microbiome NN O O
will NN O O
be NN O O
assessed NN O O
before NN O O
and NN O O
after NN O O
study NN O O
completion NN O O
. NN O O

This NN O O
study NN O O
has NN O O
been NN O O
approved NN O O
by NN O O
the NN O O
Research NN O O
Institute NN O O
of NN O O
the NN O O
McGill NN O O
University NN O O
Health NN O O
Centre NN O O
. NN O O

A NN O O
Data NN O O
Safety NN O O
Monitor NN O O
will NN O O
review NN O O
safety NN O O
information NN O O
at NN O O
regular NN O O
intervals NN O O
. NN O O

The NN O O
final NN O O
manuscript NN O O
will NN O O
be NN O O
submitted NN O O
to NN O O
an NN O O
open-access NN O O
journal NN O O
within NN O O
6 NN O O
months NN O O
of NN O O
study NN O O
completion NN O O
. NN O O

NCT03550352 NN O O
. NN O O



-DOCSTART- (31193792)

This NN O O
pilot NN O O
randomized NN O O
controlled NN O O
trial NN O O
sought NN O O
to NN O O
evaluate NN O O
whether NN O O
an NN O O
online NN O O
intervention NN O O
for NN O O
problem NN O O
gambling NN O O
could NN O O
lead NN O O
to NN O O
improved NN O O
gambling NN O O
outcomes NN O O
compared NN O O
to NN O O
a NN O O
no NN O O
intervention NN O O
control NN O O
. NN O O

Participants NN O O
were NN O O
recruited NN O O
through NN O O
a NN O O
crowdsourcing NN O O
platform NN O O
. NN O O

Participants NN O O
were NN O O
recruited NN O O
to NN O O
complete NN O O
an NN O O
online NN O O
survey NN O O
about NN O O
their NN O O
gambling NN O O
through NN O O
the NN O O
Mechanical NN O O
Turk NN O O
platform NN O O
. NN O O

Those NN O O
who NN O O
scored NN O O
5 NN O O
or NN O O
more NN O O
on NN O O
the NN O O
Problem NN O O
Gambling NN O O
Severity NN O O
Index NN O O
and NN O O
were NN O O
thinking NN O O
about NN O O
quitting NN O O
or NN O O
reducing NN O O
their NN O O
gambling NN O O
were NN O O
invited NN O O
to NN O O
complete NN O O
6-week NN O O
and NN O O
6-month NN O O
follow-ups NN O O
. NN O O

Each NN O O
potential NN O O
participant NN O O
who NN O O
agreed NN O O
was NN O O
sent NN O O
a NN O O
unique NN O O
password NN O O
. NN O O

Participants NN O O
who NN O O
used NN O O
their NN O O
password NN O O
to NN O O
log NN O O
onto NN O O
the NN O O
study NN O O
portal NN O O
were NN O O
randomized NN O O
to NN O O
either NN O O
access NN O O
an NN O O
online NN O O
intervention NN O O
for NN O O
gambling NN O O
or NN O O
to NN O O
a NN O O
no NN O O
intervention NN O O
control NN O O
. NN O O

A NN O O
total NN O O
of NN O O
321 NN O O
participants NN O O
were NN O O
recruited NN O O
, NN O O
of NN O O
which NN O O
87 NN O O
% NN O O
and NN O O
88 NN O O
% NN O O
were NN O O
followed-up NN O O
at NN O O
6 NN O O
weeks NN O O
and NN O O
6 NN O O
months NN O O
, NN O O
respectively NN O O
. NN O O

Outcome NN O O
analyses NN O O
revealed NN O O
that NN O O
, NN O O
while NN O O
there NN O O
were NN O O
reductions NN O O
in NN O O
gambling NN O O
from NN O O
baseline NN O O
to NN O O
follow-ups NN O O
, NN O O
there NN O O
was NN O O
no NN O O
significant NN O O
observable NN O O
impact NN O O
of NN O O
the NN O O
online NN O O
gambling NN O O
intervention NN O O
, NN O O
as NN O O
compared NN O O
to NN O O
a NN O O
no NN O O
intervention NN O O
control NN O O
condition NN O O
. NN O O

While NN O O
the NN O O
current NN O O
trial NN O O
observed NN O O
no NN O O
impact NN O O
of NN O O
the NN O O
intervention NN O O
, NN O O
replication NN O O
is NN O O
merited NN O O
with NN O O
a NN O O
larger NN O O
sample NN O O
size NN O O
, NN O O
and NN O O
with NN O O
participants NN O O
who NN O O
are NN O O
not NN O O
recruited NN O O
through NN O O
a NN O O
crowdsourcing NN O O
platform NN O O
. NN O O

Trial NN O O
registration NN O O
: NN O O
ClinicalTrials.govNCT03124589 NN O O
. NN O O



-DOCSTART- (30813758)

Procedural NN O O
results NN O O
for NN O O
percutaneous NN O O
coronary NN O O
intervention NN O O
( NN O O
PCI NN O O
) NN O O
in NN O O
coronary NN O O
vessels NN O O
with NN O O
chronic NN O O
total NN O O
occlusion NN O O
( NN O O
CTO NN O O
) NN O O
have NN O O
improved NN O O
in NN O O
recent NN O O
years NN O O
, NN O O
and NN O O
PCI NN O O
strategies NN O O
have NN O O
moved NN O O
toward NN O O
more NN O O
complete NN O O
revascularization NN O O
with NN O O
more NN O O
liberal NN O O
use NN O O
of NN O O
CTO-PCI NN O O
. NN O O

However NN O O
, NN O O
evidence NN O O
evaluating NN O O
CTO-PCI NN O O
is NN O O
limited NN O O
to NN O O
observational NN O O
studies NN O O
and NN O O
small NN O O
clinical NN O O
trials NN O O
. NN O O

In NN O O
this NN O O
open-label NN O O
, NN O O
multicenter NN O O
, NN O O
randomized NN O O
, NN O O
noninferiority NN O O
trial NN O O
, NN O O
PCI-eligible NN O O
patients NN O O
were NN O O
assigned NN O O
to NN O O
receive NN O O
either NN O O
1 NN O O
of NN O O
2 NN O O
strategies NN O O
: NN O O
PCI NN O O
or NN O O
no NN O O
PCI NN O O
for NN O O
the NN O O
qualifying NN O O
de NN O O
novo NN O O
CTO NN O O
lesion NN O O
with NN O O
the NN O O
option NN O O
for NN O O
PCI NN O O
of NN O O
obstructive NN O O
non-CTO NN O O
lesions NN O O
at NN O O
the NN O O
discretion NN O O
of NN O O
the NN O O
operator NN O O
. NN O O

The NN O O
primary NN O O
end NN O O
point NN O O
was NN O O
a NN O O
composite NN O O
of NN O O
death NN O O
, NN O O
myocardial NN O O
infarction NN O O
, NN O O
stroke NN O O
, NN O O
or NN O O
any NN O O
revascularization NN O O
. NN O O

Health-related NN O O
quality NN O O
of NN O O
life NN O O
was NN O O
assessed NN O O
at NN O O
baseline NN O O
and NN O O
at NN O O
1 NN O O
, NN O O
6 NN O O
, NN O O
12 NN O O
, NN O O
24 NN O O
, NN O O
and NN O O
36 NN O O
months NN O O
. NN O O

Because NN O O
of NN O O
slow NN O O
recruitment NN O O
, NN O O
the NN O O
trial NN O O
was NN O O
stopped NN O O
before NN O O
completion NN O O
of NN O O
the NN O O
1284 NN O O
planned NN O O
enrollments NN O O
. NN O O

Between NN O O
March NN O O
2010 NN O O
and NN O O
September NN O O
2016 NN O O
, NN O O
834 NN O O
patients NN O O
were NN O O
randomly NN O O
assigned NN O O
to NN O O
the NN O O
CTO-PCI NN O O
( NN O O
n=417 NN O O
) NN O O
or NN O O
no NN O O
CTO-PCI NN O O
( NN O O
n=398 NN O O
) NN O O
strategy NN O O
. NN O O

Among NN O O
the NN O O
patients NN O O
assigned NN O O
to NN O O
the NN O O
no NN O O
CTO-PCI NN O O
strategy NN O O
, NN O O
78 NN O O
( NN O O
19.6 NN O O
% NN O O
) NN O O
crossed NN O O
over NN O O
to NN O O
receive NN O O
staged NN O O
CTO-PCI NN O O
within NN O O
3 NN O O
days NN O O
of NN O O
randomization NN O O
. NN O O

The NN O O
overall NN O O
CTO-PCI NN O O
success NN O O
rate NN O O
was NN O O
90.6 NN O O
% NN O O
. NN O O

Serious NN O O
nonfatal NN O O
complications NN O O
associated NN O O
with NN O O
CTO-PCI NN O O
occurred NN O O
in NN O O
3 NN O O
patients NN O O
( NN O O
1 NN O O
stroke NN O O
, NN O O
1 NN O O
cardiac NN O O
tamponade NN O O
, NN O O
and NN O O
1 NN O O
patient NN O O
with NN O O
recurrent NN O O
episodes NN O O
of NN O O
ventricular NN O O
tachyarrhythmia NN O O
induced NN O O
by NN O O
intracoronary NN O O
thrombus NN O O
) NN O O
. NN O O

Approximately NN O O
half NN O O
of NN O O
the NN O O
patients NN O O
in NN O O
each NN O O
group NN O O
underwent NN O O
PCI NN O O
for NN O O
an NN O O
average NN O O
of NN O O
1.3 NN O O
non-CTO NN O O
lesions NN O O
, NN O O
resulting NN O O
in NN O O
a NN O O
comparable NN O O
residual NN O O
SYNTAX NN O O
score NN O O
( NN O O
Synergy NN O O
Between NN O O
PCI NN O O
With NN O O
TAXUS NN O O
and NN O O
Cardiac NN O O
Surgery NN O O
; NN O O
3.7±5.4 NN O O
versus NN O O
4.0±5.9 NN O O
, NN O O
P=0.42 NN O O
) NN O O
confined NN O O
to NN O O
non-CTO NN O O
vessels NN O O
. NN O O

During NN O O
a NN O O
median NN O O
follow-up NN O O
of NN O O
4.0 NN O O
years NN O O
( NN O O
interquartile NN O O
range NN O O
, NN O O
2.4 NN O O
to NN O O
5.1 NN O O
years NN O O
) NN O O
, NN O O
there NN O O
was NN O O
no NN O O
significant NN O O
difference NN O O
between NN O O
the NN O O
CTO-PCI NN O O
and NN O O
the NN O O
no NN O O
CTO-PCI NN O O
strategies NN O O
in NN O O
the NN O O
incidence NN O O
of NN O O
the NN O O
primary NN O O
end NN O O
point NN O O
( NN O O
22.3 NN O O
% NN O O
versus NN O O
22.4 NN O O
% NN O O
, NN O O
hazard NN O O
ratio NN O O
, NN O O
1.03 NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
0.77 NN O O
to NN O O
1.37 NN O O
; NN O O
P=0.86 NN O O
) NN O O
. NN O O

Both NN O O
CTO-PCI NN O O
and NN O O
no NN O O
CTO-PCI NN O O
strategy NN O O
were NN O O
associated NN O O
with NN O O
significant NN O O
improvements NN O O
but NN O O
without NN O O
between-group NN O O
differences NN O O
in NN O O
disease-specific NN O O
health NN O O
status NN O O
that NN O O
was NN O O
sustained NN O O
through NN O O
36 NN O O
months NN O O
. NN O O

CTO-PCI NN O O
was NN O O
feasible NN O O
with NN O O
high NN O O
success NN O O
rates NN O O
. NN O O

There NN O O
was NN O O
no NN O O
difference NN O O
in NN O O
the NN O O
incidence NN O O
of NN O O
major NN O O
adverse NN O O
cardiovascular NN O O
events NN O O
with NN O O
CTO-PCI NN O O
versus NN O O
no NN O O
CTO-PCI NN O O
, NN O O
but NN O O
the NN O O
study NN O O
was NN O O
limited NN O O
by NN O O
low NN O O
power NN O O
for NN O O
clinical NN O O
end NN O O
points NN O O
and NN O O
high NN O O
crossover NN O O
rates NN O O
between NN O O
groups NN O O
. NN O O

URL NN O O
: NN O O
https://www.clinicaltrials.gov NN O O
. NN O O

Unique NN O O
identifier NN O O
: NN O O
NCT01078051 NN O O
. NN O O



-DOCSTART- (31051499)

Telomere NN O O
attrition NN O O
may NN O O
play NN O O
an NN O O
important NN O O
role NN O O
in NN O O
the NN O O
pathogenesis NN O O
and NN O O
severity NN O O
of NN O O
type NN O O
2 NN O O
diabetes NN O O
( NN O O
T2D NN O O
) NN O O
, NN O O
increasing NN O O
the NN O O
probability NN O O
of NN O O
β NN O O
cell NN O O
senescence NN O O
and NN O O
leading NN O O
to NN O O
reduced NN O O
cell NN O O
mass NN O O
and NN O O
decreased NN O O
insulin NN O O
secretion NN O O
. NN O O

Nutrition NN O O
and NN O O
lifestyle NN O O
are NN O O
known NN O O
factors NN O O
modulating NN O O
the NN O O
aging NN O O
process NN O O
and NN O O
insulin NN O O
resistance/secretion NN O O
, NN O O
determining NN O O
the NN O O
risk NN O O
of NN O O
T2D NN O O
. NN O O

The NN O O
aim NN O O
of NN O O
this NN O O
study NN O O
was NN O O
to NN O O
evaluate NN O O
the NN O O
effects NN O O
of NN O O
pistachio NN O O
intake NN O O
on NN O O
telomere NN O O
length NN O O
and NN O O
other NN O O
cellular NN O O
aging-related NN O O
parameters NN O O
of NN O O
glucose NN O O
and NN O O
insulin NN O O
metabolism NN O O
. NN O O

Forty-nine NN O O
prediabetic NN O O
subjects NN O O
were NN O O
included NN O O
in NN O O
a NN O O
randomized NN O O
crossover NN O O
clinical NN O O
trial NN O O
. NN O O

Subjects NN O O
consumed NN O O
a NN O O
pistachio-supplemented NN O O
diet NN O O
( NN O O
PD NN O O
, NN O O
50 NN O O
E% NN O O
[ NN O O
energy NN O O
percentage NN O O
] NN O O
carbohydrates NN O O
and NN O O
33 NN O O
E% NN O O
fat NN O O
, NN O O
including NN O O
57 NN O O
g NN O O
pistachios/d NN O O
) NN O O
and NN O O
an NN O O
isocaloric NN O O
control NN O O
diet NN O O
( NN O O
CD NN O O
, NN O O
55 NN O O
E% NN O O
carbohydrates NN O O
and NN O O
30 NN O O
E% NN O O
fat NN O O
) NN O O
for NN O O
4 NN O O
mo NN O O
each NN O O
, NN O O
separated NN O O
by NN O O
a NN O O
2-wk NN O O
washout NN O O
period NN O O
. NN O O

DNA NN O O
oxidation NN O O
was NN O O
evaluated NN O O
by NN O O
DNA NN O O
damage NN O O
( NN O O
via NN O O
8-hydroxydeoxyguanosine NN O O
) NN O O
. NN O O

Leucocyte NN O O
telomere NN O O
length NN O O
and NN O O
gene NN O O
expression NN O O
related NN O O
to NN O O
either NN O O
oxidation NN O O
, NN O O
telomere NN O O
maintenance NN O O
or NN O O
glucose NN O O
, NN O O
and NN O O
insulin NN O O
metabolism NN O O
were NN O O
analyzed NN O O
by NN O O
multiplexed NN O O
quantitative NN O O
reverse NN O O
transcriptase-polymerase NN O O
chain NN O O
reaction NN O O
after NN O O
the NN O O
dietary NN O O
intervention NN O O
. NN O O

Compared NN O O
with NN O O
the NN O O
CD NN O O
, NN O O
the NN O O
PD NN O O
reduced NN O O
oxidative NN O O
damage NN O O
to NN O O
DNA NN O O
( NN O O
mean NN O O
: NN O O
-3.5 NN O O
% NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
: NN O O
-8.07 NN O O
% NN O O
, NN O O
1.05 NN O O
% NN O O
; NN O O
P NN O O
= NN O O
0.009 NN O O
) NN O O
. NN O O

Gene NN O O
expression NN O O
of NN O O
2 NN O O
telomere-related NN O O
genes NN O O
( NN O O
TERT NN O O
and NN O O
WRAP53 NN O O
) NN O O
was NN O O
significantly NN O O
upregulated NN O O
( NN O O
164 NN O O
% NN O O
and NN O O
53 NN O O
% NN O O
) NN O O
after NN O O
the NN O O
PD NN O O
compared NN O O
with NN O O
the NN O O
CD NN O O
( NN O O
P NN O O
= NN O O
0.043 NN O O
and NN O O
P NN O O
= NN O O
0.001 NN O O
, NN O O
respectively NN O O
) NN O O
. NN O O

Interestingly NN O O
, NN O O
changes NN O O
in NN O O
TERT NN O O
expression NN O O
were NN O O
negatively NN O O
correlated NN O O
to NN O O
changes NN O O
in NN O O
fasting NN O O
plasma NN O O
glucose NN O O
concentrations NN O O
and NN O O
in NN O O
the NN O O
homeostatic NN O O
model NN O O
assessment NN O O
of NN O O
insulin NN O O
resistance NN O O
. NN O O

Chronic NN O O
pistachio NN O O
consumption NN O O
reduces NN O O
oxidative NN O O
damage NN O O
to NN O O
DNA NN O O
and NN O O
increases NN O O
the NN O O
gene NN O O
expression NN O O
of NN O O
some NN O O
telomere-associated NN O O
genes NN O O
. NN O O

Lessening NN O O
oxidative NN O O
damage NN O O
to NN O O
DNA NN O O
and NN O O
telomerase NN O O
expression NN O O
through NN O O
diet NN O O
may NN O O
represent NN O O
an NN O O
intriguing NN O O
way NN O O
to NN O O
promote NN O O
healthspan NN O O
in NN O O
humans NN O O
, NN O O
reversing NN O O
certain NN O O
deleterious NN O O
metabolic NN O O
consequences NN O O
of NN O O
prediabetes NN O O
. NN O O

This NN O O
study NN O O
was NN O O
registered NN O O
at NN O O
clinicaltrials.gov NN O O
as NN O O
NCT01441921 NN O O
. NN O O



-DOCSTART- (31193477)

Non-surgical NN O O
topical NN O O
therapies NN O O
have NN O O
been NN O O
assessed NN O O
in NN O O
the NN O O
treatment NN O O
of NN O O
precancerous NN O O
lesions NN O O
of NN O O
the NN O O
cervix NN O O
. NN O O

Their NN O O
use NN O O
can NN O O
offer NN O O
logistical NN O O
and NN O O
feasibility NN O O
advantages NN O O
in NN O O
low-resource NN O O
settings NN O O
. NN O O

Antiviral NN O O
AV2 NN O O
is NN O O
a NN O O
mixture NN O O
of NN O O
natural NN O O
essential NN O O
oils NN O O
( NN O O
eugenol NN O O
, NN O O
carvone NN O O
, NN O O
nerolidol NN O O
, NN O O
geraniol NN O O
) NN O O
in NN O O
olive NN O O
oil NN O O
, NN O O
and NN O O
has NN O O
a NN O O
broad NN O O
spectrum NN O O
anti-viral NN O O
activity NN O O
. NN O O

In NN O O
a NN O O
phase NN O O
II NN O O
randomized NN O O
controlled NN O O
trial NN O O
( NN O O
RCT NN O O
) NN O O
, NN O O
AV2 NN O O
proved NN O O
effective NN O O
in NN O O
reducing NN O O
the NN O O
size NN O O
of NN O O
cervical NN O O
lesions NN O O
associated NN O O
with NN O O
human NN O O
papillomavirus NN O O
( NN O O
HPV NN O O
) NN O O
. NN O O

The NN O O
purpose NN O O
of NN O O
the NN O O
present NN O O
study NN O O
was NN O O
to NN O O
further NN O O
evaluate NN O O
the NN O O
efficacy NN O O
of NN O O
AV2 NN O O
over NN O O
placebo NN O O
in NN O O
the NN O O
topical NN O O
treatment NN O O
of NN O O
HPV-associated NN O O
cervical NN O O
lesions NN O O
. NN O O

Women NN O O
aged NN O O
25 NN O O
years NN O O
and NN O O
older NN O O
were NN O O
included NN O O
in NN O O
this NN O O
phase NN O O
3 NN O O
RCT NN O O
. NN O O

Cytology NN O O
screening NN O O
, NN O O
HPV NN O O
testing NN O O
and NN O O
visual NN O O
inspection NN O O
of NN O O
the NN O O
cervix NN O O
with NN O O
5 NN O O
% NN O O
acetic NN O O
acid NN O O
( NN O O
VIA NN O O
) NN O O
were NN O O
performed NN O O
on NN O O
all NN O O
participants NN O O
. NN O O

VIA-positive NN O O
women NN O O
were NN O O
randomized NN O O
to NN O O
one NN O O
of NN O O
two NN O O
groups NN O O
to NN O O
receive NN O O
treatment NN O O
by NN O O
either NN O O
AV2 NN O O
® NN O O
or NN O O
placebo NN O O
. NN O O

The NN O O
treatment NN O O
consisted NN O O
of NN O O
2 NN O O
puffs NN O O
of NN O O
spray NN O O
of NN O O
the NN O O
investigational NN O O
drug NN O O
directed NN O O
to NN O O
the NN O O
cervix NN O O
. NN O O

Participants NN O O
were NN O O
subjected NN O O
to NN O O
repeat NN O O
examinations NN O O
two NN O O
months NN O O
and NN O O
six NN O O
months NN O O
later NN O O
for NN O O
assessment NN O O
of NN O O
outcomes NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
was NN O O
the NN O O
change NN O O
of NN O O
lesions NN O O
on NN O O
VIA NN O O
at NN O O
2 NN O O
months NN O O
after NN O O
application NN O O
of NN O O
the NN O O
investigational NN O O
drug NN O O
. NN O O

Secondary NN O O
outcomes NN O O
were NN O O
: NN O O
HPV NN O O
clearance NN O O
and NN O O
cytologic NN O O
regression NN O O
at NN O O
2 NN O O
months NN O O
and NN O O
6 NN O O
months NN O O
, NN O O
and NN O O
number NN O O
of NN O O
participants NN O O
with NN O O
AEs NN O O
. NN O O

A NN O O
total NN O O
327 NN O O
VIA NN O O
positive NN O O
women NN O O
were NN O O
randomized NN O O
in NN O O
two NN O O
groups NN O O
( NN O O
168 NN O O
in NN O O
AV2 NN O O
group NN O O
and NN O O
159 NN O O
in NN O O
placebo NN O O
group NN O O
) NN O O
. NN O O

Women NN O O
in NN O O
the NN O O
2 NN O O
groups NN O O
were NN O O
similar NN O O
with NN O O
respect NN O O
to NN O O
baseline NN O O
demographics NN O O
and NN O O
clinical NN O O
characteristics NN O O
. NN O O

At NN O O
2 NN O O
months NN O O
, NN O O
regression NN O O
of NN O O
lesions NN O O
on NN O O
VIA NN O O
was NN O O
observed NN O O
in NN O O
127 NN O O
( NN O O
89.4 NN O O
% NN O O
) NN O O
out NN O O
of NN O O
142 NN O O
women NN O O
in NN O O
AV2 NN O O
group NN O O
compared NN O O
to NN O O
120 NN O O
( NN O O
91.6 NN O O
% NN O O
) NN O O
out NN O O
of NN O O
131 NN O O
women NN O O
in NN O O
placebo NN O O
group NN O O
( NN O O
P NN O O
= NN O O
0.7 NN O O
) NN O O
. NN O O

On NN O O
cytology NN O O
, NN O O
regression NN O O
of NN O O
lesions NN O O
occurred NN O O
in NN O O
14 NN O O
( NN O O
56 NN O O
% NN O O
) NN O O
out NN O O
of NN O O
25 NN O O
women NN O O
in NN O O
the NN O O
AV2 NN O O
arm NN O O
and NN O O
in NN O O
13 NN O O
( NN O O
48.1 NN O O
) NN O O
out NN O O
of NN O O
27 NN O O
women NN O O
in NN O O
the NN O O
placebo NN O O
arm NN O O
( NN O O
p NN O O
= NN O O
0.7 NN O O
) NN O O
, NN O O
and NN O O
HPV NN O O
clearance NN O O
rates NN O O
were NN O O
34.1 NN O O
% NN O O
and NN O O
35 NN O O
% NN O O
in NN O O
AV2 NN O O
group NN O O
and NN O O
placebo NN O O
group NN O O
respectively NN O O
( NN O O
p NN O O
= NN O O
0.8 NN O O
) NN O O
. NN O O

At NN O O
6 NN O O
months NN O O
cytologic NN O O
regression NN O O
was NN O O
observed NN O O
in NN O O
64.7 NN O O
% NN O O
of NN O O
women NN O O
in NN O O
AV2 NN O O
group NN O O
and NN O O
45.8 NN O O
% NN O O
in NN O O
placebo NN O O
group NN O O
( NN O O
p NN O O
= NN O O
0.2 NN O O
) NN O O
, NN O O
while NN O O
HPV NN O O
clearance NN O O
occurred NN O O
in NN O O
11 NN O O
( NN O O
51.9 NN O O
% NN O O
) NN O O
out NN O O
of NN O O
17 NN O O
women NN O O
in NN O O
AV2 NN O O
arm NN O O
versus NN O O
11 NN O O
( NN O O
34.4 NN O O
% NN O O
) NN O O
in NN O O
placebo NN O O
arm NN O O
( NN O O
p NN O O
= NN O O
0.3).Some NN O O
local NN O O
side NN O O
effects NN O O
( NN O O
burning NN O O
, NN O O
itching NN O O
, NN O O
irritation NN O O
) NN O O
were NN O O
similarly NN O O
noted NN O O
in NN O O
the NN O O
2 NN O O
groups NN O O
( NN O O
p-values NN O O
= NN O O
0.169 NN O O
, NN O O
0.623 NN O O
and NN O O
0.172 NN O O
respectively NN O O
) NN O O
but NN O O
they NN O O
were NN O O
mild NN O O
and NN O O
transitory NN O O
. NN O O

A NN O O
topical NN O O
application NN O O
of NN O O
AV2 NN O O
onto NN O O
the NN O O
cervix NN O O
can NN O O
induce NN O O
the NN O O
regression NN O O
of NN O O
cervical NN O O
precancerous NN O O
lesions NN O O
, NN O O
but NN O O
its NN O O
efficacy NN O O
does NN O O
not NN O O
significantly NN O O
differ NN O O
with NN O O
that NN O O
of NN O O
placebo NN O O
. NN O O

The NN O O
discrepancy NN O O
between NN O O
the NN O O
expected NN O O
and NN O O
the NN O O
recorded NN O O
sample NN O O
size NN O O
as NN O O
well NN O O
as NN O O
the NN O O
huge NN O O
number NN O O
of NN O O
lost NN O O
to NN O O
follow-up NN O O
probably NN O O
impeded NN O O
the NN O O
power NN O O
of NN O O
analyses NN O O
, NN O O
which NN O O
could NN O O
be NN O O
one NN O O
of NN O O
the NN O O
reasons NN O O
for NN O O
the NN O O
lack NN O O
of NN O O
difference NN O O
seen NN O O
between NN O O
AV2 NN O O
and NN O O
placebo NN O O
. NN O O

Further NN O O
evaluation NN O O
of NN O O
the NN O O
effects NN O O
of NN O O
AV2 NN O O
with NN O O
different NN O O
diagnostic NN O O
methods NN O O
and NN O O
treatment NN O O
regimen NN O O
and NN O O
arms NN O O
is NN O O
warranted NN O O
. NN O O

NCT02346227 NN O O
registered NN O O
on NN O O
November NN O O
8 NN O O
, NN O O
2014 NN O O
. NN O O



-DOCSTART- (30732459)

Medication-overuse NN O O
headache NN O O
leads NN O O
to NN O O
high NN O O
disability NN O O
and NN O O
decreased NN O O
quality NN O O
of NN O O
life NN O O
, NN O O
and NN O O
the NN O O
best NN O O
approach NN O O
for NN O O
withdrawal NN O O
has NN O O
been NN O O
debated NN O O
. NN O O

To NN O O
compare NN O O
change NN O O
in NN O O
disability NN O O
and NN O O
quality NN O O
of NN O O
life NN O O
between NN O O
two NN O O
withdrawal NN O O
programs NN O O
. NN O O

We NN O O
randomized NN O O
medication-overuse NN O O
headache NN O O
patients NN O O
to NN O O
program NN O O
A NN O O
( NN O O
two NN O O
months NN O O
without NN O O
acute NN O O
analgesics NN O O
or NN O O
migraine NN O O
medications NN O O
) NN O O
or NN O O
program NN O O
B NN O O
( NN O O
two NN O O
months NN O O
with NN O O
acute NN O O
medications NN O O
restricted NN O O
to NN O O
two NN O O
days/week NN O O
) NN O O
in NN O O
a NN O O
prospective NN O O
, NN O O
outpatient NN O O
study NN O O
. NN O O

At NN O O
6 NN O O
and NN O O
12 NN O O
months NN O O
, NN O O
we NN O O
measured NN O O
disability NN O O
and NN O O
headache NN O O
burden NN O O
by NN O O
the NN O O
Headache NN O O
Under-Response NN O O
to NN O O
Treatment NN O O
index NN O O
( NN O O
HURT NN O O
) NN O O
. NN O O

We NN O O
estimated NN O O
quality NN O O
of NN O O
life NN O O
by NN O O
EUROHIS-QOL NN O O
8-item NN O O
at NN O O
2- NN O O
, NN O O
6- NN O O
, NN O O
and NN O O
12-month NN O O
follow-up NN O O
. NN O O

Primary NN O O
endpoint NN O O
was NN O O
disability NN O O
change NN O O
at NN O O
12 NN O O
months NN O O
. NN O O

We NN O O
included NN O O
72 NN O O
medication-overuse NN O O
headache NN O O
patients NN O O
with NN O O
primary NN O O
migraine NN O O
and/or NN O O
tension-type NN O O
headache NN O O
. NN O O

Fifty NN O O
nine NN O O
completed NN O O
withdrawal NN O O
and NN O O
54 NN O O
completed NN O O
12-month NN O O
follow-up NN O O
. NN O O

At NN O O
12-month NN O O
follow-up NN O O
, NN O O
41 NN O O
patients NN O O
completed NN O O
HURT NN O O
and NN O O
38 NN O O
completed NN O O
EUROHIS-QOL NN O O
8-item NN O O
. NN O O

Disability NN O O
reduction NN O O
was NN O O
25 NN O O
% NN O O
in NN O O
program-A NN O O
and NN O O
7 NN O O
% NN O O
in NN O O
program-B NN O O
( NN O O
p NN O O
= NN O O
0.027 NN O O
) NN O O
. NN O O

Headache-burden NN O O
reduction NN O O
was NN O O
33 NN O O
% NN O O
in NN O O
program-A NN O O
and NN O O
3 NN O O
% NN O O
in NN O O
program-B NN O O
( NN O O
p NN O O
= NN O O
0.005 NN O O
) NN O O
. NN O O

Quality NN O O
of NN O O
life NN O O
was NN O O
increased NN O O
by NN O O
8 NN O O
% NN O O
in NN O O
both NN O O
programs NN O O
without NN O O
significant NN O O
difference NN O O
between NN O O
the NN O O
programs NN O O
( NN O O
p NN O O
= NN O O
0.30 NN O O
) NN O O
. NN O O

At NN O O
2-month NN O O
follow-up NN O O
, NN O O
quality NN O O
of NN O O
life NN O O
increased NN O O
significantly NN O O
more NN O O
in NN O O
program-A NN O O
than NN O O
program-B NN O O
( NN O O
p NN O O
= NN O O
0.006 NN O O
) NN O O
. NN O O

Both NN O O
withdrawal NN O O
programs NN O O
reduced NN O O
disability NN O O
and NN O O
increased NN O O
quality NN O O
of NN O O
life NN O O
. NN O O

Withdrawal NN O O
without NN O O
acute NN O O
medication NN O O
was NN O O
the NN O O
most NN O O
effective NN O O
in NN O O
reducing NN O O
disability NN O O
in NN O O
medication-overuse NN O O
headache NN O O
patients NN O O
. NN O O

Clinicaltrials.gov NN O O
( NN O O
NCT02903329 NN O O
) NN O O
. NN O O



-DOCSTART- (31273529)

To NN O O
compare NN O O
the NN O O
clinical NN O O
performance NN O O
of NN O O
cavities NN O O
with NN O O
no NN O O
lining NN O O
and NN O O
lining NN O O
with NN O O
resin-modified NN O O
glass NN O O
ionomer NN O O
( NN O O
RMGIC NN O O
) NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
root NN O O
surface NN O O
carious NN O O
lesions NN O O
. NN O O

The NN O O
study NN O O
included NN O O
39 NN O O
patients NN O O
( NN O O
mean NN O O
age NN O O
, NN O O
39.6 NN O O
years NN O O
) NN O O
who NN O O
visited NN O O
the NN O O
university NN O O
hospital NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
at NN O O
least NN O O
2 NN O O
root NN O O
surface NN O O
carious NN O O
lesions NN O O
. NN O O

After NN O O
caries NN O O
removal NN O O
, NN O O
the NN O O
depth NN O O
, NN O O
length NN O O
, NN O O
and NN O O
height NN O O
of NN O O
the NN O O
cavities NN O O
were NN O O
measured NN O O
. NN O O

Using NN O O
a NN O O
paired-tooth NN O O
design NN O O
and NN O O
simple NN O O
randomization NN O O
technique NN O O
, NN O O
the NN O O
cavities NN O O
were NN O O
assigned NN O O
to NN O O
one NN O O
of NN O O
two NN O O
groups NN O O
that NN O O
were NN O O
either NN O O
unlined NN O O
or NN O O
lined NN O O
with NN O O
RMGIC NN O O
( NN O O
Glass NN O O
Liner NN O O
II NN O O
) NN O O
. NN O O

All NN O O
cavities NN O O
were NN O O
restored NN O O
with NN O O
a NN O O
nanohybrid NN O O
resin-based NN O O
composite NN O O
( NN O O
Clearfil NN O O
Majesty NN O O
Esthetic NN O O
) NN O O
. NN O O

One NN O O
hundred NN O O
restorations NN O O
( NN O O
50 NN O O
lined NN O O
, NN O O
50 NN O O
unlined NN O O
) NN O O
were NN O O
placed NN O O
. NN O O

Two NN O O
examiners NN O O
other NN O O
than NN O O
the NN O O
operator NN O O
blindly NN O O
evaluated NN O O
the NN O O
restorations NN O O
at NN O O
the NN O O
follow-ups NN O O
according NN O O
to NN O O
the NN O O
modified NN O O
Havemann NN O O
criteria NN O O
for NN O O
marginal NN O O
adaptation NN O O
, NN O O
anatomic NN O O
form NN O O
, NN O O
marginal NN O O
staining NN O O
, NN O O
caries NN O O
in NN O O
the NN O O
adjacent NN O O
tooth NN O O
structure NN O O
, NN O O
caries NN O O
at NN O O
the NN O O
cavosurface NN O O
margin NN O O
, NN O O
and NN O O
tooth NN O O
sensitivity NN O O
. NN O O

Chi-square NN O O
, NN O O
Fisher NN O O
's NN O O
exact NN O O
, NN O O
Mann-Whitney NN O O
U NN O O
, NN O O
and NN O O
Cochran NN O O
Q NN O O
tests NN O O
were NN O O
used NN O O
for NN O O
the NN O O
analysis NN O O
( NN O O
p NN O O
< NN O O
0.05 NN O O
) NN O O
. NN O O

At NN O O
the NN O O
5-year NN O O
follow-up NN O O
, NN O O
12 NN O O
restorations NN O O
were NN O O
failed NN O O
. NN O O

However NN O O
, NN O O
there NN O O
was NN O O
no NN O O
significant NN O O
difference NN O O
between NN O O
the NN O O
marginal NN O O
adaptation NN O O
and NN O O
marginal NN O O
staining NN O O
of NN O O
the NN O O
materials NN O O
( NN O O
p NN O O
= NN O O
0.526 NN O O
and NN O O
p NN O O
= NN O O
0.893 NN O O
, NN O O
respectively NN O O
) NN O O
. NN O O

Four NN O O
caries NN O O
lesions NN O O
were NN O O
detected NN O O
in NN O O
the NN O O
adjacent NN O O
tooth NN O O
structure NN O O
and NN O O
at NN O O
the NN O O
cavosurface NN O O
margin NN O O
at NN O O
the NN O O
5-year NN O O
assessment NN O O
. NN O O

There NN O O
was NN O O
no NN O O
significant NN O O
difference NN O O
in NN O O
the NN O O
clinical NN O O
performance NN O O
of NN O O
the NN O O
lined NN O O
and NN O O
unlined NN O O
restorations NN O O
. NN O O

The NN O O
clinical NN O O
performance NN O O
of NN O O
both NN O O
unlined NN O O
and NN O O
RMGIC-lined NN O O
cavities NN O O
at NN O O
the NN O O
5-year NN O O
post-restoration NN O O
assessment NN O O
was NN O O
acceptable NN O O
. NN O O

NCT03802539 NN O O
. NN O O



-DOCSTART- (30674296)

Seroma NN O O
formation NN O O
is NN O O
the NN O O
most NN O O
common NN O O
complication NN O O
after NN O O
mastectomy NN O O
and NN O O
places NN O O
patients NN O O
at NN O O
risk NN O O
of NN O O
associated NN O O
morbidities NN O O
. NN O O

Microporous NN O O
polysaccharide NN O O
hemospheres NN O O
( NN O O
MPH NN O O
) NN O O
consists NN O O
of NN O O
hydrophilic NN O O
, NN O O
plant NN O O
based NN O O
, NN O O
polysaccharide NN O O
particles NN O O
and NN O O
is NN O O
currently NN O O
used NN O O
as NN O O
an NN O O
absorbable NN O O
hemostatic NN O O
agent NN O O
. NN O O

An NN O O
animal NN O O
model NN O O
evaluating NN O O
MPH NN O O
and NN O O
seroma NN O O
formation NN O O
after NN O O
mastectomy NN O O
with NN O O
axillary NN O O
lymph NN O O
node NN O O
dissection NN O O
showed NN O O
a NN O O
significant NN O O
decrease NN O O
in NN O O
seroma NN O O
volume NN O O
. NN O O

Study NN O O
aim NN O O
was NN O O
to NN O O
evaluate NN O O
topical NN O O
MPH NN O O
on NN O O
the NN O O
risk NN O O
of NN O O
post-mastectomy NN O O
seroma NN O O
formation NN O O
as NN O O
measured NN O O
by NN O O
total NN O O
drain NN O O
output NN O O
and NN O O
total NN O O
drain NN O O
days NN O O
. NN O O

Prospective NN O O
randomized NN O O
single-blinded NN O O
clinical NN O O
trial NN O O
of NN O O
patients NN O O
undergoing NN O O
mastectomy NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
breast NN O O
cancer NN O O
. NN O O

MPH NN O O
was NN O O
applied NN O O
to NN O O
the NN O O
surgical NN O O
site NN O O
in NN O O
the NN O O
study NN O O
group NN O O
and NN O O
no NN O O
application NN O O
in NN O O
the NN O O
control NN O O
group NN O O
. NN O O

Fifty NN O O
patients NN O O
were NN O O
enrolled NN O O
; NN O O
eight NN O O
were NN O O
excluded NN O O
due NN O O
to NN O O
missing NN O O
data NN O O
. NN O O

Forty-two NN O O
patients NN O O
were NN O O
evaluated NN O O
, NN O O
control NN O O
( NN O O
n NN O O
= NN O O
21 NN O O
) NN O O
vs. NN O O
MPH NN O O
( NN O O
n NN O O
= NN O O
21 NN O O
) NN O O
. NN O O

No NN O O
difference NN O O
was NN O O
identified NN O O
between NN O O
the NN O O
two NN O O
groups NN O O
regarding NN O O
demographics NN O O
, NN O O
tumor NN O O
stage NN O O
, NN O O
total NN O O
drain NN O O
days NN O O
, NN O O
total NN O O
drain NN O O
output NN O O
, NN O O
number NN O O
of NN O O
clinic NN O O
visits NN O O
, NN O O
or NN O O
complication NN O O
rates NN O O
. NN O O

On NN O O
a NN O O
subset NN O O
analysis NN O O
, NN O O
body NN O O
mass NN O O
index NN O O
( NN O O
BMI NN O O
) NN O O
greater NN O O
than NN O O
30 NN O O
was NN O O
identified NN O O
as NN O O
an NN O O
independent NN O O
risk NN O O
factor NN O O
for NN O O
high NN O O
drain NN O O
output NN O O
. NN O O

Post NN O O
hoc NN O O
analyses NN O O
of NN O O
MPH NN O O
controlling NN O O
for NN O O
BMI NN O O
also NN O O
revealed NN O O
no NN O O
statistical NN O O
difference NN O O
. NN O O

Unlike NN O O
the NN O O
data NN O O
presented NN O O
in NN O O
an NN O O
animal NN O O
model NN O O
, NN O O
no NN O O
difference NN O O
was NN O O
demonstrated NN O O
in NN O O
the NN O O
duration NN O O
and NN O O
quantity NN O O
of NN O O
serosanguinous NN O O
drainage NN O O
related NN O O
to NN O O
the NN O O
use NN O O
of NN O O
MPH NN O O
in NN O O
patients NN O O
undergoing NN O O
mastectomy NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
breast NN O O
cancer NN O O
. NN O O

BMI NN O O
greater NN O O
than NN O O
30 NN O O
was NN O O
identified NN O O
as NN O O
an NN O O
independent NN O O
risk NN O O
factor NN O O
for NN O O
high NN O O
drain NN O O
output NN O O
and NN O O
this NN O O
risk NN O O
was NN O O
not NN O O
affected NN O O
by NN O O
MPH NN O O
use NN O O
. NN O O

NCT03647930 NN O O
, NN O O
retrospectively NN O O
registered NN O O
08/2018 NN O O
. NN O O



-DOCSTART- (31079083)

Doin NN O O
therapy NN O O
is NN O O
a NN O O
manual NN O O
therapy NN O O
used NN O O
in NN O O
Korean NN O O
rehabilitation NN O O
medicine NN O O
. NN O O

Recently NN O O
, NN O O
the NN O O
use NN O O
of NN O O
acupuncture NN O O
with NN O O
Doin NN O O
has NN O O
increased NN O O
in NN O O
clinics NN O O
and NN O O
clinical NN O O
trials NN O O
have NN O O
demonstrated NN O O
its NN O O
effects NN O O
. NN O O

However NN O O
, NN O O
well-designed NN O O
studies NN O O
examining NN O O
the NN O O
efficacy NN O O
and NN O O
cost-effectiveness NN O O
of NN O O
acupuncture NN O O
with NN O O
Doin NN O O
therapy NN O O
are NN O O
rare NN O O
. NN O O

This NN O O
multicentre NN O O
, NN O O
assessor-blinded NN O O
, NN O O
randomised NN O O
controlled NN O O
trial NN O O
with NN O O
two NN O O
parallel NN O O
groups NN O O
aims NN O O
to NN O O
evaluate NN O O
the NN O O
clinical NN O O
effects NN O O
and NN O O
cost-effectiveness NN O O
of NN O O
acupuncture NN O O
with NN O O
Doin NN O O
therapy NN O O
. NN O O

A NN O O
total NN O O
of NN O O
124 NN O O
patients NN O O
( NN O O
with NN O O
a NN O O
neck NN O O
pain NN O O
duration NN O O
of NN O O
6 NN O O
months NN O O
or NN O O
longer NN O O
and NN O O
a NN O O
Numeric NN O O
Rating NN O O
Scale NN O O
≥5 NN O O
) NN O O
will NN O O
be NN O O
recruited NN O O
at NN O O
five NN O O
Korean NN O O
medicine NN O O
hospitals NN O O
. NN O O

Patients NN O O
will NN O O
be NN O O
randomly NN O O
allocated NN O O
to NN O O
acupuncture NN O O
with NN O O
Doin NN O O
therapy NN O O
( NN O O
n=62 NN O O
) NN O O
and NN O O
acupuncture NN O O
alone NN O O
( NN O O
n=62 NN O O
) NN O O
for NN O O
5 NN O O
weeks NN O O
of NN O O
treatment NN O O
. NN O O

This NN O O
study NN O O
will NN O O
be NN O O
carried NN O O
out NN O O
with NN O O
outcome NN O O
assessor NN O O
and NN O O
statistician NN O O
blinding NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
measure NN O O
will NN O O
consist NN O O
of NN O O
improvement NN O O
in NN O O
neck NN O O
pain NN O O
using NN O O
the NN O O
Visual NN O O
Analogue NN O O
Scale NN O O
at NN O O
6 NN O O
weeks NN O O
. NN O O

The NN O O
secondary NN O O
outcomes NN O O
including NN O O
measures NN O O
of NN O O
pain NN O O
, NN O O
functional NN O O
disability NN O O
, NN O O
health-related NN O O
quality NN O O
of NN O O
life NN O O
and NN O O
economic NN O O
evaluation NN O O
will NN O O
be NN O O
conducted NN O O
at NN O O
6 NN O O
weeks NN O O
, NN O O
and NN O O
3 NN O O
, NN O O
6 NN O O
, NN O O
9 NN O O
and NN O O
12 NN O O
months NN O O
after NN O O
treatment NN O O
ETHICS NN O O
AND NN O O
DISSEMINATION NN O O
: NN O O
The NN O O
project NN O O
is NN O O
approved NN O O
by NN O O
the NN O O
Institutional NN O O
Review NN O O
Board NN O O
( NN O O
IRB NN O O
) NN O O
of NN O O
the NN O O
Jaseng NN O O
Hospital NN O O
of NN O O
Korean NN O O
Medicine NN O O
and NN O O
the NN O O
Kyung NN O O
Hee NN O O
University NN O O
Korean NN O O
Medicine NN O O
Hospital NN O O
at NN O O
Gangdong NN O O
. NN O O

Dissemination NN O O
will NN O O
occur NN O O
after NN O O
the NN O O
findings NN O O
from NN O O
this NN O O
study NN O O
are NN O O
published NN O O
in NN O O
other NN O O
peer NN O O
reviewed NN O O
journals NN O O
. NN O O

NCT03558178 NN O O
; NN O O
KCT0003068 NN O O
; NN O O
Pre-results NN O O
. NN O O



-DOCSTART- (31345179)

Patients NN O O
with NN O O
breast NN O O
cancer NN O O
undergoing NN O O
chemotherapy NN O O
and NN O O
radiotherapy NN O O
experience NN O O
fatigue NN O O
and NN O O
other NN O O
treatment NN O O
side NN O O
effects NN O O
. NN O O

Integrative NN O O
therapies NN O O
combining NN O O
physical NN O O
activity NN O O
and NN O O
dietary NN O O
counseling NN O O
are NN O O
recommended NN O O
; NN O O
however NN O O
to NN O O
date NN O O
no NN O O
large NN O O
randomized NN O O
controlled NN O O
trial NN O O
has NN O O
been NN O O
conducted NN O O
during NN O O
adjuvant NN O O
therapy NN O O
. NN O O

The NN O O
Adapted NN O O
Physical NN O O
Activity NN O O
and NN O O
Diet NN O O
( NN O O
APAD NN O O
) NN O O
intervention NN O O
was NN O O
evaluated NN O O
for NN O O
its NN O O
ability NN O O
to NN O O
decrease NN O O
fatigue NN O O
( NN O O
primary NN O O
outcome NN O O
) NN O O
, NN O O
anxiety NN O O
, NN O O
depression NN O O
, NN O O
body NN O O
mass NN O O
index NN O O
( NN O O
BMI NN O O
) NN O O
, NN O O
and NN O O
fat NN O O
mass NN O O
, NN O O
and NN O O
enhance NN O O
muscular NN O O
and NN O O
cognitive NN O O
performances NN O O
, NN O O
and NN O O
quality-of-life NN O O
( NN O O
QoL NN O O
) NN O O
. NN O O

Women NN O O
diagnosed NN O O
with NN O O
early NN O O
breast NN O O
cancer NN O O
( NN O O
N NN O O
= NN O O
143 NN O O
, NN O O
mean NN O O
age NN O O
= NN O O
52 NN O O
± NN O O
10 NN O O
years NN O O
) NN O O
were NN O O
randomized NN O O
to NN O O
APAD NN O O
or NN O O
usual NN O O
care NN O O
( NN O O
UC NN O O
) NN O O
. NN O O

APAD NN O O
included NN O O
thrice-weekly NN O O
moderate-intensity NN O O
mixed NN O O
aerobic NN O O
and NN O O
resistance NN O O
exercise NN O O
sessions NN O O
and NN O O
9 NN O O
dietetic NN O O
consultations NN O O
. NN O O

Patient-reported NN O O
outcomes NN O O
( NN O O
PROs NN O O
) NN O O
and NN O O
anthropometric NN O O
, NN O O
muscular NN O O
, NN O O
and NN O O
cognitive NN O O
variables NN O O
were NN O O
measured NN O O
at NN O O
baseline NN O O
, NN O O
18 NN O O
weeks NN O O
( NN O O
end NN O O
of NN O O
chemotherapy NN O O
) NN O O
, NN O O
and NN O O
26 NN O O
weeks NN O O
( NN O O
end NN O O
of NN O O
radiotherapy NN O O
and NN O O
intervention NN O O
) NN O O
, NN O O
and NN O O
at NN O O
6- NN O O
and NN O O
12-month NN O O
post-intervention NN O O
follow-ups NN O O
. NN O O

Multi-adjusted NN O O
linear NN O O
mixed-effects NN O O
models NN O O
were NN O O
used NN O O
to NN O O
compare NN O O
groups NN O O
over NN O O
time NN O O
. NN O O

Significant NN O O
beneficial NN O O
effects NN O O
of NN O O
the NN O O
APAD NN O O
intervention NN O O
were NN O O
observed NN O O
on NN O O
all NN O O
PROs NN O O
( NN O O
i.e. NN O O
, NN O O
fatigue NN O O
, NN O O
QoL NN O O
, NN O O
anxiety NN O O
, NN O O
depression NN O O
) NN O O
at NN O O
18 NN O O
and NN O O
26 NN O O
weeks NN O O
. NN O O

The NN O O
significant NN O O
effect NN O O
on NN O O
fatigue NN O O
and NN O O
QoL NN O O
persisted NN O O
up NN O O
to NN O O
12-month NN O O
follow-up NN O O
. NN O O

Significant NN O O
decreases NN O O
in NN O O
BMI NN O O
, NN O O
fat NN O O
mass NN O O
, NN O O
and NN O O
increased NN O O
muscle NN O O
endurance NN O O
and NN O O
cognitive NN O O
flexibility NN O O
were NN O O
observed NN O O
at NN O O
26 NN O O
weeks NN O O
, NN O O
but NN O O
did NN O O
not NN O O
persist NN O O
afterward NN O O
. NN O O

Leisure NN O O
physical NN O O
activity NN O O
was NN O O
enhanced NN O O
in NN O O
the NN O O
APAD NN O O
group NN O O
vs NN O O
UC NN O O
group NN O O
at NN O O
18 NN O O
and NN O O
26 NN O O
weeks NN O O
. NN O O

No NN O O
significant NN O O
effect NN O O
of NN O O
the NN O O
intervention NN O O
was NN O O
found NN O O
on NN O O
major NN O O
macronutrients NN O O
intake NN O O
. NN O O

A NN O O
combined NN O O
diet NN O O
and NN O O
exercise NN O O
intervention NN O O
during NN O O
chemotherapy NN O O
and NN O O
radiotherapy NN O O
in NN O O
patients NN O O
with NN O O
early NN O O
breast NN O O
cancer NN O O
led NN O O
to NN O O
positive NN O O
changes NN O O
in NN O O
a NN O O
range NN O O
of NN O O
psychological NN O O
, NN O O
physiological NN O O
and NN O O
behavioral NN O O
outcomes NN O O
at NN O O
the NN O O
end NN O O
of NN O O
intervention NN O O
. NN O O

A NN O O
beneficial NN O O
effect NN O O
persisted NN O O
on NN O O
fatigue NN O O
and NN O O
QoL NN O O
at NN O O
long NN O O
term NN O O
, NN O O
i.e. NN O O
, NN O O
1 NN O O
year NN O O
post-intervention NN O O
. NN O O

Diet-exercise NN O O
supportive NN O O
care NN O O
should NN O O
be NN O O
integrated NN O O
into NN O O
the NN O O
management NN O O
of NN O O
early NN O O
breast NN O O
cancer NN O O
patients NN O O
. NN O O

The NN O O
APAD NN O O
study NN O O
was NN O O
prospectively NN O O
registered NN O O
on NN O O
ClinicalTrials.gov NN O O
( NN O O
NCT01495650 NN O O
; NN O O
date NN O O
of NN O O
registration NN O O
: NN O O
December NN O O
20 NN O O
, NN O O
2011 NN O O
) NN O O
. NN O O



-DOCSTART- (31116358)

Delirium NN O O
occurs NN O O
in NN O O
up NN O O
to NN O O
52 NN O O
% NN O O
of NN O O
patients NN O O
after NN O O
cardiac NN O O
surgery NN O O
and NN O O
may NN O O
result NN O O
from NN O O
changes NN O O
in NN O O
cerebral NN O O
perfusion NN O O
. NN O O

Using NN O O
intraoperative NN O O
cerebral NN O O
autoregulation NN O O
monitoring NN O O
to NN O O
individualize NN O O
and NN O O
optimize NN O O
cerebral NN O O
perfusion NN O O
may NN O O
be NN O O
a NN O O
useful NN O O
strategy NN O O
to NN O O
reduce NN O O
the NN O O
incidence NN O O
of NN O O
delirium NN O O
after NN O O
cardiac NN O O
surgery NN O O
. NN O O

To NN O O
determine NN O O
whether NN O O
targeting NN O O
mean NN O O
arterial NN O O
pressure NN O O
during NN O O
cardiopulmonary NN O O
bypass NN O O
( NN O O
CPB NN O O
) NN O O
using NN O O
cerebral NN O O
autoregulation NN O O
monitoring NN O O
reduces NN O O
the NN O O
incidence NN O O
of NN O O
delirium NN O O
compared NN O O
with NN O O
usual NN O O
care NN O O
. NN O O

This NN O O
randomized NN O O
clinical NN O O
trial NN O O
nested NN O O
within NN O O
a NN O O
larger NN O O
trial NN O O
enrolled NN O O
patients NN O O
older NN O O
than NN O O
55 NN O O
years NN O O
who NN O O
underwent NN O O
nonemergency NN O O
cardiac NN O O
surgery NN O O
at NN O O
a NN O O
single NN O O
US NN O O
academic NN O O
medical NN O O
center NN O O
between NN O O
October NN O O
11 NN O O
, NN O O
2012 NN O O
, NN O O
and NN O O
May NN O O
10 NN O O
, NN O O
2016 NN O O
, NN O O
and NN O O
had NN O O
a NN O O
high NN O O
risk NN O O
for NN O O
neurologic NN O O
complications NN O O
. NN O O

Patients NN O O
, NN O O
physicians NN O O
, NN O O
and NN O O
outcome NN O O
assessors NN O O
were NN O O
masked NN O O
to NN O O
the NN O O
assigned NN O O
intervention NN O O
. NN O O

A NN O O
total NN O O
of NN O O
2764 NN O O
patients NN O O
were NN O O
screened NN O O
, NN O O
and NN O O
199 NN O O
were NN O O
eligible NN O O
for NN O O
analysis NN O O
in NN O O
this NN O O
study NN O O
. NN O O

In NN O O
the NN O O
intervention NN O O
group NN O O
, NN O O
the NN O O
patient NN O O
's NN O O
lower NN O O
limit NN O O
of NN O O
cerebral NN O O
autoregulation NN O O
was NN O O
identified NN O O
during NN O O
surgery NN O O
before NN O O
CPB NN O O
. NN O O

On NN O O
CPB NN O O
, NN O O
the NN O O
patient NN O O
's NN O O
mean NN O O
arterial NN O O
pressure NN O O
was NN O O
targeted NN O O
to NN O O
be NN O O
greater NN O O
than NN O O
that NN O O
patient NN O O
's NN O O
lower NN O O
limit NN O O
of NN O O
autoregulation NN O O
. NN O O

In NN O O
the NN O O
control NN O O
group NN O O
, NN O O
mean NN O O
arterial NN O O
pressure NN O O
targets NN O O
were NN O O
determined NN O O
according NN O O
to NN O O
institutional NN O O
practice NN O O
. NN O O

The NN O O
main NN O O
outcome NN O O
was NN O O
any NN O O
incidence NN O O
of NN O O
delirium NN O O
on NN O O
postoperative NN O O
days NN O O
1 NN O O
through NN O O
4 NN O O
, NN O O
as NN O O
adjudicated NN O O
by NN O O
a NN O O
consensus NN O O
expert NN O O
panel NN O O
. NN O O

Among NN O O
the NN O O
199 NN O O
participants NN O O
in NN O O
this NN O O
study NN O O
, NN O O
mean NN O O
( NN O O
SD NN O O
) NN O O
age NN O O
was NN O O
70.3 NN O O
( NN O O
7.5 NN O O
) NN O O
years NN O O
and NN O O
150 NN O O
( NN O O
75.4 NN O O
% NN O O
) NN O O
were NN O O
male NN O O
. NN O O

One NN O O
hundred NN O O
sixty-two NN O O
( NN O O
81.4 NN O O
% NN O O
) NN O O
were NN O O
white NN O O
, NN O O
26 NN O O
( NN O O
13.1 NN O O
% NN O O
) NN O O
were NN O O
black NN O O
, NN O O
and NN O O
11 NN O O
( NN O O
5.5 NN O O
% NN O O
) NN O O
were NN O O
of NN O O
other NN O O
race NN O O
. NN O O

Of NN O O
103 NN O O
patients NN O O
randomized NN O O
to NN O O
usual NN O O
care NN O O
, NN O O
94 NN O O
were NN O O
analyzed NN O O
, NN O O
and NN O O
of NN O O
102 NN O O
patients NN O O
randomized NN O O
to NN O O
the NN O O
intervention NN O O
105 NN O O
were NN O O
analyzed NN O O
. NN O O

Excluding NN O O
5 NN O O
patients NN O O
with NN O O
coma NN O O
, NN O O
delirium NN O O
occurred NN O O
in NN O O
48 NN O O
of NN O O
the NN O O
91 NN O O
patients NN O O
( NN O O
53 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
usual NN O O
care NN O O
group NN O O
compared NN O O
with NN O O
39 NN O O
of NN O O
the NN O O
103 NN O O
patients NN O O
( NN O O
38 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
intervention NN O O
group NN O O
( NN O O
P NN O O
= NN O O
.04 NN O O
) NN O O
. NN O O

The NN O O
odds NN O O
of NN O O
delirium NN O O
were NN O O
reduced NN O O
by NN O O
45 NN O O
% NN O O
in NN O O
patients NN O O
randomized NN O O
to NN O O
the NN O O
autoregulation NN O O
group NN O O
( NN O O
odds NN O O
ratio NN O O
, NN O O
0.55 NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
0.31 NN O O
- NN O O
0.97 NN O O
; NN O O
P NN O O
= NN O O
.04 NN O O
) NN O O
. NN O O

The NN O O
results NN O O
of NN O O
this NN O O
study NN O O
suggest NN O O
that NN O O
optimizing NN O O
mean NN O O
arterial NN O O
pressure NN O O
to NN O O
be NN O O
greater NN O O
than NN O O
the NN O O
individual NN O O
patient NN O O
's NN O O
lower NN O O
limit NN O O
of NN O O
cerebral NN O O
autoregulation NN O O
during NN O O
CPB NN O O
may NN O O
reduce NN O O
the NN O O
incidence NN O O
of NN O O
delirium NN O O
after NN O O
cardiac NN O O
surgery NN O O
, NN O O
but NN O O
further NN O O
study NN O O
is NN O O
needed NN O O
. NN O O

ClinicalTrials.gov NN O O
identifier NN O O
: NN O O
NCT00981474 NN O O
. NN O O



-DOCSTART- (30601990)

Cervical NN O O
headgear NN O O
( NN O O
CH NN O O
) NN O O
is NN O O
a NN O O
commonly NN O O
used NN O O
orthodontic NN O O
appliance NN O O
and NN O O
its NN O O
dentoalveolar NN O O
changes NN O O
are NN O O
known NN O O
. NN O O

However NN O O
, NN O O
the NN O O
effects NN O O
related NN O O
to NN O O
gender NN O O
and NN O O
timing NN O O
have NN O O
gained NN O O
less NN O O
attention NN O O
. NN O O

To NN O O
examine NN O O
dimensions NN O O
of NN O O
dental NN O O
arches NN O O
among NN O O
children NN O O
with NN O O
Class NN O O
II NN O O
occlusion NN O O
without NN O O
posterior NN O O
mandibular NN O O
rotation NN O O
according NN O O
to NN O O
timing NN O O
of NN O O
Kloehn-type NN O O
CH NN O O
treatment NN O O
. NN O O

Prospective NN O O
, NN O O
randomized NN O O
, NN O O
parallel-group NN O O
controlled NN O O
trial NN O O
. NN O O

Sixty-seven NN O O
seven-year-old NN O O
children NN O O
with NN O O
a NN O O
Class NN O O
II NN O O
occlusion NN O O
were NN O O
included NN O O
in NN O O
the NN O O
study NN O O
. NN O O

The NN O O
children NN O O
were NN O O
randomized NN O O
into NN O O
two NN O O
equal-size NN O O
groups NN O O
in NN O O
1:1 NN O O
ratio NN O O
by NN O O
sealed-envelope NN O O
randomization NN O O
. NN O O

The NN O O
early NN O O
group NN O O
( NN O O
EG NN O O
, NN O O
n NN O O
= NN O O
33 NN O O
) NN O O
was NN O O
treated NN O O
between NN O O
T0 NN O O
and NN O O
T1 NN O O
( NN O O
26 NN O O
months NN O O
) NN O O
, NN O O
right NN O O
after NN O O
eruption NN O O
of NN O O
the NN O O
first NN O O
maxillary NN O O
molars NN O O
. NN O O

The NN O O
late NN O O
group NN O O
( NN O O
LG NN O O
, NN O O
n NN O O
= NN O O
34 NN O O
) NN O O
was NN O O
treated NN O O
between NN O O
T1 NN O O
and NN O O
T2 NN O O
( NN O O
24 NN O O
months NN O O
) NN O O
. NN O O

The NN O O
children NN O O
were NN O O
treated NN O O
with NN O O
CH NN O O
until NN O O
normal NN O O
Class NN O O
I NN O O
occlusion NN O O
on NN O O
first NN O O
molars NN O O
was NN O O
achieved NN O O
. NN O O

Impressions NN O O
for NN O O
dental NN O O
casts NN O O
were NN O O
taken NN O O
from NN O O
all NN O O
participants NN O O
at NN O O
T0 NN O O
, NN O O
T1 NN O O
, NN O O
and NN O O
T2 NN O O
. NN O O

Blinding NN O O
was NN O O
applicable NN O O
for NN O O
outcome NN O O
assessors NN O O
. NN O O

Changes NN O O
in NN O O
dental NN O O
cast NN O O
measurements NN O O
were NN O O
compared NN O O
between NN O O
the NN O O
groups NN O O
and NN O O
genders NN O O
using NN O O
t-test NN O O
, NN O O
Mann-Whitney NN O O
U-test NN O O
, NN O O
and NN O O
repeated NN O O
measures NN O O
analysis NN O O
of NN O O
variance NN O O
. NN O O

Of NN O O
the NN O O
children NN O O
, NN O O
56 NN O O
completed NN O O
the NN O O
study NN O O
. NN O O

The NN O O
maxillary NN O O
arch NN O O
length NN O O
and NN O O
the NN O O
transversal NN O O
changes NN O O
between NN O O
the NN O O
upper NN O O
canines NN O O
and NN O O
upper NN O O
first NN O O
molars NN O O
were NN O O
significantly NN O O
increased NN O O
in NN O O
EG NN O O
at NN O O
T0-T1 NN O O
( NN O O
P NN O O
< NN O O
0.001 NN O O
) NN O O
. NN O O

At NN O O
T2 NN O O
, NN O O
the NN O O
transversal NN O O
dimension NN O O
between NN O O
the NN O O
upper NN O O
first NN O O
molars NN O O
was NN O O
larger NN O O
( NN O O
P NN O O
< NN O O
0.05 NN O O
) NN O O
, NN O O
and NN O O
in NN O O
the NN O O
lower NN O O
arch NN O O
the NN O O
mandibular NN O O
arch NN O O
length NN O O
( NN O O
P NN O O
< NN O O
0.05 NN O O
) NN O O
and NN O O
the NN O O
transversal NN O O
dimension NN O O
between NN O O
the NN O O
lower NN O O
first NN O O
molars NN O O
( NN O O
P NN O O
< NN O O
0.01 NN O O
) NN O O
were NN O O
increased NN O O
in NN O O
EG NN O O
males NN O O
compared NN O O
to NN O O
LG NN O O
males NN O O
. NN O O

No NN O O
harms NN O O
were NN O O
encountered NN O O
. NN O O

The NN O O
male NN O O
gender NN O O
benefits NN O O
most NN O O
from NN O O
early NN O O
timing NN O O
of NN O O
the NN O O
CH NN O O
treatment NN O O
, NN O O
showing NN O O
larger NN O O
dimensions NN O O
at NN O O
the NN O O
end NN O O
of NN O O
the NN O O
follow-up NN O O
. NN O O

The NN O O
results NN O O
clearly NN O O
indicated NN O O
a NN O O
wider NN O O
and NN O O
longer NN O O
upper NN O O
dental NN O O
arch NN O O
and NN O O
spontaneous NN O O
expansion NN O O
of NN O O
the NN O O
lower NN O O
dental NN O O
arch NN O O
after NN O O
treatment NN O O
. NN O O

NCT02010346 NN O O
. NN O O



-DOCSTART- (31286871)

Despite NN O O
numerous NN O O
guidelines NN O O
, NN O O
nearly NN O O
one NN O O
of NN O O
two NN O O
patients NN O O
with NN O O
cancer NN O O
pain NN O O
remains NN O O
undertreated NN O O
, NN O O
thereby NN O O
affecting NN O O
their NN O O
quality NN O O
of NN O O
life NN O O
. NN O O

Active NN O O
patient NN O O
involvement NN O O
through NN O O
Therapeutic NN O O
Patient NN O O
Education NN O O
( NN O O
TPE NN O O
) NN O O
is NN O O
considered NN O O
as NN O O
a NN O O
relevant NN O O
strategy NN O O
to NN O O
overcoming NN O O
hurdles NN O O
in NN O O
pain NN O O
management NN O O
. NN O O

The NN O O
aim NN O O
of NN O O
the NN O O
EFFADOL NN O O
study NN O O
is NN O O
to NN O O
assess NN O O
the NN O O
effectiveness NN O O
of NN O O
a NN O O
TPE NN O O
program NN O O
in NN O O
improving NN O O
cancer NN O O
pain NN O O
management NN O O
. NN O O

The NN O O
EFFADOL NN O O
study NN O O
is NN O O
a NN O O
stepped-wedge NN O O
randomised NN O O
controlled NN O O
trial NN O O
. NN O O

A NN O O
total NN O O
of NN O O
260 NN O O
cancer NN O O
patients NN O O
with NN O O
unbalanced NN O O
background NN O O
pain NN O O
will NN O O
be NN O O
randomised NN O O
over NN O O
the NN O O
institutional NN O O
level NN O O
, NN O O
i.e. NN O O
stepped-wedge NN O O
cluster NN O O
design NN O O
. NN O O

Six NN O O
clusters NN O O
will NN O O
be NN O O
formed NN O O
, NN O O
one NN O O
at NN O O
the NN O O
regional NN O O
level NN O O
of NN O O
" NN O O
Basse-Normandie NN O O
" NN O O
for NN O O
patients NN O O
receiving NN O O
the NN O O
educational NN O O
approach NN O O
by NN O O
health NN O O
providers NN O O
already NN O O
trained NN O O
to NN O O
TPE NN O O
. NN O O

Then NN O O
, NN O O
five NN O O
additional NN O O
centers NN O O
will NN O O
be NN O O
gradually NN O O
included NN O O
at NN O O
the NN O O
national NN O O
level NN O O
, NN O O
making NN O O
it NN O O
possible NN O O
to NN O O
compare NN O O
the NN O O
" NN O O
conventional NN O O
" NN O O
management NN O O
of NN O O
pain NN O O
( NN O O
before NN O O
medical NN O O
staff NN O O
training NN O O
to NN O O
TPE NN O O
) NN O O
with NN O O
the NN O O
educational NN O O
approach NN O O
( NN O O
after NN O O
being NN O O
trained NN O O
) NN O O
. NN O O

The NN O O
main NN O O
study NN O O
parameter NN O O
is NN O O
pain NN O O
interference NN O O
on NN O O
daily NN O O
life NN O O
assessed NN O O
with NN O O
the NN O O
self-administrated NN O O
and NN O O
validated NN O O
Brief NN O O
Pain NN O O
Inventory NN O O
questionnaire NN O O
. NN O O

Secondary NN O O
objectives NN O O
comprised NN O O
the NN O O
evaluation NN O O
of NN O O
patients NN O O
' NN O O
adherence NN O O
to NN O O
pain NN O O
education NN O O
program NN O O
, NN O O
the NN O O
description NN O O
of NN O O
pain NN O O
intensity NN O O
, NN O O
pain NN O O
relief NN O O
, NN O O
analgesic NN O O
adherence NN O O
and NN O O
pain NN O O
emotional NN O O
impact NN O O
. NN O O

Educational NN O O
dimension NN O O
of NN O O
the NN O O
program NN O O
will NN O O
be NN O O
evaluated NN O O
through NN O O
the NN O O
patients NN O O
' NN O O
acquisition NN O O
of NN O O
knowledge NN O O
and NN O O
skills NN O O
about NN O O
their NN O O
pain NN O O
and NN O O
treatment NN O O
as NN O O
well NN O O
as NN O O
their NN O O
self-efficacy NN O O
to NN O O
participate NN O O
actively NN O O
in NN O O
pain NN O O
management NN O O
. NN O O

The NN O O
patient NN O O
's NN O O
feeling NN O O
of NN O O
pain NN O O
changes NN O O
will NN O O
be NN O O
measured NN O O
. NN O O

Finally NN O O
, NN O O
the NN O O
satisfaction NN O O
of NN O O
participants NN O O
and NN O O
educators NN O O
will NN O O
be NN O O
reported NN O O
. NN O O

We NN O O
hypothetise NN O O
active NN O O
involvement NN O O
of NN O O
patients NN O O
in NN O O
TPE NN O O
will NN O O
lead NN O O
to NN O O
an NN O O
improved NN O O
pain NN O O
management NN O O
compared NN O O
to NN O O
standard NN O O
care NN O O
. NN O O

Analyzing NN O O
the NN O O
impact NN O O
of NN O O
a NN O O
TPE NN O O
program NN O O
in NN O O
cancer NN O O
pain NN O O
patients NN O O
will NN O O
improve NN O O
their NN O O
pain NN O O
management NN O O
and NN O O
quality NN O O
of NN O O
life NN O O
. NN O O

We NN O O
expect NN O O
that NN O O
the NN O O
dissemination NN O O
of NN O O
our NN O O
project NN O O
educational NN O O
approach NN O O
through NN O O
the NN O O
French NN O O
territory NN O O
will NN O O
be NN O O
accompanied NN O O
by NN O O
long NN O O
term NN O O
change NN O O
in NN O O
clinical NN O O
practices NN O O
with NN O O
mutual NN O O
benefit NN O O
to NN O O
patients NN O O
and NN O O
caregiver-educators NN O O
. NN O O

NCT03297723 NN O O
, NN O O
registered NN O O
: NN O O
09/28/2017 NN O O
. NN O O

Protocol NN O O
version NN O O
: NN O O
Version NN O O
n NN O O
° NN O O
1.1 NN O O
dated NN O O
from NN O O
2016/09/08 NN O O
. NN O O



-DOCSTART- (31120501)

Autophagy NN O O
is NN O O
a NN O O
mechanism NN O O
of NN O O
treatment NN O O
resistance NN O O
to NN O O
chemotherapy NN O O
that NN O O
has NN O O
a NN O O
role NN O O
in NN O O
the NN O O
maintenance NN O O
of NN O O
pancreatic NN O O
cancer NN O O
. NN O O

Hydroxychloroquine NN O O
sulfate NN O O
( NN O O
HCQ NN O O
) NN O O
is NN O O
an NN O O
inhibitor NN O O
of NN O O
autophagy NN O O
that NN O O
inhibits NN O O
the NN O O
fusion NN O O
of NN O O
the NN O O
autophagosome NN O O
to NN O O
the NN O O
lysosome NN O O
. NN O O

To NN O O
determine NN O O
whether NN O O
HCQ NN O O
improves NN O O
overall NN O O
survival NN O O
at NN O O
1 NN O O
year NN O O
in NN O O
combination NN O O
with NN O O
gemcitabine NN O O
hydrochloride NN O O
and NN O O
nab-paclitaxel NN O O
( NN O O
GA NN O O
) NN O O
among NN O O
patients NN O O
with NN O O
metastatic NN O O
pancreatic NN O O
cancer NN O O
. NN O O

Open-label NN O O
, NN O O
phase NN O O
2 NN O O
randomized NN O O
clinical NN O O
trial NN O O
conducted NN O O
between NN O O
March NN O O
18 NN O O
, NN O O
2013 NN O O
, NN O O
and NN O O
November NN O O
16 NN O O
, NN O O
2017 NN O O
, NN O O
at NN O O
the NN O O
University NN O O
of NN O O
Pennsylvania NN O O
, NN O O
HonorHealth NN O O
, NN O O
and NN O O
The NN O O
Johns NN O O
Hopkins NN O O
University NN O O
among NN O O
112 NN O O
patients NN O O
with NN O O
previously NN O O
untreated NN O O
metastatic NN O O
or NN O O
advanced NN O O
pancreatic NN O O
ductal NN O O
adenocarcinoma NN O O
, NN O O
Eastern NN O O
Cooperative NN O O
Oncology NN O O
Group NN O O
performance NN O O
status NN O O
of NN O O
0 NN O O
or NN O O
1 NN O O
, NN O O
and NN O O
adequate NN O O
marrow NN O O
and NN O O
organ NN O O
function NN O O
. NN O O

All NN O O
efficacy NN O O
analyses NN O O
were NN O O
performed NN O O
for NN O O
the NN O O
intention-to-treat NN O O
population NN O O
. NN O O

Patients NN O O
were NN O O
randomized NN O O
in NN O O
a NN O O
1:1 NN O O
ratio NN O O
to NN O O
receive NN O O
GA NN O O
with NN O O
or NN O O
without NN O O
HCQ NN O O
. NN O O

All NN O O
patients NN O O
received NN O O
standard NN O O
doses NN O O
of NN O O
GA NN O O
, NN O O
and NN O O
those NN O O
randomized NN O O
to NN O O
receive NN O O
HCQ NN O O
were NN O O
treated NN O O
continuously NN O O
with NN O O
600 NN O O
mg NN O O
orally NN O O
twice NN O O
daily NN O O
. NN O O

Overall NN O O
survival NN O O
at NN O O
1 NN O O
year NN O O
. NN O O

A NN O O
total NN O O
of NN O O
112 NN O O
patients NN O O
( NN O O
45 NN O O
women NN O O
and NN O O
67 NN O O
men NN O O
; NN O O
median NN O O
age NN O O
, NN O O
65 NN O O
years NN O O
; NN O O
range NN O O
, NN O O
43 NN O O
- NN O O
86 NN O O
years NN O O
) NN O O
were NN O O
enrolled NN O O
; NN O O
55 NN O O
were NN O O
randomized NN O O
to NN O O
receive NN O O
GA NN O O
plus NN O O
HCQ NN O O
, NN O O
and NN O O
57 NN O O
to NN O O
receive NN O O
GA NN O O
. NN O O

Overall NN O O
survival NN O O
at NN O O
12 NN O O
months NN O O
was NN O O
41 NN O O
% NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
27%-53 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
HCQ NN O O
group NN O O
and NN O O
49 NN O O
% NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
35%-61 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
non-HCQ NN O O
group NN O O
. NN O O

Median NN O O
progression-free NN O O
survival NN O O
was NN O O
5.7 NN O O
months NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
4.0 NN O O
- NN O O
9.3 NN O O
months NN O O
) NN O O
in NN O O
the NN O O
HCQ NN O O
group NN O O
and NN O O
6.4 NN O O
months NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
4.5 NN O O
- NN O O
7.6 NN O O
months NN O O
) NN O O
in NN O O
the NN O O
non-HCQ NN O O
group NN O O
. NN O O

Median NN O O
overall NN O O
survival NN O O
was NN O O
11.1 NN O O
months NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
9.0 NN O O
- NN O O
14.2 NN O O
months NN O O
) NN O O
in NN O O
the NN O O
HCQ NN O O
group NN O O
and NN O O
12.1 NN O O
months NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
9.3 NN O O
- NN O O
15.5 NN O O
months NN O O
) NN O O
in NN O O
the NN O O
non-HCQ NN O O
group NN O O
. NN O O

Overall NN O O
response NN O O
rate NN O O
was NN O O
38.2 NN O O
% NN O O
( NN O O
n NN O O
= NN O O
21 NN O O
) NN O O
in NN O O
the NN O O
HCQ NN O O
group NN O O
and NN O O
21.1 NN O O
% NN O O
( NN O O
n NN O O
= NN O O
12 NN O O
) NN O O
in NN O O
the NN O O
non-HCQ NN O O
group NN O O
( NN O O
P NN O O
= NN O O
.047 NN O O
) NN O O
. NN O O

Treatment-related NN O O
grade NN O O
3 NN O O
or NN O O
4 NN O O
adverse NN O O
events NN O O
that NN O O
differed NN O O
between NN O O
the NN O O
HCQ NN O O
and NN O O
non-HCQ NN O O
groups NN O O
were NN O O
neutropenia NN O O
( NN O O
23 NN O O
of NN O O
54 NN O O
[ NN O O
42.6 NN O O
% NN O O
] NN O O
vs NN O O
12 NN O O
of NN O O
53 NN O O
[ NN O O
22.6 NN O O
% NN O O
] NN O O
) NN O O
, NN O O
anemia NN O O
( NN O O
2 NN O O
of NN O O
54 NN O O
[ NN O O
3.7 NN O O
% NN O O
] NN O O
vs NN O O
9 NN O O
of NN O O
53 NN O O
[ NN O O
17.0 NN O O
% NN O O
] NN O O
) NN O O
, NN O O
fatigue NN O O
( NN O O
4 NN O O
of NN O O
54 NN O O
[ NN O O
7.4 NN O O
% NN O O
] NN O O
vs NN O O
0 NN O O
) NN O O
, NN O O
nausea NN O O
( NN O O
5 NN O O
of NN O O
54 NN O O
[ NN O O
9.3 NN O O
% NN O O
] NN O O
vs NN O O
0 NN O O
) NN O O
, NN O O
peripheral NN O O
neuropathy NN O O
( NN O O
7 NN O O
of NN O O
54 NN O O
[ NN O O
13.0 NN O O
% NN O O
] NN O O
vs NN O O
3 NN O O
of NN O O
53 NN O O
[ NN O O
5.7 NN O O
% NN O O
] NN O O
) NN O O
, NN O O
visual NN O O
changes NN O O
( NN O O
3 NN O O
of NN O O
54 NN O O
[ NN O O
5.6 NN O O
% NN O O
] NN O O
vs NN O O
0 NN O O
) NN O O
, NN O O
and NN O O
neuropsychiatric NN O O
symptoms NN O O
( NN O O
3 NN O O
of NN O O
54 NN O O
[ NN O O
5.6 NN O O
% NN O O
] NN O O
vs NN O O
0 NN O O
) NN O O
. NN O O

The NN O O
addition NN O O
of NN O O
HCQ NN O O
to NN O O
block NN O O
autophagy NN O O
did NN O O
not NN O O
improve NN O O
the NN O O
primary NN O O
end NN O O
point NN O O
of NN O O
overall NN O O
survival NN O O
at NN O O
12 NN O O
months NN O O
. NN O O

These NN O O
data NN O O
do NN O O
not NN O O
support NN O O
the NN O O
routine NN O O
use NN O O
of NN O O
GA NN O O
plus NN O O
HCQ NN O O
for NN O O
metastatic NN O O
pancreatic NN O O
cancer NN O O
in NN O O
the NN O O
absence NN O O
of NN O O
a NN O O
biomarker NN O O
. NN O O

However NN O O
, NN O O
improvement NN O O
seen NN O O
in NN O O
the NN O O
overall NN O O
response NN O O
rate NN O O
with NN O O
HCQ NN O O
may NN O O
indicate NN O O
a NN O O
role NN O O
for NN O O
HCQ NN O O
in NN O O
the NN O O
locally NN O O
advanced NN O O
setting NN O O
, NN O O
where NN O O
tumor NN O O
response NN O O
may NN O O
permit NN O O
resection NN O O
. NN O O

ClinicalTrials.gov NN O O
identifier NN O O
: NN O O
NCT01506973 NN O O
. NN O O



-DOCSTART- (31327689)

Lenalidomide NN O O
and NN O O
dexamethasone NN O O
has NN O O
been NN O O
a NN O O
standard NN O O
of NN O O
care NN O O
in NN O O
transplant-ineligible NN O O
patients NN O O
with NN O O
newly NN O O
diagnosed NN O O
multiple NN O O
myeloma NN O O
. NN O O

The NN O O
addition NN O O
of NN O O
a NN O O
third NN O O
drug NN O O
to NN O O
the NN O O
combination NN O O
is NN O O
likely NN O O
to NN O O
improve NN O O
treatment NN O O
efficacy NN O O
. NN O O

KEYNOTE-185 NN O O
assessed NN O O
the NN O O
efficacy NN O O
and NN O O
safety NN O O
of NN O O
lenalidomide NN O O
and NN O O
dexamethasone NN O O
with NN O O
and NN O O
without NN O O
pembrolizumab NN O O
in NN O O
patients NN O O
with NN O O
previously NN O O
untreated NN O O
multiple NN O O
myeloma NN O O
. NN O O

Here NN O O
, NN O O
we NN O O
present NN O O
the NN O O
results NN O O
of NN O O
an NN O O
unplanned NN O O
interim NN O O
analysis NN O O
done NN O O
to NN O O
assess NN O O
the NN O O
benefit-risk NN O O
of NN O O
the NN O O
combination NN O O
at NN O O
the NN O O
request NN O O
of NN O O
the NN O O
US NN O O
Food NN O O
and NN O O
Drug NN O O
Administration NN O O
( NN O O
FDA NN O O
) NN O O
. NN O O

KEYNOTE-185 NN O O
was NN O O
a NN O O
randomised NN O O
, NN O O
open-label NN O O
, NN O O
phase NN O O
3 NN O O
trial NN O O
done NN O O
at NN O O
95 NN O O
medical NN O O
centres NN O O
across NN O O
15 NN O O
countries NN O O
( NN O O
Australia NN O O
, NN O O
Canada NN O O
, NN O O
France NN O O
, NN O O
Germany NN O O
, NN O O
Ireland NN O O
, NN O O
Israel NN O O
, NN O O
Italy NN O O
, NN O O
Japan NN O O
, NN O O
New NN O O
Zealand NN O O
, NN O O
Norway NN O O
, NN O O
Russia NN O O
, NN O O
South NN O O
Africa NN O O
, NN O O
Spain NN O O
, NN O O
UK NN O O
, NN O O
and NN O O
USA NN O O
) NN O O
. NN O O

Transplantation-ineligible NN O O
patients NN O O
aged NN O O
18 NN O O
years NN O O
and NN O O
older NN O O
with NN O O
newly NN O O
diagnosed NN O O
multiple NN O O
myeloma NN O O
, NN O O
Eastern NN O O
Cooperative NN O O
Oncology NN O O
Group NN O O
performance NN O O
status NN O O
of NN O O
0 NN O O
or NN O O
1 NN O O
, NN O O
and NN O O
who NN O O
were NN O O
treatment NN O O
naive NN O O
were NN O O
enrolled NN O O
, NN O O
and NN O O
randomly NN O O
assigned NN O O
1:1 NN O O
to NN O O
receive NN O O
either NN O O
pembrolizumab NN O O
plus NN O O
lenalidomide NN O O
and NN O O
dexamethasone NN O O
or NN O O
lenalidomide NN O O
and NN O O
dexamethasone NN O O
alone NN O O
using NN O O
an NN O O
interactive NN O O
voice NN O O
or NN O O
integrated NN O O
web NN O O
response NN O O
system NN O O
. NN O O

Patients NN O O
received NN O O
oral NN O O
lenalidomide NN O O
25 NN O O
mg NN O O
on NN O O
days NN O O
1 NN O O
- NN O O
21 NN O O
and NN O O
oral NN O O
dexamethasone NN O O
40 NN O O
mg NN O O
on NN O O
days NN O O
1 NN O O
, NN O O
8 NN O O
, NN O O
15 NN O O
, NN O O
and NN O O
22 NN O O
of NN O O
repeated NN O O
28-day NN O O
cycles NN O O
, NN O O
with NN O O
or NN O O
without NN O O
intravenous NN O O
pembrolizumab NN O O
200 NN O O
mg NN O O
every NN O O
3 NN O O
weeks NN O O
. NN O O

The NN O O
primary NN O O
endpoint NN O O
was NN O O
progression-free NN O O
survival NN O O
, NN O O
which NN O O
was NN O O
investigator-assessed NN O O
because NN O O
of NN O O
early NN O O
trial NN O O
termination NN O O
. NN O O

Efficacy NN O O
was NN O O
analysed NN O O
in NN O O
all NN O O
randomly NN O O
assigned NN O O
patients NN O O
and NN O O
safety NN O O
was NN O O
analysed NN O O
in NN O O
all NN O O
patients NN O O
who NN O O
received NN O O
at NN O O
least NN O O
one NN O O
dose NN O O
of NN O O
study NN O O
drug NN O O
. NN O O

This NN O O
trial NN O O
is NN O O
registered NN O O
at NN O O
ClinicalTrials.gov NN O O
, NN O O
number NN O O
NCT02579863 NN O O
, NN O O
and NN O O
it NN O O
is NN O O
closed NN O O
for NN O O
accrual NN O O
. NN O O

Between NN O O
Jan NN O O
7 NN O O
, NN O O
2016 NN O O
, NN O O
and NN O O
June NN O O
9 NN O O
, NN O O
2017 NN O O
, NN O O
301 NN O O
patients NN O O
were NN O O
randomly NN O O
assigned NN O O
to NN O O
the NN O O
pembrolizumab NN O O
plus NN O O
lenalidomide NN O O
and NN O O
dexamethasone NN O O
group NN O O
( NN O O
n=151 NN O O
) NN O O
or NN O O
the NN O O
lenalidomide NN O O
and NN O O
dexamethasone NN O O
group NN O O
( NN O O
n=150 NN O O
) NN O O
. NN O O

On NN O O
July NN O O
3 NN O O
, NN O O
2017 NN O O
, NN O O
the NN O O
FDA NN O O
decided NN O O
to NN O O
halt NN O O
the NN O O
study NN O O
because NN O O
of NN O O
the NN O O
imbalance NN O O
in NN O O
the NN O O
proportion NN O O
of NN O O
death NN O O
between NN O O
groups NN O O
. NN O O

At NN O O
database NN O O
cutoff NN O O
( NN O O
June NN O O
2 NN O O
, NN O O
2017 NN O O
) NN O O
, NN O O
with NN O O
a NN O O
median NN O O
follow-up NN O O
of NN O O
6·6 NN O O
months NN O O
( NN O O
IQR NN O O
3·4 NN O O
- NN O O
9·6 NN O O
) NN O O
, NN O O
149 NN O O
patients NN O O
in NN O O
the NN O O
pembrolizumab NN O O
plus NN O O
lenalidomide NN O O
and NN O O
dexamethasone NN O O
group NN O O
and NN O O
145 NN O O
in NN O O
the NN O O
lenalidomide NN O O
and NN O O
dexamethasone NN O O
group NN O O
had NN O O
received NN O O
their NN O O
assigned NN O O
study NN O O
drug NN O O
. NN O O

Median NN O O
progression-free NN O O
survival NN O O
was NN O O
not NN O O
reached NN O O
in NN O O
either NN O O
group NN O O
; NN O O
progression-free NN O O
survival NN O O
estimates NN O O
at NN O O
6-months NN O O
were NN O O
82·0 NN O O
% NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
73·2 NN O O
- NN O O
88·1 NN O O
) NN O O
versus NN O O
85·0 NN O O
% NN O O
( NN O O
76·8 NN O O
- NN O O
90·5 NN O O
; NN O O
hazard NN O O
ratio NN O O
[ NN O O
HR NN O O
] NN O O
1·22 NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
0·67 NN O O
- NN O O
2·22 NN O O
; NN O O
p=0·75 NN O O
) NN O O
. NN O O

Serious NN O O
adverse NN O O
events NN O O
were NN O O
reported NN O O
in NN O O
81 NN O O
( NN O O
54 NN O O
% NN O O
) NN O O
patients NN O O
in NN O O
the NN O O
pembrolizumab NN O O
plus NN O O
lenalidomide NN O O
and NN O O
dexamethasone NN O O
group NN O O
versus NN O O
57 NN O O
( NN O O
39 NN O O
% NN O O
) NN O O
patients NN O O
in NN O O
the NN O O
lenalidomide NN O O
and NN O O
dexamethasone NN O O
group NN O O
; NN O O
the NN O O
most NN O O
common NN O O
serious NN O O
adverse NN O O
events NN O O
were NN O O
pneumonia NN O O
( NN O O
nine NN O O
[ NN O O
6 NN O O
% NN O O
] NN O O
) NN O O
and NN O O
pyrexia NN O O
( NN O O
seven NN O O
[ NN O O
5 NN O O
% NN O O
] NN O O
) NN O O
in NN O O
the NN O O
pembrolizumab NN O O
plus NN O O
lenalidomide NN O O
and NN O O
dexamethasone NN O O
group NN O O
and NN O O
pneumonia NN O O
( NN O O
eight NN O O
[ NN O O
6 NN O O
% NN O O
] NN O O
) NN O O
and NN O O
sepsis NN O O
( NN O O
two NN O O
[ NN O O
1 NN O O
% NN O O
] NN O O
) NN O O
in NN O O
the NN O O
lenalidomide NN O O
and NN O O
dexamethasone NN O O
group NN O O
. NN O O

Six NN O O
( NN O O
4 NN O O
% NN O O
) NN O O
treatment-related NN O O
deaths NN O O
occurred NN O O
in NN O O
the NN O O
pembrolizumab NN O O
plus NN O O
lenalidomide NN O O
and NN O O
dexamethasone NN O O
group NN O O
( NN O O
cardiac NN O O
arrest NN O O
, NN O O
cardiac NN O O
failure NN O O
, NN O O
myocarditis NN O O
, NN O O
large NN O O
intestine NN O O
perforation NN O O
, NN O O
pneumonia NN O O
, NN O O
and NN O O
pulmonary NN O O
embolism NN O O
) NN O O
and NN O O
two NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
lenalidomide NN O O
and NN O O
dexamethasone NN O O
group NN O O
( NN O O
upper NN O O
gastrointestinal NN O O
haemorrhage NN O O
and NN O O
respiratory NN O O
failure NN O O
) NN O O
. NN O O

The NN O O
results NN O O
from NN O O
this NN O O
unplanned NN O O
, NN O O
FDA-requested NN O O
, NN O O
interim NN O O
analysis NN O O
showed NN O O
that NN O O
the NN O O
benefit-risk NN O O
profile NN O O
of NN O O
pembrolizumab NN O O
plus NN O O
lenalidomide NN O O
and NN O O
dexamethasone NN O O
is NN O O
unfavourable NN O O
for NN O O
patients NN O O
with NN O O
newly NN O O
diagnosed NN O O
, NN O O
previously NN O O
untreated NN O O
multiple NN O O
myeloma NN O O
. NN O O

Long-term NN O O
safety NN O O
and NN O O
survival NN O O
follow-up NN O O
is NN O O
ongoing NN O O
. NN O O

Merck NN O O
Sharp NN O O
& NN O O
Dohme NN O O
, NN O O
a NN O O
subsidiary NN O O
of NN O O
Merck NN O O
& NN O O
Co NN O O
, NN O O
Inc NN O O
( NN O O
Kenilworth NN O O
, NN O O
NJ NN O O
, NN O O
USA NN O O
) NN O O
. NN O O



-DOCSTART- (30840040)

Publicly NN O O
funded NN O O
mental NN O O
health NN O O
services NN O O
play NN O O
an NN O O
important NN O O
role NN O O
in NN O O
addressing NN O O
co-occurring NN O O
mental NN O O
health NN O O
problems NN O O
in NN O O
children NN O O
with NN O O
autism NN O O
spectrum NN O O
disorder NN O O
( NN O O
ASD NN O O
) NN O O
; NN O O
however NN O O
, NN O O
therapists NN O O
report NN O O
lacking NN O O
training NN O O
to NN O O
effectively NN O O
serve NN O O
this NN O O
complex NN O O
population NN O O
. NN O O

To NN O O
test NN O O
the NN O O
effectiveness NN O O
of NN O O
training NN O O
community NN O O
therapists NN O O
in NN O O
An NN O O
Individualized NN O O
Mental NN O O
Health NN O O
Intervention NN O O
for NN O O
ASD NN O O
( NN O O
AIM NN O O
HI NN O O
) NN O O
on NN O O
challenging NN O O
behaviors NN O O
across NN O O
18 NN O O
months NN O O
among NN O O
children NN O O
with NN O O
ASD NN O O
and NN O O
identify NN O O
moderators NN O O
and NN O O
mediators NN O O
of NN O O
any NN O O
intervention NN O O
effects NN O O
. NN O O

Cluster NN O O
randomized NN O O
trial NN O O
conducted NN O O
in NN O O
29 NN O O
publicly NN O O
funded NN O O
outpatient NN O O
and NN O O
school-based NN O O
mental NN O O
health NN O O
programs NN O O
in NN O O
southern NN O O
California NN O O
from NN O O
2012 NN O O
to NN O O
2017 NN O O
. NN O O

Programs NN O O
were NN O O
randomized NN O O
to NN O O
receive NN O O
immediate NN O O
AIM NN O O
HI NN O O
training NN O O
or NN O O
provide NN O O
usual NN O O
care NN O O
followed NN O O
by NN O O
receipt NN O O
of NN O O
AIM NN O O
HI NN O O
training NN O O
. NN O O

Therapist NN O O
participants NN O O
were NN O O
recruited NN O O
from NN O O
enrolled NN O O
programs NN O O
, NN O O
and NN O O
child NN O O
participants NN O O
were NN O O
recruited NN O O
from NN O O
participant NN O O
therapists NN O O
' NN O O
caseloads NN O O
. NN O O

Data NN O O
were NN O O
analyzed NN O O
from NN O O
202 NN O O
children NN O O
with NN O O
ASD NN O O
who NN O O
were NN O O
aged NN O O
5 NN O O
to NN O O
13 NN O O
years NN O O
. NN O O

The NN O O
AIM NN O O
HI NN O O
protocol NN O O
is NN O O
a NN O O
package NN O O
of NN O O
parent-mediated NN O O
and NN O O
child-focused NN O O
strategies NN O O
aimed NN O O
to NN O O
reduce NN O O
challenging NN O O
behaviors NN O O
in NN O O
children NN O O
with NN O O
ASD NN O O
who NN O O
are NN O O
5 NN O O
to NN O O
13 NN O O
years NN O O
old NN O O
. NN O O

It NN O O
was NN O O
designed NN O O
for NN O O
delivery NN O O
in NN O O
publicly NN O O
funded NN O O
mental NN O O
health NN O O
services NN O O
based NN O O
on NN O O
a NN O O
systematic NN O O
assessment NN O O
of NN O O
therapist NN O O
training NN O O
needs NN O O
and NN O O
child NN O O
clinical NN O O
needs NN O O
. NN O O

The NN O O
therapist NN O O
training NN O O
and NN O O
consultation NN O O
process NN O O
takes NN O O
approximately NN O O
6 NN O O
months NN O O
and NN O O
includes NN O O
an NN O O
introductory NN O O
workshop NN O O
, NN O O
11 NN O O
structured NN O O
consultation NN O O
meetings NN O O
as NN O O
the NN O O
therapist NN O O
delivers NN O O
AIM NN O O
HI NN O O
with NN O O
a NN O O
current NN O O
client NN O O
, NN O O
and NN O O
case-specific NN O O
performance NN O O
feedback NN O O
from NN O O
trainers NN O O
. NN O O

Child NN O O
participants NN O O
were NN O O
assessed NN O O
for NN O O
challenging NN O O
behaviors NN O O
using NN O O
the NN O O
Eyberg NN O O
Child NN O O
Behavior NN O O
Inventory NN O O
( NN O O
ECBI NN O O
) NN O O
and NN O O
Social NN O O
Skills NN O O
Improvement NN O O
System NN O O
( NN O O
SSIS NN O O
) NN O O
Competing NN O O
Problem NN O O
Behaviors NN O O
scales NN O O
based NN O O
on NN O O
parent NN O O
report NN O O
at NN O O
baseline NN O O
and NN O O
at NN O O
6-month NN O O
intervals NN O O
for NN O O
18 NN O O
months NN O O
. NN O O

Outcomes NN O O
were NN O O
analyzed NN O O
using NN O O
intent-to-treat NN O O
models NN O O
. NN O O

In NN O O
total NN O O
, NN O O
202 NN O O
children NN O O
with NN O O
ASD NN O O
( NN O O
mean NN O O
[ NN O O
SD NN O O
] NN O O
age NN O O
, NN O O
9.1 NN O O
[ NN O O
2.4 NN O O
] NN O O
years NN O O
; NN O O
170 NN O O
[ NN O O
84.2 NN O O
% NN O O
] NN O O
male NN O O
; NN O O
121 NN O O
[ NN O O
59.9 NN O O
% NN O O
] NN O O
Latinx NN O O
) NN O O
were NN O O
eligible NN O O
, NN O O
enrolled NN O O
, NN O O
and NN O O
included NN O O
in NN O O
the NN O O
analyses NN O O
. NN O O

Statistically NN O O
significant NN O O
group NN O O
by NN O O
time NN O O
interactions NN O O
for NN O O
the NN O O
ECBI NN O O
Intensity NN O O
( NN O O
B NN O O
= NN O O
-0.38 NN O O
; NN O O
P NN O O
= NN O O
.02 NN O O
) NN O O
and NN O O
ECBI NN O O
Problem NN O O
( NN O O
B NN O O
= NN O O
-1.00 NN O O
; NN O O
P NN O O
= NN O O
.005 NN O O
) NN O O
scales NN O O
were NN O O
observed NN O O
, NN O O
with NN O O
significantly NN O O
larger NN O O
decreases NN O O
in NN O O
ECBI NN O O
Intensity NN O O
scores NN O O
in NN O O
the NN O O
AIM NN O O
HI NN O O
group NN O O
( NN O O
B NN O O
= NN O O
-1.36 NN O O
; NN O O
P NN O O
< NN O O
.001 NN O O
) NN O O
relative NN O O
to NN O O
the NN O O
usual NN O O
care NN O O
group NN O O
( NN O O
B NN O O
= NN O O
-0.98 NN O O
; NN O O
P NN O O
< NN O O
.001 NN O O
) NN O O
and NN O O
a NN O O
significantly NN O O
larger NN O O
decrease NN O O
in NN O O
ECBI NN O O
Problem NN O O
scores NN O O
in NN O O
the NN O O
AIM NN O O
HI NN O O
group NN O O
( NN O O
B NN O O
= NN O O
-1.22 NN O O
; NN O O
P NN O O
< NN O O
.001 NN O O
) NN O O
relative NN O O
to NN O O
the NN O O
usual NN O O
care NN O O
group NN O O
( NN O O
B NN O O
= NN O O
-0.20 NN O O
; NN O O
P NN O O
= NN O O
.29 NN O O
) NN O O
. NN O O

Therapist NN O O
fidelity NN O O
moderated NN O O
these NN O O
intervention NN O O
effects NN O O
. NN O O

The NN O O
present NN O O
findings NN O O
support NN O O
the NN O O
effectiveness NN O O
of NN O O
training NN O O
therapists NN O O
to NN O O
deliver NN O O
the NN O O
AIM NN O O
HI NN O O
model NN O O
to NN O O
children NN O O
with NN O O
ASD NN O O
receiving NN O O
publicly NN O O
funded NN O O
mental NN O O
health NN O O
services NN O O
. NN O O

ClinicalTrials.gov NN O O
identifier NN O O
: NN O O
NCT02416323 NN O O
. NN O O



-DOCSTART- (30541065)

Low-grade NN O O
chronic NN O O
inflammation NN O O
, NN O O
characterized NN O O
by NN O O
elevations NN O O
in NN O O
plasma NN O O
Interleukin-6 NN O O
( NN O O
IL-6 NN O O
) NN O O
, NN O O
is NN O O
an NN O O
independent NN O O
risk NN O O
factor NN O O
of NN O O
impaired NN O O
mobility NN O O
in NN O O
older NN O O
persons NN O O
. NN O O

Angiotensin NN O O
receptor NN O O
blockers NN O O
and NN O O
omega-3 NN O O
polyunsaturated NN O O
fatty NN O O
acids NN O O
( NN O O
ω-3 NN O O
) NN O O
may NN O O
reduce NN O O
IL-6 NN O O
and NN O O
may NN O O
potentially NN O O
improve NN O O
physical NN O O
function NN O O
. NN O O

To NN O O
assess NN O O
the NN O O
main NN O O
effects NN O O
of NN O O
the NN O O
angiotensin NN O O
receptor NN O O
blocker NN O O
losartan NN O O
and NN O O
ω-3 NN O O
as NN O O
fish NN O O
oil NN O O
on NN O O
IL-6 NN O O
and NN O O
400 NN O O
m NN O O
walking NN O O
speed NN O O
, NN O O
we NN O O
conducted NN O O
the NN O O
ENRGISE NN O O
Pilot NN O O
multicenter NN O O
randomized NN O O
clinical NN O O
trial NN O O
. NN O O

The NN O O
ENRGISE NN O O
Pilot NN O O
enrolled NN O O
participants NN O O
between NN O O
April NN O O
2016 NN O O
and NN O O
June NN O O
2017 NN O O
, NN O O
who NN O O
participated NN O O
for NN O O
12 NN O O
months NN O O
. NN O O

Participants NN O O
were NN O O
aged NN O O
> NN O O
= NN O O
70 NN O O
years NN O O
with NN O O
mobility NN O O
impairment NN O O
, NN O O
had NN O O
IL-6 NN O O
between NN O O
2.5 NN O O
and NN O O
30 NN O O
pg/ml NN O O
, NN O O
and NN O O
were NN O O
able NN O O
to NN O O
walk NN O O
400 NN O O
meters NN O O
at NN O O
baseline NN O O
. NN O O

Participants NN O O
were NN O O
randomized NN O O
in NN O O
three NN O O
strata NN O O
2 NN O O
X NN O O
2 NN O O
factorial NN O O
to NN O O
: NN O O
a NN O O
) NN O O
losartan NN O O
50 NN O O
to NN O O
100 NN O O
mg/day NN O O
or NN O O
placebo NN O O
( NN O O
n=43 NN O O
) NN O O
, NN O O
b NN O O
) NN O O
fish NN O O
oil NN O O
1400 NN O O
to NN O O
2800 NN O O
mg/day NN O O
or NN O O
placebo NN O O
( NN O O
n=180 NN O O
) NN O O
, NN O O
and NN O O
c NN O O
) NN O O
with NN O O
both NN O O
( NN O O
n=66 NN O O
) NN O O
. NN O O

289 NN O O
participants NN O O
were NN O O
randomized NN O O
( NN O O
mean NN O O
ag/e NN O O
78.3 NN O O
years NN O O
, NN O O
47.4 NN O O
% NN O O
women NN O O
, NN O O
17.0 NN O O
% NN O O
black NN O O
) NN O O
. NN O O

There NN O O
was NN O O
no NN O O
effect NN O O
of NN O O
losartan NN O O
( NN O O
difference NN O O
of NN O O
means=-0.065±0.116 NN O O
[ NN O O
SE NN O O
] NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
: NN O O
-0.293 NN O O
to NN O O
0.163 NN O O
, NN O O
P=0.58 NN O O
) NN O O
or NN O O
fish NN O O
oil NN O O
( NN O O
-0.020±0.077 NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
: NN O O
-0.171 NN O O
to NN O O
0.132 NN O O
, NN O O
P=0.80 NN O O
) NN O O
on NN O O
the NN O O
log NN O O
of NN O O
IL-6 NN O O
. NN O O

Similarly NN O O
, NN O O
there NN O O
was NN O O
no NN O O
effect NN O O
of NN O O
losartan NN O O
( NN O O
-0.025±0.026 NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
: NN O O
-0.076 NN O O
to NN O O
0.026 NN O O
, NN O O
P=0.34 NN O O
) NN O O
or NN O O
fish NN O O
oil NN O O
( NN O O
0.010±0.017 NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
: NN O O
-0.025 NN O O
to NN O O
0.044 NN O O
, NN O O
P=0.58 NN O O
) NN O O
on NN O O
walking NN O O
speed NN O O
( NN O O
m/s NN O O
) NN O O
. NN O O

CONCLUSIONS NN O O
. NN O O

These NN O O
results NN O O
do NN O O
not NN O O
support NN O O
use NN O O
of NN O O
these NN O O
interventions NN O O
to NN O O
prevent NN O O
mobility NN O O
loss NN O O
in NN O O
older NN O O
adults NN O O
at NN O O
risk NN O O
of NN O O
disability NN O O
with NN O O
low-grade NN O O
chronic NN O O
inflammation NN O O
. NN O O

Clinicaltrials.gov NN O O
NCT02676466 NN O O
. NN O O



-DOCSTART- (30567497)

Most NN O O
patients NN O O
with NN O O
antihypertensive NN O O
medication NN O O
do NN O O
not NN O O
achieve NN O O
their NN O O
blood NN O O
pressure NN O O
( NN O O
BP NN O O
) NN O O
target NN O O
. NN O O

The NN O O
most NN O O
important NN O O
factor NN O O
behind NN O O
this NN O O
failure NN O O
is NN O O
poor NN O O
medication NN O O
adherence NN O O
. NN O O

However NN O O
, NN O O
non-adherence NN O O
to NN O O
therapy NN O O
does NN O O
not NN O O
concern NN O O
only NN O O
patients NN O O
. NN O O

Clinicians NN O O
also NN O O
tend NN O O
to NN O O
lack NN O O
adherence NN O O
to NN O O
hypertension NN O O
guidelines NN O O
, NN O O
overestimate NN O O
BP NN O O
control NN O O
and NN O O
be NN O O
satisfied NN O O
with NN O O
inadequate NN O O
BP NN O O
control NN O O
. NN O O

The NN O O
aim NN O O
of NN O O
this NN O O
non-blinded NN O O
, NN O O
cluster-randomised NN O O
, NN O O
controlled NN O O
study NN O O
was NN O O
to NN O O
investigate NN O O
if NN O O
using NN O O
a NN O O
checklist NN O O
would NN O O
improve NN O O
the NN O O
quality NN O O
of NN O O
care NN O O
in NN O O
the NN O O
initiation NN O O
of NN O O
new NN O O
antihypertensive NN O O
medication NN O O
and NN O O
help NN O O
reduce NN O O
non-adherence NN O O
. NN O O

The NN O O
study NN O O
was NN O O
conducted NN O O
in NN O O
eight NN O O
primary NN O O
care NN O O
study NN O O
centres NN O O
in NN O O
Central NN O O
Finland NN O O
, NN O O
randomised NN O O
to NN O O
function NN O O
as NN O O
either NN O O
intervention NN O O
( NN O O
n NN O O
= NN O O
4 NN O O
) NN O O
or NN O O
control NN O O
sites NN O O
( NN O O
n NN O O
= NN O O
4 NN O O
) NN O O
. NN O O

We NN O O
included NN O O
patients NN O O
aged NN O O
30 NN O O
- NN O O
75 NN O O
years NN O O
who NN O O
were NN O O
prescribed NN O O
antihypertensive NN O O
medication NN O O
for NN O O
the NN O O
first NN O O
time NN O O
. NN O O

Initiation NN O O
of NN O O
medication NN O O
in NN O O
the NN O O
intervention NN O O
group NN O O
was NN O O
carried NN O O
out NN O O
with NN O O
a NN O O
9-item NN O O
checklist NN O O
, NN O O
filled NN O O
in NN O O
together NN O O
by NN O O
the NN O O
treating NN O O
physician NN O O
and NN O O
the NN O O
patient NN O O
. NN O O

Hypertension NN O O
treatment NN O O
in NN O O
the NN O O
control NN O O
group NN O O
was NN O O
managed NN O O
by NN O O
the NN O O
treating NN O O
physician NN O O
without NN O O
a NN O O
study-specific NN O O
protocol NN O O
. NN O O

In NN O O
total NN O O
, NN O O
119 NN O O
patients NN O O
were NN O O
included NN O O
in NN O O
the NN O O
study NN O O
, NN O O
of NN O O
which NN O O
118 NN O O
were NN O O
included NN O O
in NN O O
the NN O O
analysis NN O O
( NN O O
n NN O O
= NN O O
59 NN O O
in NN O O
the NN O O
control NN O O
group NN O O
, NN O O
n NN O O
= NN O O
59 NN O O
in NN O O
the NN O O
intervention NN O O
group NN O O
) NN O O
. NN O O

When NN O O
initiating NN O O
antihypertensive NN O O
medication NN O O
, NN O O
an NN O O
adequate NN O O
BP NN O O
target NN O O
was NN O O
set NN O O
for NN O O
19 NN O O
% NN O O
of NN O O
the NN O O
patients NN O O
in NN O O
the NN O O
control NN O O
group NN O O
and NN O O
for NN O O
68 NN O O
% NN O O
in NN O O
the NN O O
intervention NN O O
group NN O O
. NN O O

Shortly NN O O
after NN O O
the NN O O
appointment NN O O
, NN O O
only NN O O
14 NN O O
% NN O O
of NN O O
the NN O O
patients NN O O
in NN O O
the NN O O
control NN O O
group NN O O
were NN O O
able NN O O
to NN O O
remember NN O O
the NN O O
adequate NN O O
BP NN O O
target NN O O
, NN O O
compared NN O O
with NN O O
32 NN O O
% NN O O
in NN O O
the NN O O
intervention NN O O
group NN O O
. NN O O

The NN O O
use NN O O
of NN O O
the NN O O
checklist NN O O
was NN O O
also NN O O
related NN O O
to NN O O
more NN O O
regular NN O O
agreement NN O O
on NN O O
the NN O O
next NN O O
follow-up NN O O
appointment NN O O
( NN O O
64 NN O O
% NN O O
in NN O O
the NN O O
control NN O O
group NN O O
versus NN O O
95 NN O O
% NN O O
in NN O O
the NN O O
intervention NN O O
group NN O O
) NN O O
. NN O O

No NN O O
adverse NN O O
events NN O O
or NN O O
side NN O O
effects NN O O
were NN O O
related NN O O
to NN O O
the NN O O
intervention NN O O
. NN O O

Even NN O O
highly NN O O
motivated NN O O
new NN O O
hypertensive NN O O
patients NN O O
in NN O O
Finnish NN O O
primary NN O O
care NN O O
have NN O O
significant NN O O
gaps NN O O
in NN O O
their NN O O
informational NN O O
and NN O O
behavioural NN O O
skills NN O O
. NN O O

The NN O O
use NN O O
of NN O O
a NN O O
checklist NN O O
for NN O O
initiation NN O O
of NN O O
antihypertensive NN O O
medication NN O O
was NN O O
related NN O O
to NN O O
significant NN O O
improvement NN O O
in NN O O
these NN O O
skills NN O O
. NN O O

Based NN O O
on NN O O
our NN O O
findings NN O O
, NN O O
the NN O O
use NN O O
of NN O O
a NN O O
checklist NN O O
might NN O O
be NN O O
a NN O O
practical NN O O
tool NN O O
for NN O O
addressing NN O O
this NN O O
problem NN O O
. NN O O

NCT02377960 NN O O
. NN O O

Date NN O O
of NN O O
registration NN O O
: NN O O
February NN O O
26th NN O O
, NN O O
2015 NN O O
. NN O O



-DOCSTART- (31169723)

Thoracic NN O O
epidural NN O O
analgesia NN O O
is NN O O
associated NN O O
with NN O O
a NN O O
high NN O O
rate NN O O
of NN O O
postoperative NN O O
urine NN O O
retention NN O O
( NN O O
POUR NN O O
) NN O O
. NN O O

Auriculotherapy NN O O
can NN O O
reduce NN O O
visceral NN O O
dysfunction NN O O
and NN O O
can NN O O
be NN O O
helpful NN O O
in NN O O
anesthesiology NN O O
and NN O O
pain NN O O
control NN O O
. NN O O

The NN O O
aim NN O O
of NN O O
this NN O O
study NN O O
was NN O O
to NN O O
test NN O O
the NN O O
efficacy NN O O
of NN O O
preoperative NN O O
auriculotherapy NN O O
to NN O O
decrease NN O O
the NN O O
occurrence NN O O
of NN O O
POUR NN O O
. NN O O

This NN O O
single-center NN O O
, NN O O
double-blinded NN O O
, NN O O
2-arm NN O O
randomized NN O O
study NN O O
was NN O O
performed NN O O
between NN O O
January NN O O
2015 NN O O
and NN O O
May NN O O
2016 NN O O
in NN O O
a NN O O
tertiary NN O O
care NN O O
university NN O O
hospital NN O O
. NN O O

Male NN O O
patients NN O O
scheduled NN O O
for NN O O
an NN O O
elective NN O O
lung NN O O
surgical NN O O
procedure NN O O
under NN O O
combined NN O O
general NN O O
anesthesia NN O O
and NN O O
thoracic NN O O
epidural NN O O
analgesia NN O O
were NN O O
included NN O O
. NN O O

Auriculotherapy NN O O
( NN O O
A NN O O
group NN O O
) NN O O
was NN O O
performed NN O O
once NN O O
the NN O O
patient NN O O
was NN O O
under NN O O
general NN O O
anesthesia NN O O
with NN O O
5 NN O O
semi-permanent NN O O
needles NN O O
inserted NN O O
in NN O O
both NN O O
ears NN O O
at NN O O
the NN O O
" NN O O
Shen NN O O
Men NN O O
" NN O O
" NN O O
bladder NN O O
" NN O O
, NN O O
" NN O O
pelvic NN O O
parasympathetic NN O O
" NN O O
, NN O O
" NN O O
anterior NN O O
hypothalamus NN O O
" NN O O
, NN O O
and NN O O
" NN O O
frontal NN O O
lobe NN O O
" NN O O
points NN O O
. NN O O

Five NN O O
small NN O O
round NN O O
patches NN O O
of NN O O
adhesive NN O O
pads NN O O
were NN O O
positioned NN O O
bilaterally NN O O
at NN O O
the NN O O
same NN O O
points NN O O
in NN O O
the NN O O
control NN O O
group NN O O
( NN O O
C NN O O
group NN O O
) NN O O
. NN O O

The NN O O
main NN O O
outcome NN O O
measure NN O O
was NN O O
the NN O O
requirement NN O O
for NN O O
bladder NN O O
catheterization NN O O
during NN O O
the NN O O
day NN O O
and NN O O
the NN O O
first NN O O
night NN O O
following NN O O
surgery NN O O
. NN O O

Fifty-three NN O O
patients NN O O
were NN O O
randomized NN O O
and NN O O
25 NN O O
analyzed NN O O
in NN O O
each NN O O
group NN O O
. NN O O

Requirement NN O O
for NN O O
bladder NN O O
catheterization NN O O
was NN O O
different NN O O
between NN O O
groups NN O O
: NN O O
24 NN O O
C NN O O
group NN O O
patients NN O O
( NN O O
96 NN O O
% NN O O
) NN O O
and NN O O
18 NN O O
A NN O O
group NN O O
patients NN O O
( NN O O
72 NN O O
% NN O O
) NN O O
( NN O O
P NN O O
= NN O O
.049 NN O O
, NN O O
Fisher NN O O
exact NN O O
test NN O O
; NN O O
Odds NN O O
Ratio NN O O
= NN O O
0.11 NN O O
[ NN O O
0.01 NN O O
- NN O O
0.95 NN O O
] NN O O
. NN O O

The NN O O
number NN O O
of NN O O
patients NN O O
needed NN O O
to NN O O
treat NN O O
with NN O O
auriculotherapy NN O O
to NN O O
avoid NN O O
1 NN O O
case NN O O
of NN O O
bladder NN O O
catheterization NN O O
was NN O O
4 NN O O
. NN O O

No NN O O
adverse NN O O
effect NN O O
was NN O O
observed NN O O
due NN O O
to NN O O
auriculotherapy NN O O
. NN O O

This NN O O
study NN O O
demonstrates NN O O
that NN O O
auriculotherapy NN O O
is NN O O
a NN O O
safe NN O O
and NN O O
useful NN O O
technique NN O O
reducing NN O O
POUR NN O O
in NN O O
thoracotomy NN O O
patients NN O O
benefiting NN O O
from NN O O
thoracic NN O O
epidural NN O O
analgesia NN O O
. NN O O

Clinicaltrials.gov NN O O
identifier NN O O
: NN O O
NCT02290054 NN O O
( NN O O
November NN O O
13 NN O O
, NN O O
2014 NN O O
) NN O O
. NN O O



-DOCSTART- (30528227)

Sanfilippo NN O O
syndrome NN O O
type NN O O
A NN O O
( NN O O
mucopolysaccharidosis NN O O
type NN O O
IIIA NN O O
) NN O O
is NN O O
a NN O O
lysosomal NN O O
disorder NN O O
wherein NN O O
deficient NN O O
heparan-N-sulfatase NN O O
( NN O O
HNS NN O O
) NN O O
activity NN O O
results NN O O
in NN O O
the NN O O
accumulation NN O O
of NN O O
heparan NN O O
sulfate NN O O
in NN O O
the NN O O
central NN O O
nervous NN O O
system NN O O
and NN O O
is NN O O
associated NN O O
with NN O O
progressive NN O O
neurodegeneration NN O O
in NN O O
early NN O O
childhood NN O O
. NN O O

We NN O O
report NN O O
on NN O O
the NN O O
efficacy NN O O
, NN O O
pharmacokinetics NN O O
, NN O O
safety NN O O
, NN O O
and NN O O
tolerability NN O O
of NN O O
intrathecal NN O O
( NN O O
IT NN O O
) NN O O
administration NN O O
of NN O O
recombinant NN O O
human NN O O
HNS NN O O
( NN O O
rhHNS NN O O
) NN O O
from NN O O
a NN O O
phase NN O O
IIb NN O O
randomized NN O O
open-label NN O O
trial NN O O
. NN O O

Twenty-one NN O O
patients NN O O
, NN O O
randomized NN O O
1:1:1 NN O O
to NN O O
rhHNS NN O O
IT NN O O
45 NN O O
mg NN O O
administered NN O O
every NN O O
2 NN O O
weeks NN O O
( NN O O
Q2W NN O O
) NN O O
, NN O O
every NN O O
4 NN O O
weeks NN O O
( NN O O
Q4W NN O O
) NN O O
, NN O O
or NN O O
no NN O O
treatment NN O O
, NN O O
were NN O O
assessed NN O O
for NN O O
amelioration NN O O
in NN O O
neurocognitive NN O O
decline NN O O
as NN O O
determined NN O O
by NN O O
the NN O O
Bayley NN O O
Scales NN O O
of NN O O
Infant NN O O
and NN O O
Toddler NN O O
Development NN O O
® NN O O
, NN O O
Third NN O O
Edition NN O O
. NN O O

The NN O O
primary NN O O
efficacy NN O O
goal NN O O
was NN O O
defined NN O O
as NN O O
≤10-point NN O O
decline NN O O
( NN O O
responder NN O O
) NN O O
in NN O O
at NN O O
least NN O O
three NN O O
patients NN O O
in NN O O
a NN O O
dosing NN O O
cohort NN O O
after NN O O
48 NN O O
weeks NN O O
. NN O O

Other NN O O
efficacy NN O O
assessments NN O O
included NN O O
adaptive NN O O
behavioral NN O O
function NN O O
, NN O O
assessments NN O O
of NN O O
cortical NN O O
gray NN O O
matter NN O O
volume NN O O
, NN O O
and NN O O
glycosaminoglycan NN O O
( NN O O
GAG NN O O
) NN O O
levels NN O O
in NN O O
urine NN O O
. NN O O

A NN O O
clinical NN O O
response NN O O
to NN O O
rhHNS NN O O
IT NN O O
was NN O O
observed NN O O
in NN O O
three NN O O
treated NN O O
patients NN O O
( NN O O
two NN O O
in NN O O
the NN O O
Q2W NN O O
group NN O O
, NN O O
one NN O O
in NN O O
the NN O O
Q4W NN O O
group NN O O
) NN O O
. NN O O

Cerebrospinal NN O O
fluid NN O O
heparan NN O O
sulfate NN O O
and NN O O
urine NN O O
GAG NN O O
levels NN O O
were NN O O
reduced NN O O
in NN O O
all NN O O
treated NN O O
patients NN O O
. NN O O

However NN O O
, NN O O
most NN O O
secondary NN O O
efficacy NN O O
assessments NN O O
were NN O O
similar NN O O
between NN O O
treated NN O O
patients NN O O
( NN O O
n NN O O
= NN O O
14 NN O O
; NN O O
age NN O O
, NN O O
17.8 NN O O
- NN O O
47.8 NN O O
months NN O O
) NN O O
and NN O O
untreated NN O O
controls NN O O
( NN O O
n NN O O
= NN O O
7 NN O O
; NN O O
age NN O O
, NN O O
12.6 NN O O
- NN O O
45.0 NN O O
months NN O O
) NN O O
. NN O O

Treatment-emergent NN O O
adverse NN O O
events NN O O
that NN O O
occurred NN O O
with NN O O
rhHNS NN O O
IT NN O O
were NN O O
mostly NN O O
mild NN O O
, NN O O
none NN O O
led NN O O
to NN O O
study NN O O
discontinuation NN O O
, NN O O
and NN O O
there NN O O
were NN O O
no NN O O
deaths NN O O
. NN O O

rhHNS NN O O
IT NN O O
treatment NN O O
reduced NN O O
heparan NN O O
sulfate NN O O
and NN O O
GAG NN O O
levels NN O O
in NN O O
treated NN O O
patients NN O O
. NN O O

Though NN O O
the NN O O
primary NN O O
neurocognitive NN O O
endpoint NN O O
was NN O O
not NN O O
met NN O O
, NN O O
important NN O O
lessons NN O O
in NN O O
the NN O O
design NN O O
and NN O O
endpoints NN O O
for NN O O
evaluation NN O O
of NN O O
cognitive NN O O
and NN O O
behavioral NN O O
diseases NN O O
resulted NN O O
. NN O O

ClinicalTrials.govNCT02060526 NN O O
; NN O O
EudraCT NN O O
2013 NN O O
- NN O O
003450 NN O O
- NN O O
24 NN O O
. NN O O



-DOCSTART- (31227019)

A NN O O
large NN O O
proportion NN O O
of NN O O
abortion-related NN O O
mortality NN O O
and NN O O
morbidity NN O O
occurs NN O O
in NN O O
the NN O O
second NN O O
trimester NN O O
of NN O O
pregnancy NN O O
. NN O O

The NN O O
Uganda NN O O
Ministry NN O O
of NN O O
Health NN O O
policy NN O O
restricts NN O O
management NN O O
of NN O O
second-trimester NN O O
incomplete NN O O
abortion NN O O
to NN O O
physicians NN O O
who NN O O
are NN O O
few NN O O
and NN O O
unequally NN O O
distributed NN O O
, NN O O
with NN O O
most NN O O
practicing NN O O
in NN O O
urban NN O O
regions NN O O
. NN O O

Unsafe NN O O
and NN O O
outdated NN O O
methods NN O O
like NN O O
sharp NN O O
curettage NN O O
are NN O O
frequently NN O O
used NN O O
. NN O O

Medical NN O O
management NN O O
of NN O O
second-trimester NN O O
post-abortion NN O O
care NN O O
by NN O O
midwives NN O O
offers NN O O
an NN O O
advantage NN O O
given NN O O
the NN O O
difficulty NN O O
in NN O O
providing NN O O
surgical NN O O
management NN O O
in NN O O
low-income NN O O
settings NN O O
and NN O O
current NN O O
health NN O O
worker NN O O
shortages NN O O
. NN O O

The NN O O
study NN O O
aims NN O O
to NN O O
assess NN O O
the NN O O
safety NN O O
, NN O O
effectiveness NN O O
and NN O O
acceptability NN O O
of NN O O
treatment NN O O
of NN O O
incomplete NN O O
second-trimester NN O O
abortion NN O O
using NN O O
misoprostol NN O O
provided NN O O
by NN O O
midwives NN O O
compared NN O O
with NN O O
physicians NN O O
. NN O O

A NN O O
randomized NN O O
controlled NN O O
equivalence NN O O
trial NN O O
implemented NN O O
at NN O O
eight NN O O
hospitals NN O O
and NN O O
health NN O O
centers NN O O
in NN O O
Central NN O O
Uganda NN O O
will NN O O
include NN O O
1192 NN O O
eligible NN O O
women NN O O
with NN O O
incomplete NN O O
abortion NN O O
of NN O O
uterine NN O O
size NN O O
> NN O O
12 NN O O
weeks NN O O
up NN O O
to NN O O
18 NN O O
weeks NN O O
. NN O O

Each NN O O
participant NN O O
will NN O O
be NN O O
randomly NN O O
assigned NN O O
to NN O O
undergo NN O O
a NN O O
clinical NN O O
assessment NN O O
and NN O O
treatment NN O O
by NN O O
either NN O O
a NN O O
midwife NN O O
( NN O O
intervention NN O O
arm NN O O
) NN O O
or NN O O
a NN O O
physician NN O O
( NN O O
control NN O O
arm NN O O
) NN O O
. NN O O

Enrolled NN O O
participants NN O O
will NN O O
receive NN O O
400 NN O O
μg NN O O
misoprostol NN O O
administered NN O O
sublingually NN O O
every NN O O
3 NN O O
h NN O O
up NN O O
to NN O O
five NN O O
doses NN O O
within NN O O
24 NN O O
h NN O O
at NN O O
the NN O O
health NN O O
facility NN O O
until NN O O
a NN O O
complete NN O O
abortion NN O O
is NN O O
confirmed NN O O
. NN O O

Women NN O O
who NN O O
do NN O O
not NN O O
achieve NN O O
complete NN O O
abortion NN O O
within NN O O
24 NN O O
h NN O O
will NN O O
undergo NN O O
surgical NN O O
uterine NN O O
evacuation NN O O
. NN O O

Pre NN O O
discharge NN O O
, NN O O
participants NN O O
will NN O O
receive NN O O
contraceptive NN O O
counseling NN O O
and NN O O
information NN O O
on NN O O
what NN O O
to NN O O
expect NN O O
in NN O O
terms NN O O
of NN O O
side NN O O
effects NN O O
and NN O O
signs NN O O
of NN O O
complications NN O O
, NN O O
with NN O O
follow-up NN O O
14 NN O O
days NN O O
later NN O O
to NN O O
assess NN O O
secondary NN O O
outcomes NN O O
. NN O O

Analyses NN O O
will NN O O
be NN O O
by NN O O
intention NN O O
to NN O O
treat NN O O
. NN O O

Background NN O O
characteristics NN O O
and NN O O
outcomes NN O O
will NN O O
be NN O O
presented NN O O
using NN O O
descriptive NN O O
statistics NN O O
. NN O O

Differences NN O O
between NN O O
groups NN O O
will NN O O
be NN O O
analyzed NN O O
using NN O O
risk NN O O
difference NN O O
( NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
) NN O O
and NN O O
equivalence NN O O
established NN O O
if NN O O
this NN O O
lies NN O O
between NN O O
the NN O O
predefined NN O O
range NN O O
of NN O O
- NN O O
5 NN O O
% NN O O
and NN O O
+ NN O O
5 NN O O
% NN O O
. NN O O

Chi-square NN O O
tests NN O O
will NN O O
be NN O O
used NN O O
for NN O O
comparison NN O O
of NN O O
outcome NN O O
and NN O O
t NN O O
tests NN O O
used NN O O
to NN O O
compare NN O O
mean NN O O
values NN O O
. NN O O

P NN O O
≤ NN O O
0.05 NN O O
will NN O O
be NN O O
considered NN O O
statistically NN O O
significant NN O O
. NN O O

Our NN O O
study NN O O
will NN O O
provide NN O O
evidence NN O O
to NN O O
inform NN O O
national NN O O
and NN O O
international NN O O
policies NN O O
, NN O O
standard NN O O
care NN O O
guidelines NN O O
and NN O O
training NN O O
program NN O O
curricula NN O O
on NN O O
treatment NN O O
of NN O O
second-trimester NN O O
incomplete NN O O
abortion NN O O
for NN O O
improved NN O O
access NN O O
. NN O O

ClinicalTrials.gov NN O O
, NN O O
NCT03622073 NN O O
. NN O O

Registered NN O O
on NN O O
9 NN O O
August NN O O
2018 NN O O
. NN O O



-DOCSTART- (30659987)

Data NN O O
on NN O O
immuno-oncology NN O O
agents NN O O
in NN O O
Chinese NN O O
patients NN O O
are NN O O
limited NN O O
despite NN O O
a NN O O
need NN O O
for NN O O
new NN O O
therapies NN O O
. NN O O

We NN O O
evaluated NN O O
the NN O O
efficacy NN O O
and NN O O
safety NN O O
of NN O O
nivolumab NN O O
in NN O O
a NN O O
predominantly NN O O
Chinese NN O O
patient NN O O
population NN O O
with NN O O
previously NN O O
treated NN O O
NSCLC NN O O
. NN O O

CheckMate NN O O
078 NN O O
was NN O O
a NN O O
randomized NN O O
, NN O O
open-label NN O O
, NN O O
phase NN O O
III NN O O
clinical NN O O
trial NN O O
in NN O O
patients NN O O
from NN O O
China NN O O
, NN O O
Russia NN O O
, NN O O
and NN O O
Singapore NN O O
with NN O O
squamous NN O O
or NN O O
nonsquamous NN O O
NSCLC NN O O
that NN O O
had NN O O
progressed NN O O
during/after NN O O
platinum-based NN O O
doublet NN O O
chemotherapy NN O O
( NN O O
ClinicalTrials.gov NN O O
: NN O O
NCT02613507 NN O O
) NN O O
. NN O O

Patients NN O O
with NN O O
EGFR/ALK NN O O
alterations NN O O
were NN O O
excluded NN O O
. NN O O

Patients NN O O
( NN O O
N NN O O
= NN O O
504 NN O O
) NN O O
were NN O O
randomized NN O O
2:1 NN O O
to NN O O
nivolumab NN O O
( NN O O
3 NN O O
mg/kg NN O O
every NN O O
2 NN O O
weeks NN O O
) NN O O
or NN O O
docetaxel NN O O
( NN O O
75 NN O O
mg/m NN O O
every NN O O
3 NN O O
weeks NN O O
) NN O O
, NN O O
stratified NN O O
by NN O O
performance NN O O
status NN O O
, NN O O
tumor NN O O
histology NN O O
, NN O O
and NN O O
tumor NN O O
programmed NN O O
death NN O O
ligand NN O O
1 NN O O
expression NN O O
. NN O O

The NN O O
primary NN O O
endpoint NN O O
was NN O O
overall NN O O
survival NN O O
( NN O O
OS NN O O
) NN O O
; NN O O
secondary NN O O
endpoints NN O O
included NN O O
objective NN O O
response NN O O
rate NN O O
, NN O O
progression-free NN O O
survival NN O O
, NN O O
and NN O O
safety NN O O
. NN O O

OS NN O O
was NN O O
significantly NN O O
improved NN O O
with NN O O
nivolumab NN O O
( NN O O
n NN O O
= NN O O
338 NN O O
) NN O O
versus NN O O
docetaxel NN O O
( NN O O
n NN O O
= NN O O
166 NN O O
) NN O O
; NN O O
median NN O O
OS NN O O
( NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
) NN O O
: NN O O
12.0 NN O O
( NN O O
10.4 NN O O
- NN O O
14.0 NN O O
) NN O O
versus NN O O
9.6 NN O O
( NN O O
7.6 NN O O
- NN O O
11.2 NN O O
) NN O O
months NN O O
, NN O O
respectively NN O O
; NN O O
hazard NN O O
ratio NN O O
( NN O O
97.7 NN O O
% NN O O
confidence NN O O
interval NN O O
) NN O O
: NN O O
0.68 NN O O
( NN O O
0.52 NN O O
- NN O O
0.90 NN O O
) NN O O
; NN O O
p NN O O
= NN O O
0.0006 NN O O
. NN O O

Objective NN O O
response NN O O
rate NN O O
was NN O O
17 NN O O
% NN O O
with NN O O
nivolumab NN O O
versus NN O O
4 NN O O
% NN O O
with NN O O
docetaxel NN O O
; NN O O
median NN O O
duration NN O O
of NN O O
response NN O O
was NN O O
not NN O O
reached NN O O
versus NN O O
5.3 NN O O
months NN O O
. NN O O

Minimum NN O O
follow-up NN O O
was NN O O
8.8 NN O O
months NN O O
. NN O O

The NN O O
frequency NN O O
of NN O O
grade NN O O
3 NN O O
or NN O O
greater NN O O
treatment-related NN O O
adverse NN O O
events NN O O
was NN O O
10 NN O O
% NN O O
with NN O O
nivolumab NN O O
and NN O O
48 NN O O
% NN O O
with NN O O
docetaxel NN O O
. NN O O

This NN O O
is NN O O
the NN O O
first NN O O
phase NN O O
III NN O O
study NN O O
in NN O O
a NN O O
predominantly NN O O
Chinese NN O O
population NN O O
reporting NN O O
results NN O O
with NN O O
a NN O O
programmed NN O O
death NN O O
1 NN O O
inhibitor NN O O
. NN O O

In NN O O
this NN O O
population NN O O
with NN O O
previously NN O O
treated NN O O
advanced NN O O
NSCLC NN O O
, NN O O
nivolumab NN O O
improved NN O O
OS NN O O
versus NN O O
docetaxel NN O O
. NN O O

Results NN O O
were NN O O
consistent NN O O
with NN O O
global NN O O
CheckMate NN O O
017 NN O O
and NN O O
057 NN O O
studies NN O O
. NN O O



-DOCSTART- (30431501)

The NN O O
usefulness NN O O
of NN O O
ultrasound-guided NN O O
techniques NN O O
for NN O O
radial NN O O
arterial NN O O
catheterisation NN O O
has NN O O
been NN O O
well NN O O
identified NN O O
; NN O O
however NN O O
, NN O O
its NN O O
usefulness NN O O
has NN O O
not NN O O
been NN O O
completely NN O O
evaluated NN O O
in NN O O
infants NN O O
under NN O O
12 NN O O
months NN O O
of NN O O
age NN O O
, NN O O
who NN O O
are NN O O
generally NN O O
considered NN O O
the NN O O
most NN O O
difficult NN O O
group NN O O
for NN O O
arterial NN O O
catheterisation NN O O
. NN O O

We NN O O
evaluated NN O O
whether NN O O
ultrasound NN O O
guidance NN O O
would NN O O
improve NN O O
success NN O O
rates NN O O
and NN O O
reduce NN O O
the NN O O
number NN O O
of NN O O
attempts NN O O
at NN O O
radial NN O O
arterial NN O O
catheterisation NN O O
in NN O O
infants NN O O
. NN O O

A NN O O
randomised NN O O
, NN O O
controlled NN O O
and NN O O
patient-blinded NN O O
study NN O O
. NN O O

Single-centre NN O O
trial NN O O
, NN O O
study NN O O
period NN O O
from NN O O
June NN O O
2016 NN O O
to NN O O
February NN O O
2017 NN O O
. NN O O

Seventy-four NN O O
infants NN O O
undergoing NN O O
elective NN O O
cardiac NN O O
surgery NN O O
. NN O O

Patients NN O O
were NN O O
allocated NN O O
randomly NN O O
into NN O O
either NN O O
ultrasound-guided NN O O
group NN O O
( NN O O
group NN O O
US NN O O
) NN O O
or NN O O
palpation-guided NN O O
group NN O O
( NN O O
group NN O O
P NN O O
) NN O O
( NN O O
each NN O O
n=37 NN O O
) NN O O
according NN O O
to NN O O
the NN O O
technique NN O O
applied NN O O
for NN O O
radial NN O O
arterial NN O O
catheterisation NN O O
. NN O O

All NN O O
arterial NN O O
catheterisations NN O O
were NN O O
performed NN O O
by NN O O
one NN O O
of NN O O
two NN O O
experienced NN O O
anaesthesiologists NN O O
based NN O O
on NN O O
group NN O O
assignment NN O O
and NN O O
were NN O O
recorded NN O O
on NN O O
video NN O O
. NN O O

The NN O O
primary NN O O
endpoint NN O O
was NN O O
the NN O O
first-pass NN O O
success NN O O
. NN O O

The NN O O
number NN O O
of NN O O
attempts NN O O
and NN O O
total NN O O
duration NN O O
of NN O O
the NN O O
procedure NN O O
until NN O O
successful NN O O
catheterisation NN O O
were NN O O
also NN O O
analysed NN O O
. NN O O

The NN O O
first-pass NN O O
success NN O O
rate NN O O
was NN O O
significantly NN O O
higher NN O O
in NN O O
the NN O O
group NN O O
US NN O O
than NN O O
in NN O O
the NN O O
group NN O O
P NN O O
( NN O O
68 NN O O
vs. NN O O
38 NN O O
% NN O O
, NN O O
P NN O O
= NN O O
0.019 NN O O
) NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
fewer NN O O
attempts NN O O
were NN O O
needed NN O O
for NN O O
successful NN O O
catheterisation NN O O
in NN O O
the NN O O
group NN O O
US NN O O
than NN O O
in NN O O
the NN O O
group NN O O
P NN O O
( NN O O
median NN O O
1 NN O O
[ NN O O
IQR NN O O
1 NN O O
to NN O O
2 NN O O
] NN O O
vs. NN O O
2 NN O O
[ NN O O
1 NN O O
to NN O O
4 NN O O
] NN O O
, NN O O
P NN O O
= NN O O
0.023 NN O O
) NN O O
. NN O O

However NN O O
, NN O O
the NN O O
median NN O O
[ NN O O
IQR NN O O
] NN O O
procedural NN O O
time NN O O
( NN O O
s NN O O
) NN O O
until NN O O
successful NN O O
catheterisation NN O O
in NN O O
the NN O O
two NN O O
groups NN O O
was NN O O
not NN O O
significantly NN O O
different NN O O
( NN O O
102 NN O O
[ NN O O
49 NN O O
to NN O O
394 NN O O
] NN O O
vs. NN O O
218 NN O O
[ NN O O
73 NN O O
to NN O O
600 NN O O
] NN O O
, NN O O
P NN O O
= NN O O
0.054 NN O O
) NN O O
. NN O O

The NN O O
current NN O O
study NN O O
demonstrated NN O O
that NN O O
the NN O O
ultrasound-guided NN O O
technique NN O O
for NN O O
radial NN O O
arterial NN O O
catheterisation NN O O
in NN O O
infants NN O O
effectively NN O O
improved NN O O
first-pass NN O O
success NN O O
rate NN O O
and NN O O
also NN O O
reduced NN O O
the NN O O
number NN O O
of NN O O
attempts NN O O
required NN O O
. NN O O

ClinicalTrials.gov NN O O
NCT02795468 NN O O
. NN O O



-DOCSTART- (30518584)

The NN O O
implementation NN O O
of NN O O
first NN O O
aid NN O O
processes NN O O
for NN O O
patients NN O O
with NN O O
trauma NN O O
in NN O O
China NN O O
faces NN O O
significant NN O O
challenges NN O O
. NN O O

These NN O O
challenges NN O O
include NN O O
long NN O O
response NN O O
times NN O O
of NN O O
prehospital NN O O
first NN O O
aid NN O O
services NN O O
, NN O O
lack NN O O
of NN O O
information NN O O
exchange NN O O
between NN O O
prehospital NN O O
first NN O O
aid NN O O
services NN O O
and NN O O
in-hospital NN O O
emergency NN O O
services NN O O
, NN O O
lack NN O O
of NN O O
a NN O O
professional NN O O
rescue NN O O
team NN O O
in NN O O
the NN O O
majority NN O O
of NN O O
hospitals NN O O
, NN O O
and NN O O
lack NN O O
of NN O O
standardised NN O O
training NN O O
for NN O O
prehospital NN O O
and NN O O
in-hospital NN O O
emergency NN O O
personnel NN O O
. NN O O

The NN O O
purpose NN O O
of NN O O
the NN O O
trial NN O O
is NN O O
to NN O O
guide NN O O
the NN O O
establishment NN O O
of NN O O
an NN O O
urban NN O O
trauma NN O O
treatment NN O O
system NN O O
in NN O O
China NN O O
, NN O O
highlight NN O O
the NN O O
construction NN O O
of NN O O
a NN O O
trauma NN O O
treatment NN O O
system NN O O
tailored NN O O
to NN O O
the NN O O
Chinese NN O O
context NN O O
and NN O O
improve NN O O
levels NN O O
of NN O O
medical NN O O
treatment NN O O
by NN O O
selecting NN O O
approximately NN O O
100 NN O O
counties NN O O
across NN O O
China NN O O
as NN O O
pilots NN O O
to NN O O
establish NN O O
a NN O O
regional NN O O
trauma NN O O
treatment NN O O
system NN O O
. NN O O

A NN O O
cluster-randomised NN O O
controlled NN O O
trial NN O O
will NN O O
be NN O O
performed NN O O
in NN O O
98 NN O O
county-level NN O O
research NN O O
institutes NN O O
. NN O O

Included NN O O
research NN O O
institutes NN O O
will NN O O
be NN O O
randomised NN O O
into NN O O
an NN O O
experimental NN O O
group NN O O
and NN O O
a NN O O
control NN O O
group NN O O
. NN O O

Patients NN O O
in NN O O
both NN O O
experimental NN O O
and NN O O
control NN O O
groups NN O O
will NN O O
receive NN O O
basic NN O O
treatments NN O O
. NN O O

A NN O O
trauma NN O O
treatment NN O O
team NN O O
will NN O O
be NN O O
established NN O O
in NN O O
the NN O O
experimental NN O O
group NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
measure NN O O
is NN O O
in-hospital NN O O
mortality NN O O
rate NN O O
of NN O O
patients NN O O
. NN O O

The NN O O
secondary NN O O
outcome NN O O
measures NN O O
include NN O O
mortality NN O O
rate NN O O
of NN O O
patients NN O O
within NN O O
30 NN O O
days NN O O
after NN O O
trauma NN O O
attack NN O O
and NN O O
within NN O O
30 NN O O
days NN O O
after NN O O
discharge NN O O
, NN O O
the NN O O
time NN O O
between NN O O
arrival NN O O
in NN O O
the NN O O
institution NN O O
and NN O O
receiving NN O O
consultation NN O O
, NN O O
and NN O O
the NN O O
time NN O O
from NN O O
admission NN O O
to NN O O
the NN O O
start NN O O
of NN O O
surgery NN O O
. NN O O

The NN O O
effects NN O O
of NN O O
establishment NN O O
of NN O O
trauma NN O O
treatment NN O O
teams NN O O
on NN O O
the NN O O
treatment NN O O
of NN O O
severe NN O O
trauma NN O O
will NN O O
be NN O O
evaluated NN O O
in NN O O
all NN O O
counties NN O O
. NN O O

The NN O O
procedures NN O O
have NN O O
been NN O O
approved NN O O
by NN O O
The NN O O
Medical NN O O
Ethics NN O O
Committee NN O O
of NN O O
Peking NN O O
University NN O O
People NN O O
's NN O O
Hospital NN O O
( NN O O
No.2017PHB098 NN O O
- NN O O
01 NN O O
) NN O O
and NN O O
conform NN O O
to NN O O
the NN O O
Declaration NN O O
of NN O O
Helsinki NN O O
. NN O O

Data NN O O
will NN O O
be NN O O
collected NN O O
and NN O O
analysed NN O O
in NN O O
accordance NN O O
with NN O O
participant NN O O
privacy NN O O
laws NN O O
and NN O O
regulations NN O O
. NN O O

Results NN O O
will NN O O
be NN O O
disseminated NN O O
through NN O O
policy NN O O
briefs NN O O
, NN O O
workshops NN O O
, NN O O
peer-reviewed NN O O
publications NN O O
and NN O O
conferences NN O O
. NN O O

NCT03363880 NN O O
; NN O O
Pre-results NN O O
. NN O O



-DOCSTART- (31151474)

Patients NN O O
undergoing NN O O
cardiac NN O O
surgery NN O O
with NN O O
cardiopulmonary NN O O
bypass NN O O
are NN O O
at NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
developing NN O O
postoperative NN O O
pulmonary NN O O
complications NN O O
, NN O O
potentially NN O O
leading NN O O
to NN O O
excess NN O O
morbidity NN O O
and NN O O
mortality NN O O
. NN O O

It NN O O
is NN O O
likely NN O O
that NN O O
pulmonary NN O O
ischemia-reperfusion NN O O
( NN O O
IR NN O O
) NN O O
injury NN O O
during NN O O
cardiopulmonary NN O O
bypass NN O O
is NN O O
a NN O O
major NN O O
contributor NN O O
to NN O O
perioperative NN O O
lung NN O O
injury NN O O
. NN O O

Therefore NN O O
, NN O O
interventions NN O O
that NN O O
can NN O O
minimize NN O O
IR NN O O
injury NN O O
would NN O O
be NN O O
valuable NN O O
in NN O O
reducing NN O O
the NN O O
excess NN O O
burden NN O O
of NN O O
this NN O O
potentially NN O O
preventable NN O O
disease NN O O
process NN O O
. NN O O

Volatile NN O O
anesthetics NN O O
including NN O O
sevoflurane NN O O
have NN O O
been NN O O
shown NN O O
in NN O O
both NN O O
preclinical NN O O
and NN O O
human NN O O
trials NN O O
to NN O O
effectively NN O O
limit NN O O
pulmonary NN O O
inflammation NN O O
in NN O O
a NN O O
number NN O O
of NN O O
settings NN O O
including NN O O
ischemia-reperfusion NN O O
injury NN O O
. NN O O

However NN O O
, NN O O
this NN O O
finding NN O O
has NN O O
not NN O O
yet NN O O
been NN O O
demonstrated NN O O
in NN O O
the NN O O
cardiac NN O O
surgery NN O O
population NN O O
. NN O O

The NN O O
Anesthetics NN O O
to NN O O
Prevent NN O O
Lung NN O O
Injury NN O O
in NN O O
Cardiac NN O O
Surgery NN O O
( NN O O
APLICS NN O O
) NN O O
trial NN O O
is NN O O
a NN O O
randomized NN O O
controlled NN O O
trial NN O O
( NN O O
RCT NN O O
) NN O O
investigating NN O O
whether NN O O
sevoflurane NN O O
anesthetic NN O O
maintenance NN O O
can NN O O
modulate NN O O
pulmonary NN O O
inflammation NN O O
occurring NN O O
during NN O O
cardiac NN O O
surgery NN O O
with NN O O
cardiopulmonary NN O O
bypass NN O O
and NN O O
whether NN O O
this NN O O
potential NN O O
effect NN O O
can NN O O
translate NN O O
to NN O O
a NN O O
reduction NN O O
in NN O O
postoperative NN O O
pulmonary NN O O
complications NN O O
. NN O O

APLICS NN O O
is NN O O
a NN O O
prospective NN O O
RCT NN O O
of NN O O
adult NN O O
cardiac NN O O
surgical NN O O
patients NN O O
. NN O O

Participants NN O O
will NN O O
be NN O O
randomized NN O O
to NN O O
receive NN O O
intraoperative NN O O
anesthetic NN O O
maintenance NN O O
with NN O O
either NN O O
sevoflurane NN O O
or NN O O
propofol NN O O
. NN O O

Patients NN O O
in NN O O
both NN O O
groups NN O O
will NN O O
be NN O O
ventilated NN O O
according NN O O
to NN O O
protocols NN O O
intended NN O O
to NN O O
minimize NN O O
the NN O O
influences NN O O
of NN O O
ventilator-induced NN O O
lung NN O O
injury NN O O
and NN O O
hyperoxia NN O O
. NN O O

Bronchoalveolar NN O O
lavage NN O O
( NN O O
BAL NN O O
) NN O O
and NN O O
blood NN O O
sampling NN O O
will NN O O
take NN O O
place NN O O
after NN O O
anesthetic NN O O
induction NN O O
and NN O O
2 NN O O
- NN O O
4 NN O O
h NN O O
after NN O O
pulmonary NN O O
reperfusion NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
is NN O O
a NN O O
difference NN O O
between NN O O
groups NN O O
in NN O O
the NN O O
degree NN O O
of NN O O
post-bypass NN O O
lung NN O O
inflammation NN O O
, NN O O
defined NN O O
by NN O O
BAL NN O O
concentrations NN O O
of NN O O
TNFα NN O O
. NN O O

Secondary NN O O
outcomes NN O O
will NN O O
include NN O O
differences NN O O
in NN O O
additional NN O O
relevant NN O O
BAL NN O O
and NN O O
systemic NN O O
inflammatory NN O O
markers NN O O
and NN O O
the NN O O
incidence NN O O
of NN O O
postoperative NN O O
pulmonary NN O O
complications NN O O
. NN O O

APLICS NN O O
investigates NN O O
whether NN O O
anesthetic NN O O
choice NN O O
can NN O O
influence NN O O
lung NN O O
inflammation NN O O
and NN O O
pulmonary NN O O
outcomes NN O O
following NN O O
cardiac NN O O
surgery NN O O
with NN O O
cardiopulmonary NN O O
bypass NN O O
. NN O O

A NN O O
positive NN O O
result NN O O
from NN O O
this NN O O
trial NN O O
would NN O O
add NN O O
to NN O O
the NN O O
growing NN O O
body NN O O
of NN O O
evidence NN O O
describing NN O O
the NN O O
lung NN O O
protective NN O O
properties NN O O
of NN O O
the NN O O
volatile NN O O
anesthetics NN O O
and NN O O
potentially NN O O
reduce NN O O
unnecessary NN O O
morbidity NN O O
for NN O O
cardiac NN O O
surgery NN O O
patients NN O O
. NN O O

ClinicalTrials.gov NN O O
, NN O O
NCT02918877 NN O O
. NN O O

Registered NN O O
on NN O O
29 NN O O
September NN O O
2016 NN O O
. NN O O



-DOCSTART- (31216065)

Minimally NN O O
invasive NN O O
surgery NN O O
( NN O O
MIS NN O O
) NN O O
and NN O O
enhanced NN O O
recovery NN O O
protocols NN O O
( NN O O
ERPs NN O O
) NN O O
have NN O O
improved NN O O
postoperative NN O O
recovery NN O O
and NN O O
shortened NN O O
length NN O O
of NN O O
hospital NN O O
stay NN O O
( NN O O
LOS NN O O
) NN O O
. NN O O

Telemedicine NN O O
technology NN O O
has NN O O
potential NN O O
to NN O O
improve NN O O
outcomes NN O O
and NN O O
patient NN O O
experience NN O O
further NN O O
. NN O O

This NN O O
study NN O O
was NN O O
designed NN O O
to NN O O
determine NN O O
whether NN O O
the NN O O
combination NN O O
of NN O O
MIS NN O O
, NN O O
ERP NN O O
and NN O O
a NN O O
structured NN O O
telemedicine NN O O
programme NN O O
( NN O O
TeleRecovery NN O O
) NN O O
could NN O O
shorten NN O O
total NN O O
30-day NN O O
LOS NN O O
by NN O O
50 NN O O
per NN O O
cent NN O O
. NN O O

This NN O O
was NN O O
a NN O O
phase NN O O
II NN O O
prospective NN O O
RCT NN O O
at NN O O
a NN O O
large NN O O
academic NN O O
medical NN O O
centre NN O O
. NN O O

Eligible NN O O
patients NN O O
aged NN O O
18 NN O O
- NN O O
80 NN O O
years NN O O
undergoing NN O O
minimally NN O O
invasive NN O O
colorectal NN O O
resection NN O O
using NN O O
an NN O O
ERP NN O O
were NN O O
randomized NN O O
after NN O O
surgery NN O O
. NN O O

The NN O O
experimental NN O O
arm NN O O
( NN O O
RecoverMI NN O O
) NN O O
included NN O O
accelerated NN O O
discharge NN O O
on NN O O
postoperative NN O O
day NN O O
( NN O O
POD NN O O
) NN O O
1 NN O O
with NN O O
or NN O O
without NN O O
evidence NN O O
of NN O O
bowel NN O O
function NN O O
and NN O O
a NN O O
televideoconference NN O O
on NN O O
POD NN O O
2 NN O O
. NN O O

The NN O O
control NN O O
arm NN O O
was NN O O
standard NN O O
postoperative NN O O
care NN O O
. NN O O

The NN O O
primary NN O O
endpoint NN O O
was NN O O
total NN O O
30-day NN O O
LOS NN O O
( NN O O
postoperative NN O O
stay NN O O
plus NN O O
readmission/emergency NN O O
department/observation NN O O
days NN O O
) NN O O
. NN O O

Secondary NN O O
endpoints NN O O
included NN O O
patient-reported NN O O
outcomes NN O O
measured NN O O
by NN O O
EQ-5D-5L NN O O
™ NN O O
, NN O O
Brief NN O O
Pain NN O O
Inventory NN O O
( NN O O
BPI NN O O
) NN O O
and NN O O
a NN O O
satisfaction NN O O
questionnaire NN O O
. NN O O

Thirty NN O O
patients NN O O
were NN O O
randomized NN O O
after NN O O
robotic NN O O
( NN O O
21 NN O O
patients NN O O
) NN O O
or NN O O
laparoscopic NN O O
( NN O O
9 NN O O
) NN O O
colectomy NN O O
, NN O O
including NN O O
14 NN O O
patients NN O O
in NN O O
the NN O O
RecoverMI NN O O
arm NN O O
. NN O O

Median NN O O
30-day NN O O
total NN O O
LOS NN O O
was NN O O
28·3 NN O O
( NN O O
i.q.r NN O O
. NN O O

23·7 NN O O
- NN O O
43·6 NN O O
) NN O O
h NN O O
in NN O O
the NN O O
RecoverMI NN O O
arm NN O O
and NN O O
51·5 NN O O
( NN O O
43·8 NN O O
- NN O O
67·0 NN O O
) NN O O
h NN O O
in NN O O
the NN O O
control NN O O
arm NN O O
( NN O O
P NN O O
= NN O O
0·041 NN O O
) NN O O
. NN O O

There NN O O
were NN O O
no NN O O
differences NN O O
in NN O O
severe NN O O
adverse NN O O
events NN O O
or NN O O
EQ-5D-5L NN O O
™ NN O O
score NN O O
between NN O O
the NN O O
study NN O O
arms NN O O
. NN O O

The NN O O
BPI NN O O
revealed NN O O
low NN O O
pain NN O O
scores NN O O
regardless NN O O
of NN O O
treatment NN O O
arm NN O O
. NN O O

Satisfaction NN O O
was NN O O
high NN O O
in NN O O
both NN O O
arms NN O O
. NN O O

In NN O O
patients NN O O
having NN O O
surgery NN O O
for NN O O
colorectal NN O O
neoplasms NN O O
, NN O O
the NN O O
trimodal NN O O
combination NN O O
of NN O O
MIS NN O O
, NN O O
ERP NN O O
and NN O O
TeleRecovery NN O O
can NN O O
reduce NN O O
30-day NN O O
LOS NN O O
while NN O O
preserving NN O O
patients NN O O
' NN O O
quality NN O O
of NN O O
life NN O O
and NN O O
satisfaction NN O O
. NN O O

Registration NN O O
number NN O O
: NN O O
NCT02613728 NN O O
( NN O O
https://clinicaltrials.gov NN O O
) NN O O
. NN O O

La NN O O
cirugía NN O O
mínimamente NN O O
invasiva NN O O
( NN O O
minimally NN O O
invasive NN O O
surgery NN O O
, NN O O
MIS NN O O
) NN O O
y NN O O
los NN O O
protocolos NN O O
de NN O O
recuperación NN O O
intensificada NN O O
( NN O O
enhanced NN O O
recovery NN O O
protocols NN O O
, NN O O
ERP NN O O
) NN O O
han NN O O
mejorado NN O O
la NN O O
recuperación NN O O
postoperatoria NN O O
y NN O O
acortan NN O O
la NN O O
duración NN O O
de NN O O
la NN O O
estancia NN O O
( NN O O
length NN O O
of NN O O
stay NN O O
, NN O O
LOS NN O O
) NN O O
. NN O O

La NN O O
tecnología NN O O
de NN O O
la NN O O
telemedicina NN O O
tiene NN O O
potencial NN O O
para NN O O
mejorar NN O O
aún NN O O
más NN O O
los NN O O
resultados NN O O
y NN O O
la NN O O
experiencia NN O O
del NN O O
paciente NN O O
. NN O O

Este NN O O
estudio NN O O
se NN O O
diseñó NN O O
para NN O O
determinar NN O O
si NN O O
la NN O O
combinación NN O O
de NN O O
MIS NN O O
, NN O O
ERP NN O O
y NN O O
un NN O O
programa NN O O
estructurado NN O O
de NN O O
telemedicina NN O O
( NN O O
TeleRecovery NN O O
) NN O O
podría NN O O
acortar NN O O
la NN O O
LOS NN O O
total NN O O
a NN O O
los NN O O
30 NN O O
días NN O O
en NN O O
un NN O O
50 NN O O
% NN O O
. NN O O

MÉTODOS NN O O
: NN O O
Se NN O O
efectuó NN O O
un NN O O
ensayo NN O O
controlado NN O O
aleatorizado NN O O
, NN O O
prospectivo NN O O
, NN O O
de NN O O
fase NN O O
II NN O O
en NN O O
un NN O O
gran NN O O
centro NN O O
médico NN O O
académico NN O O
. NN O O

Los NN O O
pacientes NN O O
elegibles NN O O
de NN O O
18 NN O O
- NN O O
80 NN O O
años NN O O
de NN O O
edad NN O O
que NN O O
se NN O O
sometieron NN O O
a NN O O
resección NN O O
colorrectal NN O O
MIS NN O O
mediante NN O O
ERP NN O O
se NN O O
asignaron NN O O
al NN O O
azar NN O O
después NN O O
de NN O O
la NN O O
resección NN O O
quirúrgica NN O O
. NN O O

El NN O O
brazo NN O O
experimental NN O O
( NN O O
RecoverMI NN O O
) NN O O
incluyó NN O O
el NN O O
alta NN O O
acelerada NN O O
en NN O O
el NN O O
día NN O O
1 NN O O
del NN O O
postoperatorio NN O O
( NN O O
postoperative NN O O
day NN O O
, NN O O
POD NN O O
) NN O O
con NN O O
o NN O O
sin NN O O
evidencia NN O O
de NN O O
recuperación NN O O
del NN O O
tránsito NN O O
intestinal NN O O
y NN O O
una NN O O
televideoconferencia NN O O
en NN O O
el NN O O
día NN O O
2 NN O O
POD NN O O
. NN O O

Los NN O O
pacientes NN O O
en NN O O
el NN O O
grupo NN O O
control NN O O
recibieron NN O O
los NN O O
cuidados NN O O
postoperatorios NN O O
habituales NN O O
. NN O O

El NN O O
criterio NN O O
de NN O O
valoración NN O O
principal NN O O
fue NN O O
la NN O O
LOS NN O O
total NN O O
( NN O O
estancia NN O O
postoperatoria NN O O
más NN O O
reingreso/estancia NN O O
en NN O O
urgencias/días NN O O
de NN O O
observación NN O O
) NN O O
a NN O O
los NN O O
30 NN O O
días NN O O
. NN O O

Los NN O O
criterios NN O O
de NN O O
valoración NN O O
secundarios NN O O
incluyeron NN O O
los NN O O
resultados NN O O
referidos NN O O
por NN O O
los NN O O
pacientes NN O O
medidos NN O O
por NN O O
los NN O O
cuestionarios NN O O
EQ-5D-5L NN O O
, NN O O
el NN O O
Cuestionario NN O O
Breve NN O O
del NN O O
Dolor NN O O
( NN O O
Brief NN O O
Pain NN O O
Inventory NN O O
, NN O O
BPI NN O O
) NN O O
y NN O O
un NN O O
cuestionario NN O O
de NN O O
satisfacción NN O O
. NN O O

Treinta NN O O
pacientes NN O O
fueron NN O O
aleatorizados NN O O
después NN O O
de NN O O
una NN O O
colectomía NN O O
robótica NN O O
( NN O O
21 NN O O
) NN O O
o NN O O
laparoscópica NN O O
( NN O O
9 NN O O
) NN O O
, NN O O
incluidos NN O O
14 NN O O
pacientes NN O O
en NN O O
el NN O O
grupo NN O O
de NN O O
RecoverMI NN O O
. NN O O

La NN O O
mediana NN O O
de NN O O
la NN O O
LOS NN O O
total NN O O
a NN O O
los NN O O
30 NN O O
días NN O O
fue NN O O
de NN O O
28,3 NN O O
horas NN O O
( NN O O
rango NN O O
intercuartílico NN O O
, NN O O
RIQ NN O O
23,7 NN O O
- NN O O
43,6 NN O O
) NN O O
en NN O O
el NN O O
grupo NN O O
de NN O O
RecoverMI NN O O
y NN O O
de NN O O
51,5 NN O O
horas NN O O
( NN O O
RIQ NN O O
43,8 NN O O
- NN O O
67,0 NN O O
) NN O O
en NN O O
el NN O O
grupo NN O O
control NN O O
( NN O O
P NN O O
= NN O O
0,04 NN O O
) NN O O
. NN O O

No NN O O
hubo NN O O
diferencias NN O O
entre NN O O
los NN O O
grupos NN O O
de NN O O
estudio NN O O
en NN O O
los NN O O
eventos NN O O
adversos NN O O
graves NN O O
o NN O O
en NN O O
las NN O O
puntuaciones NN O O
del NN O O
EQ-5D-5L NN O O
. NN O O

El NN O O
BPI NN O O
mostró NN O O
puntuaciones NN O O
bajas NN O O
de NN O O
dolor NN O O
independientemente NN O O
del NN O O
grupo NN O O
de NN O O
tratamiento NN O O
. NN O O

La NN O O
satisfacción NN O O
fue NN O O
alta NN O O
en NN O O
ambos NN O O
grupos NN O O
. NN O O

CONCLUSIÓN NN O O
: NN O O
Entre NN O O
los NN O O
pacientes NN O O
que NN O O
se NN O O
someten NN O O
a NN O O
cirugía NN O O
por NN O O
cáncer NN O O
colorrectal NN O O
, NN O O
la NN O O
combinación NN O O
trimodal NN O O
de NN O O
MIS NN O O
, NN O O
ERP NN O O
y NN O O
TeleRecovery NN O O
puede NN O O
reducir NN O O
la NN O O
LOS NN O O
a NN O O
los NN O O
30 NN O O
días NN O O
, NN O O
preservando NN O O
la NN O O
calidad NN O O
de NN O O
vida NN O O
y NN O O
la NN O O
satisfacción NN O O
del NN O O
paciente NN O O
. NN O O



-DOCSTART- (30670158)

Twenty-eight NN O O
per NN O O
cent NN O O
( NN O O
28 NN O O
% NN O O
) NN O O
of NN O O
adults NN O O
sleep NN O O
at NN O O
least NN O O
1 NN O O
hour NN O O
less NN O O
than NN O O
they NN O O
consider NN O O
optimal NN O O
, NN O O
yet NN O O
the NN O O
effects NN O O
of NN O O
such NN O O
cumulative NN O O
mild NN O O
partial NN O O
sleep NN O O
deprivation NN O O
on NN O O
cognitive NN O O
functions NN O O
are NN O O
unknown NN O O
. NN O O

The NN O O
objective NN O O
of NN O O
this NN O O
study NN O O
was NN O O
to NN O O
examine NN O O
how NN O O
cumulative NN O O
mild NN O O
partial NN O O
sleep NN O O
deprivation NN O O
over NN O O
6 NN O O
nights NN O O
can NN O O
impact NN O O
working NN O O
memory NN O O
, NN O O
sustained NN O O
attention NN O O
, NN O O
response NN O O
inhibition NN O O
, NN O O
and NN O O
decision NN O O
making NN O O
. NN O O

A NN O O
double-blind NN O O
placebo-controlled NN O O
randomized NN O O
study NN O O
was NN O O
conducted NN O O
to NN O O
determine NN O O
the NN O O
impact NN O O
of NN O O
sleep NN O O
restriction NN O O
( NN O O
elimination NN O O
of NN O O
1 NN O O
hour NN O O
of NN O O
sleep NN O O
relative NN O O
to NN O O
the NN O O
baseline NN O O
habitual NN O O
sleep NN O O
duration NN O O
) NN O O
vs NN O O
placebo NN O O
( NN O O
exposure NN O O
to NN O O
a NN O O
lamp NN O O
with NN O O
no NN O O
known NN O O
therapeutic NN O O
effect NN O O
) NN O O
on NN O O
cognitive NN O O
performance NN O O
. NN O O

The NN O O
primary NN O O
outcomes NN O O
were NN O O
performance NN O O
on NN O O
tasks NN O O
that NN O O
measure NN O O
working NN O O
memory NN O O
, NN O O
sustained NN O O
attention NN O O
, NN O O
response NN O O
inhibition NN O O
, NN O O
and NN O O
decision NN O O
making NN O O
. NN O O

The NN O O
participants NN O O
consisted NN O O
of NN O O
93 NN O O
adults NN O O
( NN O O
mean NN O O
age NN O O
24.3 NN O O
years NN O O
, NN O O
SD NN O O
4.7 NN O O
; NN O O
46 NN O O
men NN O O
, NN O O
47 NN O O
women NN O O
) NN O O
with NN O O
no NN O O
reported NN O O
sleep NN O O
problem NN O O
, NN O O
behavioral NN O O
issue NN O O
, NN O O
or NN O O
medical NN O O
issue NN O O
. NN O O

Performance NN O O
on NN O O
the NN O O
working NN O O
memory NN O O
capacity NN O O
task NN O O
improved NN O O
between NN O O
the NN O O
baseline NN O O
and NN O O
experimental NN O O
sessions NN O O
for NN O O
the NN O O
placebo NN O O
group NN O O
but NN O O
not NN O O
the NN O O
sleep-restriction NN O O
group NN O O
. NN O O

Performance NN O O
on NN O O
tasks NN O O
measuring NN O O
sustained NN O O
attention NN O O
, NN O O
response NN O O
inhibition NN O O
, NN O O
and NN O O
decision NN O O
making NN O O
did NN O O
not NN O O
change NN O O
under NN O O
either NN O O
experimental NN O O
condition NN O O
. NN O O

Cumulative NN O O
partial NN O O
sleep NN O O
deprivation NN O O
negatively NN O O
affects NN O O
performance NN O O
on NN O O
a NN O O
test NN O O
of NN O O
working NN O O
memory NN O O
capacity NN O O
but NN O O
does NN O O
not NN O O
affect NN O O
performance NN O O
on NN O O
tests NN O O
of NN O O
sustained NN O O
attention NN O O
, NN O O
response NN O O
inhibition NN O O
, NN O O
or NN O O
decision NN O O
making NN O O
. NN O O



-DOCSTART- (30417737)

The NN O O
saphenous-vein NN O O
graft NN O O
is NN O O
the NN O O
most NN O O
common NN O O
conduit NN O O
for NN O O
coronary-artery NN O O
bypass NN O O
grafting NN O O
( NN O O
CABG NN O O
) NN O O
. NN O O

The NN O O
influence NN O O
of NN O O
the NN O O
vein-graft NN O O
harvesting NN O O
technique NN O O
on NN O O
long-term NN O O
clinical NN O O
outcomes NN O O
has NN O O
not NN O O
been NN O O
well NN O O
characterized NN O O
. NN O O

We NN O O
randomly NN O O
assigned NN O O
patients NN O O
undergoing NN O O
CABG NN O O
at NN O O
16 NN O O
Veterans NN O O
Affairs NN O O
cardiac NN O O
surgery NN O O
centers NN O O
to NN O O
either NN O O
open NN O O
or NN O O
endoscopic NN O O
vein-graft NN O O
harvesting NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
was NN O O
a NN O O
composite NN O O
of NN O O
major NN O O
adverse NN O O
cardiac NN O O
events NN O O
, NN O O
including NN O O
death NN O O
from NN O O
any NN O O
cause NN O O
, NN O O
nonfatal NN O O
myocardial NN O O
infarction NN O O
, NN O O
and NN O O
repeat NN O O
revascularization NN O O
. NN O O

Leg-wound NN O O
complications NN O O
were NN O O
also NN O O
evaluated NN O O
. NN O O

A NN O O
total NN O O
of NN O O
1150 NN O O
patients NN O O
underwent NN O O
randomization NN O O
. NN O O

Over NN O O
a NN O O
median NN O O
follow-up NN O O
of NN O O
2.78 NN O O
years NN O O
, NN O O
the NN O O
primary NN O O
outcome NN O O
occurred NN O O
in NN O O
89 NN O O
patients NN O O
( NN O O
15.5 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
open-harvest NN O O
group NN O O
and NN O O
80 NN O O
patients NN O O
( NN O O
13.9 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
endoscopic-harvest NN O O
group NN O O
( NN O O
hazard NN O O
ratio NN O O
, NN O O
1.12 NN O O
; NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
[ NN O O
CI NN O O
] NN O O
, NN O O
0.83 NN O O
to NN O O
1.51 NN O O
; NN O O
P=0.47 NN O O
) NN O O
. NN O O

A NN O O
total NN O O
of NN O O
46 NN O O
patients NN O O
( NN O O
8.0 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
open-harvest NN O O
group NN O O
and NN O O
37 NN O O
patients NN O O
( NN O O
6.4 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
endoscopic-harvest NN O O
group NN O O
died NN O O
( NN O O
hazard NN O O
ratio NN O O
, NN O O
1.25 NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
0.81 NN O O
to NN O O
1.92 NN O O
) NN O O
; NN O O
myocardial NN O O
infarctions NN O O
occurred NN O O
in NN O O
34 NN O O
patients NN O O
( NN O O
5.9 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
open-harvest NN O O
group NN O O
and NN O O
27 NN O O
patients NN O O
( NN O O
4.7 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
endoscopic-harvest NN O O
group NN O O
( NN O O
hazard NN O O
ratio NN O O
, NN O O
1.27 NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
0.77 NN O O
to NN O O
2.11 NN O O
) NN O O
, NN O O
and NN O O
revascularization NN O O
occurred NN O O
in NN O O
35 NN O O
patients NN O O
( NN O O
6.1 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
open-harvest NN O O
group NN O O
and NN O O
31 NN O O
patients NN O O
( NN O O
5.4 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
endoscopic-harvest NN O O
group NN O O
( NN O O
hazard NN O O
ratio NN O O
, NN O O
1.14 NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
0.70 NN O O
to NN O O
1.85 NN O O
) NN O O
. NN O O

Leg-wound NN O O
infections NN O O
occurred NN O O
in NN O O
18 NN O O
patients NN O O
( NN O O
3.1 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
open-harvest NN O O
group NN O O
and NN O O
in NN O O
8 NN O O
patients NN O O
( NN O O
1.4 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
endoscopic-harvest NN O O
group NN O O
( NN O O
relative NN O O
risk NN O O
, NN O O
2.26 NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
0.99 NN O O
to NN O O
5.15 NN O O
) NN O O
. NN O O

Among NN O O
patients NN O O
undergoing NN O O
CABG NN O O
, NN O O
we NN O O
did NN O O
not NN O O
find NN O O
a NN O O
significant NN O O
difference NN O O
between NN O O
open NN O O
vein-graft NN O O
harvesting NN O O
and NN O O
endoscopic NN O O
vein-graft NN O O
harvesting NN O O
in NN O O
the NN O O
risk NN O O
of NN O O
major NN O O
adverse NN O O
cardiac NN O O
events NN O O
. NN O O

( NN O O
Funded NN O O
by NN O O
the NN O O
Cooperative NN O O
Studies NN O O
Program NN O O
, NN O O
Office NN O O
of NN O O
Research NN O O
and NN O O
Development NN O O
, NN O O
Department NN O O
of NN O O
Veterans NN O O
Affairs NN O O
; NN O O
REGROUP NN O O
ClinicalTrials.gov NN O O
number NN O O
, NN O O
NCT01850082 NN O O
. NN O O
) NN O O
. NN O O



-DOCSTART- (30476999)

Gait NN O O
and NN O O
balance NN O O
impairment NN O O
is NN O O
associated NN O O
with NN O O
poorer NN O O
functional NN O O
recovery NN O O
after NN O O
stroke NN O O
. NN O O

The NN O O
cerebellum NN O O
is NN O O
known NN O O
to NN O O
be NN O O
strongly NN O O
implicated NN O O
in NN O O
the NN O O
functional NN O O
reorganization NN O O
of NN O O
motor NN O O
networks NN O O
in NN O O
patients NN O O
with NN O O
stroke NN O O
, NN O O
especially NN O O
for NN O O
gait NN O O
and NN O O
balance NN O O
functions NN O O
. NN O O

To NN O O
determine NN O O
whether NN O O
cerebellar NN O O
intermittent NN O O
θ-burst NN O O
stimulation NN O O
( NN O O
CRB-iTBS NN O O
) NN O O
can NN O O
improve NN O O
balance NN O O
and NN O O
gait NN O O
functions NN O O
in NN O O
patients NN O O
with NN O O
hemiparesis NN O O
due NN O O
to NN O O
stroke NN O O
. NN O O

This NN O O
randomized NN O O
, NN O O
double-blind NN O O
, NN O O
sham-controlled NN O O
phase NN O O
IIa NN O O
trial NN O O
investigated NN O O
efficacy NN O O
and NN O O
safety NN O O
of NN O O
a NN O O
3-week NN O O
treatment NN O O
of NN O O
CRB-iTBS NN O O
coupled NN O O
with NN O O
physiotherapy NN O O
in NN O O
promoting NN O O
gait NN O O
and NN O O
balance NN O O
recovery NN O O
in NN O O
patients NN O O
with NN O O
stroke NN O O
. NN O O

Thirty-six NN O O
patients NN O O
with NN O O
consecutive NN O O
ischemic NN O O
chronic NN O O
stroke NN O O
in NN O O
the NN O O
territory NN O O
of NN O O
the NN O O
contralateral NN O O
middle NN O O
cerebral NN O O
artery NN O O
with NN O O
hemiparesis NN O O
were NN O O
recruited NN O O
from NN O O
a NN O O
neuro-rehabilitation NN O O
hospital NN O O
. NN O O

Participants NN O O
were NN O O
screened NN O O
and NN O O
enrolled NN O O
from NN O O
March NN O O
2013 NN O O
to NN O O
June NN O O
2017 NN O O
. NN O O

Intention-to-treat NN O O
analysis NN O O
was NN O O
performed NN O O
. NN O O

Patients NN O O
were NN O O
randomly NN O O
assigned NN O O
to NN O O
treatment NN O O
with NN O O
CRB-iTBS NN O O
or NN O O
sham NN O O
iTBS NN O O
applied NN O O
over NN O O
the NN O O
cerebellar NN O O
hemisphere NN O O
ipsilateral NN O O
to NN O O
the NN O O
affected NN O O
body NN O O
side NN O O
immediately NN O O
before NN O O
physiotherapy NN O O
daily NN O O
during NN O O
3 NN O O
weeks NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
was NN O O
the NN O O
between-group NN O O
difference NN O O
in NN O O
change NN O O
from NN O O
baseline NN O O
in NN O O
the NN O O
Berg NN O O
Balance NN O O
Scale NN O O
. NN O O

Secondary NN O O
exploratory NN O O
measures NN O O
included NN O O
the NN O O
between-group NN O O
difference NN O O
in NN O O
change NN O O
from NN O O
baseline NN O O
in NN O O
Fugl-Meyer NN O O
Assessment NN O O
scale NN O O
, NN O O
Barthel NN O O
Index NN O O
, NN O O
and NN O O
locomotion NN O O
assessment NN O O
with NN O O
gait NN O O
analysis NN O O
and NN O O
cortical NN O O
activity NN O O
measured NN O O
by NN O O
transcranial NN O O
magnetic NN O O
stimulation NN O O
in NN O O
combination NN O O
with NN O O
electroencephalogram NN O O
. NN O O

A NN O O
total NN O O
of NN O O
34 NN O O
patients NN O O
( NN O O
mean NN O O
[ NN O O
SD NN O O
] NN O O
age NN O O
, NN O O
64 NN O O
[ NN O O
11.3 NN O O
] NN O O
years NN O O
; NN O O
13 NN O O
women NN O O
[ NN O O
38.2 NN O O
% NN O O
] NN O O
) NN O O
completed NN O O
the NN O O
study NN O O
. NN O O

Patients NN O O
treated NN O O
with NN O O
CRB-iTBS NN O O
, NN O O
but NN O O
not NN O O
with NN O O
sham NN O O
iTBS NN O O
, NN O O
showed NN O O
an NN O O
improvement NN O O
of NN O O
gait NN O O
and NN O O
balance NN O O
functions NN O O
, NN O O
as NN O O
revealed NN O O
by NN O O
a NN O O
pronounced NN O O
increase NN O O
in NN O O
the NN O O
mean NN O O
( NN O O
SE NN O O
) NN O O
Berg NN O O
Balance NN O O
Scale NN O O
score NN O O
( NN O O
baseline NN O O
: NN O O
34.5 NN O O
[ NN O O
3.4 NN O O
] NN O O
; NN O O
3 NN O O
weeks NN O O
after NN O O
treatment NN O O
: NN O O
43.4 NN O O
[ NN O O
2.6 NN O O
] NN O O
; NN O O
3 NN O O
weeks NN O O
after NN O O
the NN O O
end NN O O
of NN O O
treatment NN O O
: NN O O
47.5 NN O O
[ NN O O
1.8 NN O O
] NN O O
; NN O O
P NN O O
< NN O O
.001 NN O O
) NN O O
. NN O O

No NN O O
overall NN O O
treatment-associated NN O O
differences NN O O
were NN O O
noted NN O O
in NN O O
the NN O O
Fugl-Meyer NN O O
Assessment NN O O
( NN O O
mean NN O O
[ NN O O
SE NN O O
] NN O O
, NN O O
baseline NN O O
: NN O O
163.8 NN O O
[ NN O O
6.8 NN O O
] NN O O
; NN O O
3 NN O O
weeks NN O O
after NN O O
treatment NN O O
: NN O O
171.1 NN O O
[ NN O O
7.2 NN O O
] NN O O
; NN O O
3 NN O O
weeks NN O O
after NN O O
the NN O O
end NN O O
of NN O O
treatment NN O O
: NN O O
173.5 NN O O
[ NN O O
6.9 NN O O
] NN O O
; NN O O
P NN O O
> NN O O
.05 NN O O
) NN O O
and NN O O
Barthel NN O O
Index NN O O
scores NN O O
( NN O O
mean NN O O
[ NN O O
SE NN O O
] NN O O
, NN O O
baseline NN O O
: NN O O
71.1 NN O O
[ NN O O
4.92 NN O O
] NN O O
; NN O O
3 NN O O
weeks NN O O
after NN O O
treatment NN O O
: NN O O
88.8 NN O O
[ NN O O
2.1 NN O O
] NN O O
; NN O O
3 NN O O
weeks NN O O
after NN O O
the NN O O
end NN O O
of NN O O
treatment NN O O
: NN O O
92.2 NN O O
[ NN O O
2.4 NN O O
] NN O O
; NN O O
P NN O O
> NN O O
.05 NN O O
) NN O O
. NN O O

Patients NN O O
treated NN O O
with NN O O
CRB-iTBS NN O O
, NN O O
but NN O O
not NN O O
sham NN O O
iTBS NN O O
, NN O O
showed NN O O
a NN O O
reduction NN O O
of NN O O
step NN O O
width NN O O
at NN O O
the NN O O
gait NN O O
analysis NN O O
( NN O O
mean NN O O
[ NN O O
SE NN O O
] NN O O
, NN O O
baseline NN O O
: NN O O
16.8 NN O O
[ NN O O
4.8 NN O O
] NN O O
cm NN O O
; NN O O
3 NN O O
weeks NN O O
after NN O O
treatment NN O O
: NN O O
14.3 NN O O
[ NN O O
6.2 NN O O
] NN O O
cm NN O O
; NN O O
P NN O O
< NN O O
.05 NN O O
) NN O O
and NN O O
an NN O O
increase NN O O
of NN O O
neural NN O O
activity NN O O
over NN O O
the NN O O
posterior NN O O
parietal NN O O
cortex NN O O
. NN O O

Cerebellar NN O O
intermittent NN O O
θ-burst NN O O
stimulation NN O O
promotes NN O O
gait NN O O
and NN O O
balance NN O O
recovery NN O O
in NN O O
patients NN O O
with NN O O
stroke NN O O
by NN O O
acting NN O O
on NN O O
cerebello-cortical NN O O
plasticity NN O O
. NN O O

These NN O O
results NN O O
are NN O O
important NN O O
to NN O O
increase NN O O
the NN O O
level NN O O
of NN O O
independent NN O O
walking NN O O
and NN O O
reduce NN O O
the NN O O
risk NN O O
of NN O O
falling NN O O
. NN O O

ClinicalTrials.gov NN O O
Identifier NN O O
: NN O O
NCT03456362 NN O O
. NN O O



-DOCSTART- (30589829)

Maintaining NN O O
or NN O O
improving NN O O
muscle NN O O
mass NN O O
and NN O O
muscle NN O O
strength NN O O
is NN O O
an NN O O
important NN O O
treatment NN O O
goal NN O O
in NN O O
pancreatic NN O O
cancer NN O O
( NN O O
PC NN O O
) NN O O
patients NN O O
because NN O O
of NN O O
high NN O O
risk NN O O
of NN O O
cachexia NN O O
. NN O O

Therefore NN O O
, NN O O
we NN O O
assessed NN O O
feasibility NN O O
and NN O O
effectivity NN O O
of NN O O
a NN O O
6-month NN O O
progressive NN O O
resistance NN O O
training NN O O
( NN O O
RT NN O O
) NN O O
in NN O O
PC NN O O
patients NN O O
within NN O O
a NN O O
randomized NN O O
controlled NN O O
trial NN O O
. NN O O

Sixty-five NN O O
PC NN O O
patients NN O O
were NN O O
randomly NN O O
assigned NN O O
to NN O O
either NN O O
supervised NN O O
progressive NN O O
RT NN O O
( NN O O
RT1 NN O O
) NN O O
, NN O O
home-based NN O O
RT NN O O
( NN O O
RT2 NN O O
) NN O O
, NN O O
or NN O O
usual NN O O
care NN O O
control NN O O
group NN O O
( NN O O
CON NN O O
) NN O O
. NN O O

Both NN O O
exercise NN O O
groups NN O O
performed NN O O
training NN O O
2 NN O O
times NN O O
per NN O O
week NN O O
for NN O O
6 NN O O
months NN O O
. NN O O

Muscle NN O O
strength NN O O
for NN O O
knee NN O O
, NN O O
elbow NN O O
, NN O O
and NN O O
hip NN O O
extensors NN O O
and NN O O
flexors NN O O
and NN O O
cardiorespiratory NN O O
fitness NN O O
and NN O O
body NN O O
weight NN O O
were NN O O
assessed NN O O
before NN O O
and NN O O
after NN O O
the NN O O
intervention NN O O
period NN O O
. NN O O

Of NN O O
65 NN O O
patients NN O O
, NN O O
43 NN O O
patients NN O O
were NN O O
analyzed NN O O
. NN O O

Adherence NN O O
rates NN O O
were NN O O
64.1 NN O O
% NN O O
( NN O O
RT1 NN O O
) NN O O
and NN O O
78.4 NN O O
% NN O O
( NN O O
RT2 NN O O
) NN O O
of NN O O
the NN O O
prescribed NN O O
training NN O O
sessions NN O O
. NN O O

RT1 NN O O
showed NN O O
significant NN O O
improvements NN O O
in NN O O
elbow NN O O
flexor/extensor NN O O
muscle NN O O
strength NN O O
and NN O O
in NN O O
maximal NN O O
work NN O O
load NN O O
versus NN O O
CON NN O O
and NN O O
RT2 NN O O
( NN O O
P NN O O
< NN O O
0.05 NN O O
) NN O O
. NN O O

Further NN O O
, NN O O
knee NN O O
extensors NN O O
were NN O O
significantly NN O O
improved NN O O
for NN O O
RT1 NN O O
versus NN O O
CON NN O O
( NN O O
P NN O O
< NN O O
0.05 NN O O
) NN O O
. NN O O

Body NN O O
weight NN O O
revealed NN O O
no NN O O
significant NN O O
group NN O O
differences NN O O
over NN O O
time NN O O
. NN O O

Progressive NN O O
RT NN O O
was NN O O
feasible NN O O
in NN O O
PC NN O O
patients NN O O
and NN O O
improved NN O O
muscle NN O O
strength NN O O
with NN O O
significant NN O O
results NN O O
for NN O O
some NN O O
muscle NN O O
groups NN O O
. NN O O

Supervised NN O O
RT NN O O
seemed NN O O
to NN O O
be NN O O
more NN O O
effective NN O O
than NN O O
home-based NN O O
RT NN O O
. NN O O



-DOCSTART- (31036468)

Tucidinostat NN O O
( NN O O
formerly NN O O
known NN O O
as NN O O
chidamide NN O O
) NN O O
is NN O O
an NN O O
oral NN O O
subtype-selective NN O O
histone NN O O
deacetylase NN O O
inhibitor NN O O
. NN O O

In NN O O
an NN O O
exploratory NN O O
study NN O O
, NN O O
the NN O O
combination NN O O
of NN O O
tucidinostat NN O O
with NN O O
exemestane NN O O
showed NN O O
preliminary NN O O
signs NN O O
of NN O O
encouraging NN O O
anti-tumour NN O O
activity NN O O
in NN O O
patients NN O O
with NN O O
advanced NN O O
hormone NN O O
receptor-positive NN O O
breast NN O O
cancer NN O O
. NN O O

To NN O O
build NN O O
on NN O O
these NN O O
findings NN O O
, NN O O
we NN O O
aimed NN O O
to NN O O
assess NN O O
the NN O O
efficacy NN O O
and NN O O
safety NN O O
of NN O O
this NN O O
combination NN O O
in NN O O
a NN O O
randomised NN O O
trial NN O O
in NN O O
a NN O O
larger NN O O
population NN O O
of NN O O
postmenopausal NN O O
patients NN O O
with NN O O
advanced NN O O
, NN O O
hormone NN O O
receptor-positive NN O O
breast NN O O
cancer NN O O
. NN O O

We NN O O
did NN O O
the NN O O
randomised NN O O
, NN O O
double-blind NN O O
, NN O O
placebo-controlled NN O O
, NN O O
phase NN O O
3 NN O O
ACE NN O O
trial NN O O
at NN O O
22 NN O O
specialist NN O O
cancer NN O O
centres NN O O
in NN O O
China NN O O
. NN O O

Eligible NN O O
patients NN O O
were NN O O
postmenopausal NN O O
women NN O O
( NN O O
aged NN O O
≥60 NN O O
years NN O O
or NN O O
aged NN O O
< NN O O
60 NN O O
years NN O O
if NN O O
their NN O O
serum NN O O
follicle-stimulating NN O O
hormone NN O O
and NN O O
oestradiol NN O O
concentrations NN O O
were NN O O
within NN O O
postmenopausal NN O O
ranges NN O O
) NN O O
with NN O O
hormone NN O O
receptor-positive NN O O
, NN O O
HER2-negative NN O O
breast NN O O
cancer NN O O
, NN O O
whose NN O O
disease NN O O
had NN O O
relapsed NN O O
or NN O O
progressed NN O O
after NN O O
at NN O O
least NN O O
one NN O O
endocrine NN O O
therapy NN O O
( NN O O
either NN O O
in NN O O
advanced NN O O
or NN O O
metastatic NN O O
or NN O O
adjuvant NN O O
setting NN O O
) NN O O
, NN O O
and NN O O
who NN O O
had NN O O
at NN O O
least NN O O
one NN O O
measurable NN O O
lesion NN O O
, NN O O
adequate NN O O
organ NN O O
function NN O O
, NN O O
Eastern NN O O
Cooperative NN O O
Oncology NN O O
Group NN O O
( NN O O
ECOG NN O O
) NN O O
performance NN O O
status NN O O
of NN O O
0 NN O O
- NN O O
1 NN O O
, NN O O
and NN O O
adequate NN O O
haematological NN O O
and NN O O
biochemical NN O O
parameters NN O O
. NN O O

Endocrine NN O O
therapy NN O O
did NN O O
not NN O O
have NN O O
to NN O O
be NN O O
the NN O O
most NN O O
recent NN O O
therapy NN O O
before NN O O
randomisation NN O O
, NN O O
but NN O O
recurrence NN O O
or NN O O
progression NN O O
after NN O O
the NN O O
most NN O O
recent NN O O
therapy NN O O
was NN O O
a NN O O
prerequisite NN O O
. NN O O

Patients NN O O
were NN O O
randomly NN O O
assigned NN O O
( NN O O
2:1 NN O O
) NN O O
by NN O O
a NN O O
dynamic NN O O
randomisation NN O O
scheme NN O O
via NN O O
an NN O O
interactive NN O O
web-response NN O O
system NN O O
to NN O O
receive NN O O
30 NN O O
mg NN O O
oral NN O O
tucidinostat NN O O
or NN O O
placebo NN O O
twice NN O O
weekly NN O O
. NN O O

All NN O O
patients NN O O
in NN O O
both NN O O
groups NN O O
also NN O O
received NN O O
25 NN O O
mg NN O O
oral NN O O
exemestane NN O O
daily NN O O
. NN O O

Randomisation NN O O
was NN O O
stratified NN O O
according NN O O
to NN O O
the NN O O
presence NN O O
of NN O O
visceral NN O O
metastases NN O O
( NN O O
yes NN O O
vs NN O O
no NN O O
) NN O O
. NN O O

Patients NN O O
, NN O O
investigators NN O O
, NN O O
study NN O O
site NN O O
staff NN O O
, NN O O
and NN O O
the NN O O
sponsor NN O O
were NN O O
masked NN O O
to NN O O
treatment NN O O
assignment NN O O
. NN O O

The NN O O
primary NN O O
endpoint NN O O
was NN O O
investigator-assessed NN O O
progression-free NN O O
survival NN O O
. NN O O

Efficacy NN O O
analyses NN O O
were NN O O
done NN O O
in NN O O
the NN O O
full NN O O
analysis NN O O
set NN O O
population NN O O
, NN O O
comprising NN O O
all NN O O
patients NN O O
who NN O O
received NN O O
at NN O O
least NN O O
one NN O O
dose NN O O
of NN O O
any NN O O
study NN O O
treatment NN O O
, NN O O
and NN O O
safety NN O O
analyses NN O O
were NN O O
done NN O O
in NN O O
all NN O O
patients NN O O
who NN O O
received NN O O
at NN O O
least NN O O
one NN O O
dose NN O O
of NN O O
any NN O O
study NN O O
treatment NN O O
and NN O O
for NN O O
whom NN O O
at NN O O
least NN O O
one NN O O
safety NN O O
case NN O O
report NN O O
form NN O O
was NN O O
available NN O O
. NN O O

This NN O O
study NN O O
is NN O O
registered NN O O
with NN O O
ClinicalTrials.gov NN O O
, NN O O
number NN O O
NCT02482753 NN O O
. NN O O

The NN O O
study NN O O
has NN O O
reached NN O O
the NN O O
required NN O O
number NN O O
of NN O O
events NN O O
for NN O O
final NN O O
analysis NN O O
of NN O O
the NN O O
primary NN O O
endpoint NN O O
. NN O O

The NN O O
trial NN O O
is NN O O
no NN O O
longer NN O O
enrolling NN O O
patients NN O O
, NN O O
but NN O O
follow-up NN O O
for NN O O
investigation NN O O
of NN O O
overall NN O O
survival NN O O
is NN O O
ongoing NN O O
. NN O O

Between NN O O
July NN O O
20 NN O O
, NN O O
2015 NN O O
, NN O O
and NN O O
June NN O O
26 NN O O
, NN O O
2017 NN O O
, NN O O
365 NN O O
patients NN O O
were NN O O
enrolled NN O O
and NN O O
randomly NN O O
assigned NN O O
, NN O O
244 NN O O
to NN O O
the NN O O
tucidinostat NN O O
group NN O O
and NN O O
121 NN O O
to NN O O
the NN O O
placebo NN O O
group NN O O
. NN O O

The NN O O
median NN O O
duration NN O O
of NN O O
follow-up NN O O
was NN O O
13·9 NN O O
months NN O O
( NN O O
IQR NN O O
9·8 NN O O
- NN O O
17·5 NN O O
) NN O O
. NN O O

Investigator-assessed NN O O
median NN O O
progression-free NN O O
survival NN O O
was NN O O
7·4 NN O O
months NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
5·5 NN O O
- NN O O
9·2 NN O O
) NN O O
in NN O O
the NN O O
tucidinostat NN O O
group NN O O
and NN O O
3·8 NN O O
months NN O O
( NN O O
3·7 NN O O
- NN O O
5·5 NN O O
) NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
( NN O O
HR NN O O
0·75 NN O O
[ NN O O
95 NN O O
% NN O O
CI NN O O
0·58 NN O O
- NN O O
0·98 NN O O
] NN O O
; NN O O
p=0·033 NN O O
) NN O O
. NN O O

The NN O O
most NN O O
common NN O O
grade NN O O
3 NN O O
or NN O O
4 NN O O
adverse NN O O
events NN O O
in NN O O
either NN O O
group NN O O
were NN O O
neutropenia NN O O
( NN O O
124 NN O O
[ NN O O
51 NN O O
% NN O O
] NN O O
of NN O O
244 NN O O
patients NN O O
in NN O O
the NN O O
tucidinostat NN O O
group NN O O
vs NN O O
three NN O O
[ NN O O
2 NN O O
% NN O O
] NN O O
of NN O O
121 NN O O
patients NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
) NN O O
, NN O O
thrombocytopenia NN O O
( NN O O
67 NN O O
[ NN O O
27 NN O O
% NN O O
] NN O O
vs NN O O
three NN O O
[ NN O O
2 NN O O
% NN O O
] NN O O
) NN O O
, NN O O
and NN O O
leucopenia NN O O
( NN O O
46 NN O O
[ NN O O
19 NN O O
% NN O O
] NN O O
vs NN O O
three NN O O
[ NN O O
2 NN O O
% NN O O
] NN O O
) NN O O
. NN O O

Serious NN O O
adverse NN O O
events NN O O
of NN O O
any NN O O
cause NN O O
occurred NN O O
in NN O O
51 NN O O
( NN O O
21 NN O O
% NN O O
) NN O O
of NN O O
244 NN O O
patients NN O O
in NN O O
the NN O O
tucidinostat NN O O
group NN O O
and NN O O
seven NN O O
( NN O O
6 NN O O
% NN O O
) NN O O
of NN O O
121 NN O O
patients NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
. NN O O

No NN O O
treatment-related NN O O
deaths NN O O
were NN O O
reported NN O O
. NN O O

Tucidinostat NN O O
plus NN O O
exemestane NN O O
improved NN O O
progression-free NN O O
survival NN O O
compared NN O O
with NN O O
placebo NN O O
plus NN O O
exemestane NN O O
in NN O O
patients NN O O
with NN O O
advanced NN O O
, NN O O
hormone NN O O
receptor-positive NN O O
, NN O O
HER2-negative NN O O
breast NN O O
cancer NN O O
that NN O O
progressed NN O O
after NN O O
previous NN O O
endocrine NN O O
therapy NN O O
. NN O O

Grade NN O O
3 NN O O
- NN O O
4 NN O O
haematological NN O O
adverse NN O O
events NN O O
were NN O O
more NN O O
common NN O O
in NN O O
the NN O O
tucidinostat NN O O
plus NN O O
exemestane NN O O
group NN O O
than NN O O
in NN O O
the NN O O
placebo NN O O
plus NN O O
exemestane NN O O
group NN O O
. NN O O

Tucidinostat NN O O
plus NN O O
exemestane NN O O
could NN O O
represent NN O O
a NN O O
new NN O O
treatment NN O O
option NN O O
for NN O O
these NN O O
patients NN O O
. NN O O

Chipscreen NN O O
Biosciences NN O O
. NN O O



-DOCSTART- (30938751)

In NN O O
the NN O O
context NN O O
of NN O O
patient NN O O
broad NN O O
consent NN O O
for NN O O
future NN O O
research NN O O
uses NN O O
of NN O O
their NN O O
identifiable NN O O
health NN O O
record NN O O
data NN O O
, NN O O
we NN O O
compare NN O O
the NN O O
effectiveness NN O O
of NN O O
interactive NN O O
trust-enhanced NN O O
e-consent NN O O
, NN O O
interactive-only NN O O
e-consent NN O O
, NN O O
and NN O O
standard NN O O
e-consent NN O O
( NN O O
no NN O O
interactivity NN O O
, NN O O
no NN O O
trust NN O O
enhancement NN O O
) NN O O
. NN O O

A NN O O
randomized NN O O
trial NN O O
was NN O O
conducted NN O O
involving NN O O
adult NN O O
participants NN O O
making NN O O
a NN O O
scheduled NN O O
primary NN O O
care NN O O
visit NN O O
. NN O O

Participants NN O O
were NN O O
randomized NN O O
into NN O O
1 NN O O
of NN O O
the NN O O
3 NN O O
e-consent NN O O
conditions NN O O
. NN O O

Primary NN O O
outcomes NN O O
were NN O O
patient-reported NN O O
satisfaction NN O O
with NN O O
and NN O O
subjective NN O O
understanding NN O O
of NN O O
the NN O O
e-consent NN O O
. NN O O

Secondary NN O O
outcomes NN O O
were NN O O
objective NN O O
knowledge NN O O
, NN O O
perceived NN O O
voluntariness NN O O
, NN O O
trust NN O O
in NN O O
medical NN O O
researchers NN O O
, NN O O
consent NN O O
decision NN O O
, NN O O
and NN O O
time NN O O
spent NN O O
using NN O O
the NN O O
application NN O O
. NN O O

Outcomes NN O O
were NN O O
assessed NN O O
immediately NN O O
after NN O O
use NN O O
of NN O O
the NN O O
e-consent NN O O
and NN O O
at NN O O
1-week NN O O
follow-up NN O O
. NN O O

Across NN O O
all NN O O
conditions NN O O
, NN O O
participants NN O O
( NN O O
N NN O O
= NN O O
734 NN O O
) NN O O
reported NN O O
moderate-to-high NN O O
satisfaction NN O O
with NN O O
consent NN O O
( NN O O
mean NN O O
4.3 NN O O
of NN O O
5 NN O O
) NN O O
and NN O O
subjective NN O O
understanding NN O O
( NN O O
79.1 NN O O
of NN O O
100 NN O O
) NN O O
. NN O O

Over NN O O
94 NN O O
% NN O O
agreed NN O O
to NN O O
share NN O O
their NN O O
health NN O O
record NN O O
data NN O O
. NN O O

No NN O O
statistically NN O O
significant NN O O
differences NN O O
in NN O O
outcomes NN O O
were NN O O
observed NN O O
between NN O O
conditions NN O O
. NN O O

Irrespective NN O O
of NN O O
condition NN O O
, NN O O
black NN O O
participants NN O O
and NN O O
those NN O O
with NN O O
lower NN O O
education NN O O
reported NN O O
lower NN O O
satisfaction NN O O
, NN O O
subjective NN O O
understanding NN O O
, NN O O
knowledge NN O O
, NN O O
perceived NN O O
voluntariness NN O O
, NN O O
and NN O O
trust NN O O
in NN O O
medical NN O O
researchers NN O O
, NN O O
as NN O O
well NN O O
as NN O O
spent NN O O
more NN O O
time NN O O
consenting NN O O
. NN O O

A NN O O
large NN O O
majority NN O O
of NN O O
patients NN O O
were NN O O
willing NN O O
to NN O O
share NN O O
their NN O O
identifiable NN O O
health NN O O
records NN O O
for NN O O
research NN O O
, NN O O
and NN O O
they NN O O
reported NN O O
positive NN O O
consent NN O O
experiences NN O O
. NN O O

However NN O O
, NN O O
incorporating NN O O
optional NN O O
additional NN O O
information NN O O
and NN O O
messages NN O O
designed NN O O
to NN O O
enhance NN O O
trust NN O O
in NN O O
the NN O O
research NN O O
process NN O O
did NN O O
not NN O O
improve NN O O
consent NN O O
experiences NN O O
. NN O O

To NN O O
improve NN O O
poorer NN O O
consent NN O O
experiences NN O O
of NN O O
racial NN O O
and NN O O
ethnic NN O O
minority NN O O
participants NN O O
and NN O O
those NN O O
with NN O O
lower NN O O
education NN O O
, NN O O
other NN O O
novel NN O O
consent NN O O
technologies NN O O
and NN O O
processes NN O O
may NN O O
be NN O O
valuable NN O O
. NN O O

( NN O O
An NN O O
Interactive NN O O
Patient-Centered NN O O
Consent NN O O
for NN O O
Research NN O O
Using NN O O
Medical NN O O
Records NN O O
; NN O O
NCT03063268 NN O O
) NN O O
. NN O O



-DOCSTART- (31289971)

The NN O O
purpose NN O O
of NN O O
this NN O O
paper NN O O
is NN O O
to NN O O
investigate NN O O
which NN O O
elements NN O O
of NN O O
tooth NN O O
colour NN O O
are NN O O
most NN O O
influenced NN O O
by NN O O
whitening NN O O
and NN O O
to NN O O
identify NN O O
the NN O O
short-term NN O O
changes NN O O
in NN O O
satisfaction NN O O
with NN O O
smile NN O O
aesthetics NN O O
and NN O O
quality NN O O
of NN O O
life NN O O
induced NN O O
by NN O O
tooth NN O O
whitening NN O O
and NN O O
the NN O O
role NN O O
of NN O O
global NN O O
self-esteem NN O O
. NN O O

Sixty NN O O
participants NN O O
were NN O O
randomly NN O O
assigned NN O O
to NN O O
a NN O O
treated NN O O
or NN O O
a NN O O
placebo NN O O
group NN O O
( NN O O
each NN O O
group NN O O
N NN O O
= NN O O
30 NN O O
) NN O O
. NN O O

Their NN O O
anterior NN O O
teeth NN O O
were NN O O
bleached NN O O
with NN O O
a NN O O
photo-activated NN O O
whitening NN O O
gel NN O O
, NN O O
or NN O O
subjected NN O O
to NN O O
a NN O O
placebo NN O O
. NN O O

Lightness NN O O
, NN O O
chroma NN O O
and NN O O
the NN O O
translucency NN O O
of NN O O
teeth NN O O
were NN O O
assessed NN O O
before NN O O
and NN O O
1 NN O O
week NN O O
after NN O O
the NN O O
procedure NN O O
using NN O O
a NN O O
spectrophotometer NN O O
. NN O O

The NN O O
Self-Esteem NN O O
Scale NN O O
, NN O O
Psychosocial NN O O
Impact NN O O
of NN O O
Dental NN O O
Aesthetics NN O O
Questionnaire NN O O
, NN O O
the NN O O
Orofacial NN O O
Aesthetic NN O O
Scale NN O O
and NN O O
the NN O O
Oral NN O O
Health NN O O
Impact NN O O
Profile NN O O
were NN O O
administered NN O O
to NN O O
subjects NN O O
. NN O O

Changes NN O O
in NN O O
colour NN O O
and NN O O
chroma NN O O
were NN O O
greater NN O O
in NN O O
the NN O O
treated NN O O
than NN O O
the NN O O
placebo NN O O
group NN O O
( NN O O
3.8 NN O O
± NN O O
1.5 NN O O
vs. NN O O
1.7 NN O O
± NN O O
1.5 NN O O
and NN O O
- NN O O
3.2 NN O O
± NN O O
1.5 NN O O
vs. NN O O
0.0 NN O O
± NN O O
1.1 NN O O
; NN O O
p NN O O
< NN O O
0.001 NN O O
) NN O O
. NN O O

The NN O O
treated NN O O
group NN O O
reported NN O O
increased NN O O
satisfaction NN O O
with NN O O
appearance NN O O
and NN O O
a NN O O
decrease NN O O
in NN O O
psychological NN O O
and NN O O
social NN O O
impacts NN O O
( NN O O
p NN O O
< NN O O
0.05 NN O O
) NN O O
. NN O O

In NN O O
the NN O O
placebo NN O O
group NN O O
there NN O O
was NN O O
no NN O O
objective NN O O
change NN O O
in NN O O
colour NN O O
but NN O O
the NN O O
subjects NN O O
reported NN O O
an NN O O
increase NN O O
in NN O O
satisfaction NN O O
and NN O O
dental NN O O
self-confidence NN O O
, NN O O
as NN O O
well NN O O
as NN O O
a NN O O
decrease NN O O
in NN O O
psychological NN O O
impact NN O O
( NN O O
p NN O O
< NN O O
0.05 NN O O
) NN O O
. NN O O

Self-esteem NN O O
did NN O O
not NN O O
have NN O O
a NN O O
moderation NN O O
nor NN O O
a NN O O
mediation NN O O
effect NN O O
. NN O O

In NN O O
conclusion NN O O
, NN O O
patients NN O O
are NN O O
not NN O O
able NN O O
to NN O O
accurately NN O O
detect NN O O
the NN O O
colour NN O O
change NN O O
induced NN O O
by NN O O
tooth NN O O
whitening NN O O
after NN O O
1 NN O O
week NN O O
, NN O O
but NN O O
they NN O O
are NN O O
also NN O O
largely NN O O
suggestible NN O O
when NN O O
evaluating NN O O
the NN O O
changes NN O O
in NN O O
quality NN O O
of NN O O
life NN O O
. NN O O

Changes NN O O
in NN O O
quality NN O O
of NN O O
life NN O O
induced NN O O
by NN O O
tooth NN O O
whitening NN O O
are NN O O
not NN O O
influenced NN O O
by NN O O
global NN O O
self-esteem NN O O
. NN O O

ClinicalTrials.gov NN O O
Identifier NN O O
NCT03380702 NN O O
. NN O O



-DOCSTART- (30794296)

Several NN O O
functional NN O O
limitations NN O O
persist NN O O
after NN O O
total NN O O
knee NN O O
replacement NN O O
( NN O O
TKR NN O O
) NN O O
. NN O O

Intensive NN O O
exercise NN O O
programs NN O O
could NN O O
resolve NN O O
these NN O O
limitations NN O O
but NN O O
are NN O O
not NN O O
well NN O O
tolerated NN O O
by NN O O
many NN O O
patients NN O O
until NN O O
a NN O O
later NN O O
stage NN O O
( NN O O
> NN O O
2 NN O O
months NN O O
) NN O O
after NN O O
surgery NN O O
. NN O O

Evidence NN O O
for NN O O
exercise NN O O
at NN O O
a NN O O
later NN O O
stage NN O O
after NN O O
TKR NN O O
is NN O O
limited NN O O
. NN O O

To NN O O
compare NN O O
the NN O O
effectiveness NN O O
of NN O O
later-stage NN O O
exercise NN O O
programs NN O O
after NN O O
TKR NN O O
and NN O O
to NN O O
explore NN O O
heterogeneity NN O O
of NN O O
treatment NN O O
effects NN O O
. NN O O

Three-arm NN O O
single-blind NN O O
randomized NN O O
clinical NN O O
trial NN O O
( NN O O
January NN O O
7 NN O O
, NN O O
2015 NN O O
, NN O O
to NN O O
November NN O O
9 NN O O
, NN O O
2017 NN O O
) NN O O
using NN O O
an NN O O
intent-to-treat NN O O
approach NN O O
with NN O O
follow-ups NN O O
at NN O O
3 NN O O
months NN O O
and NN O O
6 NN O O
months NN O O
. NN O O

The NN O O
setting NN O O
was NN O O
Allegheny NN O O
County NN O O
, NN O O
Pennsylvania NN O O
( NN O O
an NN O O
outpatient NN O O
physical NN O O
therapy NN O O
clinic NN O O
and NN O O
4 NN O O
community NN O O
centers NN O O
) NN O O
. NN O O

Participants NN O O
had NN O O
primary NN O O
TKR NN O O
performed NN O O
more NN O O
than NN O O
2 NN O O
months NN O O
previously NN O O
, NN O O
were NN O O
60 NN O O
years NN O O
or NN O O
older NN O O
, NN O O
experienced NN O O
moderate NN O O
functional NN O O
limitations NN O O
, NN O O
and NN O O
were NN O O
medically NN O O
cleared NN O O
to NN O O
exercise NN O O
. NN O O

Clinic-based NN O O
physical NN O O
therapy NN O O
exercise NN O O
( NN O O
physical NN O O
therapy NN O O
arm NN O O
) NN O O
, NN O O
community-based NN O O
group NN O O
exercise NN O O
( NN O O
community NN O O
arm NN O O
) NN O O
, NN O O
and NN O O
usual NN O O
care NN O O
( NN O O
control NN O O
arm NN O O
) NN O O
. NN O O

The NN O O
control NN O O
arm NN O O
continued NN O O
their NN O O
usual NN O O
care NN O O
, NN O O
whereas NN O O
the NN O O
exercise NN O O
arms NN O O
participated NN O O
in NN O O
supervised NN O O
exercise NN O O
programs NN O O
lasting NN O O
12 NN O O
weeks NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
was NN O O
arm NN O O
differences NN O O
in NN O O
the NN O O
Western NN O O
Ontario NN O O
and NN O O
McMaster NN O O
Universities NN O O
Osteoarthritis NN O O
Index-Physical NN O O
Function NN O O
( NN O O
WOMAC-PF NN O O
) NN O O
at NN O O
3 NN O O
months NN O O
. NN O O

The NN O O
secondary NN O O
outcomes NN O O
included NN O O
performance-based NN O O
tests NN O O
germane NN O O
to NN O O
knee NN O O
replacement NN O O
and NN O O
additional NN O O
surveys NN O O
of NN O O
physical NN O O
function NN O O
. NN O O

Data NN O O
were NN O O
analyzed NN O O
by NN O O
linear NN O O
mixed NN O O
models NN O O
and NN O O
responder NN O O
analysis NN O O
. NN O O

A NN O O
total NN O O
of NN O O
240 NN O O
participants NN O O
( NN O O
mean NN O O
[ NN O O
SD NN O O
] NN O O
age NN O O
, NN O O
70 NN O O
[ NN O O
7 NN O O
] NN O O
years NN O O
; NN O O
61.7 NN O O
% NN O O
female NN O O
) NN O O
were NN O O
allocated NN O O
to NN O O
physical NN O O
therapy NN O O
( NN O O
n NN O O
= NN O O
96 NN O O
) NN O O
, NN O O
community NN O O
exercise NN O O
( NN O O
n NN O O
= NN O O
96 NN O O
) NN O O
, NN O O
or NN O O
control NN O O
( NN O O
n NN O O
= NN O O
48 NN O O
) NN O O
. NN O O

All NN O O
3 NN O O
arms NN O O
demonstrated NN O O
clinically NN O O
important NN O O
improvement NN O O
. NN O O

At NN O O
3 NN O O
months NN O O
, NN O O
between-arm NN O O
analyses NN O O
for NN O O
the NN O O
WOMAC-PF NN O O
demonstrated NN O O
no NN O O
differences NN O O
between NN O O
physical NN O O
therapy NN O O
and NN O O
community NN O O
( NN O O
-2.2 NN O O
; NN O O
98.3 NN O O
% NN O O
CI NN O O
, NN O O
-4.5 NN O O
to NN O O
0.1 NN O O
) NN O O
, NN O O
physical NN O O
therapy NN O O
and NN O O
control NN O O
( NN O O
-2.1 NN O O
; NN O O
98.3 NN O O
% NN O O
CI NN O O
, NN O O
-4.9 NN O O
to NN O O
0.7 NN O O
) NN O O
, NN O O
and NN O O
community NN O O
and NN O O
control NN O O
( NN O O
0.1 NN O O
; NN O O
98.3 NN O O
% NN O O
CI NN O O
, NN O O
-2.7 NN O O
to NN O O
2.9 NN O O
) NN O O
. NN O O

Performance-based NN O O
tests NN O O
demonstrated NN O O
greater NN O O
improvement NN O O
in NN O O
the NN O O
physical NN O O
therapy NN O O
arm NN O O
compared NN O O
with NN O O
both NN O O
the NN O O
community NN O O
( NN O O
0.1 NN O O
z NN O O
score NN O O
units NN O O
; NN O O
98.3 NN O O
% NN O O
CI NN O O
, NN O O
0.0 NN O O
- NN O O
0.2 NN O O
) NN O O
and NN O O
control NN O O
( NN O O
0.3 NN O O
z NN O O
score NN O O
units NN O O
; NN O O
98.3 NN O O
% NN O O
CI NN O O
, NN O O
0.1 NN O O
- NN O O
0.4 NN O O
) NN O O
arms NN O O
and NN O O
the NN O O
community NN O O
arm NN O O
compared NN O O
with NN O O
the NN O O
control NN O O
arm NN O O
( NN O O
0.2 NN O O
z NN O O
score NN O O
units NN O O
; NN O O
98.3 NN O O
% NN O O
CI NN O O
, NN O O
0.0 NN O O
- NN O O
0.3 NN O O
) NN O O
. NN O O

The NN O O
physical NN O O
therapy NN O O
arm NN O O
had NN O O
more NN O O
than NN O O
17.7 NN O O
% NN O O
responders NN O O
than NN O O
the NN O O
community NN O O
arm NN O O
and NN O O
more NN O O
than NN O O
19.0 NN O O
% NN O O
responders NN O O
than NN O O
the NN O O
control NN O O
arm NN O O
. NN O O

There NN O O
was NN O O
no NN O O
difference NN O O
in NN O O
responder NN O O
rates NN O O
between NN O O
the NN O O
community NN O O
and NN O O
control NN O O
arms NN O O
. NN O O

Based NN O O
on NN O O
the NN O O
primary NN O O
outcome NN O O
, NN O O
participation NN O O
in NN O O
late-stage NN O O
exercise NN O O
programs NN O O
after NN O O
TKR NN O O
offered NN O O
no NN O O
benefit NN O O
over NN O O
usual NN O O
care NN O O
. NN O O

The NN O O
benefits NN O O
of NN O O
physical NN O O
therapy NN O O
identified NN O O
by NN O O
the NN O O
secondary NN O O
outcomes NN O O
and NN O O
responder NN O O
analysis NN O O
require NN O O
confirmation NN O O
. NN O O

ClinicalTrials.gov NN O O
Identifier NN O O
: NN O O
NCT02237911 NN O O
. NN O O



-DOCSTART- (30924492)

In NN O O
a NN O O
randomized NN O O
, NN O O
double-blind NN O O
, NN O O
placebo-controlled NN O O
trial NN O O
of NN O O
tenofovir NN O O
disoproxil NN O O
fumarate NN O O
( NN O O
TDF NN O O
) NN O O
use NN O O
from NN O O
28 NN O O
weeks NN O O
gestational NN O O
age NN O O
to NN O O
2 NN O O
months NN O O
postpartum NN O O
to NN O O
prevent NN O O
mother-to-child NN O O
transmission NN O O
of NN O O
hepatitis NN O O
B NN O O
virus NN O O
, NN O O
there NN O O
was NN O O
no NN O O
significant NN O O
effect NN O O
of NN O O
maternal NN O O
TDF NN O O
use NN O O
on NN O O
maternal NN O O
or NN O O
infant NN O O
bone NN O O
mineral NN O O
density NN O O
1 NN O O
year NN O O
after NN O O
delivery/birth NN O O
. NN O O

Clinical NN O O
Trials NN O O
Registration NN O O
. NN O O

NCT01745822 NN O O
. NN O O



-DOCSTART- (30636636)

Excessive NN O O
gestational NN O O
weight NN O O
gain NN O O
( NN O O
GWG NN O O
) NN O O
leads NN O O
to NN O O
obstetric NN O O
complications NN O O
, NN O O
maternal NN O O
postpartum NN O O
weight NN O O
retention NN O O
and NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
offspring NN O O
obesity NN O O
. NN O O

The NN O O
GeliS NN O O
study NN O O
examines NN O O
the NN O O
effect NN O O
of NN O O
a NN O O
lifestyle NN O O
intervention NN O O
during NN O O
pregnancy NN O O
on NN O O
the NN O O
proportion NN O O
of NN O O
women NN O O
with NN O O
excessive NN O O
GWG NN O O
and NN O O
pregnancy NN O O
and NN O O
obstetric NN O O
complications NN O O
, NN O O
as NN O O
well NN O O
as NN O O
the NN O O
long-term NN O O
risk NN O O
of NN O O
maternal NN O O
and NN O O
infant NN O O
obesity NN O O
. NN O O

The NN O O
GeliS NN O O
study NN O O
is NN O O
a NN O O
cluster-randomised NN O O
multicentre NN O O
controlled NN O O
trial NN O O
including NN O O
2286 NN O O
women NN O O
with NN O O
a NN O O
pre-pregnancy NN O O
BMI NN O O
between NN O O
18.5 NN O O
and NN O O
40.0 NN O O
kg/m NN O O
recruited NN O O
from NN O O
gynaecological NN O O
and NN O O
midwifery NN O O
practices NN O O
prior NN O O
to NN O O
the NN O O
end NN O O
of NN O O
the NN O O
12 NN O O
week NN O O
of NN O O
gestation NN O O
in NN O O
five NN O O
Bavarian NN O O
regions NN O O
. NN O O

In NN O O
the NN O O
intervention NN O O
regions NN O O
, NN O O
four NN O O
lifestyle NN O O
counselling NN O O
sessions NN O O
covering NN O O
a NN O O
balanced NN O O
healthy NN O O
diet NN O O
, NN O O
regular NN O O
physical NN O O
activity NN O O
and NN O O
self-monitoring NN O O
of NN O O
weight NN O O
gain NN O O
were NN O O
performed NN O O
by NN O O
trained NN O O
healthcare NN O O
providers NN O O
alongside NN O O
routine NN O O
pre- NN O O
and NN O O
postnatal NN O O
practice NN O O
visits NN O O
. NN O O

In NN O O
the NN O O
control NN O O
regions NN O O
, NN O O
leaflets NN O O
with NN O O
general NN O O
recommendations NN O O
for NN O O
a NN O O
healthy NN O O
lifestyle NN O O
during NN O O
pregnancy NN O O
were NN O O
provided NN O O
. NN O O

The NN O O
intervention NN O O
did NN O O
not NN O O
result NN O O
in NN O O
a NN O O
significant NN O O
reduction NN O O
of NN O O
women NN O O
showing NN O O
excessive NN O O
GWG NN O O
( NN O O
adjusted NN O O
OR NN O O
0.95 NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
0.66 NN O O
- NN O O
1.38 NN O O
, NN O O
p NN O O
= NN O O
0.789 NN O O
) NN O O
, NN O O
with NN O O
45.1 NN O O
% NN O O
and NN O O
45.7 NN O O
% NN O O
of NN O O
women NN O O
in NN O O
the NN O O
intervention NN O O
and NN O O
control NN O O
groups NN O O
, NN O O
respectively NN O O
, NN O O
gaining NN O O
weight NN O O
above NN O O
the NN O O
Institute NN O O
of NN O O
Medicine NN O O
recommendations NN O O
. NN O O

Gestational NN O O
diabetes NN O O
mellitus NN O O
was NN O O
diagnosed NN O O
in NN O O
10.8 NN O O
% NN O O
and NN O O
11.1 NN O O
% NN O O
of NN O O
women NN O O
in NN O O
the NN O O
intervention NN O O
and NN O O
control NN O O
groups NN O O
, NN O O
respectively NN O O
( NN O O
p NN O O
= NN O O
0.622 NN O O
) NN O O
. NN O O

Mean NN O O
birth NN O O
weight NN O O
and NN O O
length NN O O
were NN O O
slightly NN O O
lower NN O O
in NN O O
the NN O O
intervention NN O O
group NN O O
( NN O O
3313 NN O O
± NN O O
536 NN O O
g NN O O
vs. NN O O
3363 NN O O
± NN O O
498 NN O O
g NN O O
, NN O O
p NN O O
= NN O O
0.020 NN O O
; NN O O
51.1 NN O O
± NN O O
2.7 NN O O
cm NN O O
vs. NN O O
51.6 NN O O
± NN O O
2.5 NN O O
cm NN O O
, NN O O
p NN O O
= NN O O
0.001 NN O O
) NN O O
. NN O O

In NN O O
the NN O O
setting NN O O
of NN O O
routine NN O O
prenatal NN O O
care NN O O
, NN O O
lifestyle NN O O
advice NN O O
given NN O O
by NN O O
trained NN O O
healthcare NN O O
providers NN O O
was NN O O
not NN O O
successful NN O O
in NN O O
limiting NN O O
GWG NN O O
and NN O O
pregnancy NN O O
complications NN O O
. NN O O

Nevertheless NN O O
, NN O O
the NN O O
potential NN O O
long-term NN O O
effects NN O O
of NN O O
the NN O O
intervention NN O O
remain NN O O
to NN O O
be NN O O
assessed NN O O
. NN O O

NCT01958307 NN O O
, NN O O
ClinicalTrials.gov NN O O
, NN O O
retrospectively NN O O
registered NN O O
October NN O O
9 NN O O
, NN O O
2013 NN O O
. NN O O



-DOCSTART- (30616014)

Intestinal NN O O
carriage NN O O
with NN O O
extended NN O O
spectrum NN O O
β-lactamase NN O O
Enterobacteriaceae NN O O
( NN O O
ESBL-E NN O O
) NN O O
and NN O O
carbapenemase-producing NN O O
Enterobacteriaceae NN O O
( NN O O
CPE NN O O
) NN O O
can NN O O
persist NN O O
for NN O O
months NN O O
. NN O O

We NN O O
aimed NN O O
to NN O O
evaluate NN O O
whether NN O O
oral NN O O
antibiotics NN O O
followed NN O O
by NN O O
faecal NN O O
microbiota NN O O
transplantation NN O O
( NN O O
FMT NN O O
) NN O O
can NN O O
eradicate NN O O
intestinal NN O O
carriage NN O O
with NN O O
ESBL-E/CPE NN O O
. NN O O

Randomized NN O O
, NN O O
open-label NN O O
, NN O O
superiority NN O O
trial NN O O
in NN O O
four NN O O
tertiary-care NN O O
centres NN O O
( NN O O
Geneva NN O O
( NN O O
G NN O O
) NN O O
, NN O O
Paris NN O O
( NN O O
P NN O O
) NN O O
, NN O O
Utrecht NN O O
( NN O O
U NN O O
) NN O O
, NN O O
Tel NN O O
Aviv NN O O
( NN O O
T NN O O
) NN O O
) NN O O
. NN O O

Non-immunocompromised NN O O
adult NN O O
patients NN O O
were NN O O
randomized NN O O
1 NN O O
: NN O O
1 NN O O
to NN O O
either NN O O
no NN O O
intervention NN O O
( NN O O
control NN O O
) NN O O
or NN O O
a NN O O
5-day NN O O
course NN O O
of NN O O
oral NN O O
antibiotics NN O O
( NN O O
colistin NN O O
sulphate NN O O
2 NN O O
× NN O O
10 NN O O
IU NN O O
4 NN O O
× NN O O
/day NN O O
; NN O O
neomycin NN O O
sulphate NN O O
500 NN O O
mg NN O O
4 NN O O
× NN O O
/day NN O O
) NN O O
followed NN O O
by NN O O
frozen NN O O
FMT NN O O
obtained NN O O
from NN O O
unrelated NN O O
healthy NN O O
donors NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
was NN O O
detectable NN O O
intestinal NN O O
carriage NN O O
of NN O O
ESBL-E/CPE NN O O
by NN O O
stool NN O O
culture NN O O
35 NN O O
- NN O O
48 NN O O
days NN O O
after NN O O
randomization NN O O
( NN O O
V4 NN O O
) NN O O
. NN O O

ClinicalTrials.govNCT02472600 NN O O
. NN O O

The NN O O
trial NN O O
was NN O O
funded NN O O
by NN O O
the NN O O
European NN O O
Commission NN O O
( NN O O
FP7 NN O O
) NN O O
. NN O O

Thirty-nine NN O O
patients NN O O
( NN O O
G NN O O
= NN O O
14 NN O O
; NN O O
P NN O O
= NN O O
16 NN O O
; NN O O
U NN O O
= NN O O
7 NN O O
; NN O O
T NN O O
= NN O O
2 NN O O
) NN O O
colonized NN O O
by NN O O
ESBL-E NN O O
( NN O O
n NN O O
= NN O O
36 NN O O
) NN O O
and/or NN O O
CPE NN O O
( NN O O
n NN O O
= NN O O
11 NN O O
) NN O O
were NN O O
enrolled NN O O
between NN O O
February NN O O
2016 NN O O
and NN O O
June NN O O
2017 NN O O
. NN O O

In NN O O
the NN O O
intention-to-treat NN O O
analysis NN O O
9/22 NN O O
( NN O O
41 NN O O
% NN O O
) NN O O
patients NN O O
assigned NN O O
to NN O O
the NN O O
intervention NN O O
arm NN O O
were NN O O
negative NN O O
for NN O O
ESBL-E/CPE NN O O
at NN O O
V4 NN O O
( NN O O
1/22 NN O O
not NN O O
receiving NN O O
the NN O O
intervention NN O O
imputed NN O O
as NN O O
positive NN O O
) NN O O
whereas NN O O
in NN O O
the NN O O
control NN O O
arm NN O O
5/17 NN O O
( NN O O
29 NN O O
% NN O O
) NN O O
patients NN O O
were NN O O
negative NN O O
( NN O O
one NN O O
lost NN O O
to NN O O
follow NN O O
up NN O O
imputed NN O O
as NN O O
negative NN O O
) NN O O
resulting NN O O
in NN O O
an NN O O
OR NN O O
for NN O O
decolonization NN O O
success NN O O
of NN O O
1.7 NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
0.4 NN O O
- NN O O
6.4 NN O O
) NN O O
. NN O O

Study NN O O
drugs NN O O
were NN O O
well NN O O
tolerated NN O O
overall NN O O
but NN O O
three NN O O
patients NN O O
in NN O O
the NN O O
intervention NN O O
group NN O O
prematurely NN O O
stopped NN O O
the NN O O
study NN O O
antibiotics NN O O
because NN O O
of NN O O
diarrhoea NN O O
( NN O O
all NN O O
received NN O O
FMT NN O O
) NN O O
. NN O O

Non-absorbable NN O O
antibiotics NN O O
followed NN O O
by NN O O
FMT NN O O
slightly NN O O
decreased NN O O
ESBL-E/CPE NN O O
carriage NN O O
compared NN O O
with NN O O
controls NN O O
; NN O O
this NN O O
difference NN O O
was NN O O
not NN O O
statistically NN O O
significant NN O O
, NN O O
potentially NN O O
due NN O O
to NN O O
early NN O O
trial NN O O
termination NN O O
. NN O O

Further NN O O
clinical NN O O
investigations NN O O
seem NN O O
warranted NN O O
. NN O O



-DOCSTART- (30744679)

Catheter-related NN O O
bacteremia NN O O
( NN O O
CRB NN O O
) NN O O
is NN O O
the NN O O
most NN O O
frequent NN O O
nosocomial NN O O
infection NN O O
in NN O O
neonatal NN O O
intensive NN O O
care NN O O
unit NN O O
( NN O O
NICU NN O O
) NN O O
patients NN O O
, NN O O
especially NN O O
in NN O O
very NN O O
low-birth-weight NN O O
infants NN O O
. NN O O

Administration NN O O
of NN O O
injectable NN O O
drugs NN O O
in NN O O
premature NN O O
newborn NN O O
infants NN O O
has NN O O
many NN O O
particularities NN O O
and NN O O
several NN O O
types NN O O
of NN O O
infusion NN O O
incidents NN O O
have NN O O
been NN O O
reported NN O O
. NN O O

The NN O O
Edelvaiss NN O O
® NN O O
Multiline NN O O
NEO NN O O
device NN O O
is NN O O
a NN O O
novel NN O O
multi-lumen NN O O
access NN O O
infusion NN O O
device NN O O
adapted NN O O
to NN O O
the NN O O
specificities NN O O
of NN O O
infusion NN O O
in NN O O
neonatology NN O O
. NN O O

This NN O O
multicenter NN O O
, NN O O
randomized NN O O
, NN O O
controlled NN O O
study NN O O
was NN O O
therefore NN O O
designed NN O O
to NN O O
determine NN O O
whether NN O O
or NN O O
not NN O O
Edelvaiss NN O O
® NN O O
Multiline NN O O
NEO NN O O
reduces NN O O
the NN O O
risk NN O O
of NN O O
CRB NN O O
in NN O O
preterm NN O O
newborn NN O O
infants NN O O
in NN O O
an NN O O
NICU NN O O
. NN O O

This NN O O
is NN O O
a NN O O
multicenter NN O O
, NN O O
randomized NN O O
, NN O O
controlled NN O O
trial NN O O
, NN O O
using NN O O
a NN O O
cluster-randomized NN O O
crossover NN O O
design NN O O
. NN O O

Four NN O O
investigator NN O O
centers NN O O
( NN O O
four NN O O
clusters NN O O
) NN O O
will NN O O
participate NN O O
in NN O O
the NN O O
study NN O O
and NN O O
will NN O O
be NN O O
randomized NN O O
into NN O O
two NN O O
groups NN O O
, NN O O
corresponding NN O O
to NN O O
two NN O O
different NN O O
sequences NN O O
( NN O O
either NN O O
the NN O O
Edelvaiss NN O O
® NN O O
Multiline NN O O
NEO NN O O
or NN O O
standard NN O O
infusion NN O O
system NN O O
sequence NN O O
, NN O O
then NN O O
vice NN O O
versa NN O O
) NN O O
. NN O O

A NN O O
total NN O O
of NN O O
280 NN O O
patients NN O O
will NN O O
be NN O O
recruited NN O O
. NN O O

Infants NN O O
will NN O O
be NN O O
enrolled NN O O
in NN O O
the NN O O
study NN O O
at NN O O
the NN O O
time NN O O
of NN O O
placing NN O O
a NN O O
single-lumen NN O O
central NN O O
venous NN O O
catheter NN O O
. NN O O

Three NN O O
visits NN O O
recording NN O O
specific NN O O
data NN O O
are NN O O
planned NN O O
in NN O O
the NN O O
study NN O O
protocol NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
measure NN O O
is NN O O
the NN O O
incidence NN O O
density NN O O
( NN O O
ID NN O O
) NN O O
of NN O O
CRB NN O O
. NN O O

For NN O O
each NN O O
patient NN O O
, NN O O
the NN O O
total NN O O
number NN O O
of NN O O
catheters NN O O
and NN O O
CRB NN O O
incidents NN O O
as NN O O
well NN O O
as NN O O
the NN O O
duration NN O O
of NN O O
stay NN O O
in NN O O
the NN O O
NICU NN O O
will NN O O
be NN O O
computed NN O O
and NN O O
considered NN O O
for NN O O
analysis NN O O
. NN O O

The NN O O
study NN O O
will NN O O
provide NN O O
high-quality NN O O
evidence NN O O
to NN O O
determine NN O O
whether NN O O
the NN O O
Multiline NN O O
NEO NN O O
device NN O O
reduces NN O O
the NN O O
risk NN O O
of NN O O
CRB NN O O
in NN O O
preterm NN O O
newborns NN O O
in NN O O
NICUs NN O O
or NN O O
not NN O O
. NN O O

ClinicalTrials.gov NN O O
, NN O O
NCT02633124 NN O O
. NN O O

Registered NN O O
on NN O O
7 NN O O
December NN O O
2015 NN O O
. NN O O



-DOCSTART- (30702322)

Little NN O O
is NN O O
known NN O O
about NN O O
the NN O O
mechanisms NN O O
through NN O O
which NN O O
routine NN O O
outcome NN O O
monitoring NN O O
( NN O O
ROM NN O O
) NN O O
influences NN O O
psychotherapy NN O O
outcomes NN O O
. NN O O

In NN O O
this NN O O
secondary NN O O
analysis NN O O
of NN O O
data NN O O
from NN O O
a NN O O
randomized NN O O
clinical NN O O
trial NN O O
( NN O O
Brattland NN O O
et NN O O
al. NN O O
, NN O O
2018 NN O O
) NN O O
, NN O O
we NN O O
investigated NN O O
whether NN O O
the NN O O
working NN O O
alliance NN O O
mediated NN O O
the NN O O
effect NN O O
of NN O O
the NN O O
Partners NN O O
for NN O O
Change NN O O
Outcome NN O O
Monitoring NN O O
System NN O O
( NN O O
PCOMS NN O O
) NN O O
, NN O O
a NN O O
ROM NN O O
system NN O O
that NN O O
provides NN O O
session-by-session NN O O
feedback NN O O
on NN O O
clients NN O O
' NN O O
well-being NN O O
and NN O O
the NN O O
alliance NN O O
. NN O O

Adult NN O O
individuals NN O O
( NN O O
N NN O O
= NN O O
170 NN O O
) NN O O
referred NN O O
for NN O O
hospital-based NN O O
outpatient NN O O
mental NN O O
health NN O O
treatment NN O O
were NN O O
randomized NN O O
to NN O O
individual NN O O
psychotherapy NN O O
either NN O O
with NN O O
the NN O O
PCOMS NN O O
ROM NN O O
system NN O O
, NN O O
or NN O O
without NN O O
( NN O O
treatment NN O O
as NN O O
usual NN O O
[ NN O O
TAU NN O O
] NN O O
) NN O O
. NN O O

Treatment NN O O
was NN O O
provided NN O O
by NN O O
the NN O O
same NN O O
therapists NN O O
( NN O O
N NN O O
= NN O O
20 NN O O
) NN O O
in NN O O
both NN O O
conditions NN O O
. NN O O

A NN O O
multilevel NN O O
mediation NN O O
model NN O O
was NN O O
developed NN O O
to NN O O
test NN O O
if NN O O
there NN O O
was NN O O
a NN O O
significant NN O O
indirect NN O O
effect NN O O
of NN O O
ROM NN O O
on NN O O
client NN O O
impairment NN O O
at NN O O
posttreatment NN O O
through NN O O
the NN O O
alliance NN O O
at NN O O
2 NN O O
months NN O O
' NN O O
treatment NN O O
controlled NN O O
for NN O O
first-session NN O O
alliance NN O O
. NN O O

Alliance NN O O
ratings NN O O
increased NN O O
more NN O O
from NN O O
session NN O O
1 NN O O
to NN O O
2 NN O O
months NN O O
' NN O O
treatment NN O O
in NN O O
the NN O O
ROM NN O O
than NN O O
TAU NN O O
condition NN O O
, NN O O
and NN O O
alliance NN O O
increase NN O O
was NN O O
associated NN O O
with NN O O
less NN O O
posttreatment NN O O
impairment NN O O
. NN O O

A NN O O
significant NN O O
indirect NN O O
effect NN O O
of NN O O
ROM NN O O
on NN O O
treatment NN O O
outcomes NN O O
through NN O O
alliance NN O O
increase NN O O
( NN O O
p NN O O
= NN O O
.043 NN O O
) NN O O
explained NN O O
an NN O O
estimated NN O O
23.0 NN O O
% NN O O
of NN O O
the NN O O
effect NN O O
of NN O O
ROM NN O O
on NN O O
outcomes NN O O
. NN O O

The NN O O
results NN O O
were NN O O
consistent NN O O
with NN O O
a NN O O
theory NN O O
of NN O O
the NN O O
alliance NN O O
as NN O O
one NN O O
mechanism NN O O
through NN O O
which NN O O
ROM NN O O
works NN O O
. NN O O

( NN O O
PsycINFO NN O O
Database NN O O
Record NN O O
( NN O O
c NN O O
) NN O O
2019 NN O O
APA NN O O
, NN O O
all NN O O
rights NN O O
reserved NN O O
) NN O O
. NN O O



-DOCSTART- (31153358)

The NN O O
purpose NN O O
of NN O O
this NN O O
study NN O O
was NN O O
to NN O O
compare NN O O
the NN O O
effects NN O O
of NN O O
scalp NN O O
nerve NN O O
block NN O O
( NN O O
SNB NN O O
) NN O O
and NN O O
local NN O O
anesthetic NN O O
infiltration NN O O
( NN O O
LA NN O O
) NN O O
with NN O O
0.75 NN O O
% NN O O
ropivacaine NN O O
on NN O O
postoperative NN O O
inflammatory NN O O
response NN O O
, NN O O
intraoperative NN O O
hemodynamic NN O O
response NN O O
, NN O O
and NN O O
postoperative NN O O
pain NN O O
control NN O O
in NN O O
patients NN O O
undergoing NN O O
craniotomy NN O O
. NN O O

Fifty-seven NN O O
patients NN O O
were NN O O
admitted NN O O
for NN O O
elective NN O O
craniotomy NN O O
for NN O O
surgical NN O O
clipping NN O O
of NN O O
a NN O O
cerebral NN O O
aneurysm NN O O
. NN O O

They NN O O
were NN O O
randomly NN O O
divided NN O O
into NN O O
three NN O O
groups NN O O
: NN O O
Group NN O O
S NN O O
( NN O O
SNB NN O O
with NN O O
15 NN O O
mL NN O O
of NN O O
0.75 NN O O
% NN O O
ropivacaine NN O O
) NN O O
, NN O O
group NN O O
I NN O O
( NN O O
LA NN O O
with NN O O
15 NN O O
mL NN O O
of NN O O
0.75 NN O O
% NN O O
ropivacaine NN O O
) NN O O
and NN O O
group NN O O
C NN O O
( NN O O
that NN O O
only NN O O
received NN O O
routine NN O O
intravenous NN O O
analgesia NN O O
) NN O O
. NN O O

Pro-inflammatory NN O O
cytokine NN O O
levels NN O O
in NN O O
plasma NN O O
for NN O O
72 NN O O
h NN O O
postoperatively NN O O
, NN O O
hemodynamic NN O O
response NN O O
to NN O O
skin NN O O
incision NN O O
, NN O O
and NN O O
postoperative NN O O
pain NN O O
intensity NN O O
were NN O O
measured NN O O
. NN O O

The NN O O
SNB NN O O
with NN O O
0.75 NN O O
% NN O O
ropivacaine NN O O
not NN O O
only NN O O
decreased NN O O
IL-6 NN O O
levels NN O O
in NN O O
plasma NN O O
6 NN O O
h NN O O
after NN O O
craniotomy NN O O
but NN O O
also NN O O
decreased NN O O
plasma NN O O
CRP NN O O
levels NN O O
and NN O O
increased NN O O
plasma NN O O
IL-10 NN O O
levels NN O O
12 NN O O
and NN O O
24 NN O O
h NN O O
after NN O O
surgery NN O O
compared NN O O
to NN O O
LA NN O O
and NN O O
routine NN O O
analgesia NN O O
. NN O O

There NN O O
were NN O O
significant NN O O
increases NN O O
in NN O O
mean NN O O
arterial NN O O
pressure NN O O
2 NN O O
and NN O O
5 NN O O
mins NN O O
after NN O O
the NN O O
incision NN O O
and NN O O
during NN O O
dura NN O O
opening NN O O
in NN O O
Groups NN O O
I NN O O
and NN O O
C NN O O
compared NN O O
with NN O O
Group NN O O
S. NN O O
Group NN O O
S NN O O
had NN O O
lower NN O O
postoperative NN O O
pain NN O O
intensity NN O O
, NN O O
longer NN O O
duration NN O O
before NN O O
the NN O O
first NN O O
dose NN O O
of NN O O
oxycodone NN O O
, NN O O
less NN O O
consumption NN O O
of NN O O
oxycodone NN O O
and NN O O
lower NN O O
incidence NN O O
of NN O O
PONV NN O O
through NN O O
48 NN O O
h NN O O
postoperatively NN O O
than NN O O
Groups NN O O
I NN O O
and NN O O
C. NN O O
Preoperative NN O O
SNB NN O O
attenuated NN O O
inflammatory NN O O
response NN O O
to NN O O
craniotomy NN O O
for NN O O
cerebral NN O O
aneurysms NN O O
, NN O O
blunted NN O O
the NN O O
hemodynamic NN O O
response NN O O
to NN O O
scalp NN O O
incision NN O O
, NN O O
and NN O O
controlled NN O O
postoperative NN O O
pain NN O O
better NN O O
than NN O O
LA NN O O
or NN O O
routine NN O O
analgesia NN O O
. NN O O

Clinicaltrials.gov NN O O
NCT03073889 NN O O
( NN O O
PI NN O O
: NN O O
Xi NN O O
Yang NN O O
; NN O O
date NN O O
of NN O O
registration:08/03/2017 NN O O
) NN O O
. NN O O



-DOCSTART- (30883951)

Conventional NN O O
infiltration NN O O
anaesthesia NN O O
( NN O O
CIA NN O O
) NN O O
is NN O O
the NN O O
most NN O O
frequently NN O O
used NN O O
in NN O O
paediatric NN O O
oral NN O O
health NN O O
care NN O O
. NN O O

However NN O O
, NN O O
other NN O O
techniques NN O O
are NN O O
available NN O O
, NN O O
such NN O O
as NN O O
intraosseous NN O O
anaesthesia NN O O
( NN O O
IOA NN O O
) NN O O
, NN O O
that NN O O
can NN O O
beneficiate NN O O
from NN O O
newly NN O O
developed NN O O
technologies NN O O
. NN O O

To NN O O
compare NN O O
the NN O O
pain NN O O
caused NN O O
by NN O O
CIA NN O O
and NN O O
IOA NN O O
delivered NN O O
by NN O O
the NN O O
computerized NN O O
system NN O O
( NN O O
QuickSleeper NN O O
™ NN O O
) NN O O
in NN O O
children NN O O
. NN O O

We NN O O
used NN O O
an NN O O
innovative NN O O
design NN O O
consisting NN O O
in NN O O
simultaneously NN O O
conducting NN O O
a NN O O
multicentre NN O O
split-mouth NN O O
and NN O O
parallel-arm NN O O
randomized NN O O
controlled NN O O
trial NN O O
( NN O O
RCT NN O O
) NN O O
to NN O O
allow NN O O
for NN O O
increased NN O O
power NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
was NN O O
pain NN O O
reported NN O O
by NN O O
the NN O O
patient NN O O
on NN O O
a NN O O
visual NN O O
analogue NN O O
scale NN O O
( NN O O
0 NN O O
- NN O O
10 NN O O
cm NN O O
) NN O O
concerning NN O O
the NN O O
insertion NN O O
of NN O O
the NN O O
needle NN O O
and NN O O
injection NN O O
. NN O O

A NN O O
total NN O O
of NN O O
30 NN O O
children NN O O
were NN O O
included NN O O
in NN O O
the NN O O
split-mouth NN O O
RCT NN O O
and NN O O
128 NN O O
in NN O O
the NN O O
parallel-arm NN O O
RCT NN O O
. NN O O

We NN O O
combined NN O O
treatment NN O O
effect NN O O
estimates NN O O
by NN O O
using NN O O
an NN O O
inverse-variance NN O O
weighting NN O O
meta-analysis NN O O
approach NN O O
. NN O O

Pain NN O O
scores NN O O
were NN O O
significantly NN O O
decreased NN O O
with NN O O
IOA NN O O
vs NN O O
CIA NN O O
( NN O O
mean NN O O
difference NN O O
-0.69 NN O O
cm NN O O
, NN O O
95 NN O O
% NN O O
confidence NN O O
intervals NN O O
-1.13 NN O O
to NN O O
-0.25 NN O O
cm NN O O
) NN O O
. NN O O

For NN O O
each NN O O
patient NN O O
enrolled NN O O
in NN O O
the NN O O
split-mouth NN O O
RCT NN O O
, NN O O
about NN O O
five NN O O
were NN O O
enrolled NN O O
in NN O O
the NN O O
parallel-arm NN O O
RCT NN O O
, NN O O
which NN O O
allowed NN O O
for NN O O
not NN O O
losing NN O O
any NN O O
eligible NN O O
patients NN O O
. NN O O

Pain NN O O
during NN O O
the NN O O
insertion NN O O
of NN O O
the NN O O
needle NN O O
and NN O O
injection NN O O
was NN O O
less NN O O
with NN O O
IOA NN O O
vs NN O O
CIA NN O O
in NN O O
children NN O O
. NN O O

The NN O O
design NN O O
of NN O O
this NN O O
study NN O O
allowed NN O O
for NN O O
increasing NN O O
statistical NN O O
power NN O O
and NN O O
using NN O O
all NN O O
generated NN O O
evidence NN O O
. NN O O

( NN O O
ClinicalTrials.gov NN O O
NCT02084433 NN O O
) NN O O
. NN O O



-DOCSTART- (30640504)

This NN O O
study NN O O
examines NN O O
effects NN O O
of NN O O
a NN O O
randomized NN O O
controlled NN O O
trial NN O O
for NN O O
an NN O O
online NN O O
, NN O O
family-based NN O O
prevention NN O O
program NN O O
for NN O O
older NN O O
teens NN O O
, NN O O
Smart NN O O
Choices NN O O
4 NN O O
Teens NN O O
, NN O O
on NN O O
alcohol NN O O
use NN O O
and NN O O
related NN O O
outcomes NN O O
. NN O O

Families NN O O
( NN O O
N NN O O
= NN O O
411 NN O O
; NN O O
teen NN O O
age NN O O
M NN O O
= NN O O
16.4 NN O O
, NN O O
SD NN O O
= NN O O
0.5 NN O O
) NN O O
were NN O O
randomly NN O O
assigned NN O O
to NN O O
the NN O O
intervention NN O O
or NN O O
control NN O O
condition NN O O
in NN O O
2014 NN O O
- NN O O
2015 NN O O
. NN O O

Both NN O O
intent NN O O
to NN O O
treat NN O O
( NN O O
ITT NN O O
) NN O O
and NN O O
dosage NN O O
models NN O O
were NN O O
conducted NN O O
. NN O O

ITT NN O O
models NN O O
: NN O O
At NN O O
the NN O O
6-month NN O O
follow-up NN O O
, NN O O
teens NN O O
in NN O O
the NN O O
experimental NN O O
condition NN O O
reported NN O O
fewer NN O O
friends NN O O
who NN O O
had NN O O
been NN O O
drunk NN O O
, NN O O
and NN O O
parents NN O O
in NN O O
the NN O O
experimental NN O O
group NN O O
reported NN O O
more NN O O
communication NN O O
about NN O O
social NN O O
host NN O O
laws NN O O
. NN O O

At NN O O
the NN O O
12-month NN O O
follow-up NN O O
, NN O O
parents NN O O
in NN O O
the NN O O
experimental NN O O
condition NN O O
reported NN O O
consuming NN O O
fewer NN O O
drinks NN O O
than NN O O
parents NN O O
in NN O O
the NN O O
control NN O O
group NN O O
. NN O O

Dosage NN O O
models NN O O
: NN O O
At NN O O
the NN O O
6-month NN O O
follow-up NN O O
, NN O O
dosage NN O O
was NN O O
inversely NN O O
related NN O O
to NN O O
teen NN O O
drinking NN O O
in NN O O
the NN O O
past NN O O
6 NN O O
months NN O O
or NN O O
30 NN O O
days NN O O
, NN O O
frequency NN O O
of NN O O
teen NN O O
drinking NN O O
during NN O O
the NN O O
past NN O O
6 NN O O
months NN O O
and NN O O
30 NN O O
days NN O O
, NN O O
drinks NN O O
consumed NN O O
by NN O O
teens NN O O
over NN O O
the NN O O
past NN O O
6 NN O O
months NN O O
, NN O O
teen NN O O
drunkenness NN O O
and NN O O
binge-drinking NN O O
during NN O O
the NN O O
past NN O O
30 NN O O
days NN O O
, NN O O
teen NN O O
reported NN O O
communication NN O O
about NN O O
safe NN O O
drinking NN O O
and NN O O
positively NN O O
related NN O O
to NN O O
parent NN O O
and NN O O
teen NN O O
reported NN O O
communication NN O O
about NN O O
social NN O O
host NN O O
laws NN O O
. NN O O

At NN O O
12 NN O O
months NN O O
, NN O O
dosage NN O O
was NN O O
inversely NN O O
related NN O O
to NN O O
teen NN O O
alcohol NN O O
use NN O O
, NN O O
frequency NN O O
of NN O O
teen NN O O
drinking NN O O
over NN O O
the NN O O
past NN O O
30 NN O O
days NN O O
, NN O O
drinks NN O O
consumed NN O O
by NN O O
teens NN O O
over NN O O
the NN O O
past NN O O
6 NN O O
months NN O O
and NN O O
30 NN O O
days NN O O
, NN O O
and NN O O
teen NN O O
drunkenness NN O O
over NN O O
the NN O O
past NN O O
6 NN O O
months NN O O
. NN O O

Results NN O O
suggest NN O O
that NN O O
Smart NN O O
Choices NN O O
4 NN O O
Teens NN O O
is NN O O
beneficial NN O O
for NN O O
families NN O O
. NN O O

Dissemination NN O O
and NN O O
implementation NN O O
strategies NN O O
that NN O O
motivate NN O O
completion NN O O
of NN O O
program NN O O
content NN O O
will NN O O
improve NN O O
outcomes NN O O
related NN O O
to NN O O
older NN O O
teens NN O O
' NN O O
alcohol NN O O
use NN O O
. NN O O

( NN O O
PsycINFO NN O O
Database NN O O
Record NN O O
( NN O O
c NN O O
) NN O O
2019 NN O O
APA NN O O
, NN O O
all NN O O
rights NN O O
reserved NN O O
) NN O O
. NN O O



-DOCSTART- (31056685)

Changes NN O O
in NN O O
the NN O O
intestinal NN O O
microbiota NN O O
have NN O O
been NN O O
associated NN O O
with NN O O
the NN O O
pathogenesis NN O O
of NN O O
SSc NN O O
. NN O O

Probiotics NN O O
act NN O O
by NN O O
modulating NN O O
the NN O O
microbiome NN O O
and NN O O
the NN O O
immune NN O O
response NN O O
. NN O O

This NN O O
study NN O O
aimed NN O O
to NN O O
evaluate NN O O
the NN O O
efficacy NN O O
of NN O O
probiotics NN O O
on NN O O
gastrointestinal NN O O
( NN O O
GI NN O O
) NN O O
symptoms NN O O
and NN O O
immune NN O O
responses NN O O
in NN O O
SSc NN O O
patients NN O O
. NN O O

Patients NN O O
with NN O O
SSc NN O O
with NN O O
a NN O O
moderate-severe NN O O
total NN O O
score NN O O
on NN O O
the NN O O
University NN O O
of NN O O
California NN O O
Los NN O O
Angeles NN O O
Scleroderma NN O O
Clinical NN O O
Trials NN O O
Consortium NN O O
Gastrointestinal NN O O
Tract NN O O
2.0 NN O O
( NN O O
UCLA NN O O
GIT NN O O
2.0 NN O O
) NN O O
instrument NN O O
were NN O O
randomly NN O O
assigned NN O O
to NN O O
receive NN O O
a NN O O
daily NN O O
dose NN O O
of NN O O
probiotics NN O O
( NN O O
Lactobacillus NN O O
paracasei NN O O
, NN O O
Lactobacillus NN O O
rhamnosus NN O O
, NN O O
Lactobacillus NN O O
acidophillus NN O O
and NN O O
Bifidobacterium NN O O
lactis NN O O
, NN O O
109 NN O O
colony-forming NN O O
units NN O O
per NN O O
capsule NN O O
) NN O O
or NN O O
placebo NN O O
for NN O O
8 NN O O
weeks NN O O
. NN O O

The NN O O
primary NN O O
endpoint NN O O
was NN O O
improvement NN O O
in NN O O
the NN O O
UCLA NN O O
GIT NN O O
2.0 NN O O
total NN O O
score NN O O
after NN O O
8 NN O O
weeks NN O O
. NN O O

Secondary NN O O
outcomes NN O O
included NN O O
changes NN O O
in NN O O
Th1 NN O O
, NN O O
Th2 NN O O
, NN O O
Th17 NN O O
and NN O O
regulatory NN O O
T NN O O
cell NN O O
circulating NN O O
levels NN O O
and NN O O
in NN O O
the NN O O
HAQ NN O O
Disability NN O O
Index NN O O
( NN O O
HAQ-DI NN O O
) NN O O
score NN O O
. NN O O

Parameters NN O O
were NN O O
assessed NN O O
at NN O O
baseline NN O O
and NN O O
after NN O O
4 NN O O
and NN O O
8 NN O O
weeks NN O O
of NN O O
treatment NN O O
. NN O O

A NN O O
total NN O O
of NN O O
73 NN O O
patients NN O O
were NN O O
randomized NN O O
to NN O O
receive NN O O
probiotics NN O O
( NN O O
n NN O O
= NN O O
37 NN O O
) NN O O
or NN O O
placebo NN O O
( NN O O
n NN O O
= NN O O
36 NN O O
) NN O O
. NN O O

After NN O O
8 NN O O
weeks NN O O
, NN O O
there NN O O
was NN O O
no NN O O
difference NN O O
in NN O O
the NN O O
UCLA NN O O
GIT NN O O
2.0 NN O O
score NN O O
between NN O O
the NN O O
two NN O O
groups NN O O
. NN O O

At NN O O
week NN O O
8 NN O O
, NN O O
the NN O O
probiotic NN O O
group NN O O
showed NN O O
a NN O O
significant NN O O
decrease NN O O
in NN O O
the NN O O
proportion NN O O
of NN O O
Th17 NN O O
cells NN O O
compared NN O O
with NN O O
placebo NN O O
( NN O O
P NN O O
= NN O O
0.003 NN O O
) NN O O
. NN O O

There NN O O
was NN O O
no NN O O
difference NN O O
in NN O O
the NN O O
proportion NN O O
of NN O O
Th1 NN O O
, NN O O
Th2 NN O O
and NN O O
regulatory NN O O
T NN O O
cells NN O O
or NN O O
in NN O O
the NN O O
HAQ-DI NN O O
score NN O O
between NN O O
the NN O O
groups NN O O
. NN O O

Probiotics NN O O
did NN O O
not NN O O
improve NN O O
GI NN O O
symptoms NN O O
in NN O O
SSc NN O O
patients NN O O
. NN O O

The NN O O
reduction NN O O
in NN O O
Th17 NN O O
cell NN O O
levels NN O O
suggests NN O O
an NN O O
immunomodulatory NN O O
effect NN O O
of NN O O
probiotics NN O O
on NN O O
SSc NN O O
. NN O O

ClinicalTrials.gov NN O O
( NN O O
http://clinicaltrials.gov NN O O
) NN O O
, NN O O
NCT02302352 NN O O
. NN O O



-DOCSTART- (31311674)

Rimegepant NN O O
, NN O O
a NN O O
small NN O O
molecule NN O O
calcitonin NN O O
gene-related NN O O
peptide NN O O
receptor NN O O
antagonist NN O O
, NN O O
has NN O O
shown NN O O
efficacy NN O O
in NN O O
the NN O O
acute NN O O
treatment NN O O
of NN O O
migraine NN O O
using NN O O
a NN O O
standard NN O O
tablet NN O O
formulation NN O O
. NN O O

The NN O O
objective NN O O
of NN O O
this NN O O
trial NN O O
was NN O O
to NN O O
compare NN O O
the NN O O
efficacy NN O O
, NN O O
safety NN O O
, NN O O
and NN O O
tolerability NN O O
of NN O O
a NN O O
novel NN O O
orally NN O O
disintegrating NN O O
tablet NN O O
formulation NN O O
of NN O O
rimegepant NN O O
at NN O O
75 NN O O
mg NN O O
with NN O O
placebo NN O O
in NN O O
the NN O O
acute NN O O
treatment NN O O
of NN O O
migraine NN O O
. NN O O

In NN O O
this NN O O
double-blind NN O O
, NN O O
randomised NN O O
, NN O O
placebo-controlled NN O O
, NN O O
multicentre NN O O
phase NN O O
3 NN O O
trial NN O O
, NN O O
adults NN O O
aged NN O O
18 NN O O
years NN O O
or NN O O
older NN O O
with NN O O
history NN O O
of NN O O
migraine NN O O
of NN O O
at NN O O
least NN O O
1 NN O O
year NN O O
were NN O O
recruited NN O O
to NN O O
69 NN O O
study NN O O
centres NN O O
in NN O O
the NN O O
USA NN O O
. NN O O

Participants NN O O
were NN O O
randomly NN O O
assigned NN O O
to NN O O
receive NN O O
rimegepant NN O O
( NN O O
75 NN O O
mg NN O O
orally NN O O
disintegrating NN O O
tablet NN O O
) NN O O
or NN O O
placebo NN O O
and NN O O
instructed NN O O
to NN O O
treat NN O O
a NN O O
single NN O O
migraine NN O O
attack NN O O
of NN O O
moderate NN O O
or NN O O
severe NN O O
pain NN O O
intensity NN O O
. NN O O

The NN O O
randomisation NN O O
was NN O O
stratified NN O O
by NN O O
the NN O O
use NN O O
of NN O O
prophylactic NN O O
medication NN O O
( NN O O
yes NN O O
or NN O O
no NN O O
) NN O O
, NN O O
and NN O O
was NN O O
carried NN O O
out NN O O
using NN O O
an NN O O
interactive NN O O
web NN O O
response NN O O
system NN O O
that NN O O
was NN O O
accessed NN O O
by NN O O
each NN O O
clinical NN O O
site NN O O
. NN O O

All NN O O
participants NN O O
, NN O O
investigators NN O O
, NN O O
and NN O O
the NN O O
sponsor NN O O
were NN O O
masked NN O O
to NN O O
treatment NN O O
group NN O O
assignment NN O O
. NN O O

The NN O O
coprimary NN O O
endpoints NN O O
were NN O O
freedom NN O O
from NN O O
pain NN O O
and NN O O
freedom NN O O
from NN O O
the NN O O
most NN O O
bothersome NN O O
symptom NN O O
at NN O O
2 NN O O
h NN O O
postdose NN O O
. NN O O

The NN O O
efficacy NN O O
analyses NN O O
used NN O O
the NN O O
modified NN O O
intention-to-treat NN O O
population NN O O
, NN O O
which NN O O
included NN O O
all NN O O
patients NN O O
who NN O O
were NN O O
randomly NN O O
assigned NN O O
, NN O O
had NN O O
a NN O O
migraine NN O O
attack NN O O
with NN O O
pain NN O O
of NN O O
moderate NN O O
or NN O O
severe NN O O
intensity NN O O
, NN O O
took NN O O
a NN O O
dose NN O O
of NN O O
rimegepant NN O O
or NN O O
placebo NN O O
, NN O O
and NN O O
had NN O O
at NN O O
least NN O O
one NN O O
efficacy NN O O
assessment NN O O
after NN O O
administration NN O O
of NN O O
the NN O O
dose NN O O
. NN O O

The NN O O
safety NN O O
analyses NN O O
included NN O O
all NN O O
randomly NN O O
assigned NN O O
participants NN O O
who NN O O
received NN O O
at NN O O
least NN O O
one NN O O
dose NN O O
of NN O O
study NN O O
medication NN O O
. NN O O

This NN O O
study NN O O
is NN O O
registered NN O O
with NN O O
ClinicalTrials.gov NN O O
, NN O O
number NN O O
NCT03461757 NN O O
, NN O O
and NN O O
is NN O O
closed NN O O
to NN O O
accrual NN O O
. NN O O

Between NN O O
Feb NN O O
27 NN O O
and NN O O
Aug NN O O
28 NN O O
, NN O O
2018 NN O O
, NN O O
1811 NN O O
participants NN O O
were NN O O
recruited NN O O
and NN O O
assessed NN O O
for NN O O
eligibility NN O O
. NN O O

1466 NN O O
participants NN O O
were NN O O
randomly NN O O
assigned NN O O
to NN O O
the NN O O
rimegepant NN O O
( NN O O
n=732 NN O O
) NN O O
or NN O O
placebo NN O O
( NN O O
n=734 NN O O
) NN O O
groups NN O O
, NN O O
of NN O O
whom NN O O
1375 NN O O
received NN O O
treatment NN O O
with NN O O
rimegepant NN O O
( NN O O
n=682 NN O O
) NN O O
or NN O O
placebo NN O O
( NN O O
n=693 NN O O
) NN O O
, NN O O
and NN O O
1351 NN O O
were NN O O
evaluated NN O O
for NN O O
efficacy NN O O
( NN O O
rimegepant NN O O
n=669 NN O O
, NN O O
placebo NN O O
n=682 NN O O
) NN O O
. NN O O

At NN O O
2 NN O O
h NN O O
postdose NN O O
, NN O O
rimegepant NN O O
orally NN O O
disintegrating NN O O
tablet NN O O
was NN O O
superior NN O O
to NN O O
placebo NN O O
for NN O O
freedom NN O O
from NN O O
pain NN O O
( NN O O
21 NN O O
% NN O O
vs NN O O
11 NN O O
% NN O O
, NN O O
p<0·0001 NN O O
; NN O O
risk NN O O
difference NN O O
10 NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
6 NN O O
- NN O O
14 NN O O
) NN O O
and NN O O
freedom NN O O
from NN O O
the NN O O
most NN O O
bothersome NN O O
symptom NN O O
( NN O O
35 NN O O
% NN O O
vs NN O O
27 NN O O
% NN O O
, NN O O
p=0·0009 NN O O
; NN O O
risk NN O O
difference NN O O
8 NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
3 NN O O
- NN O O
13 NN O O
) NN O O
. NN O O

The NN O O
most NN O O
common NN O O
adverse NN O O
events NN O O
were NN O O
nausea NN O O
( NN O O
rimegepant NN O O
n=11 NN O O
[ NN O O
2 NN O O
% NN O O
] NN O O
; NN O O
placebo NN O O
n=3 NN O O
[ NN O O
< NN O O
1 NN O O
% NN O O
] NN O O
) NN O O
and NN O O
urinary NN O O
tract NN O O
infection NN O O
( NN O O
rimegepant NN O O
n=10 NN O O
[ NN O O
1 NN O O
% NN O O
] NN O O
; NN O O
placebo NN O O
n=4 NN O O
[ NN O O
1 NN O O
% NN O O
] NN O O
) NN O O
. NN O O

One NN O O
participant NN O O
in NN O O
each NN O O
treatment NN O O
group NN O O
had NN O O
a NN O O
transaminase NN O O
concentration NN O O
of NN O O
more NN O O
than NN O O
3 NN O O
× NN O O
the NN O O
upper NN O O
limit NN O O
of NN O O
normal NN O O
; NN O O
neither NN O O
was NN O O
related NN O O
to NN O O
study NN O O
medication NN O O
, NN O O
and NN O O
no NN O O
elevations NN O O
in NN O O
bilirubin NN O O
greater NN O O
than NN O O
2 NN O O
× NN O O
the NN O O
upper NN O O
limit NN O O
of NN O O
normal NN O O
were NN O O
reported NN O O
. NN O O

Treated NN O O
participants NN O O
reported NN O O
no NN O O
serious NN O O
adverse NN O O
events NN O O
. NN O O

In NN O O
the NN O O
acute NN O O
treatment NN O O
of NN O O
migraine NN O O
, NN O O
a NN O O
single NN O O
75 NN O O
mg NN O O
dose NN O O
of NN O O
rimegepant NN O O
in NN O O
an NN O O
orally NN O O
disintegrating NN O O
tablet NN O O
formulation NN O O
was NN O O
more NN O O
effective NN O O
than NN O O
placebo NN O O
. NN O O

Tolerability NN O O
was NN O O
similar NN O O
to NN O O
placebo NN O O
, NN O O
with NN O O
no NN O O
safety NN O O
concerns NN O O
. NN O O

Biohaven NN O O
Pharmaceuticals NN O O
. NN O O



-DOCSTART- (31056202)

To NN O O
assess NN O O
the NN O O
feasibility NN O O
and NN O O
initial NN O O
efficacy NN O O
of NN O O
a NN O O
structured NN O O
parent NN O O
training NN O O
program NN O O
for NN O O
children NN O O
with NN O O
autism NN O O
spectrum NN O O
disorder NN O O
and NN O O
moderate NN O O
food NN O O
selectivity NN O O
. NN O O

This NN O O
16-week NN O O
randomized NN O O
trial NN O O
compared NN O O
the NN O O
Managing NN O O
Eating NN O O
Aversions NN O O
and NN O O
Limited NN O O
variety NN O O
( NN O O
MEAL NN O O
) NN O O
Plan NN O O
with NN O O
parent NN O O
education NN O O
. NN O O

MEAL NN O O
Plan NN O O
( NN O O
10 NN O O
core NN O O
and NN O O
3 NN O O
booster NN O O
sessions NN O O
) NN O O
provided NN O O
parents NN O O
with NN O O
nutrition NN O O
education NN O O
and NN O O
strategies NN O O
to NN O O
structure NN O O
meals NN O O
and NN O O
expand NN O O
the NN O O
child NN O O
's NN O O
diet NN O O
. NN O O

Parent NN O O
education NN O O
( NN O O
10 NN O O
sessions NN O O
) NN O O
provided NN O O
information NN O O
about NN O O
autism NN O O
without NN O O
guidance NN O O
on NN O O
nutrition NN O O
, NN O O
meal NN O O
structure NN O O
, NN O O
or NN O O
diet NN O O
. NN O O

In NN O O
addition NN O O
to NN O O
feasibility NN O O
outcomes NN O O
, NN O O
primary NN O O
efficacy NN O O
outcomes NN O O
included NN O O
the NN O O
Clinical NN O O
Global NN O O
Impression NN O O
- NN O O
Improvement NN O O
scale NN O O
and NN O O
the NN O O
Brief NN O O
Autism NN O O
Mealtime NN O O
Behaviors NN O O
Inventory NN O O
. NN O O

Grams NN O O
consumed NN O O
during NN O O
a NN O O
meal NN O O
observation NN O O
served NN O O
as NN O O
a NN O O
secondary NN O O
outcome NN O O
. NN O O

There NN O O
were NN O O
38 NN O O
eligible NN O O
children NN O O
( NN O O
19 NN O O
per NN O O
group NN O O
, NN O O
32 NN O O
males NN O O
) NN O O
. NN O O

For NN O O
MEAL NN O O
Plan NN O O
, NN O O
attrition NN O O
was NN O O
< NN O O
10 NN O O
% NN O O
and NN O O
attendance NN O O
> NN O O
80 NN O O
% NN O O
. NN O O

Therapists NN O O
achieved NN O O
> NN O O
90 NN O O
% NN O O
fidelity NN O O
. NN O O

At NN O O
week NN O O
16 NN O O
, NN O O
positive NN O O
response NN O O
rates NN O O
on NN O O
the NN O O
Clinical NN O O
Global NN O O
Impression NN O O
- NN O O
Improvement NN O O
scale NN O O
were NN O O
47.4 NN O O
% NN O O
for NN O O
the NN O O
MEAL NN O O
Plan NN O O
and NN O O
5.3 NN O O
% NN O O
for NN O O
parent NN O O
education NN O O
( NN O O
P NN O O
< NN O O
.05 NN O O
) NN O O
. NN O O

The NN O O
adjusted NN O O
mean NN O O
difference NN O O
( NN O O
SE NN O O
) NN O O
on NN O O
Brief NN O O
Autism NN O O
Mealtime NN O O
Behaviors NN O O
Inventory NN O O
at NN O O
week NN O O
16 NN O O
was NN O O
7.04 NN O O
( NN O O
2.71 NN O O
) NN O O
points NN O O
( NN O O
P NN O O
= NN O O
.01 NN O O
) NN O O
in NN O O
favor NN O O
of NN O O
MEAL NN O O
Plan NN O O
. NN O O

For NN O O
grams NN O O
consumed NN O O
, NN O O
the NN O O
adjusted NN O O
standard NN O O
mean NN O O
difference NN O O
( NN O O
SE NN O O
) NN O O
was NN O O
30.76 NN O O
( NN O O
6.75 NN O O
) NN O O
, NN O O
also NN O O
in NN O O
favor NN O O
of NN O O
MEAL NN O O
Plan NN O O
( NN O O
P NN O O
= NN O O
.001 NN O O
) NN O O
. NN O O

The NN O O
MEAL NN O O
Plan NN O O
seems NN O O
to NN O O
be NN O O
feasible NN O O
, NN O O
and NN O O
preliminary NN O O
efficacy NN O O
results NN O O
are NN O O
encouraging NN O O
. NN O O

If NN O O
further NN O O
study NN O O
replicates NN O O
these NN O O
results NN O O
, NN O O
the NN O O
MEAL NN O O
Plan NN O O
could NN O O
expand NN O O
treatment NN O O
options NN O O
for NN O O
children NN O O
with NN O O
autism NN O O
spectrum NN O O
disorder NN O O
and NN O O
moderate NN O O
food NN O O
selectivity NN O O
. NN O O

Clinicaltrials.gov NN O O
: NN O O
NCT02712281 NN O O
. NN O O



-DOCSTART- (30792007)

RBP-6000 NN O O
, NN O O
referred NN O O
to NN O O
as NN O O
BUP-XR NN O O
( NN O O
extended-release NN O O
buprenorphine NN O O
) NN O O
, NN O O
is NN O O
a NN O O
subcutaneously NN O O
injected NN O O
, NN O O
monthly NN O O
buprenorphine NN O O
treatment NN O O
for NN O O
opioid NN O O
use NN O O
disorder NN O O
. NN O O

BUP-XR NN O O
provides NN O O
sustained NN O O
buprenorphine NN O O
plasma NN O O
concentrations NN O O
to NN O O
block NN O O
drug-liking NN O O
of NN O O
abused NN O O
opioids NN O O
over NN O O
the NN O O
entire NN O O
monthly NN O O
dosing NN O O
period NN O O
, NN O O
while NN O O
controlling NN O O
withdrawal NN O O
and NN O O
craving NN O O
symptoms NN O O
. NN O O

Administration NN O O
of NN O O
BUP-XR NN O O
in NN O O
a NN O O
health-care NN O O
setting NN O O
also NN O O
mitigates NN O O
abuse NN O O
, NN O O
misuse NN O O
, NN O O
diversion NN O O
, NN O O
and NN O O
unintentional NN O O
exposure NN O O
. NN O O

We NN O O
aimed NN O O
to NN O O
investigate NN O O
the NN O O
efficacy NN O O
of NN O O
different NN O O
BUP-XR NN O O
dosing NN O O
regimens NN O O
in NN O O
participants NN O O
with NN O O
opioid NN O O
use NN O O
disorder NN O O
. NN O O

This NN O O
randomised NN O O
, NN O O
double-blind NN O O
, NN O O
placebo-controlled NN O O
, NN O O
phase NN O O
3 NN O O
trial NN O O
was NN O O
done NN O O
at NN O O
36 NN O O
treatment NN O O
centres NN O O
in NN O O
the NN O O
USA NN O O
. NN O O

Treatment-seeking NN O O
adults NN O O
aged NN O O
18 NN O O
- NN O O
65 NN O O
years NN O O
who NN O O
had NN O O
moderate NN O O
or NN O O
severe NN O O
opioid NN O O
use NN O O
disorder NN O O
( NN O O
as NN O O
defined NN O O
by NN O O
the NN O O
fifth NN O O
edition NN O O
of NN O O
the NN O O
Diagnostic NN O O
and NN O O
Statistical NN O O
Manual NN O O
of NN O O
Mental NN O O
Disorders NN O O
) NN O O
entered NN O O
an NN O O
open-label NN O O
run-in NN O O
phase NN O O
of NN O O
up NN O O
to NN O O
2 NN O O
weeks NN O O
' NN O O
treatment NN O O
with NN O O
buprenorphine-naloxone NN O O
sublingual NN O O
film NN O O
. NN O O

Eligible NN O O
participants NN O O
were NN O O
then NN O O
randomly NN O O
assigned NN O O
( NN O O
4:4:1:1 NN O O
) NN O O
with NN O O
an NN O O
interactive NN O O
voice/web-response NN O O
system NN O O
to NN O O
receive NN O O
BUP-XR NN O O
300 NN O O
mg/300 NN O O
mg NN O O
( NN O O
six NN O O
injections NN O O
of NN O O
300 NN O O
mg NN O O
) NN O O
, NN O O
BUP-XR NN O O
300 NN O O
mg/100 NN O O
mg NN O O
( NN O O
two NN O O
injections NN O O
of NN O O
300 NN O O
mg NN O O
plus NN O O
four NN O O
injections NN O O
of NN O O
100 NN O O
mg NN O O
) NN O O
, NN O O
or NN O O
volume-matched NN O O
placebo NN O O
every NN O O
28 NN O O
days NN O O
, NN O O
and NN O O
received NN O O
weekly NN O O
individual NN O O
drug NN O O
counselling NN O O
. NN O O

No NN O O
supplemental NN O O
buprenorphine NN O O
was NN O O
allowed NN O O
. NN O O

The NN O O
primary NN O O
efficacy NN O O
endpoint NN O O
was NN O O
participants NN O O
' NN O O
percentage NN O O
abstinence NN O O
from NN O O
opioid NN O O
use NN O O
, NN O O
defined NN O O
as NN O O
the NN O O
percentage NN O O
of NN O O
each NN O O
participant NN O O
's NN O O
negative NN O O
urine NN O O
samples NN O O
and NN O O
self-reports NN O O
of NN O O
illicit NN O O
opioid NN O O
use NN O O
from NN O O
week NN O O
5 NN O O
to NN O O
week NN O O
24 NN O O
, NN O O
analysed NN O O
in NN O O
the NN O O
full NN O O
analysis NN O O
set NN O O
. NN O O

Safety NN O O
was NN O O
assessed NN O O
in NN O O
all NN O O
participants NN O O
who NN O O
received NN O O
at NN O O
least NN O O
one NN O O
dose NN O O
of NN O O
BUP-XR NN O O
or NN O O
placebo NN O O
. NN O O

This NN O O
study NN O O
is NN O O
registered NN O O
with NN O O
ClinicalTrials.gov NN O O
, NN O O
number NN O O
NCT02357901 NN O O
. NN O O

From NN O O
Jan NN O O
28 NN O O
, NN O O
2015 NN O O
, NN O O
to NN O O
Nov NN O O
12 NN O O
, NN O O
2015 NN O O
, NN O O
1187 NN O O
potential NN O O
participants NN O O
were NN O O
screened NN O O
, NN O O
665 NN O O
entered NN O O
run-in NN O O
, NN O O
and NN O O
504 NN O O
received NN O O
BUP-XR NN O O
300 NN O O
mg/300 NN O O
mg NN O O
( NN O O
n=201 NN O O
) NN O O
, NN O O
BUP-XR NN O O
300 NN O O
mg/100 NN O O
mg NN O O
( NN O O
n=203 NN O O
) NN O O
, NN O O
or NN O O
placebo NN O O
( NN O O
n=100 NN O O
) NN O O
. NN O O

Mean NN O O
participants NN O O
' NN O O
percentage NN O O
abstinence NN O O
was NN O O
41·3 NN O O
% NN O O
( NN O O
SD NN O O
39·7 NN O O
) NN O O
for NN O O
BUP-XR NN O O
300 NN O O
mg/300 NN O O
mg NN O O
and NN O O
42·7 NN O O
% NN O O
( NN O O
38·5 NN O O
) NN O O
for NN O O
300 NN O O
mg/100 NN O O
mg NN O O
, NN O O
compared NN O O
with NN O O
5·0 NN O O
% NN O O
( NN O O
17·0 NN O O
) NN O O
for NN O O
placebo NN O O
( NN O O
p<0·0001 NN O O
for NN O O
both NN O O
BUP-XR NN O O
regimens NN O O
) NN O O
. NN O O

No NN O O
compensatory NN O O
non-opioid NN O O
drug NN O O
use NN O O
was NN O O
observed NN O O
during NN O O
BUP-XR NN O O
treatment NN O O
. NN O O

The NN O O
most NN O O
common NN O O
adverse NN O O
events NN O O
were NN O O
headache NN O O
( NN O O
17 NN O O
[ NN O O
8 NN O O
% NN O O
] NN O O
participants NN O O
in NN O O
the NN O O
BUP-XR NN O O
300 NN O O
mg/300 NN O O
mg NN O O
group NN O O
vs NN O O
19 NN O O
[ NN O O
9 NN O O
% NN O O
] NN O O
participants NN O O
in NN O O
the NN O O
BUP-XR NN O O
300 NN O O
mg/100 NN O O
mg NN O O
group NN O O
vs NN O O
six NN O O
[ NN O O
6 NN O O
% NN O O
] NN O O
participants NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
) NN O O
, NN O O
constipation NN O O
( NN O O
16 NN O O
[ NN O O
8 NN O O
% NN O O
] NN O O
vs NN O O
19 NN O O
[ NN O O
9 NN O O
% NN O O
] NN O O
vs NN O O
0 NN O O
) NN O O
, NN O O
nausea NN O O
( NN O O
16 NN O O
[ NN O O
8 NN O O
% NN O O
] NN O O
vs NN O O
18 NN O O
[ NN O O
9 NN O O
% NN O O
] NN O O
vs NN O O
five NN O O
[ NN O O
5 NN O O
% NN O O
] NN O O
) NN O O
, NN O O
and NN O O
injection-site NN O O
pruritis NN O O
( NN O O
19 NN O O
[ NN O O
9 NN O O
% NN O O
] NN O O
vs NN O O
13 NN O O
[ NN O O
6 NN O O
% NN O O
] NN O O
vs NN O O
four NN O O
[ NN O O
4 NN O O
% NN O O
] NN O O
) NN O O
. NN O O

The NN O O
BUP-XR NN O O
safety NN O O
profile NN O O
was NN O O
consistent NN O O
with NN O O
other NN O O
buprenorphine NN O O
products NN O O
for NN O O
treatment NN O O
of NN O O
opioid NN O O
use NN O O
disorder NN O O
, NN O O
except NN O O
for NN O O
injection-site NN O O
reactions NN O O
, NN O O
which NN O O
were NN O O
reported NN O O
in NN O O
more NN O O
than NN O O
5 NN O O
% NN O O
of NN O O
all NN O O
participants NN O O
who NN O O
received NN O O
BUP-XR NN O O
, NN O O
but NN O O
were NN O O
mostly NN O O
mild NN O O
and NN O O
not NN O O
treatment-limiting NN O O
. NN O O

Participants NN O O
' NN O O
percentage NN O O
abstinence NN O O
was NN O O
significantly NN O O
higher NN O O
in NN O O
both NN O O
BUP-XR NN O O
groups NN O O
than NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
. NN O O

Treatment NN O O
with NN O O
BUP-XR NN O O
was NN O O
also NN O O
well NN O O
tolerated NN O O
. NN O O

The NN O O
availability NN O O
of NN O O
this NN O O
monthly NN O O
formulation NN O O
, NN O O
delivered NN O O
by NN O O
health-care NN O O
providers NN O O
, NN O O
represents NN O O
an NN O O
advance NN O O
in NN O O
treatment NN O O
for NN O O
opioid NN O O
use NN O O
disorder NN O O
that NN O O
enhances NN O O
the NN O O
benefits NN O O
of NN O O
buprenorphine NN O O
by NN O O
delivering NN O O
sustained NN O O
, NN O O
optimal NN O O
exposure NN O O
, NN O O
while NN O O
reducing NN O O
risks NN O O
of NN O O
current NN O O
buprenorphine NN O O
products NN O O
. NN O O

Indivior NN O O
. NN O O



-DOCSTART- (30819228)

The NN O O
overall NN O O
goal NN O O
of NN O O
the NN O O
Supporting NN O O
Adolescent NN O O
Adherence NN O O
in NN O O
Vietnam NN O O
( NN O O
SAAV NN O O
) NN O O
study NN O O
is NN O O
to NN O O
improve NN O O
understanding NN O O
of NN O O
an NN O O
adherence NN O O
feedback NN O O
mHealth NN O O
intervention NN O O
designed NN O O
to NN O O
help NN O O
adolescents NN O O
living NN O O
with NN O O
HIV NN O O
( NN O O
ALHIV NN O O
) NN O O
maintain NN O O
high NN O O
adherence NN O O
to NN O O
antiretroviral NN O O
therapy NN O O
( NN O O
ART NN O O
) NN O O
, NN O O
critical NN O O
to NN O O
effective NN O O
treatment NN O O
. NN O O

Specifically NN O O
, NN O O
we NN O O
aim NN O O
to NN O O
: NN O O
( NN O O
1 NN O O
) NN O O
conduct NN O O
formative NN O O
research NN O O
with NN O O
Vietnamese NN O O
ALHIV NN O O
and NN O O
their NN O O
caregivers NN O O
to NN O O
better NN O O
understand NN O O
adherence NN O O
challenges NN O O
and NN O O
refine NN O O
the NN O O
personalized NN O O
mHealth NN O O
intervention NN O O
package NN O O
; NN O O
and NN O O
( NN O O
2 NN O O
) NN O O
assess NN O O
the NN O O
feasibility NN O O
, NN O O
acceptability NN O O
, NN O O
and NN O O
efficacy NN O O
of NN O O
the NN O O
intervention NN O O
to NN O O
improve NN O O
ART NN O O
adherence NN O O
by NN O O
implementing NN O O
a NN O O
randomized NN O O
controlled NN O O
trial NN O O
( NN O O
RCT NN O O
) NN O O
. NN O O

The NN O O
study NN O O
will NN O O
utilize NN O O
mixed NN O O
methods NN O O
. NN O O

The NN O O
formative NN O O
phase NN O O
will NN O O
include NN O O
40 NN O O
in-depth NN O O
interviews NN O O
( NN O O
IDIs NN O O
) NN O O
with NN O O
20 NN O O
adolescent NN O O
( NN O O
12 NN O O
- NN O O
17 NN O O
years)/caregiver NN O O
dyads NN O O
and NN O O
eight NN O O
focus NN O O
group NN O O
discussions NN O O
with NN O O
adolescents NN O O
, NN O O
caregivers NN O O
, NN O O
and NN O O
clinicians NN O O
at NN O O
the NN O O
National NN O O
Hospital NN O O
for NN O O
Pediatrics NN O O
( NN O O
NHP NN O O
) NN O O
in NN O O
Hanoi NN O O
, NN O O
Vietnam NN O O
. NN O O

We NN O O
will NN O O
also NN O O
conduct NN O O
20 NN O O
IDIs NN O O
with NN O O
older NN O O
adolescents NN O O
( NN O O
18 NN O O
- NN O O
21 NN O O
years NN O O
) NN O O
who NN O O
have NN O O
transitioned NN O O
to NN O O
adult NN O O
care NN O O
at NN O O
outpatient NN O O
clinics NN O O
in NN O O
Hanoi NN O O
. NN O O

We NN O O
will NN O O
then NN O O
implement NN O O
a NN O O
seven-month NN O O
RCT NN O O
at NN O O
NHP NN O O
. NN O O

We NN O O
will NN O O
recruit NN O O
80 NN O O
adolescents NN O O
on NN O O
ART NN O O
, NN O O
monitor NN O O
their NN O O
adherence NN O O
for NN O O
one NN O O
month NN O O
to NN O O
establish NN O O
baseline NN O O
adherence NN O O
using NN O O
a NN O O
wireless NN O O
pill NN O O
container NN O O
( NN O O
WPC NN O O
) NN O O
, NN O O
and NN O O
then NN O O
randomize NN O O
participants NN O O
to NN O O
intervention NN O O
versus NN O O
control NN O O
within NN O O
optimal NN O O
( NN O O
≥ NN O O
95 NN O O
% NN O O
on-time NN O O
doses NN O O
) NN O O
versus NN O O
suboptimal NN O O
( NN O O
< NN O O
95 NN O O
% NN O O
on-time NN O O
doses NN O O
) NN O O
baseline NN O O
adherence NN O O
strata NN O O
. NN O O

Intervention NN O O
participants NN O O
will NN O O
receive NN O O
a NN O O
reminder NN O O
of NN O O
their NN O O
choice NN O O
( NN O O
cellphone NN O O
text NN O O
message/call NN O O
or NN O O
bottle-based NN O O
flash/alarm NN O O
) NN O O
, NN O O
triggered NN O O
when NN O O
they NN O O
miss NN O O
a NN O O
dose NN O O
, NN O O
and NN O O
engage NN O O
in NN O O
monthly NN O O
counseling NN O O
informed NN O O
by NN O O
their NN O O
adherence NN O O
data NN O O
. NN O O

Comparison NN O O
participants NN O O
will NN O O
receive NN O O
usual NN O O
care NN O O
and NN O O
offer NN O O
of NN O O
counseling NN O O
at NN O O
routine NN O O
monthly NN O O
clinic NN O O
visits NN O O
. NN O O

After NN O O
six NN O O
months NN O O
, NN O O
we NN O O
will NN O O
compare NN O O
ART NN O O
adherence NN O O
, NN O O
CD4 NN O O
count NN O O
, NN O O
and NN O O
HIV NN O O
viral NN O O
suppression NN O O
between NN O O
arms NN O O
, NN O O
in NN O O
addition NN O O
to NN O O
acceptability NN O O
and NN O O
feasibility NN O O
of NN O O
the NN O O
intervention NN O O
. NN O O

Findings NN O O
will NN O O
contribute NN O O
valuable NN O O
information NN O O
on NN O O
perceived NN O O
barriers NN O O
and NN O O
facilitators NN O O
affecting NN O O
adolescents NN O O
' NN O O
ART NN O O
adherence NN O O
, NN O O
mHealth NN O O
approaches NN O O
as NN O O
adherence NN O O
support NN O O
tools NN O O
for NN O O
ALHIV NN O O
, NN O O
and NN O O
factors NN O O
affecting NN O O
adolescents NN O O
' NN O O
ART NN O O
adherence NN O O
. NN O O

This NN O O
information NN O O
will NN O O
be NN O O
useful NN O O
to NN O O
researchers NN O O
, NN O O
medical NN O O
personnel NN O O
, NN O O
and NN O O
policy-makers NN O O
as NN O O
they NN O O
develop NN O O
and NN O O
implement NN O O
adherence NN O O
programs NN O O
for NN O O
ALHIV NN O O
, NN O O
with NN O O
potential NN O O
relevance NN O O
to NN O O
other NN O O
chronic NN O O
diseases NN O O
during NN O O
transition NN O O
from NN O O
adolescent NN O O
to NN O O
adult NN O O
care NN O O
. NN O O

ClinicalTrials.gov NN O O
, NN O O
NCT03031197 NN O O
. NN O O

Registered NN O O
on NN O O
21 NN O O
January NN O O
2017 NN O O
. NN O O



-DOCSTART- (30865795)

Surgical NN O O
intervention NN O O
is NN O O
needed NN O O
in NN O O
some NN O O
cases NN O O
of NN O O
spontaneous NN O O
abortion NN O O
to NN O O
remove NN O O
retained NN O O
products NN O O
of NN O O
conception NN O O
. NN O O

Antibiotic NN O O
prophylaxis NN O O
may NN O O
reduce NN O O
the NN O O
risk NN O O
of NN O O
pelvic NN O O
infection NN O O
, NN O O
which NN O O
is NN O O
an NN O O
important NN O O
complication NN O O
of NN O O
this NN O O
surgery NN O O
, NN O O
particularly NN O O
in NN O O
low-resource NN O O
countries NN O O
. NN O O

We NN O O
conducted NN O O
a NN O O
double-blind NN O O
, NN O O
placebo-controlled NN O O
, NN O O
randomized NN O O
trial NN O O
investigating NN O O
whether NN O O
antibiotic NN O O
prophylaxis NN O O
before NN O O
surgery NN O O
to NN O O
complete NN O O
a NN O O
spontaneous NN O O
abortion NN O O
would NN O O
reduce NN O O
pelvic NN O O
infection NN O O
among NN O O
women NN O O
and NN O O
adolescents NN O O
in NN O O
low-resource NN O O
countries NN O O
. NN O O

We NN O O
randomly NN O O
assigned NN O O
patients NN O O
to NN O O
a NN O O
single NN O O
preoperative NN O O
dose NN O O
of NN O O
400 NN O O
mg NN O O
of NN O O
oral NN O O
doxycycline NN O O
and NN O O
400 NN O O
mg NN O O
of NN O O
oral NN O O
metronidazole NN O O
or NN O O
identical NN O O
placebos NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
was NN O O
pelvic NN O O
infection NN O O
within NN O O
14 NN O O
days NN O O
after NN O O
surgery NN O O
. NN O O

Pelvic NN O O
infection NN O O
was NN O O
defined NN O O
by NN O O
the NN O O
presence NN O O
of NN O O
two NN O O
or NN O O
more NN O O
of NN O O
four NN O O
clinical NN O O
features NN O O
( NN O O
purulent NN O O
vaginal NN O O
discharge NN O O
, NN O O
pyrexia NN O O
, NN O O
uterine NN O O
tenderness NN O O
, NN O O
and NN O O
leukocytosis NN O O
) NN O O
or NN O O
by NN O O
the NN O O
presence NN O O
of NN O O
one NN O O
of NN O O
these NN O O
features NN O O
and NN O O
the NN O O
clinically NN O O
identified NN O O
need NN O O
to NN O O
administer NN O O
antibiotics NN O O
. NN O O

The NN O O
definition NN O O
of NN O O
pelvic NN O O
infection NN O O
was NN O O
changed NN O O
before NN O O
the NN O O
unblinding NN O O
of NN O O
the NN O O
data NN O O
; NN O O
the NN O O
original NN O O
strict NN O O
definition NN O O
was NN O O
two NN O O
or NN O O
more NN O O
of NN O O
the NN O O
clinical NN O O
features NN O O
, NN O O
without NN O O
reference NN O O
to NN O O
the NN O O
administration NN O O
of NN O O
antibiotics NN O O
. NN O O

We NN O O
enrolled NN O O
3412 NN O O
patients NN O O
in NN O O
Malawi NN O O
, NN O O
Pakistan NN O O
, NN O O
Tanzania NN O O
, NN O O
and NN O O
Uganda NN O O
. NN O O

A NN O O
total NN O O
of NN O O
1705 NN O O
patients NN O O
were NN O O
assigned NN O O
to NN O O
receive NN O O
antibiotics NN O O
and NN O O
1707 NN O O
to NN O O
receive NN O O
placebo NN O O
. NN O O

The NN O O
risk NN O O
of NN O O
pelvic NN O O
infection NN O O
was NN O O
4.1 NN O O
% NN O O
( NN O O
68 NN O O
of NN O O
1676 NN O O
pregnancies NN O O
) NN O O
in NN O O
the NN O O
antibiotics NN O O
group NN O O
and NN O O
5.3 NN O O
% NN O O
( NN O O
90 NN O O
of NN O O
1684 NN O O
pregnancies NN O O
) NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
( NN O O
risk NN O O
ratio NN O O
, NN O O
0.77 NN O O
; NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
[ NN O O
CI NN O O
] NN O O
, NN O O
0.56 NN O O
to NN O O
1.04 NN O O
; NN O O
P NN O O
= NN O O
0.09 NN O O
) NN O O
. NN O O

Pelvic NN O O
infection NN O O
according NN O O
to NN O O
original NN O O
strict NN O O
criteria NN O O
was NN O O
diagnosed NN O O
in NN O O
1.5 NN O O
% NN O O
( NN O O
26 NN O O
of NN O O
1700 NN O O
pregnancies NN O O
) NN O O
and NN O O
2.6 NN O O
% NN O O
( NN O O
44 NN O O
of NN O O
1704 NN O O
pregnancies NN O O
) NN O O
, NN O O
respectively NN O O
( NN O O
risk NN O O
ratio NN O O
, NN O O
0.60 NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
0.37 NN O O
to NN O O
0.96 NN O O
) NN O O
. NN O O

There NN O O
were NN O O
no NN O O
significant NN O O
between-group NN O O
differences NN O O
in NN O O
adverse NN O O
events NN O O
. NN O O

Antibiotic NN O O
prophylaxis NN O O
before NN O O
miscarriage NN O O
surgery NN O O
did NN O O
not NN O O
result NN O O
in NN O O
a NN O O
significantly NN O O
lower NN O O
risk NN O O
of NN O O
pelvic NN O O
infection NN O O
, NN O O
as NN O O
defined NN O O
by NN O O
pragmatic NN O O
broad NN O O
criteria NN O O
, NN O O
than NN O O
placebo NN O O
. NN O O

( NN O O
Funded NN O O
by NN O O
the NN O O
Medical NN O O
Research NN O O
Council NN O O
and NN O O
others NN O O
; NN O O
AIMS NN O O
Current NN O O
Controlled NN O O
Trials NN O O
number NN O O
, NN O O
ISRCTN97143849 NN O O
. NN O O
) NN O O
. NN O O



-DOCSTART- (30926430)

Combining NN O O
simethicone NN O O
( NN O O
SIM NN O O
) NN O O
with NN O O
a NN O O
colon NN O O
preparation NN O O
agent NN O O
has NN O O
been NN O O
shown NN O O
to NN O O
improve NN O O
mucosal NN O O
visibility NN O O
during NN O O
screening NN O O
colonoscopy NN O O
, NN O O
but NN O O
its NN O O
effect NN O O
on NN O O
the NN O O
adenoma NN O O
detection NN O O
rate NN O O
( NN O O
ADR NN O O
) NN O O
remains NN O O
unclear NN O O
. NN O O

SIM NN O O
is NN O O
commonly NN O O
used NN O O
through NN O O
the NN O O
endoscope NN O O
to NN O O
eliminate NN O O
bubbles NN O O
during NN O O
endoscopy NN O O
. NN O O

However NN O O
, NN O O
this NN O O
practice NN O O
recently NN O O
has NN O O
been NN O O
associated NN O O
with NN O O
endoscope-transmitted NN O O
infections NN O O
. NN O O

Our NN O O
aims NN O O
were NN O O
to NN O O
determine NN O O
the NN O O
role NN O O
of NN O O
SIM NN O O
added NN O O
to NN O O
a NN O O
polyethylene NN O O
glycol NN O O
preparation NN O O
on NN O O
the NN O O
ADR NN O O
, NN O O
procedure NN O O
times NN O O
, NN O O
colon NN O O
preparation NN O O
, NN O O
and NN O O
intraprocedural NN O O
use NN O O
of NN O O
SIM NN O O
. NN O O

This NN O O
was NN O O
a NN O O
randomized NN O O
, NN O O
controlled NN O O
, NN O O
observer-blinded NN O O
, NN O O
clinical NN O O
trial NN O O
of NN O O
patients NN O O
undergoing NN O O
screening NN O O
colonoscopy NN O O
. NN O O

Patients NN O O
with NN O O
a NN O O
high NN O O
risk NN O O
of NN O O
colorectal NN O O
cancer NN O O
were NN O O
excluded NN O O
. NN O O

Patients NN O O
were NN O O
randomly NN O O
assigned NN O O
to NN O O
2 NN O O
different NN O O
preparations NN O O
: NN O O
polyethylene NN O O
glycol NN O O
plus NN O O
SIM NN O O
or NN O O
polyethylene NN O O
glycol NN O O
. NN O O

Two NN O O
endoscopists NN O O
blinded NN O O
to NN O O
patient NN O O
preparation NN O O
regimens NN O O
scored NN O O
its NN O O
quality NN O O
by NN O O
using NN O O
the NN O O
Boston NN O O
Bowel NN O O
Preparation NN O O
scale NN O O
( NN O O
BBPS NN O O
) NN O O
and NN O O
the NN O O
bubble NN O O
scale NN O O
. NN O O

Interobserver NN O O
agreement NN O O
was NN O O
calculated NN O O
. NN O O

The NN O O
polyp NN O O
detection NN O O
rate NN O O
, NN O O
ADR NN O O
, NN O O
intraprocedural NN O O
use NN O O
of NN O O
SIM NN O O
, NN O O
cecal NN O O
intubation NN O O
time NN O O
, NN O O
and NN O O
withdrawal NN O O
time NN O O
were NN O O
recorded NN O O
. NN O O

For NN O O
study NN O O
purposes NN O O
, NN O O
cecal NN O O
intubation NN O O
time NN O O
and NN O O
withdrawal NN O O
time NN O O
were NN O O
combined NN O O
to NN O O
determine NN O O
the NN O O
effective NN O O
procedure NN O O
time NN O O
. NN O O

No NN O O
significant NN O O
difference NN O O
between NN O O
the NN O O
polyethylene NN O O
glycol NN O O
plus NN O O
SIM NN O O
and NN O O
polyethylene NN O O
glycol NN O O
arms NN O O
was NN O O
seen NN O O
regarding NN O O
the NN O O
ADR NN O O
( NN O O
33.3 NN O O
% NN O O
vs NN O O
38.8 NN O O
% NN O O
; NN O O
P NN O O
= NN O O
.881 NN O O
) NN O O
and NN O O
effective NN O O
procedure NN O O
time NN O O
( NN O O
759.3 NN O O
± NN O O
253.1 NN O O
seconds NN O O
vs NN O O
800.2 NN O O
± NN O O
459.6 NN O O
seconds NN O O
; NN O O
P NN O O
= NN O O
.373 NN O O
) NN O O
, NN O O
respectively NN O O
. NN O O

Intraprocedural NN O O
use NN O O
of NN O O
SIM NN O O
as NN O O
well NN O O
as NN O O
the NN O O
bubble NN O O
scale NN O O
score NN O O
were NN O O
significantly NN O O
lower NN O O
in NN O O
the NN O O
polyethylene NN O O
glycol NN O O
plus NN O O
SIM NN O O
arm NN O O
( NN O O
1.6 NN O O
% NN O O
vs NN O O
48.9 NN O O
% NN O O
; NN O O
P NN O O
≤ NN O O
.05 NN O O
) NN O O
and NN O O
( NN O O
0.1 NN O O
vs NN O O
2.1 NN O O
; NN O O
P NN O O
≤ NN O O
.05 NN O O
) NN O O
, NN O O
respectively NN O O
. NN O O

Conversely NN O O
, NN O O
no NN O O
difference NN O O
was NN O O
found NN O O
in NN O O
the NN O O
BBPS NN O O
scores NN O O
. NN O O

The NN O O
interobserver NN O O
agreement NN O O
for NN O O
both NN O O
scores NN O O
was NN O O
strong NN O O
( NN O O
bubble NN O O
scale NN O O
score NN O O
kappa NN O O
= NN O O
.537 NN O O
; NN O O
P NN O O
< NN O O
.05 NN O O
; NN O O
BBPS NN O O
score NN O O
kappa NN O O
= NN O O
.184 NN O O
; NN O O
P NN O O
< NN O O
.05 NN O O
) NN O O
. NN O O

Adding NN O O
SIM NN O O
to NN O O
a NN O O
polyethylene NN O O
glycol NN O O
preparation NN O O
did NN O O
not NN O O
improve NN O O
the NN O O
ADR NN O O
or NN O O
effective NN O O
procedure NN O O
time NN O O
. NN O O

Nevertheless NN O O
, NN O O
it NN O O
resulted NN O O
in NN O O
lower NN O O
bubble NN O O
scale NN O O
scores NN O O
, NN O O
and NN O O
more NN O O
importantly NN O O
, NN O O
in NN O O
less NN O O
intraprocedural NN O O
use NN O O
of NN O O
SIM NN O O
. NN O O

This NN O O
simple NN O O
and NN O O
inexpensive NN O O
intervention NN O O
may NN O O
have NN O O
the NN O O
potential NN O O
to NN O O
reduce NN O O
the NN O O
risk NN O O
of NN O O
endoscope-transmitted NN O O
infections NN O O
. NN O O

( NN O O
Clinical NN O O
trial NN O O
registration NN O O
number NN O O
: NN O O
NCT03119168 NN O O
. NN O O
) NN O O
. NN O O



-DOCSTART- (31217257)

To NN O O
investigate NN O O
whether NN O O
mammalian NN O O
target NN O O
of NN O O
rapamycin NN O O
inhibitor NN O O
everolimus NN O O
can NN O O
improve NN O O
intellectual NN O O
disability NN O O
, NN O O
autism NN O O
, NN O O
and NN O O
other NN O O
neuropsychological NN O O
deficits NN O O
in NN O O
children NN O O
with NN O O
tuberous NN O O
sclerosis NN O O
complex NN O O
( NN O O
TSC NN O O
) NN O O
. NN O O

In NN O O
this NN O O
12-month NN O O
, NN O O
randomized NN O O
, NN O O
double-blind NN O O
, NN O O
placebo-controlled NN O O
trial NN O O
, NN O O
we NN O O
attempted NN O O
to NN O O
enroll NN O O
60 NN O O
children NN O O
with NN O O
TSC NN O O
and NN O O
IQ NN O O
< NN O O
80 NN O O
, NN O O
learning NN O O
disability NN O O
, NN O O
special NN O O
schooling NN O O
, NN O O
or NN O O
autism NN O O
, NN O O
aged NN O O
4 NN O O
- NN O O
17 NN O O
years NN O O
, NN O O
without NN O O
intractable NN O O
seizures NN O O
to NN O O
be NN O O
assigned NN O O
to NN O O
receive NN O O
everolimus NN O O
or NN O O
placebo NN O O
. NN O O

Everolimus NN O O
was NN O O
titrated NN O O
to NN O O
blood NN O O
trough NN O O
levels NN O O
of NN O O
5 NN O O
- NN O O
10 NN O O
ng/mL. NN O O
Primary NN O O
outcome NN O O
was NN O O
full-scale NN O O
IQ NN O O
; NN O O
secondary NN O O
outcomes NN O O
included NN O O
autism NN O O
, NN O O
neuropsychological NN O O
functioning NN O O
, NN O O
and NN O O
behavioral NN O O
problems NN O O
. NN O O

Thirty-two NN O O
children NN O O
with NN O O
TSC NN O O
were NN O O
randomized NN O O
. NN O O

Intention-to-treat NN O O
analysis NN O O
showed NN O O
no NN O O
benefit NN O O
of NN O O
everolimus NN O O
on NN O O
full-scale NN O O
IQ NN O O
( NN O O
treatment NN O O
effect NN O O
-5.6 NN O O
IQ NN O O
points NN O O
, NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
-12.3 NN O O
to NN O O
1.0 NN O O
) NN O O
. NN O O

No NN O O
effect NN O O
was NN O O
found NN O O
on NN O O
secondary NN O O
outcomes NN O O
, NN O O
including NN O O
autism NN O O
and NN O O
neuropsychological NN O O
functioning NN O O
, NN O O
and NN O O
questionnaires NN O O
examining NN O O
behavioral NN O O
problems NN O O
, NN O O
social NN O O
functioning NN O O
, NN O O
communication NN O O
skills NN O O
, NN O O
executive NN O O
functioning NN O O
, NN O O
sleep NN O O
, NN O O
quality NN O O
of NN O O
life NN O O
, NN O O
and NN O O
sensory NN O O
processing NN O O
. NN O O

All NN O O
patients NN O O
had NN O O
adverse NN O O
events NN O O
. NN O O

Two NN O O
patients NN O O
on NN O O
everolimus NN O O
and NN O O
2 NN O O
patients NN O O
on NN O O
placebo NN O O
discontinued NN O O
treatment NN O O
due NN O O
to NN O O
adverse NN O O
events NN O O
. NN O O

Everolimus NN O O
did NN O O
not NN O O
improve NN O O
cognitive NN O O
functioning NN O O
, NN O O
autism NN O O
, NN O O
or NN O O
neuropsychological NN O O
deficits NN O O
in NN O O
children NN O O
with NN O O
TSC NN O O
. NN O O

The NN O O
use NN O O
of NN O O
everolimus NN O O
in NN O O
children NN O O
with NN O O
TSC NN O O
with NN O O
the NN O O
aim NN O O
of NN O O
improving NN O O
cognitive NN O O
function NN O O
and NN O O
behavior NN O O
should NN O O
not NN O O
be NN O O
encouraged NN O O
in NN O O
this NN O O
age NN O O
group NN O O
. NN O O

NCT01730209 NN O O
. NN O O

This NN O O
study NN O O
provides NN O O
Class NN O O
I NN O O
evidence NN O O
that NN O O
for NN O O
children NN O O
with NN O O
TSC NN O O
, NN O O
everolimus NN O O
does NN O O
not NN O O
improve NN O O
intellectual NN O O
disability NN O O
, NN O O
autism NN O O
, NN O O
behavioral NN O O
problems NN O O
, NN O O
or NN O O
other NN O O
neuropsychological NN O O
deficits NN O O
. NN O O



-DOCSTART- (30782342)

In NN O O
laboratory NN O O
animals NN O O
, NN O O
exposure NN O O
to NN O O
most NN O O
general NN O O
anaesthetics NN O O
leads NN O O
to NN O O
neurotoxicity NN O O
manifested NN O O
by NN O O
neuronal NN O O
cell NN O O
death NN O O
and NN O O
abnormal NN O O
behaviour NN O O
and NN O O
cognition NN O O
. NN O O

Some NN O O
large NN O O
human NN O O
cohort NN O O
studies NN O O
have NN O O
shown NN O O
an NN O O
association NN O O
between NN O O
general NN O O
anaesthesia NN O O
at NN O O
a NN O O
young NN O O
age NN O O
and NN O O
subsequent NN O O
neurodevelopmental NN O O
deficits NN O O
, NN O O
but NN O O
these NN O O
studies NN O O
are NN O O
prone NN O O
to NN O O
bias NN O O
. NN O O

Others NN O O
have NN O O
found NN O O
no NN O O
evidence NN O O
for NN O O
an NN O O
association NN O O
. NN O O

We NN O O
aimed NN O O
to NN O O
establish NN O O
whether NN O O
general NN O O
anaesthesia NN O O
in NN O O
early NN O O
infancy NN O O
affects NN O O
neurodevelopmental NN O O
outcomes NN O O
. NN O O

In NN O O
this NN O O
international NN O O
, NN O O
assessor-masked NN O O
, NN O O
equivalence NN O O
, NN O O
randomised NN O O
, NN O O
controlled NN O O
trial NN O O
conducted NN O O
at NN O O
28 NN O O
hospitals NN O O
in NN O O
Australia NN O O
, NN O O
Italy NN O O
, NN O O
the NN O O
USA NN O O
, NN O O
the NN O O
UK NN O O
, NN O O
Canada NN O O
, NN O O
the NN O O
Netherlands NN O O
, NN O O
and NN O O
New NN O O
Zealand NN O O
, NN O O
we NN O O
recruited NN O O
infants NN O O
of NN O O
less NN O O
than NN O O
60 NN O O
weeks NN O O
' NN O O
postmenstrual NN O O
age NN O O
who NN O O
were NN O O
born NN O O
at NN O O
more NN O O
than NN O O
26 NN O O
weeks NN O O
' NN O O
gestation NN O O
and NN O O
were NN O O
undergoing NN O O
inguinal NN O O
herniorrhaphy NN O O
, NN O O
without NN O O
previous NN O O
exposure NN O O
to NN O O
general NN O O
anaesthesia NN O O
or NN O O
risk NN O O
factors NN O O
for NN O O
neurological NN O O
injury NN O O
. NN O O

Patients NN O O
were NN O O
randomly NN O O
assigned NN O O
( NN O O
1:1 NN O O
) NN O O
by NN O O
use NN O O
of NN O O
a NN O O
web-based NN O O
randomisation NN O O
service NN O O
to NN O O
receive NN O O
either NN O O
awake-regional NN O O
anaesthetic NN O O
or NN O O
sevoflurane-based NN O O
general NN O O
anaesthetic NN O O
. NN O O

Anaesthetists NN O O
were NN O O
aware NN O O
of NN O O
group NN O O
allocation NN O O
, NN O O
but NN O O
individuals NN O O
administering NN O O
the NN O O
neurodevelopmental NN O O
assessments NN O O
were NN O O
not NN O O
. NN O O

Parents NN O O
were NN O O
informed NN O O
of NN O O
their NN O O
infants NN O O
group NN O O
allocation NN O O
upon NN O O
request NN O O
, NN O O
but NN O O
were NN O O
told NN O O
to NN O O
mask NN O O
this NN O O
information NN O O
from NN O O
assessors NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
measure NN O O
was NN O O
full-scale NN O O
intelligence NN O O
quotient NN O O
( NN O O
FSIQ NN O O
) NN O O
on NN O O
the NN O O
Wechsler NN O O
Preschool NN O O
and NN O O
Primary NN O O
Scale NN O O
of NN O O
Intelligence NN O O
, NN O O
third NN O O
edition NN O O
( NN O O
WPPSI-III NN O O
) NN O O
, NN O O
at NN O O
5 NN O O
years NN O O
of NN O O
age NN O O
. NN O O

The NN O O
primary NN O O
analysis NN O O
was NN O O
done NN O O
on NN O O
a NN O O
per-protocol NN O O
basis NN O O
, NN O O
adjusted NN O O
for NN O O
gestational NN O O
age NN O O
at NN O O
birth NN O O
and NN O O
country NN O O
, NN O O
with NN O O
multiple NN O O
imputation NN O O
used NN O O
to NN O O
account NN O O
for NN O O
missing NN O O
data NN O O
. NN O O

An NN O O
intention-to-treat NN O O
analysis NN O O
was NN O O
also NN O O
done NN O O
. NN O O

A NN O O
difference NN O O
in NN O O
means NN O O
of NN O O
5 NN O O
points NN O O
was NN O O
predefined NN O O
as NN O O
the NN O O
clinical NN O O
equivalence NN O O
margin NN O O
. NN O O

This NN O O
completed NN O O
trial NN O O
is NN O O
registered NN O O
with NN O O
ANZCTR NN O O
, NN O O
number NN O O
ACTRN12606000441516 NN O O
, NN O O
and NN O O
ClinicalTrials.gov NN O O
, NN O O
number NN O O
NCT00756600 NN O O
. NN O O

Between NN O O
Feb NN O O
9 NN O O
, NN O O
2007 NN O O
, NN O O
and NN O O
Jan NN O O
31 NN O O
, NN O O
2013 NN O O
, NN O O
4023 NN O O
infants NN O O
were NN O O
screened NN O O
and NN O O
722 NN O O
were NN O O
randomly NN O O
allocated NN O O
: NN O O
363 NN O O
( NN O O
50 NN O O
% NN O O
) NN O O
to NN O O
the NN O O
awake-regional NN O O
anaesthesia NN O O
group NN O O
and NN O O
359 NN O O
( NN O O
50 NN O O
% NN O O
) NN O O
to NN O O
the NN O O
general NN O O
anaesthesia NN O O
group NN O O
. NN O O

There NN O O
were NN O O
74 NN O O
protocol NN O O
violations NN O O
in NN O O
the NN O O
awake-regional NN O O
anaesthesia NN O O
group NN O O
and NN O O
two NN O O
in NN O O
the NN O O
general NN O O
anaesthesia NN O O
group NN O O
. NN O O

Primary NN O O
outcome NN O O
data NN O O
for NN O O
the NN O O
per-protocol NN O O
analysis NN O O
were NN O O
obtained NN O O
from NN O O
205 NN O O
children NN O O
in NN O O
the NN O O
awake-regional NN O O
anaesthesia NN O O
group NN O O
and NN O O
242 NN O O
in NN O O
the NN O O
general NN O O
anaesthesia NN O O
group NN O O
. NN O O

The NN O O
median NN O O
duration NN O O
of NN O O
general NN O O
anaesthesia NN O O
was NN O O
54 NN O O
min NN O O
( NN O O
IQR NN O O
41 NN O O
- NN O O
70 NN O O
) NN O O
. NN O O

The NN O O
mean NN O O
FSIQ NN O O
score NN O O
was NN O O
99·08 NN O O
( NN O O
SD NN O O
18·35 NN O O
) NN O O
in NN O O
the NN O O
awake-regional NN O O
anaesthesia NN O O
group NN O O
and NN O O
98·97 NN O O
( NN O O
19·66 NN O O
) NN O O
in NN O O
the NN O O
general NN O O
anaesthesia NN O O
group NN O O
, NN O O
with NN O O
a NN O O
difference NN O O
in NN O O
means NN O O
( NN O O
awake-regional NN O O
anaesthesia NN O O
minus NN O O
general NN O O
anaesthesia NN O O
) NN O O
of NN O O
0·23 NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
-2·59 NN O O
to NN O O
3·06 NN O O
) NN O O
, NN O O
providing NN O O
strong NN O O
evidence NN O O
of NN O O
equivalence NN O O
. NN O O

The NN O O
results NN O O
of NN O O
the NN O O
intention-to-treat NN O O
analysis NN O O
were NN O O
similar NN O O
to NN O O
those NN O O
of NN O O
the NN O O
per-protocol NN O O
analysis NN O O
. NN O O

Slightly NN O O
less NN O O
than NN O O
1 NN O O
h NN O O
of NN O O
general NN O O
anaesthesia NN O O
in NN O O
early NN O O
infancy NN O O
does NN O O
not NN O O
alter NN O O
neurodevelopmental NN O O
outcome NN O O
at NN O O
age NN O O
5 NN O O
years NN O O
compared NN O O
with NN O O
awake-regional NN O O
anaesthesia NN O O
in NN O O
a NN O O
predominantly NN O O
male NN O O
study NN O O
population NN O O
. NN O O

US NN O O
National NN O O
Institutes NN O O
of NN O O
Health NN O O
, NN O O
US NN O O
Food NN O O
and NN O O
Drug NN O O
Administration NN O O
, NN O O
Thrasher NN O O
Research NN O O
Fund NN O O
, NN O O
Australian NN O O
National NN O O
Health NN O O
and NN O O
Medical NN O O
Research NN O O
Council NN O O
, NN O O
Health NN O O
Technologies NN O O
Assessment-National NN O O
Institute NN O O
for NN O O
Health NN O O
Research NN O O
( NN O O
UK NN O O
) NN O O
, NN O O
Australian NN O O
and NN O O
New NN O O
Zealand NN O O
College NN O O
of NN O O
Anaesthetists NN O O
, NN O O
Murdoch NN O O
Children NN O O
's NN O O
Research NN O O
Institute NN O O
, NN O O
Canadian NN O O
Institutes NN O O
of NN O O
Health NN O O
Research NN O O
, NN O O
Canadian NN O O
Anesthesiologists NN O O
Society NN O O
, NN O O
Pfizer NN O O
Canada NN O O
, NN O O
Italian NN O O
Ministry NN O O
of NN O O
Health NN O O
, NN O O
Fonds NN O O
NutsOhra NN O O
, NN O O
UK NN O O
Clinical NN O O
Research NN O O
Network NN O O
, NN O O
Perth NN O O
Children NN O O
's NN O O
Hospital NN O O
Foundation NN O O
, NN O O
the NN O O
Stan NN O O
Perron NN O O
Charitable NN O O
Trust NN O O
, NN O O
and NN O O
the NN O O
Callahan NN O O
Estate NN O O
. NN O O



-DOCSTART- (30673030)

Pain NN O O
due NN O O
to NN O O
administration NN O O
of NN O O
local NN O O
anesthetics NN O O
is NN O O
the NN O O
primary NN O O
reason NN O O
for NN O O
patients NN O O
' NN O O
fear NN O O
and NN O O
anxiety NN O O
, NN O O
and NN O O
various NN O O
methods NN O O
are NN O O
used NN O O
to NN O O
minimize NN O O
it NN O O
. NN O O

This NN O O
study NN O O
aimed NN O O
to NN O O
measure NN O O
the NN O O
degree NN O O
of NN O O
pain NN O O
during NN O O
administration NN O O
of NN O O
anesthesia NN O O
and NN O O
determine NN O O
the NN O O
latency NN O O
time NN O O
and NN O O
duration NN O O
of NN O O
pulpal NN O O
anesthesia NN O O
using NN O O
two NN O O
anesthetic NN O O
methods NN O O
in NN O O
the NN O O
maxilla NN O O
. NN O O

A NN O O
randomized NN O O
, NN O O
single-blind NN O O
, NN O O
split-mouth NN O O
clinical NN O O
trial NN O O
was NN O O
conducted NN O O
with NN O O
41 NN O O
volunteers NN O O
who NN O O
required NN O O
class NN O O
I NN O O
restorations NN O O
in NN O O
the NN O O
maxillary NN O O
first NN O O
molars NN O O
. NN O O

Local NN O O
anesthesia NN O O
was NN O O
administered NN O O
with NN O O
a NN O O
needleless NN O O
jet NN O O
injection NN O O
system NN O O
( NN O O
experimental NN O O
group NN O O
) NN O O
or NN O O
with NN O O
a NN O O
carpule NN O O
syringe NN O O
( NN O O
control NN O O
) NN O O
using NN O O
a NN O O
30-gauge NN O O
short NN O O
needle NN O O
. NN O O

The NN O O
method NN O O
of NN O O
anesthesia NN O O
and NN O O
laterality NN O O
of NN O O
the NN O O
maxilla NN O O
were NN O O
randomized NN O O
. NN O O

A NN O O
pulp NN O O
electric NN O O
tester NN O O
measured NN O O
the NN O O
latency NN O O
time NN O O
and NN O O
duration NN O O
of NN O O
anesthesia NN O O
in NN O O
the NN O O
second NN O O
molar NN O O
. NN O O

Visual NN O O
analogue NN O O
scale NN O O
( NN O O
VAS NN O O
) NN O O
was NN O O
used NN O O
to NN O O
measure NN O O
the NN O O
degree NN O O
of NN O O
pain NN O O
during NN O O
the NN O O
anesthetic NN O O
method NN O O
. NN O O

Data NN O O
were NN O O
tabulated NN O O
and NN O O
then NN O O
analyzed NN O O
by NN O O
a NN O O
statistician NN O O
. NN O O

The NN O O
t-test NN O O
was NN O O
used NN O O
to NN O O
analyze NN O O
the NN O O
differences NN O O
between NN O O
the NN O O
groups NN O O
for NN O O
basal NN O O
electrical NN O O
stimulation NN O O
. NN O O

Duration NN O O
of NN O O
anesthesia NN O O
and NN O O
degree NN O O
of NN O O
pain NN O O
were NN O O
compared NN O O
using NN O O
the NN O O
Mann-Whitney NN O O
test NN O O
. NN O O

A NN O O
5 NN O O
% NN O O
significance NN O O
level NN O O
was NN O O
considered NN O O
. NN O O

There NN O O
was NN O O
no NN O O
statistical NN O O
difference NN O O
in NN O O
the NN O O
basal NN O O
electrical NN O O
stimulation NN O O
threshold NN O O
( NN O O
mA NN O O
) NN O O
and NN O O
degree NN O O
of NN O O
pain NN O O
between NN O O
the NN O O
two NN O O
methods NN O O
of NN O O
anesthesia NN O O
( NN O O
p>0.05 NN O O
) NN O O
. NN O O

Latency NN O O
time NN O O
was NN O O
2 NN O O
minutes NN O O
for NN O O
all NN O O
subjects NN O O
. NN O O

The NN O O
duration NN O O
of NN O O
pulpal NN O O
anesthesia NN O O
showed NN O O
no NN O O
statistical NN O O
difference NN O O
( NN O O
minutes NN O O
) NN O O
between NN O O
the NN O O
two NN O O
methods NN O O
( NN O O
p<0.001 NN O O
) NN O O
, NN O O
with NN O O
a NN O O
longer NN O O
duration NN O O
for NN O O
the NN O O
traditional NN O O
method NN O O
of NN O O
anesthesia NN O O
( NN O O
median NN O O
of NN O O
40 NN O O
minutes NN O O
) NN O O
. NN O O

The NN O O
two NN O O
anesthetics NN O O
methods NN O O
did NN O O
not NN O O
differ NN O O
concerning NN O O
the NN O O
pain NN O O
experienced NN O O
during NN O O
anesthesia NN O O
. NN O O

Latency NN O O
lasted NN O O
2 NN O O
minutes NN O O
for NN O O
all NN O O
subjects NN O O
; NN O O
the NN O O
traditional NN O O
infiltration NN O O
anesthesia NN O O
resulted NN O O
in NN O O
a NN O O
longer NN O O
anesthetic NN O O
duration NN O O
compared NN O O
with NN O O
the NN O O
needleless NN O O
jet NN O O
injection NN O O
. NN O O



-DOCSTART- (31146543)

This NN O O
study NN O O
aims NN O O
to NN O O
investigate NN O O
the NN O O
effect NN O O
of NN O O
an NN O O
integrated NN O O
intervention NN O O
of NN O O
art NN O O
activities NN O O
and NN O O
Qigong NN O O
exercise NN O O
on NN O O
the NN O O
well-being NN O O
of NN O O
older NN O O
adults NN O O
in NN O O
nursing NN O O
homes NN O O
in NN O O
Indonesia NN O O
. NN O O

We NN O O
employed NN O O
a NN O O
randomized NN O O
controlled NN O O
trial NN O O
with NN O O
4 NN O O
specific NN O O
groups NN O O
, NN O O
i.e. NN O O
art NN O O
, NN O O
Qigong NN O O
, NN O O
integration NN O O
of NN O O
art NN O O
and NN O O
Qigong NN O O
, NN O O
and NN O O
control NN O O
group NN O O
. NN O O

A NN O O
total NN O O
of NN O O
267 NN O O
participants NN O O
aged NN O O
50 NN O O
years NN O O
or NN O O
older NN O O
were NN O O
recruited NN O O
from NN O O
9 NN O O
nursing NN O O
homes NN O O
in NN O O
Jakarta NN O O
, NN O O
Indonesia NN O O
. NN O O

The NN O O
participants NN O O
were NN O O
randomly NN O O
allocated NN O O
to NN O O
one NN O O
of NN O O
the NN O O
four NN O O
groups NN O O
, NN O O
attending NN O O
two NN O O
intervention NN O O
sessions NN O O
per NN O O
week NN O O
for NN O O
eight NN O O
weeks NN O O
( NN O O
16 NN O O
sessions NN O O
) NN O O
, NN O O
lasting NN O O
90 NN O O
minutes NN O O
each NN O O
. NN O O

Measurements NN O O
were NN O O
administered NN O O
at NN O O
baseline NN O O
( NN O O
T NN O O
) NN O O
and NN O O
post-intervention NN O O
( NN O O
T NN O O
) NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
was NN O O
well-being NN O O
( NN O O
WHOQOL-Bref NN O O
) NN O O
and NN O O
secondary NN O O
outcomes NN O O
were NN O O
satisfaction NN O O
with NN O O
life NN O O
( NN O O
SWLS NN O O
) NN O O
, NN O O
depression NN O O
( NN O O
BDI-II NN O O
) NN O O
, NN O O
and NN O O
health NN O O
status NN O O
( NN O O
SF-36 NN O O
) NN O O
. NN O O

The NN O O
art NN O O
intervention NN O O
had NN O O
a NN O O
significant NN O O
positive NN O O
effect NN O O
on NN O O
well-being NN O O
, NN O O
in NN O O
particular NN O O
in NN O O
the NN O O
domain NN O O
of NN O O
social NN O O
relations NN O O
. NN O O

It NN O O
also NN O O
led NN O O
to NN O O
a NN O O
decrease NN O O
in NN O O
depressive NN O O
symptoms NN O O
, NN O O
as NN O O
did NN O O
the NN O O
integration NN O O
intervention NN O O
. NN O O

No NN O O
significant NN O O
effects NN O O
were NN O O
visible NN O O
in NN O O
the NN O O
Qigong NN O O
group NN O O
nor NN O O
in NN O O
the NN O O
integrated NN O O
intervention NN O O
compared NN O O
to NN O O
either NN O O
art NN O O
or NN O O
Qigong NN O O
alone NN O O
. NN O O

Interventions NN O O
such NN O O
as NN O O
art NN O O
programs NN O O
and NN O O
an NN O O
integration NN O O
of NN O O
art NN O O
and NN O O
Qigong NN O O
may NN O O
give NN O O
psychological NN O O
benefits NN O O
to NN O O
older NN O O
adults NN O O
. NN O O

Yet NN O O
, NN O O
results NN O O
of NN O O
the NN O O
study NN O O
need NN O O
to NN O O
be NN O O
interpreted NN O O
with NN O O
caution NN O O
and NN O O
need NN O O
to NN O O
be NN O O
replicated NN O O
. NN O O

A NN O O
qualitative NN O O
approach NN O O
would NN O O
be NN O O
welcome NN O O
to NN O O
get NN O O
an NN O O
in-depth NN O O
understanding NN O O
of NN O O
why NN O O
art NN O O
intervention NN O O
is NN O O
especially NN O O
beneficial NN O O
. NN O O

( NN O O
Trial NN O O
registration NN O O
: NN O O
Clinicaltrials.gov NN O O
NCT02957773 NN O O
, NN O O
registered NN O O
28 NN O O
September NN O O
2016 NN O O
) NN O O
. NN O O



-DOCSTART- (30640653)

In NN O O
the NN O O
context NN O O
of NN O O
opioid-sparing NN O O
perioperative NN O O
management NN O O
, NN O O
there NN O O
is NN O O
still NN O O
little NN O O
evidence NN O O
from NN O O
randomized NN O O
controlled NN O O
trials NN O O
regarding NN O O
the NN O O
effectiveness NN O O
of NN O O
interfascial NN O O
thoracic NN O O
blocks NN O O
. NN O O

This NN O O
study NN O O
hypothesizes NN O O
that NN O O
receiving NN O O
a NN O O
serratus NN O O
plane NN O O
block NN O O
reduces NN O O
opioid NN O O
requirements NN O O
, NN O O
pain NN O O
scores NN O O
, NN O O
and NN O O
rescue NN O O
medication NN O O
needs NN O O
. NN O O

This NN O O
double-blind NN O O
, NN O O
randomized NN O O
controlled NN O O
study NN O O
was NN O O
conducted NN O O
on NN O O
60 NN O O
adult NN O O
females NN O O
undergoing NN O O
oncologic NN O O
breast NN O O
surgery NN O O
. NN O O

After NN O O
general NN O O
anesthesia NN O O
, NN O O
patients NN O O
were NN O O
randomly NN O O
allocated NN O O
to NN O O
either NN O O
conventional NN O O
analgesia NN O O
( NN O O
control NN O O
group NN O O
, NN O O
n=30 NN O O
) NN O O
or NN O O
single-injection NN O O
serratus NN O O
block NN O O
with NN O O
L-bupivacaine NN O O
0.25 NN O O
% NN O O
30mL NN O O
( NN O O
study NN O O
group NN O O
, NN O O
n=30 NN O O
) NN O O
. NN O O

First NN O O
24-hour NN O O
total NN O O
morphine NN O O
consumption NN O O
( NN O O
primary NN O O
outcome NN O O
) NN O O
, NN O O
pain NN O O
scores NN O O
at NN O O
1 NN O O
, NN O O
3 NN O O
, NN O O
6 NN O O
, NN O O
12 NN O O
, NN O O
and NN O O
24 NN O O
hours NN O O
, NN O O
time-to-first NN O O
opioid NN O O
rescue NN O O
analgesia NN O O
, NN O O
and NN O O
adverse NN O O
effects NN O O
were NN O O
recorded NN O O
. NN O O

Median NN O O
24 NN O O
hours NN O O
' NN O O
opioid NN O O
dose NN O O
was NN O O
greater NN O O
in NN O O
the NN O O
control NN O O
group NN O O
( NN O O
median NN O O
difference NN O O
9 NN O O
mg NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
4 NN O O
to NN O O
14.5 NN O O
mg NN O O
) NN O O
; NN O O
p<0.001 NN O O
) NN O O
. NN O O

Proportional NN O O
odds NN O O
model NN O O
showed NN O O
that NN O O
the NN O O
study NN O O
group NN O O
has NN O O
a NN O O
lower NN O O
probability NN O O
of NN O O
receiving NN O O
opioid NN O O
drugs NN O O
( NN O O
OR=0.26 NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
0.10 NN O O
to NN O O
0.68 NN O O
) NN O O
; NN O O
p<0.001 NN O O
) NN O O
, NN O O
while NN O O
mastectomies NN O O
have NN O O
a NN O O
higher NN O O
probability NN O O
of NN O O
receiving NN O O
them NN O O
( NN O O
OR=4.11 NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
1.25 NN O O
to NN O O
13.58 NN O O
) NN O O
; NN O O
p=0.002 NN O O
) NN O O
. NN O O

Pain NN O O
scores NN O O
in NN O O
the NN O O
study NN O O
group NN O O
were NN O O
significantly NN O O
lower NN O O
throughout NN O O
the NN O O
follow-up NN O O
period NN O O
( NN O O
p<0.001 NN O O
) NN O O
. NN O O

Control NN O O
group NN O O
subjects NN O O
needed NN O O
earlier NN O O
morphine NN O O
rescue NN O O
and NN O O
had NN O O
a NN O O
higher NN O O
risk NN O O
of NN O O
rescue NN O O
dose NN O O
requirement NN O O
( NN O O
p=0.002 NN O O
) NN O O
. NN O O

Interfascial NN O O
serratus NN O O
plane NN O O
block NN O O
reduces NN O O
opioid NN O O
requirements NN O O
and NN O O
is NN O O
associated NN O O
with NN O O
better NN O O
pain NN O O
scores NN O O
and NN O O
lower NN O O
and NN O O
later NN O O
rescue NN O O
analgesia NN O O
needs NN O O
in NN O O
the NN O O
first NN O O
24 NN O O
hours NN O O
, NN O O
compared NN O O
with NN O O
conventional NN O O
intravenous NN O O
analgesia NN O O
, NN O O
in NN O O
breast NN O O
surgery NN O O
. NN O O

NCT02905149 NN O O
. NN O O



-DOCSTART- (31373615)

Previous NN O O
mass NN O O
screening NN O O
studies NN O O
have NN O O
shown NN O O
that NN O O
IgA NN O O
antibodies NN O O
against NN O O
Epstein-Barr NN O O
Virus NN O O
( NN O O
EBV NN O O
) NN O O
can NN O O
facilitate NN O O
early NN O O
detection NN O O
of NN O O
Nasopharyngeal NN O O
carcinoma NN O O
( NN O O
NPC NN O O
) NN O O
, NN O O
but NN O O
the NN O O
impact NN O O
of NN O O
EBV-antibody NN O O
screening NN O O
for NN O O
NPC-specific NN O O
mortality NN O O
remains NN O O
unknown NN O O
. NN O O

A NN O O
prospective NN O O
, NN O O
cluster NN O O
randomized NN O O
, NN O O
controlled NN O O
trial NN O O
for NN O O
NPC NN O O
screening NN O O
( NN O O
PRO-NPC-001 NN O O
) NN O O
was NN O O
conducted NN O O
in NN O O
3 NN O O
selected NN O O
towns NN O O
of NN O O
Zhongshan NN O O
City NN O O
and NN O O
13 NN O O
selected NN O O
towns NN O O
of NN O O
Sihui NN O O
City NN O O
in NN O O
southern NN O O
China NN O O
beginning NN O O
in NN O O
2008 NN O O
. NN O O

Serum NN O O
samples NN O O
of NN O O
the NN O O
screening NN O O
group NN O O
were NN O O
tested NN O O
for NN O O
two NN O O
previously NN O O
selected NN O O
anti-EBV NN O O
antibodies NN O O
. NN O O

Subjects NN O O
with NN O O
serological NN O O
medium NN O O
risk NN O O
were NN O O
subsequently NN O O
retested NN O O
annually NN O O
for NN O O
three NN O O
years NN O O
, NN O O
and NN O O
those NN O O
with NN O O
serological NN O O
high NN O O
risk NN O O
were NN O O
referred NN O O
to NN O O
otorhinolaryngologists NN O O
for NN O O
diagnostic NN O O
check-up NN O O
. NN O O

An NN O O
interim NN O O
analysis NN O O
was NN O O
performed NN O O
to NN O O
evaluate NN O O
the NN O O
primary NN O O
endpoints NN O O
of NN O O
the NN O O
NPC-specific NN O O
mortality NN O O
and NN O O
the NN O O
early NN O O
disgnositic NN O O
rate NN O O
, NN O O
and NN O O
the NN O O
secondary NN O O
endopoint NN O O
of NN O O
the NN O O
NPC NN O O
incidence NN O O
, NN O O
through NN O O
linakage NN O O
with NN O O
the NN O O
database NN O O
of NN O O
Zhongshan NN O O
City NN O O
. NN O O

Among NN O O
70,296 NN O O
total NN O O
subjects NN O O
, NN O O
29,413 NN O O
screened NN O O
participants NN O O
( NN O O
41.8 NN O O
% NN O O
of NN O O
the NN O O
total NN O O
subjects NN O O
) NN O O
in NN O O
the NN O O
screening NN O O
group NN O O
and NN O O
50,636 NN O O
in NN O O
the NN O O
control NN O O
group NN O O
, NN O O
153 NN O O
( NN O O
43.3 NN O O
per NN O O
100,000 NN O O
person-year NN O O
) NN O O
, NN O O
62 NN O O
( NN O O
55.3 NN O O
per NN O O
100,000 NN O O
person-year NN O O
) NN O O
and NN O O
99 NN O O
( NN O O
33.1 NN O O
per NN O O
100,000 NN O O
person-year NN O O
) NN O O
NPC NN O O
cases NN O O
were NN O O
identified NN O O
. NN O O

The NN O O
early NN O O
diagnositic NN O O
rates NN O O
of NN O O
NPC NN O O
were NN O O
significantly NN O O
higher NN O O
in NN O O
the NN O O
participants NN O O
( NN O O
79.0 NN O O
% NN O O
, NN O O
P NN O O
< NN O O
0.0001 NN O O
) NN O O
and NN O O
the NN O O
screening NN O O
group NN O O
( NN O O
45.9 NN O O
% NN O O
, NN O O
P NN O O
< NN O O
0.0001 NN O O
) NN O O
compared NN O O
with NN O O
the NN O O
control NN O O
group NN O O
( NN O O
20.6 NN O O
% NN O O
) NN O O
. NN O O

Although NN O O
no NN O O
differences NN O O
were NN O O
found NN O O
between NN O O
NPC-specific NN O O
mortality NN O O
of NN O O
the NN O O
screening NN O O
group NN O O
and NN O O
the NN O O
control NN O O
group NN O O
( NN O O
RR NN O O
= NN O O
0.82 NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
0.37- NN O O
1.79 NN O O
) NN O O
, NN O O
lower NN O O
NPC-specific NN O O
mortality NN O O
was NN O O
noticed NN O O
among NN O O
participants NN O O
from NN O O
the NN O O
screening NN O O
group NN O O
vs.the NN O O
control NN O O
group NN O O
( NN O O
RR NN O O
= NN O O
0.22 NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
0.09 NN O O
- NN O O
0.49 NN O O
) NN O O
. NN O O

IgA NN O O
antibodies NN O O
against NN O O
EBV NN O O
can NN O O
identify NN O O
high NN O O
risk NN O O
population NN O O
and NN O O
was NN O O
effective NN O O
in NN O O
screening NN O O
for NN O O
early NN O O
asymptomatic NN O O
NPC NN O O
. NN O O

Although NN O O
the NN O O
mortality NN O O
reduction NN O O
was NN O O
not NN O O
significant NN O O
in NN O O
the NN O O
primary NN O O
endpoint NN O O
, NN O O
we NN O O
noted NN O O
encouraging NN O O
evidence NN O O
of NN O O
a NN O O
mortality NN O O
reduction NN O O
in NN O O
screening NN O O
participants NN O O
in NN O O
this NN O O
interim NN O O
analysis NN O O
. NN O O

NCT00941538 NN O O
. NN O O



-DOCSTART- (30844973)

Clinical NN O O
guidelines NN O O
recommend NN O O
either NN O O
a NN O O
clear-liquid NN O O
diet NN O O
or NN O O
a NN O O
low-fiber NN O O
diet NN O O
for NN O O
colonoscopy NN O O
preparation NN O O
. NN O O

Participants NN O O
in NN O O
a NN O O
screening NN O O
program NN O O
are NN O O
usually NN O O
motivated NN O O
healthy NN O O
individuals NN O O
in NN O O
which NN O O
a NN O O
good NN O O
tolerability NN O O
is NN O O
important NN O O
to NN O O
improve NN O O
adherence NN O O
to NN O O
potential NN O O
surveillance NN O O
colonoscopies NN O O
. NN O O

Our NN O O
aim NN O O
was NN O O
to NN O O
assess NN O O
whether NN O O
or NN O O
not NN O O
a NN O O
normocaloric NN O O
low-fiber NN O O
diet NN O O
followed NN O O
the NN O O
day NN O O
before NN O O
a NN O O
screening NN O O
colonoscopy NN O O
compromises NN O O
the NN O O
efficacy NN O O
of NN O O
bowel NN O O
cleansing NN O O
and NN O O
may NN O O
improve NN O O
the NN O O
tolerability NN O O
of NN O O
bowel NN O O
preparation NN O O
. NN O O

This NN O O
is NN O O
a NN O O
randomized NN O O
, NN O O
endoscopist-blinded NN O O
, NN O O
noninferiority NN O O
clinical NN O O
trial NN O O
. NN O O

The NN O O
study NN O O
was NN O O
conducted NN O O
at NN O O
a NN O O
tertiary NN O O
care NN O O
center NN O O
. NN O O

A NN O O
total NN O O
of NN O O
276 NN O O
consecutive NN O O
participants NN O O
of NN O O
the NN O O
Barcelona NN O O
colorectal NN O O
cancer NN O O
screening NN O O
program NN O O
were NN O O
included NN O O
. NN O O

Participants NN O O
were NN O O
randomly NN O O
assigned NN O O
to NN O O
a NN O O
clear-liquid NN O O
diet NN O O
or NN O O
a NN O O
normocaloric NN O O
low-fiber NN O O
diet NN O O
the NN O O
day NN O O
before NN O O
the NN O O
colonoscopy NN O O
. NN O O

Both NN O O
groups NN O O
received NN O O
4 NN O O
L NN O O
of NN O O
polyethylene NN O O
glycol NN O O
in NN O O
a NN O O
split-dose NN O O
regimen NN O O
. NN O O

Primary NN O O
outcome NN O O
was NN O O
the NN O O
adequate NN O O
bowel NN O O
preparation NN O O
rate NN O O
measured NN O O
with NN O O
the NN O O
Boston NN O O
bowel NN O O
preparation NN O O
scale NN O O
. NN O O

Secondary NN O O
outcomes NN O O
included NN O O
tolerability NN O O
, NN O O
fluid-intake NN O O
perception NN O O
, NN O O
hunger NN O O
, NN O O
side NN O O
effects NN O O
, NN O O
and NN O O
acceptability NN O O
. NN O O

Participants NN O O
in NN O O
both NN O O
groups NN O O
were NN O O
similar NN O O
in NN O O
baseline NN O O
characteristics NN O O
. NN O O

Adequate NN O O
bowel NN O O
preparation NN O O
was NN O O
achieved NN O O
in NN O O
89.1 NN O O
% NN O O
vs NN O O
95.7 NN O O
% NN O O
in NN O O
clear-liquid NN O O
diet NN O O
and NN O O
low-fiber NN O O
diet NN O O
groups NN O O
, NN O O
showing NN O O
not NN O O
only NN O O
noninferiority NN O O
, NN O O
but NN O O
also NN O O
superiority NN O O
( NN O O
p NN O O
= NN O O
0.04 NN O O
) NN O O
. NN O O

Low-fiber NN O O
diet NN O O
participants NN O O
reported NN O O
less NN O O
fluid-intake NN O O
perception NN O O
( NN O O
p NN O O
= NN O O
0.04 NN O O
) NN O O
and NN O O
less NN O O
hunger NN O O
( NN O O
p NN O O
= NN O O
0.006 NN O O
) NN O O
, NN O O
with NN O O
no NN O O
differences NN O O
in NN O O
bloating NN O O
or NN O O
nausea NN O O
. NN O O

The NN O O
single-center NN O O
design NN O O
of NN O O
the NN O O
study NN O O
could NN O O
limit NN O O
the NN O O
external NN O O
validity NN O O
of NN O O
the NN O O
results NN O O
. NN O O

The NN O O
present NN O O
findings NN O O
may NN O O
not NN O O
be NN O O
comparable NN O O
to NN O O
other NN O O
clinical NN O O
settings NN O O
. NN O O

A NN O O
normocaloric NN O O
low-fiber NN O O
diet NN O O
the NN O O
day NN O O
before NN O O
a NN O O
screening NN O O
colonoscopy NN O O
achieved NN O O
better NN O O
results NN O O
than NN O O
a NN O O
clear-liquid NN O O
diet NN O O
in NN O O
terms NN O O
of NN O O
adequate NN O O
colon NN O O
preparation NN O O
. NN O O

Moreover NN O O
, NN O O
it NN O O
also NN O O
improved NN O O
the NN O O
perception NN O O
of NN O O
hunger NN O O
and NN O O
excessive NN O O
fluid NN O O
intake NN O O
. NN O O

Registered NN O O
at NN O O
clinicaltrials.gov NN O O
: NN O O
NCT02401802 NN O O
. NN O O

See NN O O
Video NN O O
Abstract NN O O
at NN O O
http://links.lww.com/DCR/A829 NN O O
. NN O O



-DOCSTART- (30649238)

No NN O O
experimental NN O O
study NN O O
has NN O O
shown NN O O
that NN O O
the NN O O
myocardium NN O O
of NN O O
a NN O O
remotely NN O O
preconditioned NN O O
patient NN O O
is NN O O
more NN O O
resistant NN O O
to NN O O
a NN O O
standardized NN O O
ischaemic/hypoxic NN O O
insult NN O O
. NN O O

This NN O O
was NN O O
a NN O O
single-centre NN O O
randomized NN O O
( NN O O
1:1 NN O O
) NN O O
, NN O O
double-blinded NN O O
, NN O O
sham-controlled NN O O
, NN O O
parallel-group NN O O
study NN O O
. NN O O

Patients NN O O
referred NN O O
for NN O O
elective NN O O
coronary NN O O
bypass NN O O
surgery NN O O
were NN O O
allocated NN O O
to NN O O
either NN O O
remote NN O O
ischaemic NN O O
preconditioning NN O O
( NN O O
3 NN O O
cycles NN O O
of NN O O
5-min NN O O
ischaemia/5-min NN O O
reperfusion NN O O
of NN O O
the NN O O
right NN O O
arm NN O O
using NN O O
a NN O O
blood NN O O
pressure NN O O
cuff NN O O
inflated NN O O
to NN O O
200 NN O O
mmHg NN O O
) NN O O
or NN O O
sham NN O O
intervention NN O O
. NN O O

One NN O O
hundred NN O O
and NN O O
thirty-four NN O O
patients NN O O
were NN O O
recruited NN O O
, NN O O
of NN O O
whom NN O O
10 NN O O
dropped NN O O
out NN O O
, NN O O
and NN O O
4 NN O O
were NN O O
excluded NN O O
from NN O O
the NN O O
per-protocol NN O O
analysis NN O O
. NN O O

The NN O O
right NN O O
atrial NN O O
trabecula NN O O
harvested NN O O
on NN O O
cannulation NN O O
for NN O O
cardiopulmonary NN O O
bypass NN O O
was NN O O
subjected NN O O
to NN O O
60 NN O O
min NN O O
of NN O O
simulated NN O O
ischaemia NN O O
and NN O O
120 NN O O
min NN O O
of NN O O
reoxygenation NN O O
in NN O O
an NN O O
isolated NN O O
organ NN O O
experiment NN O O
. NN O O

Postoperative NN O O
troponin NN O O
T NN O O
release NN O O
and NN O O
haemodynamics NN O O
were NN O O
assessed NN O O
in NN O O
an NN O O
in NN O O
vivo NN O O
study NN O O
. NN O O

The NN O O
atrial NN O O
trabeculae NN O O
obtained NN O O
from NN O O
remotely NN O O
preconditioned NN O O
patients NN O O
recovered NN O O
41.9 NN O O
% NN O O
( NN O O
36.3 NN O O
- NN O O
48.3 NN O O
) NN O O
of NN O O
the NN O O
initial NN O O
contraction NN O O
force NN O O
, NN O O
whereas NN O O
those NN O O
from NN O O
non-preconditioned NN O O
patients NN O O
recovered NN O O
45.9 NN O O
% NN O O
( NN O O
39.1 NN O O
- NN O O
53.7 NN O O
) NN O O
( NN O O
P NN O O
= NN O O
0.399 NN O O
) NN O O
. NN O O

Overall NN O O
, NN O O
the NN O O
content NN O O
of NN O O
cleaved NN O O
poly NN O O
( NN O O
ADP NN O O
ribose NN O O
) NN O O
polymerase NN O O
in NN O O
the NN O O
right NN O O
atrial NN O O
muscle NN O O
increased NN O O
from NN O O
9.4 NN O O
% NN O O
( NN O O
6.0 NN O O
- NN O O
13.5 NN O O
) NN O O
to NN O O
19.1 NN O O
% NN O O
( NN O O
13.2 NN O O
- NN O O
23.8 NN O O
) NN O O
( NN O O
P NN O O
< NN O O
0.001 NN O O
) NN O O
after NN O O
1 NN O O
h NN O O
of NN O O
ischaemia NN O O
and NN O O
2 NN O O
h NN O O
of NN O O
reperfusion NN O O
in NN O O
vitro NN O O
. NN O O

The NN O O
amount NN O O
of NN O O
activated NN O O
Caspase NN O O
3 NN O O
and NN O O
the NN O O
number NN O O
of NN O O
terminal NN O O
deoxynucleotidyl NN O O
transferase NN O O
dUTP NN O O
nick NN O O
end NN O O
labeling-positive NN O O
cells NN O O
also NN O O
significantly NN O O
increased NN O O
. NN O O

No NN O O
difference NN O O
was NN O O
observed NN O O
between NN O O
the NN O O
remotely NN O O
preconditioned NN O O
and NN O O
sham-treated NN O O
myocardium NN O O
. NN O O

In NN O O
the NN O O
in NN O O
vivo NN O O
trial NN O O
, NN O O
the NN O O
area NN O O
under NN O O
the NN O O
curve NN O O
for NN O O
postoperative NN O O
concentration NN O O
of NN O O
troponin NN O O
T NN O O
over NN O O
72 NN O O
h NN O O
was NN O O
16.4 NN O O
ng⋅h/ml NN O O
( NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
14.2 NN O O
- NN O O
18.9 NN O O
) NN O O
for NN O O
the NN O O
remote NN O O
ischaemic NN O O
preconditioning NN O O
and NN O O
15.5 NN O O
ng⋅h/ml NN O O
( NN O O
13.4 NN O O
- NN O O
17.9 NN O O
) NN O O
for NN O O
the NN O O
control NN O O
group NN O O
in NN O O
the NN O O
intention-to-treat NN O O
analysis NN O O
. NN O O

This NN O O
translated NN O O
into NN O O
an NN O O
area NN O O
under NN O O
the NN O O
curve NN O O
ratio NN O O
of NN O O
1.06 NN O O
( NN O O
0.86 NN O O
- NN O O
1.30 NN O O
; NN O O
P NN O O
= NN O O
0.586 NN O O
) NN O O
. NN O O

Remote NN O O
ischaemic NN O O
preconditioning NN O O
with NN O O
3 NN O O
cycles NN O O
of NN O O
5-min NN O O
ischaemia/reperfusion NN O O
of NN O O
the NN O O
upper NN O O
limb NN O O
before NN O O
cardiac NN O O
surgery NN O O
does NN O O
not NN O O
make NN O O
human NN O O
myocardium NN O O
more NN O O
resistant NN O O
to NN O O
ischaemia/reperfusion NN O O
injury NN O O
. NN O O

NCT01994707 NN O O
. NN O O



-DOCSTART- (31182123)

Electronic NN O O
consultation NN O O
( NN O O
eConsult NN O O
) NN O O
services NN O O
are NN O O
secure NN O O
online NN O O
applications NN O O
facilitating NN O O
provider-to-provider NN O O
communication NN O O
. NN O O

They NN O O
have NN O O
been NN O O
found NN O O
to NN O O
improve NN O O
access NN O O
to NN O O
specialist NN O O
care NN O O
. NN O O

However NN O O
, NN O O
little NN O O
is NN O O
known NN O O
about NN O O
eConsult NN O O
's NN O O
impact NN O O
on NN O O
family NN O O
physicians NN O O
' NN O O
referral NN O O
rates NN O O
to NN O O
specialty NN O O
care NN O O
. NN O O

The NN O O
objective NN O O
of NN O O
this NN O O
study NN O O
was NN O O
to NN O O
assess NN O O
the NN O O
impact NN O O
of NN O O
a NN O O
multispecialty NN O O
eConsult NN O O
service NN O O
on NN O O
referral NN O O
rates NN O O
from NN O O
primary NN O O
care NN O O
. NN O O

In NN O O
this NN O O
parallel-arm NN O O
, NN O O
randomized NN O O
controlled NN O O
trial NN O O
, NN O O
we NN O O
recruited NN O O
primary NN O O
care NN O O
providers NN O O
across NN O O
Ontario NN O O
not NN O O
previously NN O O
enrolled NN O O
with NN O O
eConsult NN O O
. NN O O

We NN O O
randomly NN O O
assigned NN O O
participants NN O O
to NN O O
intervention NN O O
and NN O O
control NN O O
arms NN O O
. NN O O

Participants NN O O
in NN O O
the NN O O
intervention NN O O
arm NN O O
received NN O O
access NN O O
to NN O O
eConsult NN O O
for NN O O
a NN O O
period NN O O
of NN O O
1 NN O O
year NN O O
while NN O O
those NN O O
in NN O O
the NN O O
control NN O O
arm NN O O
received NN O O
no NN O O
access NN O O
to NN O O
eConsult NN O O
. NN O O

The NN O O
main NN O O
outcome NN O O
was NN O O
specialist NN O O
referral NN O O
rate NN O O
, NN O O
expressed NN O O
as NN O O
the NN O O
total NN O O
number NN O O
of NN O O
referrals NN O O
to NN O O
( NN O O
1 NN O O
) NN O O
specialties NN O O
available NN O O
through NN O O
eConsult NN O O
, NN O O
and NN O O
( NN O O
2 NN O O
) NN O O
all NN O O
medical NN O O
specialties NN O O
, NN O O
per NN O O
100 NN O O
patients NN O O
seen NN O O
. NN O O

Multivariable NN O O
negative NN O O
binomial NN O O
regression NN O O
analysis NN O O
was NN O O
used NN O O
to NN O O
evaluate NN O O
the NN O O
effect NN O O
of NN O O
the NN O O
intervention NN O O
before NN O O
and NN O O
after NN O O
adjusting NN O O
for NN O O
provider NN O O
characteristics NN O O
, NN O O
using NN O O
health NN O O
administrative NN O O
data NN O O
. NN O O

One NN O O
hundred NN O O
and NN O O
thirteen NN O O
participants NN O O
were NN O O
randomized NN O O
( NN O O
56 NN O O
to NN O O
control NN O O
and NN O O
57 NN O O
to NN O O
intervention NN O O
) NN O O
. NN O O

For NN O O
the NN O O
primary NN O O
outcome NN O O
( NN O O
referrals NN O O
to NN O O
eConsult NN O O
specialties NN O O
) NN O O
, NN O O
the NN O O
results NN O O
show NN O O
a NN O O
statistically NN O O
significant NN O O
reduction NN O O
in NN O O
the NN O O
number NN O O
of NN O O
referrals NN O O
in NN O O
both NN O O
arms NN O O
( NN O O
control-arm NN O O
Rate NN O O
Ratio NN O O
( NN O O
RR NN O O
) NN O O
, NN O O
0.85 NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
0.79 NN O O
to NN O O
0.91 NN O O
; NN O O
intervention-arm NN O O
RR NN O O
, NN O O
0.80 NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
0.74 NN O O
to NN O O
0.85 NN O O
; NN O O
unadjusted NN O O
and NN O O
adjusted NN O O
RR NN O O
values NN O O
almost NN O O
identical NN O O
) NN O O
, NN O O
as NN O O
compared NN O O
to NN O O
the NN O O
baseline NN O O
data NN O O
collected NN O O
during NN O O
the NN O O
12-month NN O O
period NN O O
before NN O O
randomization NN O O
, NN O O
with NN O O
a NN O O
non-statistically NN O O
significant NN O O
6 NN O O
% NN O O
greater NN O O
reduction NN O O
in NN O O
referrals NN O O
in NN O O
the NN O O
intervention NN O O
arm NN O O
, NN O O
compared NN O O
to NN O O
the NN O O
control NN O O
arm NN O O
( NN O O
unadjusted NN O O
RR NN O O
0.94 NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
0.85 NN O O
to NN O O
1.03 NN O O
; NN O O
adjusted NN O O
RR NN O O
0.93 NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
0.85 NN O O
to NN O O
1.03 NN O O
) NN O O
. NN O O

Our NN O O
randomized NN O O
controlled NN O O
trial NN O O
of NN O O
a NN O O
multispecialty NN O O
eConsult NN O O
service NN O O
demonstrated NN O O
inconclusive NN O O
results NN O O
in NN O O
terms NN O O
of NN O O
the NN O O
impact NN O O
of NN O O
eConsult NN O O
on NN O O
physician NN O O
referral NN O O
rates NN O O
. NN O O

Findings NN O O
are NN O O
discussed NN O O
in NN O O
light NN O O
of NN O O
important NN O O
limitations NN O O
associated NN O O
with NN O O
conducting NN O O
randomized NN O O
controlled NN O O
trials NN O O
( NN O O
RCTs NN O O
) NN O O
of NN O O
complex NN O O
interventions NN O O
in NN O O
the NN O O
primary NN O O
care NN O O
context NN O O
with NN O O
intent NN O O
to NN O O
inform NN O O
the NN O O
design NN O O
and NN O O
analysis NN O O
of NN O O
future NN O O
trials NN O O
. NN O O

Clinicaltrials.gov NN O O
, NN O O
ID NN O O
: NN O O
NCT02053467 NN O O
. NN O O

Registered NN O O
prospectively NN O O
on NN O O
3 NN O O
February NN O O
2014 NN O O
. NN O O



-DOCSTART- (30696475)

Older NN O O
adults NN O O
with NN O O
Mild NN O O
Cognitive NN O O
Impairment NN O O
( NN O O
MCI NN O O
) NN O O
are NN O O
at NN O O
high NN O O
risk NN O O
of NN O O
progressing NN O O
to NN O O
Alzheimer NN O O
's NN O O
disease NN O O
( NN O O
AD NN O O
) NN O O
. NN O O

Slowing NN O O
down NN O O
the NN O O
effect NN O O
of NN O O
dementia NN O O
by NN O O
enhancing NN O O
brain NN O O
plasticity NN O O
represents NN O O
one NN O O
of NN O O
the NN O O
most NN O O
prominent NN O O
challenges NN O O
. NN O O

Neurofeedback NN O O
( NN O O
NF NN O O
) NN O O
has NN O O
shown NN O O
promising NN O O
results NN O O
in NN O O
improving NN O O
working NN O O
memory NN O O
but NN O O
has NN O O
never NN O O
been NN O O
evaluated NN O O
in NN O O
people NN O O
with NN O O
MCI NN O O
. NN O O

We NN O O
aim NN O O
to NN O O
examine NN O O
whether NN O O
NF NN O O
training NN O O
can NN O O
decrease NN O O
cognitive NN O O
disorders NN O O
, NN O O
targeting NN O O
memory NN O O
, NN O O
attention NN O O
functions NN O O
and NN O O
brain NN O O
electrical NN O O
activity NN O O
in NN O O
elderly NN O O
patients NN O O
with NN O O
MCI NN O O
. NN O O

In NN O O
this NN O O
single-blind NN O O
, NN O O
randomized NN O O
controlled NN O O
trial NN O O
( NN O O
RCT NN O O
) NN O O
protocol NN O O
, NN O O
we NN O O
will NN O O
investigate NN O O
the NN O O
effects NN O O
of NN O O
two NN O O
NF NN O O
training NN O O
protocols NN O O
on NN O O
cognitive NN O O
performances NN O O
and NN O O
on NN O O
brain NN O O
electrical NN O O
activity NN O O
. NN O O

Sixty NN O O
MCI NN O O
patients NN O O
will NN O O
be NN O O
assigned NN O O
either NN O O
to NN O O
an NN O O
intervention NN O O
program NN O O
or NN O O
to NN O O
psycho-pedagogical NN O O
care NN O O
as NN O O
a NN O O
control NN O O
condition NN O O
. NN O O

Participants NN O O
in NN O O
the NN O O
intervention NN O O
group NN O O
will NN O O
attend NN O O
30 NN O O
sessions NN O O
of NN O O
sensorimotor/delta-ratio NN O O
NF NN O O
training NN O O
or NN O O
beta1/theta-ratio NN O O
NF NN O O
training NN O O
. NN O O

Neuropsychological NN O O
assessment NN O O
, NN O O
questionnaires NN O O
and NN O O
electroencephalography NN O O
( NN O O
EEG NN O O
) NN O O
assessment NN O O
parameters NN O O
will NN O O
be NN O O
used NN O O
as NN O O
dependent NN O O
variables NN O O
in NN O O
three NN O O
periods NN O O
: NN O O
at NN O O
baseline NN O O
( NN O O
T0 NN O O
) NN O O
, NN O O
immediately NN O O
after NN O O
the NN O O
last NN O O
NF NN O O
training NN O O
session NN O O
at NN O O
4 NN O O
months NN O O
( NN O O
T1 NN O O
) NN O O
and NN O O
at NN O O
3-month NN O O
follow-up NN O O
( NN O O
T2 NN O O
) NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
will NN O O
be NN O O
the NN O O
change NN O O
in NN O O
attention NN O O
measured NN O O
with NN O O
the NN O O
Trail NN O O
Making NN O O
Test NN O O
B. NN O O
Secondary NN O O
outcome NN O O
will NN O O
be NN O O
the NN O O
changes NN O O
in NN O O
cognitive NN O O
performance NN O O
and NN O O
in NN O O
EEG NN O O
activities NN O O
. NN O O

If NN O O
the NN O O
results NN O O
of NN O O
our NN O O
study NN O O
show NN O O
improvement NN O O
in NN O O
cognitive NN O O
performances NN O O
of NN O O
older NN O O
adults NN O O
with NN O O
MCI NN O O
, NN O O
this NN O O
non-invasive NN O O
, NN O O
low-cost NN O O
technique NN O O
may NN O O
deserve NN O O
better NN O O
consideration NN O O
as NN O O
a NN O O
therapeutic NN O O
intervention NN O O
to NN O O
delay NN O O
cognitive NN O O
decline NN O O
and NN O O
dementia NN O O
. NN O O

Consequently NN O O
, NN O O
research NN O O
in NN O O
NF NN O O
will NN O O
need NN O O
to NN O O
review NN O O
and NN O O
develop NN O O
the NN O O
rigor NN O O
of NN O O
its NN O O
application NN O O
in NN O O
gerontology NN O O
. NN O O

ClinicalTrials.gov NN O O
, NN O O
ID NN O O
: NN O O
NCT03526692 NN O O
. NN O O

Registered NN O O
on NN O O
16 NN O O
May NN O O
2018 NN O O
. NN O O



-DOCSTART- (30531234)

To NN O O
investigate NN O O
the NN O O
safety NN O O
and NN O O
efficacy NN O O
of NN O O
lofexidine NN O O
for NN O O
treating NN O O
opioid NN O O
withdrawal NN O O
syndrome NN O O
( NN O O
OWS NN O O
) NN O O
and NN O O
facilitating NN O O
completion NN O O
of NN O O
opioid NN O O
withdrawal NN O O
. NN O O

A NN O O
multicenter NN O O
, NN O O
double-blind NN O O
, NN O O
placebo-controlled NN O O
study NN O O
was NN O O
conducted NN O O
at NN O O
18 NN O O
US NN O O
centers NN O O
from NN O O
June NN O O
2013 NN O O
to NN O O
December NN O O
2014 NN O O
. NN O O

Participants NN O O
( NN O O
n NN O O
= NN O O
603 NN O O
) NN O O
aged NN O O
≥18 NN O O
years NN O O
, NN O O
dependent NN O O
on NN O O
short-acting NN O O
opioids NN O O
, NN O O
and NN O O
seeking NN O O
withdrawal NN O O
treatment NN O O
, NN O O
randomized NN O O
3:3:2 NN O O
to NN O O
receive NN O O
lofexidine NN O O
2.88 NN O O
mg/d NN O O
( NN O O
n NN O O
= NN O O
222 NN O O
) NN O O
, NN O O
lofexidine NN O O
2.16 NN O O
mg/d NN O O
( NN O O
n NN O O
= NN O O
230 NN O O
) NN O O
, NN O O
or NN O O
placebo NN O O
( NN O O
n NN O O
= NN O O
151 NN O O
) NN O O
for NN O O
7 NN O O
days NN O O
. NN O O

Primary NN O O
outcome NN O O
was NN O O
the NN O O
Short NN O O
Opiate NN O O
Withdrawal NN O O
Scale NN O O
of NN O O
Gossop NN O O
( NN O O
SOWS-Gossop NN O O
) NN O O
scores NN O O
rating NN O O
withdrawal NN O O
symptoms NN O O
over NN O O
days NN O O
1 NN O O
to NN O O
7 NN O O
. NN O O

Participants NN O O
were NN O O
of NN O O
mean NN O O
age NN O O
, NN O O
35 NN O O
years NN O O
; NN O O
71 NN O O
% NN O O
male NN O O
. NN O O

Pairwise NN O O
differences NN O O
in NN O O
overall NN O O
SOWS-Gossop NN O O
log-transformed NN O O
least NN O O
squares NN O O
means NN O O
were NN O O
statistically NN O O
significant NN O O
for NN O O
lofexidine NN O O
2.16 NN O O
mg NN O O
( NN O O
difference NN O O
, NN O O
-0.21 NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
-0.37 NN O O
to NN O O
-0.04 NN O O
; NN O O
P NN O O
= NN O O
0.02 NN O O
) NN O O
and NN O O
2.88 NN O O
mg NN O O
( NN O O
-0.26 NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
-0.44 NN O O
to NN O O
-0.09 NN O O
; NN O O
P NN O O
= NN O O
0.003 NN O O
) NN O O
compared NN O O
with NN O O
placebo NN O O
. NN O O

Fewer NN O O
than NN O O
half NN O O
of NN O O
participants NN O O
in NN O O
both NN O O
groups NN O O
completed NN O O
the NN O O
study NN O O
. NN O O

Completion NN O O
rates NN O O
for NN O O
lofexidine NN O O
2.16 NN O O
mg NN O O
( NN O O
41.5 NN O O
% NN O O
; NN O O
odds NN O O
ratio NN O O
[ NN O O
OR NN O O
] NN O O
, NN O O
1.85 NN O O
; NN O O
P NN O O
= NN O O
0.007 NN O O
) NN O O
and NN O O
2.88 NN O O
mg NN O O
( NN O O
39.6 NN O O
% NN O O
; NN O O
OR NN O O
, NN O O
1.71 NN O O
; NN O O
P NN O O
= NN O O
0.02 NN O O
) NN O O
were NN O O
significantly NN O O
better NN O O
compared NN O O
with NN O O
placebo NN O O
( NN O O
27.8 NN O O
% NN O O
) NN O O
. NN O O

Overall NN O O
adverse NN O O
event NN O O
( NN O O
AE NN O O
) NN O O
rates NN O O
were NN O O
similar NN O O
across NN O O
groups NN O O
. NN O O

Common NN O O
AEs NN O O
for NN O O
lofexidine NN O O
included NN O O
orthostatic NN O O
hypotension NN O O
, NN O O
hypotension NN O O
, NN O O
and NN O O
bradycardia NN O O
, NN O O
but NN O O
resulted NN O O
in NN O O
few NN O O
study NN O O
discontinuations NN O O
. NN O O

Lofexidine NN O O
2.16 NN O O
mg NN O O
and NN O O
2.88 NN O O
mg NN O O
significantly NN O O
reduced NN O O
symptoms NN O O
of NN O O
OWS NN O O
versus NN O O
placebo NN O O
, NN O O
and NN O O
increased NN O O
absolute NN O O
rates NN O O
of NN O O
completing NN O O
the NN O O
7-day NN O O
study NN O O
by NN O O
14 NN O O
% NN O O
and NN O O
12 NN O O
% NN O O
, NN O O
respectively NN O O
( NN O O
a NN O O
relative NN O O
increase NN O O
of NN O O
85 NN O O
% NN O O
and NN O O
71 NN O O
% NN O O
) NN O O
. NN O O

Data NN O O
suggest NN O O
that NN O O
lofexidine NN O O
is NN O O
a NN O O
generally NN O O
safe NN O O
and NN O O
effective NN O O
nonopioid NN O O
treatment NN O O
for NN O O
opioid NN O O
withdrawal NN O O
. NN O O

Lofexidine NN O O
could NN O O
serve NN O O
as NN O O
a NN O O
withdrawal NN O O
treatment NN O O
option NN O O
when NN O O
a NN O O
nonopioid NN O O
agent NN O O
is NN O O
preferred NN O O
or NN O O
required NN O O
, NN O O
when NN O O
agonist-assisted NN O O
withdrawal NN O O
is NN O O
unavailable NN O O
, NN O O
when NN O O
agonist NN O O
discontinuation NN O O
caused NN O O
OWS NN O O
, NN O O
and NN O O
during NN O O
induction NN O O
into NN O O
maintenance NN O O
treatment NN O O
with NN O O
opioid NN O O
agonists NN O O
or NN O O
antagonists NN O O
. NN O O

ClinicalTrials.gov NN O O
identifier NN O O
: NN O O
NCT01863186 NN O O
. NN O O



-DOCSTART- (30526440)

Autologous NN O O
blood NN O O
is NN O O
a NN O O
novel NN O O
, NN O O
high-efficacy NN O O
sclerosant NN O O
for NN O O
treatment NN O O
of NN O O
malignant NN O O
pleural NN O O
effusion NN O O
( NN O O
MPE NN O O
) NN O O
, NN O O
similar NN O O
to NN O O
tetracycline NN O O
. NN O O

There NN O O
has NN O O
been NN O O
no NN O O
comparative NN O O
data NN O O
between NN O O
autologous NN O O
blood NN O O
and NN O O
a NN O O
worldwide NN O O
sclerosant NN O O
like NN O O
talc NN O O
. NN O O

We NN O O
aimed NN O O
to NN O O
compare NN O O
the NN O O
effectiveness NN O O
of NN O O
autologous NN O O
blood NN O O
versus NN O O
talc NN O O
pleurodesis NN O O
. NN O O

A NN O O
prospective NN O O
study NN O O
was NN O O
conducted NN O O
at NN O O
Songklanagarind NN O O
Hospital NN O O
, NN O O
Songkhla NN O O
, NN O O
Thailand NN O O
. NN O O

A NN O O
total NN O O
of NN O O
123 NN O O
symptomatic NN O O
MPE NN O O
cases NN O O
were NN O O
randomized NN O O
to NN O O
receive NN O O
autologous NN O O
blood NN O O
pleurodesis NN O O
( NN O O
ABP NN O O
) NN O O
versus NN O O
pleurodesis NN O O
with NN O O
talc NN O O
slurry NN O O
. NN O O

In NN O O
the NN O O
ABP NN O O
group NN O O
, NN O O
100 NN O O
ml NN O O
of NN O O
autologous NN O O
venous NN O O
blood NN O O
was NN O O
instilled NN O O
through NN O O
a NN O O
chest NN O O
drain NN O O
, NN O O
followed NN O O
by NN O O
50 NN O O
ml NN O O
of NN O O
sterile NN O O
normal NN O O
saline NN O O
( NN O O
NSS NN O O
) NN O O
. NN O O

In NN O O
the NN O O
talc NN O O
group NN O O
, NN O O
20 NN O O
ml NN O O
of NN O O
1 NN O O
% NN O O
lidocaine NN O O
diluted NN O O
in NN O O
30 NN O O
ml NN O O
NSS NN O O
was NN O O
instilled NN O O
, NN O O
followed NN O O
by NN O O
4 NN O O
g NN O O
of NN O O
sterile NN O O
talc NN O O
( NN O O
Steritalc NN O O
® NN O O
, NN O O
a NN O O
non-small NN O O
particle NN O O
size NN O O
talc NN O O
) NN O O
suspended NN O O
in NN O O
100 NN O O
ml NN O O
of NN O O
NSS NN O O
. NN O O

A NN O O
30-day NN O O
pleurodesis NN O O
efficacy NN O O
( NN O O
according NN O O
to NN O O
Paladine NN O O
's NN O O
criteria NN O O
) NN O O
, NN O O
along NN O O
with NN O O
the NN O O
adverse NN O O
events NN O O
, NN O O
was NN O O
evaluated NN O O
. NN O O

Fifty-six NN O O
cases NN O O
in NN O O
the NN O O
ABP NN O O
, NN O O
and NN O O
54 NN O O
cases NN O O
in NN O O
the NN O O
talc NN O O
group NN O O
completed NN O O
the NN O O
study NN O O
. NN O O

There NN O O
was NN O O
no NN O O
difference NN O O
between NN O O
the NN O O
two NN O O
groups NN O O
in NN O O
the NN O O
demographic NN O O
data NN O O
. NN O O

The NN O O
overall NN O O
pleurodesis NN O O
success NN O O
rate NN O O
at NN O O
30 NN O O
days NN O O
was NN O O
82.0 NN O O
% NN O O
in NN O O
the NN O O
ABP NN O O
group NN O O
, NN O O
comparable NN O O
to NN O O
the NN O O
talc NN O O
pleurodesis NN O O
group NN O O
( NN O O
87.0 NN O O
% NN O O
, NN O O
p NN O O
= NN O O
0.12 NN O O
) NN O O
. NN O O

The NN O O
percentage NN O O
of NN O O
fever NN O O
( NN O O
9.0 NN O O
% NN O O
versus NN O O
28.0 NN O O
% NN O O
, NN O O
p NN O O
= NN O O
0.04 NN O O
) NN O O
, NN O O
amount NN O O
of NN O O
acetaminophen NN O O
required NN O O
by NN O O
each NN O O
participant NN O O
( NN O O
2.2 NN O O
± NN O O
0.7 NN O O
versus NN O O
4.6 NN O O
± NN O O
0.9 NN O O
tablets NN O O
, NN O O
p NN O O
= NN O O
0.03 NN O O
) NN O O
, NN O O
pain NN O O
score NN O O
and NN O O
percentage NN O O
of NN O O
cases NN O O
who NN O O
needed NN O O
opioids NN O O
( NN O O
9.0 NN O O
% NN O O
versus NN O O
26.0 NN O O
% NN O O
, NN O O
p NN O O
= NN O O
0.02 NN O O
) NN O O
and NN O O
hospital NN O O
stay NN O O
( NN O O
10.2 NN O O
± NN O O
2.7 NN O O
versus NN O O
12.8 NN O O
± NN O O
3.4 NN O O
, NN O O
p NN O O
= NN O O
0.04 NN O O
) NN O O
were NN O O
significantly NN O O
lower NN O O
in NN O O
the NN O O
ABP NN O O
group NN O O
; NN O O
no NN O O
infectious NN O O
or NN O O
serious NN O O
events NN O O
occurred NN O O
. NN O O

ABP NN O O
had NN O O
an NN O O
equivalent NN O O
efficacy NN O O
compared NN O O
to NN O O
talc NN O O
pleurodesis NN O O
for NN O O
MPE NN O O
treatment NN O O
. NN O O

ABP NN O O
offered NN O O
less NN O O
fever NN O O
and NN O O
pain NN O O
and NN O O
could NN O O
shorten NN O O
hospital NN O O
stays NN O O
, NN O O
and NN O O
neither NN O O
produced NN O O
means NN O O
ABP NN O O
did NN O O
not NN O O
produce NN O O
clotted NN O O
drainage NN O O
, NN O O
pulmonary NN O O
or NN O O
systemic NN O O
adverse NN O O
events NN O O
. NN O O



-DOCSTART- (30552064)

In NN O O
winter NN O O
in NN O O
Mongolia NN O O
, NN O O
80 NN O O
% NN O O
of NN O O
adults NN O O
have NN O O
25-hydroxyvitamin NN O O
D NN O O
( NN O O
25(OH)D NN O O
) NN O O
concentrations NN O O
< NN O O
25 NN O O
nmol/l NN O O
( NN O O
< NN O O
10 NN O O
ng/ml NN O O
) NN O O
and NN O O
99 NN O O
% NN O O
have NN O O
< NN O O
50 NN O O
nmol/l NN O O
( NN O O
< NN O O
20 NN O O
ng/ml NN O O
) NN O O
. NN O O

The NN O O
vitamin NN O O
D NN O O
dose NN O O
to NN O O
avert NN O O
deficiency NN O O
during NN O O
pregnancy NN O O
in NN O O
this NN O O
population NN O O
is NN O O
unknown NN O O
. NN O O

We NN O O
conducted NN O O
a NN O O
randomized NN O O
, NN O O
controlled NN O O
, NN O O
double-blind NN O O
trial NN O O
of NN O O
daily NN O O
600 NN O O
, NN O O
2000 NN O O
, NN O O
or NN O O
4000 NN O O
IU NN O O
vitamin NN O O
D NN O O
for NN O O
pregnant NN O O
women NN O O
in NN O O
Mongolia NN O O
( NN O O
Clinicaltrials.gov NN O O
# NN O O
NCT02395081 NN O O
) NN O O
. NN O O

We NN O O
examined NN O O
25(OH)D NN O O
concentrations NN O O
at NN O O
baseline NN O O
( NN O O
12 NN O O
- NN O O
16 NN O O
weeks NN O O
' NN O O
gestation NN O O
) NN O O
, NN O O
36 NN O O
- NN O O
40 NN O O
weeks NN O O
' NN O O
gestation NN O O
and NN O O
in NN O O
umbilical NN O O
cord NN O O
blood NN O O
, NN O O
using NN O O
enzyme NN O O
linked NN O O
fluorescent NN O O
assay NN O O
. NN O O

Sample NN O O
size NN O O
was NN O O
determined NN O O
to NN O O
detect NN O O
0.4 NN O O
standard NN O O
deviation NN O O
differences NN O O
in NN O O
25(OH)D NN O O
concentrations NN O O
with NN O O
80 NN O O
% NN O O
power NN O O
. NN O O

119 NN O O
pregnant NN O O
women NN O O
were NN O O
assigned NN O O
600 NN O O
IU NN O O
, NN O O
121 NN O O
assigned NN O O
2000 NN O O
IU NN O O
and NN O O
120 NN O O
assigned NN O O
4000 NN O O
IU NN O O
from NN O O
February NN O O
2015 NN O O
through NN O O
December NN O O
2016 NN O O
. NN O O

Eighty-eight NN O O
percent NN O O
of NN O O
participants NN O O
took NN O O
≥80 NN O O
% NN O O
of NN O O
assigned NN O O
supplements NN O O
. NN O O

At NN O O
baseline NN O O
, NN O O
25(OH)D NN O O
concentrations NN O O
were NN O O
similar NN O O
across NN O O
arms NN O O
; NN O O
overall NN O O
mean NN O O
± NN O O
standard NN O O
deviation NN O O
concentration NN O O
was NN O O
19 NN O O
± NN O O
22 NN O O
nmol/l NN O O
; NN O O
91 NN O O
% NN O O
were NN O O
< NN O O
50 NN O O
nmol/l NN O O
. NN O O

At NN O O
36 NN O O
- NN O O
40 NN O O
weeks NN O O
, NN O O
25(OH)D NN O O
concentrations NN O O
increased NN O O
to NN O O
46 NN O O
± NN O O
21 NN O O
, NN O O
70 NN O O
± NN O O
23 NN O O
, NN O O
and NN O O
81 NN O O
± NN O O
29 NN O O
nmol/l NN O O
for NN O O
women NN O O
assigned NN O O
600 NN O O
, NN O O
2000 NN O O
, NN O O
and NN O O
4000 NN O O
IU NN O O
, NN O O
respectively NN O O
( NN O O
p NN O O
< NN O O
0.0001 NN O O
across NN O O
arms NN O O
; NN O O
p NN O O
= NN O O
0.002 NN O O
for NN O O
2000 NN O O
vs. NN O O
4000 NN O O
IU NN O O
) NN O O
. NN O O

Mean NN O O
umbilical NN O O
cord NN O O
25(OH)D NN O O
concentrations NN O O
differed NN O O
by NN O O
study NN O O
arm NN O O
( NN O O
p NN O O
< NN O O
0.0001 NN O O
across NN O O
arms NN O O
; NN O O
p NN O O
< NN O O
0.0001 NN O O
for NN O O
2000 NN O O
vs. NN O O
4000 NN O O
IU NN O O
) NN O O
and NN O O
were NN O O
proportional NN O O
to NN O O
maternal NN O O
concentrations NN O O
. NN O O

There NN O O
were NN O O
no NN O O
adverse NN O O
events NN O O
, NN O O
including NN O O
hypercalcemia NN O O
, NN O O
attributable NN O O
to NN O O
vitamin NN O O
D NN O O
supplementation NN O O
. NN O O

Daily NN O O
supplementation NN O O
of NN O O
4000 NN O O
IU NN O O
during NN O O
pregnancy NN O O
is NN O O
safe NN O O
and NN O O
achieved NN O O
higher NN O O
maternal NN O O
and NN O O
neonatal NN O O
25(OH)D NN O O
concentrations NN O O
than NN O O
2000 NN O O
IU NN O O
. NN O O

Daily NN O O
600 NN O O
IU NN O O
supplements NN O O
are NN O O
insufficient NN O O
to NN O O
prevent NN O O
vitamin NN O O
D NN O O
deficiency NN O O
in NN O O
Mongolia NN O O
. NN O O

FUND NN O O
: NN O O
Anonymous NN O O
foundation NN O O
and NN O O
Brigham NN O O
and NN O O
Women NN O O
's NN O O
Hospital NN O O
. NN O O



-DOCSTART- (30626409)

Major NN O O
depressive NN O O
disorder NN O O
( NN O O
MDD NN O O
) NN O O
is NN O O
a NN O O
prevalent NN O O
and NN O O
disabling NN O O
disorder NN O O
that NN O O
can NN O O
lead NN O O
to NN O O
heavy NN O O
individual NN O O
, NN O O
familial NN O O
, NN O O
and NN O O
societal NN O O
burdens NN O O
. NN O O

Although NN O O
pharmaceutical NN O O
interventions NN O O
still NN O O
play NN O O
an NN O O
essential NN O O
role NN O O
in NN O O
therapeutic NN O O
measures NN O O
, NN O O
limitations NN O O
, NN O O
including NN O O
effects NN O O
that NN O O
are NN O O
delayed NN O O
for NN O O
weeks NN O O
, NN O O
are NN O O
noteworthy NN O O
. NN O O

Antidepressants NN O O
with NN O O
rapid NN O O
efficacy NN O O
and NN O O
acceptable NN O O
tolerance NN O O
have NN O O
been NN O O
investigated NN O O
for NN O O
many NN O O
years NN O O
; NN O O
rapid NN O O
antidepressant NN O O
effects NN O O
and NN O O
promising NN O O
clinical NN O O
applications NN O O
have NN O O
been NN O O
obtained NN O O
with NN O O
intravenous NN O O
and NN O O
oral NN O O
scopolamine NN O O
. NN O O

This NN O O
study NN O O
aims NN O O
to NN O O
evaluate NN O O
the NN O O
efficacy NN O O
of NN O O
repeated NN O O
intramuscular NN O O
scopolamine NN O O
as NN O O
an NN O O
add-on NN O O
treatment NN O O
to NN O O
escitalopram NN O O
. NN O O

This NN O O
is NN O O
a NN O O
single-center NN O O
, NN O O
saline-controlled NN O O
, NN O O
double-blind NN O O
, NN O O
three-armed NN O O
, NN O O
randomized NN O O
trial NN O O
. NN O O

Sixty-six NN O O
participants NN O O
diagnosed NN O O
with NN O O
MDD NN O O
will NN O O
be NN O O
recruited NN O O
at NN O O
Beijing NN O O
Anding NN O O
Hospital NN O O
and NN O O
randomly NN O O
assigned NN O O
to NN O O
one NN O O
of NN O O
three NN O O
groups NN O O
: NN O O
a NN O O
high-dose NN O O
intramuscular NN O O
scopolamine NN O O
augmentation NN O O
group NN O O
; NN O O
a NN O O
low-dose NN O O
intramuscular NN O O
scopolamine NN O O
augmentation NN O O
group NN O O
; NN O O
and NN O O
a NN O O
placebo NN O O
control NN O O
group NN O O
. NN O O

Our NN O O
primary NN O O
endpoint NN O O
is NN O O
improvement NN O O
in NN O O
the NN O O
17-Item NN O O
Hamilton NN O O
Rating NN O O
Scale NN O O
for NN O O
Depression NN O O
( NN O O
HRSD17 NN O O
) NN O O
score NN O O
from NN O O
the NN O O
baseline NN O O
( NN O O
at NN O O
least NN O O
a NN O O
20 NN O O
% NN O O
reduction NN O O
) NN O O
. NN O O

Prespecified NN O O
secondary NN O O
endpoints NN O O
include NN O O
response NN O O
rates NN O O
and NN O O
remission NN O O
rates NN O O
as NN O O
well NN O O
as NN O O
changes NN O O
in NN O O
the NN O O
total NN O O
or NN O O
subscale NN O O
scores NN O O
between NN O O
the NN O O
baseline NN O O
and NN O O
week NN O O
4 NN O O
. NN O O

This NN O O
study NN O O
will NN O O
provide NN O O
the NN O O
first NN O O
insight NN O O
regarding NN O O
the NN O O
rapid NN O O
antidepressant NN O O
efficacy NN O O
and NN O O
tolerability NN O O
of NN O O
an NN O O
intramuscular NN O O
scopolamine NN O O
add-on NN O O
to NN O O
the NN O O
usual NN O O
treatment NN O O
in NN O O
Chinese NN O O
MDD NN O O
patients NN O O
. NN O O

The NN O O
first NN O O
discussion NN O O
concerns NN O O
whether NN O O
augmentation NN O O
can NN O O
accelerate NN O O
early NN O O
antidepressant NN O O
efficacy NN O O
. NN O O

A NN O O
pilot NN O O
study NN O O
of NN O O
intramuscular NN O O
scopolamine NN O O
is NN O O
performed NN O O
. NN O O

The NN O O
limitations NN O O
of NN O O
this NN O O
study NN O O
include NN O O
its NN O O
small NN O O
sample NN O O
size NN O O
and NN O O
it NN O O
being NN O O
a NN O O
single-center NN O O
study NN O O
, NN O O
suggesting NN O O
the NN O O
need NN O O
for NN O O
further NN O O
confirmation NN O O
with NN O O
trials NN O O
enrolling NN O O
larger NN O O
populations NN O O
. NN O O

The NN O O
study NN O O
protocol NN O O
and NN O O
all NN O O
related NN O O
materials NN O O
have NN O O
been NN O O
approved NN O O
by NN O O
the NN O O
Institutional NN O O
Ethics NN O O
Committee NN O O
of NN O O
the NN O O
Beijing NN O O
Anding NN O O
Hospital NN O O
( NN O O
No. NN O O
2016 NN O O
- NN O O
106 NN O O
, NN O O
Beijing NN O O
, NN O O
China NN O O
) NN O O
. NN O O

The NN O O
findings NN O O
will NN O O
be NN O O
disseminated NN O O
through NN O O
peer-reviewed NN O O
journals NN O O
and NN O O
at NN O O
national NN O O
and NN O O
international NN O O
conferences NN O O
. NN O O

ClinicalTrials.gov NN O O
, NN O O
NCT03131050 NN O O
. NN O O

Registered NN O O
on NN O O
18 NN O O
April NN O O
2017 NN O O
. NN O O



-DOCSTART- (30680617)

Lack NN O O
of NN O O
physical NN O O
activity NN O O
( NN O O
PA NN O O
) NN O O
, NN O O
weight NN O O
gain NN O O
, NN O O
and NN O O
overweight NN O O
have NN O O
been NN O O
associated NN O O
with NN O O
increased NN O O
risk NN O O
of NN O O
recurrence NN O O
and NN O O
mortality NN O O
after NN O O
breast NN O O
cancer NN O O
diagnosis NN O O
. NN O O

We NN O O
evaluated NN O O
the NN O O
feasibility NN O O
of NN O O
implementing NN O O
an NN O O
individualized NN O O
exercise NN O O
program NN O O
and NN O O
nutritional NN O O
counseling NN O O
during NN O O
adjuvant NN O O
treatment NN O O
of NN O O
localized NN O O
invasive NN O O
breast NN O O
cancer NN O O
. NN O O

Sixty-one NN O O
patients NN O O
eligible NN O O
for NN O O
adjuvant NN O O
chemotherapy NN O O
were NN O O
randomized NN O O
2:1 NN O O
to NN O O
receive NN O O
a NN O O
6-month NN O O
program NN O O
of NN O O
weekly NN O O
aerobic NN O O
exercises NN O O
associated NN O O
with NN O O
nutritional NN O O
counseling NN O O
( NN O O
n NN O O
= NN O O
41 NN O O
) NN O O
or NN O O
usual NN O O
care NN O O
with NN O O
nutritional NN O O
counseling NN O O
( NN O O
n NN O O
= NN O O
20 NN O O
, NN O O
one NN O O
withdrawal NN O O
) NN O O
. NN O O

The NN O O
primary NN O O
endpoints NN O O
were NN O O
the NN O O
proportion NN O O
of NN O O
patients NN O O
compliant NN O O
with NN O O
two NN O O
weekly NN O O
supervised NN O O
sessions NN O O
and NN O O
their NN O O
overall NN O O
adherence NN O O
( NN O O
i.e. NN O O
, NN O O
proportion NN O O
of NN O O
supervised NN O O
and NN O O
unsupervised NN O O
sessions NN O O
completed NN O O
versus NN O O
planned NN O O
sessions NN O O
) NN O O
. NN O O

Ten NN O O
percent NN O O
of NN O O
patients NN O O
in NN O O
the NN O O
intervention NN O O
group NN O O
were NN O O
compliant NN O O
with NN O O
the NN O O
two NN O O
weekly NN O O
supervised NN O O
sessions NN O O
for NN O O
6 NN O O
months NN O O
, NN O O
but NN O O
the NN O O
overall NN O O
median NN O O
adherence NN O O
rate NN O O
was NN O O
85 NN O O
% NN O O
of NN O O
supervised NN O O
and NN O O
non-supervised NN O O
sessions NN O O
completed NN O O
. NN O O

Non-adherence NN O O
was NN O O
mainly NN O O
due NN O O
to NN O O
intrinsic NN O O
reasons NN O O
( NN O O
medical NN O O
, NN O O
organizational NN O O
, NN O O
psychological NN O O
barriers NN O O
) NN O O
. NN O O

Adherence NN O O
was NN O O
positively NN O O
associated NN O O
with NN O O
education NN O O
and NN O O
baseline NN O O
PA NN O O
level NN O O
and NN O O
inversely NN O O
associated NN O O
with NN O O
baseline NN O O
weight NN O O
and NN O O
tumor NN O O
grade NN O O
. NN O O

No NN O O
statistically NN O O
significant NN O O
benefits NN O O
were NN O O
observed NN O O
in NN O O
the NN O O
intervention NN O O
group NN O O
, NN O O
even NN O O
if NN O O
overall NN O O
PA NN O O
level NN O O
and NN O O
body NN O O
composition NN O O
improved NN O O
and NN O O
anthropometrics NN O O
were NN O O
maintained NN O O
over NN O O
time NN O O
( NN O O
p NN O O
< NN O O
0.05 NN O O
) NN O O
. NN O O

Overall NN O O
, NN O O
there NN O O
was NN O O
good NN O O
adherence NN O O
with NN O O
the NN O O
6-month NN O O
exercise NN O O
program NN O O
during NN O O
adjuvant NN O O
treatment NN O O
for NN O O
breast NN O O
cancer NN O O
, NN O O
despite NN O O
poor NN O O
compliance NN O O
to NN O O
twice-weekly NN O O
supervised NN O O
sessions NN O O
. NN O O

This NN O O
study NN O O
highlights NN O O
the NN O O
need NN O O
for NN O O
flexible NN O O
exercise NN O O
modalities NN O O
and NN O O
innovative NN O O
experimental NN O O
design NN O O
to NN O O
reach NN O O
patients NN O O
who NN O O
would NN O O
most NN O O
adhere NN O O
and NN O O
benefit NN O O
from NN O O
intervention NN O O
. NN O O

ClinicalTrials.gov NN O O
Identifier NN O O
: NN O O
NCT01331772 NN O O
. NN O O

Registered NN O O
8 NN O O
April NN O O
2011 NN O O
, NN O O
https://clinicaltrials.gov/ct2/show/NCT01331772?term=pasapas&rank=1 NN O O
. NN O O



-DOCSTART- (30851623)

Research NN O O
highlights NN O O
the NN O O
detrimental NN O O
effects NN O O
of NN O O
obesity NN O O
on NN O O
gait NN O O
biomechanics NN O O
and NN O O
the NN O O
accompanied NN O O
risk NN O O
of NN O O
lower-extremity NN O O
skeletal NN O O
malalignments NN O O
, NN O O
increased NN O O
joint NN O O
stress NN O O
, NN O O
pain NN O O
and NN O O
discomfort NN O O
. NN O O

Individuals NN O O
with NN O O
obesity NN O O
typically NN O O
show NN O O
increased NN O O
knee NN O O
valgus NN O O
angles NN O O
combined NN O O
with NN O O
an NN O O
increased NN O O
step NN O O
width NN O O
. NN O O

Accompanying NN O O
muscular NN O O
dysfunctions NN O O
impede NN O O
their NN O O
ability NN O O
to NN O O
compensate NN O O
for NN O O
these NN O O
alterations NN O O
, NN O O
especially NN O O
in NN O O
the NN O O
frontal NN O O
plane NN O O
. NN O O

To NN O O
date NN O O
, NN O O
no NN O O
studies NN O O
are NN O O
available NN O O
, NN O O
which NN O O
evaluated NN O O
the NN O O
potential NN O O
effects NN O O
of NN O O
an NN O O
exercise NN O O
program NN O O
( NN O O
EP NN O O
) NN O O
in NN O O
reducing NN O O
these NN O O
unfavorable NN O O
biomechanical NN O O
changes NN O O
. NN O O

Is NN O O
a NN O O
12-week NN O O
EP NN O O
, NN O O
which NN O O
includes NN O O
hip NN O O
abductor NN O O
and NN O O
knee NN O O
extensor NN O O
strength NN O O
exercises NN O O
and NN O O
fosters NN O O
dynamic NN O O
knee NN O O
alignment NN O O
, NN O O
effective NN O O
in NN O O
positively NN O O
altering NN O O
gait NN O O
biomechanics NN O O
in NN O O
children NN O O
and NN O O
adolescents NN O O
with NN O O
obesity NN O O
? NN O O

This NN O O
study NN O O
was NN O O
a NN O O
randomized NN O O
controlled NN O O
trial NN O O
having NN O O
children NN O O
and NN O O
adolescents NN O O
with NN O O
obesity NN O O
assigned NN O O
to NN O O
an NN O O
EP NN O O
( NN O O
n NN O O
= NN O O
19 NN O O
) NN O O
or NN O O
control NN O O
( NN O O
n NN O O
= NN O O
16 NN O O
) NN O O
group NN O O
. NN O O

Pain NN O O
, NN O O
self-rated NN O O
knee NN O O
function NN O O
, NN O O
muscle NN O O
strength NN O O
and NN O O
3D NN O O
gait NN O O
analysis NN O O
during NN O O
walking NN O O
and NN O O
stair NN O O
climbing NN O O
were NN O O
evaluated NN O O
. NN O O

Results NN O O
indicate NN O O
that NN O O
the NN O O
EP NN O O
was NN O O
able NN O O
to NN O O
increase NN O O
muscular NN O O
strength NN O O
especially NN O O
in NN O O
the NN O O
hip NN O O
abductors NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
children NN O O
from NN O O
the NN O O
EP NN O O
group NN O O
walked NN O O
with NN O O
less NN O O
maximum NN O O
hip NN O O
adduction NN O O
and NN O O
reduced NN O O
pelvic NN O O
drop NN O O
during NN O O
weight NN O O
acceptance NN O O
at NN O O
follow-up NN O O
. NN O O

No NN O O
changes NN O O
were NN O O
present NN O O
in NN O O
self-rated NN O O
knee NN O O
function NN O O
, NN O O
pain NN O O
or NN O O
discomfort NN O O
. NN O O

Even NN O O
though NN O O
effects NN O O
were NN O O
small NN O O
, NN O O
results NN O O
indicate NN O O
that NN O O
an NN O O
EP NN O O
is NN O O
an NN O O
effective NN O O
short-term NN O O
possibility NN O O
to NN O O
counteract NN O O
the NN O O
progressive NN O O
development NN O O
of NN O O
biomechanical NN O O
malalignments NN O O
of NN O O
the NN O O
lower NN O O
extremity NN O O
. NN O O

Clinical NN O O
parameters NN O O
indicated NN O O
that NN O O
the NN O O
program NN O O
was NN O O
feasible NN O O
. NN O O

Nonetheless NN O O
, NN O O
low NN O O
adherence NN O O
highlights NN O O
the NN O O
need NN O O
to NN O O
develop NN O O
more NN O O
attractive NN O O
programs NN O O
. NN O O

CLINICAL NN O O
TRIALS NN O O
REG NN O O
. NN O O

NO NN O O
: NN O O
clinicaltrials.gov NN O O
( NN O O
NCT02545764 NN O O
) NN O O
. NN O O



-DOCSTART- (30430372)

Restless NN O O
legs NN O O
syndrome NN O O
is NN O O
a NN O O
movement NN O O
sleep NN O O
disorder NN O O
that NN O O
may NN O O
be NN O O
linked NN O O
to NN O O
dopaminergic NN O O
dysfunction NN O O
and NN O O
in NN O O
which NN O O
vitamin NN O O
D NN O O
may NN O O
play NN O O
a NN O O
role NN O O
. NN O O

This NN O O
12-week NN O O
randomized NN O O
, NN O O
placebo-controlled NN O O
trial NN O O
elucidated NN O O
the NN O O
efficacy NN O O
of NN O O
vitamin NN O O
D NN O O
supplements NN O O
in NN O O
decreasing NN O O
restless NN O O
legs NN O O
syndrome NN O O
symptom NN O O
severity NN O O
. NN O O

Thirty-five NN O O
subjects NN O O
with NN O O
restless NN O O
legs NN O O
syndrome NN O O
, NN O O
diagnosed NN O O
using NN O O
the NN O O
International NN O O
Restless NN O O
Legs NN O O
Syndrome NN O O
Study NN O O
Group NN O O
criteria NN O O
, NN O O
were NN O O
enrolled NN O O
. NN O O

The NN O O
subjects NN O O
were NN O O
randomized NN O O
to NN O O
orally NN O O
receive NN O O
either NN O O
vitamin NN O O
D NN O O
( NN O O
50,000 NN O O
IU NN O O
caplets NN O O
) NN O O
or NN O O
a NN O O
placebo NN O O
. NN O O

All NN O O
medications NN O O
were NN O O
administered NN O O
weekly NN O O
using NN O O
a NN O O
direct NN O O
observation NN O O
technique NN O O
. NN O O

Clinical NN O O
assessments NN O O
, NN O O
including NN O O
those NN O O
for NN O O
restless NN O O
legs NN O O
syndrome NN O O
severity NN O O
, NN O O
were NN O O
conducted NN O O
at NN O O
baseline NN O O
and NN O O
the NN O O
end NN O O
of NN O O
the NN O O
study NN O O
using NN O O
the NN O O
International NN O O
Restless NN O O
Legs NN O O
Syndrome NN O O
Study NN O O
Group NN O O
rating NN O O
scale NN O O
. NN O O

The NN O O
serum NN O O
vitamin NN O O
D NN O O
levels NN O O
and NN O O
bone NN O O
profiles NN O O
were NN O O
measured NN O O
at NN O O
baseline NN O O
and NN O O
every NN O O
4 NN O O
weeks NN O O
. NN O O

The NN O O
primary NN O O
endpoint NN O O
was NN O O
the NN O O
change NN O O
in NN O O
the NN O O
restless NN O O
legs NN O O
syndrome NN O O
severity NN O O
score NN O O
from NN O O
baseline NN O O
to NN O O
week NN O O
12 NN O O
. NN O O

There NN O O
were NN O O
17 NN O O
and NN O O
18 NN O O
patients NN O O
in NN O O
the NN O O
vitamin NN O O
D NN O O
and NN O O
placebo NN O O
groups NN O O
, NN O O
respectively NN O O
. NN O O

The NN O O
groups NN O O
did NN O O
not NN O O
differ NN O O
with NN O O
respect NN O O
to NN O O
age NN O O
, NN O O
sex NN O O
, NN O O
restless NN O O
legs NN O O
syndrome NN O O
severity NN O O
, NN O O
or NN O O
vitamin NN O O
D NN O O
levels NN O O
. NN O O

Participants NN O O
in NN O O
the NN O O
vitamin NN O O
D NN O O
group NN O O
showed NN O O
no NN O O
significant NN O O
change NN O O
in NN O O
the NN O O
mean NN O O
restless NN O O
legs NN O O
syndrome NN O O
severity NN O O
score NN O O
compared NN O O
with NN O O
the NN O O
placebo NN O O
group NN O O
. NN O O

The NN O O
results NN O O
suggest NN O O
that NN O O
vitamin NN O O
D NN O O
supplementation NN O O
does NN O O
not NN O O
improve NN O O
restless NN O O
legs NN O O
syndrome NN O O
symptoms NN O O
. NN O O

ClinicalTrials.gov NN O O
: NN O O
NCT02256215 NN O O
( NN O O
available NN O O
from NN O O
: NN O O
https://clinicaltrials.gov/ct2/show/NCT02256215 NN O O
) NN O O
. NN O O



-DOCSTART- (31351832)

To NN O O
date NN O O
there NN O O
has NN O O
been NN O O
no NN O O
comparison NN O O
of NN O O
outcomes NN O O
of NN O O
endovenous NN O O
radiofrequency NN O O
( NN O O
RF NN O O
) NN O O
devices NN O O
. NN O O

The NN O O
3-RF NN O O
trial NN O O
is NN O O
the NN O O
first NN O O
randomised NN O O
controlled NN O O
trial NN O O
of NN O O
three NN O O
commercially NN O O
available NN O O
RF NN O O
ablation NN O O
technologies NN O O
. NN O O

Patients NN O O
were NN O O
recruited NN O O
[ NN O O
182/302 NN O O
patients NN O O
with NN O O
great NN O O
saphenous NN O O
vein NN O O
( NN O O
GSV NN O O
) NN O O
incompetence NN O O
] NN O O
into NN O O
a NN O O
prospective NN O O
double NN O O
blind NN O O
randomised NN O O
trial NN O O
of NN O O
Venefit NN O O
, NN O O
radiofrequency NN O O
induced NN O O
thermal NN O O
therapy NN O O
( NN O O
RFITT NN O O
) NN O O
, NN O O
and NN O O
endovenous NN O O
radiofrequency NN O O
( NN O O
EVRF NN O O
) NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
measure NN O O
was NN O O
GSV NN O O
closure NN O O
( NN O O
total/partial/failed NN O O
) NN O O
at NN O O
six NN O O
months NN O O
. NN O O

Secondary NN O O
outcome NN O O
measures NN O O
included NN O O
ablation NN O O
times NN O O
, NN O O
complications NN O O
, NN O O
pain NN O O
scores NN O O
, NN O O
analgesia NN O O
requirements NN O O
, NN O O
and NN O O
quality NN O O
of NN O O
life NN O O
( NN O O
QoL NN O O
) NN O O
scores NN O O
to NN O O
12 NN O O
months NN O O
. NN O O

Patients NN O O
treated NN O O
[ NN O O
180 NN O O
: NN O O
Venefit NN O O
( NN O O
57 NN O O
) NN O O
, NN O O
RFITT NN O O
( NN O O
64 NN O O
) NN O O
, NN O O
EVRF NN O O
( NN O O
59 NN O O
) NN O O
] NN O O
were NN O O
matched NN O O
for NN O O
age NN O O
, NN O O
sex NN O O
, NN O O
and NN O O
vein NN O O
characteristics NN O O
. NN O O

At NN O O
six NN O O
months NN O O
, NN O O
complete NN O O
GSV NN O O
closure NN O O
was NN O O
significantly NN O O
better NN O O
after NN O O
Venefit NN O O
and NN O O
RFITT NN O O
treatment NN O O
( NN O O
100 NN O O
% NN O O
and NN O O
98 NN O O
% NN O O
, NN O O
respectively NN O O
) NN O O
compared NN O O
with NN O O
EVRF NN O O
treatment NN O O
( NN O O
79 NN O O
% NN O O
, NN O O
p NN O O
< NN O O
.001 NN O O
) NN O O
. NN O O

Mean NN O O
treatment NN O O
time NN O O
was NN O O
significantly NN O O
faster NN O O
for NN O O
RFITT NN O O
than NN O O
for NN O O
Venefit NN O O
and NN O O
EVRF NN O O
( NN O O
p NN O O
< NN O O
.0001 NN O O
) NN O O
. NN O O

Euroqol NN O O
5D NN O O
( NN O O
EQ5D NN O O
) NN O O
visual NN O O
analogue NN O O
score NN O O
( NN O O
VAS NN O O
) NN O O
did NN O O
not NN O O
differ NN O O
between NN O O
groups NN O O
at NN O O
any NN O O
time NN O O
point NN O O
. NN O O

The NN O O
only NN O O
difference NN O O
between NN O O
groups NN O O
in NN O O
EQ5D NN O O
domain NN O O
scores NN O O
was NN O O
for NN O O
the NN O O
pain/discomfort NN O O
domain NN O O
at NN O O
two NN O O
weeks NN O O
when NN O O
significantly NN O O
fewer NN O O
EVRF NN O O
patients NN O O
reported NN O O
no NN O O
problems NN O O
compared NN O O
with NN O O
Venefit NN O O
and NN O O
RFITT NN O O
. NN O O

This NN O O
difference NN O O
had NN O O
disappeared NN O O
at NN O O
six NN O O
and NN O O
12 NN O O
months NN O O
. NN O O

The NN O O
Aberdeen NN O O
Varicose NN O O
Vein NN O O
Questionnaire NN O O
( NN O O
AVVQ NN O O
) NN O O
improved NN O O
for NN O O
all NN O O
groups NN O O
at NN O O
six NN O O
and NN O O
12 NN O O
months NN O O
compared NN O O
with NN O O
pre-treatment NN O O
levels NN O O
; NN O O
however NN O O
, NN O O
there NN O O
was NN O O
no NN O O
significant NN O O
difference NN O O
between NN O O
groups NN O O
. NN O O

Compared NN O O
with NN O O
Venefit NN O O
and NN O O
RFITT NN O O
, NN O O
EVRF NN O O
was NN O O
associated NN O O
with NN O O
significant NN O O
failure NN O O
of NN O O
truncal NN O O
ablation NN O O
at NN O O
six NN O O
months NN O O
; NN O O
however NN O O
, NN O O
clinical NN O O
outcomes NN O O
did NN O O
not NN O O
differ NN O O
significantly NN O O
at NN O O
12 NN O O
months NN O O
. NN O O

clinicaltrials.gov NN O O
identifier NN O O
: NN O O
NCT02441881 NN O O
, NN O O
NHS NN O O
Health NN O O
Research NN O O
Authority NN O O
( NN O O
Hampstead NN O O
Research NN O O
Ethics NN O O
Committee NN O O
) NN O O
number NN O O
: NN O O
14/LO/1232 NN O O
. NN O O



-DOCSTART- (30681717)

Patients NN O O
with NN O O
serious NN O O
illnesses NN O O
are NN O O
often NN O O
encouraged NN O O
to NN O O
actively NN O O
deliberate NN O O
about NN O O
the NN O O
desirability NN O O
of NN O O
life NN O O
support NN O O
. NN O O

Yet NN O O
it NN O O
is NN O O
unknown NN O O
whether NN O O
deliberation NN O O
changes NN O O
the NN O O
substance NN O O
or NN O O
quality NN O O
of NN O O
such NN O O
decisions NN O O
. NN O O

To NN O O
identify NN O O
differences NN O O
in NN O O
decisions NN O O
about NN O O
life NN O O
support NN O O
interventions NN O O
and NN O O
goals NN O O
of NN O O
care NN O O
made NN O O
intuitively NN O O
vs NN O O
deliberatively NN O O
by NN O O
patients NN O O
with NN O O
serious NN O O
illnesses NN O O
. NN O O

Randomized NN O O
clinical NN O O
trial NN O O
in NN O O
which NN O O
patients NN O O
were NN O O
asked NN O O
to NN O O
express NN O O
treatment NN O O
preferences NN O O
in NN O O
a NN O O
series NN O O
of NN O O
clinical NN O O
scenarios NN O O
. NN O O

Participants NN O O
were NN O O
199 NN O O
hospitalized NN O O
patients NN O O
aged NN O O
60 NN O O
years NN O O
and NN O O
older NN O O
with NN O O
serious NN O O
oncologic NN O O
, NN O O
cardiac NN O O
, NN O O
and NN O O
pulmonary NN O O
illnesses NN O O
treated NN O O
in NN O O
a NN O O
large NN O O
, NN O O
urban NN O O
academic NN O O
hospital NN O O
from NN O O
July NN O O
1 NN O O
, NN O O
2015 NN O O
, NN O O
through NN O O
March NN O O
15 NN O O
, NN O O
2016 NN O O
. NN O O

Patients NN O O
in NN O O
the NN O O
intuitive NN O O
group NN O O
were NN O O
subjected NN O O
to NN O O
a NN O O
cognitive NN O O
load NN O O
and NN O O
instructed NN O O
to NN O O
answer NN O O
each NN O O
question NN O O
immediately NN O O
based NN O O
on NN O O
gut NN O O
instinct NN O O
. NN O O

Patients NN O O
in NN O O
the NN O O
deliberative NN O O
group NN O O
were NN O O
not NN O O
cognitively NN O O
loaded NN O O
, NN O O
were NN O O
instructed NN O O
to NN O O
think NN O O
carefully NN O O
about NN O O
their NN O O
answers NN O O
, NN O O
and NN O O
were NN O O
required NN O O
to NN O O
explain NN O O
their NN O O
answers NN O O
. NN O O

Choices NN O O
regarding NN O O
life NN O O
support NN O O
( NN O O
4 NN O O
scenarios NN O O
) NN O O
and NN O O
goals NN O O
of NN O O
care NN O O
( NN O O
1 NN O O
scenario NN O O
) NN O O
, NN O O
concordance NN O O
of NN O O
these NN O O
choices NN O O
with NN O O
patients NN O O
' NN O O
valuations NN O O
of NN O O
health NN O O
states NN O O
that NN O O
could NN O O
follow NN O O
from NN O O
them NN O O
, NN O O
and NN O O
decisional NN O O
uncertainty NN O O
. NN O O

Of NN O O
199 NN O O
patients NN O O
, NN O O
132 NN O O
( NN O O
66 NN O O
% NN O O
) NN O O
were NN O O
male NN O O
and NN O O
the NN O O
mean NN O O
( NN O O
SD NN O O
) NN O O
age NN O O
was NN O O
67.2 NN O O
( NN O O
5.0 NN O O
) NN O O
years NN O O
. NN O O

Similar NN O O
proportions NN O O
of NN O O
patients NN O O
in NN O O
the NN O O
intuitive NN O O
group NN O O
( NN O O
n NN O O
= NN O O
97 NN O O
) NN O O
and NN O O
the NN O O
deliberative NN O O
group NN O O
( NN O O
n NN O O
= NN O O
102 NN O O
) NN O O
said NN O O
they NN O O
would NN O O
accept NN O O
a NN O O
feeding NN O O
tube NN O O
for NN O O
chronic NN O O
aspiration NN O O
( NN O O
42 NN O O
% NN O O
vs NN O O
44 NN O O
% NN O O
, NN O O
respectively NN O O
; NN O O
difference NN O O
, NN O O
-2 NN O O
% NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
-16 NN O O
% NN O O
to NN O O
12 NN O O
% NN O O
; NN O O
P NN O O
= NN O O
.79 NN O O
) NN O O
, NN O O
antibiotics NN O O
for NN O O
life-threatening NN O O
infection NN O O
in NN O O
the NN O O
event NN O O
of NN O O
terminal NN O O
illness NN O O
( NN O O
39 NN O O
% NN O O
vs NN O O
43 NN O O
% NN O O
, NN O O
respectively NN O O
; NN O O
difference NN O O
, NN O O
-4 NN O O
% NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
-18 NN O O
% NN O O
to NN O O
10 NN O O
% NN O O
; NN O O
P NN O O
= NN O O
.57 NN O O
) NN O O
, NN O O
a NN O O
trial NN O O
of NN O O
mechanical NN O O
ventilation NN O O
( NN O O
59 NN O O
% NN O O
vs NN O O
60 NN O O
% NN O O
, NN O O
respectively NN O O
; NN O O
difference,-1 NN O O
% NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
-15 NN O O
% NN O O
to NN O O
13 NN O O
% NN O O
; NN O O
P NN O O
= NN O O
.88 NN O O
) NN O O
, NN O O
and NN O O
a NN O O
tracheostomy NN O O
tube NN O O
( NN O O
37 NN O O
% NN O O
vs NN O O
41 NN O O
% NN O O
, NN O O
respectively NN O O
; NN O O
difference NN O O
, NN O O
-4 NN O O
% NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
-22 NN O O
% NN O O
to NN O O
13 NN O O
% NN O O
; NN O O
P NN O O
= NN O O
.64 NN O O
) NN O O
. NN O O

Patients NN O O
in NN O O
the NN O O
deliberative NN O O
group NN O O
were NN O O
slightly NN O O
more NN O O
likely NN O O
than NN O O
patients NN O O
in NN O O
the NN O O
intuitive NN O O
group NN O O
to NN O O
choose NN O O
a NN O O
palliative NN O O
approach NN O O
to NN O O
treatment NN O O
in NN O O
the NN O O
event NN O O
of NN O O
serious NN O O
illness NN O O
( NN O O
45 NN O O
% NN O O
vs NN O O
30 NN O O
% NN O O
, NN O O
respectively NN O O
; NN O O
difference NN O O
, NN O O
15 NN O O
% NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
1%-29 NN O O
% NN O O
; NN O O
P NN O O
= NN O O
.04 NN O O
) NN O O
. NN O O

Across NN O O
scenarios NN O O
, NN O O
decisional NN O O
uncertainty NN O O
was NN O O
similar NN O O
between NN O O
the NN O O
2 NN O O
groups NN O O
( NN O O
all NN O O
P NN O O
> NN O O
.05 NN O O
) NN O O
, NN O O
and NN O O
intuitive NN O O
decisions NN O O
were NN O O
either NN O O
equally NN O O
or NN O O
more NN O O
closely NN O O
aligned NN O O
with NN O O
patients NN O O
' NN O O
health NN O O
state NN O O
valuations NN O O
than NN O O
deliberative NN O O
decisions NN O O
. NN O O

In NN O O
this NN O O
study NN O O
, NN O O
encouraging NN O O
hospitalized NN O O
patients NN O O
with NN O O
serious NN O O
illnesses NN O O
to NN O O
deliberate NN O O
on NN O O
end-of-life NN O O
decisions NN O O
did NN O O
not NN O O
change NN O O
the NN O O
content NN O O
or NN O O
improve NN O O
the NN O O
quality NN O O
of NN O O
these NN O O
decisions NN O O
. NN O O

It NN O O
is NN O O
important NN O O
to NN O O
evaluate NN O O
whether NN O O
decision NN O O
aids NN O O
and NN O O
structured NN O O
communication NN O O
interventions NN O O
improve NN O O
seriously NN O O
ill NN O O
patients NN O O
' NN O O
choices NN O O
. NN O O

ClinicalTrials.gov NN O O
Identifier NN O O
: NN O O
NCT02487810 NN O O
. NN O O



-DOCSTART- (30455171)

Any NN O O
study NN O O
with NN O O
human NN O O
subjects NN O O
must NN O O
have NN O O
a NN O O
robust NN O O
consent NN O O
process NN O O
to NN O O
ensure NN O O
that NN O O
participants NN O O
understand NN O O
the NN O O
study NN O O
and NN O O
can NN O O
decide NN O O
whether NN O O
they NN O O
want NN O O
to NN O O
be NN O O
involved NN O O
. NN O O

Investigators NN O O
must NN O O
determine NN O O
whether NN O O
a NN O O
potential NN O O
study NN O O
participant NN O O
is NN O O
able NN O O
to NN O O
make NN O O
an NN O O
informed NN O O
decision NN O O
and NN O O
what NN O O
modifications NN O O
or NN O O
supports NN O O
are NN O O
needed NN O O
to NN O O
maximize NN O O
participation NN O O
in NN O O
decision NN O O
making NN O O
. NN O O

A NN O O
variety NN O O
of NN O O
approaches NN O O
have NN O O
been NN O O
used NN O O
to NN O O
modify NN O O
consent NN O O
forms NN O O
and NN O O
the NN O O
consent NN O O
process NN O O
to NN O O
increase NN O O
the NN O O
research NN O O
participants NN O O
' NN O O
decisional NN O O
capacity NN O O
. NN O O

This NN O O
protocol NN O O
describes NN O O
a NN O O
randomized NN O O
controlled NN O O
trial NN O O
( NN O O
RCT NN O O
) NN O O
of NN O O
a NN O O
digital NN O O
health NN O O
app NN O O
to NN O O
support NN O O
decision NN O O
making NN O O
among NN O O
individuals NN O O
contemplating NN O O
providing NN O O
consent NN O O
to NN O O
participate NN O O
in NN O O
a NN O O
clinical NN O O
trial NN O O
. NN O O

The NN O O
objective NN O O
of NN O O
this NN O O
RCT NN O O
will NN O O
be NN O O
to NN O O
determine NN O O
if NN O O
the NN O O
use NN O O
of NN O O
a NN O O
tablet-based NN O O
app NN O O
facilitates NN O O
greater NN O O
participation NN O O
in NN O O
and NN O O
satisfaction NN O O
with NN O O
the NN O O
consent NN O O
process NN O O
compared NN O O
with NN O O
standard NN O O
practice NN O O
and NN O O
identify NN O O
which NN O O
individual NN O O
factors NN O O
are NN O O
associated NN O O
with NN O O
better NN O O
response NN O O
to NN O O
the NN O O
decision NN O O
aid NN O O
. NN O O

We NN O O
hypothesize NN O O
that NN O O
the NN O O
tablet-based NN O O
version NN O O
of NN O O
the NN O O
consent NN O O
process NN O O
will NN O O
promote NN O O
more NN O O
informed NN O O
decision NN O O
making NN O O
, NN O O
including NN O O
decisions NN O O
that NN O O
are NN O O
more NN O O
consistent NN O O
with NN O O
individual NN O O
preferences NN O O
and NN O O
values NN O O
expressed NN O O
during NN O O
qualitative NN O O
data NN O O
collection NN O O
. NN O O

A NN O O
two-arm NN O O
RCT NN O O
will NN O O
be NN O O
conducted NN O O
in NN O O
a NN O O
sample NN O O
of NN O O
approximately NN O O
100 NN O O
individuals NN O O
with NN O O
fragile NN O O
X NN O O
syndrome NN O O
in NN O O
their NN O O
homes NN O O
across NN O O
the NN O O
United NN O O
States NN O O
. NN O O

Data NN O O
analysis NN O O
will NN O O
be NN O O
completed NN O O
by NN O O
late NN O O
2018 NN O O
. NN O O

By NN O O
developing NN O O
and NN O O
testing NN O O
a NN O O
novel NN O O
consent NN O O
decision NN O O
aid NN O O
, NN O O
we NN O O
will NN O O
have NN O O
a NN O O
better NN O O
understanding NN O O
of NN O O
whether NN O O
and NN O O
how NN O O
technological NN O O
support NN O O
can NN O O
optimize NN O O
the NN O O
fit NN O O
between NN O O
the NN O O
decisional NN O O
capacity NN O O
and NN O O
the NN O O
decisional NN O O
process NN O O
. NN O O

ClinicalTrials.gov NN O O
NCT02465931 NN O O
; NN O O
https://clinicaltrials.gov/ct2/show/NCT02465931 NN O O
( NN O O
Archived NN O O
by NN O O
WebCite NN O O
at NN O O
http://www.webcitation.org/72Q3xJQAw NN O O
) NN O O
. NN O O

PRR1 NN O O
- NN O O
10.2196/10360 NN O O
. NN O O



-DOCSTART- (30927922)

The NN O O
intubating NN O O
laryngeal NN O O
mask NN O O
Fastrach NN O O
™ NN O O
is NN O O
considered NN O O
a NN O O
gold NN O O
standard NN O O
for NN O O
blind NN O O
intubation NN O O
as NN O O
well NN O O
as NN O O
for NN O O
fibreoptic NN O O
guided NN O O
intubation NN O O
via NN O O
a NN O O
laryngeal NN O O
mask NN O O
. NN O O

Recently NN O O
, NN O O
a NN O O
single NN O O
use NN O O
version NN O O
of NN O O
the NN O O
mask NN O O
has NN O O
been NN O O
introduced NN O O
. NN O O

We NN O O
compared NN O O
the NN O O
Fastrach NN O O
single NN O O
use NN O O
with NN O O
the NN O O
new NN O O
, NN O O
low-priced NN O O
single NN O O
use NN O O
intubating NN O O
laryngeal NN O O
mask NN O O
Ambu NN O O
Aura-i NN O O
™ NN O O
. NN O O

We NN O O
hypothesised NN O O
that NN O O
the NN O O
LMA NN O O
Ambu NN O O
Aura-i NN O O
and NN O O
the NN O O
LMA NN O O
Fastrach NN O O
are NN O O
comparable NN O O
with NN O O
respect NN O O
to NN O O
success NN O O
rates NN O O
for NN O O
mask NN O O
placement NN O O
and NN O O
blind NN O O
tracheal NN O O
intubation NN O O
through NN O O
the NN O O
LMA NN O O
device NN O O
. NN O O

A NN O O
prospective NN O O
, NN O O
randomised NN O O
clinical NN O O
trial NN O O
. NN O O

University NN O O
Hospital NN O O
Schleswig-Holstein NN O O
, NN O O
Campus NN O O
Kiel NN O O
, NN O O
from NN O O
April NN O O
2011 NN O O
to NN O O
April NN O O
2012 NN O O
. NN O O

Eighty NN O O
patients NN O O
undergoing NN O O
general NN O O
anaesthesia NN O O
with NN O O
planned NN O O
tracheal NN O O
intubation NN O O
were NN O O
randomised NN O O
and NN O O
enrolled NN O O
in NN O O
the NN O O
study NN O O
. NN O O

Blind NN O O
intubation NN O O
was NN O O
performed NN O O
with NN O O
either NN O O
laryngeal NN O O
mask NN O O
using NN O O
two NN O O
different NN O O
tracheal NN O O
tubes NN O O
( NN O O
Rüsch NN O O
Super NN O O
Safety NN O O
Silk NN O O
™ NN O O
and NN O O
LMA NN O O
ETT NN O O
™ NN O O
) NN O O
. NN O O

A NN O O
crossover-design NN O O
was NN O O
performed NN O O
after NN O O
an NN O O
unsuccessful NN O O
procedure NN O O
. NN O O

Primary NN O O
outcome NN O O
measure NN O O
was NN O O
the NN O O
overall NN O O
success NN O O
rate NN O O
of NN O O
blind NN O O
intubation NN O O
. NN O O

Secondary NN O O
outcome NN O O
measures NN O O
were NN O O
the NN O O
time NN O O
to NN O O
the NN O O
first NN O O
adequate NN O O
ventilation NN O O
, NN O O
a NN O O
subjective NN O O
handling NN O O
score NN O O
, NN O O
and NN O O
a NN O O
fibreoptic NN O O
control NN O O
of NN O O
placement NN O O
, NN O O
as NN O O
well NN O O
as NN O O
the NN O O
success NN O O
rate NN O O
of NN O O
mask NN O O
placement NN O O
, NN O O
time NN O O
for NN O O
mask NN O O
removal NN O O
after NN O O
successful NN O O
intubation NN O O
, NN O O
differences NN O O
in NN O O
airway NN O O
leak NN O O
pressure NN O O
, NN O O
and NN O O
the NN O O
incidence NN O O
of NN O O
postoperative NN O O
sore NN O O
throat NN O O
and NN O O
hoarseness NN O O
. NN O O

The NN O O
success NN O O
rate NN O O
of NN O O
tracheal NN O O
intubation NN O O
with NN O O
the NN O O
Fastrach NN O O
for NN O O
the NN O O
first NN O O
and NN O O
second NN O O
attempt NN O O
was NN O O
significantly NN O O
better NN O O
compared NN O O
with NN O O
the NN O O
Ambu NN O O
Aura-i NN O O
. NN O O

Tracheal NN O O
intubation NN O O
was NN O O
also NN O O
significantly NN O O
faster NN O O
( NN O O
14.1 NN O O
s. NN O O
±4.4 NN O O
versus NN O O
21.3 NN O O
s. NN O O
±9.0 NN O O
; NN O O
p NN O O
< NN O O
0.01 NN O O
) NN O O
, NN O O
and NN O O
the NN O O
time NN O O
interval NN O O
for NN O O
mask NN O O
removal NN O O
after NN O O
successful NN O O
intubation NN O O
was NN O O
significantly NN O O
shorter NN O O
using NN O O
the NN O O
Fastrach NN O O
device NN O O
( NN O O
24.0 NN O O
s. NN O O
±8.2 NN O O
versus NN O O
29.4 NN O O
s. NN O O
±7.5 NN O O
; NN O O
p NN O O
< NN O O
0.001 NN O O
) NN O O
. NN O O

There NN O O
were NN O O
no NN O O
significant NN O O
differences NN O O
between NN O O
groups NN O O
regarding NN O O
the NN O O
incidence NN O O
of NN O O
postoperative NN O O
sore NN O O
throat NN O O
and NN O O
hoarseness NN O O
. NN O O

Both NN O O
laryngeal NN O O
mask NN O O
devices NN O O
are NN O O
suitable NN O O
for NN O O
ventilation NN O O
and NN O O
oxygenation NN O O
. NN O O

Blind NN O O
intubation NN O O
remains NN O O
the NN O O
domain NN O O
of NN O O
the NN O O
LMA NN O O
Fastrach NN O O
, NN O O
the NN O O
Ambu NN O O
Aura-i NN O O
is NN O O
not NN O O
suitable NN O O
for NN O O
blind NN O O
intubation NN O O
. NN O O

Clinicaltrials.gov NN O O

Identification NN O O
Number NN O O
NCT03109678 NN O O
, NN O O
retrospectively NN O O
registered NN O O
on NN O O
April NN O O
12 NN O O
, NN O O
2017 NN O O
. NN O O



-DOCSTART- (31204294)

For NN O O
people NN O O
with NN O O
plantar NN O O
fasciopathy NN O O
, NN O O
is NN O O
a NN O O
12-week NN O O
self-dosed NN O O
heavy-slow NN O O
resistance NN O O
training NN O O
program NN O O
more NN O O
beneficial NN O O
than NN O O
a NN O O
12-week NN O O
pre-determined NN O O
heavy-slow NN O O
resistance NN O O
training NN O O
program NN O O
? NN O O

A NN O O
randomised NN O O
trial NN O O
with NN O O
concealed NN O O
allocation NN O O
, NN O O
partial NN O O
blinding NN O O
, NN O O
and NN O O
intention-to-treat NN O O
analysis NN O O
. NN O O

Seventy NN O O
people NN O O
with NN O O
plantar NN O O
fasciopathy NN O O
confirmed NN O O
on NN O O
ultrasonography NN O O
. NN O O

Both NN O O
groups NN O O
performed NN O O
a NN O O
repeated NN O O
heel NN O O
raise NN O O
exercise NN O O
in NN O O
standing NN O O
for NN O O
12 NN O O
weeks NN O O
. NN O O

Participants NN O O
in NN O O
the NN O O
experimental NN O O
group NN O O
were NN O O
self-dosed NN O O
( NN O O
ie NN O O
, NN O O
they NN O O
performed NN O O
as NN O O
many NN O O
sets NN O O
as NN O O
possible NN O O
with NN O O
as NN O O
heavy NN O O
a NN O O
load NN O O
as NN O O
possible NN O O
, NN O O
but NN O O
no NN O O
heavier NN O O
than NN O O
8 NN O O
repetition NN O O
maximum NN O O
) NN O O
. NN O O

The NN O O
exercise NN O O
regimen NN O O
for NN O O
the NN O O
control NN O O
group NN O O
was NN O O
pre-determined NN O O
( NN O O
ie NN O O
, NN O O
it NN O O
followed NN O O
a NN O O
standardised NN O O
progressive NN O O
protocol NN O O
) NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
was NN O O
the NN O O
Foot NN O O
Health NN O O
Status NN O O
Questionnaire NN O O
pain NN O O
domain NN O O
. NN O O

Secondary NN O O
outcomes NN O O
included NN O O
: NN O O
a NN O O
7-point NN O O
Likert NN O O
scale NN O O
of NN O O
Global NN O O
Rating NN O O
of NN O O
Change NN O O
dichotomised NN O O
to NN O O
' NN O O
improved NN O O
' NN O O
or NN O O
' NN O O
not NN O O
improved NN O O
' NN O O
; NN O O
Patient NN O O
Acceptable NN O O
Symptom NN O O
State NN O O
defined NN O O
as NN O O
when NN O O
participants NN O O
felt NN O O
no NN O O
further NN O O
need NN O O
for NN O O
treatment NN O O
; NN O O
and NN O O
number NN O O
of NN O O
training NN O O
sessions NN O O
performed NN O O
. NN O O

There NN O O
was NN O O
no NN O O
significant NN O O
between-group NN O O
difference NN O O
in NN O O
the NN O O
improvement NN O O
of NN O O
Foot NN O O
Health NN O O
Status NN O O
Questionnaire NN O O
pain NN O O
after NN O O
12 NN O O
weeks NN O O
( NN O O
adjusted NN O O
MD NN O O
-6.9 NN O O
points NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
-15.5 NN O O
to NN O O
1.7 NN O O
) NN O O
. NN O O

According NN O O
to NN O O
the NN O O
Global NN O O
Rating NN O O
of NN O O
Change NN O O
, NN O O
24 NN O O
of NN O O
33 NN O O
in NN O O
the NN O O
experimental NN O O
group NN O O
and NN O O
20 NN O O
of NN O O
32 NN O O
in NN O O
the NN O O
control NN O O
group NN O O
were NN O O
improved NN O O
( NN O O
RR NN O O
= NN O O
1.16 NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
0.83 NN O O
to NN O O
1.64 NN O O
) NN O O
. NN O O

Only NN O O
four NN O O
participants NN O O
achieved NN O O
Patient NN O O
Acceptable NN O O
Symptom NN O O
State NN O O
: NN O O
three NN O O
of NN O O
35 NN O O
in NN O O
the NN O O
experimental NN O O
group NN O O
and NN O O
one NN O O
of NN O O
35 NN O O
in NN O O
the NN O O
control NN O O
group NN O O
. NN O O

No NN O O
significant NN O O
between-group NN O O
difference NN O O
was NN O O
found NN O O
in NN O O
the NN O O
number NN O O
of NN O O
training NN O O
sessions NN O O
that NN O O
were NN O O
performed NN O O
( NN O O
MD NN O O
-2 NN O O
sessions NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
-8 NN O O
to NN O O
3 NN O O
) NN O O
. NN O O

Self-dosed NN O O
and NN O O
pre-determined NN O O
heavy-slow NN O O
resistance NN O O
exercise NN O O
programs NN O O
are NN O O
associated NN O O
with NN O O
similar NN O O
effects NN O O
on NN O O
plantar NN O O
fasciopathy NN O O
pain NN O O
and NN O O
other NN O O
outcomes NN O O
over NN O O
12 NN O O
weeks NN O O
. NN O O

Advising NN O O
people NN O O
with NN O O
plantar NN O O
fasciopathy NN O O
to NN O O
self-dose NN O O
their NN O O
slow-heavy NN O O
resistance NN O O
training NN O O
regimen NN O O
did NN O O
not NN O O
substantially NN O O
increase NN O O
the NN O O
achieved NN O O
dose NN O O
compared NN O O
with NN O O
a NN O O
pre-determined NN O O
regimen NN O O
. NN O O

These NN O O
regimens NN O O
are NN O O
not NN O O
sufficient NN O O
to NN O O
achieve NN O O
acceptable NN O O
symptom NN O O
state NN O O
in NN O O
the NN O O
majority NN O O
of NN O O
people NN O O
with NN O O
plantar NN O O
fasciopathy NN O O
. NN O O

ClinicalTrials.govNCT03304353 NN O O
. NN O O



-DOCSTART- (30558607)

Based NN O O
on NN O O
epidemiological NN O O
and NN O O
clinical NN O O
data NN O O
acute NN O O
appendicitis NN O O
can NN O O
present NN O O
either NN O O
as NN O O
uncomplicated NN O O
( NN O O
70 NN O O
- NN O O
80 NN O O
% NN O O
) NN O O
or NN O O
complicated NN O O
( NN O O
20 NN O O
- NN O O
30 NN O O
% NN O O
) NN O O
disease NN O O
. NN O O

Recent NN O O
studies NN O O
have NN O O
shown NN O O
that NN O O
antibiotic NN O O
therapy NN O O
is NN O O
both NN O O
safe NN O O
and NN O O
cost-effective NN O O
for NN O O
a NN O O
CT-scan NN O O
confirmed NN O O
uncomplicated NN O O
acute NN O O
appendicitis NN O O
. NN O O

However NN O O
, NN O O
based NN O O
on NN O O
the NN O O
study NN O O
protocols NN O O
to NN O O
ensure NN O O
patient NN O O
safety NN O O
, NN O O
these NN O O
randomised NN O O
studies NN O O
used NN O O
mainly NN O O
broad-spectrum NN O O
intravenous NN O O
antibiotics NN O O
requiring NN O O
additional NN O O
hospital NN O O
resources NN O O
and NN O O
prolonged NN O O
hospital NN O O
stay NN O O
. NN O O

As NN O O
we NN O O
now NN O O
know NN O O
that NN O O
antibiotic NN O O
therapy NN O O
for NN O O
uncomplicated NN O O
acute NN O O
appendicitis NN O O
is NN O O
feasible NN O O
and NN O O
safe NN O O
, NN O O
further NN O O
studies NN O O
evaluating NN O O
optimisation NN O O
of NN O O
the NN O O
antibiotic NN O O
treatment NN O O
regarding NN O O
both NN O O
antibiotic NN O O
spectrum NN O O
and NN O O
shorter NN O O
hospital NN O O
stay NN O O
are NN O O
needed NN O O
to NN O O
evaluate NN O O
antibiotics NN O O
as NN O O
the NN O O
first-line NN O O
treatment NN O O
for NN O O
uncomplicated NN O O
acute NN O O
appendicitis NN O O
. NN O O

APPAC NN O O
II NN O O
trial NN O O
is NN O O
a NN O O
multicentre NN O O
, NN O O
open-label NN O O
, NN O O
non-inferiority NN O O
randomised NN O O
controlled NN O O
trial NN O O
comparing NN O O
per NN O O
oral NN O O
( NN O O
p.o NN O O
. NN O O
) NN O O
antibiotic NN O O
monotherapy NN O O
with NN O O
intravenous NN O O
( NN O O
i.v NN O O
. NN O O
) NN O O
antibiotic NN O O
therapy NN O O
followed NN O O
by NN O O
p.o NN O O
. NN O O

antibiotics NN O O
in NN O O
the NN O O
treatment NN O O
of NN O O
CT-scan NN O O
confirmed NN O O
uncomplicated NN O O
acute NN O O
appendicitis NN O O
. NN O O

Adult NN O O
patients NN O O
with NN O O
CT-scan NN O O
diagnosed NN O O
uncomplicated NN O O
acute NN O O
appendicitis NN O O
will NN O O
be NN O O
enrolled NN O O
in NN O O
nine NN O O
Finnish NN O O
hospitals NN O O
. NN O O

The NN O O
intended NN O O
sample NN O O
size NN O O
is NN O O
552 NN O O
patients NN O O
. NN O O

Primary NN O O
endpoint NN O O
is NN O O
the NN O O
success NN O O
of NN O O
the NN O O
randomised NN O O
treatment NN O O
, NN O O
defined NN O O
as NN O O
resolution NN O O
of NN O O
acute NN O O
appendicitis NN O O
resulting NN O O
in NN O O
discharge NN O O
from NN O O
the NN O O
hospital NN O O
without NN O O
the NN O O
need NN O O
for NN O O
surgical NN O O
intervention NN O O
and NN O O
no NN O O
recurrent NN O O
appendicitis NN O O
during NN O O
one-year NN O O
follow-up NN O O
. NN O O

Secondary NN O O
endpoints NN O O
include NN O O
post-intervention NN O O
complications NN O O
, NN O O
late NN O O
recurrence NN O O
of NN O O
acute NN O O
appendicitis NN O O
after NN O O
one NN O O
year NN O O
, NN O O
duration NN O O
of NN O O
hospital NN O O
stay NN O O
, NN O O
pain NN O O
, NN O O
quality NN O O
of NN O O
life NN O O
, NN O O
sick NN O O
leave NN O O
and NN O O
treatment NN O O
costs NN O O
. NN O O

Primary NN O O
endpoint NN O O
will NN O O
be NN O O
evaluated NN O O
in NN O O
two NN O O
stages NN O O
: NN O O
point NN O O
estimates NN O O
with NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
( NN O O
CI NN O O
) NN O O
will NN O O
be NN O O
calculated NN O O
for NN O O
both NN O O
groups NN O O
and NN O O
proportion NN O O
difference NN O O
between NN O O
groups NN O O
with NN O O
95 NN O O
% NN O O
CI NN O O
will NN O O
be NN O O
calculated NN O O
and NN O O
evaluated NN O O
based NN O O
on NN O O
6 NN O O
percentage NN O O
point NN O O
non-inferiority NN O O
margin NN O O
. NN O O

To NN O O
our NN O O
knowledge NN O O
, NN O O
APPAC NN O O
II NN O O
trial NN O O
is NN O O
the NN O O
first NN O O
randomised NN O O
controlled NN O O
trial NN O O
comparing NN O O
per NN O O
oral NN O O
antibiotic NN O O
monotherapy NN O O
with NN O O
intravenous NN O O
antibiotic NN O O
therapy NN O O
continued NN O O
by NN O O
per NN O O
oral NN O O
antibiotics NN O O
in NN O O
the NN O O
treatment NN O O
of NN O O
uncomplicated NN O O
acute NN O O
appendicitis NN O O
. NN O O

The NN O O
APPAC NN O O
II NN O O
trial NN O O
aims NN O O
to NN O O
add NN O O
clinical NN O O
evidence NN O O
on NN O O
the NN O O
debated NN O O
role NN O O
of NN O O
antibiotics NN O O
as NN O O
the NN O O
first-line NN O O
treatment NN O O
for NN O O
a NN O O
CT-confirmed NN O O
uncomplicated NN O O
acute NN O O
appendicitis NN O O
as NN O O
well NN O O
as NN O O
to NN O O
optimise NN O O
the NN O O
non-operative NN O O
treatment NN O O
for NN O O
uncomplicated NN O O
acute NN O O
appendicitis NN O O
. NN O O

Clinicaltrials.gov NN O O
, NN O O
NCT03236961 NN O O
, NN O O
retrospectively NN O O
registered NN O O
on NN O O
the NN O O
2nd NN O O
of NN O O
August NN O O
2017 NN O O
. NN O O



-DOCSTART- (30810536)

Among NN O O
youth NN O O
living NN O O
with NN O O
HIV NN O O
( NN O O
YLH NN O O
) NN O O
aged NN O O
12 NN O O
- NN O O
24 NN O O
years NN O O
who NN O O
have NN O O
health NN O O
care NN O O
in NN O O
the NN O O
United NN O O
States NN O O
, NN O O
only NN O O
30 NN O O
% NN O O
to NN O O
40 NN O O
% NN O O
are NN O O
virally NN O O
suppressed NN O O
. NN O O

YLH NN O O
must NN O O
achieve NN O O
viral NN O O
suppression NN O O
in NN O O
order NN O O
to NN O O
reduce NN O O
the NN O O
probability NN O O
of NN O O
infecting NN O O
others NN O O
as NN O O
well NN O O
as NN O O
increasing NN O O
the NN O O
length NN O O
and NN O O
quality NN O O
of NN O O
their NN O O
own NN O O
life NN O O
. NN O O

This NN O O
randomized NN O O
controlled NN O O
trial NN O O
aimed NN O O
to NN O O
evaluate NN O O
the NN O O
efficacy NN O O
of NN O O
an NN O O
Enhanced NN O O
Standard NN O O
Care NN O O
condition NN O O
( NN O O
n=110 NN O O
) NN O O
compared NN O O
to NN O O
an NN O O
Enhanced NN O O
Stepped NN O O
Care NN O O
intervention NN O O
condition NN O O
( NN O O
n=110 NN O O
) NN O O
to NN O O
increase NN O O
viral NN O O
suppression NN O O
among NN O O
YLH NN O O
aged NN O O
12 NN O O
- NN O O
24 NN O O
years NN O O
with NN O O
established NN O O
infection NN O O
( NN O O
not NN O O
acutely NN O O
infected NN O O
) NN O O
. NN O O

YLH NN O O
( NN O O
N=220 NN O O
) NN O O
who NN O O
are NN O O
not NN O O
virally NN O O
suppressed NN O O
will NN O O
be NN O O
identified NN O O
at NN O O
homeless NN O O
shelters NN O O
, NN O O
health NN O O
clinics NN O O
, NN O O
and NN O O
gay-identified NN O O
community-based NN O O
organizations NN O O
in NN O O
Los NN O O
Angeles NN O O
, NN O O
CA NN O O
, NN O O
and NN O O
New NN O O
Orleans NN O O
, NN O O
LA NN O O
. NN O O

Informed NN O O
consent NN O O
will NN O O
be NN O O
obtained NN O O
from NN O O
all NN O O
participants NN O O
. NN O O

YLH NN O O
will NN O O
be NN O O
randomly NN O O
assigned NN O O
to NN O O
one NN O O
of NN O O
two NN O O
study NN O O
conditions NN O O
: NN O O
Enhanced NN O O
Standard NN O O
Care NN O O
, NN O O
which NN O O
includes NN O O
standard NN O O
clinical NN O O
care NN O O
plus NN O O
an NN O O
automated NN O O
messaging NN O O
and NN O O
monitoring NN O O
intervention NN O O
( NN O O
AMMI NN O O
) NN O O
, NN O O
or NN O O
an NN O O
Enhanced NN O O
Stepped NN O O
Care NN O O
, NN O O
which NN O O
includes NN O O
three NN O O
levels NN O O
of NN O O
intervention NN O O
( NN O O
AMMI NN O O
, NN O O
Peer NN O O
Support NN O O
via NN O O
social NN O O
media NN O O
plus NN O O
AMMI NN O O
, NN O O
or NN O O
Coaching NN O O
plus NN O O
Peer NN O O
Support NN O O
and NN O O
AMMI NN O O
) NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
is NN O O
viral NN O O
suppression NN O O
of NN O O
HIV NN O O
, NN O O
and NN O O
YLH NN O O
will NN O O
be NN O O
assessed NN O O
at NN O O
4-month NN O O
intervals NN O O
for NN O O
24 NN O O
months NN O O
. NN O O

For NN O O
the NN O O
Enhanced NN O O
Stepped NN O O
Care NN O O
intervention NN O O
group NN O O
, NN O O
those NN O O
who NN O O
do NN O O
not NN O O
achieve NN O O
viral NN O O
suppression NN O O
( NN O O
via NN O O
blood NN O O
draw NN O O
, NN O O
viral NN O O
load<200 NN O O
copies/mL NN O O
) NN O O
at NN O O
any NN O O
4-month NN O O
assessment NN O O
will NN O O
" NN O O
step NN O O
up NN O O
" NN O O
to NN O O
the NN O O
next NN O O
level NN O O
of NN O O
intervention NN O O
. NN O O

Secondary NN O O
outcomes NN O O
will NN O O
be NN O O
retention NN O O
in NN O O
care NN O O
, NN O O
antiretroviral NN O O
therapy NN O O
adherence NN O O
, NN O O
alcohol NN O O
use NN O O
, NN O O
substance NN O O
use NN O O
, NN O O
sexual NN O O
behavior NN O O
, NN O O
and NN O O
mental NN O O
health NN O O
symptoms NN O O
. NN O O

Recruitment NN O O
for NN O O
this NN O O
study NN O O
began NN O O
in NN O O
June NN O O
2017 NN O O
and NN O O
is NN O O
ongoing NN O O
. NN O O

We NN O O
estimate NN O O
data NN O O
collection NN O O
to NN O O
be NN O O
completed NN O O
by NN O O
the NN O O
end NN O O
of NN O O
2020 NN O O
. NN O O

This NN O O
is NN O O
the NN O O
first NN O O
known NN O O
application NN O O
of NN O O
an NN O O
Enhanced NN O O
Stepped NN O O
Care NN O O
intervention NN O O
model NN O O
for NN O O
YLH NN O O
. NN O O

By NN O O
providing NN O O
the NN O O
lowest NN O O
level NN O O
of NN O O
intervention NN O O
needed NN O O
to NN O O
achieve NN O O
viral NN O O
suppression NN O O
, NN O O
this NN O O
model NN O O
has NN O O
the NN O O
potential NN O O
to NN O O
be NN O O
a NN O O
cost-effective NN O O
method NN O O
of NN O O
helping NN O O
YLH NN O O
achieve NN O O
viral NN O O
suppression NN O O
and NN O O
improve NN O O
their NN O O
quality NN O O
of NN O O
life NN O O
. NN O O

ClinicalTrials.gov NN O O
NCT03109431 NN O O
; NN O O
https://clinicaltrials.gov/ct2/show/NCT03109431 NN O O
. NN O O

DERR1 NN O O
- NN O O
10.2196/10791 NN O O
. NN O O



-DOCSTART- (30618475)

Cariprazine NN O O
is NN O O
an NN O O
atypical NN O O
antipsychotic NN O O
currently NN O O
under NN O O
investigation NN O O
as NN O O
an NN O O
adjunctive NN O O
to NN O O
antidepressant NN O O
treatment NN O O
( NN O O
ADT NN O O
) NN O O
for NN O O
patients NN O O
with NN O O
major NN O O
depressive NN O O
disorder NN O O
( NN O O
MDD NN O O
) NN O O
. NN O O

Here NN O O
results NN O O
of NN O O
an NN O O
18- NN O O
to NN O O
19-week NN O O
randomized NN O O
double-blind NN O O
placebo-controlled NN O O
Phase NN O O
3 NN O O
study NN O O
evaluating NN O O
the NN O O
efficacy NN O O
of NN O O
adjunctive NN O O
cariprazine NN O O
( NN O O
1.5 NN O O
- NN O O
4.5 NN O O
mg/day[d NN O O
] NN O O
) NN O O
with NN O O
ADT NN O O
in NN O O
participants NN O O
with NN O O
previous NN O O
inadequate NN O O
response NN O O
to NN O O
ADT NN O O
are NN O O
presented NN O O
. NN O O

ADT NN O O
response NN O O
was NN O O
assessed NN O O
in NN O O
an NN O O
8-week NN O O
open-label NN O O
period NN O O
; NN O O
inadequate NN O O
responders NN O O
were NN O O
randomized NN O O
( NN O O
N NN O O
= NN O O
530 NN O O
) NN O O
to NN O O
open-label NN O O
ADT NN O O
plus NN O O
placebo NN O O
( NN O O
n NN O O
= NN O O
261 NN O O
) NN O O
or NN O O
cariprazine NN O O
( NN O O
n NN O O
= NN O O
269 NN O O
) NN O O
for NN O O
the NN O O
8-week NN O O
double-blind NN O O
phase NN O O
( NN O O
NCT01715805 NN O O
) NN O O
. NN O O

Primary NN O O
and NN O O
secondary NN O O
endpoints NN O O
were NN O O
changes NN O O
at NN O O
week NN O O
8 NN O O
( NN O O
cariprazine NN O O
versus NN O O
placebo NN O O
) NN O O
in NN O O
Montgomery-Åsberg NN O O
Depression NN O O
Rating NN O O
Scale NN O O
( NN O O
MADRS NN O O
) NN O O
total NN O O
score NN O O
and NN O O
in NN O O
Sheehan NN O O
Disability NN O O
Scale NN O O
( NN O O
SDS NN O O
) NN O O
score NN O O
, NN O O
respectively NN O O
, NN O O
which NN O O
were NN O O
analyzed NN O O
by NN O O
mixed-effect NN O O
models NN O O
for NN O O
repeated NN O O
measures NN O O
. NN O O

Cariprazine NN O O
did NN O O
not NN O O
significantly NN O O
improve NN O O
scores NN O O
in NN O O
either NN O O
compared NN O O
to NN O O
placebo NN O O
, NN O O
but NN O O
non-significantly NN O O
reduced NN O O
depressive NN O O
symptoms NN O O
( NN O O
MADRS NN O O
least-squares NN O O
mean NN O O
difference NN O O
[ NN O O
LSMD NN O O
] NN O O
: NN O O
-0.2 NN O O
, NN O O
P NN O O
= NN O O
0.7948 NN O O
and NN O O
SDS NN O O
LSMD NN O O
: NN O O
-0.7 NN O O
, NN O O
P NN O O
= NN O O
0.2784 NN O O
) NN O O
. NN O O

Of NN O O
additional NN O O
efficacy NN O O
parameters NN O O
, NN O O
cariprazine NN O O
significantly NN O O
improved NN O O
Clinical NN O O
Global NN O O
Impressions NN O O
- NN O O
Improvement NN O O
( NN O O
CGI-I NN O O
) NN O O
scores NN O O
versus NN O O
placebo NN O O
( NN O O
LSMD NN O O
: NN O O
-0.2 NN O O
; NN O O
P NN O O
= NN O O
0.0410 NN O O
) NN O O
. NN O O

A NN O O
greater NN O O
proportion NN O O
of NN O O
participants NN O O
achieved NN O O
MADRS NN O O
response NN O O
with NN O O
cariprazine NN O O
vs NN O O
placebo NN O O
, NN O O
but NN O O
differences NN O O
were NN O O
not NN O O
significant NN O O
. NN O O

Cariprazine NN O O
was NN O O
generally NN O O
well-tolerated NN O O
, NN O O
and NN O O
metabolic NN O O
parameters NN O O
and NN O O
body NN O O
weight NN O O
changes NN O O
were NN O O
not NN O O
meaningfully NN O O
different NN O O
than NN O O
placebo NN O O
. NN O O

Common NN O O
newly-emergent NN O O
adverse NN O O
events NN O O
included NN O O
akathisia NN O O
and NN O O
restlessness NN O O
. NN O O

The NN O O
lack NN O O
of NN O O
significant NN O O
improvement NN O O
in NN O O
depressive NN O O
symptoms NN O O
with NN O O
adjunctive NN O O
cariprazine NN O O
and NN O O
ADT NN O O
for NN O O
MDD NN O O
in NN O O
inadequate NN O O
responders NN O O
contrasts NN O O
with NN O O
previously NN O O
published NN O O
results NN O O
, NN O O
therefore NN O O
additional NN O O
studies NN O O
are NN O O
needed NN O O
to NN O O
understand NN O O
role NN O O
of NN O O
adjunctive NN O O
cariprazine NN O O
in NN O O
MDD NN O O
. NN O O



-DOCSTART- (30962729)

To NN O O
evaluate NN O O
the NN O O
analgesic NN O O
effect NN O O
of NN O O
duloxetine NN O O
in NN O O
Chinese NN O O
patients NN O O
with NN O O
osteoarthritis NN O O
( NN O O
OA NN O O
) NN O O
of NN O O
the NN O O
knee/hip NN O O
at NN O O
individual NN O O
patient NN O O
level NN O O
and NN O O
report NN O O
the NN O O
relationship NN O O
between NN O O
pain NN O O
intensity NN O O
reduction NN O O
, NN O O
overall NN O O
improvement NN O O
, NN O O
and NN O O
physical NN O O
functioning NN O O
. NN O O

Post NN O O
hoc NN O O
analysis NN O O
of NN O O
13-week NN O O
, NN O O
phase NN O O
3 NN O O
, NN O O
parallel-group NN O O
, NN O O
randomized NN O O
, NN O O
placebo-controlled NN O O
study NN O O
of NN O O
duloxetine NN O O
in NN O O
Chinese NN O O
patients NN O O
with NN O O
OA NN O O
pain NN O O
. NN O O

Patients NN O O
were NN O O
randomized NN O O
( NN O O
1:1 NN O O
, NN O O
computer-generated NN O O
, NN O O
interactive NN O O
web-response NN O O
system NN O O
) NN O O
to NN O O
duloxetine NN O O
( NN O O
60 NN O O
mg NN O O
once NN O O
daily NN O O
, NN O O
n=202 NN O O
) NN O O
or NN O O
placebo NN O O
( NN O O
n=207 NN O O
) NN O O
. NN O O

Patients NN O O
, NN O O
investigators NN O O
, NN O O
and NN O O
study NN O O
staff NN O O
were NN O O
blinded NN O O
throughout NN O O
the NN O O
study NN O O
. NN O O

Duloxetine NN O O
's NN O O
efficacy NN O O
was NN O O
evaluated NN O O
using NN O O
the NN O O
Initiative NN O O
on NN O O
Methods NN O O
, NN O O
Measurement NN O O
, NN O O
and NN O O
Pain NN O O
Assessment NN O O
in NN O O
Clinical NN O O
Trials NN O O
( NN O O
IMMPACT NN O O
) NN O O
and NN O O
the NN O O
Osteoarthritis NN O O
Research NN O O
Society NN O O
International NN O O
and NN O O
Outcome NN O O
Measures NN O O
in NN O O
Rheumatology NN O O
( NN O O
OARSI-OMERACT NN O O
) NN O O
responder NN O O
criteria NN O O
. NN O O

Analyses NN O O
were NN O O
conducted NN O O
on NN O O
all NN O O
randomized NN O O
patients NN O O
with NN O O
a NN O O
baseline NN O O
and NN O O
at NN O O
least NN O O
one NN O O
post-baseline NN O O
observation NN O O
. NN O O

At NN O O
study NN O O
endpoint NN O O
, NN O O
the NN O O
percentage NN O O
of NN O O
patients NN O O
experiencing NN O O
≥30 NN O O
% NN O O
pain NN O O
intensity NN O O
reduction NN O O
( NN O O
30 NN O O
% NN O O
responders NN O O
) NN O O
was NN O O
significantly NN O O
higher NN O O
in NN O O
the NN O O
duloxetine NN O O
group NN O O
than NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
( NN O O
63.4 NN O O
% NN O O
vs NN O O
49.7 NN O O
% NN O O
; NN O O
= NN O O
0.008 NN O O
) NN O O
. NN O O

The NN O O
percentage NN O O
of NN O O
patients NN O O
experiencing NN O O
≥50 NN O O
% NN O O
pain NN O O
intensity NN O O
reduction NN O O
( NN O O
50 NN O O
% NN O O
responders NN O O
) NN O O
in NN O O
the NN O O
duloxetine NN O O
group NN O O
was NN O O
numerically NN O O
higher NN O O
than NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
( NN O O
42.8 NN O O
% NN O O
vs NN O O
34.5 NN O O
% NN O O
; NN O O
= NN O O
0.098 NN O O
) NN O O
. NN O O

Most NN O O
of NN O O
the NN O O
30 NN O O
% NN O O
and NN O O
50 NN O O
% NN O O
responders NN O O
to NN O O
duloxetine NN O O
treatment NN O O
felt NN O O
either NN O O
" NN O O
very NN O O
much NN O O
improved NN O O
" NN O O
or NN O O
" NN O O
much NN O O
improved NN O O
" NN O O
on NN O O
the NN O O
Patient NN O O
Global NN O O
Impression-Improvement NN O O
at NN O O
endpoint NN O O
. NN O O

The NN O O
30 NN O O
% NN O O
and NN O O
50 NN O O
% NN O O
responders NN O O
to NN O O
duloxetine NN O O
treatment NN O O
also NN O O
experienced NN O O
greater NN O O
improvements NN O O
in NN O O
the NN O O
Western NN O O
Ontario NN O O
and NN O O
McMaster NN O O
Universities NN O O
Osteoarthritis NN O O
Index NN O O
physical NN O O
function NN O O
scores NN O O
at NN O O
endpoint NN O O
compared NN O O
with NN O O
non-responders NN O O
. NN O O

The NN O O
overall NN O O
percentage NN O O
of NN O O
OARSI-OMERACT NN O O
responders NN O O
was NN O O
significantly NN O O
higher NN O O
in NN O O
the NN O O
duloxetine NN O O
group NN O O
vs NN O O
the NN O O
placebo NN O O
group NN O O
( NN O O
70.1 NN O O
% NN O O
vs NN O O
54.9 NN O O
% NN O O
; NN O O
= NN O O
0.003 NN O O
) NN O O
. NN O O

Based NN O O
on NN O O
IMMPACT NN O O
and NN O O
OARSI-OMERACT NN O O
criteria NN O O
, NN O O
the NN O O
analgesic NN O O
effect NN O O
of NN O O
duloxetine NN O O
was NN O O
associated NN O O
with NN O O
clinically NN O O
relevant NN O O
benefits NN O O
in NN O O
Chinese NN O O
patients NN O O
with NN O O
OA NN O O
of NN O O
the NN O O
knee/hip NN O O
. NN O O

NCT01931475 NN O O
. NN O O



-DOCSTART- (31009399)

In NN O O
patients NN O O
with NN O O
high NN O O
bleeding NN O O
risk NN O O
, NN O O
percutaneous NN O O
coronary NN O O
intervention NN O O
is NN O O
still NN O O
debated NN O O
. NN O O

This NN O O
study NN O O
compared NN O O
9-month NN O O
angiographic NN O O
and NN O O
physiologic NN O O
results NN O O
in NN O O
patients NN O O
with NN O O
high NN O O
bleeding NN O O
risk NN O O
and NN O O
de NN O O
novo NN O O
coronary NN O O
lesions NN O O
treated NN O O
with NN O O
either NN O O
paclitaxel-coated NN O O
balloon NN O O
( NN O O
PCB NN O O
) NN O O
or NN O O
bare-metal NN O O
stent NN O O
( NN O O
BMS NN O O
) NN O O
. NN O O

A NN O O
total NN O O
of NN O O
40 NN O O
patients NN O O
( NN O O
40 NN O O
lesions NN O O
) NN O O
with NN O O
high NN O O
bleeding NN O O
risk NN O O
who NN O O
underwent NN O O
successful NN O O
balloon NN O O
angioplasty NN O O
with NN O O
fractional NN O O
flow NN O O
reserve NN O O
( NN O O
FFR NN O O
) NN O O
after NN O O
balloon NN O O
angioplasty NN O O
more NN O O
than NN O O
0.80 NN O O
were NN O O
randomized NN O O
1 NN O O
: NN O O
1 NN O O
to NN O O
treatment NN O O
with NN O O
PCB NN O O
versus NN O O
BMS NN O O
. NN O O

Dual NN O O
antiplatelet NN O O
therapy NN O O
was NN O O
limited NN O O
to NN O O
1 NN O O
month NN O O
after NN O O
the NN O O
procedure NN O O
. NN O O

Baseline NN O O
clinical NN O O
and NN O O
lesional NN O O
characteristics NN O O
were NN O O
well NN O O
balanced NN O O
between NN O O
the NN O O
two NN O O
groups NN O O
. NN O O

There NN O O
was NN O O
no NN O O
significant NN O O
difference NN O O
in NN O O
the NN O O
postprocedural NN O O
FFR NN O O
( NN O O
0.87 NN O O
± NN O O
0.06 NN O O
in NN O O
PCB NN O O
vs. NN O O
0.89 NN O O
± NN O O
0.06 NN O O
in NN O O
BMS NN O O
, NN O O
P NN O O
= NN O O
0.254 NN O O
) NN O O
. NN O O

At NN O O
9 NN O O
months NN O O
, NN O O
late NN O O
luminal NN O O
loss NN O O
was NN O O
significantly NN O O
lower NN O O
in NN O O
the NN O O
PCB NN O O
group NN O O
( NN O O
0.2 NN O O
± NN O O
0.3 NN O O
vs. NN O O
1.2 NN O O
± NN O O
0.8 NN O O
mm NN O O
, NN O O
P NN O O
< NN O O
0.001 NN O O
) NN O O
. NN O O

Restenosis NN O O
only NN O O
occurred NN O O
in NN O O
the NN O O
BMS NN O O
group NN O O
( NN O O
0 NN O O
vs. NN O O
25.0 NN O O
% NN O O
, NN O O
P NN O O
= NN O O
0.049 NN O O
) NN O O
. NN O O

In NN O O
patients NN O O
with NN O O
high NN O O
bleeding NN O O
risk NN O O
, NN O O
FFR-guided NN O O
PCB NN O O
treatment NN O O
showed NN O O
superior NN O O
efficacy NN O O
in NN O O
terms NN O O
of NN O O
angiographic NN O O
and NN O O
physiologic NN O O
patency NN O O
compared NN O O
with NN O O
BMS NN O O
at NN O O
mid-term NN O O
follow-up NN O O
with NN O O
only NN O O
1 NN O O
month NN O O
of NN O O
dual NN O O
antiplatelet NN O O
therapy NN O O
( NN O O
Clinicaltrials.gov NN O O
identifier NN O O
, NN O O
NCT02456402 NN O O
) NN O O
. NN O O



-DOCSTART- (30987813)

Vitamin NN O O
D NN O O
inadequacy NN O O
is NN O O
associated NN O O
with NN O O
a NN O O
wide NN O O
range NN O O
of NN O O
diseases NN O O
. NN O O

However NN O O
, NN O O
optimal NN O O
strategies NN O O
to NN O O
improve NN O O
vitamin NN O O
D NN O O
status NN O O
, NN O O
especially NN O O
in NN O O
Asian NN O O
populations NN O O
, NN O O
remain NN O O
unclear NN O O
. NN O O

We NN O O
tested NN O O
the NN O O
hypotheses NN O O
that NN O O
( NN O O
1 NN O O
) NN O O
relevant NN O O
sun NN O O
exposure NN O O
or NN O O
oral NN O O
vitamin NN O O
D NN O O
supplementation NN O O
would NN O O
significantly NN O O
increase NN O O
serum NN O O
25-hydroxyvitamin NN O O
D NN O O
( NN O O
25OHD NN O O
) NN O O
concentrations NN O O
compared NN O O
with NN O O
placebo NN O O
, NN O O
( NN O O
2 NN O O
) NN O O
sun NN O O
exposure NN O O
and NN O O
supplementary NN O O
vitamin NN O O
D NN O O
would NN O O
be NN O O
similar NN O O
in NN O O
serum NN O O
25OHD NN O O
increases NN O O
, NN O O
and NN O O
( NN O O
3 NN O O
) NN O O
the NN O O
two NN O O
interventions NN O O
may NN O O
have NN O O
different NN O O
effects NN O O
on NN O O
cardio-metabolic NN O O
markers NN O O
. NN O O

In NN O O
this NN O O
8-week NN O O
randomized NN O O
placebo-controlled NN O O
clinical NN O O
trial NN O O
including NN O O
vitamin NN O O
D-deficient NN O O
adults NN O O
in NN O O
Seoul NN O O
( NN O O
37 NN O O
° NN O O
N NN O O
) NN O O
, NN O O
Korea NN O O
, NN O O
changes NN O O
in NN O O
serum NN O O
25OHD NN O O
concentrations NN O O
were NN O O
compared NN O O
between NN O O
the NN O O
sun NN O O
exposure NN O O
( NN O O
daily NN O O
≥20 NN O O
- NN O O
30 NN O O
min NN O O
around NN O O
noon NN O O
, NN O O
n NN O O
= NN O O
50 NN O O
) NN O O
, NN O O
oral NN O O
vitamin NN O O
D NN O O
( NN O O
500 NN O O
IU/d NN O O
, NN O O
n NN O O
= NN O O
50 NN O O
) NN O O
, NN O O
and NN O O
control NN O O
( NN O O
placebo NN O O
, NN O O
n NN O O
= NN O O
50 NN O O
) NN O O
groups NN O O
. NN O O

Both NN O O
sun NN O O
exposure NN O O
and NN O O
oral NN O O
vitamin NN O O
D NN O O
effectively NN O O
increased NN O O
serum NN O O
25OHD NN O O
concentrations NN O O
. NN O O

Compared NN O O
with NN O O
placebo NN O O
, NN O O
the NN O O
between-group NN O O
least-squares NN O O
mean NN O O
( NN O O
LSM NN O O
) NN O O
differences NN O O
in NN O O
changes NN O O
were NN O O
2.2 NN O O
ng/mL NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
: NN O O
0.2 NN O O
, NN O O
4.2 NN O O
) NN O O
in NN O O
the NN O O
sun NN O O
exposure NN O O
group NN O O
and NN O O
8.5 NN O O
ng/mL NN O O
( NN O O
6.5 NN O O
, NN O O
10.5 NN O O
) NN O O
in NN O O
the NN O O
oral NN O O
vitamin NN O O
D NN O O
group NN O O
. NN O O

Increases NN O O
in NN O O
serum NN O O
25OHD NN O O
were NN O O
greater NN O O
with NN O O
oral NN O O
vitamin NN O O
D NN O O
than NN O O
with NN O O
sun NN O O
exposure NN O O
( NN O O
LSM NN O O
difference NN O O
in NN O O
changes NN O O
= NN O O
6.3 NN O O
ng/mL NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
: NN O O
4.3 NN O O
, NN O O
8.3 NN O O
) NN O O
. NN O O

More NN O O
participants NN O O
in NN O O
the NN O O
oral NN O O
vitamin NN O O
D NN O O
group NN O O
( NN O O
54.2 NN O O
% NN O O
) NN O O
achieved NN O O
serum NN O O
25OHD NN O O
concentrations NN O O
≥20 NN O O
ng/mL NN O O
at NN O O
week NN O O
8 NN O O
than NN O O
those NN O O
in NN O O
the NN O O
sun NN O O
exposure NN O O
( NN O O
12.2 NN O O
% NN O O
) NN O O
or NN O O
control NN O O
( NN O O
4.3 NN O O
% NN O O
) NN O O
groups NN O O
. NN O O

Compliance NN O O
with NN O O
sun NN O O
exposure NN O O
advice NN O O
was NN O O
relatively NN O O
low NN O O
, NN O O
and NN O O
only NN O O
those NN O O
with NN O O
adequate NN O O
compliance NN O O
had NN O O
a NN O O
significant NN O O
increase NN O O
in NN O O
serum NN O O
25OHD NN O O
. NN O O

Changes NN O O
in NN O O
the NN O O
cardio-metabolic NN O O
markers NN O O
were NN O O
mostly NN O O
insignificant NN O O
in NN O O
all NN O O
groups NN O O
. NN O O

Enhanced NN O O
sun NN O O
exposure NN O O
and NN O O
500 NN O O
IU/d NN O O
of NN O O
oral NN O O
vitamin NN O O
D NN O O
supplementation NN O O
significantly NN O O
increased NN O O
serum NN O O
25OHD NN O O
concentrations NN O O
. NN O O

However NN O O
, NN O O
our NN O O
protocol NN O O
for NN O O
sun NN O O
exposure NN O O
was NN O O
not NN O O
as NN O O
effective NN O O
as NN O O
500 NN O O
IU/d NN O O
of NN O O
oral NN O O
vitamin NN O O
D NN O O
supplementation NN O O
. NN O O

This NN O O
trial NN O O
was NN O O
registered NN O O
at NN O O
clinicaltrials.gov NN O O
as NN O O
NCT03310242 NN O O
. NN O O



-DOCSTART- (31162569)

Whether NN O O
exercise NN O O
reduces NN O O
subsequent NN O O
falls NN O O
in NN O O
high-risk NN O O
older NN O O
adults NN O O
who NN O O
have NN O O
already NN O O
experienced NN O O
a NN O O
fall NN O O
is NN O O
unknown NN O O
. NN O O

To NN O O
assess NN O O
the NN O O
effect NN O O
of NN O O
a NN O O
home-based NN O O
exercise NN O O
program NN O O
as NN O O
a NN O O
fall NN O O
prevention NN O O
strategy NN O O
in NN O O
older NN O O
adults NN O O
who NN O O
were NN O O
referred NN O O
to NN O O
a NN O O
fall NN O O
prevention NN O O
clinic NN O O
after NN O O
an NN O O
index NN O O
fall NN O O
. NN O O

A NN O O
12-month NN O O
, NN O O
single-blind NN O O
, NN O O
randomized NN O O
clinical NN O O
trial NN O O
conducted NN O O
from NN O O
April NN O O
22 NN O O
, NN O O
2009 NN O O
, NN O O
to NN O O
June NN O O
5 NN O O
, NN O O
2018 NN O O
, NN O O
among NN O O
adults NN O O
aged NN O O
at NN O O
least NN O O
70 NN O O
years NN O O
who NN O O
had NN O O
a NN O O
fall NN O O
within NN O O
the NN O O
past NN O O
12 NN O O
months NN O O
and NN O O
were NN O O
recruited NN O O
from NN O O
a NN O O
fall NN O O
prevention NN O O
clinic NN O O
. NN O O

Participants NN O O
were NN O O
randomized NN O O
to NN O O
receive NN O O
usual NN O O
care NN O O
plus NN O O
a NN O O
home-based NN O O
strength NN O O
and NN O O
balance NN O O
retraining NN O O
exercise NN O O
program NN O O
delivered NN O O
by NN O O
a NN O O
physical NN O O
therapist NN O O
( NN O O
intervention NN O O
group NN O O
; NN O O
n NN O O
= NN O O
173 NN O O
) NN O O
or NN O O
usual NN O O
care NN O O
, NN O O
consisting NN O O
of NN O O
fall NN O O
prevention NN O O
care NN O O
provided NN O O
by NN O O
a NN O O
geriatrician NN O O
( NN O O
usual NN O O
care NN O O
group NN O O
; NN O O
n NN O O
= NN O O
172 NN O O
) NN O O
. NN O O

Both NN O O
were NN O O
provided NN O O
for NN O O
12 NN O O
months NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
was NN O O
self-reported NN O O
number NN O O
of NN O O
falls NN O O
over NN O O
12 NN O O
months NN O O
. NN O O

Adverse NN O O
event NN O O
data NN O O
were NN O O
collected NN O O
in NN O O
the NN O O
exercise NN O O
group NN O O
only NN O O
and NN O O
consisted NN O O
of NN O O
falls NN O O
, NN O O
injuries NN O O
, NN O O
or NN O O
muscle NN O O
soreness NN O O
related NN O O
to NN O O
the NN O O
exercise NN O O
intervention NN O O
. NN O O

Among NN O O
345 NN O O
randomized NN O O
patients NN O O
( NN O O
mean NN O O
age NN O O
, NN O O
81.6 NN O O
[ NN O O
SD NN O O
, NN O O
6.1 NN O O
] NN O O
years NN O O
; NN O O
67 NN O O
% NN O O
women NN O O
) NN O O
, NN O O
296 NN O O
( NN O O
86 NN O O
% NN O O
) NN O O
completed NN O O
the NN O O
trial NN O O
. NN O O

During NN O O
a NN O O
mean NN O O
follow-up NN O O
of NN O O
338 NN O O
( NN O O
SD NN O O
, NN O O
81 NN O O
) NN O O
days NN O O
, NN O O
a NN O O
total NN O O
of NN O O
236 NN O O
falls NN O O
occurred NN O O
among NN O O
172 NN O O
participants NN O O
in NN O O
the NN O O
exercise NN O O
group NN O O
vs NN O O
366 NN O O
falls NN O O
among NN O O
172 NN O O
participants NN O O
in NN O O
the NN O O
usual NN O O
care NN O O
group NN O O
. NN O O

Estimated NN O O
incidence NN O O
rates NN O O
of NN O O
falls NN O O
per NN O O
person-year NN O O
were NN O O
1.4 NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
0.1 NN O O
- NN O O
2.0 NN O O
) NN O O
vs NN O O
2.1 NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
0.1 NN O O
- NN O O
3.2 NN O O
) NN O O
, NN O O
respectively NN O O
. NN O O

The NN O O
absolute NN O O
difference NN O O
in NN O O
fall NN O O
incidence NN O O
was NN O O
0.74 NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
0.04 NN O O
- NN O O
1.78 NN O O
; NN O O
P NN O O
= NN O O
.006 NN O O
) NN O O
falls NN O O
per NN O O
person-year NN O O
and NN O O
the NN O O
incident NN O O
rate NN O O
ratio NN O O
was NN O O
0.64 NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
0.46 NN O O
- NN O O
0.90 NN O O
; NN O O
P NN O O
= NN O O
.009 NN O O
) NN O O
. NN O O

No NN O O
adverse NN O O
events NN O O
related NN O O
to NN O O
the NN O O
intervention NN O O
were NN O O
reported NN O O
. NN O O

Among NN O O
older NN O O
adults NN O O
receiving NN O O
care NN O O
at NN O O
a NN O O
fall NN O O
prevention NN O O
clinic NN O O
after NN O O
a NN O O
fall NN O O
, NN O O
a NN O O
home-based NN O O
strength NN O O
and NN O O
balance NN O O
retraining NN O O
exercise NN O O
program NN O O
significantly NN O O
reduced NN O O
the NN O O
rate NN O O
of NN O O
subsequent NN O O
falls NN O O
compared NN O O
with NN O O
usual NN O O
care NN O O
provided NN O O
by NN O O
a NN O O
geriatrician NN O O
. NN O O

These NN O O
findings NN O O
support NN O O
the NN O O
use NN O O
of NN O O
this NN O O
home-based NN O O
exercise NN O O
program NN O O
for NN O O
secondary NN O O
fall NN O O
prevention NN O O
but NN O O
require NN O O
replication NN O O
in NN O O
other NN O O
clinical NN O O
settings NN O O
. NN O O

ClinicalTrials.gov NN O O
Identifiers NN O O
: NN O O
NCT01029171 NN O O
; NN O O
NCT00323596 NN O O
. NN O O



-DOCSTART- (31365365)

Observational NN O O
studies NN O O
have NN O O
reported NN O O
conflicting NN O O
results NN O O
with NN O O
primary NN O O
fascial NN O O
closure NN O O
( NN O O
PFC NN O O
) NN O O
versus NN O O
bridged NN O O
repair NN O O
during NN O O
laparoscopic NN O O
ventral NN O O
hernia NN O O
repair NN O O
( NN O O
LVHR NN O O
) NN O O
. NN O O

The NN O O
aim NN O O
of NN O O
the NN O O
study NN O O
was NN O O
to NN O O
determine NN O O
whether NN O O
when NN O O
evaluated NN O O
in NN O O
a NN O O
randomized NN O O
controlled NN O O
trial NN O O
( NN O O
RCT NN O O
) NN O O
, NN O O
PFC NN O O
compared NN O O
to NN O O
bridged NN O O
repair NN O O
would NN O O
improve NN O O
patient NN O O
quality NN O O
of NN O O
life NN O O
( NN O O
QoL NN O O
) NN O O
. NN O O

In NN O O
this NN O O
blinded NN O O
, NN O O
multicenter NN O O
RCT NN O O
, NN O O
patients NN O O
scheduled NN O O
for NN O O
elective NN O O
LVHR NN O O
( NN O O
hernia NN O O
defects NN O O
3 NN O O
to NN O O
10 NN O O
cm NN O O
on NN O O
computed NN O O
tomography NN O O
scan NN O O
) NN O O
were NN O O
randomized NN O O
to NN O O
PFC NN O O
versus NN O O
bridged NN O O
repair NN O O
. NN O O

Primary NN O O
outcome NN O O
was NN O O
change NN O O
in NN O O
QoL NN O O
after NN O O
LVHR NN O O
using NN O O
a NN O O
validated NN O O
, NN O O
hernia-specific NN O O
survey NN O O
( NN O O
1 NN O O
= NN O O
poor NN O O
QoL NN O O
and NN O O
100 NN O O
= NN O O
perfect NN O O
QoL NN O O
) NN O O
that NN O O
measures NN O O
pain NN O O
, NN O O
function NN O O
, NN O O
cosmesis NN O O
, NN O O
and NN O O
satisfaction NN O O
. NN O O

Secondary NN O O
outcomes NN O O
were NN O O
postoperative NN O O
surgical NN O O
site NN O O
occurrences NN O O
( NN O O
including NN O O
hematoma NN O O
, NN O O
seroma NN O O
, NN O O
surgical NN O O
site NN O O
infection NN O O
, NN O O
and NN O O
wound NN O O
dehiscence NN O O
) NN O O
, NN O O
abdominal NN O O
eventration NN O O
, NN O O
and NN O O
hernia NN O O
recurrence NN O O
. NN O O

The NN O O
trial NN O O
was NN O O
powered NN O O
to NN O O
detect NN O O
a NN O O
difference NN O O
in NN O O
change NN O O
in NN O O
QoL NN O O
of NN O O
7 NN O O
points NN O O
between NN O O
the NN O O
study NN O O
groups NN O O
. NN O O

Outcomes NN O O
were NN O O
compared NN O O
with NN O O
Mann-Whitney NN O O
U NN O O
test NN O O
or NN O O
chi-square NN O O
. NN O O

A NN O O
total NN O O
of NN O O
129 NN O O
patients NN O O
underwent NN O O
LVHR NN O O
and NN O O
107 NN O O
( NN O O
83 NN O O
% NN O O
) NN O O
completed NN O O
follow-up NN O O
at NN O O
2 NN O O
years NN O O
. NN O O

Patients NN O O
from NN O O
both NN O O
groups NN O O
were NN O O
similar NN O O
at NN O O
baseline NN O O
. NN O O

On NN O O
median NN O O
follow-up NN O O
of NN O O
24 NN O O
months NN O O
( NN O O
range NN O O
: NN O O
9 NN O O
- NN O O
42 NN O O
) NN O O
, NN O O
patients NN O O
treated NN O O
with NN O O
LVHR-PFC NN O O
had NN O O
on NN O O
average NN O O
a NN O O
12-point NN O O
higher NN O O
improvement NN O O
in NN O O
QoL NN O O
compared NN O O
to NN O O
bridged NN O O
repair NN O O
( NN O O
improvement NN O O
in NN O O
QoL NN O O
, NN O O
41.3 NN O O
± NN O O
31.5 NN O O
vs NN O O
29.7 NN O O
± NN O O
28.7 NN O O
, NN O O
P NN O O
value NN O O
= NN O O
0.047 NN O O
) NN O O
. NN O O

There NN O O
were NN O O
no NN O O
differences NN O O
in NN O O
surgical NN O O
site NN O O
occurrence NN O O
, NN O O
eventration NN O O
, NN O O
or NN O O
hernia NN O O
recurrence NN O O
between NN O O
groups NN O O
. NN O O

Among NN O O
patients NN O O
undergoing NN O O
elective NN O O
LVHR NN O O
, NN O O
the NN O O
fascial NN O O
defect NN O O
should NN O O
be NN O O
closed NN O O
. NN O O

This NN O O
is NN O O
the NN O O
first NN O O
RCT NN O O
demonstrating NN O O
that NN O O
PFC NN O O
with NN O O
LVHR NN O O
significantly NN O O
improves NN O O
patient NN O O
QoL. NN O O

This NN O O
trial NN O O
was NN O O
registered NN O O
with NN O O
clinicaltrials.gov NN O O
( NN O O
NCT02363790 NN O O
) NN O O
. NN O O



-DOCSTART- (30593268)

Recently NN O O
, NN O O
a NN O O
novel NN O O
approach NN O O
with NN O O
delaying NN O O
the NN O O
start NN O O
of NN O O
controlled NN O O
ovarian NN O O
stimulation NN O O
along NN O O
with NN O O
gonadotropin-releasing NN O O
hormone NN O O
( NN O O
GnRH NN O O
) NN O O
antagonist NN O O
pretreatment NN O O
for NN O O
7 NN O O
days NN O O
after NN O O
estrogen NN O O
priming NN O O
for NN O O
further NN O O
suppression NN O O
of NN O O
endogenous NN O O
follicle NN O O
stimulating NN O O
hormone NN O O
( NN O O
FSH NN O O
) NN O O
during NN O O
the NN O O
early NN O O
follicular NN O O
phase NN O O
, NN O O
resulting NN O O
in NN O O
more NN O O
FSH-responsive NN O O
follicles NN O O
and NN O O
thus NN O O
improving NN O O
synchronous NN O O
follicular NN O O
development NN O O
was NN O O
introduced NN O O
. NN O O

Two NN O O
clinical NN O O
trials NN O O
have NN O O
examined NN O O
this NN O O
strategy NN O O
and NN O O
reported NN O O
controversial NN O O
results NN O O
. NN O O

This NN O O
study NN O O
aimed NN O O
to NN O O
compare NN O O
the NN O O
effect NN O O
of NN O O
delayed-start NN O O
GnRH NN O O
antagonist NN O O
protocol NN O O
and NN O O
standard NN O O
GnRH NN O O
antagonist NN O O
in NN O O
patients NN O O
with NN O O
poor NN O O
ovarian NN O O
response NN O O
( NN O O
POR NN O O
) NN O O
undergoing NN O O
in NN O O
vitro NN O O
fertilization NN O O
(IVF)/ NN O O
intracytoplasmic NN O O
sperm NN O O
injection NN O O
( NN O O
ICSI NN O O
) NN O O
. NN O O

This NN O O
randomized NN O O
clinical NN O O
trial NN O O
was NN O O
conducted NN O O
at NN O O
infertility NN O O
department NN O O
of NN O O
Royan NN O O
Institute NN O O
from NN O O
January NN O O
2017 NN O O
to NN O O
June NN O O
2018 NN O O
. NN O O

Poor NN O O
ovarian NN O O
response NN O O
was NN O O
defined NN O O
according NN O O
to NN O O
the NN O O
Bologna NN O O
criteria NN O O
. NN O O

The NN O O
eligible NN O O
women NN O O
were NN O O
randomly NN O O
allocated NN O O
into NN O O
an NN O O
experimental NN O O
and NN O O
control NN O O
groups NN O O
. NN O O

In NN O O
experimental NN O O
group NN O O
, NN O O
patients NN O O
received NN O O
delayed-start NN O O
GnRH NN O O
antagonist NN O O
protocol NN O O
with NN O O
estrogen NN O O
priming NN O O
followed NN O O
by NN O O
early NN O O
follicular-phase NN O O
GnRH NN O O
antagonist NN O O
treatment NN O O
for NN O O
7 NN O O
days NN O O
before NN O O
ovarian NN O O
stimulation NN O O
with NN O O
gonadotropin NN O O
and NN O O
in NN O O
control NN O O
group NN O O
, NN O O
patients NN O O
treated NN O O
with NN O O
estrogen NN O O
priming NN O O
antagonist NN O O
protocol NN O O
. NN O O

IVF/ICSI NN O O
outcomes NN O O
were NN O O
compared NN O O
between NN O O
groups NN O O
. NN O O

Among NN O O
all NN O O
the NN O O
250 NN O O
patients NN O O
examined NN O O
156 NN O O
women NN O O
were NN O O
eligible NN O O
for NN O O
study NN O O
and NN O O
finally NN O O
120 NN O O
patients NN O O
were NN O O
allocated NN O O
to NN O O
intervention NN O O
( NN O O
n NN O O
= NN O O
60 NN O O
) NN O O
and NN O O
control NN O O
( NN O O
n NN O O
= NN O O
60 NN O O
) NN O O
groups NN O O
. NN O O

Demographic NN O O
characteristics NN O O
and NN O O
hormonal NN O O
profiles NN O O
of NN O O
the NN O O
patients NN O O
did NN O O
not NN O O
differ NN O O
between NN O O
groups NN O O
. NN O O

The NN O O
statistical NN O O
analysis NN O O
showed NN O O
that NN O O
there NN O O
were NN O O
significant NN O O
differences NN O O
between NN O O
groups NN O O
regarding NN O O
the NN O O
total NN O O
dose NN O O
of NN O O
used NN O O
gonadotropins NN O O
( NN O O
P NN O O
< NN O O
0.001 NN O O
) NN O O
, NN O O
stimulation NN O O
duration NN O O
( NN O O
P NN O O
< NN O O
0.001 NN O O
) NN O O
, NN O O
number NN O O
of NN O O
retrieved NN O O
oocytes NN O O
( NN O O
P NN O O
= NN O O
0.01 NN O O
) NN O O
and NN O O
top NN O O
quality NN O O
embryo NN O O
( NN O O
P NN O O
< NN O O
0.001 NN O O
) NN O O
and NN O O
also NN O O
cancellation NN O O
( NN O O
P NN O O
= NN O O
0.002 NN O O
) NN O O
and NN O O
fertilization NN O O
rates NN O O
( NN O O
P NN O O
= NN O O
0.002 NN O O
) NN O O
. NN O O

On NN O O
the NN O O
basis NN O O
of NN O O
present NN O O
results NN O O
the NN O O
delayed-start NN O O
protocol NN O O
in NN O O
poor NN O O
responders NN O O
can NN O O
improve NN O O
the NN O O
fertilization NN O O
rate NN O O
and NN O O
quality NN O O
of NN O O
embryos NN O O
and NN O O
reduce NN O O
the NN O O
cycle NN O O
cancellation NN O O
but NN O O
have NN O O
no NN O O
significant NN O O
effect NN O O
on NN O O
clinical NN O O
pregnancy NN O O
rate NN O O
; NN O O
however NN O O
, NN O O
larger NN O O
randomized NN O O
clinical NN O O
trials NN O O
are NN O O
required NN O O
to NN O O
compare NN O O
it NN O O
with NN O O
other NN O O
protocols NN O O
. NN O O

NCT NN O O
, NN O O
NCT03134690 NN O O
. NN O O

Registered NN O O
1 NN O O
May NN O O
2017 NN O O
- NN O O
Retrospectively NN O O
registered NN O O
, NN O O
http://www.clinicaltrial.gov NN O O
/ NN O O
NCT03134690 NN O O
. NN O O



-DOCSTART- (31320354)

Permanent NN O O
artificial NN O O
pacemaker NN O O
implantation NN O O
is NN O O
a NN O O
safe NN O O
and NN O O
effective NN O O
treatment NN O O
for NN O O
bradycardia NN O O
and NN O O
is NN O O
associated NN O O
with NN O O
extended NN O O
longevity NN O O
and NN O O
improved NN O O
quality NN O O
of NN O O
life NN O O
. NN O O

However NN O O
, NN O O
the NN O O
most NN O O
common NN O O
long-term NN O O
complication NN O O
of NN O O
standard NN O O
pacemaker NN O O
therapy NN O O
is NN O O
pacemaker-associated NN O O
heart NN O O
failure NN O O
. NN O O

Pacemaker NN O O
follow-up NN O O
is NN O O
potentially NN O O
an NN O O
opportunity NN O O
to NN O O
screen NN O O
for NN O O
heart NN O O
failure NN O O
to NN O O
assess NN O O
and NN O O
optimise NN O O
patient NN O O
devices NN O O
and NN O O
medical NN O O
therapy NN O O
. NN O O

The NN O O
study NN O O
is NN O O
a NN O O
multicentre NN O O
, NN O O
phase-3 NN O O
randomised NN O O
trial NN O O
. NN O O

The NN O O
1200 NN O O
participants NN O O
will NN O O
be NN O O
people NN O O
who NN O O
have NN O O
a NN O O
permanent NN O O
pacemaker NN O O
for NN O O
bradycardia NN O O
for NN O O
at NN O O
least NN O O
12 NN O O
months NN O O
, NN O O
randomly NN O O
assigned NN O O
to NN O O
undergo NN O O
a NN O O
transthoracic NN O O
echocardiogram NN O O
with NN O O
their NN O O
pacemaker NN O O
check NN O O
, NN O O
thereby NN O O
tailoring NN O O
their NN O O
management NN O O
directed NN O O
by NN O O
left NN O O
ventricular NN O O
function NN O O
or NN O O
the NN O O
pacemaker NN O O
check NN O O
alone NN O O
, NN O O
continuing NN O O
with NN O O
routine NN O O
follow-up NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
measure NN O O
is NN O O
time NN O O
to NN O O
all-cause NN O O
mortality NN O O
or NN O O
heart NN O O
failure NN O O
hospitalisation NN O O
. NN O O

Secondary NN O O
outcomes NN O O
include NN O O
external NN O O
validation NN O O
of NN O O
our NN O O
risk NN O O
stratification NN O O
model NN O O
to NN O O
predict NN O O
onset NN O O
of NN O O
heart NN O O
failure NN O O
and NN O O
quality NN O O
of NN O O
life NN O O
assessment NN O O
. NN O O

The NN O O
trial NN O O
design NN O O
and NN O O
protocol NN O O
have NN O O
received NN O O
national NN O O
ethical NN O O
approval NN O O
( NN O O
12/YH/0487 NN O O
) NN O O
. NN O O

The NN O O
results NN O O
of NN O O
this NN O O
randomised NN O O
trial NN O O
will NN O O
be NN O O
published NN O O
in NN O O
international NN O O
peer-reviewed NN O O
journals NN O O
, NN O O
communicated NN O O
to NN O O
healthcare NN O O
professionals NN O O
and NN O O
patient NN O O
involvement NN O O
groups NN O O
and NN O O
highlighted NN O O
using NN O O
social NN O O
media NN O O
campaigns NN O O
. NN O O

NCT01819662 NN O O
. NN O O



-DOCSTART- (30760231)

Large NN O O
volumes NN O O
of NN O O
sitting NN O O
time NN O O
have NN O O
been NN O O
associated NN O O
with NN O O
multiple NN O O
health NN O O
risks NN O O
. NN O O

To NN O O
reduce NN O O
sitting NN O O
time NN O O
of NN O O
office NN O O
workers NN O O
working NN O O
for NN O O
a NN O O
Dutch NN O O
insurance NN O O
company NN O O
, NN O O
the NN O O
Dynamic NN O O
Work NN O O
intervention NN O O
was NN O O
developed NN O O
. NN O O

The NN O O
primary NN O O
objective NN O O
of NN O O
this NN O O
paper NN O O
is NN O O
to NN O O
describe NN O O
the NN O O
study NN O O
protocol NN O O
of NN O O
the NN O O
Dynamic NN O O
Work NN O O
study NN O O
, NN O O
which NN O O
aims NN O O
to NN O O
evaluate NN O O
if NN O O
this NN O O
multicomponent NN O O
intervention NN O O
is NN O O
(cost-)effective NN O O
in NN O O
reducing NN O O
total NN O O
sitting NN O O
time NN O O
on NN O O
the NN O O
short-term NN O O
( NN O O
≈3 NN O O
months NN O O
) NN O O
and NN O O
longer-term NN O O
( NN O O
≈12 NN O O
months NN O O
) NN O O
compared NN O O
to NN O O
usual NN O O
practice NN O O
. NN O O

This NN O O
two-arm NN O O
cluster NN O O
randomized NN O O
controlled NN O O
trial NN O O
will NN O O
recruit NN O O
250 NN O O
desk-based NN O O
office NN O O
workers NN O O
working NN O O
at NN O O
different NN O O
locations NN O O
of NN O O
an NN O O
insurance NN O O
company NN O O
in NN O O
the NN O O
Netherlands NN O O
. NN O O

After NN O O
baseline NN O O
measurements NN O O
, NN O O
departments NN O O
will NN O O
be NN O O
matched NN O O
in NN O O
pairs NN O O
and NN O O
each NN O O
pair NN O O
will NN O O
be NN O O
randomly NN O O
assigned NN O O
to NN O O
the NN O O
control NN O O
or NN O O
intervention NN O O
condition NN O O
. NN O O

The NN O O
multicomponent NN O O
intervention NN O O
contains NN O O
organizational NN O O
( NN O O
i.e. NN O O
face NN O O
to NN O O
face NN O O
session NN O O
with NN O O
the NN O O
head NN O O
of NN O O
the NN O O
department NN O O
) NN O O
, NN O O
work NN O O
environmental NN O O
( NN O O
i.e. NN O O
the NN O O
introduction NN O O
of NN O O
sit-stand NN O O
desks NN O O
and NN O O
cycling NN O O
workstations NN O O
) NN O O
, NN O O
and NN O O
individual NN O O
elements NN O O
( NN O O
i.e. NN O O
counselling NN O O
and NN O O
activity/sitting NN O O
tracker NN O O
with NN O O
a NN O O
self-help NN O O
program NN O O
booklet NN O O
) NN O O
. NN O O

The NN O O
counselling NN O O
involves NN O O
two NN O O
group NN O O
intervention NN O O
sessions NN O O
and NN O O
four NN O O
on-site NN O O
department NN O O
consultations NN O O
with NN O O
an NN O O
occupational NN O O
physiotherapist NN O O
. NN O O

Sitting NN O O
time NN O O
( NN O O
primary NN O O
outcome NN O O
) NN O O
, NN O O
upright NN O O
time NN O O
and NN O O
step NN O O
counts NN O O
will NN O O
be NN O O
assessed NN O O
objectively NN O O
using NN O O
the NN O O
activPAL NN O O
activity NN O O
monitor NN O O
at NN O O
baseline NN O O
, NN O O
short-term NN O O
( NN O O
approximately NN O O
3 NN O O
months NN O O
) NN O O
and NN O O
longer-term NN O O
( NN O O
12 NN O O
months NN O O
) NN O O
. NN O O

Other NN O O
outcomes NN O O
will NN O O
include NN O O
: NN O O
self-reported NN O O
lifestyle NN O O
behaviours NN O O
, NN O O
anthropometrics NN O O
, NN O O
work-related NN O O
outcomes NN O O
( NN O O
i.e. NN O O
absenteeism NN O O
, NN O O
presenteeism NN O O
, NN O O
work NN O O
performance NN O O
, NN O O
work-related NN O O
stress NN O O
) NN O O
, NN O O
health-related NN O O
outcomes NN O O
( NN O O
i.e. NN O O
vitality NN O O
, NN O O
musculoskeletal NN O O
symptoms NN O O
, NN O O
need NN O O
for NN O O
recovery NN O O
, NN O O
quality NN O O
of NN O O
life NN O O
) NN O O
, NN O O
and NN O O
costs NN O O
from NN O O
both NN O O
company NN O O
and NN O O
societal NN O O
perspective NN O O
. NN O O

The NN O O
study NN O O
will NN O O
include NN O O
economic NN O O
and NN O O
process NN O O
evaluations NN O O
. NN O O

This NN O O
study NN O O
will NN O O
assess NN O O
the NN O O
longer-term NN O O
( NN O O
cost- NN O O
) NN O O
effectiveness NN O O
of NN O O
a NN O O
multicomponent NN O O
workplace NN O O
intervention NN O O
aimed NN O O
at NN O O
reducing NN O O
sitting NN O O
time NN O O
in NN O O
comparison NN O O
with NN O O
usual NN O O
practice NN O O
. NN O O

Furthermore NN O O
, NN O O
the NN O O
process NN O O
evaluation NN O O
will NN O O
provide NN O O
insights NN O O
in NN O O
factors NN O O
associated NN O O
with NN O O
successful NN O O
implementation NN O O
of NN O O
this NN O O
intervention NN O O
. NN O O

ClinicalTrials.gov NN O O
NCT03115645 NN O O
; NN O O
Registered NN O O
13 NN O O
April NN O O
2017 NN O O
. NN O O

Retrospectively NN O O
registered NN O O
. NN O O



-DOCSTART- (31129603)

Electronic NN O O
cigarettes NN O O
( NN O O
EC NN O O
) NN O O
mainly NN O O
with NN O O
nicotine NN O O
content NN O O
are NN O O
widely NN O O
used NN O O
worldwide NN O O
. NN O O

Although NN O O
the NN O O
number NN O O
of NN O O
publications NN O O
about NN O O
its NN O O
use NN O O
is NN O O
increasing NN O O
exponentially NN O O
, NN O O
evidence-based NN O O
, NN O O
unbiased NN O O
, NN O O
conclusive NN O O
, NN O O
head-to-head NN O O
comparisons NN O O
about NN O O
its NN O O
efficacy NN O O
and NN O O
safety NN O O
as NN O O
an NN O O
aid NN O O
for NN O O
smoking NN O O
cessation NN O O
are NN O O
lacking NN O O
. NN O O

METHODS NN O O
AND NN O O
ANALYSIS NN O O
: NN O O
randomised NN O O
, NN O O
placebo NN O O
and NN O O
reference NN O O
treatment-controlled NN O O
, NN O O
multicentre NN O O
, NN O O
double-blind NN O O
, NN O O
double-dummy NN O O
, NN O O
parallel-group NN O O
trial NN O O
. NN O O

smokers NN O O
smoking NN O O
at NN O O
least NN O O
10 NN O O
cigarettes/day NN O O
in NN O O
the NN O O
past NN O O
year NN O O
and NN O O
motivated NN O O
to NN O O
quit NN O O
, NN O O
aged NN O O
18 NN O O
- NN O O
70 NN O O
years NN O O
. NN O O
: NN O O
( NN O O
A NN O O
) NN O O
EC NN O O
without NN O O
nicotine NN O O
( NN O O
ECwoN NN O O
) NN O O
plus NN O O
placebo NN O O
tablets NN O O
of NN O O
varenicline NN O O
administered NN O O
by NN O O
oral NN O O
route NN O O
: NN O O
, NN O O
( NN O O
B NN O O
) NN O O
EC NN O O
with NN O O
nicotine NN O O
( NN O O
ECwN NN O O
) NN O O
plus NN O O
placebo NN O O
tablets NN O O
of NN O O
varenicline NN O O
: NN O O
Voltage NN O O
regulated NN O O
EC NN O O
will NN O O
be NN O O
used NN O O
with NN O O
liquid NN O O
containing NN O O
12 NN O O
mg/mL NN O O
of NN O O
nicotine NN O O
for NN O O
ad NN O O
libitum NN O O
use NN O O
. NN O O
: NN O O
blond NN O O
tobacco NN O O
. NN O O

( NN O O
C NN O O
) NN O O
: NN O O
ECwoN NN O O
plus NN O O
0.5 NN O O
mg NN O O
varenicline NN O O
tablets NN O O
: NN O O
Varenicline NN O O
administered NN O O
according NN O O
to NN O O
the NN O O
marketing NN O O
authorisationauthorisation NN O O
. NN O O
: NN O O
1 NN O O
week+3 NN O O
months NN O O
. NN O O

continuous NN O O
smoking NN O O
abstinence NN O O
rate NN O O
( NN O O
CAR NN O O
) NN O O
( NN O O
abstinence NN O O
from NN O O
conventional/combustible NN O O
cigarettes NN O O
) NN O O
during NN O O
the NN O O
last NN O O
4 NN O O
weeks NN O O
( NN O O
weeks NN O O
9 NN O O
- NN O O
12 NN O O
) NN O O
of NN O O
the NN O O
treatment NN O O
period NN O O
defined NN O O
as NN O O
self-report NN O O
of NN O O
no NN O O
smoking NN O O
during NN O O
the NN O O
previous NN O O
2 NN O O
weeks NN O O
and NN O O
expired NN O O
air NN O O
carbon NN O O
monoxide NN O O
≤8 NN O O
at NN O O
visit NN O O
4 NN O O
at NN O O
week NN O O
10 NN O O
after NN O O
target NN O O
quit NN O O
date NN O O
( NN O O
TQD NN O O
) NN O O
, NN O O
that NN O O
is NN O O
, NN O O
11 NN O O
weeks NN O O
after NN O O
treatment NN O O
initiation NN O O
AND NN O O
at NN O O
visit NN O O
5 NN O O
, NN O O
week NN O O
12 NN O O
after NN O O
TQD NN O O
, NN O O
that NN O O
is NN O O
, NN O O
13 NN O O
weeks NN O O
after NN O O
treatment NN O O
initiation NN O O
. NN O O
: NN O O
safety NN O O
profile NN O O
; NN O O
point NN O O
prevalence NN O O
abstinence NN O O
rate NN O O
; NN O O
CAR NN O O
confirmed NN O O
by NN O O
urinary NN O O
anabasine NN O O
concentration NN O O
; NN O O
changes NN O O
in NN O O
cigarettes/day NN O O
consumption NN O O
; NN O O
craving NN O O
for NN O O
tobacco NN O O
and NN O O
withdrawal NN O O
symptoms NN O O
with NN O O
respect NN O O
of NN O O
baseline NN O O
. NN O O

The NN O O
ethics NN O O
committee NN O O
approval NN O O
was NN O O
obtained NN O O
on NN O O
17 NN O O
April NN O O
2018 NN O O
. NN O O

All NN O O
data NN O O
collected NN O O
about NN O O
the NN O O
study NN O O
participants NN O O
will NN O O
be NN O O
anonymised NN O O
. NN O O

Investigators NN O O
will NN O O
communicate NN O O
trial NN O O
results NN O O
to NN O O
participants NN O O
, NN O O
health NN O O
authorities NN O O
, NN O O
healthcare NN O O
professionals NN O O
, NN O O
the NN O O
public NN O O
and NN O O
other NN O O
relevant NN O O
groups NN O O
without NN O O
any NN O O
publication NN O O
restrictions NN O O
. NN O O

NCT03630614 NN O O
; NN O O
Pre-results NN O O
. NN O O



-DOCSTART- (30497132)

OBJECTIVELocal NN O O
epidural NN O O
steroid NN O O
application NN O O
may NN O O
be NN O O
associated NN O O
with NN O O
decreased NN O O
pain NN O O
and NN O O
narcotic NN O O
use NN O O
in NN O O
the NN O O
immediate NN O O
postoperative NN O O
period NN O O
following NN O O
lumbar NN O O
discectomy NN O O
. NN O O

However NN O O
, NN O O
local NN O O
steroid NN O O
delivery NN O O
following NN O O
lumbar NN O O
fusion NN O O
procedures NN O O
has NN O O
not NN O O
been NN O O
well NN O O
characterized NN O O
. NN O O

This NN O O
study NN O O
aims NN O O
to NN O O
characterize NN O O
the NN O O
effect NN O O
of NN O O
local NN O O
intraoperative NN O O
depomedrol NN O O
application NN O O
on NN O O
perioperative NN O O
and NN O O
postoperative NN O O
outcomes NN O O
following NN O O
a NN O O
single-level NN O O
minimally NN O O
invasive NN O O
transforaminal NN O O
lumbar NN O O
interbody NN O O
fusion NN O O
( NN O O
MIS NN O O
TLIF).METHODSA NN O O
prospective NN O O
, NN O O
randomized NN O O
, NN O O
single-blinded NN O O
study NN O O
was NN O O
performed NN O O
. NN O O

A NN O O
priori NN O O
power NN O O
analysis NN O O
determined NN O O
that NN O O
86 NN O O
patients NN O O
were NN O O
needed NN O O
to NN O O
detect NN O O
a NN O O
difference NN O O
of NN O O
1 NN O O
point NN O O
in NN O O
the NN O O
visual NN O O
analog NN O O
scale NN O O
( NN O O
VAS NN O O
) NN O O
pain NN O O
score NN O O
between NN O O
groups NN O O
. NN O O

Ninety-three NN O O
patients NN O O
were NN O O
randomized NN O O
into NN O O
depomedrol NN O O
( NN O O
DEPO NN O O
) NN O O
and NN O O
no NN O O
depomedrol NN O O
( NN O O
NODEPO NN O O
) NN O O
cohorts NN O O
. NN O O

Prior NN O O
to NN O O
surgical NN O O
closure NN O O
, NN O O
DEPO NN O O
patients NN O O
received NN O O
1 NN O O
ml NN O O
depomedrol NN O O
( NN O O
80 NN O O
mg NN O O
) NN O O
applied NN O O
directly NN O O
to NN O O
the NN O O
surgical NN O O
site NN O O
by NN O O
using NN O O
a NN O O
Gelfoam NN O O
carrier NN O O
. NN O O

NODEPO NN O O
patients NN O O
received NN O O
1 NN O O
ml NN O O
saline NN O O
on NN O O
the NN O O
same NN O O
Gelfoam NN O O
carrier NN O O
. NN O O

Perioperative NN O O
outcomes NN O O
including NN O O
acute NN O O
postoperative NN O O
pain NN O O
and NN O O
narcotic NN O O
use NN O O
were NN O O
assessed NN O O
for NN O O
the NN O O
duration NN O O
of NN O O
inpatient NN O O
stay NN O O
. NN O O

Patient-reported NN O O
outcomes NN O O
( NN O O
PROs NN O O
) NN O O
questionnaires NN O O
including NN O O
VAS NN O O
back NN O O
and NN O O
leg NN O O
pain NN O O
scores NN O O
, NN O O
and NN O O
Oswestry NN O O
Disability NN O O
Index NN O O
( NN O O
ODI NN O O
) NN O O
were NN O O
administered NN O O
preoperatively NN O O
and NN O O
at NN O O
6-week NN O O
, NN O O
12-week NN O O
, NN O O
and NN O O
6-month NN O O
follow-up NN O O
. NN O O

Outcomes NN O O
for NN O O
DEPO NN O O
and NN O O
NODEPO NN O O
cohorts NN O O
were NN O O
compared NN O O
using NN O O
linear NN O O
regression NN O O
controlled NN O O
for NN O O
sex NN O O
. NN O O

RESULTSOf NN O O
the NN O O
93 NN O O
patients NN O O
, NN O O
45 NN O O
( NN O O
48.4 NN O O
% NN O O
) NN O O
were NN O O
randomized NN O O
to NN O O
DEPO NN O O
and NN O O
48 NN O O
( NN O O
51.6 NN O O
% NN O O
) NN O O
to NN O O
NODEPO NN O O
. NN O O

A NN O O
greater NN O O
percentage NN O O
of NN O O
DEPO NN O O
patients NN O O
were NN O O
female NN O O
( NN O O
53.3 NN O O
% NN O O
vs NN O O
27.1 NN O O
% NN O O
, NN O O
p NN O O
= NN O O
0.010 NN O O
) NN O O
. NN O O

There NN O O
were NN O O
no NN O O
other NN O O
significant NN O O
differences NN O O
in NN O O
patient NN O O
baseline NN O O
characteristics NN O O
. NN O O

Similarly NN O O
, NN O O
operating NN O O
time NN O O
, NN O O
estimated NN O O
blood NN O O
loss NN O O
, NN O O
and NN O O
length NN O O
of NN O O
inpatient NN O O
stay NN O O
did NN O O
not NN O O
differ NN O O
between NN O O
cohorts NN O O
. NN O O

Patients NN O O
in NN O O
the NN O O
DEPO NN O O
cohort NN O O
consumed NN O O
fewer NN O O
hourly NN O O
narcotics NN O O
on NN O O
postoperative NN O O
day NN O O
0 NN O O
( NN O O
5.3 NN O O
vs NN O O
6.3 NN O O
oral NN O O
morphine NN O O
equivalents/hour NN O O
, NN O O
p NN O O
= NN O O
0.034 NN O O
) NN O O
. NN O O

However NN O O
, NN O O
no NN O O
differences NN O O
in NN O O
acute NN O O
postoperative NN O O
pain NN O O
or NN O O
total NN O O
narcotics NN O O
consumption NN O O
were NN O O
observed NN O O
between NN O O
groups NN O O
. NN O O

Preoperative NN O O
VAS NN O O
leg NN O O
scores NN O O
were NN O O
statistically NN O O
different NN O O
between NN O O
cohorts NN O O
( NN O O
p NN O O
= NN O O
0.027 NN O O
) NN O O
. NN O O

However NN O O
, NN O O
preoperative NN O O
ODI NN O O
and NN O O
VAS NN O O
back NN O O
scores NN O O
did NN O O
not NN O O
differ NN O O
between NN O O
groups NN O O
. NN O O

Additionally NN O O
, NN O O
DEPO NN O O
and NN O O
NODEPO NN O O
groups NN O O
experienced NN O O
similar NN O O
improvements NN O O
in NN O O
PROs NN O O
at NN O O
all NN O O
postoperative NN O O
time NN O O
points NN O O
. NN O O

CONCLUSIONSLocal NN O O
depomedrol NN O O
use NN O O
did NN O O
not NN O O
lead NN O O
to NN O O
decreases NN O O
in NN O O
acute NN O O
postoperative NN O O
pain NN O O
or NN O O
narcotics NN O O
consumption NN O O
after NN O O
MIS NN O O
TLIF NN O O
. NN O O

Additionally NN O O
, NN O O
local NN O O
depomedrol NN O O
was NN O O
not NN O O
associated NN O O
with NN O O
postoperative NN O O
improvements NN O O
in NN O O
PROs NN O O
. NN O O

The NN O O
findings NN O O
of NN O O
this NN O O
randomized NN O O
trial NN O O
suggest NN O O
that NN O O
surgical NN O O
and NN O O
clinical NN O O
outcomes NN O O
following NN O O
MIS NN O O
TLIF NN O O
may NN O O
not NN O O
be NN O O
impacted NN O O
by NN O O
intraoperative NN O O
application NN O O
of NN O O
depomedrol NN O O
. NN O O

Clinical NN O O
trial NN O O
registration NN O O
no. NN O O
: NN O O
NCT03308084 NN O O
( NN O O
clinicaltrials.gov NN O O
) NN O O
. NN O O



-DOCSTART- (30772070)

Aging NN O O
is NN O O
accompanied NN O O
by NN O O
a NN O O
decline NN O O
in NN O O
immune NN O O
function NN O O
which NN O O
can NN O O
lead NN O O
to NN O O
decreased NN O O
responses NN O O
to NN O O
vaccines NN O O
. NN O O

Attenuated NN O O
recombinant NN O O
Vibrio NN O O
cholerae NN O O
O1 NN O O
vaccine NN O O
strain NN O O
CVD NN O O
103-HgR NN O O
elicits NN O O
a NN O O
rapid NN O O
serum NN O O
vibriocidal NN O O
antibody NN O O
( NN O O
SVA NN O O
) NN O O
response NN O O
and NN O O
protects NN O O
against NN O O
cholera NN O O
diarrhea NN O O
in NN O O
volunteer NN O O
challenge NN O O
studies NN O O
but NN O O
has NN O O
not NN O O
been NN O O
studied NN O O
in NN O O
older NN O O
adults NN O O
. NN O O

We NN O O
evaluated NN O O
CVD NN O O
103-HgR NN O O
( NN O O
PXVX0200 NN O O
) NN O O
in NN O O
adults NN O O
age NN O O
46 NN O O
- NN O O
64 NN O O
, NN O O
compared NN O O
them NN O O
to NN O O
previously NN O O
studied NN O O
adults NN O O
age NN O O
18 NN O O
- NN O O
45 NN O O
, NN O O
and NN O O
studied NN O O
age-related NN O O
immunogenicity NN O O
across NN O O
adults NN O O
18 NN O O
- NN O O
64 NN O O
years NN O O
of NN O O
age NN O O
. NN O O

Volunteers NN O O
were NN O O
randomized NN O O
to NN O O
receive NN O O
a NN O O
single NN O O
dose NN O O
of NN O O
1 NN O O
× NN O O
10 NN O O
CFU NN O O
of NN O O
PXVX0200 NN O O
or NN O O
placebo NN O O
. NN O O

Immunogenicity NN O O
endpoints NN O O
included NN O O
SVA NN O O
and NN O O
anti-cholera NN O O
toxin NN O O
( NN O O
CT NN O O
) NN O O
antibody NN O O
levels NN O O
on NN O O
days NN O O
1 NN O O
, NN O O
11 NN O O
, NN O O
29 NN O O
, NN O O
91 NN O O
and NN O O
181 NN O O
and NN O O
lipopolysaccharide NN O O
( NN O O
LPS NN O O
) NN O O
and NN O O
CT-specific NN O O
IgA NN O O
and NN O O
IgG NN O O
memory NN O O
B NN O O
cells NN O O
on NN O O
days NN O O
1 NN O O
, NN O O
91 NN O O
and NN O O
181 NN O O
. NN O O

Safety NN O O
was NN O O
assessed NN O O
by NN O O
comparing NN O O
solicited NN O O
signs NN O O
and NN O O
symptoms NN O O
on NN O O
days NN O O
1 NN O O
- NN O O
8 NN O O
and NN O O
other NN O O
adverse NN O O
events NN O O
through NN O O
day NN O O
181 NN O O
. NN O O

2979 NN O O
volunteers NN O O
received NN O O
vaccine NN O O
, NN O O
including NN O O
291 NN O O
age NN O O
45 NN O O
- NN O O
64 NN O O
. NN O O

Day NN O O
11 NN O O
seroconversion NN O O
occurred NN O O
in NN O O
90.4 NN O O
% NN O O
of NN O O
older NN O O
adults NN O O
vs NN O O
93.5%% NN O O
of NN O O
younger NN O O
adults NN O O
and NN O O
met NN O O
the NN O O
endpoint NN O O
of NN O O
demonstrating NN O O
non-inferiority NN O O
between NN O O
the NN O O
two NN O O
groups NN O O
. NN O O

Significant NN O O
increases NN O O
in NN O O
LPS-specific NN O O
IgG NN O O
and NN O O
IgA NN O O
and NN O O
CT-specific NN O O
memory NN O O
IgG NN O O
memory NN O O
B NN O O
cells NN O O
were NN O O
seen NN O O
at NN O O
days NN O O
91 NN O O
and NN O O
181 NN O O
. NN O O

There NN O O
appeared NN O O
to NN O O
be NN O O
a NN O O
continuous NN O O
age-related NN O O
decline NN O O
in NN O O
SVA NN O O
seroconversion NN O O
and NN O O
geometric NN O O
mean NN O O
titers NN O O
, NN O O
but NN O O
not NN O O
memory NN O O
B NN O O
cell NN O O
responses NN O O
, NN O O
across NN O O
the NN O O
18 NN O O
- NN O O
64 NN O O
year NN O O
age NN O O
range NN O O
. NN O O

Most NN O O
reactogenicity NN O O
was NN O O
mild NN O O
and NN O O
was NN O O
more NN O O
common NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
. NN O O

PXVX0200 NN O O
appears NN O O
safe NN O O
and NN O O
immunogenic NN O O
in NN O O
older NN O O
adults NN O O
. NN O O

Clinical NN O O
Trials NN O O
Registration NN O O
: NN O O
clinicaltrials.gov NN O O
NCT02100631 NN O O
. NN O O



-DOCSTART- (31114673)

Low NN O O
back NN O O
pain NN O O
( NN O O
LBP NN O O
) NN O O
is NN O O
a NN O O
common NN O O
disabling NN O O
condition NN O O
in NN O O
older NN O O
adults NN O O
which NN O O
often NN O O
limits NN O O
physical NN O O
function NN O O
and NN O O
diminishes NN O O
quality NN O O
of NN O O
life NN O O
. NN O O

Two NN O O
clinical NN O O
trials NN O O
in NN O O
older NN O O
adults NN O O
have NN O O
shown NN O O
spinal NN O O
manipulative NN O O
therapy NN O O
( NN O O
SMT NN O O
) NN O O
results NN O O
in NN O O
similar NN O O
or NN O O
small NN O O
improvements NN O O
relative NN O O
to NN O O
medical NN O O
care NN O O
; NN O O
however NN O O
, NN O O
the NN O O
effectiveness NN O O
of NN O O
adding NN O O
SMT NN O O
or NN O O
rehabilitative NN O O
exercise NN O O
to NN O O
home NN O O
exercise NN O O
is NN O O
unclear NN O O
. NN O O

We NN O O
conducted NN O O
a NN O O
randomized NN O O
clinical NN O O
trial NN O O
assessing NN O O
the NN O O
comparative NN O O
effectiveness NN O O
of NN O O
adding NN O O
SMT NN O O
or NN O O
supervised NN O O
rehabilitative NN O O
exercise NN O O
to NN O O
home NN O O
exercise NN O O
in NN O O
adults NN O O
65 NN O O
or NN O O
older NN O O
with NN O O
sub-acute NN O O
or NN O O
chronic NN O O
LBP NN O O
. NN O O

Treatments NN O O
were NN O O
provided NN O O
over NN O O
12-weeks NN O O
and NN O O
self-report NN O O
outcomes NN O O
were NN O O
collected NN O O
at NN O O
4 NN O O
, NN O O
12 NN O O
, NN O O
26 NN O O
, NN O O
and NN O O
52 NN O O
weeks NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
was NN O O
pain NN O O
severity NN O O
. NN O O

Secondary NN O O
outcomes NN O O
included NN O O
back NN O O
disability NN O O
, NN O O
health NN O O
status NN O O
, NN O O
medication NN O O
use NN O O
, NN O O
satisfaction NN O O
with NN O O
care NN O O
, NN O O
and NN O O
global NN O O
improvement NN O O
. NN O O

Linear NN O O
mixed NN O O
models NN O O
were NN O O
used NN O O
to NN O O
analyze NN O O
outcomes NN O O
. NN O O

The NN O O
primary NN O O
analysis NN O O
included NN O O
longitudinal NN O O
outcomes NN O O
in NN O O
the NN O O
short NN O O
( NN O O
week NN O O
4 NN O O
- NN O O
12 NN O O
) NN O O
and NN O O
long-term NN O O
( NN O O
week NN O O
4 NN O O
- NN O O
52 NN O O
) NN O O
. NN O O

An NN O O
omnibus NN O O
test NN O O
assessing NN O O
differences NN O O
across NN O O
all NN O O
groups NN O O
over NN O O
the NN O O
year NN O O
was NN O O
used NN O O
to NN O O
control NN O O
for NN O O
multiplicity NN O O
. NN O O

Secondary NN O O
analyses NN O O
included NN O O
outcomes NN O O
at NN O O
each NN O O
time NN O O
point NN O O
and NN O O
responder NN O O
analyses NN O O
. NN O O

This NN O O
study NN O O
was NN O O
funded NN O O
by NN O O
the NN O O
US NN O O
Department NN O O
of NN O O
Health NN O O
and NN O O
Human NN O O
Services NN O O
, NN O O
Health NN O O
Resources NN O O
and NN O O
Services NN O O
Administration NN O O
. NN O O

241 NN O O
participants NN O O
were NN O O
randomized NN O O
and NN O O
230 NN O O
( NN O O
95 NN O O
% NN O O
) NN O O
provided NN O O
complete NN O O
primary NN O O
outcome NN O O
data NN O O
. NN O O

The NN O O
primary NN O O
analysis NN O O
showed NN O O
group NN O O
differences NN O O
in NN O O
pain NN O O
over NN O O
the NN O O
one-year NN O O
were NN O O
small NN O O
and NN O O
not NN O O
statistically NN O O
significant NN O O
. NN O O

Pain NN O O
severity NN O O
was NN O O
reduced NN O O
by NN O O
30 NN O O
to NN O O
40 NN O O
% NN O O
after NN O O
treatment NN O O
in NN O O
all NN O O
3 NN O O
groups NN O O
with NN O O
the NN O O
largest NN O O
difference NN O O
( NN O O
eight NN O O
percentage NN O O
points NN O O
) NN O O
favoring NN O O
SMT NN O O
and NN O O
home NN O O
exercise NN O O
over NN O O
home NN O O
exercise NN O O
alone NN O O
. NN O O

Group NN O O
differences NN O O
at NN O O
other NN O O
time NN O O
points NN O O
ranged NN O O
from NN O O
0 NN O O
to NN O O
6 NN O O
percentage NN O O
points NN O O
with NN O O
no NN O O
consistent NN O O
pattern NN O O
favoring NN O O
one NN O O
treatment NN O O
. NN O O

One-year NN O O
post-treatment NN O O
pain NN O O
reductions NN O O
diminished NN O O
in NN O O
all NN O O
three NN O O
groups NN O O
. NN O O

Secondary NN O O
self-report NN O O
outcomes NN O O
followed NN O O
a NN O O
similar NN O O
pattern NN O O
with NN O O
no NN O O
important NN O O
group NN O O
differences NN O O
, NN O O
except NN O O
satisfaction NN O O
with NN O O
care NN O O
, NN O O
where NN O O
the NN O O
two NN O O
combination NN O O
groups NN O O
were NN O O
consistently NN O O
superior NN O O
to NN O O
home NN O O
exercise NN O O
alone NN O O
. NN O O

Adding NN O O
spinal NN O O
manipulation NN O O
or NN O O
supervised NN O O
rehabilitative NN O O
exercise NN O O
to NN O O
home NN O O
exercise NN O O
alone NN O O
does NN O O
not NN O O
appear NN O O
to NN O O
improve NN O O
pain NN O O
or NN O O
disability NN O O
in NN O O
the NN O O
short- NN O O
or NN O O
long-term NN O O
for NN O O
older NN O O
adults NN O O
with NN O O
chronic NN O O
low NN O O
back NN O O
pain NN O O
, NN O O
but NN O O
did NN O O
enhance NN O O
satisfaction NN O O
with NN O O
care NN O O
. NN O O

NCT00269321 NN O O
. NN O O



-DOCSTART- (31253621)

Neoadjuvant NN O O
chemotherapy NN O O
( NN O O
NACT NN O O
) NN O O
is NN O O
considered NN O O
the NN O O
current NN O O
standard NN O O
for NN O O
locally NN O O
advanced NN O O
gallbladder NN O O
cancer NN O O
( NN O O
GBC NN O O
) NN O O
. NN O O

There NN O O
is NN O O
no NN O O
consensus NN O O
on NN O O
the NN O O
optimal NN O O
neoadjuvant NN O O
approach NN O O
. NN O O

A NN O O
pilot NN O O
study NN O O
from NN O O
our NN O O
institution NN O O
has NN O O
shown NN O O
improved NN O O
overall NN O O
survival NN O O
( NN O O
OS NN O O
) NN O O
and NN O O
progression-free NN O O
survival NN O O
( NN O O
PFS NN O O
) NN O O
with NN O O
neoadjuvant NN O O
chemoradiation NN O O
( NN O O
NACRT NN O O
) NN O O
. NN O O

The NN O O
present NN O O
randomised NN O O
phase NN O O
III NN O O
trial NN O O
is NN O O
designed NN O O
to NN O O
compare NN O O
NACRT NN O O
with NN O O
NACT NN O O
alone NN O O
and NN O O
will NN O O
test NN O O
the NN O O
superiority NN O O
of NN O O
chemoradiation NN O O
in NN O O
terms NN O O
of NN O O
tumour NN O O
downstaging NN O O
and NN O O
improvement NN O O
in NN O O
OS NN O O
. NN O O

Patients NN O O
with NN O O
biopsy-proven NN O O
locally NN O O
advanced NN O O
GBC NN O O
( NN O O
T3 NN O O
- NN O O
4 NN O O
) NN O O
with NN O O
predefined NN O O
clinical-radiological NN O O
features NN O O
will NN O O
be NN O O
randomised NN O O
to NN O O
the NN O O
gemcitabine-based NN O O
chemotherapy-alone NN O O
arm NN O O
or NN O O
the NN O O
chemoradiation NN O O
arm NN O O
. NN O O

Patients NN O O
with NN O O
resectable NN O O
disease NN O O
or NN O O
with NN O O
distant NN O O
metastases NN O O
will NN O O
be NN O O
excluded NN O O
. NN O O

The NN O O
primary NN O O
end NN O O
point NN O O
of NN O O
the NN O O
study NN O O
is NN O O
to NN O O
compare NN O O
OS NN O O
between NN O O
the NN O O
two NN O O
arms NN O O
. NN O O

The NN O O
secondary NN O O
end NN O O
point NN O O
was NN O O
to NN O O
compare NN O O
PFS NN O O
, NN O O
R0 NN O O
resection NN O O
rates NN O O
, NN O O
acute NN O O
and NN O O
late NN O O
toxicity NN O O
, NN O O
postoperative NN O O
complications NN O O
and NN O O
quality NN O O
of NN O O
life NN O O
between NN O O
the NN O O
two NN O O
study NN O O
arms NN O O
. NN O O

The NN O O
trial NN O O
is NN O O
designed NN O O
to NN O O
detect NN O O
an NN O O
improvement NN O O
in NN O O
median NN O O
OS NN O O
by NN O O
5.5 NN O O
months NN O O
in NN O O
the NN O O
study NN O O
arm NN O O
( NN O O
11 NN O O
months NN O O
in NN O O
the NN O O
control NN O O
group NN O O
, NN O O
HR NN O O
of NN O O
0.7 NN O O
) NN O O
with NN O O
80.0 NN O O
% NN O O
power NN O O
at NN O O
a NN O O
0.05 NN O O
significance NN O O
level NN O O
. NN O O

The NN O O
resultant NN O O
sample NN O O
size NN O O
to NN O O
achieve NN O O
this NN O O
aim NN O O
is NN O O
314 NN O O
( NN O O
157 NN O O
in NN O O
each NN O O
arm NN O O
) NN O O
over NN O O
a NN O O
duration NN O O
of NN O O
5 NN O O
years NN O O
with NN O O
a NN O O
10 NN O O
% NN O O
attrition NN O O
rate NN O O
. NN O O

The NN O O
institutional NN O O
ethics NN O O
committee NN O O
has NN O O
approved NN O O
this NN O O
trial NN O O
and NN O O
will NN O O
be NN O O
routinely NN O O
monitoring NN O O
the NN O O
trial NN O O
at NN O O
frequent NN O O
intervals NN O O
. NN O O

The NN O O
results NN O O
of NN O O
the NN O O
study NN O O
will NN O O
be NN O O
disseminated NN O O
via NN O O
peer-reviewed NN O O
scientific NN O O
journals NN O O
, NN O O
conference NN O O
presentations NN O O
and NN O O
submission NN O O
to NN O O
regulatory NN O O
authorities NN O O
. NN O O

The NN O O
trial NN O O
is NN O O
registered NN O O
with NN O O
Clinical NN O O
Trials NN O O
Registry NN O O
India NN O O
( NN O O
CTRI/2016/08/007199 NN O O
) NN O O
and NN O O
ClinicalTrials.gov NN O O
( NN O O
NCT02867865 NN O O
) NN O O
. NN O O

This NN O O
trial NN O O
aims NN O O
to NN O O
assess NN O O
the NN O O
superiority NN O O
of NN O O
NACRT NN O O
over NN O O
NACT NN O O
in NN O O
locally NN O O
advanced NN O O
GBCs NN O O
in NN O O
terms NN O O
of NN O O
improvement NN O O
in NN O O
OS NN O O
. NN O O

The NN O O
results NN O O
of NN O O
this NN O O
study NN O O
will NN O O
define NN O O
the NN O O
optimal NN O O
neoadjuvant NN O O
approach NN O O
in NN O O
locally NN O O
advanced NN O O
GBC NN O O
. NN O O

NCT02867865 NN O O
; NN O O
Pre-results NN O O
. NN O O



-DOCSTART- (30782672)

Prolonged NN O O
grief NN O O
disorder NN O O
is NN O O
associated NN O O
with NN O O
significant NN O O
distress NN O O
and NN O O
impairment NN O O
and NN O O
thus NN O O
efforts NN O O
to NN O O
improve NN O O
treatments NN O O
are NN O O
essential NN O O
. NN O O

The NN O O
present NN O O
pilot NN O O
study NN O O
tested NN O O
the NN O O
efficacy NN O O
and NN O O
feasibility NN O O
of NN O O
group NN O O
Metacognitive NN O O
Grief NN O O
Therapy NN O O
( NN O O
MCGT NN O O
) NN O O
designed NN O O
specifically NN O O
for NN O O
prolonged NN O O
grief NN O O
symptomatology NN O O
to NN O O
reduce NN O O
the NN O O
psychological NN O O
distress NN O O
and NN O O
impaired NN O O
function NN O O
resulting NN O O
from NN O O
bereavement NN O O
. NN O O

Twenty-two NN O O
bereaved NN O O
adult NN O O
participants NN O O
with NN O O
prolonged NN O O
grief NN O O
symptomatology NN O O
were NN O O
randomised NN O O
to NN O O
a NN O O
wait-list NN O O
control NN O O
( NN O O
n=10 NN O O
) NN O O
or NN O O
an NN O O
intervention NN O O
condition NN O O
( NN O O
n=12 NN O O
) NN O O
with NN O O
a NN O O
3-month NN O O
and NN O O
6-month NN O O
follow-up NN O O
. NN O O

The NN O O
wait-list NN O O
control NN O O
group NN O O
was NN O O
offered NN O O
treatment NN O O
after NN O O
the NN O O
post-test NN O O
assessment NN O O
. NN O O

Participants NN O O
attended NN O O
six NN O O
group NN O O
MCGT NN O O
sessions NN O O
that NN O O
ran NN O O
for NN O O
2 NN O O
hours NN O O
per NN O O
week NN O O
. NN O O

A NN O O
primary NN O O
outcome NN O O
measure NN O O
of NN O O
prolonged NN O O
grief NN O O
symptomatology NN O O
and NN O O
secondary NN O O
outcome NN O O
measures NN O O
of NN O O
depression NN O O
, NN O O
anxiety NN O O
, NN O O
rumination NN O O
, NN O O
metacognitive NN O O
beliefs NN O O
and NN O O
quality NN O O
of NN O O
life NN O O
were NN O O
taken NN O O
pretreatment NN O O
and NN O O
post-treatment NN O O
for NN O O
both NN O O
groups NN O O
and NN O O
at NN O O
the NN O O
3-month NN O O
and NN O O
6-month NN O O
follow-up NN O O
for NN O O
the NN O O
intervention NN O O
group NN O O
. NN O O

A NN O O
Generalised NN O O
Linear NN O O
Mixed NN O O
Model NN O O
was NN O O
used NN O O
to NN O O
assess NN O O
treatment NN O O
efficacy NN O O
. NN O O

Post-treatment NN O O
intent-to-treat NN O O
analyses NN O O
showed NN O O
MCGT NN O O
reduced NN O O
prolonged NN O O
grief NN O O
symptomatology NN O O
( NN O O
Cohen NN O O
's NN O O
d=1.7 NN O O
) NN O O
, NN O O
depression NN O O
( NN O O
d=1.3 NN O O
) NN O O
, NN O O
anxiety NN O O
( NN O O
d=0.8 NN O O
) NN O O
, NN O O
stress NN O O
( NN O O
d=1.0 NN O O
) NN O O
, NN O O
rumination NN O O
( NN O O
d=0.9 NN O O
) NN O O
and NN O O
increased NN O O
quality NN O O
of NN O O
life NN O O
( NN O O
d=0.6 NN O O
) NN O O
, NN O O
and NN O O
these NN O O
effects NN O O
were NN O O
maintained NN O O
at NN O O
the NN O O
3-month NN O O
and NN O O
6-month NN O O
follow-ups NN O O
. NN O O

No NN O O
prepost NN O O
between-group NN O O
differences NN O O
were NN O O
found NN O O
in NN O O
metacognitive NN O O
beliefs NN O O
. NN O O

However NN O O
, NN O O
a NN O O
large NN O O
significant NN O O
effect NN O O
was NN O O
identified NN O O
at NN O O
the NN O O
3-month NN O O
and NN O O
6-month NN O O
follow-ups NN O O
( NN O O
d=1.0 NN O O
) NN O O
. NN O O

The NN O O
results NN O O
show NN O O
promise NN O O
for NN O O
the NN O O
utility NN O O
of NN O O
group NN O O
MCGT NN O O
for NN O O
reducing NN O O
psychological NN O O
distress NN O O
and NN O O
promoting NN O O
quality NN O O
of NN O O
life NN O O
. NN O O

Additionally NN O O
, NN O O
the NN O O
results NN O O
underscore NN O O
the NN O O
need NN O O
for NN O O
a NN O O
full NN O O
randomised NN O O
controlled NN O O
trial NN O O
of NN O O
group NN O O
MCGT NN O O
, NN O O
which NN O O
may NN O O
be NN O O
an NN O O
important NN O O
addition NN O O
to NN O O
the NN O O
treatment NN O O
armamentarium NN O O
available NN O O
to NN O O
support NN O O
people NN O O
with NN O O
prolonged NN O O
grief NN O O
. NN O O

ACTRN12613001270707 NN O O
; NN O O
Results NN O O
. NN O O

ORIGINAL NN O O
PROTOCOL NN O O
: NN O O
2015;5:e007221 NN O O
. NN O O

doi:10.1136/bmjopen-2014 NN O O
- NN O O
007221 NN O O
. NN O O



-DOCSTART- (30535345)

Physicians NN O O
frequently NN O O
use NN O O
cardiac NN O O
monitoring NN O O
, NN O O
or NN O O
telemetry NN O O
, NN O O
beyond NN O O
the NN O O
duration NN O O
recommended NN O O
by NN O O
published NN O O
practice NN O O
standards NN O O
, NN O O
resulting NN O O
in NN O O
" NN O O
alarm NN O O
fatigue NN O O
" NN O O
and NN O O
excess NN O O
cost NN O O
. NN O O

Prior NN O O
studies NN O O
have NN O O
demonstrated NN O O
an NN O O
association NN O O
between NN O O
multicomponent NN O O
quality NN O O
improvement NN O O
interventions NN O O
and NN O O
safe NN O O
reduction NN O O
of NN O O
telemetry NN O O
duration NN O O
. NN O O

To NN O O
determine NN O O
if NN O O
a NN O O
single-component NN O O
intervention NN O O
, NN O O
a NN O O
targeted NN O O
electronic NN O O
health NN O O
record NN O O
( NN O O
EHR NN O O
) NN O O
alert NN O O
, NN O O
could NN O O
achieve NN O O
similar NN O O
gains NN O O
to NN O O
multicomponent NN O O
interventions NN O O
and NN O O
safely NN O O
reduce NN O O
unnecessary NN O O
monitoring NN O O
. NN O O

This NN O O
cluster-randomized NN O O
clinical NN O O
trial NN O O
was NN O O
conducted NN O O
between NN O O
November NN O O
2016 NN O O
and NN O O
May NN O O
2017 NN O O
on NN O O
the NN O O
general NN O O
medicine NN O O
service NN O O
of NN O O
the NN O O
Division NN O O
of NN O O
Hospital NN O O
Medicine NN O O
at NN O O
the NN O O
University NN O O
of NN O O
California NN O O
, NN O O
San NN O O
Francisco NN O O
Medical NN O O
Center NN O O
and NN O O
included NN O O
physicians NN O O
of NN O O
12 NN O O
inpatient NN O O
medical NN O O
teams NN O O
( NN O O
6 NN O O
intervention NN O O
, NN O O
6 NN O O
control NN O O
) NN O O
. NN O O

The NN O O
EHR NN O O
alert NN O O
was NN O O
randomized NN O O
to NN O O
half NN O O
of NN O O
the NN O O
teams NN O O
on NN O O
the NN O O
general NN O O
medicine NN O O
service NN O O
. NN O O

The NN O O
alert NN O O
displayed NN O O
during NN O O
daytime NN O O
hours NN O O
when NN O O
physicians NN O O
attempted NN O O
to NN O O
place NN O O
an NN O O
order NN O O
for NN O O
patients NN O O
not NN O O
in NN O O
the NN O O
intensive NN O O
care NN O O
unit NN O O
whose NN O O
telemetry NN O O
order NN O O
duration NN O O
exceeded NN O O
the NN O O
recommended NN O O
duration NN O O
for NN O O
a NN O O
given NN O O
indication NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
was NN O O
telemetry NN O O
monitoring NN O O
hours NN O O
per NN O O
hospitalization NN O O
, NN O O
which NN O O
was NN O O
measured NN O O
using NN O O
time-stamped NN O O
orders NN O O
data NN O O
from NN O O
the NN O O
EHR NN O O
database NN O O
. NN O O

Physician NN O O
responses NN O O
to NN O O
the NN O O
alert NN O O
were NN O O
collected NN O O
using NN O O
EHR NN O O
reporting NN O O
tools NN O O
. NN O O

The NN O O
potential NN O O
adverse NN O O
outcomes NN O O
of NN O O
rapid-response NN O O
calls NN O O
and NN O O
medical NN O O
emergency NN O O
events NN O O
were NN O O
measured NN O O
by NN O O
counting NN O O
the NN O O
notes NN O O
documenting NN O O
these NN O O
events NN O O
in NN O O
the NN O O
EHR NN O O
. NN O O

Of NN O O
the NN O O
1021 NN O O
patients NN O O
included NN O O
in NN O O
this NN O O
study NN O O
, NN O O
in NN O O
the NN O O
intervention NN O O
arm NN O O
, NN O O
there NN O O
was NN O O
a NN O O
mean NN O O
( NN O O
SD NN O O
) NN O O
age NN O O
of NN O O
64.5 NN O O
( NN O O
18.9 NN O O
) NN O O
and NN O O
215 NN O O
( NN O O
45 NN O O
% NN O O
) NN O O
were NN O O
women NN O O
; NN O O
in NN O O
the NN O O
control NN O O
arm NN O O
, NN O O
there NN O O
was NN O O
a NN O O
mean NN O O
( NN O O
SD NN O O
) NN O O
age NN O O
of NN O O
63.8 NN O O
( NN O O
19.1 NN O O
) NN O O
and NN O O
249 NN O O
( NN O O
46 NN O O
% NN O O
) NN O O
were NN O O
women NN O O
. NN O O

The NN O O
12 NN O O
teams NN O O
were NN O O
stratified NN O O
to NN O O
8 NN O O
house-staff NN O O
teams NN O O
and NN O O
4 NN O O
hospitalist NN O O
teams NN O O
, NN O O
with NN O O
499 NN O O
hospitalizations NN O O
analyzed NN O O
in NN O O
the NN O O
intervention NN O O
arm NN O O
and NN O O
567 NN O O
hospitalizations NN O O
analyzed NN O O
in NN O O
the NN O O
control NN O O
arm NN O O
. NN O O

The NN O O
alert NN O O
prompted NN O O
a NN O O
significant NN O O
reduction NN O O
in NN O O
telemetry NN O O
monitoring NN O O
duration NN O O
( NN O O
-8.7 NN O O
hours NN O O
per NN O O
hospitalization NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
-14.1 NN O O
to NN O O
-3.5 NN O O
hours NN O O
; NN O O
P NN O O
= NN O O
.001 NN O O
) NN O O
with NN O O
no NN O O
significant NN O O
change NN O O
in NN O O
rapid-response NN O O
calls NN O O
or NN O O
medical NN O O
emergency NN O O
events NN O O
. NN O O

The NN O O
most NN O O
common NN O O
physician NN O O
response NN O O
to NN O O
the NN O O
alert NN O O
was NN O O
to NN O O
discontinue NN O O
telemetry NN O O
monitoring NN O O
( NN O O
62 NN O O
% NN O O
of NN O O
200 NN O O
alerts NN O O
) NN O O
. NN O O

A NN O O
targeted NN O O
EHR NN O O
alert NN O O
can NN O O
safely NN O O
and NN O O
successfully NN O O
reduce NN O O
cardiac NN O O
monitoring NN O O
by NN O O
prompting NN O O
discontinuation NN O O
when NN O O
appropriate NN O O
. NN O O

This NN O O
single-component NN O O
electronic NN O O
intervention NN O O
is NN O O
less NN O O
resource NN O O
intensive NN O O
than NN O O
typical NN O O
multicomponent NN O O
interventions NN O O
that NN O O
include NN O O
human NN O O
resources NN O O
. NN O O

ClinicalTrials.gov NN O O
identifier NN O O
: NN O O
NCT02529176 NN O O
. NN O O



-DOCSTART- (31322735)

Most NN O O
treatments NN O O
for NN O O
cancer NN O O
cause NN O O
a NN O O
decline NN O O
in NN O O
patients NN O O
' NN O O
health-related NN O O
quality NN O O
of NN O O
life NN O O
( NN O O
HRQoL NN O O
) NN O O
. NN O O

Limiting NN O O
this NN O O
decline NN O O
is NN O O
a NN O O
universal NN O O
goal NN O O
for NN O O
healthcare NN O O
providers NN O O
. NN O O

Using NN O O
minimally NN O O
invasive NN O O
instead NN O O
of NN O O
open NN O O
surgical NN O O
techniques NN O O
might NN O O
be NN O O
one NN O O
way NN O O
to NN O O
achieve NN O O
this NN O O
. NN O O

The NN O O
aim NN O O
of NN O O
this NN O O
study NN O O
was NN O O
to NN O O
compare NN O O
postoperative NN O O
HRQoL NN O O
after NN O O
open NN O O
and NN O O
laparoscopic NN O O
liver NN O O
resection NN O O
. NN O O

This NN O O
was NN O O
a NN O O
predefined NN O O
substudy NN O O
of NN O O
an NN O O
RCT NN O O
comparing NN O O
open NN O O
with NN O O
laparoscopic NN O O
liver NN O O
resection NN O O
. NN O O

Patients NN O O
with NN O O
colorectal NN O O
liver NN O O
metastases NN O O
were NN O O
assigned NN O O
randomly NN O O
to NN O O
open NN O O
or NN O O
laparoscopic NN O O
parenchyma-sparing NN O O
liver NN O O
resection NN O O
. NN O O

HRQoL NN O O
was NN O O
assessed NN O O
with NN O O
the NN O O
Short NN O O
Form NN O O
36 NN O O
questionnaire NN O O
at NN O O
baseline NN O O
, NN O O
and NN O O
1 NN O O
and NN O O
4 NN O O
months NN O O
after NN O O
surgery NN O O
. NN O O

A NN O O
total NN O O
of NN O O
280 NN O O
patients NN O O
were NN O O
randomized NN O O
, NN O O
of NN O O
whom NN O O
273 NN O O
underwent NN O O
surgery NN O O
( NN O O
129 NN O O
laparoscopic NN O O
, NN O O
144 NN O O
open NN O O
) NN O O
; NN O O
682 NN O O
questionnaires NN O O
( NN O O
83.3 NN O O
per NN O O
cent NN O O
) NN O O
were NN O O
available NN O O
for NN O O
analysis NN O O
. NN O O

One NN O O
month NN O O
after NN O O
surgery NN O O
, NN O O
patients NN O O
in NN O O
the NN O O
laparoscopic NN O O
surgery NN O O
group NN O O
reported NN O O
reduced NN O O
scores NN O O
in NN O O
two NN O O
HRQoL NN O O
domains NN O O
( NN O O
physical NN O O
functioning NN O O
and NN O O
role NN O O
physical NN O O
) NN O O
, NN O O
whereas NN O O
those NN O O
in NN O O
the NN O O
open NN O O
surgery NN O O
group NN O O
reported NN O O
reduced NN O O
scores NN O O
in NN O O
five NN O O
domains NN O O
( NN O O
physical NN O O
functioning NN O O
, NN O O
role NN O O
physical NN O O
, NN O O
bodily NN O O
pain NN O O
, NN O O
vitality NN O O
and NN O O
social NN O O
functioning NN O O
) NN O O
. NN O O

Four NN O O
months NN O O
after NN O O
surgery NN O O
, NN O O
HRQoL NN O O
scores NN O O
in NN O O
the NN O O
laparoscopic NN O O
group NN O O
had NN O O
returned NN O O
to NN O O
preoperative NN O O
levels NN O O
, NN O O
whereas NN O O
patients NN O O
in NN O O
the NN O O
open NN O O
group NN O O
reported NN O O
reduced NN O O
scores NN O O
for NN O O
two NN O O
domains NN O O
( NN O O
role NN O O
physical NN O O
and NN O O
general NN O O
health NN O O
) NN O O
. NN O O

The NN O O
between-group NN O O
difference NN O O
was NN O O
statistically NN O O
significant NN O O
in NN O O
favour NN O O
of NN O O
laparoscopy NN O O
for NN O O
four NN O O
domains NN O O
after NN O O
1 NN O O
month NN O O
( NN O O
role NN O O
physical NN O O
, NN O O
bodily NN O O
pain NN O O
, NN O O
vitality NN O O
and NN O O
social NN O O
functioning NN O O
) NN O O
and NN O O
for NN O O
one NN O O
domain NN O O
after NN O O
4 NN O O
months NN O O
( NN O O
role NN O O
physical NN O O
) NN O O
. NN O O

Patients NN O O
assigned NN O O
to NN O O
laparoscopic NN O O
liver NN O O
surgery NN O O
reported NN O O
better NN O O
postoperative NN O O
HRQoL NN O O
than NN O O
those NN O O
assigned NN O O
to NN O O
open NN O O
liver NN O O
surgery NN O O
. NN O O

For NN O O
role NN O O
limitations NN O O
caused NN O O
by NN O O
physical NN O O
health NN O O
problems NN O O
, NN O O
patients NN O O
in NN O O
the NN O O
laparoscopic NN O O
group NN O O
reported NN O O
better NN O O
scores NN O O
up NN O O
to NN O O
4 NN O O
months NN O O
after NN O O
surgery NN O O
. NN O O

Registration NN O O
number NN O O
: NN O O
NCT01516710 NN O O
( NN O O
http://www.clinicaltrials.gov NN O O
) NN O O
. NN O O

La NN O O
mayoría NN O O
de NN O O
los NN O O
tratamientos NN O O
para NN O O
el NN O O
cáncer NN O O
causan NN O O
una NN O O
disminución NN O O
de NN O O
la NN O O
calidad NN O O
de NN O O
vida NN O O
relacionada NN O O
con NN O O
la NN O O
salud NN O O
( NN O O
health-related NN O O
quality NN O O
of NN O O
life NN O O
, NN O O
HRQoL NN O O
) NN O O
de NN O O
los NN O O
pacientes NN O O
. NN O O

Limitar NN O O
este NN O O
declive NN O O
es NN O O
un NN O O
objetivo NN O O
universal NN O O
para NN O O
los NN O O
proveedores NN O O
de NN O O
atención NN O O
médica NN O O
. NN O O

El NN O O
uso NN O O
de NN O O
técnicas NN O O
quirúrgicas NN O O
mínimamente NN O O
invasivas NN O O
en NN O O
lugar NN O O
de NN O O
abiertas NN O O

podría NN O O
ser NN O O
una NN O O
forma NN O O
de NN O O
lograrlo NN O O
. NN O O

El NN O O
objetivo NN O O
de NN O O
este NN O O
estudio NN O O
fue NN O O
comparar NN O O
la NN O O
HRQoL NN O O
postoperatoria NN O O
después NN O O
de NN O O
la NN O O
resección NN O O
hepática NN O O
abierta NN O O
y NN O O
laparoscópica NN O O
. NN O O

MÉTODOS NN O O
: NN O O
Se NN O O
trata NN O O
de NN O O
un NN O O
subestudio NN O O
predefinido NN O O
de NN O O
un NN O O
ensayo NN O O
aleatorizado NN O O
y NN O O
controlado NN O O
que NN O O
comparó NN O O
la NN O O
resección NN O O
hepática NN O O
abierta NN O O
con NN O O
la NN O O
laparoscópica NN O O
. NN O O

Los NN O O
pacientes NN O O
con NN O O
metástasis NN O O
hepáticas NN O O
colorrectales NN O O
se NN O O
asignaron NN O O
aleatoriamente NN O O
al NN O O
grupo NN O O
de NN O O
resección NN O O
hepática NN O O
con NN O O
preservación NN O O
de NN O O
parénquima NN O O
por NN O O
vía NN O O
abierta NN O O
o NN O O
por NN O O
vía NN O O
laparoscópica NN O O
. NN O O

La NN O O
HRQoL NN O O
se NN O O
evaluó NN O O
con NN O O
el NN O O
cuestionario NN O O
abreviado NN O O
SF-36 NN O O
en NN O O
el NN O O
momento NN O O
basal NN O O
y NN O O
al NN O O
cabo NN O O
de NN O O
1 NN O O
y NN O O
4 NN O O
meses NN O O
después NN O O
de NN O O
la NN O O
cirugía NN O O
. NN O O

Un NN O O
total NN O O
de NN O O
280 NN O O
pacientes NN O O
fueron NN O O
aleatorizados NN O O
, NN O O
de NN O O
los NN O O
cuales NN O O
273 NN O O
se NN O O
sometieron NN O O
a NN O O
cirugía NN O O
( NN O O
129 NN O O
= NN O O
laparoscópica NN O O
, NN O O
144 NN O O
= NN O O
abierta NN O O
) NN O O
y NN O O
hubo NN O O
682 NN O O
cuestionarios NN O O
( NN O O
83 NN O O
% NN O O
) NN O O
disponibles NN O O
para NN O O
el NN O O
análisis NN O O
. NN O O

Un NN O O
mes NN O O
después NN O O
de NN O O
la NN O O
cirugía NN O O
, NN O O
los NN O O
pacientes NN O O
del NN O O
grupo NN O O
de NN O O
cirugía NN O O
laparoscópica NN O O
presentaron NN O O
puntuaciones NN O O
reducidas NN O O
en NN O O
dos NN O O
items NN O O
de NN O O
HRQoL NN O O
( NN O O
función NN O O
física NN O O
y NN O O
rol NN O O
físico NN O O
) NN O O
, NN O O
mientras NN O O
que NN O O
los NN O O
pacientes NN O O
del NN O O
grupo NN O O
de NN O O
cirugía NN O O
abierta NN O O
presentaron NN O O
puntuaciones NN O O
reducidas NN O O
en NN O O
cinco NN O O
items NN O O
( NN O O
función NN O O
física NN O O
, NN O O
rol NN O O
físico NN O O
, NN O O
dolor NN O O
corporal NN O O
, NN O O
vitalidad NN O O
y NN O O
función NN O O
social NN O O
) NN O O
. NN O O

Cuatro NN O O
meses NN O O
después NN O O
de NN O O
la NN O O
cirugía NN O O
, NN O O
el NN O O
grupo NN O O
de NN O O
cirugía NN O O
laparoscópica NN O O
había NN O O
vuelto NN O O
a NN O O
los NN O O
niveles NN O O
preoperatorios NN O O
de NN O O
la NN O O
HRQoL NN O O
, NN O O
mientras NN O O
que NN O O
los NN O O
pacientes NN O O
del NN O O
grupo NN O O
de NN O O
cirugía NN O O
abierta NN O O
presentaron NN O O
puntuaciones NN O O
reducidas NN O O
para NN O O
dos NN O O
items NN O O
( NN O O
función NN O O
física NN O O
y NN O O
salud NN O O
general NN O O
) NN O O
. NN O O

La NN O O
diferencia NN O O
entre NN O O
los NN O O
grupos NN O O
fue NN O O
estadísticamente NN O O
significativa NN O O
a NN O O
favor NN O O
de NN O O
la NN O O
laparoscopia NN O O
para NN O O
cuatro NN O O
items NN O O
después NN O O
de NN O O
un NN O O
mes NN O O
de NN O O
la NN O O
cirugía NN O O
( NN O O
rol NN O O
físico NN O O
, NN O O
dolor NN O O
corporal NN O O
, NN O O
vitalidad NN O O
y NN O O
función NN O O
social NN O O
) NN O O
y NN O O
para NN O O
un NN O O
ítem NN O O
( NN O O
rol NN O O
físico NN O O
) NN O O
después NN O O
de NN O O
cuatro NN O O
meses NN O O
. NN O O

CONCLUSIÓN NN O O
: NN O O
Los NN O O
pacientes NN O O
asignados NN O O
a NN O O
cirugía NN O O
hepática NN O O
laparoscópica NN O O
presentaron NN O O
mejor NN O O
HRQoL NN O O
postoperatoria NN O O
que NN O O
los NN O O
pacientes NN O O
asignados NN O O
a NN O O
cirugía NN O O
hepática NN O O
abierta NN O O
. NN O O

Para NN O O
las NN O O
limitaciones NN O O
de NN O O
roles NN O O
causadas NN O O
por NN O O
problemas NN O O
físicos NN O O
de NN O O
salud NN O O
, NN O O
los NN O O
pacientes NN O O
de NN O O
cirugía NN O O
laparoscópica NN O O
presentaron NN O O
mejores NN O O
puntuaciones NN O O
a NN O O
los NN O O
cuatro NN O O
meses NN O O
tras NN O O
la NN O O
intervención NN O O
quirúrgica NN O O
. NN O O



-DOCSTART- (30782695)

The NN O O
population NN O O
in NN O O
rural NN O O
Alaska NN O O
experiences NN O O
a NN O O
disproprionately NN O O
high NN O O
burden NN O O
of NN O O
infection-mediated NN O O
hearing NN O O
loss NN O O
. NN O O

While NN O O
the NN O O
state NN O O
mandates NN O O
school NN O O
hearing NN O O
screening NN O O
, NN O O
many NN O O
children NN O O
with NN O O
hearing NN O O
loss NN O O
are NN O O
not NN O O
identified NN O O
or NN O O
are NN O O
lost NN O O
to NN O O
follow-up NN O O
before NN O O
ever NN O O
receiving NN O O
treatment NN O O
. NN O O

A NN O O
robust NN O O
, NN O O
tribally NN O O
owned NN O O
healthcare NN O O
system NN O O
exists NN O O
in NN O O
Alaska NN O O
, NN O O
but NN O O
children NN O O
with NN O O
hearing NN O O
loss NN O O
must NN O O
first NN O O
be NN O O
identified NN O O
and NN O O
referred NN O O
for NN O O
existing NN O O
infrastructure NN O O
to NN O O
be NN O O
used NN O O
. NN O O

This NN O O
trial NN O O
will NN O O
evaluate NN O O
a NN O O
new NN O O
school NN O O
hearing NN O O
screening NN O O
and NN O O
referral NN O O
process NN O O
in NN O O
rural NN O O
Alaska NN O O
, NN O O
with NN O O
the NN O O
goal NN O O
of NN O O
improving NN O O
timely NN O O
identification NN O O
and NN O O
treatment NN O O
of NN O O
childhood NN O O
hearing NN O O
loss NN O O
. NN O O

Comparative NN O O
effectiveness NN O O
community NN O O
randomised NN O O
trial NN O O
testing NN O O
digital NN O O
innovations NN O O
to NN O O
improve NN O O
school NN O O
hearing NN O O
screening NN O O
and NN O O
referral NN O O
in NN O O
15 NN O O
communities NN O O
in NN O O
the NN O O
Norton NN O O
Sound NN O O
region NN O O
of NN O O
northwest NN O O
Alaska NN O O
, NN O O
with NN O O
data NN O O
collection NN O O
from NN O O
October NN O O
2017 NN O O
to NN O O
February NN O O
2020 NN O O
. NN O O

All NN O O
children NN O O
( NN O O
K-12 NN O O
) NN O O
attending NN O O
school NN O O
in NN O O
Bering NN O O
Strait NN O O
School NN O O
District NN O O
with NN O O
parental NN O O
informed NN O O
consent NN O O
and NN O O
child NN O O
assent NN O O
will NN O O
be NN O O
eligible NN O O
( NN O O
target NN O O
recruitment NN O O
n=1500 NN O O
) NN O O
. NN O O

Participating NN O O
children NN O O
will NN O O
undergo NN O O
both NN O O
the NN O O
current NN O O
school NN O O
hearing NN O O
screen NN O O
and NN O O
new NN O O
mobile NN O O
health NN O O
( NN O O
mHealth NN O O
) NN O O
screen NN O O
, NN O O
with NN O O
screening NN O O
test NN O O
validity NN O O
evaluated NN O O
against NN O O
an NN O O
audiometric NN O O
assessment NN O O
. NN O O

Communities NN O O
will NN O O
be NN O O
cluster NN O O
randomised NN O O
to NN O O
continue NN O O
the NN O O
current NN O O
primary NN O O
care NN O O
referral NN O O
process NN O O
or NN O O
receive NN O O
telemedicine NN O O
referral NN O O
for NN O O
follow-up NN O O
diagnosis NN O O
and NN O O
treatment NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
will NN O O
be NN O O
time NN O O
to NN O O
International NN O O
Statistical NN O O
Classification NN O O
of NN O O
Diseases NN O O
, NN O O
10th NN O O
Revision NN O O
, NN O O
ear/hearing NN O O
diagnosis NN O O
from NN O O
screening NN O O
date NN O O
, NN O O
measured NN O O
in NN O O
days NN O O
. NN O O

Secondary NN O O
outcomes NN O O
will NN O O
include NN O O
: NN O O
sensitivity NN O O
and NN O O
specificity NN O O
of NN O O
current NN O O
school NN O O
and NN O O
mHealth NN O O
screening NN O O
protocols NN O O
measured NN O O
against NN O O
a NN O O
benchmark NN O O
audiometric NN O O
assessment NN O O
( NN O O
air NN O O
and NN O O
bone NN O O
conduction NN O O
audiometry NN O O
, NN O O
tympanometry NN O O
and NN O O
digital NN O O
otoscopy NN O O
) NN O O
; NN O O
hearing NN O O
loss NN O O
prevalence NN O O
; NN O O
hearing-related NN O O
quality NN O O
of NN O O
life NN O O
; NN O O
and NN O O
school NN O O
performance NN O O
( NN O O
AIMSweb NN O O
) NN O O
. NN O O

Intention-to-treat NN O O
analysis NN O O
will NN O O
be NN O O
used NN O O
. NN O O

This NN O O
study NN O O
has NN O O
been NN O O
approved NN O O
by NN O O
the NN O O
Institutional NN O O
Review NN O O
Boards NN O O
of NN O O
Alaska NN O O
Area NN O O
, NN O O
Norton NN O O
Sound NN O O
and NN O O
Duke NN O O
University NN O O
and NN O O
is NN O O
registered NN O O
on NN O O
clinicaltrials.gov NN O O
. NN O O

Results NN O O
will NN O O
be NN O O
distributed NN O O
with NN O O
equal NN O O
emphasis NN O O
on NN O O
scientific NN O O
and NN O O
community NN O O
dissemination NN O O
. NN O O

NCT03309553 NN O O
; NN O O
Pre-results NN O O
. NN O O



-DOCSTART- (30850957)

CT-P16 NN O O
is NN O O
a NN O O
candidate NN O O
biosimilar NN O O
of NN O O
bevacizumab NN O O
, NN O O
a NN O O
monoclonal NN O O
antibody NN O O
targeting NN O O
vascular NN O O
endothelial NN O O
growth NN O O
factor NN O O
that NN O O
is NN O O
used NN O O
in NN O O
the NN O O
treatment NN O O
of NN O O
a NN O O
range NN O O
of NN O O
advanced NN O O
solid NN O O
cancers NN O O
. NN O O

The NN O O
objective NN O O
of NN O O
this NN O O
study NN O O
was NN O O
to NN O O
demonstrate NN O O
the NN O O
pharmacokinetic NN O O
equivalence NN O O
of NN O O
CT-P16 NN O O
and NN O O
European NN O O
Union NN O O
(EU)-approved NN O O
bevacizumab NN O O
( NN O O
EU-bevacizumab NN O O
) NN O O
and NN O O
US-licensed NN O O
bevacizumab NN O O
( NN O O
US-bevacizumab NN O O
) NN O O
reference NN O O
products NN O O
. NN O O

In NN O O
this NN O O
double-blind NN O O
, NN O O
parallel-group NN O O
phase NN O O
I NN O O
trial NN O O
( NN O O
ClinicalTrials.gov NN O O
identifier NN O O
NCT03247673 NN O O
) NN O O
, NN O O
healthy NN O O
adult NN O O
males NN O O
were NN O O
randomized NN O O
( NN O O
1:1:1 NN O O
) NN O O
to NN O O
receive NN O O
a NN O O
single NN O O
dose NN O O
of NN O O
CT-P16 NN O O
5 NN O O
mg/kg NN O O
, NN O O
EU-bevacizumab NN O O
5 NN O O
mg/kg NN O O
, NN O O
or NN O O
US-bevacizumab NN O O
5 NN O O
mg/kg NN O O
. NN O O

Primary NN O O
study NN O O
endpoints NN O O
were NN O O
area NN O O
under NN O O
the NN O O
concentration-time NN O O
curve NN O O
( NN O O
AUC NN O O
) NN O O
from NN O O
time NN O O
zero NN O O
to NN O O
infinity NN O O
( NN O O
AUC NN O O
) NN O O
, NN O O
AUC NN O O
from NN O O
time NN O O
zero NN O O
to NN O O
the NN O O
last NN O O
quantifiable NN O O
concentration NN O O
( NN O O
AUC NN O O
) NN O O
, NN O O
and NN O O
maximum NN O O
serum NN O O
concentration NN O O
( NN O O
C NN O O
) NN O O
. NN O O

Pharmacokinetic NN O O
equivalence NN O O
was NN O O
shown NN O O
if NN O O
the NN O O
90 NN O O
% NN O O
confidence NN O O
intervals NN O O
( NN O O
CIs NN O O
) NN O O
of NN O O
the NN O O
geometric NN O O
mean NN O O
( NN O O
GM NN O O
) NN O O
ratios NN O O
of NN O O
the NN O O
AUC NN O O
, NN O O
AUC NN O O
, NN O O
and NN O O
C NN O O
were NN O O
within NN O O
the NN O O
predefined NN O O
bioequivalence NN O O
margin NN O O
of NN O O
80 NN O O
- NN O O
125 NN O O
% NN O O
. NN O O

Safety NN O O
and NN O O
immunogenicity NN O O
were NN O O
also NN O O
evaluated NN O O
. NN O O

A NN O O
total NN O O
of NN O O
144 NN O O
subjects NN O O
were NN O O
randomized NN O O
: NN O O
47 NN O O
to NN O O
CT-P16 NN O O
, NN O O
49 NN O O
to NN O O
EU-bevacizumab NN O O
, NN O O
and NN O O
48 NN O O
to NN O O
US-bevacizumab NN O O
. NN O O

The NN O O
90 NN O O
% NN O O
CIs NN O O
for NN O O
the NN O O
GM NN O O
ratios NN O O
of NN O O
AUC NN O O
, NN O O
AUC NN O O
, NN O O
and NN O O
C NN O O
for NN O O
CT-P16/EU-bevacizumab NN O O
, NN O O
CT-P16/US-bevacizumab NN O O
, NN O O
and NN O O
EU-bevacizumab/US-bevacizumab NN O O
comparisons NN O O
were NN O O
all NN O O
within NN O O
the NN O O
bioequivalence NN O O
margin NN O O
. NN O O

Mean NN O O
serum NN O O
concentration-time NN O O
profiles NN O O
, NN O O
secondary NN O O
pharmacokinetic NN O O
parameters NN O O
, NN O O
and NN O O
safety NN O O
and NN O O
immunogenicity NN O O
profiles NN O O
were NN O O
comparable NN O O
across NN O O
all NN O O
three NN O O
treatment NN O O
groups NN O O
. NN O O

CT-P16 NN O O
demonstrated NN O O
pharmacokinetic NN O O
equivalence NN O O
to NN O O
EU-bevacizumab NN O O
and NN O O
US-bevacizumab NN O O
. NN O O

Safety NN O O
and NN O O
immunogenicity NN O O
profiles NN O O
were NN O O
similar NN O O
for NN O O
CT-P16 NN O O
, NN O O
EU-bevacizumab NN O O
, NN O O
and NN O O
US-bevacizumab NN O O
. NN O O

These NN O O
data NN O O
support NN O O
the NN O O
further NN O O
clinical NN O O
evaluation NN O O
of NN O O
CT-P16 NN O O
as NN O O
a NN O O
bevacizumab NN O O
biosimilar NN O O
. NN O O

NCT03247673 NN O O
. NN O O



-DOCSTART- (30833068)

Hepatitis NN O O
D NN O O
is NN O O
the NN O O
most NN O O
severe NN O O
form NN O O
of NN O O
chronic NN O O
viral NN O O
hepatitis NN O O
. NN O O

Treatment NN O O
guidelines NN O O
recommend NN O O
1 NN O O
year NN O O
of NN O O
peginterferon NN O O
alfa NN O O
, NN O O
which NN O O
is NN O O
effective NN O O
in NN O O
25 NN O O
- NN O O
30 NN O O
% NN O O
of NN O O
patients NN O O
only NN O O
. NN O O

Whether NN O O
prolonged NN O O
therapy NN O O
with NN O O
peginterferon NN O O
alfa-2a NN O O
for NN O O
96 NN O O
weeks NN O O
and NN O O
combination NN O O
therapy NN O O
with NN O O
tenofovir NN O O
disoproxil NN O O
fumarate NN O O
( NN O O
TDF NN O O
) NN O O
would NN O O
increase NN O O
hepatitis NN O O
D NN O O
virus NN O O
( NN O O
HDV NN O O
) NN O O
RNA NN O O
suppression NN O O
is NN O O
unknown NN O O
. NN O O

We NN O O
aimed NN O O
to NN O O
explore NN O O
whether NN O O
prolonged NN O O
treatment NN O O
of NN O O
HDV NN O O
with NN O O
96 NN O O
weeks NN O O
of NN O O
peginterferon NN O O
would NN O O
increase NN O O
HDV NN O O
RNA NN O O
response NN O O
rates NN O O
and NN O O
reduces NN O O
post-treatment NN O O
relapses NN O O
. NN O O

We NN O O
did NN O O
two NN O O
parallel NN O O
, NN O O
investigator-initiated NN O O
, NN O O
multicentre NN O O
, NN O O
double-blind NN O O
randomised NN O O
, NN O O
controlled NN O O
trials NN O O
at NN O O
14 NN O O
study NN O O
sites NN O O
in NN O O
Germany NN O O
, NN O O
Greece NN O O
, NN O O
Romania NN O O
, NN O O
and NN O O
Turkey NN O O
. NN O O

Patients NN O O
with NN O O
chronic NN O O
HDV NN O O
infection NN O O
and NN O O
compensated NN O O
liver NN O O
disease NN O O
who NN O O
were NN O O
aged NN O O
18 NN O O
years NN O O
or NN O O
older NN O O
were NN O O
eligible NN O O
for NN O O
inclusion NN O O
. NN O O

All NN O O
patients NN O O
were NN O O
HBsAg NN O O
positive NN O O
for NN O O
at NN O O
least NN O O
7 NN O O
months NN O O
, NN O O
anti-HDV NN O O
positive NN O O
for NN O O
at NN O O
least NN O O
3 NN O O
months NN O O
, NN O O
and NN O O
HDV-RNA NN O O
positive NN O O
at NN O O
the NN O O
local NN O O
laboratory NN O O
at NN O O
the NN O O
screening NN O O
visit NN O O
. NN O O

Patients NN O O
were NN O O
ineligible NN O O
if NN O O
alanine NN O O
aminotransferase NN O O
levels NN O O
were NN O O
higher NN O O
than NN O O
ten NN O O
times NN O O
above NN O O
the NN O O
upper NN O O
limit NN O O
of NN O O
normal NN O O
and NN O O
if NN O O
platelet NN O O
counts NN O O
were NN O O
lower NN O O
than NN O O
90 NN O O
000 NN O O
per NN O O
μL NN O O
, NN O O
or NN O O
if NN O O
they NN O O
had NN O O
received NN O O
interferon NN O O
therapy NN O O
or NN O O
treatment NN O O
with NN O O
a NN O O
nucleoside NN O O
and NN O O
nucleotide NN O O
analogue NN O O
within NN O O
the NN O O
preceding NN O O
6 NN O O
months NN O O
. NN O O

Patients NN O O
were NN O O
randomly NN O O
assigned NN O O
by NN O O
blinded NN O O
stratified NN O O
block NN O O
randomisation NN O O
( NN O O
1:1 NN O O
) NN O O
to NN O O
receive NN O O
180 NN O O
μg NN O O
of NN O O
peginterferon NN O O
alfa-2a NN O O
weekly NN O O
plus NN O O
either NN O O
TDF NN O O
( NN O O
300 NN O O
mg NN O O
once NN O O
daily NN O O
) NN O O
or NN O O
placebo NN O O
for NN O O
96 NN O O
weeks NN O O
. NN O O

The NN O O
primary NN O O
endpoint NN O O
was NN O O
the NN O O
percentage NN O O
of NN O O
patients NN O O
with NN O O
undetectable NN O O
HDV NN O O
RNA NN O O
at NN O O
the NN O O
end NN O O
of NN O O
treatment NN O O
assessed NN O O
by NN O O
intention NN O O
to NN O O
treat NN O O
. NN O O

The NN O O
trials NN O O
are NN O O
registered NN O O
as NN O O
NCT00932971 NN O O
and NN O O
NCT01088659 NN O O
. NN O O

Between NN O O
June NN O O
24 NN O O
, NN O O
2009 NN O O
, NN O O
and NN O O
Feb NN O O
28 NN O O
, NN O O
2011 NN O O
, NN O O
we NN O O
randomly NN O O
assigned NN O O
59 NN O O
HDV NN O O
RNA-positive NN O O
patients NN O O
to NN O O
receive NN O O
peginterferon NN O O
alfa-2a NN O O
plus NN O O
TDF NN O O
and NN O O
61 NN O O
to NN O O
receive NN O O
peginterferon NN O O
alfa-2a NN O O
plus NN O O
placebo NN O O
, NN O O
including NN O O
48 NN O O
( NN O O
40 NN O O
% NN O O
) NN O O
patients NN O O
with NN O O
cirrhosis NN O O
to NN O O
the NN O O
two NN O O
treatment NN O O
groups NN O O
( NN O O
23 NN O O
in NN O O
the NN O O
peginterferon NN O O
alfa-2a NN O O
plus NN O O
TDF NN O O
group NN O O
and NN O O
25 NN O O
in NN O O
the NN O O
peginterferon NN O O
alfa-2a NN O O
plus NN O O
placebo NN O O
group NN O O
) NN O O
. NN O O

The NN O O
primary NN O O
endpoint NN O O
was NN O O
achieved NN O O
in NN O O
28 NN O O
( NN O O
48 NN O O
% NN O O
) NN O O
of NN O O
59 NN O O
patients NN O O
in NN O O
the NN O O
peginterferon NN O O
alfa-2a NN O O
plus NN O O
TDF NN O O
group NN O O
and NN O O
in NN O O
20 NN O O
( NN O O
33 NN O O
% NN O O
) NN O O
of NN O O
61 NN O O
patients NN O O
in NN O O
the NN O O
peginterferon NN O O
alfa-2a NN O O
plus NN O O
placebo NN O O
group NN O O
( NN O O
odds NN O O
ratio NN O O
1·84 NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
0·86 NN O O
- NN O O
3·91 NN O O
, NN O O
p=0·12 NN O O
) NN O O
. NN O O

We NN O O
recorded NN O O
944 NN O O
adverse NN O O
events NN O O
( NN O O
459 NN O O
in NN O O
the NN O O
peginterferon NN O O
alfa-2a NN O O
plus NN O O
TDF NN O O
group NN O O
and NN O O
485 NN O O
in NN O O
the NN O O
peginterferon NN O O
alfa-2a NN O O
plus NN O O
placebo NN O O
group NN O O
) NN O O
. NN O O

The NN O O
most NN O O
common NN O O
adverse NN O O
events NN O O
were NN O O
haematological NN O O
, NN O O
behavioural NN O O
( NN O O
eg NN O O
, NN O O
fatigue NN O O
) NN O O
, NN O O
musculoskeletal NN O O
, NN O O
influenza-like NN O O
syndromes NN O O
, NN O O
and NN O O
psychiatric NN O O
complaints NN O O
. NN O O

Addition NN O O
of NN O O
TDF NN O O
resulted NN O O
in NN O O
no NN O O
significant NN O O
improvement NN O O
in NN O O
HDV NN O O
RNA NN O O
response NN O O
rates NN O O
at NN O O
the NN O O
end NN O O
of NN O O
treatment NN O O
. NN O O

These NN O O
findings NN O O
highlight NN O O
that NN O O
alternative NN O O
treatment NN O O
options NN O O
are NN O O
needed NN O O
for NN O O
hepatitis NN O O
D. NN O O

The NN O O
HepNet NN O O
Study-House NN O O
( NN O O
a NN O O
project NN O O
of NN O O
the NN O O
German NN O O
Liver NN O O
Foundation NN O O
founded NN O O
by NN O O
the NN O O
German NN O O
Liver NN O O
Foundation NN O O
, NN O O
the NN O O
German NN O O
Ministry NN O O
for NN O O
Education NN O O
and NN O O
Research NN O O
, NN O O
and NN O O
the NN O O
German NN O O
Center NN O O
for NN O O
Infectious NN O O
Disease NN O O
Research NN O O
) NN O O
, NN O O
Hoffmann-La NN O O
Roche NN O O
, NN O O
and NN O O
Gilead NN O O
Sciences NN O O
. NN O O



-DOCSTART- (31324209)

The NN O O
Venous NN O O
Thromboembolism NN O O
Prophylaxis NN O O
( NN O O
VTE-PRO NN O O
) NN O O
randomized NN O O
trial NN O O
is NN O O
a NN O O
pilot NN O O
study NN O O
evaluating NN O O
the NN O O
impact NN O O
of NN O O
extended-duration NN O O
prophylaxis NN O O
on NN O O
venous NN O O
thromboembolic NN O O
events NN O O
in NN O O
patients NN O O
undergoing NN O O
lung NN O O
cancer NN O O
resection NN O O
. NN O O

Enrolled NN O O
VTE-PRO NN O O
participants NN O O
self-inject NN O O
either NN O O
low-molecular NN O O
weight NN O O
heparin NN O O
or NN O O
a NN O O
saline NN O O
placebo NN O O
for NN O O
30 NN O O
days NN O O
postoperatively NN O O
. NN O O

Study NN O O
outcomes NN O O
include NN O O
feasibility NN O O
, NN O O
incidence NN O O
of NN O O
venous NN O O
thromboembolism NN O O
, NN O O
and NN O O
venous NN O O
thromboembolism-related NN O O
morbidity NN O O
and NN O O
mortality NN O O
. NN O O

Initial NN O O
analyses NN O O
demonstrated NN O O
low NN O O
rates NN O O
of NN O O
accrual NN O O
and NN O O
retention NN O O
for NN O O
the NN O O
VTE-PRO NN O O
pilot NN O O
. NN O O

Therefore NN O O
, NN O O
the NN O O
purpose NN O O
of NN O O
the NN O O
current NN O O
study NN O O
was NN O O
to NN O O
develop NN O O
a NN O O
knowledge NN O O
translation NN O O
intervention NN O O
to NN O O
improve NN O O
VTE-PRO NN O O
pilot NN O O
trial NN O O
accrual NN O O
and NN O O
retention NN O O
. NN O O

Eligible NN O O
participants NN O O
were NN O O
surveyed NN O O
to NN O O
identify NN O O
the NN O O
barriers NN O O
to NN O O
VTE-PRO NN O O
participation NN O O
. NN O O

The NN O O
Theoretical NN O O
Domains NN O O
Framework NN O O
was NN O O
used NN O O
to NN O O
categorize NN O O
these NN O O
barriers NN O O
. NN O O

Barriers NN O O
were NN O O
mapped NN O O
to NN O O
the NN O O
capabilities NN O O
, NN O O
opportunities NN O O
, NN O O
and NN O O
behavior NN O O
( NN O O
COM-B NN O O
) NN O O
behavioral NN O O
change NN O O
wheel NN O O
to NN O O
identify NN O O
potential NN O O
interventions NN O O
to NN O O
support NN O O
trial NN O O
accrual NN O O
and NN O O
retention NN O O
. NN O O

The NN O O
resulting NN O O
knowledge NN O O
translation NN O O
intervention NN O O
was NN O O
titled NN O O
Inform NN O O
, NN O O
Remind NN O O
, NN O O
Involve NN O O
and NN O O
Support NN O O
to NN O O
improve NN O O
Accrual NN O O
and NN O O
Retention NN O O
( NN O O
IRIS-AR NN O O
) NN O O
. NN O O

Key NN O O
informant NN O O
interviews NN O O
with NN O O
patients NN O O
were NN O O
held NN O O
to NN O O
refine NN O O
and NN O O
confirm NN O O
the NN O O
validity NN O O
of NN O O
identified NN O O
barriers NN O O
and NN O O
perceived NN O O
acceptability NN O O
of NN O O
the NN O O
proposed NN O O
IRIS-AR NN O O
intervention NN O O
. NN O O

Institutional NN O O
Review NN O O
Board NN O O
approval NN O O
was NN O O
granted NN O O
for NN O O
this NN O O
study NN O O
. NN O O

The NN O O
resulting NN O O
intervention NN O O
included NN O O
: NN O O
information NN O O
booklets NN O O
and NN O O
counseling NN O O
sessions NN O O
to NN O O
identify NN O O
unique NN O O
participant NN O O
challenges NN O O
to NN O O
trial NN O O
participation NN O O
( NN O O
Inform NN O O
) NN O O
; NN O O
daily NN O O
reminders NN O O
to NN O O
administer NN O O
injections NN O O
( NN O O
Remind NN O O
) NN O O
; NN O O
involvement NN O O
of NN O O
family/caregivers NN O O
in NN O O
study NN O O
processes NN O O
( NN O O
Involve NN O O
) NN O O
; NN O O
and NN O O
leverage NN O O
of NN O O
an NN O O
existing NN O O
home-care NN O O
nursing NN O O
program NN O O
to NN O O
provide NN O O
injection NN O O
support NN O O
when NN O O
needed NN O O
( NN O O
Support NN O O
) NN O O
. NN O O

Twenty-six NN O O
key NN O O
informant NN O O
participants NN O O
were NN O O
interviewed NN O O
. NN O O

The NN O O
most NN O O
common NN O O
barriers NN O O
to NN O O
trial NN O O
participation NN O O
included NN O O
lack NN O O
of NN O O
social NN O O
support NN O O
and NN O O
fear NN O O
of NN O O
needle NN O O
injection NN O O
. NN O O

Participants NN O O
generally NN O O
supported NN O O
use NN O O
of NN O O
information NN O O
booklets NN O O
, NN O O
involvement NN O O
of NN O O
family/caregivers NN O O
, NN O O
and NN O O
support NN O O
by NN O O
a NN O O
home-care NN O O
nursing NN O O
program NN O O
; NN O O
however NN O O
, NN O O
not NN O O
all NN O O
supported NN O O
the NN O O
use NN O O
of NN O O
daily NN O O
reminders NN O O
. NN O O

Developed NN O O
using NN O O
theory NN O O
and NN O O
integrated NN O O
knowledge NN O O
translation NN O O
, NN O O
the NN O O
IRIS-AR NN O O
presents NN O O
a NN O O
patient-centered NN O O
intervention NN O O
that NN O O
leverages NN O O
existing NN O O
programs NN O O
to NN O O
promote NN O O
trial NN O O
engagement NN O O
. NN O O

The NN O O
proposed NN O O
strategy NN O O
can NN O O
likely NN O O
be NN O O
adapted NN O O
to NN O O
improve NN O O
compliance NN O O
with NN O O
other NN O O
patient-directed NN O O
interventions NN O O
. NN O O

ClinicalTrials.gov NN O O
, NN O O
NCT02334007 NN O O
. NN O O

Registered NN O O
on NN O O
8 NN O O
January NN O O
2015 NN O O
. NN O O



-DOCSTART- (30927579)

The NN O O
efficacy NN O O
of NN O O
the NN O O
mindfulness-based NN O O
stress NN O O
management NN O O
program NN O O
for NN O O
maintaining NN O O
a NN O O
better NN O O
mental NN O O
state NN O O
has NN O O
not NN O O
been NN O O
examined NN O O
among NN O O
working NN O O
populations NN O O
. NN O O

We NN O O
aimed NN O O
to NN O O
explore NN O O
the NN O O
effectiveness NN O O
of NN O O
the NN O O
brief NN O O
mindfulness-based NN O O
stress NN O O
management NN O O
program NN O O
for NN O O
hospital NN O O
nurses NN O O
. NN O O

In NN O O
a NN O O
multi-center NN O O
randomized NN O O
trial NN O O
, NN O O
80 NN O O
junior NN O O
nurses NN O O
working NN O O
in NN O O
hospitals NN O O
were NN O O
randomly NN O O
allocated NN O O
either NN O O
to NN O O
the NN O O
brief NN O O
mindfulness-based NN O O
stress NN O O
management NN O O
program NN O O
or NN O O
psychoeducation NN O O
using NN O O
a NN O O
leaflet NN O O
. NN O O

The NN O O
program NN O O
consisted NN O O
of NN O O
four NN O O
30 NN O O
min NN O O
individual NN O O
sessions NN O O
conducted NN O O
by NN O O
trained NN O O
senior NN O O
nurses NN O O
using NN O O
a NN O O
detailed NN O O
manual NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
was NN O O
the NN O O
total NN O O
score NN O O
of NN O O
the NN O O
Hospital NN O O
Anxiety NN O O
and NN O O
Depression NN O O
Scale NN O O
( NN O O
HADS NN O O
) NN O O
at NN O O
week NN O O
26 NN O O
. NN O O

Secondary NN O O
outcomes NN O O
included NN O O
presence NN O O
of NN O O
a NN O O
major NN O O
depressive NN O O
episode NN O O
; NN O O
severity NN O O
of NN O O
depression NN O O
, NN O O
anxiety NN O O
, NN O O
insomnia NN O O
, NN O O
burnout NN O O
, NN O O
and NN O O
presenteeism NN O O
; NN O O
utility NN O O
scores NN O O
; NN O O
and NN O O
adverse NN O O
events NN O O
up NN O O
to NN O O
52 NN O O
weeks NN O O
. NN O O

The NN O O
mean NN O O
HADS NN O O
score NN O O
of NN O O
all NN O O
the NN O O
participants NN O O
at NN O O
baseline NN O O
was NN O O
7.2 NN O O
. NN O O

At NN O O
26 NN O O
weeks NN O O
, NN O O
adjusted NN O O
mean NN O O
scores NN O O
on NN O O
the NN O O
HADS NN O O
score NN O O
were NN O O
7.2 NN O O
( NN O O
95 NN O O
% NN O O
confidence NN O O
intervals NN O O
: NN O O
5.9 NN O O
, NN O O
8 NN O O
. NN O O
5 NN O O
) NN O O
in NN O O
the NN O O
program NN O O
group NN O O
and NN O O
6.0 NN O O
( NN O O
4.8 NN O O
, NN O O
7.2 NN O O
) NN O O
in NN O O
the NN O O
leaflet NN O O
group NN O O
, NN O O
respectively NN O O
. NN O O

The NN O O
coefficient NN O O
of NN O O
the NN O O
group NN O O
by NN O O
time NN O O
interaction NN O O
was NN O O
not NN O O
statistically NN O O
significant NN O O
at NN O O
-1.41 NN O O
( NN O O
-3.35 NN O O
, NN O O
0.54 NN O O
; NN O O
P NN O O
= NN O O
0.156 NN O O
) NN O O
. NN O O

No NN O O
significant NN O O
superiority NN O O
or NN O O
inferiority NN O O
was NN O O
observed NN O O
on NN O O
the NN O O
other NN O O
outcomes NN O O
. NN O O

We NN O O
did NN O O
not NN O O
manage NN O O
to NN O O
recruit NN O O
the NN O O
number NN O O
of NN O O
participants NN O O
we NN O O
initially NN O O
set NN O O
out NN O O
, NN O O
although NN O O
our NN O O
post-hoc NN O O
analyses NN O O
showed NN O O
that NN O O
this NN O O
did NN O O
not NN O O
lead NN O O
to NN O O
changes NN O O
in NN O O
our NN O O
conclusions NN O O
. NN O O

The NN O O
additive NN O O
value NN O O
of NN O O
the NN O O
brief NN O O
mindfulness-based NN O O
stress NN O O
management NN O O
program NN O O
was NN O O
not NN O O
confirmed NN O O
in NN O O
mental NN O O
state NN O O
and NN O O
self-evaluated NN O O
work NN O O
efficiency NN O O
. NN O O



-DOCSTART- (30799142)

Novartis NN O O
Access NN O O
is NN O O
a NN O O
Novartis NN O O
programme NN O O
that NN O O
offers NN O O
a NN O O
portfolio NN O O
of NN O O
non-communicable NN O O
disease NN O O
medicines NN O O
at NN O O
a NN O O
wholesale NN O O
price NN O O
of NN O O
US$ NN O O
1 NN O O
per NN O O
treatment NN O O
per NN O O
month NN O O
in NN O O
low-income NN O O
and NN O O
middle-income NN O O
countries NN O O
. NN O O

We NN O O
evaluated NN O O
the NN O O
effect NN O O
of NN O O
Novartis NN O O
Access NN O O
in NN O O
Kenya NN O O
, NN O O
the NN O O
first NN O O
country NN O O
to NN O O
receive NN O O
the NN O O
programme NN O O
. NN O O

We NN O O
did NN O O
a NN O O
cluster-randomised NN O O
controlled NN O O
trial NN O O
in NN O O
eight NN O O
counties NN O O
in NN O O
Kenya NN O O
. NN O O

Counties NN O O
( NN O O
clusters NN O O
) NN O O
were NN O O
randomly NN O O
assigned NN O O
to NN O O
the NN O O
intervention NN O O
or NN O O
the NN O O
control NN O O
group NN O O
with NN O O
a NN O O
covariate-constrained NN O O
randomisation NN O O
procedure NN O O
that NN O O
maximised NN O O
balance NN O O
on NN O O
a NN O O
set NN O O
of NN O O
demographic NN O O
and NN O O
health NN O O
variables NN O O
. NN O O

In NN O O
intervention NN O O
counties NN O O
, NN O O
public NN O O
and NN O O
non-profit NN O O
health NN O O
facilities NN O O
were NN O O
allowed NN O O
to NN O O
purchase NN O O
Novartis NN O O
Access NN O O
medicines NN O O
from NN O O
the NN O O
Mission NN O O
for NN O O
Essential NN O O
Drugs NN O O
and NN O O
Supplies NN O O
( NN O O
MEDS NN O O
) NN O O
. NN O O

Data NN O O
were NN O O
collected NN O O
from NN O O
all NN O O
facilities NN O O
served NN O O
by NN O O
MEDS NN O O
and NN O O
a NN O O
sample NN O O
of NN O O
households NN O O
in NN O O
study NN O O
counties NN O O
. NN O O

Households NN O O
were NN O O
eligible NN O O
if NN O O
they NN O O
had NN O O
at NN O O
least NN O O
one NN O O
adult NN O O
patient NN O O
who NN O O
had NN O O
been NN O O
diagnosed NN O O
and NN O O
prescribed NN O O
medicines NN O O
for NN O O
one NN O O
of NN O O
the NN O O
non-communicable NN O O
diseases NN O O
targeted NN O O
by NN O O
the NN O O
programme NN O O
: NN O O
hypertension NN O O
, NN O O
heart NN O O
failure NN O O
, NN O O
dyslipidaemia NN O O
, NN O O
type NN O O
2 NN O O
diabetes NN O O
, NN O O
asthma NN O O
, NN O O
or NN O O
breast NN O O
cancer NN O O
. NN O O

Primary NN O O
outcomes NN O O
were NN O O
availability NN O O
and NN O O
price NN O O
of NN O O
portfolio NN O O
medicines NN O O
at NN O O
health NN O O
facilities NN O O
, NN O O
irrespective NN O O
of NN O O
brand NN O O
; NN O O
and NN O O
availability NN O O
of NN O O
medicines NN O O
at NN O O
patient NN O O
households NN O O
. NN O O

Impacts NN O O
were NN O O
estimated NN O O
with NN O O
intention-to-treat NN O O
analysis NN O O
. NN O O

This NN O O
trial NN O O
is NN O O
registered NN O O
with NN O O
ClinicalTrials.gov NN O O
( NN O O
NCT02773095 NN O O
) NN O O
. NN O O

On NN O O
March NN O O
8 NN O O
, NN O O
2016 NN O O
, NN O O
we NN O O
randomly NN O O
assigned NN O O
eight NN O O
clusters NN O O
to NN O O
intervention NN O O
( NN O O
four NN O O
clusters NN O O
; NN O O
74 NN O O
health NN O O
facilities NN O O
; NN O O
342 NN O O
patients NN O O
) NN O O
or NN O O
control NN O O
( NN O O
four NN O O
clusters NN O O
; NN O O
63 NN O O
health NN O O
facilities NN O O
; NN O O
297 NN O O
patients NN O O
) NN O O
. NN O O

69 NN O O
intervention NN O O
and NN O O
58 NN O O
control NN O O
health NN O O
facilities NN O O
, NN O O
and NN O O
306 NN O O
intervention NN O O
and NN O O
265 NN O O
control NN O O
patients NN O O
were NN O O
evaluated NN O O
after NN O O
a NN O O
15 NN O O
month NN O O
intervention NN O O
period NN O O
( NN O O
last NN O O
visit NN O O
February NN O O
28 NN O O
, NN O O
2018 NN O O
) NN O O
. NN O O

Novartis NN O O
Access NN O O
significantly NN O O
increased NN O O
the NN O O
availability NN O O
of NN O O
amlodipine NN O O
( NN O O
adjusted NN O O
odds NN O O
ratio NN O O
[ NN O O
aOR NN O O
] NN O O
2·84 NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
1·10 NN O O
to NN O O
7·37 NN O O
; NN O O
p=0·031 NN O O
) NN O O
and NN O O
metformin NN O O
( NN O O
aOR NN O O
4·78 NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
1·44 NN O O
to NN O O
15·86 NN O O
; NN O O
p=0·011 NN O O
) NN O O
at NN O O
health NN O O
facilities NN O O
, NN O O
but NN O O
did NN O O
not NN O O
affect NN O O
the NN O O
availability NN O O
of NN O O
portfolio NN O O
medicines NN O O
overall NN O O
( NN O O
adjusted NN O O
β NN O O
[ NN O O
aβ NN O O
] NN O O
0·05 NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
-0·01 NN O O
to NN O O
0·10 NN O O
; NN O O
p=0·096 NN O O
) NN O O
or NN O O
their NN O O
price NN O O
( NN O O
aβ NN O O
0·48 NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
-1·12 NN O O
to NN O O
0·72 NN O O
; NN O O
p=0·500 NN O O
) NN O O
. NN O O

The NN O O
programme NN O O
did NN O O
not NN O O
affect NN O O
medicine NN O O
availability NN O O
at NN O O
patient NN O O
households NN O O
( NN O O
aOR NN O O
0·83 NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
0·44 NN O O
to NN O O
1·57 NN O O
; NN O O
p=0·569 NN O O
) NN O O
. NN O O

Novartis NN O O
Access NN O O
had NN O O
little NN O O
effect NN O O
in NN O O
its NN O O
first NN O O
year NN O O
in NN O O
Kenya NN O O
. NN O O

Access NN O O
programmes NN O O
operate NN O O
within NN O O
complex NN O O
health NN O O
systems NN O O
and NN O O
reducing NN O O
the NN O O
wholesale NN O O
price NN O O
of NN O O
medicines NN O O
might NN O O
not NN O O
always NN O O
or NN O O
immediately NN O O
translate NN O O
to NN O O
improved NN O O
patient NN O O
access NN O O
. NN O O

The NN O O
evidence NN O O
generated NN O O
by NN O O
this NN O O
study NN O O
will NN O O
inform NN O O
Novartis NN O O
's NN O O
efforts NN O O
to NN O O
improve NN O O
their NN O O
programme NN O O
going NN O O
forward NN O O
. NN O O

The NN O O
study NN O O
also NN O O
contributes NN O O
to NN O O
the NN O O
public NN O O
evidence NN O O
base NN O O
on NN O O
strategies NN O O
for NN O O
improving NN O O
access NN O O
to NN O O
medicines NN O O
globally NN O O
. NN O O

Sandoz NN O O
International NN O O
( NN O O
a NN O O
subsidiary NN O O
of NN O O
Novartis NN O O
International NN O O
) NN O O
. NN O O



-DOCSTART- (30840057)

Restoration NN O O
of NN O O
the NN O O
esophagogastric NN O O
junction NN O O
competence NN O O
is NN O O
critical NN O O
for NN O O
effective NN O O
long-term NN O O
treatment NN O O
of NN O O
gastroesophageal NN O O
reflux NN O O
disease NN O O
. NN O O

Surgical NN O O
repair NN O O
results NN O O
in NN O O
such NN O O
restoration NN O O
, NN O O
but NN O O
mechanical NN O O
adverse NN O O
effects NN O O
seem NN O O
unavoidable NN O O
. NN O O

Minimizing NN O O
these NN O O
adverse NN O O
effects NN O O
without NN O O
jeopardizing NN O O
reflux NN O O
control NN O O
is NN O O
warranted NN O O
. NN O O

To NN O O
determine NN O O
whether NN O O
partial NN O O
fundoplication NN O O
( NN O O
PF NN O O
) NN O O
or NN O O
total NN O O
fundoplication NN O O
( NN O O
TF NN O O
) NN O O
is NN O O
superior NN O O
in NN O O
laparoscopic NN O O
antireflux NN O O
surgery NN O O
. NN O O

In NN O O
this NN O O
double-blind NN O O
, NN O O
randomized NN O O
clinical NN O O
trial NN O O
of NN O O
1171 NN O O
patients NN O O
scheduled NN O O
for NN O O
laparoscopic NN O O
antireflux NN O O
surgery NN O O
at NN O O
a NN O O
single NN O O
university-affiliated NN O O
center NN O O
between NN O O
November NN O O
19 NN O O
, NN O O
2001 NN O O
, NN O O
and NN O O
January NN O O
24 NN O O
, NN O O
2006 NN O O
, NN O O
456 NN O O
patients NN O O
were NN O O
randomized NN O O
and NN O O
followed NN O O
up NN O O
for NN O O
5 NN O O
years NN O O
. NN O O

Data NN O O
were NN O O
collected NN O O
from NN O O
November NN O O
2001 NN O O
to NN O O
April NN O O
2012 NN O O
, NN O O
and NN O O
data NN O O
were NN O O
analyzed NN O O
from NN O O
April NN O O
2012 NN O O
to NN O O
September NN O O
2018 NN O O
. NN O O

A NN O O
270 NN O O
° NN O O
posterior NN O O
PF NN O O
or NN O O
a NN O O
360 NN O O
° NN O O
Nissen NN O O
TF NN O O
. NN O O

Esophageal NN O O
acid NN O O
exposure NN O O
at NN O O
3 NN O O
years NN O O
after NN O O
surgery NN O O
. NN O O

Of NN O O
the NN O O
456 NN O O
randomized NN O O
patients NN O O
, NN O O
268 NN O O
( NN O O
58.8 NN O O
% NN O O
) NN O O
were NN O O
male NN O O
, NN O O
and NN O O
the NN O O
mean NN O O
( NN O O
SD NN O O
) NN O O
age NN O O
was NN O O
49.0 NN O O
( NN O O
11.7 NN O O
) NN O O
years NN O O
. NN O O

A NN O O
total NN O O
of NN O O
229 NN O O
patients NN O O
were NN O O
randomized NN O O
to NN O O
PF NN O O
, NN O O
and NN O O
227 NN O O
patients NN O O
were NN O O
randomized NN O O
to NN O O
TF NN O O
. NN O O

At NN O O
3 NN O O
years NN O O
postoperatively NN O O
, NN O O
the NN O O
median NN O O
( NN O O
interquartile NN O O
range NN O O
) NN O O
esophageal NN O O
acid NN O O
exposure NN O O
was NN O O
reduced NN O O
from NN O O
14.6 NN O O
% NN O O
( NN O O
9.8 NN O O
- NN O O
21.9 NN O O
) NN O O
to NN O O
1.8 NN O O
% NN O O
( NN O O
0.7 NN O O
- NN O O
4.4 NN O O
) NN O O
after NN O O
PF NN O O
and NN O O
from NN O O
16.0 NN O O
% NN O O
( NN O O
10.4 NN O O
- NN O O
22.7 NN O O
) NN O O
to NN O O
2.5 NN O O
% NN O O
( NN O O
0.8 NN O O
- NN O O
6.8 NN O O
) NN O O
after NN O O
TF NN O O
( NN O O
P NN O O
= NN O O
.31 NN O O
) NN O O
. NN O O

Likewise NN O O
, NN O O
reflux NN O O
symptoms NN O O
were NN O O
equally NN O O
and NN O O
effectively NN O O
controlled NN O O
. NN O O

Early NN O O
postoperative NN O O
dysphagia NN O O
( NN O O
6 NN O O
weeks NN O O
) NN O O
was NN O O
common NN O O
in NN O O
both NN O O
groups NN O O
but NN O O
then NN O O
decreased NN O O
toward NN O O
normality NN O O
. NN O O

A NN O O
small NN O O
but NN O O
statistically NN O O
significant NN O O
difference NN O O
in NN O O
favor NN O O
of NN O O
PF NN O O
was NN O O
noted NN O O
in NN O O
the NN O O
mean NN O O
( NN O O
SD NN O O
) NN O O
scoring NN O O
of NN O O
dysphagia NN O O
for NN O O
liquids NN O O
at NN O O
6 NN O O
weeks NN O O
( NN O O
PF NN O O
, NN O O
1.6 NN O O
[ NN O O
0.9 NN O O
] NN O O
; NN O O
TF NN O O
, NN O O
1.9 NN O O
[ NN O O
1.3 NN O O
] NN O O
; NN O O
P NN O O
= NN O O
.01 NN O O
) NN O O
and NN O O
for NN O O
solid NN O O
food NN O O
at NN O O
12 NN O O
months NN O O
( NN O O
PF NN O O
, NN O O
1.3 NN O O
[ NN O O
1.0 NN O O
] NN O O
; NN O O
TF NN O O
, NN O O
1.9 NN O O
[ NN O O
1.4 NN O O
] NN O O
; NN O O
P NN O O
< NN O O
.001 NN O O
) NN O O
and NN O O
24 NN O O
months NN O O
( NN O O
PF NN O O
, NN O O
1.3 NN O O
[ NN O O
0.9 NN O O
] NN O O
; NN O O
TF NN O O
, NN O O
1.7 NN O O
[ NN O O
1.2 NN O O
] NN O O
; NN O O
P NN O O
= NN O O
.001 NN O O
) NN O O
. NN O O

Quality NN O O
of NN O O
life NN O O
was NN O O
reduced NN O O
before NN O O
surgery NN O O
but NN O O
increased NN O O
to NN O O
normal NN O O
values NN O O
after NN O O
surgery NN O O
and NN O O
remained NN O O
so NN O O
over NN O O
5-year NN O O
follow-up NN O O
, NN O O
with NN O O
no NN O O
difference NN O O
between NN O O
the NN O O
groups NN O O
. NN O O

The NN O O
results NN O O
from NN O O
this NN O O
randomized NN O O
clinical NN O O
trial NN O O
suggest NN O O
that NN O O
although NN O O
PF NN O O
and NN O O
TF NN O O
could NN O O
be NN O O
recommended NN O O
for NN O O
treatment NN O O
of NN O O
gastroesophageal NN O O
reflux NN O O
disease NN O O
, NN O O
PF NN O O
might NN O O
be NN O O
superior NN O O
by NN O O
inducing NN O O
less NN O O
dysphagia NN O O
. NN O O

ClinicalTrials.gov NN O O
identifier NN O O
: NN O O
NCT03659487 NN O O
. NN O O



-DOCSTART- (31177482)

Planning NN O O
to NN O O
promote NN O O
the NN O O
health NN O O
of NN O O
mothers NN O O
in NN O O
postpartum NN O O
is NN O O
important NN O O
in NN O O
all NN O O
countries NN O O
. NN O O

This NN O O
study NN O O
aimed NN O O
to NN O O
determine NN O O
the NN O O
effectiveness NN O O
of NN O O
two NN O O
counseling NN O O
method NN O O
on NN O O
prevention NN O O
of NN O O
post-traumatic NN O O
stress NN O O
after NN O O
childbirth NN O O
. NN O O

In NN O O
this NN O O
clinical NN O O
trial NN O O
, NN O O
193 NN O O
of NN O O
mothers NN O O
who NN O O
had NN O O
experienced NN O O
a NN O O
traumatic NN O O
birth NN O O
were NN O O
randomly NN O O
assigned NN O O
to NN O O
three NN O O
groups NN O O
. NN O O

Participants NN O O
were NN O O
assessed NN O O
using NN O O
IES_R NN O O
questionnaire NN O O
at NN O O
4 NN O O
- NN O O
6 NN O O
weeks NN O O
and NN O O
3 NN O O
months NN O O
after NN O O
delivery NN O O
. NN O O

Debriefing NN O O
and NN O O
brief NN O O
cognitive NN O O
behavioral NN O O
counseling NN O O
( NN O O
CBC NN O O
) NN O O
significantly NN O O
improved NN O O
the NN O O
symptoms NN O O
of NN O O
postpartum NN O O
traumatic NN O O
stress NN O O
disorder NN O O
. NN O O

After NN O O
3 NN O O
months NN O O
, NN O O
CBC NN O O
had NN O O
a NN O O
significant NN O O
effect NN O O
on NN O O
the NN O O
symptoms NN O O
. NN O O

Screening NN O O
of NN O O
traumatic NN O O
childbirth NN O O
, NN O O
implementation NN O O
of NN O O
supportive NN O O
care NN O O
, NN O O
and NN O O
early NN O O
counseling NN O O
prior NN O O
to NN O O
the NN O O
initiation NN O O
of NN O O
post-traumatic NN O O
stress NN O O
are NN O O
recommended NN O O
. NN O O

IRCT2015072522396N2 NN O O
. NN O O

http://en.search.irct.ir/view/24735 NN O O
. NN O O



-DOCSTART- (31369675)

There NN O O
is NN O O
a NN O O
lack NN O O
of NN O O
evidence NN O O
based NN O O
on NN O O
longitudinal NN O O
information NN O O
in NN O O
the NN O O
field NN O O
of NN O O
Class NN O O
II NN O O
malocclusion NN O O
management NN O O
with NN O O
cervical NN O O
headgear NN O O
( NN O O
CH NN O O
) NN O O
, NN O O
especially NN O O
in NN O O
a NN O O
randomized NN O O
setting NN O O
. NN O O

The NN O O
main NN O O
objective NN O O
of NN O O
this NN O O
study NN O O
was NN O O
to NN O O
evaluate NN O O
skeletal NN O O
facial NN O O
changes NN O O
, NN O O
particularly NN O O
in NN O O
vertical NN O O
dimensions NN O O
, NN O O
after NN O O
Kloehn-type NN O O
CH NN O O
treatment NN O O
in NN O O
children NN O O
when NN O O
the NN O O
timing NN O O
of NN O O
treatment NN O O
is NN O O
altered NN O O
. NN O O

Prospective NN O O
, NN O O
parallel-group NN O O
, NN O O
randomized NN O O
controlled NN O O
trial NN O O
. NN O O

Screened NN O O
children NN O O
with NN O O
Class NN O O
II NN O O
malocclusion NN O O
were NN O O
randomized NN O O
in NN O O
1:1 NN O O
ratio NN O O
to NN O O
two NN O O
groups NN O O
of NN O O
equal NN O O
size NN O O
by NN O O
sealed-envelope NN O O
randomization NN O O
: NN O O
the NN O O
early NN O O
group NN O O
( NN O O
EG NN O O
) NN O O
, NN O O
where NN O O
active NN O O
CH NN O O
treatment NN O O
was NN O O
started NN O O
at NN O O
the NN O O
age NN O O
of NN O O
7.8 NN O O
years NN O O
, NN O O
and NN O O
the NN O O
late NN O O
group NN O O
( NN O O
LG NN O O
) NN O O
, NN O O
where NN O O
CH NN O O
treatment NN O O
was NN O O
started NN O O
at NN O O
the NN O O
age NN O O
of NN O O
9.5 NN O O
years NN O O
. NN O O

The NN O O
active NN O O
treatment NN O O
was NN O O
continued NN O O
until NN O O
normal NN O O
Class NN O O
I NN O O
occlusion NN O O
on NN O O
first NN O O
molars NN O O
was NN O O
achieved NN O O
. NN O O

Cephalograms NN O O
were NN O O
taken NN O O
at NN O O
three NN O O
different NN O O
time NN O O
points NN O O
. NN O O

Changes NN O O
in NN O O
cephalometric NN O O
measurements NN O O
were NN O O
compared NN O O
between NN O O
groups NN O O
and NN O O
genders NN O O
. NN O O

Blinding NN O O
was NN O O
applicable NN O O
for NN O O
outcome NN O O
evaluation NN O O
. NN O O

Of NN O O
67 NN O O
randomized NN O O
children NN O O
, NN O O
56 NN O O
completed NN O O
the NN O O
study NN O O
. NN O O

Upper NN O O
face NN O O
height NN O O
increased NN O O
during NN O O
the NN O O
CH NN O O
treatment NN O O
phase NN O O
, NN O O
as NN O O
the NN O O
parameter NN O O
N-ANS NN O O
increased NN O O
significantly NN O O
during NN O O
the NN O O
active NN O O
treatments NN O O
of NN O O
EG NN O O
( NN O O
P NN O O
< NN O O
0.05 NN O O
) NN O O
and NN O O
LG NN O O
( NN O O
P NN O O
< NN O O
0.05 NN O O
) NN O O
. NN O O

Also NN O O
, NN O O
the NN O O
parameter NN O O
NSL-PL NN O O
increased NN O O
significantly NN O O
during NN O O
the NN O O
treatment NN O O
of NN O O
EG NN O O
( NN O O
P NN O O
< NN O O
0.01 NN O O
) NN O O
and NN O O
during NN O O
the NN O O
treatment NN O O
of NN O O
LG NN O O
( NN O O
P NN O O
< NN O O
0.01 NN O O
) NN O O
. NN O O

The NN O O
Gonial NN O O
angle NN O O
decreased NN O O
significantly NN O O
in NN O O
the NN O O
early NN O O
CH NN O O
treatment NN O O
group NN O O
compared NN O O
to NN O O
the NN O O
later NN O O
treatment NN O O
group NN O O
( NN O O
T0-T2 NN O O
: NN O O
P NN O O
< NN O O
0.01 NN O O
) NN O O
. NN O O

CH NN O O
improved NN O O
the NN O O
antero-posterior NN O O
jaw NN O O
relationship NN O O
. NN O O

No NN O O
harms NN O O
were NN O O
encountered NN O O
. NN O O

Although NN O O
the NN O O
upper NN O O
face NN O O
height NN O O
increased NN O O
, NN O O
the NN O O
mandible NN O O
showed NN O O
anterior NN O O
rotation NN O O
after NN O O
CH NN O O
treatment NN O O
. NN O O

The NN O O
Gonial NN O O
angle NN O O
was NN O O
significantly NN O O
decreased NN O O
in NN O O
the NN O O
EG NN O O
compared NN O O
to NN O O
the NN O O
LG NN O O
. NN O O

There NN O O
were NN O O
gender-specific NN O O
differences NN O O
in NN O O
both NN O O
sagittal NN O O
and NN O O
vertical NN O O
dimensions NN O O
when NN O O
examining NN O O
interrelations NN O O
in NN O O
dimensional NN O O
changes NN O O
. NN O O

The NN O O
differences NN O O
found NN O O
between NN O O
the NN O O
early NN O O
and NN O O
later NN O O
treatment NN O O
groups NN O O
were NN O O
not NN O O
clinically NN O O
important NN O O
when NN O O
the NN O O
cephalometric NN O O
results NN O O
are NN O O
considered NN O O
. NN O O

ClinicalTrials.gov NN O O
( NN O O
NCT02010346 NN O O
) NN O O
. NN O O



-DOCSTART- (31036337)

Anaemia NN O O
and NN O O
iron NN O O
deficiency NN O O
are NN O O
frequent NN O O
in NN O O
patients NN O O
scheduled NN O O
for NN O O
cardiac NN O O
surgery NN O O
. NN O O

This NN O O
study NN O O
assessed NN O O
whether NN O O
immediate NN O O
preoperative NN O O
treatment NN O O
could NN O O
result NN O O
in NN O O
reduced NN O O
perioperative NN O O
red NN O O
blood NN O O
cell NN O O
( NN O O
RBC NN O O
) NN O O
transfusions NN O O
and NN O O
improved NN O O
outcome NN O O
. NN O O

In NN O O
this NN O O
single-centre NN O O
, NN O O
randomised NN O O
, NN O O
double-blind NN O O
, NN O O
parallel-group NN O O
controlled NN O O
study NN O O
, NN O O
patients NN O O
undergoing NN O O
elective NN O O
cardiac NN O O
surgery NN O O
with NN O O
anaemia NN O O
( NN O O
n=253 NN O O
; NN O O
haemoglobin NN O O
concentration NN O O
( NN O O
Hb NN O O
) NN O O
< NN O O
120 NN O O
g/L NN O O
in NN O O
women NN O O
and NN O O
Hb NN O O
< NN O O
130 NN O O
g/L NN O O
in NN O O
men NN O O
) NN O O
or NN O O
isolated NN O O
iron NN O O
deficiency NN O O
( NN O O
n=252 NN O O
; NN O O
ferritin NN O O
< NN O O
100 NN O O
mcg/L NN O O
, NN O O
no NN O O
anaemia NN O O
) NN O O
were NN O O
enrolled NN O O
. NN O O

Participants NN O O
were NN O O
randomly NN O O
assigned NN O O
( NN O O
1:1 NN O O
) NN O O
with NN O O
the NN O O
use NN O O
of NN O O
a NN O O
computer-generated NN O O
range NN O O
minimisation NN O O
( NN O O
allocation NN O O
probability NN O O
0·8 NN O O
) NN O O
to NN O O
receive NN O O
either NN O O
placebo NN O O
or NN O O
combination NN O O
treatment NN O O
consisting NN O O
of NN O O
a NN O O
slow NN O O
infusion NN O O
of NN O O
20 NN O O
mg/kg NN O O
ferric NN O O
carboxymaltose NN O O
, NN O O
40 NN O O
000 NN O O
U NN O O
subcutaneous NN O O
erythropoietin NN O O
alpha NN O O
, NN O O
1 NN O O
mg NN O O
subcutaneous NN O O
vitamin NN O O
B12 NN O O
, NN O O
and NN O O
5 NN O O
mg NN O O
oral NN O O
folic NN O O
acid NN O O
or NN O O
placebo NN O O
on NN O O
the NN O O
day NN O O
before NN O O
surgery NN O O
. NN O O

Primary NN O O
outcome NN O O
was NN O O
the NN O O
number NN O O
of NN O O
RBC NN O O
transfusions NN O O
during NN O O
the NN O O
first NN O O
7 NN O O
days NN O O
. NN O O

This NN O O
trial NN O O
is NN O O
registered NN O O
with NN O O
ClinicalTrials.gov NN O O
, NN O O
number NN O O
NCT02031289 NN O O
. NN O O

Between NN O O
Jan NN O O
9 NN O O
, NN O O
2014 NN O O
, NN O O
and NN O O
July NN O O
19 NN O O
, NN O O
2017 NN O O
, NN O O
1006 NN O O
patients NN O O
were NN O O
enrolled NN O O
; NN O O
505 NN O O
with NN O O
anaemia NN O O
or NN O O
isolated NN O O
iron NN O O
deficiency NN O O
and NN O O
501 NN O O
in NN O O
the NN O O
registry NN O O
. NN O O

The NN O O
combination NN O O
treatment NN O O
significantly NN O O
reduced NN O O
RBC NN O O
transfusions NN O O
from NN O O
a NN O O
median NN O O
of NN O O
one NN O O
unit NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
( NN O O
IQR NN O O
0 NN O O
- NN O O
3 NN O O
) NN O O
to NN O O
zero NN O O
units NN O O
in NN O O
the NN O O
treatment NN O O
group NN O O
( NN O O
0 NN O O
- NN O O
2 NN O O
, NN O O
during NN O O
the NN O O
first NN O O
7 NN O O
days NN O O
( NN O O
odds NN O O
ratio NN O O
0·70 NN O O
[ NN O O
95 NN O O
% NN O O
CI NN O O
0·50 NN O O
- NN O O
0·98 NN O O
] NN O O
for NN O O
each NN O O
threshold NN O O
of NN O O
number NN O O
of NN O O
RBC NN O O
transfusions NN O O
, NN O O
p=0·036 NN O O
) NN O O
and NN O O
until NN O O
postoperative NN O O
day NN O O
90 NN O O
( NN O O
p=0·018 NN O O
) NN O O
. NN O O

Despite NN O O
fewer NN O O
RBC NN O O
units NN O O
transfused NN O O
, NN O O
patients NN O O
in NN O O
the NN O O
treatment NN O O
group NN O O
had NN O O
a NN O O
higher NN O O
haemoglobin NN O O
concentration NN O O
, NN O O
higher NN O O
reticulocyte NN O O
count NN O O
, NN O O
and NN O O
a NN O O
higher NN O O
reticulocyte NN O O
haemoglobin NN O O
content NN O O
during NN O O
the NN O O
first NN O O
7 NN O O
days NN O O
( NN O O
p≤0·001 NN O O
) NN O O
. NN O O

Combined NN O O
allogeneic NN O O
transfusions NN O O
were NN O O
less NN O O
in NN O O
the NN O O
treatment NN O O
group NN O O
( NN O O
0 NN O O
[ NN O O
IQR NN O O
0 NN O O
- NN O O
2 NN O O
] NN O O
) NN O O
versus NN O O
the NN O O
placebo NN O O
group NN O O
( NN O O
1 NN O O
[ NN O O
0 NN O O
- NN O O
3 NN O O
] NN O O
) NN O O
during NN O O
the NN O O
first NN O O
7 NN O O
days NN O O
( NN O O
p=0·038 NN O O
) NN O O
and NN O O
until NN O O
postoperative NN O O
day NN O O
90 NN O O
( NN O O
p=0·019 NN O O
) NN O O
. NN O O

73 NN O O
( NN O O
30 NN O O
% NN O O
) NN O O
serious NN O O
adverse NN O O
events NN O O
were NN O O
reported NN O O
in NN O O
the NN O O
treatment NN O O
group NN O O
group NN O O
versus NN O O
79 NN O O
( NN O O
33 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
. NN O O

An NN O O
ultra-short-term NN O O
combination NN O O
treatment NN O O
with NN O O
intravenous NN O O
iron NN O O
, NN O O
subcutaneous NN O O
erythropoietin NN O O
alpha NN O O
, NN O O
vitamin NN O O
B12 NN O O
, NN O O
and NN O O
oral NN O O
folic NN O O
acid NN O O
reduced NN O O
RBC NN O O
and NN O O
total NN O O
allogeneic NN O O
blood NN O O
product NN O O
transfusions NN O O
in NN O O
patients NN O O
with NN O O
preoperative NN O O
anaemia NN O O
or NN O O
isolated NN O O
iron NN O O
deficiency NN O O
undergoing NN O O
elective NN O O
cardiac NN O O
surgery NN O O
. NN O O

Vifor NN O O
Pharma NN O O
and NN O O
Swiss NN O O
Foundation NN O O
for NN O O
Anaesthesia NN O O
Research NN O O
. NN O O



-DOCSTART- (31274545)

Intrathecal NN O O
morphine NN O O
( NN O O
ITM NN O O
) NN O O
is NN O O
a NN O O
widely NN O O
used NN O O
technique NN O O
for NN O O
postcaesarean NN O O
section NN O O
analgesia NN O O
but NN O O
entails NN O O
a NN O O
high NN O O
risk NN O O
of NN O O
postoperative NN O O
nausea NN O O
and NN O O
vomiting NN O O
( NN O O
PONV NN O O
) NN O O
. NN O O

The NN O O
transversus NN O O
abdominis NN O O
plane NN O O
( NN O O
TAP NN O O
) NN O O
block NN O O
is NN O O
an NN O O
alternative NN O O
. NN O O

We NN O O
tested NN O O
the NN O O
hypothesis NN O O
that NN O O
a NN O O
TAP NN O O
block NN O O
including NN O O
clonidine NN O O
reduces NN O O
the NN O O
incidence NN O O
of NN O O
PONV NN O O
after NN O O
caesarean NN O O
section NN O O
when NN O O
compared NN O O
with NN O O
ITM NN O O
. NN O O

A NN O O
randomised NN O O
, NN O O
controlled NN O O
, NN O O
double-blinded NN O O
study NN O O
. NN O O

Geneva NN O O
University NN O O
Hospitals NN O O
, NN O O
Switzerland NN O O
, NN O O
from NN O O
October NN O O
2013 NN O O
to NN O O
February NN O O
2017 NN O O
. NN O O

A NN O O
total NN O O
of NN O O
182 NN O O
patients NN O O
undergoing NN O O
elective NN O O
caesarean NN O O
section NN O O
were NN O O
studied NN O O
. NN O O

Reasons NN O O
for NN O O
noninclusion NN O O
were NN O O
complicated NN O O
pregnancy NN O O
, NN O O
contraindication NN O O
to NN O O
spinal NN O O
anaesthesia NN O O
or NN O O
TAP NN O O
block NN O O
, NN O O
extreme NN O O
weight NN O O
or NN O O
height NN O O
, NN O O
allergy NN O O
to NN O O
any NN O O
medication NN O O
or NN O O
previous NN O O
median NN O O
abdominal NN O O
incision NN O O
. NN O O

Patients NN O O
were NN O O
allocated NN O O
randomly NN O O
to NN O O
one NN O O
of NN O O
two NN O O
groups NN O O
( NN O O
quadruple NN O O
blinded NN O O
) NN O O
: NN O O
100 NN O O
μg NN O O
of NN O O
morphine NN O O
added NN O O
to NN O O
the NN O O
spinal NN O O
local NN O O
anaesthetic NN O O
or NN O O
a NN O O
bilateral NN O O
TAP NN O O
block NN O O
with NN O O
20 NN O O
ml NN O O
of NN O O
ropivacaine NN O O
0.375 NN O O
% NN O O
+ NN O O
75 NN O O
μg NN O O
of NN O O
clonidine NN O O
on NN O O
each NN O O
side NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
measure NN O O
was NN O O
the NN O O
total NN O O
number NN O O
of NN O O
patients NN O O
presenting NN O O
with NN O O
PONV NN O O
at NN O O
24 NN O O
h. NN O O
Secondary NN O O
aims NN O O
were NN O O
to NN O O
compare NN O O
other NN O O
adverse NN O O
effects NN O O
( NN O O
pruritus NN O O
, NN O O
respiratory NN O O
depression NN O O
, NN O O
hypotension NN O O
, NN O O
bradycardia NN O O
, NN O O
sedation NN O O
) NN O O
, NN O O
analgesic NN O O
efficacy NN O O
and NN O O
the NN O O
quality NN O O
of NN O O
postoperative NN O O
recovery NN O O
. NN O O

At NN O O
24 NN O O
h NN O O
, NN O O
there NN O O
was NN O O
no NN O O
significant NN O O
difference NN O O
between NN O O
ITM NN O O
and NN O O
TAP NN O O
groups NN O O
in NN O O
the NN O O
total NN O O
number NN O O
of NN O O
patients NN O O
presenting NN O O
with NN O O
PONV NN O O
: NN O O
17/92 NN O O
patients NN O O
( NN O O
18.5 NN O O
% NN O O
, NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
11.1 NN O O
to NN O O
27.9 NN O O
) NN O O
and NN O O
27/88 NN O O
patients NN O O
( NN O O
30.7 NN O O
% NN O O
, NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
21.3 NN O O
to NN O O
41.4 NN O O
) NN O O
in NN O O
TAP NN O O
and NN O O
ITM NN O O
groups NN O O
, NN O O
respectively NN O O
( NN O O
P NN O O
= NN O O
0.065 NN O O
) NN O O
. NN O O

Pain NN O O
scores NN O O
at NN O O
6 NN O O
h NN O O
and NN O O
cumulative NN O O
morphine NN O O
consumption NN O O
at NN O O
24 NN O O
h NN O O
were NN O O
lower NN O O
in NN O O
the NN O O
ITM NN O O
group NN O O
( NN O O
P NN O O
< NN O O
0.0001 NN O O
for NN O O
morphine NN O O
consumption NN O O
at NN O O
24 NN O O
h NN O O
) NN O O
. NN O O

The NN O O
incidence NN O O
of NN O O
hypotension NN O O
was NN O O
higher NN O O
in NN O O
the NN O O
TAP NN O O
group NN O O
( NN O O
54.3 NN O O
vs. NN O O
29.2 NN O O
% NN O O
, NN O O
P NN O O
= NN O O
0.0006 NN O O
) NN O O
. NN O O

Maternal NN O O
satisfaction NN O O
was NN O O
high NN O O
and NN O O
not NN O O
different NN O O
between NN O O
groups NN O O
. NN O O

A NN O O
TAP NN O O
block NN O O
with NN O O
clonidine NN O O
and NN O O
local NN O O
anaesthetic NN O O
does NN O O
not NN O O
reduce NN O O
significantly NN O O
the NN O O
incidence NN O O
of NN O O
PONV NN O O
compared NN O O
with NN O O
ITM NN O O
. NN O O

We NN O O
confirm NN O O
the NN O O
superiority NN O O
of NN O O
ITM NN O O
on NN O O
acute NN O O
postcaesarean NN O O
section NN O O
analgesia NN O O
compared NN O O
with NN O O
a NN O O
TAP NN O O
block NN O O
, NN O O
even NN O O
with NN O O
clonidine NN O O
as NN O O
an NN O O
adjunct NN O O
. NN O O

ClinicalTrials.gov NN O O
identifier NN O O
: NN O O
NCT01931215 NN O O
. NN O O



-DOCSTART- (30513108)

In NN O O
sub-Saharan NN O O
Africa NN O O
, NN O O
individuals NN O O
infected NN O O
with NN O O
HIV NN O O
who NN O O
are NN O O
severely NN O O
immunocompromised NN O O
have NN O O
high NN O O
mortality NN O O
( NN O O
about NN O O
10 NN O O
% NN O O
) NN O O
shortly NN O O
after NN O O
starting NN O O
antiretroviral NN O O
therapy NN O O
( NN O O
ART NN O O
) NN O O
. NN O O

This NN O O
group NN O O
also NN O O
has NN O O
the NN O O
greatest NN O O
risk NN O O
of NN O O
morbidity NN O O
and NN O O
mortality NN O O
associated NN O O
with NN O O
immune NN O O
reconstitution NN O O
inflammatory NN O O
syndrome NN O O
( NN O O
IRIS NN O O
) NN O O
, NN O O
a NN O O
paradoxical NN O O
response NN O O
to NN O O
successful NN O O
ART NN O O
. NN O O

Integrase NN O O
inhibitors NN O O
lead NN O O
to NN O O
significantly NN O O
more NN O O
rapid NN O O
declines NN O O
in NN O O
HIV NN O O
viral NN O O
load NN O O
( NN O O
VL NN O O
) NN O O
than NN O O
all NN O O
other NN O O
ART NN O O
classes NN O O
. NN O O

We NN O O
hypothesised NN O O
that NN O O
intensifying NN O O
standard NN O O
triple-drug NN O O
ART NN O O
with NN O O
the NN O O
integrase NN O O
inhibitor NN O O
, NN O O
raltegravir NN O O
, NN O O
would NN O O
reduce NN O O
HIV NN O O
VL NN O O
faster NN O O
and NN O O
hence NN O O
reduce NN O O
early NN O O
mortality NN O O
, NN O O
although NN O O
this NN O O
strategy NN O O
could NN O O
also NN O O
risk NN O O
more NN O O
IRIS NN O O
events NN O O
. NN O O

In NN O O
a NN O O
2 NN O O
× NN O O
2 NN O O
× NN O O
2 NN O O
factorial NN O O
open-label NN O O
parallel-group NN O O
trial NN O O
, NN O O
treatment-naive NN O O
adults NN O O
, NN O O
adolescents NN O O
, NN O O
and NN O O
children NN O O
> NN O O
5 NN O O
years NN O O
old NN O O
infected NN O O
with NN O O
HIV NN O O
, NN O O
with NN O O
cluster NN O O
of NN O O
differentiation NN O O
4 NN O O
( NN O O
CD4 NN O O
) NN O O
< NN O O
100 NN O O
cells/mm3 NN O O
, NN O O
from NN O O
eight NN O O
urban/peri-urban NN O O
HIV NN O O
clinics NN O O
at NN O O
regional NN O O
hospitals NN O O
in NN O O
Kenya NN O O
, NN O O
Malawi NN O O
, NN O O
Uganda NN O O
, NN O O
and NN O O
Zimbabwe NN O O
were NN O O
randomised NN O O
1:1 NN O O
to NN O O
initiate NN O O
standard NN O O
triple-drug NN O O
ART NN O O
, NN O O
with NN O O
or NN O O
without NN O O
12-week NN O O
raltegravir NN O O
intensification NN O O
, NN O O
and NN O O
followed NN O O
for NN O O
48 NN O O
weeks NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
was NN O O
24-week NN O O
mortality NN O O
, NN O O
analysed NN O O
by NN O O
intention NN O O
to NN O O
treat NN O O
. NN O O

Of NN O O
2,356 NN O O
individuals NN O O
screened NN O O
for NN O O
eligibility NN O O
, NN O O
1,805 NN O O
were NN O O
randomised NN O O
between NN O O
18 NN O O
June NN O O
2013 NN O O
and NN O O
10 NN O O
April NN O O
2015 NN O O
. NN O O

Of NN O O
the NN O O
1,805 NN O O
participants NN O O
, NN O O
961 NN O O
( NN O O
53.2 NN O O
% NN O O
) NN O O
were NN O O
male NN O O
, NN O O
72 NN O O
( NN O O
4.0 NN O O
% NN O O
) NN O O
were NN O O
children/adolescents NN O O
, NN O O
median NN O O
age NN O O
was NN O O
36 NN O O
years NN O O
, NN O O
CD4 NN O O
count NN O O
was NN O O
37 NN O O
cells/mm3 NN O O
, NN O O
and NN O O
plasma NN O O
viraemia NN O O
was NN O O
249,770 NN O O
copies/mL. NN O O
Fifty-six NN O O
participants NN O O
( NN O O
3.1 NN O O
% NN O O
) NN O O
were NN O O
lost NN O O
to NN O O
follow-up NN O O
at NN O O
48 NN O O
weeks NN O O
. NN O O

By NN O O
24 NN O O
weeks NN O O
, NN O O
97/902 NN O O
( NN O O
10.9 NN O O
% NN O O
) NN O O
raltegravir-intensified NN O O
ART NN O O
versus NN O O
91/903 NN O O
( NN O O
10.2 NN O O
% NN O O
) NN O O
standard NN O O
ART NN O O
participants NN O O
had NN O O
died NN O O
( NN O O
adjusted NN O O
hazard NN O O
ratio NN O O
[ NN O O
aHR NN O O
] NN O O
= NN O O
1.10 NN O O
[ NN O O
95 NN O O
% NN O O
CI NN O O
0.82 NN O O
- NN O O
1.46 NN O O
] NN O O
, NN O O
p NN O O
= NN O O
0.53 NN O O
) NN O O
, NN O O
with NN O O
no NN O O
evidence NN O O
of NN O O
interaction NN O O
with NN O O
other NN O O
randomisations NN O O
( NN O O
pheterogeneity NN O O
> NN O O
0.7 NN O O
) NN O O
and NN O O
despite NN O O
significantly NN O O
greater NN O O
VL NN O O
suppression NN O O
with NN O O
raltegravir-intensified NN O O
ART NN O O
at NN O O
4 NN O O
weeks NN O O
( NN O O
343/836 NN O O
[ NN O O
41.0 NN O O
% NN O O
] NN O O
versus NN O O
113/841 NN O O
[ NN O O
13.4 NN O O
% NN O O
] NN O O
with NN O O
standard NN O O
ART NN O O
, NN O O
p NN O O
< NN O O
0.001 NN O O
) NN O O
and NN O O
12 NN O O
weeks NN O O
( NN O O
567/789 NN O O
[ NN O O
71.9 NN O O
% NN O O
] NN O O
versus NN O O
415/803 NN O O
[ NN O O
51.7 NN O O
% NN O O
] NN O O
with NN O O
standard NN O O
ART NN O O
, NN O O
p NN O O
< NN O O
0.001 NN O O
) NN O O
. NN O O

Through NN O O
48 NN O O
weeks NN O O
, NN O O
there NN O O
was NN O O
no NN O O
evidence NN O O
of NN O O
differences NN O O
in NN O O
mortality NN O O
( NN O O
aHR NN O O
= NN O O
0.98 NN O O
[ NN O O
95 NN O O
% NN O O
CI NN O O
0.76 NN O O
- NN O O
1.28 NN O O
] NN O O
, NN O O
p NN O O
= NN O O
0.91 NN O O
) NN O O
; NN O O
in NN O O
serious NN O O
( NN O O
aHR NN O O
= NN O O
0.99 NN O O
[ NN O O
0.81 NN O O
- NN O O
1.21 NN O O
] NN O O
, NN O O
p NN O O
= NN O O
0.88 NN O O
) NN O O
, NN O O
grade-4 NN O O
( NN O O
aHR NN O O
= NN O O
0.88 NN O O
[ NN O O
0.71 NN O O
- NN O O
1.09 NN O O
] NN O O
, NN O O
p NN O O
= NN O O
0.29 NN O O
) NN O O
, NN O O
or NN O O
ART-modifying NN O O
( NN O O
aHR NN O O
= NN O O
0.90 NN O O
[ NN O O
0.63 NN O O
- NN O O
1.27 NN O O
] NN O O
, NN O O
p NN O O
= NN O O
0.54 NN O O
) NN O O
adverse NN O O
events NN O O
( NN O O
the NN O O
latter NN O O
occurring NN O O
in NN O O
59 NN O O
[ NN O O
6.5 NN O O
% NN O O
] NN O O
participants NN O O
with NN O O
raltegravir-intensified NN O O
ART NN O O
versus NN O O
66 NN O O
[ NN O O
7.3 NN O O
% NN O O
] NN O O
with NN O O
standard NN O O
ART NN O O
) NN O O
; NN O O
in NN O O
events NN O O
judged NN O O
compatible NN O O
with NN O O
IRIS NN O O
( NN O O
occurring NN O O
in NN O O
89 NN O O
[ NN O O
9.9 NN O O
% NN O O
] NN O O
participants NN O O
with NN O O
raltegravir-intensified NN O O
ART NN O O
versus NN O O
86 NN O O
[ NN O O
9.5 NN O O
% NN O O
] NN O O
with NN O O
standard NN O O
ART NN O O
, NN O O
p NN O O
= NN O O
0.79 NN O O
) NN O O
or NN O O
in NN O O
hospitalisations NN O O
( NN O O
aHR NN O O
= NN O O
0.94 NN O O
[ NN O O
95 NN O O
% NN O O
CI NN O O
0.76 NN O O
- NN O O
1.17 NN O O
] NN O O
, NN O O
p NN O O
= NN O O
0.59 NN O O
) NN O O
. NN O O

At NN O O
12 NN O O
weeks NN O O
, NN O O
one NN O O
and NN O O
two NN O O
raltegravir-intensified NN O O
participants NN O O
had NN O O
predicted NN O O
intermediate-level NN O O
and NN O O
high-level NN O O
raltegravir NN O O
resistance NN O O
, NN O O
respectively NN O O
. NN O O

At NN O O
48 NN O O
weeks NN O O
, NN O O
the NN O O
nucleoside NN O O
reverse NN O O
transcriptase NN O O
inhibitor NN O O
( NN O O
NRTI NN O O
) NN O O
mutation NN O O
K219E/Q NN O O
( NN O O
p NN O O
= NN O O
0.004 NN O O
) NN O O
and NN O O
the NN O O
non-nucleoside NN O O
reverse NN O O
transcriptase NN O O
inhibitor NN O O
( NN O O
NNRTI NN O O
) NN O O
mutations NN O O
K101E/P NN O O
( NN O O
p NN O O
= NN O O
0.03 NN O O
) NN O O
and NN O O
P225H NN O O
( NN O O
p NN O O
= NN O O
0.007 NN O O
) NN O O
were NN O O
less NN O O
common NN O O
in NN O O
virus NN O O
from NN O O
participants NN O O
with NN O O
raltegravir-intensified NN O O
ART NN O O
, NN O O
with NN O O
weak NN O O
evidence NN O O
of NN O O
less NN O O
intermediate- NN O O
or NN O O
high-level NN O O
resistance NN O O
to NN O O
tenofovir NN O O
( NN O O
p NN O O
= NN O O
0.06 NN O O
) NN O O
, NN O O
abacavir NN O O
( NN O O
p NN O O
= NN O O
0.08 NN O O
) NN O O
, NN O O
and NN O O
rilpivirine NN O O
( NN O O
p NN O O
= NN O O
0.07 NN O O
) NN O O
. NN O O

Limitations NN O O
of NN O O
the NN O O
study NN O O
include NN O O
limited NN O O
clinical NN O O
, NN O O
radiological NN O O
, NN O O
and/or NN O O
microbiological NN O O
information NN O O
for NN O O
some NN O O
participants NN O O
, NN O O
reflecting NN O O
available NN O O
services NN O O
at NN O O
the NN O O
centres NN O O
, NN O O
and NN O O
lack NN O O
of NN O O
baseline NN O O
genotypes NN O O
. NN O O

Although NN O O
12 NN O O
weeks NN O O
of NN O O
raltegravir NN O O
intensification NN O O
was NN O O
well NN O O
tolerated NN O O
and NN O O
reduced NN O O
HIV NN O O
viraemia NN O O
significantly NN O O
faster NN O O
than NN O O
standard NN O O
triple-drug NN O O
ART NN O O
during NN O O
the NN O O
time NN O O
of NN O O
greatest NN O O
risk NN O O
for NN O O
early NN O O
death NN O O
, NN O O
this NN O O
strategy NN O O
did NN O O
not NN O O
reduce NN O O
mortality NN O O
or NN O O
clinical NN O O
events NN O O
in NN O O
this NN O O
group NN O O
and NN O O
is NN O O
not NN O O
warranted NN O O
. NN O O

There NN O O
was NN O O
no NN O O
excess NN O O
of NN O O
IRIS-compatible NN O O
events NN O O
, NN O O
suggesting NN O O
that NN O O
integrase NN O O
inhibitors NN O O
can NN O O
be NN O O
used NN O O
safely NN O O
as NN O O
part NN O O
of NN O O
standard NN O O
triple-drug NN O O
first-line NN O O
therapy NN O O
in NN O O
severely NN O O
immunocompromised NN O O
individuals NN O O
. NN O O

ClinicalTrials.gov NN O O
NCT01825031 NN O O
. NN O O

International NN O O
Standard NN O O
Randomised NN O O
Controlled NN O O
Trials NN O O
Number NN O O
ISRCTN NN O O
43622374 NN O O
. NN O O



-DOCSTART- (31026037)

Adverse NN O O
childhood NN O O
experiences NN O O
are NN O O
common NN O O
and NN O O
are NN O O
associated NN O O
with NN O O
changes NN O O
in NN O O
early NN O O
development NN O O
and NN O O
learning NN O O
, NN O O
but NN O O
training NN O O
early NN O O
childhood NN O O
educators NN O O
in NN O O
trauma-informed NN O O
approaches NN O O
to NN O O
care NN O O
has NN O O
not NN O O
been NN O O
evaluated NN O O
with NN O O
randomized NN O O
clinical NN O O
trials NN O O
. NN O O

To NN O O
determine NN O O
whether NN O O
a NN O O
6-session NN O O
( NN O O
12-week NN O O
) NN O O
professional NN O O
development NN O O
course NN O O
, NN O O
" NN O O
Enhancing NN O O
Trauma NN O O
Awareness NN O O
, NN O O
" NN O O
improved NN O O
the NN O O
quality NN O O
of NN O O
teachers NN O O
' NN O O
relationships NN O O
with NN O O
the NN O O
children NN O O
in NN O O
their NN O O
classrooms NN O O
. NN O O

This NN O O
cluster NN O O
randomized NN O O
clinical NN O O
trial NN O O
conducted NN O O
from NN O O
September NN O O
2017 NN O O
to NN O O
May NN O O
2018 NN O O
allocated NN O O
classrooms NN O O
by NN O O
a NN O O
computer-generated NN O O
random NN O O
sequence NN O O
to NN O O
intervention NN O O
( NN O O
attend NN O O
Enhancing NN O O
Trauma NN O O
Awareness NN O O
course NN O O
) NN O O
and NN O O
control NN O O
( NN O O
no NN O O
course NN O O
) NN O O
groups NN O O
. NN O O

Outcomes NN O O
were NN O O
reported NN O O
by NN O O
participants NN O O
via NN O O
survey NN O O
and NN O O
analyzed NN O O
by NN O O
group NN O O
allocation NN O O
. NN O O

Classrooms NN O O
under NN O O
the NN O O
auspice NN O O
of NN O O
the NN O O
School NN O O
District NN O O
of NN O O
Philadelphia NN O O
, NN O O
Pennsylvania NN O O
, NN O O
serving NN O O
3- NN O O
and NN O O
4-year-old NN O O
children NN O O
living NN O O
in NN O O
low-income NN O O
households NN O O
were NN O O
invited NN O O
to NN O O
participate NN O O
. NN O O

Lead NN O O
and/or NN O O
assistant NN O O
teachers NN O O
from NN O O
63 NN O O
of NN O O
348 NN O O
eligible NN O O
classrooms NN O O
( NN O O
18.1 NN O O
% NN O O
) NN O O
agreed NN O O
to NN O O
participate NN O O
, NN O O
and NN O O
none NN O O
were NN O O
excluded NN O O
. NN O O

Of NN O O
96 NN O O
enrolled NN O O
teachers NN O O
, NN O O
93 NN O O
( NN O O
96.9 NN O O
% NN O O
) NN O O
were NN O O
assessed NN O O
at NN O O
follow-up NN O O
( NN O O
61 NN O O
of NN O O
63 NN O O
classrooms NN O O
[ NN O O
96.8 NN O O
% NN O O
] NN O O
) NN O O
. NN O O

In NN O O
September NN O O
2017 NN O O
, NN O O
32 NN O O
classrooms NN O O
( NN O O
48 NN O O
teachers NN O O
) NN O O
were NN O O
assigned NN O O
to NN O O
receive NN O O
a NN O O
professional NN O O
development NN O O
course NN O O
that NN O O
taught NN O O
about NN O O
the NN O O
effects NN O O
of NN O O
trauma NN O O
using NN O O
a NN O O
group-based NN O O
relational NN O O
process NN O O
, NN O O
and NN O O
31 NN O O
classrooms NN O O
( NN O O
48 NN O O
teachers NN O O
) NN O O
received NN O O
no NN O O
intervention NN O O
. NN O O

Teachers NN O O
completed NN O O
online NN O O
surveys NN O O
immediately NN O O
before NN O O
and NN O O
after NN O O
the NN O O
course NN O O
. NN O O

Exploratory NN O O
focus NN O O
groups NN O O
with NN O O
intervention NN O O
teachers NN O O
( NN O O
n NN O O
= NN O O
15 NN O O
) NN O O
were NN O O
conducted NN O O
5 NN O O
months NN O O
after NN O O
the NN O O
course NN O O
ended NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
was NN O O
teacher-children NN O O
relationship NN O O
quality NN O O
, NN O O
with NN O O
a NN O O
hypothesized NN O O
decrease NN O O
in NN O O
teacher-children NN O O
conflict NN O O
scores NN O O
. NN O O

Secondary NN O O
outcomes NN O O
included NN O O
relational NN O O
capacities NN O O
( NN O O
eg NN O O
, NN O O
empathy NN O O
, NN O O
emotion NN O O
regulation NN O O
, NN O O
and NN O O
dispositional NN O O
mindfulness NN O O
) NN O O
. NN O O

Focus NN O O
group NN O O
themes NN O O
described NN O O
teachers NN O O
' NN O O
experience NN O O
of NN O O
the NN O O
course NN O O
. NN O O

Of NN O O
96 NN O O
teachers NN O O
enrolled NN O O
, NN O O
93 NN O O
( NN O O
96.9 NN O O
% NN O O
) NN O O
were NN O O
women NN O O
, NN O O
and NN O O
58 NN O O
( NN O O
60.4 NN O O
% NN O O
) NN O O
were NN O O
40 NN O O
years NN O O
and NN O O
older NN O O
. NN O O

Follow-up NN O O
surveys NN O O
were NN O O
completed NN O O
by NN O O
46 NN O O
teachers NN O O
( NN O O
95.8 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
control NN O O
group NN O O
and NN O O
47 NN O O
( NN O O
97.9 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
intervention NN O O
group NN O O
, NN O O
of NN O O
whom NN O O
38 NN O O
( NN O O
79.2 NN O O
% NN O O
) NN O O
attended NN O O
4 NN O O
or NN O O
more NN O O
course NN O O
sessions NN O O
. NN O O

Adjusting NN O O
for NN O O
baseline NN O O
values NN O O
, NN O O
mean NN O O
( NN O O
SE NN O O
) NN O O
conflict NN O O
scores NN O O
after NN O O
the NN O O
course NN O O
were NN O O
not NN O O
significantly NN O O
different NN O O
between NN O O
course NN O O
participants NN O O
( NN O O
15.8 NN O O
[ NN O O
0.6 NN O O
] NN O O
) NN O O
and NN O O
controls NN O O
( NN O O
15.0 NN O O
[ NN O O
0.6 NN O O
] NN O O
) NN O O
( NN O O
effect NN O O
size NN O O
= NN O O
0.16 NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
-0.19 NN O O
to NN O O
0.52 NN O O
) NN O O
. NN O O

There NN O O
were NN O O
no NN O O
significant NN O O
between-group NN O O
differences NN O O
in NN O O
secondary NN O O
outcomes NN O O
. NN O O

However NN O O
, NN O O
in NN O O
focus NN O O
groups NN O O
, NN O O
the NN O O
teachers NN O O
reported NN O O
improvements NN O O
in NN O O
teacher-children NN O O
relationship NN O O
quality NN O O
and NN O O
several NN O O
related NN O O
relational NN O O
capacities NN O O
. NN O O

A NN O O
course NN O O
to NN O O
enhance NN O O
trauma NN O O
awareness NN O O
among NN O O
preschool NN O O
teachers NN O O
did NN O O
not NN O O
reduce NN O O
teacher-children NN O O
conflict NN O O
scores NN O O
, NN O O
yet NN O O
qualitative NN O O
assessments NN O O
suggested NN O O
the NN O O
potential NN O O
for NN O O
improved NN O O
teacher-children NN O O
relationship NN O O
quality NN O O
. NN O O

ClinicalTrials.gov NN O O
identifier NN O O
: NN O O
NCT03303482 NN O O
. NN O O



-DOCSTART- (30477529)

Pain NN O O
during NN O O
labour NN O O
is NN O O
one NN O O
of NN O O
the NN O O
most NN O O
intense NN O O
pain NN O O
that NN O O
women NN O O
may NN O O
experience NN O O
in NN O O
their NN O O
lifetime NN O O
. NN O O

There NN O O
are NN O O
several NN O O
non-pharmacological NN O O
analgesic NN O O
methods NN O O
to NN O O
relieve NN O O
pain NN O O
during NN O O
labour NN O O
, NN O O
among NN O O
them NN O O
transcutaneous NN O O
electrical NN O O
nerve NN O O
stimulation NN O O
( NN O O
TENS NN O O
) NN O O
. NN O O

TENS NN O O
is NN O O
a NN O O
low-frequency NN O O
electrotherapy NN O O
technique NN O O
, NN O O
analgesic NN O O
type NN O O
, NN O O
generally NN O O
used NN O O
in NN O O
musculoskeletal NN O O
pathology NN O O
, NN O O
but NN O O
it NN O O
has NN O O
also NN O O
come NN O O
to NN O O
be NN O O
used NN O O
as NN O O
an NN O O
alternative NN O O
treatment NN O O
during NN O O
labour NN O O
. NN O O

The NN O O
purpose NN O O
of NN O O
this NN O O
study NN O O
is NN O O
to NN O O
investigate NN O O
the NN O O
pain-relieving NN O O
effect NN O O
of NN O O
a NN O O
TENS NN O O
application NN O O
during NN O O
labour NN O O
and NN O O
to NN O O
find NN O O
out NN O O
the NN O O
most NN O O
effective NN O O
dose NN O O
. NN O O

This NN O O
study NN O O
is NN O O
a NN O O
randomized NN O O
, NN O O
double-blind NN O O
, NN O O
placebo-controlled NN O O
trial NN O O
. NN O O

TENS NN O O
therapy NN O O
was NN O O
initiated NN O O
at NN O O
the NN O O
beginning NN O O
of NN O O
the NN O O
active NN O O
phase NN O O
of NN O O
labour NN O O
. NN O O

Participants NN O O
were NN O O
randomly NN O O
assigned NN O O
to NN O O
three NN O O
groups NN O O
( NN O O
21 NN O O
per NN O O
group NN O O
: NN O O
two NN O O
active NN O O
TENS NN O O
and NN O O
one NN O O
placebo NN O O
) NN O O
. NN O O

Active NN O O
TENS NN O O
1 NN O O
intervention NN O O
consisted NN O O
in NN O O
a NN O O
constant NN O O
frequency NN O O
of NN O O
100-Hz NN O O
, NN O O
100-μs NN O O
, NN O O
active NN O O
TENS NN O O
2 NN O O
intervention NN O O
consisted NN O O
in NN O O
a NN O O
varying NN O O
high-frequency NN O O
( NN O O
80 NN O O
- NN O O
100 NN O O
Hz NN O O
) NN O O
, NN O O
350 NN O O
μs NN O O
, NN O O
and NN O O
in NN O O
a NN O O
placebo NN O O
group NN O O
, NN O O
participants NN O O
were NN O O
connected NN O O
to NN O O
the NN O O
TENS NN O O
unit NN O O
without NN O O
electrical NN O O
stimulation NN O O
. NN O O

TENS NN O O
was NN O O
applied NN O O
with NN O O
two NN O O
self-adhesive NN O O
electrodes NN O O
placed NN O O
parallel NN O O
to NN O O
the NN O O
spinal NN O O
cord NN O O
( NN O O
T10-L1 NN O O
and NN O O
S2-S4 NN O O
levels NN O O
) NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
was NN O O
pain NN O O
intensity NN O O
( NN O O
0 NN O O
- NN O O
10 NN O O
cm NN O O
) NN O O
measured NN O O
on NN O O
a NN O O
visual NN O O
analogue NN O O
scale NN O O
( NN O O
VAS NN O O
) NN O O
at NN O O
several NN O O
stages NN O O
( NN O O
at NN O O
baseline NN O O
and NN O O
at NN O O
10 NN O O
and NN O O
30 NN O O
min NN O O
later NN O O
) NN O O
. NN O O

Secondary NN O O
outcomes NN O O
included NN O O
women NN O O
's NN O O
satisfaction NN O O
( NN O O
via NN O O
the NN O O
Care NN O O
in NN O O
Obstetrics NN O O
: NN O O
Measure NN O O
for NN O O
Testing NN O O
Satisfaction NN O O
scale NN O O
) NN O O
. NN O O

Sixty-three NN O O
women NN O O
participated NN O O
. NN O O

Regarding NN O O
baseline NN O O
characteristics NN O O
, NN O O
no NN O O
differences NN O O
were NN O O
found NN O O
among NN O O
the NN O O
three NN O O
groups NN O O
. NN O O

The NN O O
active NN O O
TENS NN O O
2 NN O O
group NN O O
obtained NN O O
an NN O O
improvement NN O O
with NN O O
clinically NN O O
significant NN O O
VAS NN O O
results NN O O
( NN O O
- NN O O
2.9 NN O O
, NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
- NN O O
4.1 NN O O
to NN O O
- NN O O
1.6 NN O O
, NN O O
p NN O O
< NN O O
0.001 NN O O
) NN O O
. NN O O

Regarding NN O O
satisfaction NN O O
, NN O O
the NN O O
results NN O O
also NN O O
revealed NN O O
better NN O O
results NN O O
in NN O O
the NN O O
active NN O O
TENS NN O O
than NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
. NN O O

TENS NN O O
with NN O O
high NN O O
frequencies NN O O
modified NN O O
in NN O O
time NN O O
as NN O O
well NN O O
as NN O O
high NN O O
pulse NN O O
width NN O O
are NN O O
effective NN O O
for NN O O
relieving NN O O
labour NN O O
pain NN O O
, NN O O
and NN O O
they NN O O
are NN O O
well NN O O
considered NN O O
by NN O O
pregnant NN O O
participants NN O O
. NN O O

ClinicalTrials.gov NN O O
, NN O O
NCT03137251 NN O O
. NN O O

Registered NN O O
on NN O O
2 NN O O
May NN O O
2017 NN O O
. NN O O



-DOCSTART- (31014382)

To NN O O
determine NN O O
the NN O O
efficacy NN O O
of NN O O
platelet-rich NN O O
plasma NN O O
( NN O O
PRP NN O O
) NN O O
compared NN O O
to NN O O
lidocaine NN O O
as NN O O
a NN O O
tenotomy NN O O
adjuvant NN O O
for NN O O
people NN O O
with NN O O
elbow NN O O
tendinopathy NN O O
. NN O O

Our NN O O
study NN O O
was NN O O
a NN O O
parallel-group NN O O
, NN O O
double-blind NN O O
, NN O O
randomized NN O O
trial NN O O
involving NN O O
71 NN O O
patients NN O O
with NN O O
recalcitrant NN O O
elbow NN O O
tendinopathy NN O O
who NN O O
received NN O O
two NN O O
sessions NN O O
of NN O O
ultrasound-guided NN O O
tenotomy NN O O
with NN O O
either NN O O
PRP NN O O
or NN O O
lidocaine NN O O
in NN O O
a NN O O
tertiary NN O O
public NN O O
hospital NN O O
. NN O O

The NN O O
primary NN O O
end NN O O
point NN O O
was NN O O
the NN O O
percentage NN O O
of NN O O
patients NN O O
with NN O O
an NN O O
improvement NN O O
exceeding NN O O
25 NN O O
% NN O O
reduction NN O O
in NN O O
disability NN O O
( NN O O
Spanish NN O O
version NN O O
of NN O O
the NN O O
Disabilities NN O O
of NN O O
the NN O O
Arm NN O O
, NN O O
Shoulder NN O O
and NN O O
Hand NN O O
questionnaires-DASH-E NN O O
) NN O O
at NN O O
6 NN O O
and NN O O
12 NN O O
months NN O O
; NN O O
the NN O O
secondary NN O O
outcome NN O O
was NN O O
the NN O O
percentage NN O O
of NN O O
patients NN O O
exceeding NN O O
25 NN O O
% NN O O
reduction NN O O
in NN O O
pain NN O O
( NN O O
VAS-P NN O O
) NN O O
. NN O O

There NN O O
was NN O O
no NN O O
evidence NN O O
of NN O O
significant NN O O
differences NN O O
in NN O O
the NN O O
proportion NN O O
of NN O O
patients NN O O
who NN O O
experienced NN O O
clinically NN O O
relevant NN O O
improvements NN O O
. NN O O

After NN O O
6 NN O O
months NN O O
, NN O O
18 NN O O
patients NN O O
( NN O O
78.59 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
lidocaine NN O O
group NN O O
and NN O O
19 NN O O
patients NN O O
( NN O O
73.08 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
PRP NN O O
group NN O O
showed NN O O
improved NN O O
function NN O O
above NN O O
25 NN O O
% NN O O
( NN O O
unadjusted NN O O
odds NN O O
ratio NN O O
, NN O O
0.90 NN O O
; NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
[ NN O O
CI NN O O
] NN O O
, NN O O
0.90 NN O O
( NN O O
0.17 NN O O
to NN O O
4.60 NN O O
) NN O O
) NN O O
; NN O O
21 NN O O
patients NN O O
( NN O O
72.21 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
lidocaine NN O O
group NN O O
versus NN O O
22 NN O O
patients NN O O
( NN O O
84.62 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
PRP NN O O
group NN O O
achieved NN O O
more NN O O
than NN O O
25 NN O O
% NN O O
pain NN O O
reduction NN O O
( NN O O
unadjusted NN O O
odds NN O O
ratio NN O O
, NN O O
0.48 NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
0.10 NN O O
to NN O O
2.37 NN O O
) NN O O
. NN O O

After NN O O
12 NN O O
months NN O O
, NN O O
17 NN O O
patients NN O O
( NN O O
70.83 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
lidocaine NN O O
group NN O O
versus NN O O
19 NN O O
patients NN O O
( NN O O
76 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
PRP NN O O
group NN O O
had NN O O
improved NN O O
function NN O O
( NN O O
unadjusted NN O O
odds NN O O
ratio NN O O
, NN O O
0.71 NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
0.13 NN O O
to NN O O
3.84 NN O O
) NN O O
, NN O O
and NN O O
19 NN O O
patients NN O O
( NN O O
76 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
lidocaine NN O O
group NN O O
versus NN O O
20 NN O O
patients NN O O
( NN O O
90.91 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
PRP NN O O
group NN O O
had NN O O
improved NN O O
pain NN O O
above NN O O
25 NN O O
% NN O O
( NN O O
unadjusted NN O O
odds NN O O
ratio NN O O
, NN O O
0.35 NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
0.06 NN O O
to NN O O
2.51 NN O O
) NN O O
. NN O O

Hypercholesterolemia NN O O
and NN O O
baseline NN O O
vascularization NN O O
influenced NN O O
outcomes NN O O
. NN O O

There NN O O
were NN O O
no NN O O
differences NN O O
between NN O O
groups NN O O
in NN O O
the NN O O
adjusted NN O O
odds NN O O
ratios NN O O
. NN O O

PRP NN O O
results NN O O
in NN O O
similar NN O O
improvements NN O O
to NN O O
those NN O O
obtained NN O O
with NN O O
lidocaine NN O O
. NN O O

Selecting NN O O
patients NN O O
according NN O O
to NN O O
their NN O O
pretreatment NN O O
status NN O O
can NN O O
improve NN O O
treatment NN O O
efficacy NN O O
. NN O O

NCT01945528 NN O O
, NN O O
EudraCT NN O O
2013 NN O O
- NN O O
000478 NN O O
- NN O O
32 NN O O
. NN O O

Registered NN O O
18 NN O O
August NN O O
2013 NN O O
, NN O O
enrolment NN O O
of NN O O
the NN O O
first NN O O
participant NN O O
10 NN O O
March NN O O
2014 NN O O
. NN O O



-DOCSTART- (30870556)

Earlier NN O O
clinician-patient NN O O
conversations NN O O
about NN O O
patients NN O O
' NN O O
values NN O O
, NN O O
goals NN O O
, NN O O
and NN O O
preferences NN O O
in NN O O
serious NN O O
illness NN O O
( NN O O
ie NN O O
, NN O O
serious NN O O
illness NN O O
conversations NN O O
) NN O O
are NN O O
associated NN O O
with NN O O
better NN O O
outcomes NN O O
but NN O O
occur NN O O
inconsistently NN O O
in NN O O
cancer NN O O
care NN O O
. NN O O

To NN O O
evaluate NN O O
the NN O O
efficacy NN O O
of NN O O
a NN O O
communication NN O O
quality-improvement NN O O
intervention NN O O
in NN O O
improving NN O O
the NN O O
occurrence NN O O
, NN O O
timing NN O O
, NN O O
quality NN O O
, NN O O
and NN O O
accessibility NN O O
of NN O O
documented NN O O
serious NN O O
illness NN O O
conversations NN O O
between NN O O
oncology NN O O
clinicians NN O O
and NN O O
patients NN O O
with NN O O
advanced NN O O
cancer NN O O
. NN O O

This NN O O
cluster NN O O
randomized NN O O
clinical NN O O
trial NN O O
in NN O O
outpatient NN O O
oncology NN O O
was NN O O
conducted NN O O
at NN O O
the NN O O
Dana-Farber NN O O
Cancer NN O O
Institute NN O O
and NN O O
included NN O O
physicians NN O O
, NN O O
advanced-practice NN O O
clinicians NN O O
, NN O O
and NN O O
patients NN O O
with NN O O
cancer NN O O
who NN O O
were NN O O
at NN O O
high NN O O
risk NN O O
of NN O O
death NN O O
. NN O O

The NN O O
primary NN O O
outcomes NN O O
( NN O O
goal-concordant NN O O
care NN O O
and NN O O
peacefulness NN O O
at NN O O
the NN O O
end NN O O
of NN O O
life NN O O
) NN O O
are NN O O
published NN O O
elsewhere NN O O
. NN O O

Secondary NN O O
outcomes NN O O
are NN O O
reported NN O O
herein NN O O
, NN O O
including NN O O
( NN O O
1 NN O O
) NN O O
documentation NN O O
of NN O O
at NN O O
least NN O O
1 NN O O
serious NN O O
illness NN O O
conversation NN O O
before NN O O
death NN O O
, NN O O
( NN O O
2 NN O O
) NN O O
timing NN O O
of NN O O
the NN O O
initial NN O O
conversation NN O O
before NN O O
death NN O O
, NN O O
( NN O O
3 NN O O
) NN O O
quality NN O O
of NN O O
conversations NN O O
, NN O O
and NN O O
( NN O O
4 NN O O
) NN O O
their NN O O
accessibility NN O O
in NN O O
the NN O O
electronic NN O O
medical NN O O
record NN O O
( NN O O
EMR NN O O
) NN O O
. NN O O

We NN O O
enrolled NN O O
91 NN O O
clinicians NN O O
( NN O O
48 NN O O
intervention NN O O
, NN O O
43 NN O O
control NN O O
) NN O O
and NN O O
278 NN O O
patients NN O O
( NN O O
134 NN O O
intervention NN O O
, NN O O
144 NN O O
control NN O O
) NN O O
. NN O O

Of NN O O
enrolled NN O O
patients NN O O
, NN O O
58 NN O O
% NN O O
died NN O O
during NN O O
the NN O O
study NN O O
( NN O O
n=161 NN O O
) NN O O
; NN O O
mean NN O O
age NN O O
was NN O O
62.3 NN O O
years NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
58.9 NN O O
- NN O O
65.6 NN O O
years NN O O
) NN O O
; NN O O
55 NN O O
% NN O O
were NN O O
women NN O O
( NN O O
n=88 NN O O
) NN O O
. NN O O

These NN O O
patients NN O O
were NN O O
cared NN O O
for NN O O
by NN O O
76 NN O O
of NN O O
the NN O O
91 NN O O
enrolled NN O O
clinicians NN O O
( NN O O
37 NN O O
intervention NN O O
, NN O O
39 NN O O
control NN O O
) NN O O
; NN O O
years NN O O
in NN O O
practice NN O O
, NN O O
11.5 NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
9.2 NN O O
- NN O O
13.8 NN O O
) NN O O
; NN O O
57 NN O O
% NN O O
female NN O O
( NN O O
n=43 NN O O
) NN O O
. NN O O

Medical NN O O
record NN O O
review NN O O
after NN O O
patients NN O O
' NN O O
death NN O O
demonstrated NN O O
that NN O O
a NN O O
significantly NN O O
higher NN O O
proportion NN O O
of NN O O
intervention NN O O
patients NN O O
had NN O O
a NN O O
documented NN O O
discussion NN O O
compared NN O O
with NN O O
controls NN O O
( NN O O
96 NN O O
% NN O O
vs NN O O
79 NN O O
% NN O O
, NN O O
P NN O O
= NN O O
.005 NN O O
) NN O O
and NN O O
intervention NN O O
conversations NN O O
occurred NN O O
a NN O O
median NN O O
of NN O O
2.4 NN O O
months NN O O
earlier NN O O
( NN O O
median NN O O
, NN O O
143 NN O O
days NN O O
vs NN O O
71 NN O O
days NN O O
, NN O O
P NN O O
< NN O O
.001 NN O O
) NN O O
. NN O O

Conversation NN O O
documentation NN O O
for NN O O
intervention NN O O
patients NN O O
was NN O O
significantly NN O O
more NN O O
comprehensive NN O O
and NN O O
patient NN O O
centered NN O O
, NN O O
with NN O O
a NN O O
greater NN O O
focus NN O O
on NN O O
values NN O O
or NN O O
goals NN O O
( NN O O
89 NN O O
% NN O O
vs NN O O
44 NN O O
% NN O O
, NN O O
P NN O O
< NN O O
.001 NN O O
) NN O O
, NN O O
prognosis NN O O
or NN O O
illness NN O O
understanding NN O O
( NN O O
91 NN O O
% NN O O
vs NN O O
48 NN O O
% NN O O
, NN O O
P NN O O
< NN O O
.001 NN O O
) NN O O
, NN O O
and NN O O
life-sustaining NN O O
treatment NN O O
preferences NN O O
( NN O O
63 NN O O
% NN O O
vs NN O O
32 NN O O
% NN O O
, NN O O
P NN O O
= NN O O
.004 NN O O
) NN O O
. NN O O

Documentation NN O O
about NN O O
end-of-life NN O O
care NN O O
planning NN O O
did NN O O
not NN O O
differ NN O O
between NN O O
arms NN O O
( NN O O
80 NN O O
% NN O O
intervention NN O O
vs NN O O
68 NN O O
% NN O O
control NN O O
, NN O O
P NN O O
= NN O O
.08 NN O O
) NN O O
. NN O O

Significantly NN O O
more NN O O
intervention NN O O
patients NN O O
had NN O O
documentation NN O O
that NN O O
was NN O O
accessible NN O O
in NN O O
the NN O O
EMR NN O O
( NN O O
61 NN O O
% NN O O
vs NN O O
11 NN O O
% NN O O
, NN O O
P NN O O
< NN O O
.001 NN O O
) NN O O
. NN O O

This NN O O
communication NN O O
quality-improvement NN O O
intervention NN O O
resulted NN O O
in NN O O
more NN O O
, NN O O
earlier NN O O
, NN O O
better NN O O
, NN O O
and NN O O
more NN O O
accessible NN O O
serious NN O O
illness NN O O
conversations NN O O
documented NN O O
in NN O O
the NN O O
EMR NN O O
. NN O O

To NN O O
our NN O O
knowledge NN O O
, NN O O
this NN O O
is NN O O
the NN O O
first NN O O
such NN O O
study NN O O
to NN O O
demonstrate NN O O
improvement NN O O
in NN O O
all NN O O
4 NN O O
of NN O O
these NN O O
outcomes NN O O
. NN O O

ClinicalTrials.gov NN O O
identifier NN O O
: NN O O
NCT01786811 NN O O
. NN O O



-DOCSTART- (30720582)

Despite NN O O
optimal NN O O
medical NN O O
management NN O O
( NN O O
OMM NN O O
) NN O O
, NN O O
low NN O O
back NN O O
pain NN O O
( NN O O
LBP NN O O
) NN O O
can NN O O
be NN O O
disabling NN O O
, NN O O
particularly NN O O
after NN O O
spinal NN O O
surgery NN O O
. NN O O

Spinal NN O O
cord NN O O
stimulation NN O O
( NN O O
SCS NN O O
) NN O O
is NN O O
effective NN O O
in NN O O
reducing NN O O
neuropathic NN O O
leg NN O O
pain NN O O
; NN O O
however NN O O
, NN O O
evidence NN O O
is NN O O
limited NN O O
for NN O O
LBP NN O O
. NN O O

This NN O O
prospective NN O O
, NN O O
open-label NN O O
, NN O O
parallel-group NN O O
trial NN O O
randomized NN O O
( NN O O
1:1 NN O O
) NN O O
failed NN O O
back NN O O
surgery NN O O
syndrome NN O O
( NN O O
FBSS NN O O
) NN O O
patients NN O O
with NN O O
predominant NN O O
LBP NN O O
to NN O O
SCS NN O O
plus NN O O
OMM NN O O
( NN O O
SCS NN O O
group NN O O
) NN O O
or NN O O
OMM NN O O
alone NN O O
( NN O O
OMM NN O O
group NN O O
) NN O O
at NN O O
28 NN O O
sites NN O O
in NN O O
Europe NN O O
and NN O O
the NN O O
Americas NN O O
. NN O O

If NN O O
trial NN O O
stimulation NN O O
was NN O O
successful NN O O
, NN O O
a NN O O
multicolumn NN O O
SCS NN O O
system NN O O
was NN O O
implanted NN O O
. NN O O

Outcomes NN O O
were NN O O
assessed NN O O
at NN O O
baseline NN O O
( NN O O
before NN O O
randomization NN O O
) NN O O
and NN O O
at NN O O
1 NN O O
, NN O O
3 NN O O
, NN O O
6 NN O O
, NN O O
and NN O O
12 NN O O
months NN O O
after NN O O
randomization NN O O
. NN O O

Patients NN O O
could NN O O
change NN O O
treatment NN O O
groups NN O O
at NN O O
6 NN O O
months NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
was NN O O
the NN O O
proportion NN O O
of NN O O
patients NN O O
with NN O O
≥50 NN O O
% NN O O
reduction NN O O
in NN O O
LBP NN O O
( NN O O
responder NN O O
) NN O O
at NN O O
6 NN O O
months NN O O
. NN O O

Secondary NN O O
outcomes NN O O
included NN O O
change NN O O
in NN O O
pain NN O O
intensity NN O O
, NN O O
functional NN O O
disability NN O O
, NN O O
and NN O O
health-related NN O O
quality NN O O
of NN O O
life NN O O
( NN O O
HRQoL NN O O
) NN O O
. NN O O

The NN O O
results NN O O
are NN O O
posted NN O O
at NN O O
ClinicalTrials.gov NN O O
under NN O O
registration NN O O
number NN O O
NCT01697358 NN O O
. NN O O

In NN O O
the NN O O
intent-to-treat NN O O
analysis NN O O
, NN O O
there NN O O
were NN O O
more NN O O
responders NN O O
in NN O O
the NN O O
SCS NN O O
group NN O O
than NN O O
in NN O O
the NN O O
OMM NN O O
group NN O O
( NN O O
13.6 NN O O
% NN O O
, NN O O
15/110 NN O O
vs NN O O
4.6 NN O O
% NN O O
, NN O O
5/108 NN O O
, NN O O
difference NN O O
9 NN O O
% NN O O
with NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
0.6%-17.5 NN O O
% NN O O
, NN O O
P NN O O
= NN O O
0.036 NN O O
) NN O O
at NN O O
6 NN O O
months NN O O
. NN O O

The NN O O
SCS NN O O
group NN O O
improved NN O O
in NN O O
all NN O O
secondary NN O O
outcomes NN O O
compared NN O O
with NN O O
the NN O O
OMM NN O O
group NN O O
. NN O O

The NN O O
OMM NN O O
group NN O O
only NN O O
improved NN O O
in NN O O
HRQoL. NN O O
In NN O O
the NN O O
SCS NN O O
group NN O O
, NN O O
17.6 NN O O
% NN O O
( NN O O
18/102 NN O O
) NN O O
experienced NN O O
SCS-related NN O O
adverse NN O O
events NN O O
through NN O O
6 NN O O
months NN O O
, NN O O
with NN O O
11.8 NN O O
% NN O O
( NN O O
12/102 NN O O
) NN O O
requiring NN O O
surgical NN O O
reintervention NN O O
. NN O O

Adding NN O O
multicolumn NN O O
SCS NN O O
to NN O O
OMM NN O O
improved NN O O
pain NN O O
relief NN O O
, NN O O
HRQoL NN O O
, NN O O
and NN O O
function NN O O
in NN O O
a NN O O
traditionally NN O O
difficult-to-treat NN O O
population NN O O
of NN O O
failed NN O O
back NN O O
surgery NN O O
syndrome NN O O
patients NN O O
with NN O O
predominant NN O O
LBP NN O O
. NN O O

Improvements NN O O
were NN O O
sustained NN O O
at NN O O
12 NN O O
and NN O O
24 NN O O
months NN O O
. NN O O



-DOCSTART- (31240513)

Purpose NN O O
Cancer NN O O
therapy-associated NN O O
paronychia NN O O
( NN O O
CAP NN O O
) NN O O
is NN O O
a NN O O
frequent NN O O
adverse NN O O
event NN O O
associated NN O O
with NN O O
cytotoxic NN O O
and NN O O
targeted NN O O
therapies NN O O
that NN O O
may NN O O
impact NN O O
dosing NN O O
of NN O O
anticancer NN O O
therapies NN O O
and NN O O
patient NN O O
quality NN O O
of NN O O
life NN O O
( NN O O
QoL NN O O
) NN O O
. NN O O

There NN O O
are NN O O
currently NN O O
no NN O O
evidence-based NN O O
management NN O O
strategies NN O O
or NN O O
approved NN O O
treatments NN O O
for NN O O
CAP NN O O
. NN O O

Materials NN O O
and NN O O
Methods NN O O
This NN O O
was NN O O
a NN O O
prospective NN O O
, NN O O
multicenter NN O O
, NN O O
randomized NN O O
, NN O O
double-blind NN O O
, NN O O
vehicle-controlled NN O O
phase NN O O
2 NN O O
study NN O O
that NN O O
evaluated NN O O
the NN O O
efficacy NN O O
and NN O O
safety NN O O
of NN O O
6 NN O O
to NN O O
8 NN O O
weeks NN O O
of NN O O
1 NN O O
% NN O O
or NN O O
2 NN O O
% NN O O
povidone-iodine NN O O
( NN O O
PVP-I NN O O
) NN O O
topical NN O O
solution NN O O
versus NN O O
vehicle-control NN O O
in NN O O
adult NN O O
patients NN O O
with NN O O
CAP NN O O
. NN O O

Patients NN O O
were NN O O
randomized NN O O
to NN O O
one NN O O
of NN O O
three NN O O
treatment NN O O
arms NN O O
administered NN O O
twice NN O O
daily NN O O
: NN O O
1 NN O O
% NN O O
PVP-I NN O O
( NN O O
Cohort NN O O
A NN O O
) NN O O
, NN O O
2 NN O O
% NN O O
PVP-I NN O O
( NN O O
Cohort NN O O
B NN O O
) NN O O
, NN O O
or NN O O
vehicle-control NN O O
( NN O O
Cohort NN O O
C NN O O
) NN O O
. NN O O

The NN O O
primary NN O O
endpoint NN O O
was NN O O
a NN O O
two-grade NN O O
reduction NN O O
( NN O O
or NN O O
reduction NN O O
to NN O O
grade NN O O
0 NN O O
if NN O O
involved NN O O
nails NN O O
were NN O O
grade NN O O
1 NN O O
) NN O O
on NN O O
the NN O O
six-point NN O O
Paronychia NN O O
Severity NN O O
Grading NN O O
( NN O O
PSG NN O O
) NN O O
scale NN O O
. NN O O

Secondary NN O O
endpoints NN O O
included NN O O
safety NN O O
and NN O O
the NN O O
effect NN O O
on NN O O
QoL NN O O
and NN O O
microbiota NN O O
. NN O O

Results NN O O
A NN O O
total NN O O
of NN O O
102 NN O O
patients NN O O
with NN O O
cancer NN O O
were NN O O
randomized NN O O
to NN O O
the NN O O
study NN O O
. NN O O

In NN O O
Cohort NN O O
A NN O O
, NN O O
83 NN O O
of NN O O
205 NN O O
( NN O O
40.5 NN O O
% NN O O
, NN O O
P NN O O
= NN O O
0.6059 NN O O
) NN O O
affected NN O O
nails NN O O
met NN O O
the NN O O
primary NN O O
endpoint NN O O
versus NN O O
Cohort NN O O
C. NN O O
In NN O O
Cohort NN O O
B NN O O
, NN O O
88 NN O O
of NN O O
167 NN O O
( NN O O
52.7 NN O O
% NN O O
, NN O O
P NN O O
= NN O O
0.0063 NN O O
) NN O O
affected NN O O
nails NN O O
met NN O O
the NN O O
primary NN O O
endpoint NN O O
versus NN O O
64 NN O O
of NN O O
169 NN O O
( NN O O
37.9 NN O O
% NN O O
) NN O O
in NN O O
Cohort NN O O
C. NN O O
Nineteen NN O O
of NN O O
29 NN O O
patients NN O O
( NN O O
65.5 NN O O
% NN O O
) NN O O
in NN O O
Cohort NN O O
B NN O O
reported NN O O
moderately NN O O
or NN O O
very NN O O
painful NN O O
nails NN O O
at NN O O
baseline NN O O
that NN O O
decreased NN O O
to NN O O
15 NN O O
patients NN O O
( NN O O
51.7 NN O O
% NN O O
) NN O O
at NN O O
visit NN O O
2 NN O O
and NN O O
five NN O O
patients NN O O
( NN O O
17.2 NN O O
% NN O O
) NN O O
at NN O O
visit NN O O
3 NN O O
. NN O O

Conclusions NN O O
Treatment NN O O
with NN O O
twice-daily NN O O
topical NN O O
2 NN O O
% NN O O
PVP-I NN O O
was NN O O
safe NN O O
and NN O O
resulted NN O O
in NN O O
improvement NN O O
in NN O O
CAP NN O O
compared NN O O
with NN O O
control NN O O
. NN O O

Clinicaltrials.gov NN O O
identifier NN O O
: NN O O
NCT03207906 NN O O
. NN O O

https://clinicaltrials.gov/ct2/show/NCT03207906 NN O O
. NN O O



-DOCSTART- (31118090)

Smoking NN O O
in NN O O
pregnancy NN O O
is NN O O
a NN O O
major NN O O
international NN O O
public NN O O
health NN O O
problem NN O O
. NN O O

Self-help NN O O
support NN O O
( NN O O
SHS NN O O
) NN O O
increases NN O O
the NN O O
likelihood NN O O
of NN O O
women NN O O
stopping NN O O
smoking NN O O
in NN O O
pregnancy NN O O
and NN O O
delivering NN O O
this NN O O
kind NN O O
of NN O O
support NN O O
by NN O O
text NN O O
message NN O O
could NN O O
be NN O O
a NN O O
cost-effective NN O O
way NN O O
to NN O O
deliver NN O O
SHS NN O O
to NN O O
pregnant NN O O
women NN O O
who NN O O
smoke NN O O
. NN O O

SHS NN O O
delivered NN O O
by NN O O
text NN O O
message NN O O
helps NN O O
non-pregnant NN O O
smokers NN O O
to NN O O
stop NN O O
but NN O O
the NN O O
currently NN O O
available NN O O
message NN O O
programmes NN O O
are NN O O
not NN O O
appropriate NN O O
for NN O O
use NN O O
in NN O O
pregnancy NN O O
. NN O O

A NN O O
randomised NN O O
controlled NN O O
trial NN O O
( NN O O
RCT NN O O
) NN O O
has NN O O
demonstrated NN O O
the NN O O
feasibility NN O O
and NN O O
acceptability NN O O
of NN O O
using NN O O
a NN O O
programme NN O O
called NN O O
' NN O O
MiQuit NN O O
' NN O O
to NN O O
text NN O O
SHS NN O O
support NN O O
to NN O O
pregnant NN O O
women NN O O
who NN O O
smoke NN O O
. NN O O

Another NN O O
pilot NN O O
RCT NN O O
has NN O O
shown NN O O
that NN O O
it NN O O
would NN O O
be NN O O
feasible NN O O
to NN O O
run NN O O
a NN O O
larger NN O O
, NN O O
multi-centre NN O O
trial NN O O
within NN O O
the NN O O
UK NN O O
National NN O O
Health NN O O
Service NN O O
( NN O O
NHS NN O O
) NN O O
. NN O O

The NN O O
aim NN O O
of NN O O
this NN O O
third NN O O
RCT NN O O
is NN O O
to NN O O
complete NN O O
MiQuit NN O O
's NN O O
evaluation NN O O
, NN O O
demonstrating NN O O
whether NN O O
or NN O O
not NN O O
this NN O O
is NN O O
efficacious NN O O
for NN O O
smoking NN O O
cessation NN O O
in NN O O
pregnancy NN O O
. NN O O

This NN O O
is NN O O
a NN O O
multi-centre NN O O
, NN O O
parallel-group NN O O
RCT NN O O
. NN O O

Pregnant NN O O
women NN O O
aged NN O O
over NN O O
16 NN O O
years NN O O
, NN O O
of NN O O
less NN O O
than NN O O
25 NN O O
weeks NN O O
' NN O O
gestation NN O O
who NN O O
smoke NN O O
one NN O O
or NN O O
more NN O O
daily NN O O
cigarettes NN O O
but NN O O
smoked NN O O
at NN O O
least NN O O
five NN O O
daily NN O O
cigarettes NN O O
before NN O O
pregnancy NN O O
and NN O O
who NN O O
understand NN O O
written NN O O
English NN O O
and NN O O
are NN O O
being NN O O
identified NN O O
in NN O O
24 NN O O
English NN O O
antenatal NN O O
care NN O O
hospitals NN O O
. NN O O

Participants NN O O
are NN O O
randomised NN O O
to NN O O
control NN O O
or NN O O
intervention NN O O
groups NN O O
in NN O O
a NN O O
1:1 NN O O
ratio NN O O
stratified NN O O
by NN O O
gestation NN O O
( NN O O
< NN O O
16 NN O O
weeks NN O O
versus NN O O
≥ NN O O
16 NN O O
weeks NN O O
) NN O O
. NN O O

All NN O O
participants NN O O
receive NN O O
a NN O O
leaflet NN O O
on NN O O
stopping NN O O
smoking NN O O
during NN O O
pregnancy NN O O
; NN O O
they NN O O
are NN O O
also NN O O
able NN O O
to NN O O
access NN O O
standard NN O O
NHS NN O O
smoking NN O O
cessation NN O O
support NN O O
. NN O O

Intervention NN O O
group NN O O
women NN O O
also NN O O
receive NN O O
the NN O O
12-week NN O O
MiQuit NN O O
programme NN O O
of NN O O
tailored NN O O
, NN O O
interactive NN O O
text NN O O
message NN O O
, NN O O
and NN O O
self-help NN O O
cessation NN O O
support NN O O
. NN O O

Women NN O O
are NN O O
followed NN O O
up NN O O
by NN O O
telephone NN O O
at NN O O
4 NN O O
weeks NN O O
after NN O O
randomisation NN O O
and NN O O
36 NN O O
weeks NN O O
' NN O O
gestation NN O O
. NN O O

The NN O O
RCT NN O O
will NN O O
recruit NN O O
692 NN O O
women NN O O
( NN O O
346 NN O O
per NN O O
group NN O O
) NN O O
, NN O O
enabling NN O O
a NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
for NN O O
the NN O O
difference NN O O
in NN O O
quit NN O O
rates NN O O
to NN O O
be NN O O
estimated NN O O
within NN O O
± NN O O
3 NN O O
% NN O O
. NN O O

To NN O O
determine NN O O
whether NN O O
or NN O O
not NN O O
MiQuit NN O O
helps NN O O
pregnant NN O O
smokers NN O O
to NN O O
stop NN O O
, NN O O
intervention NN O O
group NN O O
quit NN O O
rates NN O O
from NN O O
this NN O O
trial NN O O
will NN O O
be NN O O
combined NN O O
with NN O O
those NN O O
from NN O O
the NN O O
two NN O O
earlier NN O O
trials NN O O
in NN O O
a NN O O
Trial NN O O
Sequential NN O O
Analysis NN O O
( NN O O
TSA NN O O
) NN O O
meta-analysis NN O O
to NN O O
derive NN O O
a NN O O
pooled NN O O
efficacy NN O O
estimate NN O O
. NN O O

If NN O O
effective NN O O
, NN O O
MiQuit NN O O
will NN O O
be NN O O
a NN O O
cheap NN O O
, NN O O
cost-effective NN O O
method NN O O
to NN O O
help NN O O
pregnant NN O O
women NN O O
to NN O O
stop NN O O
smoking NN O O
. NN O O

ClinicalTrials.gov NN O O
, NN O O
ID NN O O
: NN O O
NCT03231553 NN O O
. NN O O

Registered NN O O
on NN O O
20 NN O O
July NN O O
2017 NN O O
. NN O O



-DOCSTART- (30580974)

To NN O O
evaluate NN O O
the NN O O
optimal NN O O
zinc NN O O
supplementation NN O O
strategy NN O O
for NN O O
improving NN O O
growth NN O O
and NN O O
hematologic NN O O
and NN O O
micronutrient NN O O
status NN O O
in NN O O
young NN O O
Laotian NN O O
children NN O O
. NN O O

In NN O O
total NN O O
, NN O O
3407 NN O O
children NN O O
aged NN O O
6 NN O O
- NN O O
23 NN O O
months NN O O
were NN O O
randomized NN O O
to NN O O
receive NN O O
either NN O O
daily NN O O
preventive NN O O
zinc NN O O
tablets NN O O
( NN O O
7 NN O O
mg/d NN O O
) NN O O
, NN O O
high-zinc NN O O
, NN O O
low-iron NN O O
micronutrient NN O O
powder NN O O
( NN O O
10 NN O O
mg/d NN O O
zinc NN O O
, NN O O
6 NN O O
mg/d NN O O
iron NN O O
, NN O O
and NN O O
13 NN O O
other NN O O
micronutrients NN O O
) NN O O
, NN O O
therapeutic NN O O
zinc NN O O
supplementation NN O O
for NN O O
diarrhea NN O O
( NN O O
20 NN O O
mg/d NN O O
for NN O O
10 NN O O
days NN O O
per NN O O
episode NN O O
) NN O O
, NN O O
or NN O O
daily NN O O
placebo NN O O
powder NN O O
; NN O O
all NN O O
were NN O O
followed NN O O
for NN O O
~9 NN O O
months NN O O
. NN O O

Anthropometry NN O O
, NN O O
hemoglobin NN O O
, NN O O
zinc NN O O
, NN O O
and NN O O
iron NN O O
status NN O O
were NN O O
assessed NN O O
at NN O O
baseline NN O O
and NN O O
endline NN O O
. NN O O

Analyses NN O O
were NN O O
by NN O O
intention-to-treat NN O O
, NN O O
using NN O O
linear NN O O
and NN O O
modified NN O O
Poisson NN O O
regression NN O O
. NN O O

At NN O O
baseline NN O O
, NN O O
mean NN O O
( NN O O
±SD NN O O
) NN O O
age NN O O
was NN O O
14.2 NN O O
± NN O O
5.1 NN O O
months NN O O
and NN O O
stunting NN O O
and NN O O
anemia NN O O
prevalence NN O O
were NN O O
37.9 NN O O
% NN O O
and NN O O
55.6 NN O O
% NN O O
, NN O O
respectively NN O O
. NN O O

At NN O O
endline NN O O
, NN O O
zinc NN O O
deficiency NN O O
in NN O O
the NN O O
preventive NN O O
zinc NN O O
( NN O O
50.7 NN O O
% NN O O
) NN O O
and NN O O
micronutrient NN O O
powder NN O O
( NN O O
59.1 NN O O
% NN O O
) NN O O
groups NN O O
were NN O O
significantly NN O O
lower NN O O
than NN O O
in NN O O
the NN O O
therapeutic NN O O
zinc NN O O
( NN O O
79.2 NN O O
% NN O O
) NN O O
and NN O O
control NN O O
groups NN O O
( NN O O
78.6 NN O O
% NN O O
; NN O O
P NN O O
< NN O O
.001 NN O O
) NN O O
, NN O O
with NN O O
no NN O O
impact NN O O
on NN O O
stunting NN O O
( NN O O
37.1%-41.3 NN O O
% NN O O
across NN O O
the NN O O
groups NN O O
, NN O O
P NN O O
= NN O O
.37 NN O O
) NN O O
. NN O O

The NN O O
micronutrient NN O O
powder NN O O
reduced NN O O
iron NN O O
deficiency NN O O
by NN O O
44%-55 NN O O
% NN O O
compared NN O O
with NN O O
other NN O O
groups NN O O
( NN O O
P NN O O
< NN O O
.001 NN O O
) NN O O
, NN O O
with NN O O
no NN O O
overall NN O O
impact NN O O
on NN O O
anemia NN O O
( NN O O
P NN O O
= NN O O
.14 NN O O
) NN O O
. NN O O

Micronutrient NN O O
powder NN O O
tended NN O O
to NN O O
reduce NN O O
anemia NN O O
by NN O O
11%-16 NN O O
% NN O O
among NN O O
children NN O O
who NN O O
were NN O O
anemic NN O O
at NN O O
baseline NN O O
( NN O O
P NN O O
= NN O O
.06 NN O O
) NN O O
. NN O O

Despite NN O O
improving NN O O
zinc NN O O
status NN O O
, NN O O
preventive NN O O
zinc NN O O
and NN O O
micronutrient NN O O
powder NN O O
had NN O O
no NN O O
impact NN O O
on NN O O
growth NN O O
. NN O O

The NN O O
micronutrient NN O O
powder NN O O
improved NN O O
iron NN O O
status NN O O
and NN O O
tended NN O O
to NN O O
reduce NN O O
anemia NN O O
among NN O O
the NN O O
subset NN O O
of NN O O
previously NN O O
anemic NN O O
children NN O O
. NN O O

ClinicalTrials.govNCT02428647 NN O O
. NN O O



-DOCSTART- (31161202)

Biological NN O O
signaling NN O O
and NN O O
communication NN O O
between NN O O
mothers NN O O
and NN O O
infants NN O O
during NN O O
breastfeeding NN O O
may NN O O
shape NN O O
infant NN O O
behavior NN O O
and NN O O
feeding NN O O
. NN O O

This NN O O
signaling NN O O
is NN O O
complex NN O O
and NN O O
little NN O O
explored NN O O
in NN O O
humans NN O O
, NN O O
although NN O O
it NN O O
is NN O O
potentially NN O O
relevant NN O O
for NN O O
initiatives NN O O
to NN O O
improve NN O O
breastfeeding NN O O
rates NN O O
. NN O O

The NN O O
aim NN O O
of NN O O
this NN O O
study NN O O
was NN O O
to NN O O
investigate NN O O
physiological NN O O
and NN O O
psychological NN O O
aspects NN O O
of NN O O
mother-infant NN O O
signaling NN O O
during NN O O
breastfeeding NN O O
experimentally NN O O
, NN O O
testing NN O O
the NN O O
effects NN O O
of NN O O
a NN O O
relaxation NN O O
intervention NN O O
on NN O O
maternal NN O O
psychological NN O O
state NN O O
, NN O O
breast NN O O
milk NN O O
intake NN O O
, NN O O
milk NN O O
cortisol NN O O
levels NN O O
, NN O O
and NN O O
infant NN O O
behavior NN O O
and NN O O
growth NN O O
. NN O O

Primiparous NN O O
breastfeeding NN O O
mothers NN O O
and NN O O
full-term NN O O
infants NN O O
were NN O O
randomly NN O O
assigned NN O O
to NN O O
receive NN O O
relaxation NN O O
therapy NN O O
[ NN O O
intervention NN O O
relaxation NN O O
group NN O O
; NN O O
n NN O O
= NN O O
33 NN O O
( NN O O
RG NN O O
) NN O O
] NN O O
or NN O O
to NN O O
the NN O O
control NN O O
group NN O O
[ NN O O
n NN O O
= NN O O
31 NN O O
( NN O O
CG NN O O
) NN O O
; NN O O
no NN O O
relaxation NN O O
therapy NN O O
] NN O O
at NN O O
2 NN O O
wk NN O O
postpartum NN O O
. NN O O

Both NN O O
groups NN O O
received NN O O
standard NN O O
breastfeeding NN O O
support NN O O
. NN O O

Home NN O O
visits NN O O
were NN O O
conducted NN O O
at NN O O
2 NN O O
( NN O O
HV1 NN O O
) NN O O
, NN O O
6 NN O O
( NN O O
HV2 NN O O
) NN O O
, NN O O
12 NN O O
( NN O O
HV3 NN O O
) NN O O
and NN O O
14 NN O O
( NN O O
HV4 NN O O
) NN O O
wk NN O O
to NN O O
measure NN O O
maternal NN O O
stress NN O O
and NN O O
anxiety NN O O
, NN O O
breast NN O O
milk NN O O
intake NN O O
and NN O O
milk NN O O
cortisol NN O O
, NN O O
and NN O O
infant NN O O
behavior NN O O
and NN O O
growth NN O O
. NN O O

RG NN O O
mothers NN O O
had NN O O
lower NN O O
stress NN O O
scores NN O O
postintervention NN O O
than NN O O
the NN O O
CG NN O O
( NN O O
HV3 NN O O
∆ NN O O
= NN O O
-3.13 NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
: NN O O
-5.9 NN O O
, NN O O
-0.3 NN O O
) NN O O
and NN O O
lower NN O O
hindmilk NN O O
cortisol NN O O
at NN O O
HV1 NN O O
( NN O O
∆ NN O O
= NN O O
-44.5 NN O O
% NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
: NN O O
-76.1 NN O O
% NN O O
, NN O O
-12.9 NN O O
% NN O O
) NN O O
but NN O O
not NN O O
at NN O O
HV2 NN O O
. NN O O

RG NN O O
infants NN O O
had NN O O
longer NN O O
sleep NN O O
duration NN O O
( NN O O
∆ NN O O
= NN O O
82 NN O O
min/d NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
: NN O O
16 NN O O
, NN O O
149 NN O O
min/d NN O O
) NN O O
at NN O O
HV2 NN O O
and NN O O
higher NN O O
gains NN O O
in NN O O
weight NN O O
and NN O O
body NN O O
mass NN O O
index NN O O
standardized NN O O
deviation NN O O
score NN O O
than NN O O
the NN O O
CG NN O O
infants NN O O
( NN O O
∆ NN O O
= NN O O
0.76 NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
: NN O O
0.3 NN O O
, NN O O
1.22 NN O O
; NN O O
and NN O O
∆ NN O O
= NN O O
0.59 NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
: NN O O
0.09 NN O O
, NN O O
1.1 NN O O
, NN O O
respectively NN O O
) NN O O
. NN O O

RG NN O O
infants NN O O
had NN O O
a NN O O
mean NN O O
milk NN O O
intake NN O O
at NN O O
HV3 NN O O
that NN O O
was NN O O
227 NN O O
g/d NN O O
higher NN O O
than NN O O
that NN O O
of NN O O
the NN O O
CG NN O O
infants NN O O
( NN O O
P NN O O
= NN O O
0.031 NN O O
) NN O O
after NN O O
controlling NN O O
for NN O O
gender NN O O
and NN O O
milk NN O O
intake NN O O
at NN O O
HV1 NN O O
. NN O O

The NN O O
trial NN O O
shows NN O O
the NN O O
effectiveness NN O O
of NN O O
a NN O O
simple NN O O
relaxation NN O O
intervention NN O O
for NN O O
improving NN O O
maternal NN O O
and NN O O
infant NN O O
outcomes NN O O
and NN O O
identifies NN O O
some NN O O
potential NN O O
signaling NN O O
mechanisms NN O O
for NN O O
investigation NN O O
in NN O O
future NN O O
and NN O O
larger NN O O
studies NN O O
, NN O O
especially NN O O
in NN O O
settings NN O O
where NN O O
mothers NN O O
are NN O O
more NN O O
stressed NN O O
, NN O O
such NN O O
as NN O O
those NN O O
with NN O O
preterm NN O O
or NN O O
low NN O O
birth NN O O
weight NN O O
infants NN O O
. NN O O

This NN O O
trial NN O O
was NN O O
registered NN O O
at NN O O
clinicaltrials.gov NN O O
as NN O O
NCT01971216 NN O O
. NN O O



-DOCSTART- (31278095)

Active NN O O
surveillance NN O O
( NN O O
AS NN O O
) NN O O
is NN O O
the NN O O
preferred NN O O
primary NN O O
treatment NN O O
strategy NN O O
for NN O O
men NN O O
with NN O O
low-risk NN O O
clinically NN O O
localised NN O O
prostate NN O O
cancer NN O O
( NN O O
PCa NN O O
) NN O O
; NN O O
however NN O O
, NN O O
the NN O O
majority NN O O
of NN O O
these NN O O
men NN O O
still NN O O
receive NN O O
radical NN O O
treatment NN O O
within NN O O
10 NN O O
years NN O O
due NN O O
to NN O O
disease NN O O
progression NN O O
and/or NN O O
fear NN O O
of NN O O
cancer NN O O
progression NN O O
. NN O O

Interventions NN O O
designed NN O O
to NN O O
suppress NN O O
tumour NN O O
growth NN O O
, NN O O
mitigate NN O O
fear NN O O
of NN O O
cancer NN O O
progression NN O O
and NN O O
precondition NN O O
men NN O O
for NN O O
impending NN O O
radical NN O O
treatments NN O O
are NN O O
an NN O O
unmet NN O O
clinical NN O O
need NN O O
. NN O O

Exercise NN O O
has NN O O
been NN O O
shown NN O O
to NN O O
delay NN O O
the NN O O
progression NN O O
of NN O O
prostate NN O O
tumours NN O O
in NN O O
animal NN O O
models NN O O
, NN O O
improve NN O O
physical NN O O
and NN O O
functional NN O O
health NN O O
and NN O O
manage NN O O
psychological NN O O
outcomes NN O O
in NN O O
cancer NN O O
patients NN O O
; NN O O
however NN O O
, NN O O
these NN O O
outcomes NN O O
have NN O O
not NN O O
been NN O O
demonstrated NN O O
in NN O O
PCa NN O O
patients NN O O
undergoing NN O O
AS NN O O
. NN O O

This NN O O
phase NN O O
II NN O O
randomised NN O O
controlled NN O O
trial NN O O
will NN O O
randomise NN O O
66 NN O O
men NN O O
undergoing NN O O
AS NN O O
to NN O O
either NN O O
an NN O O
exercise NN O O
group NN O O
or NN O O
a NN O O
usual NN O O
care NN O O
group NN O O
. NN O O

The NN O O
exercise NN O O
group NN O O
will NN O O
perform NN O O
a NN O O
12-week NN O O
, NN O O
supervised NN O O
, NN O O
high-intensity NN O O
interval NN O O
training NN O O
programme NN O O
, NN O O
consisting NN O O
of NN O O
3 NN O O
sessions/week NN O O
for NN O O
28 NN O O
- NN O O
40 NN O O
min/session NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
will NN O O
be NN O O
cardiorespiratory NN O O
fitness NN O O
. NN O O

Secondary NN O O
outcomes NN O O
will NN O O
include NN O O
immunosurveillance NN O O
and NN O O
cancer-related NN O O
biomarkers NN O O
, NN O O
psychosocial NN O O
outcomes NN O O
including NN O O
fear NN O O
of NN O O
cancer NN O O
progression NN O O
and NN O O
quality NN O O
of NN O O
life NN O O
and NN O O
physical NN O O
function NN O O
. NN O O

Exploratory NN O O
outcomes NN O O
will NN O O
include NN O O
clinical NN O O
indicators NN O O
of NN O O
disease NN O O
progression NN O O
. NN O O

The NN O O
trial NN O O
has NN O O
80 NN O O
% NN O O
power NN O O
to NN O O
detect NN O O
a NN O O
significant NN O O
between-group NN O O
difference NN O O
in NN O O
VO NN O O
of NN O O
3.5 NN O O
mL/kg/min NN O O
with NN O O
a NN O O
two-tailed NN O O
alpha NN O O
level NN O O
< NN O O
0.05 NN O O
and NN O O
a NN O O
10 NN O O
% NN O O
dropout NN O O
rate NN O O
. NN O O

The NN O O
study NN O O
has NN O O
received NN O O
full NN O O
ethical NN O O
approval NN O O
from NN O O
the NN O O
Health NN O O
Research NN O O
Ethics NN O O
Board NN O O
of NN O O
Alberta NN O O
- NN O O
Cancer NN O O
Committee NN O O
( NN O O
Protocol NN O O
Number NN O O
: NN O O
HREBA.CC-17 NN O O
- NN O O
0248 NN O O
) NN O O
. NN O O

The NN O O
findings NN O O
of NN O O
the NN O O
study NN O O
will NN O O
be NN O O
disseminated NN O O
through NN O O
public NN O O
and NN O O
scientific NN O O
channels NN O O
. NN O O

NCT03203460 NN O O
; NN O O
Pre-results NN O O
. NN O O



-DOCSTART- (30787641)

Outcomes NN O O
investigating NN O O
the NN O O
effect NN O O
of NN O O
vitamin NN O O
D3 NN O O
( NN O O
VD3 NN O O
) NN O O
and NN O O
omega-3 NN O O
fatty NN O O
acids NN O O
( NN O O
Omega-3FA NN O O
) NN O O
on NN O O
serum NN O O
estradiol NN O O
( NN O O
E2 NN O O
) NN O O
are NN O O
scarce NN O O
and NN O O
conflicting NN O O
. NN O O

No NN O O
previous NN O O
study NN O O
has NN O O
investigated NN O O
the NN O O
effect NN O O
of NN O O
VD3 NN O O
combination NN O O
with NN O O
Omega-3FA NN O O
on NN O O
E2 NN O O
levels NN O O
. NN O O

This NN O O
study NN O O
was NN O O
designed NN O O
to NN O O
investigate NN O O
the NN O O
effect NN O O
of NN O O
VD3 NN O O
, NN O O
Omega-3FA NN O O
and NN O O
VD3 NN O O
plus NN O O
Omega-3FA NN O O
on NN O O
serum NN O O
E2 NN O O
levels NN O O
in NN O O
premenopausal NN O O
females NN O O
diagnosed NN O O
with NN O O
vitamin NN O O
D NN O O
deficiency NN O O
( NN O O
VDD NN O O
) NN O O
. NN O O

This NN O O
randomized NN O O
, NN O O
placebo-controlled NN O O
clinical NN O O
trial NN O O
was NN O O
designed NN O O
to NN O O
evaluate NN O O
the NN O O
effects NN O O
of NN O O
50,000 NN O O
IU NN O O
VD3 NN O O
taken NN O O
weekly NN O O
, NN O O
300 NN O O
mg NN O O
Omega-3FA NN O O
taken NN O O
daily NN O O
and NN O O
their NN O O
combination NN O O
by NN O O
the NN O O
study NN O O
participants NN O O
for NN O O
8 NN O O
weeks NN O O
. NN O O

The NN O O
mid-follicular NN O O
serum NN O O
levels NN O O
of NN O O
E2 NN O O
and NN O O
25-hydroxy NN O O
vitamin NN O O
D NN O O
( NN O O
25OHD NN O O
) NN O O
were NN O O
assessed NN O O
at NN O O
8 NN O O
weeks NN O O
. NN O O

The NN O O
study NN O O
was NN O O
conducted NN O O
during NN O O
winter NN O O
on NN O O
a NN O O
convenience NN O O
sample NN O O
of NN O O
healthy NN O O
premenopausal NN O O
Jordanian NN O O
females NN O O
with NN O O
diagnosed NN O O
VDD NN O O
. NN O O

Fasting NN O O
serum NN O O
levels NN O O
for NN O O
25OHD NN O O
and NN O O
E2 NN O O
were NN O O
assessed NN O O
at NN O O
baseline NN O O
and NN O O
the NN O O
end NN O O
of NN O O
the NN O O
trial NN O O
( NN O O
after NN O O
8 NN O O
weeks NN O O
) NN O O
. NN O O

Data NN O O
were NN O O
entered NN O O
into NN O O
SPSS NN O O
and NN O O
analyzed NN O O
. NN O O

Healthy NN O O
premenopausal NN O O
Jordanian NN O O
females NN O O
( NN O O
N=86 NN O O
) NN O O
with NN O O
diagnosed NN O O
VDD NN O O
, NN O O
mean NN O O
age NN O O
32.8±8.9 NN O O
years NN O O
, NN O O
were NN O O
recruited NN O O
into NN O O
the NN O O
study NN O O
. NN O O

Supplementation NN O O
of NN O O
VD3 NN O O
alone NN O O
resulted NN O O
in NN O O
a NN O O
significant NN O O
increase NN O O
in NN O O
serum NN O O
25OHD NN O O
( NN O O
13.4±7.9 NN O O
- NN O O
28.2±7.1 NN O O
ng/mL NN O O
, NN O O
< NN O O
0.001 NN O O
) NN O O
and NN O O
a NN O O
significant NN O O
decrease NN O O
in NN O O
E2 NN O O
levels NN O O
( NN O O
85.7±16.5 NN O O
- NN O O
60.3±20.6 NN O O
pg/mL NN O O
, NN O O
= NN O O
0.001 NN O O
) NN O O
. NN O O

Omega-3FA NN O O
intake NN O O
led NN O O
to NN O O
a NN O O
significant NN O O
decrease NN O O
in NN O O
serum NN O O
25OHD NN O O
levels NN O O
( NN O O
21.2±12.8 NN O O
- NN O O
13.6±9.2 NN O O
ng/mL NN O O
, NN O O
= NN O O
0.001 NN O O
) NN O O
and NN O O
a NN O O
significant NN O O
increase NN O O
in NN O O
E2 NN O O
levels NN O O
( NN O O
56.3±19.2 NN O O
- NN O O
78.4±23.7 NN O O
pg/mL NN O O
, NN O O
= NN O O
0.006 NN O O
) NN O O
. NN O O

Combination NN O O
therapy NN O O
( NN O O
VD3 NN O O
plus NN O O
Omega-3FA NN O O
) NN O O
resulted NN O O
in NN O O
a NN O O
significant NN O O
increase NN O O
in NN O O
both NN O O
25OHD NN O O
( NN O O
12.0±4.7 NN O O
- NN O O
35.1±9.5 NN O O
ng/mL NN O O
, NN O O
< NN O O
0.001 NN O O
) NN O O
and NN O O
E2 NN O O
( NN O O
43.0±23.4 NN O O
- NN O O
57.3±31.5 NN O O
pg/mL NN O O
, NN O O
= NN O O
0.028 NN O O
) NN O O
levels NN O O
. NN O O

Results NN O O
of NN O O
this NN O O
study NN O O
provide NN O O
vital NN O O
insight NN O O
into NN O O
the NN O O
effects NN O O
of NN O O
D3 NN O O
, NN O O
Omega-3FA NN O O
and NN O O
a NN O O
combination NN O O
of NN O O
their NN O O
supplementation NN O O
on NN O O
premenopausal NN O O
Jordanian NN O O
females NN O O
with NN O O
diagnosed NN O O
VDD NN O O
. NN O O

Eight NN O O
weeks NN O O
of NN O O
therapy NN O O
led NN O O
to NN O O
decreased NN O O
E2 NN O O
level NN O O
by NN O O
VD3 NN O O
and NN O O
increased NN O O
level NN O O
by NN O O
Omega-3FA NN O O
supplementation NN O O
. NN O O

With NN O O
regard NN O O
to NN O O
25OHD NN O O
, NN O O
its NN O O
level NN O O
was NN O O
increased NN O O
by NN O O
VD3 NN O O
and NN O O
decreased NN O O
by NN O O
Omega-3FA NN O O
supplementation NN O O
. NN O O

Combination NN O O
of NN O O
VD3 NN O O
plus NN O O
Omega-3FA NN O O
increased NN O O
the NN O O
levels NN O O
of NN O O
both NN O O
E2 NN O O
and NN O O
25OHD NN O O
. NN O O

This NN O O
trial NN O O
was NN O O
registered NN O O
at NN O O
clinicaltrials.gov NN O O
as NN O O
NCT03333564 NN O O
. NN O O



-DOCSTART- (31391076)

Neuralgic NN O O
amyotrophy NN O O
( NN O O
NA NN O O
) NN O O
is NN O O
a NN O O
distinct NN O O
peripheral NN O O
neurological NN O O
disorder NN O O
of NN O O
the NN O O
brachial NN O O
plexus NN O O
with NN O O
a NN O O
yearly NN O O
incidence NN O O
of NN O O
1/1000 NN O O
, NN O O
which NN O O
is NN O O
characterised NN O O
by NN O O
acute NN O O
severe NN O O
upper NN O O
extremity NN O O
pain NN O O
. NN O O

Weakness NN O O
of NN O O
the NN O O
stabilising NN O O
shoulder NN O O
muscles NN O O
in NN O O
the NN O O
acute NN O O
phase NN O O
leads NN O O
to NN O O
compensatory NN O O
strategies NN O O
and NN O O
abnormal NN O O
motor NN O O
control NN O O
of NN O O
the NN O O
shoulder NN O O
- NN O O
scapular NN O O
dyskinesia NN O O
. NN O O

Despite NN O O
peripheral NN O O
nerve NN O O
recovery NN O O
, NN O O
scapular NN O O
dyskinesia NN O O
often NN O O
persists NN O O
, NN O O
leading NN O O
to NN O O
debilitating NN O O
residual NN O O
complaints NN O O
including NN O O
pain NN O O
and NN O O
fatigue NN O O
. NN O O

Evidence NN O O
suggests NN O O
that NN O O
persistent NN O O
scapular NN O O
dyskinesia NN O O
in NN O O
NA NN O O
may NN O O
result NN O O
from NN O O
maladaptive NN O O
cerebral NN O O
neuroplasticity NN O O
, NN O O
altering NN O O
motor NN O O
planning NN O O
. NN O O

Currently NN O O
there NN O O
is NN O O
no NN O O
proven NN O O
effective NN O O
causative NN O O
treatment NN O O
for NN O O
the NN O O
residual NN O O
symptoms NN O O
in NN O O
NA NN O O
. NN O O

Moreover NN O O
, NN O O
the NN O O
role NN O O
of NN O O
cerebral NN O O
mechanisms NN O O
in NN O O
persistent NN O O
scapular NN O O
dyskinesia NN O O
remains NN O O
unclear NN O O
. NN O O

NA-CONTROL NN O O
is NN O O
a NN O O
single-centre NN O O
, NN O O
randomised NN O O
controlled NN O O
trial NN O O
comparing NN O O
specific NN O O
rehabilitation NN O O
to NN O O
usual NN O O
care NN O O
in NN O O
NA NN O O
. NN O O

The NN O O
rehabilitation NN O O
programme NN O O
combines NN O O
relearning NN O O
of NN O O
motor NN O O
control NN O O
, NN O O
targeting NN O O
cerebral NN O O
mechanisms NN O O
, NN O O
with NN O O
self-management NN O O
strategies NN O O
. NN O O

Fifty NN O O
patients NN O O
will NN O O
be NN O O
included NN O O
. NN O O

Patients NN O O
are NN O O
recruited NN O O
through NN O O
the NN O O
Radboud NN O O
university NN O O
medical NN O O
center NN O O
Nijmegen NN O O
, NN O O
the NN O O
Netherlands NN O O
. NN O O

Patients NN O O
with NN O O
a NN O O
( NN O O
suspected NN O O
) NN O O
diagnosis NN O O
of NN O O
NA NN O O
, NN O O
with NN O O
lateralized NN O O
symptoms NN O O
and NN O O
scapular NN O O
dyskinesia NN O O
in NN O O
the NN O O
right NN O O
upper NN O O
extremity NN O O
, NN O O
who NN O O
are NN O O
18 NN O O
years NN O O
or NN O O
older NN O O
and NN O O
not NN O O
in NN O O
the NN O O
acute NN O O
phase NN O O
can NN O O
be NN O O
included NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
is NN O O
the NN O O
Shoulder NN O O
Rating NN O O
Questionnaire NN O O
score NN O O
, NN O O
which NN O O
measures NN O O
functional NN O O
capability NN O O
of NN O O
the NN O O
upper NN O O
extremity NN O O
. NN O O

Secondary NN O O
clinical NN O O
outcomes NN O O
include NN O O
measures NN O O
of NN O O
pain NN O O
, NN O O
fatigue NN O O
, NN O O
participation NN O O
, NN O O
reachable NN O O
workspace NN O O
, NN O O
muscle NN O O
strength NN O O
and NN O O
quality NN O O
of NN O O
life NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
motor NN O O
planning NN O O
is NN O O
assessed NN O O
with NN O O
first-person NN O O
motor NN O O
imagery NN O O
and NN O O
functional NN O O
magnetic NN O O
resonance NN O O
imaging NN O O
. NN O O

In NN O O
a NN O O
sub-study NN O O
the NN O O
patients NN O O
are NN O O
compared NN O O
to NN O O
25 NN O O
healthy NN O O
participants NN O O
, NN O O
to NN O O
determine NN O O
the NN O O
involvement NN O O
of NN O O
cerebral NN O O
mechanisms NN O O
. NN O O

This NN O O
will NN O O
enable NN O O
interpretation NN O O
of NN O O
cerebral NN O O
changes NN O O
associated NN O O
with NN O O
the NN O O
rehabilitation NN O O
programme NN O O
and NN O O
functional NN O O
impairments NN O O
in NN O O
NA NN O O
. NN O O

NA-CONTROL NN O O
is NN O O
the NN O O
first NN O O
randomised NN O O
trial NN O O
to NN O O
investigate NN O O
the NN O O
effect NN O O
of NN O O
specific NN O O
rehabilitation NN O O
on NN O O
residual NN O O
complaints NN O O
in NN O O
NA NN O O
. NN O O

It NN O O
also NN O O
is NN O O
the NN O O
first NN O O
study NN O O
into NN O O
the NN O O
cerebral NN O O
mechanisms NN O O
that NN O O
might NN O O
underlie NN O O
persistent NN O O
scapular NN O O
dyskinesia NN O O
in NN O O
NA NN O O
. NN O O

It NN O O
thus NN O O
may NN O O
aid NN O O
the NN O O
further NN O O
development NN O O
of NN O O
mechanism-based NN O O
interventions NN O O
for NN O O
disturbed NN O O
motor NN O O
control NN O O
in NN O O
NA NN O O
and NN O O
in NN O O
other NN O O
peripheral NN O O
neurological NN O O
disorders NN O O
. NN O O

ClinicalTrials.gov NN O O
, NN O O
NCT03441347 NN O O
. NN O O

Registered NN O O
on NN O O
20 NN O O
February NN O O
2018 NN O O
. NN O O



-DOCSTART- (31060544)

At NN O O
present NN O O
, NN O O
palliative NN O O
systemic NN O O
chemotherapy NN O O
is NN O O
the NN O O
standard NN O O
treatment NN O O
in NN O O
the NN O O
Netherlands NN O O
for NN O O
gastric NN O O
cancer NN O O
patients NN O O
with NN O O
peritoneal NN O O
dissemination NN O O
. NN O O

In NN O O
contrast NN O O
to NN O O
lymphatic NN O O
and NN O O
haematogenous NN O O
dissemination NN O O
, NN O O
peritoneal NN O O
dissemination NN O O
may NN O O
be NN O O
regarded NN O O
as NN O O
locoregional NN O O
spread NN O O
of NN O O
disease NN O O
. NN O O

Administering NN O O
cytotoxic NN O O
drugs NN O O
directly NN O O
into NN O O
the NN O O
peritoneal NN O O
cavity NN O O
has NN O O
an NN O O
advantage NN O O
over NN O O
systemic NN O O
chemotherapy NN O O
since NN O O
high NN O O
concentrations NN O O
can NN O O
be NN O O
delivered NN O O
directly NN O O
into NN O O
the NN O O
peritoneal NN O O
cavity NN O O
with NN O O
limited NN O O
systemic NN O O
toxicity NN O O
. NN O O

The NN O O
combination NN O O
of NN O O
a NN O O
radical NN O O
gastrectomy NN O O
with NN O O
cytoreductive NN O O
surgery NN O O
( NN O O
CRS NN O O
) NN O O
and NN O O
hyperthermic NN O O
intraperitoneal NN O O
chemotherapy NN O O
( NN O O
HIPEC NN O O
) NN O O
has NN O O
shown NN O O
promising NN O O
results NN O O
in NN O O
patients NN O O
with NN O O
gastric NN O O
cancer NN O O
in NN O O
Asia NN O O
. NN O O

However NN O O
, NN O O
the NN O O
results NN O O
obtained NN O O
in NN O O
Asian NN O O
patients NN O O
can NN O O
not NN O O
be NN O O
extrapolated NN O O
to NN O O
Western NN O O
patients NN O O
. NN O O

The NN O O
aim NN O O
of NN O O
this NN O O
study NN O O
is NN O O
to NN O O
compare NN O O
the NN O O
overall NN O O
survival NN O O
between NN O O
patients NN O O
with NN O O
gastric NN O O
cancer NN O O
with NN O O
limited NN O O
peritoneal NN O O
dissemination NN O O
and/or NN O O
tumour NN O O
positive NN O O
peritoneal NN O O
cytology NN O O
treated NN O O
with NN O O
palliative NN O O
systemic NN O O
chemotherapy NN O O
, NN O O
and NN O O
those NN O O
treated NN O O
with NN O O
gastrectomy NN O O
, NN O O
CRS NN O O
and NN O O
HIPEC NN O O
after NN O O
neoadjuvant NN O O
systemic NN O O
chemotherapy NN O O
. NN O O

In NN O O
this NN O O
multicentre NN O O
randomised NN O O
controlled NN O O
two-armed NN O O
phase NN O O
III NN O O
trial NN O O
, NN O O
106 NN O O
patients NN O O
will NN O O
be NN O O
randomised NN O O
( NN O O
1:1 NN O O
) NN O O
between NN O O
palliative NN O O
systemic NN O O
chemotherapy NN O O
only NN O O
( NN O O
standard NN O O
treatment NN O O
) NN O O
and NN O O
gastrectomy NN O O
, NN O O
CRS NN O O
and NN O O
HIPEC NN O O
( NN O O
experimental NN O O
treatment NN O O
) NN O O
after NN O O
3 NN O O
- NN O O
4 NN O O
cycles NN O O
of NN O O
systemic NN O O
chemotherapy NN O O
. NN O O

Patients NN O O
with NN O O
gastric NN O O
cancer NN O O
are NN O O
eligible NN O O
for NN O O
inclusion NN O O
if NN O O
( NN O O
1 NN O O
) NN O O
the NN O O
primary NN O O
cT3-cT4 NN O O
gastric NN O O
tumour NN O O
including NN O O
regional NN O O
lymph NN O O
nodes NN O O
is NN O O
considered NN O O
to NN O O
be NN O O
resectable NN O O
, NN O O
( NN O O
2 NN O O
) NN O O
limited NN O O
peritoneal NN O O
dissemination NN O O
( NN O O
Peritoneal NN O O
Cancer NN O O
Index NN O O
< NN O O
7 NN O O
) NN O O
and/or NN O O
tumour NN O O
positive NN O O
peritoneal NN O O
cytology NN O O
are NN O O
confirmed NN O O
by NN O O
laparoscopy NN O O
or NN O O
laparotomy NN O O
, NN O O
and NN O O
( NN O O
3 NN O O
) NN O O
systemic NN O O
chemotherapy NN O O
was NN O O
given NN O O
( NN O O
prior NN O O
to NN O O
inclusion NN O O
) NN O O
without NN O O
disease NN O O
progression NN O O
. NN O O

The NN O O
PERISCOPE NN O O
II NN O O
study NN O O
will NN O O
determine NN O O
whether NN O O
gastric NN O O
cancer NN O O
patients NN O O
with NN O O
limited NN O O
peritoneal NN O O
dissemination NN O O
and/or NN O O
tumour NN O O
positive NN O O
peritoneal NN O O
cytology NN O O
treated NN O O
with NN O O
systemic NN O O
chemotherapy NN O O
, NN O O
gastrectomy NN O O
, NN O O
CRS NN O O
and NN O O
HIPEC NN O O
have NN O O
a NN O O
survival NN O O
benefit NN O O
over NN O O
patients NN O O
treated NN O O
with NN O O
palliative NN O O
systemic NN O O
chemotherapy NN O O
only NN O O
. NN O O

clinicaltrials.gov NN O O
NCT03348150 NN O O
; NN O O
registration NN O O
date NN O O
November NN O O
2017 NN O O
; NN O O
first NN O O
enrolment NN O O
November NN O O
2017 NN O O
; NN O O
expected NN O O
end NN O O
date NN O O
December NN O O
2022 NN O O
; NN O O
trial NN O O
status NN O O
: NN O O
Ongoing NN O O
. NN O O



-DOCSTART- (30621787)

School NN O O
absenteeism NN O O
( NN O O
SA NN O O
) NN O O
is NN O O
associated NN O O
with NN O O
anxiety NN O O
, NN O O
depression NN O O
, NN O O
and NN O O
disruptive NN O O
behavior NN O O
. NN O O

It NN O O
is NN O O
a NN O O
risk NN O O
factor NN O O
for NN O O
academic NN O O
difficulties NN O O
and NN O O
school NN O O
dropout NN O O
, NN O O
which NN O O
predict NN O O
problems NN O O
in NN O O
adulthood NN O O
such NN O O
as NN O O
social NN O O
, NN O O
work-related NN O O
, NN O O
and NN O O
health NN O O
problems NN O O
. NN O O

The NN O O
main NN O O
goal NN O O
of NN O O
this NN O O
study NN O O
is NN O O
to NN O O
examine NN O O
the NN O O
initial NN O O
effectiveness NN O O
of NN O O
a NN O O
modular NN O O
transdiagnostic NN O O
cognitive NN O O
behavioral NN O O
therapy NN O O
( NN O O
CBT NN O O
) NN O O
intervention NN O O
( NN O O
Back2School NN O O
) NN O O
for NN O O
increasing NN O O
school NN O O
attendance NN O O
and NN O O
decreasing NN O O
psychological NN O O
problems NN O O
, NN O O
relative NN O O
to NN O O
a NN O O
comparator NN O O
control NN O O
arm NN O O
( NN O O
treatment NN O O
as NN O O
usual NN O O
[ NN O O
TAU NN O O
] NN O O
) NN O O
. NN O O

One NN O O
hundred NN O O
sixty NN O O
children NN O O
, NN O O
aged NN O O
7 NN O O
to NN O O
16 NN O O
years NN O O
, NN O O
will NN O O
be NN O O
randomly NN O O
assigned NN O O
to NN O O
either NN O O
Back2School NN O O
or NN O O
TAU NN O O
. NN O O

The NN O O
design NN O O
is NN O O
a NN O O
two NN O O
( NN O O
Back2School NN O O
and NN O O
TAU NN O O
) NN O O
by NN O O
four NN O O
( NN O O
preassessment NN O O
[ NN O O
T1 NN O O
] NN O O
, NN O O
postassessment NN O O
[ NN O O
T2 NN O O
] NN O O
, NN O O
and NN O O
3-month NN O O
[ NN O O
T3 NN O O
] NN O O
and NN O O
1-year NN O O
[ NN O O
T4 NN O O
] NN O O
assessments NN O O
) NN O O
mixed NN O O
between-within NN O O
design NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
is NN O O
school NN O O
attendance NN O O
based NN O O
on NN O O
daily NN O O
registration NN O O
. NN O O

Secondary NN O O
outcomes NN O O
pertain NN O O
to NN O O
youth NN O O
psychosocial NN O O
functioning NN O O
, NN O O
quality NN O O
of NN O O
life NN O O
, NN O O
bullying NN O O
, NN O O
self-efficacy NN O O
, NN O O
and NN O O
teacher-parent NN O O
collaboration NN O O
. NN O O

These NN O O
secondary NN O O
outcomes NN O O
are NN O O
measured NN O O
via NN O O
youth NN O O
, NN O O
parent NN O O
, NN O O
and NN O O
teacher NN O O
reports NN O O
. NN O O

This NN O O
study NN O O
will NN O O
provide NN O O
critically NN O O
needed NN O O
empirical NN O O
evidence NN O O
on NN O O
the NN O O
initial NN O O
effectiveness NN O O
of NN O O
a NN O O
manualized NN O O
treatment NN O O
program NN O O
for NN O O
youth NN O O
with NN O O
SA NN O O
. NN O O

If NN O O
the NN O O
intervention NN O O
is NN O O
found NN O O
to NN O O
be NN O O
effective NN O O
, NN O O
the NN O O
program NN O O
can NN O O
be NN O O
further NN O O
implemented NN O O
and NN O O
tested NN O O
in NN O O
a NN O O
larger NN O O
school NN O O
health NN O O
effectiveness NN O O
trial NN O O
. NN O O

ClinicalTrials.gov NN O O
, NN O O
NCT03459677 NN O O
. NN O O

Retrospectively NN O O
registered NN O O
on NN O O
9 NN O O
March NN O O
2018 NN O O
. NN O O



-DOCSTART- (30867034)

Neratinib NN O O
is NN O O
an NN O O
irreversible NN O O
pan-HER NN O O
tyrosine NN O O
kinase NN O O
inhibitor NN O O
that NN O O
inhibits NN O O
PI3K/Akt NN O O
and NN O O
MAPK NN O O
signaling NN O O
pathways NN O O
after NN O O
HER2 NN O O
receptor NN O O
activation NN O O
. NN O O

The NN O O
ExteNET NN O O
study NN O O
showed NN O O
that NN O O
neratinib NN O O
significantly NN O O
improved NN O O
5-year NN O O
invasive NN O O
disease-free NN O O
survival NN O O
( NN O O
iDFS NN O O
) NN O O
in NN O O
women NN O O
who NN O O
completed NN O O
trastuzumab-based NN O O
adjuvant NN O O
therapy NN O O
for NN O O
early NN O O
breast NN O O
cancer NN O O
( NN O O
EBC NN O O
) NN O O
. NN O O

We NN O O
assessed NN O O
the NN O O
prognostic NN O O
and NN O O
predictive NN O O
significance NN O O
of NN O O
PIK3CA NN O O
alterations NN O O
in NN O O
patients NN O O
in NN O O
ExteNET NN O O
. NN O O

Participants NN O O
were NN O O
women NN O O
aged NN O O
≥ NN O O
18 NN O O
years NN O O
( NN O O
≥ NN O O
20 NN O O
years NN O O
in NN O O
Japan NN O O
) NN O O
with NN O O
stage NN O O
1 NN O O
- NN O O
3c NN O O
( NN O O
modified NN O O
to NN O O
stage NN O O
2 NN O O
- NN O O
3c NN O O
in NN O O
February NN O O
2010 NN O O
) NN O O
operable NN O O
breast NN O O
cancer NN O O
, NN O O
who NN O O
had NN O O
completed NN O O
(neo)adjuvant NN O O
chemotherapy NN O O
plus NN O O
trastuzumab NN O O
≤ NN O O
2 NN O O
years NN O O
before NN O O
randomization NN O O
, NN O O
with NN O O
no NN O O
evidence NN O O
of NN O O
disease NN O O
recurrence NN O O
or NN O O
metastatic NN O O
disease NN O O
at NN O O
study NN O O
entry NN O O
. NN O O

Patients NN O O
were NN O O
randomized NN O O
to NN O O
oral NN O O
neratinib NN O O
240 NN O O
mg/day NN O O
or NN O O
placebo NN O O
for NN O O
1 NN O O
year NN O O
. NN O O

Formalin-fixed NN O O
, NN O O
paraffin-embedded NN O O
primary NN O O
tumor NN O O
specimens NN O O
underwent NN O O
polymerase NN O O
chain NN O O
reaction NN O O
( NN O O
PCR NN O O
) NN O O
PIK3CA NN O O
testing NN O O
for NN O O
two NN O O
hotspot NN O O
mutations NN O O
in NN O O
exon NN O O
9 NN O O
, NN O O
one NN O O
hot-spot NN O O
mutation NN O O
in NN O O
exon NN O O
20 NN O O
, NN O O
and NN O O
fluorescence NN O O
in NN O O
situ NN O O
hybridization NN O O
( NN O O
FISH NN O O
) NN O O
analysis NN O O
for NN O O
PIK3CA NN O O
amplification NN O O
. NN O O

The NN O O
primary NN O O
endpoint NN O O
( NN O O
iDFS NN O O
) NN O O
was NN O O
tested NN O O
with NN O O
log-rank NN O O
test NN O O
and NN O O
hazard NN O O
ratios NN O O
( NN O O
HRs NN O O
) NN O O
estimated NN O O
using NN O O
Cox NN O O
proportional-hazards NN O O
models NN O O
. NN O O

Among NN O O
the NN O O
intent-to-treat NN O O
population NN O O
( NN O O
n NN O O
= NN O O
2840 NN O O
) NN O O
, NN O O
tumor NN O O
specimens NN O O
were NN O O
available NN O O
for NN O O
PCR NN O O
testing NN O O
( NN O O
991 NN O O
patients NN O O
) NN O O
and NN O O
PIK3CA NN O O
FISH NN O O
( NN O O
702 NN O O
patients NN O O
) NN O O
. NN O O

Overall NN O O
, NN O O
262 NN O O
samples NN O O
were NN O O
PIK3CA NN O O
altered NN O O
: NN O O
201 NN O O
were NN O O
mutated NN O O
( NN O O
77 NN O O
% NN O O
) NN O O
, NN O O
52 NN O O
( NN O O
20 NN O O
% NN O O
) NN O O
were NN O O
amplified NN O O
, NN O O
and NN O O
9 NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
were NN O O
mutated NN O O
and NN O O
amplified NN O O
. NN O O

iDFS NN O O
was NN O O
non-significantly NN O O
worse NN O O
in NN O O
placebo-treated NN O O
patients NN O O
with NN O O
altered NN O O
vs NN O O
wild-type NN O O
PIK3CA NN O O
( NN O O
HR NN O O
1.34 NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
0.72 NN O O
- NN O O
2.50 NN O O
; NN O O
P NN O O
= NN O O
0.357 NN O O
) NN O O
. NN O O

Neratinib NN O O
's NN O O
effect NN O O
over NN O O
placebo NN O O
was NN O O
significant NN O O
in NN O O
patients NN O O
with NN O O
PIK3CA-altered NN O O
tumors NN O O
( NN O O
HR NN O O
0.41 NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
0.17 NN O O
- NN O O
0.90 NN O O
, NN O O
P NN O O
= NN O O
0.028 NN O O
) NN O O
but NN O O
not NN O O
PIK3CA NN O O
wild-type NN O O
tumors NN O O
( NN O O
HR NN O O
0.72 NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
0.36 NN O O
- NN O O
1.41 NN O O
; NN O O
P NN O O
= NN O O
0.34 NN O O
) NN O O
. NN O O

The NN O O
interaction NN O O
test NN O O
was NN O O
non-significant NN O O
( NN O O
P NN O O
= NN O O
0.309 NN O O
) NN O O
. NN O O

Although NN O O
there NN O O
was NN O O
a NN O O
greater NN O O
absolute NN O O
risk NN O O
reduction NN O O
associated NN O O
with NN O O
neratinib NN O O
treatment NN O O
of NN O O
patients NN O O
with NN O O
PIK3CA-altered NN O O
tumors NN O O
in NN O O
ExteNET NN O O
, NN O O
current NN O O
data NN O O
do NN O O
not NN O O
support NN O O
PIK3CA NN O O
alteration NN O O
as NN O O
a NN O O
predictive NN O O
biomarker NN O O
of NN O O
response NN O O
to NN O O
neratinib NN O O
in NN O O
HER2-positive NN O O
EBC NN O O
. NN O O

ClinicalTrials.gov NN O O
, NN O O
NCT00878709 NN O O
. NN O O

Trial NN O O
registered NN O O
April NN O O
9 NN O O
, NN O O
2009 NN O O
. NN O O



-DOCSTART- (31162568)

Heart NN O O
failure NN O O
with NN O O
preserved NN O O
ejection NN O O
fraction NN O O
( NN O O
HFpEF NN O O
) NN O O
lacks NN O O
effective NN O O
treatments NN O O
. NN O O

Based NN O O
on NN O O
preclinical NN O O
studies NN O O
, NN O O
neladenoson NN O O
bialanate NN O O
, NN O O
a NN O O
first-in-class NN O O
partial NN O O
adenosine NN O O
A1 NN O O
receptor NN O O
agonist NN O O
, NN O O
has NN O O
the NN O O
potential NN O O
to NN O O
improve NN O O
several NN O O
heart NN O O
failure-related NN O O
cardiac NN O O
and NN O O
noncardiac NN O O
abnormalities NN O O
but NN O O
has NN O O
not NN O O
been NN O O
evaluated NN O O
to NN O O
treat NN O O
HFpEF NN O O
. NN O O

To NN O O
determine NN O O
whether NN O O
neladenoson NN O O
improves NN O O
exercise NN O O
capacity NN O O
, NN O O
physical NN O O
activity NN O O
, NN O O
cardiac NN O O
biomarkers NN O O
, NN O O
and NN O O
quality NN O O
of NN O O
life NN O O
in NN O O
patients NN O O
with NN O O
HFpEF NN O O
and NN O O
to NN O O
find NN O O
the NN O O
optimal NN O O
dose NN O O
. NN O O

Phase NN O O
2b NN O O
randomized NN O O
clinical NN O O
trial NN O O
conducted NN O O
at NN O O
76 NN O O
centers NN O O
in NN O O
the NN O O
United NN O O
States NN O O
, NN O O
Europe NN O O
, NN O O
and NN O O
Japan NN O O
. NN O O

Patients NN O O
( NN O O
N NN O O
= NN O O
305 NN O O
) NN O O
with NN O O
New NN O O
York NN O O
Heart NN O O
Association NN O O
class NN O O
II NN O O
or NN O O
III NN O O
HFpEF NN O O
with NN O O
elevated NN O O
natriuretic NN O O
peptide NN O O
levels NN O O
were NN O O
enrolled NN O O
between NN O O
May NN O O
10 NN O O
, NN O O
2017 NN O O
, NN O O
and NN O O
December NN O O
7 NN O O
, NN O O
2017 NN O O
( NN O O
date NN O O
of NN O O
final NN O O
follow-up NN O O
: NN O O
June NN O O
20 NN O O
, NN O O
2018 NN O O
) NN O O
. NN O O

Participants NN O O
were NN O O
randomized NN O O
( NN O O
1:2:2:2:2:3 NN O O
) NN O O
to NN O O
neladenoson NN O O
( NN O O
n NN O O
= NN O O
27 NN O O
[ NN O O
5 NN O O
mg NN O O
] NN O O
, NN O O
n NN O O
= NN O O
50 NN O O
[ NN O O
10 NN O O
mg NN O O
] NN O O
, NN O O
n NN O O
= NN O O
51 NN O O
[ NN O O
20 NN O O
mg NN O O
] NN O O
, NN O O
n NN O O
= NN O O
50 NN O O
[ NN O O
30 NN O O
mg NN O O
] NN O O
, NN O O
and NN O O
n NN O O
= NN O O
51 NN O O
[ NN O O
40 NN O O
mg NN O O
] NN O O
) NN O O
or NN O O
matching NN O O
placebo NN O O
( NN O O
n NN O O
= NN O O
76 NN O O
) NN O O
for NN O O
20 NN O O
weeks NN O O
of NN O O
treatment NN O O
. NN O O

The NN O O
primary NN O O
end NN O O
point NN O O
was NN O O
change NN O O
in NN O O
6-minute NN O O
walk NN O O
test NN O O
distance NN O O
from NN O O
baseline NN O O
to NN O O
20 NN O O
weeks NN O O
( NN O O
minimal NN O O
clinically NN O O
important NN O O
difference NN O O
, NN O O
40 NN O O
m NN O O
) NN O O
. NN O O

Key NN O O
safety NN O O
measures NN O O
included NN O O
bradyarrhythmias NN O O
and NN O O
adverse NN O O
events NN O O
. NN O O

To NN O O
evaluate NN O O
the NN O O
effects NN O O
of NN O O
varying NN O O
doses NN O O
of NN O O
neladenoson NN O O
, NN O O
a NN O O
multiple NN O O
comparison NN O O
procedure NN O O
with NN O O
5 NN O O
modeling NN O O
techniques NN O O
( NN O O
linear NN O O
, NN O O
Emax NN O O
, NN O O
2 NN O O
variations NN O O
of NN O O
sigmoidal NN O O
Emax NN O O
, NN O O
and NN O O
quadratic NN O O
) NN O O
was NN O O
used NN O O
to NN O O
evaluate NN O O
diverse NN O O
dose-response NN O O
profiles NN O O
. NN O O

Among NN O O
305 NN O O
patients NN O O
who NN O O
were NN O O
randomized NN O O
( NN O O
mean NN O O
age NN O O
, NN O O
74 NN O O
years NN O O
; NN O O
160 NN O O
[ NN O O
53 NN O O
% NN O O
] NN O O
women NN O O
; NN O O
mean NN O O
6-minute NN O O
walk NN O O
test NN O O
distance NN O O
, NN O O
321.5 NN O O
m NN O O
) NN O O
, NN O O
261 NN O O
( NN O O
86 NN O O
% NN O O
) NN O O
completed NN O O
the NN O O
trial NN O O
and NN O O
were NN O O
included NN O O
in NN O O
the NN O O
primary NN O O
analysis NN O O
. NN O O

After NN O O
20 NN O O
weeks NN O O
of NN O O
treatment NN O O
, NN O O
the NN O O
mean NN O O
absolute NN O O
changes NN O O
from NN O O
baseline NN O O
in NN O O
6-minute NN O O
walk NN O O
test NN O O
distance NN O O
were NN O O
0.2 NN O O
m NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
-12.1 NN O O
to NN O O
12.4 NN O O
m NN O O
) NN O O
for NN O O
the NN O O
placebo NN O O
group NN O O
; NN O O
19.4 NN O O
m NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
-10.8 NN O O
to NN O O
49.7 NN O O
m NN O O
) NN O O
for NN O O
the NN O O
5 NN O O
mg NN O O
of NN O O
neladenoson NN O O
group NN O O
; NN O O
29.4 NN O O
m NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
3.0 NN O O
to NN O O
55.8 NN O O
m NN O O
) NN O O
for NN O O
10 NN O O
mg NN O O
of NN O O
neladenoson NN O O
group NN O O
; NN O O
13.8 NN O O
m NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
-2.3 NN O O
to NN O O
29.8 NN O O
m NN O O
) NN O O
for NN O O
20 NN O O
mg NN O O
of NN O O
neladenoson NN O O
group NN O O
; NN O O
16.3 NN O O
m NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
-1.1 NN O O
to NN O O
33.6 NN O O
m NN O O
) NN O O
for NN O O
30 NN O O
mg NN O O
of NN O O
neladenoson NN O O
group NN O O
; NN O O
and NN O O
13.0 NN O O
m NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
-5.9 NN O O
to NN O O
31.9 NN O O
m NN O O
) NN O O
for NN O O
40 NN O O
mg NN O O
of NN O O
neladenoson NN O O
group NN O O
. NN O O

Because NN O O
none NN O O
of NN O O
the NN O O
neladenoson NN O O
groups NN O O
achieved NN O O
the NN O O
clinically NN O O
relevant NN O O
40-m NN O O
increase NN O O
in NN O O
6-minute NN O O
walk NN O O
test NN O O
distance NN O O
from NN O O
baseline NN O O
, NN O O
an NN O O
optimal NN O O
dose NN O O
of NN O O
neladenoson NN O O
was NN O O
not NN O O
identified NN O O
. NN O O

There NN O O
was NN O O
no NN O O
significant NN O O
dose-response NN O O
relationship NN O O
for NN O O
the NN O O
change NN O O
in NN O O
6-minute NN O O
walk NN O O
test NN O O
distance NN O O
among NN O O
the NN O O
5 NN O O
different NN O O
dose-response NN O O
models NN O O
( NN O O
P NN O O
= NN O O
.05 NN O O
for NN O O
Emax NN O O
; NN O O
P NN O O
= NN O O
.18 NN O O
for NN O O
quadratic NN O O
; NN O O
P NN O O
= NN O O
.21 NN O O
for NN O O
sigmoidal NN O O
Emax NN O O
1 NN O O
; NN O O
P NN O O
= NN O O
.39 NN O O
for NN O O
linear NN O O
; NN O O
and NN O O
P NN O O
= NN O O
.52 NN O O
for NN O O
sigmoidal NN O O
Emax NN O O
2 NN O O
) NN O O
. NN O O

Serious NN O O
adverse NN O O
events NN O O
were NN O O
similar NN O O
among NN O O
the NN O O
neladenoson NN O O
groups NN O O
( NN O O
61/229 NN O O
[ NN O O
26.6 NN O O
% NN O O
] NN O O
) NN O O
and NN O O
the NN O O
placebo NN O O
group NN O O
( NN O O
21/76 NN O O
[ NN O O
27.6 NN O O
% NN O O
] NN O O
) NN O O
. NN O O

Among NN O O
patients NN O O
with NN O O
HFpEF NN O O
, NN O O
there NN O O
was NN O O
no NN O O
significant NN O O
dose-response NN O O
relationship NN O O
detected NN O O
for NN O O
neladenoson NN O O
with NN O O
regard NN O O
to NN O O
the NN O O
change NN O O
in NN O O
exercise NN O O
capacity NN O O
from NN O O
baseline NN O O
to NN O O
20 NN O O
weeks NN O O
. NN O O

In NN O O
light NN O O
of NN O O
these NN O O
findings NN O O
, NN O O
novel NN O O
approaches NN O O
will NN O O
be NN O O
needed NN O O
if NN O O
further NN O O
development NN O O
of NN O O
neladenoson NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
patients NN O O
with NN O O
HFpEF NN O O
is NN O O
pursued NN O O
. NN O O

ClinicalTrials.gov NN O O
Identifier NN O O
: NN O O
NCT03098979 NN O O
. NN O O



-DOCSTART- (30664496)

Colorectal NN O O
cancer NN O O
is NN O O
one NN O O
of NN O O
the NN O O
most NN O O
common NN O O
cancers NN O O
and NN O O
causes NN O O
of NN O O
cancer-related NN O O
death NN O O
. NN O O

Up NN O O
to NN O O
approximately NN O O
70 NN O O
% NN O O
of NN O O
patients NN O O
with NN O O
metastatic NN O O
colorectal NN O O
cancer NN O O
( NN O O
mCRC NN O O
) NN O O
have NN O O
metastases NN O O
to NN O O
the NN O O
liver NN O O
at NN O O
initial NN O O
diagnosis NN O O
. NN O O

Second-line NN O O
systemic NN O O
treatment NN O O
in NN O O
mCRC NN O O
can NN O O
prolong NN O O
survival NN O O
after NN O O
development NN O O
of NN O O
disease NN O O
progression NN O O
during NN O O
or NN O O
after NN O O
first-line NN O O
treatment NN O O
and NN O O
in NN O O
those NN O O
who NN O O
are NN O O
intolerant NN O O
to NN O O
first-line NN O O
treatment NN O O
. NN O O

The NN O O
objective NN O O
of NN O O
this NN O O
study NN O O
is NN O O
to NN O O
evaluate NN O O
the NN O O
efficacy NN O O
and NN O O
safety NN O O
of NN O O
transarterial NN O O
radioembolization NN O O
( NN O O
TARE NN O O
) NN O O
with NN O O
TheraSphere NN O O
yttrium-90 NN O O
( NN O O
Y NN O O
) NN O O
glass NN O O
microspheres NN O O
combined NN O O
with NN O O
second-line NN O O
therapy NN O O
in NN O O
patients NN O O
with NN O O
mCRC NN O O
of NN O O
the NN O O
liver NN O O
who NN O O
had NN O O
disease NN O O
progression NN O O
during NN O O
or NN O O
after NN O O
first-line NN O O
chemotherapy NN O O
. NN O O

EPOCH NN O O
is NN O O
an NN O O
open-label NN O O
, NN O O
prospective NN O O
, NN O O
multicenter NN O O
, NN O O
randomized NN O O
, NN O O
phase NN O O
3 NN O O
trial NN O O
being NN O O
conducted NN O O
at NN O O
up NN O O
to NN O O
100 NN O O
sites NN O O
in NN O O
the NN O O
United NN O O
States NN O O
, NN O O
Canada NN O O
, NN O O
Europe NN O O
, NN O O
and NN O O
Asia NN O O
. NN O O

Eligible NN O O
patients NN O O
have NN O O
mCRC NN O O
of NN O O
the NN O O
liver NN O O
and NN O O
disease NN O O
progression NN O O
after NN O O
first-line NN O O
chemotherapy NN O O
with NN O O
either NN O O
an NN O O
oxaliplatin-based NN O O
or NN O O
irinotecan-based NN O O
regimen NN O O
and NN O O
are NN O O
eligible NN O O
for NN O O
second-line NN O O
chemotherapy NN O O
with NN O O
the NN O O
alternate NN O O
regimen NN O O
. NN O O

Patients NN O O
were NN O O
randomized NN O O
1:1 NN O O
to NN O O
the NN O O
TARE NN O O
group NN O O
( NN O O
chemotherapy NN O O
with NN O O
TARE NN O O
in NN O O
place NN O O
of NN O O
the NN O O
second NN O O
chemotherapy NN O O
infusion NN O O
and NN O O
subsequent NN O O
resumption NN O O
of NN O O
chemotherapy NN O O
) NN O O
or NN O O
the NN O O
control NN O O
group NN O O
( NN O O
chemotherapy NN O O
alone NN O O
) NN O O
. NN O O

The NN O O
addition NN O O
of NN O O
targeted NN O O
agents NN O O
is NN O O
permitted NN O O
. NN O O

The NN O O
primary NN O O
end NN O O
points NN O O
are NN O O
progression-free NN O O
survival NN O O
and NN O O
hepatic NN O O
progression-free NN O O
survival NN O O
. NN O O

The NN O O
study NN O O
objective NN O O
will NN O O
be NN O O
considered NN O O
achieved NN O O
if NN O O
at NN O O
least NN O O
one NN O O
primary NN O O
end NN O O
point NN O O
is NN O O
statistically NN O O
significant NN O O
. NN O O

Secondary NN O O
end NN O O
points NN O O
are NN O O
overall NN O O
survival NN O O
, NN O O
time NN O O
to NN O O
symptomatic NN O O
progression NN O O
defined NN O O
as NN O O
Eastern NN O O
Cooperative NN O O
Oncology NN O O
Group NN O O
Performance NN O O
Status NN O O
score NN O O
of NN O O
2 NN O O
or NN O O
higher NN O O
, NN O O
objective NN O O
response NN O O
rate NN O O
, NN O O
disease NN O O
control NN O O
rate NN O O
, NN O O
quality-of-life NN O O
assessment NN O O
by NN O O
the NN O O
Functional NN O O
Assessment NN O O
of NN O O
Cancer NN O O
Therapy-Colorectal NN O O
Cancer NN O O
questionnaire NN O O
, NN O O
and NN O O
adverse NN O O
events NN O O
. NN O O

The NN O O
study NN O O
is NN O O
an NN O O
adaptive NN O O
trial NN O O
, NN O O
comprising NN O O
a NN O O
group NN O O
sequential NN O O
design NN O O
with NN O O
2 NN O O
interim NN O O
analyses NN O O
with NN O O
a NN O O
planned NN O O
maximum NN O O
of NN O O
420 NN O O
patients NN O O
. NN O O

The NN O O
study NN O O
is NN O O
designed NN O O
to NN O O
detect NN O O
a NN O O
2.5-month NN O O
increase NN O O
in NN O O
median NN O O
progression-free NN O O
survival NN O O
, NN O O
from NN O O
6 NN O O
months NN O O
in NN O O
the NN O O
control NN O O
group NN O O
to NN O O
8.5 NN O O
months NN O O
in NN O O
the NN O O
TARE NN O O
group NN O O
( NN O O
hazard NN O O
ratio NN O O
[ NN O O
HR NN O O
] NN O O
0.71 NN O O
) NN O O
, NN O O
and NN O O
a NN O O
3.5-month NN O O
increase NN O O
in NN O O
median NN O O
hepatic NN O O
progression-free NN O O
survival NN O O
time NN O O
, NN O O
from NN O O
6.5 NN O O
months NN O O
in NN O O
the NN O O
control NN O O
group NN O O
to NN O O
10 NN O O
months NN O O
in NN O O
the NN O O
TARE NN O O
group NN O O
( NN O O
HR NN O O
0.65 NN O O
) NN O O
. NN O O

On NN O O
the NN O O
basis NN O O
of NN O O
simulations NN O O
, NN O O
the NN O O
power NN O O
to NN O O
detect NN O O
the NN O O
target NN O O
difference NN O O
in NN O O
either NN O O
progression-free NN O O
survival NN O O
or NN O O
hepatic NN O O
progression-free NN O O
survival NN O O
is NN O O
> NN O O
90 NN O O
% NN O O
, NN O O
and NN O O
the NN O O
power NN O O
to NN O O
detect NN O O
the NN O O
target NN O O
difference NN O O
in NN O O
each NN O O
end NN O O
point NN O O
alone NN O O
is NN O O
> NN O O
80 NN O O
% NN O O
. NN O O

Patient NN O O
enrollment NN O O
ended NN O O
in NN O O
October NN O O
2018 NN O O
. NN O O

The NN O O
first NN O O
interim NN O O
analysis NN O O
in NN O O
June NN O O
2018 NN O O
resulted NN O O
in NN O O
continuation NN O O
of NN O O
the NN O O
study NN O O
without NN O O
any NN O O
changes NN O O
. NN O O

The NN O O
EPOCH NN O O
study NN O O
may NN O O
contribute NN O O
toward NN O O
the NN O O
establishment NN O O
of NN O O
the NN O O
role NN O O
of NN O O
combination NN O O
therapy NN O O
with NN O O
TARE NN O O
and NN O O
oxaliplatin- NN O O
or NN O O
irinotecan-based NN O O
chemotherapy NN O O
in NN O O
the NN O O
second-line NN O O
treatment NN O O
of NN O O
mCRC NN O O
of NN O O
the NN O O
liver NN O O
. NN O O

ClinicalTrials.gov NN O O
NCT01483027 NN O O
; NN O O
https://clinicaltrials.gov/ct2/show/NCT01483027 NN O O
( NN O O
Archived NN O O
by NN O O
WebCite NN O O
at NN O O
http://www.webcitation.org/734A6PAYW NN O O
) NN O O
. NN O O

RR1 NN O O
- NN O O
10.2196/11545 NN O O
. NN O O



-DOCSTART- (31387559)

A NN O O
minority NN O O
of NN O O
patients NN O O
presenting NN O O
with NN O O
lower NN O O
respiratory NN O O
tract NN O O
infection NN O O
( NN O O
LRTI NN O O
) NN O O
to NN O O
their NN O O
general NN O O
practitioner NN O O
( NN O O
GP NN O O
) NN O O
have NN O O
community-acquired NN O O
pneumonia NN O O
( NN O O
CAP NN O O
) NN O O
and NN O O
require NN O O
antibiotic NN O O
therapy NN O O
. NN O O

Identifying NN O O
them NN O O
is NN O O
challenging NN O O
, NN O O
because NN O O
of NN O O
overlapping NN O O
symptomatology NN O O
and NN O O
low NN O O
diagnostic NN O O
performance NN O O
of NN O O
chest NN O O
X-ray NN O O
. NN O O

Procalcitonin NN O O
( NN O O
PCT NN O O
) NN O O
can NN O O
be NN O O
safely NN O O
used NN O O
to NN O O
decide NN O O
on NN O O
antibiotic NN O O
prescription NN O O
in NN O O
patients NN O O
with NN O O
LRTI NN O O
. NN O O

Lung NN O O
ultrasound NN O O
( NN O O
LUS NN O O
) NN O O
is NN O O
effective NN O O
in NN O O
detecting NN O O
lung NN O O
consolidation NN O O
in NN O O
pneumonia NN O O
and NN O O
might NN O O
compensate NN O O
for NN O O
the NN O O
lack NN O O
of NN O O
specificity NN O O
of NN O O
PCT NN O O
. NN O O

We NN O O
hypothesize NN O O
that NN O O
combining NN O O
PCT NN O O
and NN O O
LUS NN O O
, NN O O
available NN O O
as NN O O
point-of NN O O
care NN O O
tests NN O O
( NN O O
POCT NN O O
) NN O O
, NN O O
might NN O O
reduce NN O O
antibiotic NN O O
prescription NN O O
in NN O O
LRTIs NN O O
without NN O O
impacting NN O O
patient NN O O
safety NN O O
in NN O O
the NN O O
primary NN O O
care NN O O
setting NN O O
. NN O O

This NN O O
is NN O O
a NN O O
three-arm NN O O
pragmatic NN O O
cluster NN O O
randomized NN O O
controlled NN O O
clinical NN O O
trial NN O O
. NN O O

GPs NN O O
are NN O O
randomized NN O O
either NN O O
to NN O O
PCT NN O O
and NN O O
LUS-guided NN O O
antibiotic NN O O
therapy NN O O
or NN O O
to NN O O
PCT NN O O
only-guided NN O O
therapy NN O O
or NN O O
to NN O O
usual NN O O
care NN O O
. NN O O

Consecutive NN O O
adult NN O O
patients NN O O
with NN O O
an NN O O
acute NN O O
cough NN O O
due NN O O
to NN O O
a NN O O
respiratory NN O O
infection NN O O
will NN O O
be NN O O
screened NN O O
and NN O O
included NN O O
if NN O O
they NN O O
present NN O O
a NN O O
clinical NN O O
pneumonia NN O O
as NN O O
defined NN O O
by NN O O
European NN O O
guidelines NN O O
. NN O O

Exclusion NN O O
criteria NN O O
are NN O O
previous NN O O
antibiotics NN O O
for NN O O
the NN O O
current NN O O
episode NN O O
, NN O O
working NN O O
diagnosis NN O O
of NN O O
sinusitis NN O O
, NN O O
severe NN O O
underlying NN O O
lung NN O O
disease NN O O
, NN O O
severe NN O O
immunosuppression NN O O
, NN O O
hospital NN O O
admission NN O O
, NN O O
pregnancy NN O O
, NN O O
inability NN O O
to NN O O
provide NN O O
informed NN O O
consent NN O O
and NN O O
unavailability NN O O
of NN O O
the NN O O
GP NN O O
. NN O O

Patients NN O O
will NN O O
fill NN O O
in NN O O
a NN O O
28 NN O O
day-symptom NN O O
diary NN O O
and NN O O
will NN O O
be NN O O
contacted NN O O
by NN O O
phone NN O O
on NN O O
days NN O O
7 NN O O
and NN O O
28 NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
is NN O O
the NN O O
proportion NN O O
of NN O O
patients NN O O
prescribed NN O O
any NN O O
antibiotic NN O O
up NN O O
to NN O O
day NN O O
28 NN O O
. NN O O

Secondary NN O O
outcomes NN O O
include NN O O
clinical NN O O
failure NN O O
by NN O O
day NN O O
7 NN O O
( NN O O
death NN O O
, NN O O
admission NN O O
to NN O O
hospital NN O O
, NN O O
absence NN O O
of NN O O
amelioration NN O O
or NN O O
worsening NN O O
of NN O O
relevant NN O O
symptoms NN O O
) NN O O
and NN O O
by NN O O
day NN O O
28 NN O O
, NN O O
duration NN O O
of NN O O
restricted NN O O
daily NN O O
activities NN O O
, NN O O
episode NN O O
duration NN O O
as NN O O
defined NN O O
by NN O O
symptom NN O O
score NN O O
, NN O O
number NN O O
of NN O O
medical NN O O
visits NN O O
, NN O O
number NN O O
of NN O O
days NN O O
with NN O O
side NN O O
effects NN O O
due NN O O
to NN O O
antibiotics NN O O
and NN O O
a NN O O
composite NN O O
outcome NN O O
combining NN O O
death NN O O
, NN O O
admission NN O O
to NN O O
hospital NN O O
and NN O O
complications NN O O
due NN O O
to NN O O
LRTI NN O O
by NN O O
day NN O O
28 NN O O
. NN O O

An NN O O
evaluation NN O O
of NN O O
the NN O O
cost-effectiveness NN O O
and NN O O
of NN O O
processes NN O O
in NN O O
the NN O O
clinic NN O O
using NN O O
a NN O O
mixed NN O O
qualitative NN O O
and NN O O
quantitative NN O O
approach NN O O
will NN O O
also NN O O
be NN O O
conducted NN O O
. NN O O

Our NN O O
intervention NN O O
targets NN O O
only NN O O
patients NN O O
with NN O O
clinically NN O O
suspected NN O O
CAP NN O O
who NN O O
have NN O O
a NN O O
higher NN O O
pretest NN O O
probability NN O O
of NN O O
definite NN O O
pneumonia NN O O
. NN O O

The NN O O
intervention NN O O
will NN O O
not NN O O
substitute NN O O
clinical NN O O
assessment NN O O
but NN O O
completes NN O O
it NN O O
by NN O O
introducing NN O O
new NN O O
easy-to-perform NN O O
tests NN O O
. NN O O

The NN O O
study NN O O
was NN O O
registered NN O O
on NN O O
the NN O O
19th NN O O
of NN O O
June NN O O
2017 NN O O
on NN O O
the NN O O
clinicaltrials.gov NN O O
registry NN O O
using NN O O
reference NN O O
number NN O O
; NN O O
NCT03191071 NN O O
. NN O O



-DOCSTART- (31387822)

Thirty-day NN O O
all-cause NN O O
readmissions NN O O
are NN O O
high NN O O
after NN O O
aortic NN O O
valve NN O O
replacement NN O O
( NN O O
AVR NN O O
) NN O O
. NN O O

We NN O O
aimed NN O O
to NN O O
assess NN O O
the NN O O
effectiveness NN O O
of NN O O
a NN O O
structured NN O O
telephone NN O O
follow-up NN O O
( NN O O
TFU NN O O
) NN O O
and NN O O
a NN O O
24/7 NN O O
hotline NN O O
on NN O O
reducing NN O O
30-day NN O O
all-cause NN O O
readmission NN O O
( NN O O
30-DACR NN O O
) NN O O
after NN O O
AVR NN O O
, NN O O
on NN O O
reducing NN O O
symptoms NN O O
of NN O O
anxiety NN O O
and NN O O
depression NN O O
and NN O O
on NN O O
improving NN O O
perceived NN O O
health NN O O
state NN O O
. NN O O

A NN O O
prospective NN O O
randomized NN O O
controlled NN O O
trial NN O O
was NN O O
conducted NN O O
. NN O O

Patients NN O O
( NN O O
n NN O O
= NN O O
288 NN O O
) NN O O
were NN O O
randomly NN O O
allocated NN O O
to NN O O
either NN O O
post-discharge NN O O
usual NN O O
care NN O O
or NN O O
to NN O O
care NN O O
that NN O O
provided NN O O
TFU NN O O
and NN O O
access NN O O
to NN O O
a NN O O
24/7 NN O O
hotline NN O O
after NN O O
AVR NN O O
. NN O O

Ancillary NN O O
endpoints NN O O
were NN O O
time-to-event NN O O
( NN O O
readmission NN O O
) NN O O
, NN O O
proportion NN O O
of NN O O
avoidable NN O O
versus NN O O
unavoidable NN O O
readmissions NN O O
after NN O O
AVR NN O O
, NN O O
and NN O O
predictors NN O O
of NN O O
30-DACR NN O O
after NN O O
AVR NN O O
. NN O O

30-DACR NN O O
was NN O O
22.3 NN O O
% NN O O
. NN O O

The NN O O
structured NN O O
TFU NN O O
and NN O O
24/7 NN O O
hotline NN O O
intervention NN O O
failed NN O O
to NN O O
reduce NN O O
30-DACR NN O O
rates NN O O
after NN O O
AVR NN O O
( NN O O
P NN O O
= NN O O
0.274 NN O O
) NN O O
. NN O O

Symptoms NN O O
of NN O O
anxiety NN O O
were NN O O
significantly NN O O
reduced NN O O
30 NN O O
days NN O O
after NN O O
surgery NN O O
( NN O O
P NN O O
= NN O O
0.031 NN O O
) NN O O
, NN O O
an NN O O
effect NN O O
that NN O O
did NN O O
not NN O O
persist NN O O
one NN O O
year NN O O
after NN O O
surgery NN O O
( NN O O
P NN O O
= NN O O
0.108 NN O O
) NN O O
. NN O O

Most NN O O
readmissions NN O O
occurred NN O O
before NN O O
15 NN O O
days NN O O
post-discharge NN O O
, NN O O
and NN O O
75 NN O O
% NN O O
of NN O O
them NN O O
were NN O O
deemed NN O O
to NN O O
be NN O O
unavoidable NN O O
. NN O O

Pleural NN O O
drainage NN O O
before NN O O
hospital NN O O
discharge NN O O
( NN O O
P NN O O
= NN O O
0.027 NN O O
) NN O O
and NN O O
symptoms NN O O
of NN O O
anxiety NN O O
before NN O O
surgery NN O O
( NN O O
P NN O O
= NN O O
0.003 NN O O
) NN O O
were NN O O
predictors NN O O
of NN O O
30-DACR NN O O
after NN O O
AVR NN O O
. NN O O

The NN O O
TFU NN O O
and NN O O
24/7 NN O O
hotline NN O O
had NN O O
no NN O O
effect NN O O
on NN O O
reducing NN O O
30-DACR NN O O
after NN O O
AVR NN O O
. NN O O

However NN O O
, NN O O
we NN O O
did NN O O
measure NN O O
reduced NN O O
symptoms NN O O
of NN O O
anxiety NN O O
the NN O O
first NN O O
month NN O O
after NN O O
AVR NN O O
. NN O O

Anxiety NN O O
reduction NN O O
appeared NN O O
to NN O O
be NN O O
an NN O O
important NN O O
target NN O O
for NN O O
intervention NN O O
, NN O O
because NN O O
we NN O O
found NN O O
it NN O O
to NN O O
be NN O O
a NN O O
risk NN O O
factor NN O O
for NN O O
readmission NN O O
. NN O O

Future NN O O
research NN O O
should NN O O
focus NN O O
on NN O O
the NN O O
effectiveness NN O O
of NN O O
interventions NN O O
to NN O O
prevent NN O O
avoidable NN O O
unplanned NN O O
readmissions NN O O
. NN O O

ClinicalTrial.gov NN O O
, NN O O
NCT02522663 NN O O
. NN O O



-DOCSTART- (31153360)

To NN O O
investigate NN O O
the NN O O
optimal NN O O
dose NN O O
of NN O O
pretreated-dexmedetomidine NN O O
in NN O O
fentanyl-induced NN O O
cough NN O O
( NN O O
FIC NN O O
) NN O O
suppression NN O O
. NN O O

Patients NN O O
of NN O O
180 NN O O
undergoing NN O O
elective NN O O
surgery NN O O
with NN O O
general NN O O
anesthesia NN O O
, NN O O
aged NN O O
18 NN O O
- NN O O
65 NN O O
years NN O O
, NN O O
BMI NN O O
18.5 NN O O
- NN O O
30 NN O O
kg/m NN O O
, NN O O
ASA NN O O
I NN O O
or NN O O
II NN O O
, NN O O
were NN O O
equally NN O O
randomized NN O O
into NN O O
four NN O O
groups NN O O
( NN O O
n NN O O
= NN O O
45 NN O O
) NN O O
to NN O O
receive NN O O
intravenous NN O O
pretreatment NN O O
of NN O O
dexmedetomidine NN O O
with NN O O
0 NN O O
( NN O O
group NN O O
1 NN O O
) NN O O
, NN O O
0.3 NN O O
( NN O O
group NN O O
2 NN O O
) NN O O
, NN O O
0.6 NN O O
( NN O O
group NN O O
3 NN O O
) NN O O
and NN O O
0.9 NN O O
( NN O O
group NN O O
4 NN O O
) NN O O
mcg/kg NN O O
over NN O O
10 NN O O
mins NN O O
, NN O O
respectively NN O O
. NN O O

After NN O O
the NN O O
pretreatment NN O O
, NN O O
all NN O O
patients NN O O
were NN O O
given NN O O
a NN O O
5-s NN O O
intravenous NN O O
injection NN O O
of NN O O
fentanyl NN O O
4 NN O O
mcg/kg NN O O
. NN O O

The NN O O
symptoms NN O O
of NN O O
irritating NN O O
cough NN O O
including NN O O
the NN O O
severity NN O O
and NN O O
onset NN O O
time NN O O
were NN O O
recorded NN O O
for NN O O
1 NN O O
min NN O O
after NN O O
fentanyl NN O O
injection NN O O
. NN O O

General NN O O
anesthesia NN O O
induction NN O O
was NN O O
completed NN O O
with NN O O
midazolam NN O O
, NN O O
propofol NN O O
and NN O O
cisatracurium NN O O
, NN O O
then NN O O
endotracheal NN O O
tube NN O O
or NN O O
laryngeal NN O O
mask NN O O
was NN O O
inserted NN O O
and NN O O
connected NN O O
to NN O O
an NN O O
anesthesia NN O O
machine NN O O
. NN O O

MAP NN O O
, NN O O
HR NN O O
and NN O O
SpO NN O O
at NN O O
the NN O O
beginning NN O O
of NN O O
pretreatment NN O O
( NN O O
T0 NN O O
) NN O O
, NN O O
3 NN O O
min NN O O
( NN O O
T1 NN O O
) NN O O
, NN O O
6 NN O O
min NN O O
( NN O O
T2 NN O O
) NN O O
, NN O O
9 NN O O
min NN O O
( NN O O
T3 NN O O
) NN O O
and NN O O
12 NN O O
min NN O O
( NN O O
T4 NN O O
) NN O O
after NN O O
the NN O O
beginning NN O O
of NN O O
pretreatment NN O O
were NN O O
recorded NN O O
. NN O O

Side NN O O
effects NN O O
of NN O O
dexmedetomidine NN O O
, NN O O
such NN O O
as NN O O
bradycardia NN O O
, NN O O
hypertension NN O O
, NN O O
hypotension NN O O
, NN O O
and NN O O
respiratory NN O O
depression NN O O
were NN O O
also NN O O
recorded NN O O
during NN O O
the NN O O
course NN O O
. NN O O

Totally NN O O
168 NN O O
patients NN O O
completed NN O O
the NN O O
study NN O O
. NN O O

The NN O O
incidences NN O O
of NN O O
cough NN O O
were NN O O
52.4 NN O O
, NN O O
42.9 NN O O
, NN O O
11.9 NN O O
, NN O O
and NN O O
14.3 NN O O
% NN O O
in NN O O
groups NN O O
1 NN O O
, NN O O
2 NN O O
, NN O O
3 NN O O
, NN O O
and NN O O
4 NN O O
, NN O O
respectively NN O O
, NN O O
with NN O O
no NN O O
significant NN O O
differences NN O O
between NN O O
groups NN O O
1 NN O O
and NN O O
2 NN O O
( NN O O
P NN O O
> NN O O
0.05 NN O O
) NN O O
and NN O O
between NN O O
groups NN O O
3 NN O O
and NN O O
4 NN O O
( NN O O
P NN O O
> NN O O
0.05 NN O O
) NN O O
. NN O O

The NN O O
incidence NN O O
and NN O O
severity NN O O
of NN O O
cough NN O O
in NN O O
groups NN O O
3 NN O O
and NN O O
4 NN O O
were NN O O
significantly NN O O
lower NN O O
than NN O O
those NN O O
in NN O O
groups NN O O
1 NN O O
and NN O O
2 NN O O
( NN O O
P NN O O
< NN O O
0.05 NN O O
) NN O O
. NN O O

Compared NN O O
to NN O O
T0 NN O O
, NN O O
HR NN O O
at NN O O
T2 NN O O
( NN O O
P NN O O
< NN O O
0.05 NN O O
) NN O O
, NN O O
T3 NN O O
( NN O O
P NN O O
< NN O O
0.01 NN O O
) NN O O
, NN O O
and NN O O
T4 NN O O
( NN O O
P NN O O
< NN O O
0.01 NN O O
) NN O O
decreased NN O O
significantly NN O O
and NN O O
MAP NN O O
at NN O O
T4 NN O O
decreased NN O O
significantly NN O O
( NN O O
P NN O O
< NN O O
0.05 NN O O
) NN O O
in NN O O
group NN O O
4 NN O O
. NN O O

Bradycardia NN O O
occurred NN O O
in NN O O
1 NN O O
case NN O O
and NN O O
respiratory NN O O
depression NN O O
occurred NN O O
in NN O O
1 NN O O
case NN O O
in NN O O
group NN O O
4 NN O O
. NN O O

Compared NN O O
to NN O O
group NN O O
1 NN O O
, NN O O
the NN O O
onset NN O O
time NN O O
of NN O O
cough NN O O
in NN O O
the NN O O
other NN O O
3 NN O O
groups NN O O
were NN O O
delayed NN O O
significantly NN O O
( NN O O
P NN O O
< NN O O
0.05 NN O O
) NN O O
. NN O O

Pretreated NN O O
dexmedetomidine NN O O
0.6 NN O O
mcg/kg NN O O
blous NN O O
intravenous NN O O
infusion NN O O
over NN O O
10 NN O O
mins NN O O
could NN O O
reduce NN O O
FIC NN O O
effectively NN O O
without NN O O
side NN O O
effects NN O O
. NN O O

This NN O O
study NN O O
was NN O O
registered NN O O
in NN O O
ClinicalTrials.gov NN O O
( NN O O
NCT03126422 NN O O
) NN O O
, NN O O
April NN O O
13 NN O O
, NN O O
2017 NN O O
. NN O O



-DOCSTART- (30762508)

A NN O O
third NN O O
of NN O O
patients NN O O
diagnosed NN O O
with NN O O
major NN O O
depressive NN O O
disorder NN O O
( NN O O
MDD NN O O
) NN O O
experience NN O O
treatment-resistant NN O O
depression NN O O
( NN O O
TRD NN O O
) NN O O
. NN O O

Relatively NN O O
few NN O O
pharmacological NN O O
agents NN O O
have NN O O
established NN O O
efficacy NN O O
for NN O O
TRD NN O O
. NN O O

Therefore NN O O
, NN O O
the NN O O
evaluation NN O O
of NN O O
novel NN O O
treatments NN O O
for NN O O
TRD NN O O
is NN O O
a NN O O
pressing NN O O
priority NN O O
. NN O O

Statins NN O O
are NN O O
pleiotropic NN O O
agents NN O O
and NN O O
preclinical NN O O
studies NN O O
as NN O O
well NN O O
as NN O O
preliminary NN O O
clinical NN O O
trials NN O O
have NN O O
suggested NN O O
that NN O O
these NN O O
drugs NN O O
may NN O O
have NN O O
antidepressant NN O O
properties NN O O
. NN O O

AimsTo NN O O
report NN O O
on NN O O
a NN O O
protocol NN O O
for NN O O
a NN O O
12-week NN O O
, NN O O
randomised NN O O
, NN O O
double-blind NN O O
, NN O O
placebo-controlled NN O O
trial NN O O
of NN O O
add-on NN O O
treatment NN O O
with NN O O
simvastatin NN O O
for NN O O
patients NN O O
meeting NN O O
DSM-5 NN O O
criteria NN O O
for NN O O
MDD NN O O
who NN O O
have NN O O
failed NN O O
to NN O O
respond NN O O
to NN O O
at NN O O
least NN O O
two NN O O
adequate NN O O
trials NN O O
with NN O O
approved NN O O
antidepressants NN O O
. NN O O

The NN O O
trial NN O O
has NN O O
been NN O O
registered NN O O
with NN O O
Clinicaltrials.gov NN O O
in NN O O
( NN O O
ClinicalTrials.gov NN O O
identifier NN O O
: NN O O
NCT03435744 NN O O
) NN O O
. NN O O

After NN O O
screening NN O O
and NN O O
randomisation NN O O
to NN O O
the NN O O
two NN O O
parallel NN O O
arms NN O O
of NN O O
the NN O O
trial NN O O
, NN O O
75 NN O O
patients NN O O
will NN O O
receive NN O O
simvastatin NN O O
and NN O O
75 NN O O
patients NN O O
will NN O O
receive NN O O
placebo NN O O
as NN O O
adjuncts NN O O
to NN O O
treatment NN O O
as NN O O
usual NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
is NN O O
change NN O O
in NN O O
Montgomery-Åsberg NN O O
Depression NN O O
Rating NN O O
Scale NN O O
scores NN O O
from NN O O
baseline NN O O
to NN O O
week NN O O
12 NN O O
and NN O O
secondary NN O O
outcomes NN O O
include NN O O
changes NN O O
in NN O O
scores NN O O
on NN O O
the NN O O
24-item NN O O
Hamilton NN O O
Rating NN O O
Scale NN O O
for NN O O
Depression NN O O
, NN O O
the NN O O
Clinical NN O O
Global NN O O
Impression NN O O
scale NN O O
, NN O O
the NN O O
7-item NN O O
Generalized NN O O
Anxiety NN O O
Disorder NN O O
scale NN O O
and NN O O
change NN O O
in NN O O
body NN O O
mass NN O O
index NN O O
from NN O O
baseline NN O O
to NN O O
week NN O O
12 NN O O
. NN O O

Assessments NN O O
will NN O O
take NN O O
place NN O O
at NN O O
screening NN O O
, NN O O
baseline NN O O
, NN O O
and NN O O
weeks NN O O
2 NN O O
, NN O O
4 NN O O
, NN O O
8 NN O O
and NN O O
12 NN O O
. NN O O

Checklists NN O O
for NN O O
adverse NN O O
effects NN O O
will NN O O
be NN O O
undertaken NN O O
at NN O O
each NN O O
visit NN O O
. NN O O

Simvastatin NN O O
( NN O O
20 NN O O
mg NN O O
) NN O O
will NN O O
be NN O O
given NN O O
once NN O O
daily NN O O
. NN O O

Other NN O O
secondary NN O O
outcomes NN O O
include NN O O
C-reactive NN O O
protein NN O O
and NN O O
plasma NN O O
lipids NN O O
measured NN O O
at NN O O
baseline NN O O
and NN O O
week NN O O
12 NN O O
. NN O O

This NN O O
trial NN O O
will NN O O
assess NN O O
simvastatin NN O O
's NN O O
efficacy NN O O
and NN O O
tolerability NN O O
as NN O O
an NN O O
add-on NN O O
treatment NN O O
option NN O O
for NN O O
patients NN O O
with NN O O
TRD NN O O
and NN O O
provide NN O O
insights NN O O
into NN O O
its NN O O
putative NN O O
mechanisms NN O O
of NN O O
action NN O O
. NN O O

As NN O O
the NN O O
first NN O O
trial NN O O
investigating NN O O
the NN O O
use NN O O
of NN O O
simvastatin NN O O
as NN O O
an NN O O
augmentation NN O O
strategy NN O O
in NN O O
patients NN O O
with NN O O
TRD NN O O
, NN O O
if NN O O
the NN O O
results NN O O
indicate NN O O
that NN O O
adjuvant NN O O
simvastatin NN O O
is NN O O
efficacious NN O O
in NN O O
reducing NN O O
depressive NN O O
symptoms NN O O
, NN O O
it NN O O
will NN O O
deliver NN O O
immediate NN O O
clinical NN O O
benefit NN O O
. NN O O

Declaration NN O O
of NN O O
interestI.B.C. NN O O
and NN O O
N.H. NN O O
have NN O O
given NN O O
lectures NN O O
and NN O O
advice NN O O
to NN O O
Eli NN O O
Lilly NN O O
, NN O O
Bristol NN O O
Myers NN O O
Squibb NN O O
, NN O O
Lundbeck NN O O
, NN O O
Astra NN O O
Zeneca NN O O
and NN O O
Janssen NN O O
pharmaceuticals NN O O
for NN O O
which NN O O
they NN O O
or NN O O
their NN O O
employing NN O O
institution NN O O
have NN O O
been NN O O
reimbursed NN O O
. NN O O

R.R. NN O O
and NN O O
M.M.H. NN O O
have NN O O
received NN O O
educational NN O O
grants NN O O
and NN O O
support NN O O
for NN O O
academic NN O O
meetings NN O O
from NN O O
Pfizer NN O O
, NN O O
Roche NN O O
, NN O O
Novartis NN O O
and NN O O
Nabiqasim NN O O
. NN O O

A.H.Y. NN O O
has NN O O
been NN O O
commissioned NN O O
to NN O O
provide NN O O
lectures NN O O
and NN O O
advice NN O O
to NN O O
all NN O O
major NN O O
pharmaceutical NN O O
companies NN O O
with NN O O
drugs NN O O
used NN O O
in NN O O
affective NN O O
and NN O O
related NN O O
disorders NN O O
. NN O O

A.H.Y. NN O O
has NN O O
undertaken NN O O
investigator-initiated NN O O
studies NN O O
from NN O O
Astra NN O O
Zeneca NN O O
, NN O O
Eli NN O O
Lilly NN O O
, NN O O
Lundbeck NN O O
and NN O O
Wyeth NN O O
. NN O O

None NN O O
of NN O O
the NN O O
companies NN O O
have NN O O
a NN O O
financial NN O O
interest NN O O
in NN O O
this NN O O
research NN O O
. NN O O



-DOCSTART- (31221280)

We NN O O
tested NN O O
the NN O O
hypothesis NN O O
that NN O O
a NN O O
normal NN O O
sodium NN O O
diet NN O O
could NN O O
be NN O O
associated NN O O
with NN O O
preservation NN O O
of NN O O
serum NN O O
sodium NN O O
during NN O O
treatment NN O O
of NN O O
acute NN O O
decompensated NN O O
heart NN O O
failure NN O O
( NN O O
ADHF NN O O
) NN O O
. NN O O

Forty-four NN O O
patients NN O O
hospitalized NN O O
for NN O O
ADHF NN O O
were NN O O
blindly NN O O
randomized NN O O
by NN O O
using NN O O
block NN O O
method NN O O
to NN O O
a NN O O
low NN O O
sodium NN O O
diet NN O O
( NN O O
LS NN O O
: NN O O
3 NN O O
g/day NN O O
of NN O O
dietary NN O O
sodium NN O O
chloride NN O O
; NN O O
n NN O O
= NN O O
22 NN O O
, NN O O
59.5 NN O O
± NN O O
11.9 NN O O
y.o NN O O
. NN O O
, NN O O
50 NN O O
% NN O O
males NN O O
. NN O O

LVEF NN O O
= NN O O
30.0 NN O O
± NN O O
13.6 NN O O
% NN O O
) NN O O
; NN O O
and NN O O
a NN O O
normal NN O O
sodium NN O O
diet NN O O
( NN O O
NS NN O O
: NN O O
7 NN O O
g/day NN O O
; NN O O
n NN O O
= NN O O
22 NN O O
, NN O O
56.4 NN O O
± NN O O
10.3 NN O O
y.o NN O O
. NN O O
, NN O O
68 NN O O
% NN O O
males NN O O
; NN O O
LVEF NN O O
= NN O O
27.8 NN O O
± NN O O
11.7 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
both NN O O
groups NN O O
were NN O O
submitted NN O O
to NN O O
fluid NN O O
restriction NN O O
of NN O O
1.000 NN O O
mL/day NN O O
. NN O O

At NN O O
the NN O O
7th NN O O
day NN O O
of NN O O
intervention NN O O
16 NN O O
patients NN O O
of NN O O
LS NN O O
group NN O O
and NN O O
15 NN O O
patients NN O O
of NN O O
NS NN O O
group NN O O
were NN O O
assessed NN O O
for NN O O
difference NN O O
in NN O O
serum NN O O
sodium NN O O
. NN O O

Both NN O O
groups NN O O
had NN O O
equivalent NN O O
decongestion NN O O
, NN O O
reflected NN O O
by NN O O
similar NN O O
percent NN O O
reduction NN O O
of NN O O
body NN O O
weight NN O O
( NN O O
LS NN O O
: NN O O
-5.0 NN O O
± NN O O
4.7 NN O O
% NN O O
vs NN O O
NS NN O O
: NN O O
-4.5 NN O O
± NN O O
5.2 NN O O
% NN O O
. NN O O

p NN O O
= NN O O
0.41 NN O O
) NN O O
. NN O O

Reduction NN O O
of NN O O
the NN O O
N NN O O
terminal NN O O
fragment NN O O
of NN O O
type NN O O
B NN O O
natriuretic NN O O
peptide NN O O
( NN O O
NT-proBNP NN O O
) NN O O
was NN O O
significant NN O O
only NN O O
in NN O O
the NN O O
NS NN O O
( NN O O
-1497.0 NN O O
[ NN O O
-18843.0 NN O O
- NN O O
1191.0 NN O O
] NN O O
. NN O O

p NN O O
= NN O O
0.04 NN O O
) NN O O
. NN O O

The NN O O
LS NN O O
group NN O O
showed NN O O
lower NN O O
levels NN O O
of NN O O
serum NN O O
sodium NN O O
( NN O O
135.4 NN O O
± NN O O
3.5 NN O O
mmol/L NN O O
) NN O O
compared NN O O
to NN O O
the NN O O
NS NN O O
group NN O O
( NN O O
137.5 NN O O
± NN O O
1.9 NN O O
mmol/L NN O O
; NN O O
p NN O O
= NN O O
0.04 NN O O
) NN O O
. NN O O

Four NN O O
cases NN O O
of NN O O
hyponatremia NN O O
were NN O O
observed NN O O
only NN O O
in NN O O
the NN O O
LS NN O O
group NN O O
( NN O O
22 NN O O
% NN O O
) NN O O
. NN O O

The NN O O
NS NN O O
group NN O O
exhibited NN O O
higher NN O O
mean NN O O
blood NN O O
pressure NN O O
values NN O O
( NN O O
79.4 NN O O
± NN O O
2.4 NN O O
mmHg NN O O
vs NN O O
75.5 NN O O
± NN O O
3.0 NN O O
mmHg NN O O
. NN O O

p NN O O
= NN O O
0.03 NN O O
) NN O O
, NN O O
and NN O O
lower NN O O
heart NN O O
rate NN O O
( NN O O
73.2 NN O O
± NN O O
1.6 NN O O
bpm NN O O
vs NN O O
75.5 NN O O
± NN O O
2.1 NN O O
bpm NN O O
. NN O O

p NN O O
= NN O O
0.02 NN O O
) NN O O
. NN O O

These NN O O
results NN O O
suggest NN O O
that NN O O
a NN O O
normal NN O O
sodium NN O O
diet NN O O
, NN O O
when NN O O
compared NN O O
to NN O O
a NN O O
low NN O O
sodium NN O O
diet NN O O
, NN O O
is NN O O
associated NN O O
with NN O O
similar NN O O
degrees NN O O
of NN O O
decongestion NN O O
, NN O O
but NN O O
with NN O O
higher NN O O
levels NN O O
of NN O O
natremia NN O O
, NN O O
blood NN O O
pressure NN O O
and NN O O
lower NN O O
neurohormonal NN O O
activation NN O O
during NN O O
ADHF NN O O
treatment NN O O
. NN O O

clinicaltrials.gov NN O O
Identifier NN O O
no. NN O O
NCT03722069 NN O O
. NN O O



-DOCSTART- (30753101)

Needle-free NN O O
intranasal NN O O
vaccines NN O O
offer NN O O
major NN O O
potential NN O O
advantages NN O O
, NN O O
especially NN O O
against NN O O
pathogens NN O O
entering NN O O
via NN O O
mucosal NN O O
surfaces NN O O
. NN O O

As NN O O
yet NN O O
, NN O O
there NN O O
is NN O O
no NN O O
effective NN O O
vaccine NN O O
against NN O O
respiratory NN O O
syncytial NN O O
virus NN O O
( NN O O
RSV NN O O
) NN O O
, NN O O
a NN O O
ubiquitous NN O O
pathogen NN O O
of NN O O
global NN O O
importance NN O O
that NN O O
preferentially NN O O
infects NN O O
respiratory NN O O
epithelial NN O O
cells NN O O
; NN O O
new NN O O
strategies NN O O
are NN O O
urgently NN O O
required NN O O
. NN O O

Here NN O O
, NN O O
we NN O O
report NN O O
the NN O O
safety NN O O
and NN O O
immunogenicity NN O O
of NN O O
a NN O O
novel NN O O
mucosal NN O O
RSV NN O O
F NN O O
protein NN O O
vaccine NN O O
linked NN O O
to NN O O
an NN O O
immunostimulatory NN O O
bacterium-like NN O O
particle NN O O
( NN O O
BLP NN O O
) NN O O
. NN O O

In NN O O
this NN O O
phase NN O O
I NN O O
, NN O O
randomised NN O O
, NN O O
double-blind NN O O
placebo-controlled NN O O
trial NN O O
, NN O O
48 NN O O
healthy NN O O
volunteers NN O O
aged NN O O
18 NN O O
- NN O O
49 NN O O
years NN O O
were NN O O
randomly NN O O
assigned NN O O
to NN O O
receive NN O O
placebo NN O O
or NN O O
SynGEM NN O O
( NN O O
low- NN O O
or NN O O
high-dose NN O O
) NN O O
intranasally NN O O
by NN O O
prime-boost NN O O
administration NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
was NN O O
safety NN O O
and NN O O
tolerability NN O O
, NN O O
with NN O O
secondary NN O O
objectives NN O O
assessing NN O O
virus-specific NN O O
immunogenicity NN O O
. NN O O

There NN O O
were NN O O
no NN O O
significant NN O O
differences NN O O
in NN O O
adverse NN O O
events NN O O
between NN O O
placebo NN O O
and NN O O
vaccinated NN O O
groups NN O O
. NN O O

SynGEM NN O O
induced NN O O
systemic NN O O
plasmablast NN O O
responses NN O O
and NN O O
significant NN O O
, NN O O
durable NN O O
increases NN O O
in NN O O
RSV-specific NN O O
serum NN O O
antibody NN O O
in NN O O
healthy NN O O
seropositive NN O O
adults NN O O
. NN O O

Volunteers NN O O
given NN O O
low-dose NN O O
SynGEM NN O O
( NN O O
140 NN O O
µg NN O O
F NN O O
, NN O O
2 NN O O
mg NN O O
BLP NN O O
) NN O O
required NN O O
a NN O O
boost NN O O
at NN O O
day NN O O
28 NN O O
to NN O O
achieve NN O O
plateau NN O O
responses NN O O
with NN O O
a NN O O
maximum NN O O
fold-change NN O O
of NN O O
2.4 NN O O
, NN O O
whereas NN O O
high-dose NN O O
recipients NN O O
( NN O O
350 NN O O
µg NN O O
F NN O O
, NN O O
5 NN O O
mg NN O O
BLP NN O O
) NN O O
achieved NN O O
plateau NN O O
responses NN O O
with NN O O
a NN O O
fold-change NN O O
of NN O O
1.5 NN O O
after NN O O
first NN O O
vaccination NN O O
that NN O O
remained NN O O
elevated NN O O
up NN O O
to NN O O
180 NN O O
days NN O O
post-vaccination NN O O
irrespective NN O O
of NN O O
further NN O O
boosting NN O O
. NN O O

Palivizumab-like NN O O
antibodies NN O O
were NN O O
consistently NN O O
induced NN O O
, NN O O
but NN O O
F NN O O
protein NN O O
site NN O O
Ø-specific NN O O
antibodies NN O O
were NN O O
not NN O O
detected NN O O
and NN O O
virus-specific NN O O
nasal NN O O
IgA NN O O
responses NN O O
were NN O O
heterogeneous NN O O
, NN O O
with NN O O
strongest NN O O
responses NN O O
in NN O O
individuals NN O O
with NN O O
lower NN O O
pre-existing NN O O
antibody NN O O
levels NN O O
. NN O O

SynGEM NN O O
is NN O O
thus NN O O
the NN O O
first NN O O
non-replicating NN O O
intranasal NN O O
RSV NN O O
subunit NN O O
vaccine NN O O
to NN O O
induce NN O O
persistent NN O O
antibody NN O O
responses NN O O
in NN O O
human NN O O
volunteers NN O O
. NN O O

Clinical NN O O
trial NN O O
registration NN O O
available NN O O
at NN O O
www.clinicaltrials.gov NN O O
, NN O O
ID NN O O
NCT02958540 NN O O
. NN O O



-DOCSTART- (30796816)

During NN O O
the NN O O
2014 NN O O
West NN O O
African NN O O
Ebola NN O O
outbreak NN O O
, NN O O
Ebola NN O O
vaccine NN O O
development NN O O
was NN O O
accelerated NN O O
. NN O O

The NN O O
phase NN O O
1 NN O O
VAC52150EBL1003 NN O O
study NN O O
was NN O O
performed NN O O
to NN O O
investigate NN O O
2-dose NN O O
heterologous NN O O
vaccination NN O O
with NN O O
Ad26.ZEBOV NN O O
and NN O O
MVA-BN-Filo NN O O
in NN O O
an NN O O
African NN O O
population NN O O
located NN O O
in NN O O
a NN O O
high-altitude NN O O
setting NN O O
in NN O O
Nairobi NN O O
, NN O O
Kenya NN O O
. NN O O

Healthy NN O O
adult NN O O
volunteers NN O O
were NN O O
randomized NN O O
to NN O O
receive NN O O
one NN O O
of NN O O
four NN O O
2-dose NN O O
vaccination NN O O
schedules NN O O
. NN O O

The NN O O
first NN O O
vaccination NN O O
was NN O O
administered NN O O
at NN O O
baseline NN O O
( NN O O
Ad26.ZEBOV NN O O
or NN O O
MVA-BN-Filo NN O O
) NN O O
, NN O O
followed NN O O
by NN O O
the NN O O
second NN O O
vaccination NN O O
with NN O O
the NN O O
alternate NN O O
vaccine NN O O
after NN O O
either NN O O
28 NN O O
or NN O O
56 NN O O
days NN O O
. NN O O

Each NN O O
schedule NN O O
had NN O O
a NN O O
placebo NN O O
comparator NN O O
group NN O O
. NN O O

The NN O O
primary NN O O
objective NN O O
was NN O O
to NN O O
assess NN O O
the NN O O
safety NN O O
and NN O O
tolerability NN O O
of NN O O
these NN O O
regimens NN O O
. NN O O

Seventy-two NN O O
volunteers NN O O
were NN O O
randomized NN O O
into NN O O
4 NN O O
groups NN O O
of NN O O
18 NN O O
( NN O O
15 NN O O
received NN O O
vaccine NN O O
, NN O O
and NN O O
3 NN O O
received NN O O
placebo NN O O
) NN O O
. NN O O

The NN O O
most NN O O
frequent NN O O
solicited NN O O
systemic NN O O
adverse NN O O
event NN O O
was NN O O
headache NN O O
( NN O O
frequency NN O O
, NN O O
50 NN O O
% NN O O
, NN O O
61 NN O O
% NN O O
, NN O O
and NN O O
42 NN O O
% NN O O
per NN O O
dose NN O O
for NN O O
MVA-BN-Filo NN O O
, NN O O
Ad26.ZEBOV NN O O
, NN O O
and NN O O
placebo NN O O
, NN O O
respectively NN O O
) NN O O
. NN O O

The NN O O
most NN O O
frequent NN O O
solicited NN O O
local NN O O
AE NN O O
was NN O O
injection NN O O
site NN O O
pain NN O O
( NN O O
frequency NN O O
, NN O O
78 NN O O
% NN O O
, NN O O
63 NN O O
% NN O O
, NN O O
and NN O O
33 NN O O
% NN O O
per NN O O
dose NN O O
for NN O O
MVA-BN-Filo NN O O
, NN O O
Ad26.ZEBOV NN O O
, NN O O
and NN O O
placebo NN O O
, NN O O
respectively NN O O
) NN O O
. NN O O

No NN O O
differences NN O O
in NN O O
adverse NN O O
events NN O O
were NN O O
observed NN O O
among NN O O
the NN O O
different NN O O
vaccine NN O O
regimens NN O O
. NN O O

High NN O O
levels NN O O
of NN O O
binding NN O O
and NN O O
neutralizing NN O O
anti-Ebola NN O O
virus NN O O
glycoprotein NN O O
antibodies NN O O
were NN O O
induced NN O O
by NN O O
all NN O O
regimens NN O O
and NN O O
sustained NN O O
to NN O O
day NN O O
360 NN O O
after NN O O
the NN O O
first NN O O
dose NN O O
. NN O O

Two-dose NN O O
heterologous NN O O
vaccination NN O O
with NN O O
Ad26.ZEBOV NN O O
and NN O O
MVA-BN-Filo NN O O
was NN O O
well NN O O
tolerated NN O O
and NN O O
highly NN O O
immunogenic NN O O
against NN O O
Ebola NN O O
virus NN O O
glycoprotein NN O O
. NN O O

NCT02376426 NN O O
. NN O O



-DOCSTART- (30691013)

. NN O O

Physical NN O O
inactivity NN O O
is NN O O
currently NN O O
seen NN O O
as NN O O
one NN O O
of NN O O
the NN O O
biggest NN O O
global NN O O
public NN O O
health NN O O
issue NN O O
. NN O O

Remote NN O O
physical NN O O
activity NN O O
( NN O O
PA NN O O
) NN O O
promotion NN O O
programs NN O O
are NN O O
expected NN O O
to NN O O
be NN O O
effective NN O O
if NN O O
they NN O O
are NN O O
individually NN O O
tailored NN O O
and NN O O
include NN O O
behavior NN O O
change NN O O
techniques NN O O
, NN O O
personal NN O O
coaching NN O O
, NN O O
and NN O O
regular NN O O
prompting NN O O
. NN O O

However NN O O
, NN O O
it NN O O
is NN O O
still NN O O
not NN O O
fully NN O O
understood NN O O
which NN O O
intervention NN O O
components NN O O
are NN O O
most NN O O
effective NN O O
. NN O O

This NN O O
paper NN O O
describes NN O O
the NN O O
rationale NN O O
and NN O O
design NN O O
of NN O O
a NN O O
study NN O O
on NN O O
an NN O O
individually NN O O
tailored NN O O
remote NN O O
PA NN O O
promotion NN O O
program NN O O
comparing NN O O
the NN O O
efficacy NN O O
of NN O O
coaching NN O O
and NN O O
prompting NN O O
with NN O O
a NN O O
single NN O O
written NN O O
advice NN O O
. NN O O
. NN O O

In NN O O
total NN O O
, NN O O
288 NN O O
adults NN O O
( NN O O
age NN O O
20 NN O O
to NN O O
65 NN O O
years NN O O
) NN O O
were NN O O
randomly NN O O
assigned NN O O
to NN O O
three NN O O
different NN O O
intervention NN O O
arms NN O O
of NN O O
a NN O O
6-month-long NN O O
PA NN O O
promotion NN O O
program NN O O
. NN O O

A NN O O
minimal NN O O
intervention NN O O
group NN O O
received NN O O
a NN O O
single NN O O
written NN O O
PA NN O O
recommendation NN O O
. NN O O

The NN O O
two NN O O
remaining NN O O
groups NN O O
either NN O O
received NN O O
telephone NN O O
coaching NN O O
sessions NN O O
( NN O O
= NN O O
12 NN O O
calls NN O O
) NN O O
with NN O O
or NN O O
without NN O O
additional NN O O
short NN O O
message NN O O
service NN O O
( NN O O
SMS NN O O
) NN O O
prompting NN O O
( NN O O
= NN O O
48 NN O O
SMSs NN O O
for NN O O
each NN O O
participant NN O O
) NN O O
. NN O O

Data NN O O
assessment NN O O
took NN O O
place NN O O
at NN O O
baseline NN O O
, NN O O
at NN O O
the NN O O
end NN O O
of NN O O
the NN O O
intervention NN O O
, NN O O
and NN O O
after NN O O
a NN O O
six-month NN O O
follow-up-period NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
of NN O O
the NN O O
study NN O O
was NN O O
self-reported NN O O
PA NN O O
. NN O O

Objectively NN O O
assessed NN O O
PA NN O O
, NN O O
psychosocial NN O O
determinants NN O O
of NN O O
PA NN O O
, NN O O
well-being NN O O
, NN O O
body NN O O
mass NN O O
index NN O O
( NN O O
BMI NN O O
) NN O O
, NN O O
and NN O O
adherence NN O O
were NN O O
assessed NN O O
as NN O O
secondary NN O O
outcomes NN O O
. NN O O
. NN O O

Findings NN O O
of NN O O
this NN O O
three-arm NN O O
study NN O O
will NN O O
provide NN O O
insight NN O O
into NN O O
the NN O O
short NN O O
and NN O O
long-term NN O O
effects NN O O
of NN O O
coaching NN O O
and NN O O
prompting NN O O
for NN O O
PA NN O O
promotion NN O O
. NN O O



-DOCSTART- (30573499)

To NN O O
determine NN O O
the NN O O
effect NN O O
of NN O O
topical NN O O
brimonidine NN O O
tartrate NN O O
prophylaxis NN O O
on NN O O
intraocular NN O O
pressure NN O O
( NN O O
IOP NN O O
) NN O O
spikes NN O O
following NN O O
intravitreal NN O O
injection NN O O
of NN O O
antivascular NN O O
endothelial NN O O
growth NN O O
factor NN O O
( NN O O
anti-VEGF NN O O
) NN O O
agents NN O O
. NN O O

This NN O O
is NN O O
a NN O O
randomised NN O O
crossover NN O O
trial NN O O
of NN O O
consecutive NN O O
non-glaucomatous NN O O
eyes NN O O
receiving NN O O
intravitreal NN O O
anti-VEGF NN O O
injections NN O O
between NN O O
December NN O O
2016 NN O O
and NN O O
July NN O O
2017 NN O O
. NN O O

All NN O O
eyes NN O O
were NN O O
randomly NN O O
assigned NN O O
to NN O O
no NN O O
prophylaxis NN O O
or NN O O
topical NN O O
brimonidine NN O O
tartrate NN O O
0.15 NN O O
% NN O O
administered NN O O
20 NN O O
min NN O O
prior NN O O
to NN O O
injection NN O O
in NN O O
one NN O O
of NN O O
two NN O O
consecutive NN O O
visits NN O O
. NN O O

Measurements NN O O
of NN O O
IOP NN O O
were NN O O
obtained NN O O
immediately NN O O
( NN O O
T0 NN O O
) NN O O
, NN O O
10 NN O O
min NN O O
( NN O O
T10 NN O O
) NN O O
and NN O O
20 NN O O
min NN O O
( NN O O
T20 NN O O
) NN O O
after NN O O
injection NN O O
during NN O O
the NN O O
visits NN O O
with NN O O
and NN O O
without NN O O
prophylaxis NN O O
. NN O O

Among NN O O
the NN O O
58 NN O O
eyes NN O O
of NN O O
55 NN O O
patients NN O O
( NN O O
116 NN O O
visits NN O O
) NN O O
, NN O O
the NN O O
mean NN O O
( NN O O
SD NN O O
) NN O O
age NN O O
was NN O O
74.3 NN O O
( NN O O
11.6 NN O O
) NN O O
, NN O O
and NN O O
62 NN O O
% NN O O
were NN O O
female NN O O
. NN O O

The NN O O
mean NN O O
baseline NN O O
IOP NN O O
was NN O O
15.3 NN O O
( NN O O
2.3 NN O O
) NN O O
mm NN O O
Hg NN O O
( NN O O
range NN O O
: NN O O
11 NN O O
- NN O O
20 NN O O
) NN O O
. NN O O

On NN O O
average NN O O
, NN O O
the NN O O
immediate NN O O
postinjection NN O O
IOP NN O O
during NN O O
the NN O O
visit NN O O
without NN O O
prophylaxis NN O O
was NN O O
41.6 NN O O
( NN O O
12 NN O O
) NN O O
mm NN O O
Hg NN O O
( NN O O
range NN O O
: NN O O
17 NN O O
- NN O O
81 NN O O
) NN O O
. NN O O

Compared NN O O
with NN O O
no NN O O
prophylaxis NN O O
, NN O O
the NN O O
visit NN O O
with NN O O
preadministered NN O O
topical NN O O
brimonidine NN O O
tartrate NN O O
had NN O O
a NN O O
lower NN O O
IOP NN O O
at NN O O
T0 NN O O
( NN O O
p<0.001 NN O O
) NN O O
, NN O O
T10 NN O O
( NN O O
p=0.001 NN O O
) NN O O
and NN O O
T20 NN O O
( NN O O
p=0.043 NN O O
) NN O O
, NN O O
and NN O O
a NN O O
smaller NN O O
proportion NN O O
of NN O O
eyes NN O O
with NN O O
IOP NN O O
elevation NN O O
of NN O O
greater NN O O
than NN O O
20 NN O O
mm NN O O
Hg NN O O
from NN O O
preinjection NN O O
( NN O O
p=0.002 NN O O
) NN O O
and NN O O
IOP NN O O
greater NN O O
than NN O O
50 NN O O
mm NN O O
Hg NN O O
at NN O O
T0 NN O O
( NN O O
p=0.036 NN O O
) NN O O
. NN O O

Without NN O O
prophylaxis NN O O
, NN O O
two NN O O
eyes NN O O
( NN O O
two NN O O
patients NN O O
) NN O O
had NN O O
an NN O O
IOP NN O O
of NN O O
greater NN O O
than NN O O
70 NN O O
mm NN O O
Hg NN O O
at NN O O
T0 NN O O
and NN O O
thus NN O O
underwent NN O O
anterior NN O O
chamber NN O O
paracentesis NN O O
. NN O O

Topical NN O O
brimonidine NN O O
tartrate NN O O
prophylaxis NN O O
for NN O O
intravitreal NN O O
injection NN O O
of NN O O
anti-VEGF NN O O
agents NN O O
effectively NN O O
reduces NN O O
IOP NN O O
spikes NN O O
in NN O O
non-glaucomatous NN O O
eyes NN O O
and NN O O
may NN O O
be NN O O
easily NN O O
incorporated NN O O
into NN O O
ophthalmologists NN O O
' NN O O
current NN O O
practice NN O O
. NN O O

NCT03513172 NN O O
. NN O O



-DOCSTART- (30409178)

Chronic NN O O
rhinosinusitis NN O O
( NN O O
CRS NN O O
) NN O O
affects NN O O
up NN O O
to NN O O
16 NN O O
% NN O O
of NN O O
the NN O O
population NN O O
. NN O O

When NN O O
medical NN O O
treatment NN O O
fails NN O O
, NN O O
endoscopic NN O O
sinus NN O O
surgery NN O O
( NN O O
ESS NN O O
) NN O O
is NN O O
considered NN O O
. NN O O

The NN O O
value NN O O
of NN O O
resecting NN O O
the NN O O
middle NN O O
turbinate NN O O
to NN O O
optimize NN O O
surgical NN O O
outcomes NN O O
has NN O O
been NN O O
hypothesized NN O O
but NN O O
remains NN O O
controversial NN O O
and NN O O
unproven NN O O
. NN O O

Whether NN O O
the NN O O
middle NN O O
turbinate NN O O
should NN O O
be NN O O
left NN O O
in NN O O
place NN O O
or NN O O
resected NN O O
is NN O O
controversial NN O O
. NN O O

Our NN O O
objective NN O O
is NN O O
to NN O O
determine NN O O
if NN O O
middle NN O O
turbinectomy NN O O
improves NN O O
objective NN O O
surgical NN O O
outcomes NN O O
after NN O O
ESS NN O O
. NN O O

Sixteen NN O O
patients NN O O
( NN O O
15 NN O O
men NN O O
, NN O O
15 NN O O
primary NN O O
surgery NN O O
) NN O O
undergoing NN O O
bilateral NN O O
complete NN O O
ESS NN O O
for NN O O
CRS NN O O
with NN O O
nasal NN O O
polyposis NN O O
were NN O O
recruited NN O O
. NN O O

Nasal NN O O
cavities NN O O
were NN O O
randomized NN O O
so NN O O
that NN O O
middle NN O O
turbinectomy NN O O
was NN O O
performed NN O O
on NN O O
one NN O O
side NN O O
while NN O O
the NN O O
middle NN O O
turbinate NN O O
was NN O O
preserved NN O O
on NN O O
the NN O O
other NN O O
. NN O O

Each NN O O
participant NN O O
acted NN O O
as NN O O
their NN O O
own NN O O
control NN O O
. NN O O

Nasal NN O O
cavities NN O O
were NN O O
compared NN O O
using NN O O
Perioperative NN O O
Sinus NN O O
Endoscopy NN O O
( NN O O
POSE NN O O
) NN O O
and NN O O
Lund-Kennedy NN O O
( NN O O
LKES NN O O
) NN O O
scores NN O O
pre-operatively NN O O
, NN O O
and NN O O
at NN O O
1 NN O O
, NN O O
3 NN O O
and NN O O
6 NN O O
months NN O O
after NN O O
ESS NN O O
. NN O O

Results NN O O
were NN O O
analyzed NN O O
using NN O O
Wilcoxon NN O O
signed-rank NN O O
test NN O O
. NN O O

Pre-operatively NN O O
, NN O O
the NN O O
POSE NN O O
( NN O O
12.4 NN O O
± NN O O
2.9 NN O O
vs NN O O
12.8 NN O O
± NN O O
2.6 NN O O
, NN O O
p NN O O
= NN O O
0.33 NN O O
, NN O O
for NN O O
the NN O O
preserved NN O O
side NN O O
and NN O O
the NN O O
resected NN O O
side NN O O
, NN O O
respectively NN O O
) NN O O
and NN O O
LKES NN O O
( NN O O
5.0 NN O O
± NN O O
1.0 NN O O
vs NN O O
4.8 NN O O
± NN O O
1.2 NN O O
, NN O O
p NN O O
= NN O O
0.33 NN O O
) NN O O
scores NN O O
were NN O O
similar NN O O
between NN O O
sides NN O O
. NN O O

During NN O O
follow NN O O
up NN O O
, NN O O
resection NN O O
was NN O O
associated NN O O
with NN O O
more NN O O
crusting NN O O
at NN O O
1 NN O O
month NN O O
following NN O O
ESS NN O O
( NN O O
1.0 NN O O
± NN O O
0.7 NN O O
vs NN O O
0.4 NN O O
± NN O O
0.6 NN O O
, NN O O
p NN O O
= NN O O
0.02 NN O O
) NN O O
. NN O O

There NN O O
was NN O O
a NN O O
small NN O O
, NN O O
but NN O O
statistically NN O O
significant NN O O
, NN O O
difference NN O O
between NN O O
the NN O O
nasal NN O O
cavities NN O O
at NN O O
3 NN O O
months NN O O
, NN O O
where NN O O
the NN O O
resected NN O O
side NN O O
showed NN O O
better NN O O
endoscopic NN O O
appearance NN O O
( NN O O
2.0 NN O O
± NN O O
2.2 NN O O
vs NN O O
3.4 NN O O
± NN O O
2.8 NN O O
, NN O O
p NN O O
= NN O O
0.01 NN O O
) NN O O
. NN O O

No NN O O
difference NN O O
was NN O O
found NN O O
at NN O O
6 NN O O
months NN O O
. NN O O

Frontal NN O O
sinus NN O O
scores NN O O
were NN O O
similar NN O O
between NN O O
sides NN O O
at NN O O
6 NN O O
months NN O O
( NN O O
0.7 NN O O
± NN O O
0.5 NN O O
vs NN O O
0.7 NN O O
± NN O O
0.5 NN O O
, NN O O
p NN O O
= NN O O
1.00 NN O O
) NN O O
. NN O O

Our NN O O
results NN O O
show NN O O
no NN O O
sustained NN O O
objective NN O O
endoscopic NN O O
benefit NN O O
of NN O O
routine NN O O
middle NN O O
turbinectomy NN O O
, NN O O
at NN O O
least NN O O
within NN O O
the NN O O
first NN O O
six NN O O
postoperative NN O O
months NN O O
, NN O O
in NN O O
patients NN O O
undergoing NN O O
primary NN O O
ESS NN O O
for NN O O
CRS NN O O
with NN O O
polyposis NN O O
. NN O O

NCT NN O O
, NN O O
NCT02855931 NN O O
. NN O O

Registered NN O O
16 NN O O
August NN O O
2016 NN O O
. NN O O



-DOCSTART- (30836981)

Chronic NN O O
treatment NN O O
of NN O O
hypertension NN O O
or NN O O
heart NN O O
failure NN O O
very NN O O
often NN O O
includes NN O O
an NN O O
angiotensin-converting NN O O
enzyme NN O O
inhibitors NN O O
( NN O O
ACE-Is NN O O
) NN O O
or NN O O
angiotensin NN O O
receptor NN O O
blockers NN O O
( NN O O
ARBs NN O O
) NN O O
as NN O O
renin-angiotensin NN O O
system NN O O
inhibitors NN O O
( NN O O
RASi NN O O
) NN O O
treatments NN O O
. NN O O

To NN O O
stop NN O O
or NN O O
not NN O O
to NN O O
stop NN O O
these NN O O
medications NN O O
before NN O O
major NN O O
surgery NN O O
remains NN O O
an NN O O
unresolved NN O O
issue NN O O
. NN O O

The NN O O
lack NN O O
of NN O O
evidence NN O O
leads NN O O
to NN O O
conflicting NN O O
guidelines NN O O
with NN O O
respect NN O O
to NN O O
RASi NN O O
management NN O O
before NN O O
major NN O O
surgery NN O O
. NN O O

The NN O O
purpose NN O O
of NN O O
this NN O O
study NN O O
is NN O O
to NN O O
evaluate NN O O
the NN O O
impact NN O O
of NN O O
a NN O O
strategy NN O O
of NN O O
RASi NN O O
continuation NN O O
or NN O O
discontinuation NN O O
on NN O O
perioperative NN O O
complications NN O O
in NN O O
patients NN O O
undergoing NN O O
major NN O O
non-cardiac NN O O
surgery NN O O
. NN O O

This NN O O
is NN O O
a NN O O
multicenter NN O O
, NN O O
open-labeled NN O O
randomized NN O O
controlled NN O O
trial NN O O
in NN O O
> NN O O
30 NN O O
French NN O O
centers NN O O
. NN O O

In NN O O
the NN O O
experimental NN O O
group NN O O
, NN O O
RASi NN O O
will NN O O
be NN O O
continued NN O O
while NN O O
the NN O O
treatment NN O O
will NN O O
be NN O O
stopped NN O O
48 NN O O
h NN O O
before NN O O
the NN O O
surgery NN O O
in NN O O
the NN O O
control NN O O
arm NN O O
. NN O O

The NN O O
primary NN O O
endpoint NN O O
is NN O O
a NN O O
composite NN O O
endpoint NN O O
of NN O O
major NN O O
complications NN O O
after NN O O
surgery NN O O
. NN O O

An NN O O
endpoint NN O O
adjudication NN O O
committee NN O O
will NN O O
review NN O O
clinical NN O O
data NN O O
and NN O O
adjudicate NN O O
efficacy NN O O
endpoints NN O O
while NN O O
blinded NN O O
to NN O O
the NN O O
assigned NN O O
study NN O O
drug NN O O
group NN O O
. NN O O

Main NN O O
analysis NN O O
will NN O O
be NN O O
by NN O O
intention-to-treat NN O O
comparing NN O O
the NN O O
composite NN O O
outcome NN O O
measure NN O O
at NN O O
28 NN O O
days NN O O
in NN O O
the NN O O
two NN O O
groups NN O O
. NN O O

A NN O O
total NN O O
of NN O O
2222 NN O O
patients NN O O
are NN O O
planned NN O O
to NN O O
detect NN O O
an NN O O
absolute NN O O
complications NN O O
difference NN O O
of NN O O
5 NN O O
% NN O O
. NN O O

The NN O O
results NN O O
of NN O O
the NN O O
trial NN O O
should NN O O
provide NN O O
robust NN O O
evidence NN O O
to NN O O
anesthesiologists NN O O
and NN O O
surgeons NN O O
regarding NN O O
management NN O O
of NN O O
RASi NN O O
before NN O O
major NN O O
non-cardiac NN O O
surgery NN O O
. NN O O

ClinicalTrials.gov NN O O
, NN O O
NCT03374449 NN O O
. NN O O

Registered NN O O
on NN O O
11 NN O O
December NN O O
2017 NN O O
. NN O O



-DOCSTART- (31209699)

The NN O O
aim NN O O
of NN O O
this NN O O
study NN O O
was NN O O
to NN O O
evaluate NN O O
the NN O O
dimensions NN O O
of NN O O
the NN O O
vaginal NN O O
canal NN O O
in NN O O
patients NN O O
undergoing NN O O
gynaecological NN O O
brachytherapy NN O O
and NN O O
the NN O O
effect NN O O
of NN O O
the NN O O
use NN O O
of NN O O
vaginal NN O O
dilators NN O O
( NN O O
VD NN O O
) NN O O
used NN O O
in NN O O
the NN O O
follow-up NN O O
of NN O O
pelvic NN O O
physiotherapy NN O O
. NN O O

A NN O O
total NN O O
of NN O O
88 NN O O
patients NN O O
were NN O O
randomly NN O O
allocated NN O O
to NN O O
the NN O O
control NN O O
group NN O O
( NN O O
CG NN O O
) NN O O
and NN O O
intervention NN O O
group NN O O
( NN O O
IG NN O O
) NN O O
. NN O O

Three NN O O
evaluations NN O O
were NN O O
performed NN O O
: NN O O
pre-brachytherapy NN O O
, NN O O
post-brachytherapy NN O O
and NN O O
follow-up NN O O
of NN O O
3 NN O O
months NN O O
. NN O O

The NN O O
CG NN O O
received NN O O
standard NN O O
guidance NN O O
from NN O O
the NN O O
health NN O O
team NN O O
while NN O O
the NN O O
IG NN O O
was NN O O
instructed NN O O
to NN O O
use NN O O
VD NN O O
for NN O O
3 NN O O
months NN O O
. NN O O

The NN O O
dimensions NN O O
of NN O O
the NN O O
vaginal NN O O
canal NN O O
( NN O O
main NN O O
outcome NN O O
) NN O O
were NN O O
defined NN O O
by NN O O
the NN O O
length NN O O
of NN O O
the NN O O
vagina NN O O
( NN O O
centimetres NN O O
) NN O O
, NN O O
width NN O O
( NN O O
number NN O O
of NN O O
full NN O O
clockwise NN O O
turns NN O O
of NN O O
the NN O O
opening NN O O
thread NN O O
of NN O O
a NN O O
gynaecological NN O O
speculum NN O O
) NN O O
and NN O O
area NN O O
( NN O O
defined NN O O
by NN O O
the NN O O
size NN O O
of NN O O
the NN O O
VD NN O O
) NN O O
. NN O O

Quality NN O O
of NN O O
life NN O O
and NN O O
pelvic NN O O
floor NN O O
( NN O O
PF NN O O
) NN O O
functionality NN O O
were NN O O
also NN O O
evaluated NN O O
. NN O O

There NN O O
was NN O O
no NN O O
effect NN O O
of NN O O
the NN O O
VD NN O O
on NN O O
vaginal NN O O
length NN O O
, NN O O
width NN O O
and NN O O
area NN O O
among NN O O
the NN O O
intention-to-treat NN O O
( NN O O
ITT NN O O
) NN O O
population NN O O
. NN O O

However NN O O
, NN O O
in NN O O
the NN O O
analysis NN O O
stratified NN O O
by NN O O
adhesion NN O O
, NN O O
the NN O O
CG NN O O
had NN O O
a NN O O
significant NN O O
decrease NN O O
in NN O O
the NN O O
vaginal NN O O
area NN O O
. NN O O

PF NN O O
was NN O O
predominantly NN O O
hypoactive NN O O
throughout NN O O
the NN O O
follow-up NN O O
. NN O O

Quality NN O O
of NN O O
life NN O O
improved NN O O
in NN O O
both NN O O
groups NN O O
, NN O O
but NN O O
the NN O O
reduction NN O O
of NN O O
constipation NN O O
, NN O O
vaginal NN O O
dryness NN O O
and NN O O
stress NN O O
urinary NN O O
incontinence NN O O
manifested NN O O
only NN O O
in NN O O
the NN O O
IG NN O O
. NN O O

The NN O O
use NN O O
of NN O O
VD NN O O
did NN O O
not NN O O
alter NN O O
the NN O O
dimensions NN O O
of NN O O
the NN O O
vaginal NN O O
canal NN O O
within NN O O
the NN O O
first NN O O
3 NN O O
months NN O O
after NN O O
the NN O O
end NN O O
of NN O O
radiotherapy NN O O
treatment NN O O
. NN O O

However NN O O
, NN O O
there NN O O
was NN O O
a NN O O
large NN O O
sample NN O O
loss NN O O
during NN O O
follow-up NN O O
so NN O O
studies NN O O
with NN O O
a NN O O
larger NN O O
sample NN O O
number NN O O
and NN O O
longer NN O O
follow-up NN O O
time NN O O
need NN O O
to NN O O
be NN O O
conducted NN O O
. NN O O

ClinicalTrials.gov NN O O
Identifier NN O O
NCT03090217 NN O O
. NN O O



-DOCSTART- (30835309)

There NN O O
is NN O O
no NN O O
definitive NN O O
evidence NN O O
that NN O O
changes NN O O
in NN O O
physical NN O O
activity/sedentary NN O O
behavior NN O O
can NN O O
be NN O O
maintained NN O O
long NN O O
term NN O O
in NN O O
individuals NN O O
with NN O O
type NN O O
2 NN O O
diabetes NN O O
. NN O O

To NN O O
investigate NN O O
whether NN O O
a NN O O
behavioral NN O O
intervention NN O O
strategy NN O O
can NN O O
produce NN O O
a NN O O
sustained NN O O
increase NN O O
in NN O O
physical NN O O
activity NN O O
and NN O O
reduction NN O O
in NN O O
sedentary NN O O
time NN O O
among NN O O
individuals NN O O
with NN O O
type NN O O
2 NN O O
diabetes NN O O
. NN O O

The NN O O
Italian NN O O
Diabetes NN O O
and NN O O
Exercise NN O O
Study NN O O
2 NN O O
was NN O O
an NN O O
open-label NN O O
, NN O O
assessor-blinded NN O O
, NN O O
randomized NN O O
clinical NN O O
superiority NN O O
trial NN O O
, NN O O
with NN O O
recruitment NN O O
from NN O O
October NN O O
2012 NN O O
to NN O O
February NN O O
2014 NN O O
and NN O O
follow-up NN O O
until NN O O
February NN O O
2017 NN O O
. NN O O

In NN O O
3 NN O O
outpatient NN O O
diabetes NN O O
clinics NN O O
in NN O O
Rome NN O O
, NN O O
300 NN O O
physically NN O O
inactive NN O O
and NN O O
sedentary NN O O
patients NN O O
with NN O O
type NN O O
2 NN O O
diabetes NN O O
were NN O O
randomized NN O O
1:1 NN O O
( NN O O
stratified NN O O
by NN O O
center NN O O
, NN O O
age NN O O
, NN O O
and NN O O
diabetes NN O O
treatment NN O O
) NN O O
to NN O O
receive NN O O
a NN O O
behavioral NN O O
intervention NN O O
or NN O O
standard NN O O
care NN O O
for NN O O
3 NN O O
years NN O O
. NN O O

All NN O O
participants NN O O
received NN O O
usual NN O O
care NN O O
targeted NN O O
to NN O O
meet NN O O
American NN O O
Diabetes NN O O
Association NN O O
guideline NN O O
recommendations NN O O
. NN O O

Participants NN O O
in NN O O
the NN O O
behavioral NN O O
intervention NN O O
group NN O O
( NN O O
n NN O O
= NN O O
150 NN O O
) NN O O
received NN O O
1 NN O O
individual NN O O
theoretical NN O O
counseling NN O O
session NN O O
and NN O O
8 NN O O
individual NN O O
biweekly NN O O
theoretical NN O O
and NN O O
practical NN O O
counseling NN O O
sessions NN O O
each NN O O
year NN O O
. NN O O

Participants NN O O
in NN O O
the NN O O
standard NN O O
care NN O O
group NN O O
( NN O O
n NN O O
= NN O O
150 NN O O
) NN O O
received NN O O
only NN O O
general NN O O
physician NN O O
recommendations NN O O
. NN O O

Co-primary NN O O
end NN O O
points NN O O
were NN O O
sustained NN O O
change NN O O
in NN O O
physical NN O O
activity NN O O
volume NN O O
, NN O O
time NN O O
spent NN O O
in NN O O
light-intensity NN O O
and NN O O
moderate- NN O O
to NN O O
vigorous-intensity NN O O
physical NN O O
activity NN O O
, NN O O
and NN O O
sedentary NN O O
time NN O O
, NN O O
measured NN O O
by NN O O
an NN O O
accelerometer NN O O
. NN O O

Of NN O O
the NN O O
300 NN O O
randomized NN O O
participants NN O O
( NN O O
mean NN O O
[ NN O O
SD NN O O
] NN O O
age NN O O
, NN O O
61.6 NN O O
[ NN O O
8.5 NN O O
] NN O O
years NN O O
; NN O O
116 NN O O
women NN O O
[ NN O O
38.7 NN O O
% NN O O
] NN O O
) NN O O
, NN O O
267 NN O O
completed NN O O
the NN O O
study NN O O
( NN O O
133 NN O O
in NN O O
the NN O O
behavioral NN O O
intervention NN O O
group NN O O
and NN O O
134 NN O O
in NN O O
the NN O O
standard NN O O
care NN O O
group NN O O
) NN O O
. NN O O

Median NN O O
follow-up NN O O
was NN O O
3.0 NN O O
years NN O O
. NN O O

Participants NN O O
in NN O O
the NN O O
behavioral NN O O
intervention NN O O
and NN O O
standard NN O O
care NN O O
groups NN O O
accumulated NN O O
, NN O O
respectively NN O O
, NN O O
13.8 NN O O
vs NN O O
10.5 NN O O
metabolic NN O O
equivalent-h/wk NN O O
of NN O O
physical NN O O
activity NN O O
volume NN O O
( NN O O
difference NN O O
, NN O O
3.3 NN O O
[ NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
2.2 NN O O
- NN O O
4.4 NN O O
] NN O O
; NN O O
P NN O O
< NN O O
.001 NN O O
) NN O O
, NN O O
18.9 NN O O
vs NN O O
12.5 NN O O
min/dof NN O O
moderate- NN O O
to NN O O
vigorous-intensity NN O O
physical NN O O
activity NN O O
( NN O O
difference NN O O
, NN O O
6.4 NN O O
[ NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
5.0 NN O O
- NN O O
7.8 NN O O
] NN O O
; NN O O
P NN O O
< NN O O
.001 NN O O
) NN O O
, NN O O
4.6 NN O O
vs NN O O
3.8 NN O O
h/d NN O O
of NN O O
light-intensity NN O O
physical NN O O
activity NN O O
( NN O O
difference NN O O
, NN O O
0.8 NN O O
[ NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
0.5 NN O O
- NN O O
1.1 NN O O
] NN O O
; NN O O
P NN O O
< NN O O
.001 NN O O
) NN O O
, NN O O
and NN O O
10.9 NN O O
vs NN O O
11.7 NN O O
h/d NN O O
of NN O O
sedentary NN O O
time NN O O
( NN O O
difference NN O O
, NN O O
-0.8 NN O O
[ NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
-1.0 NN O O
to NN O O
-0.5 NN O O
] NN O O
; NN O O
P NN O O
< NN O O
.001 NN O O
) NN O O
. NN O O

Significant NN O O
between-group NN O O
differences NN O O
were NN O O
maintained NN O O
throughout NN O O
the NN O O
study NN O O
, NN O O
but NN O O
the NN O O
between-group NN O O
difference NN O O
in NN O O
moderate- NN O O
to NN O O
vigorous-intensity NN O O
physical NN O O
activity NN O O
decreased NN O O
during NN O O
the NN O O
third NN O O
year NN O O
from NN O O
6.5 NN O O
to NN O O
3.6 NN O O
min/d NN O O
. NN O O

There NN O O
were NN O O
41 NN O O
adverse NN O O
events NN O O
in NN O O
the NN O O
behavioral NN O O
intervention NN O O
group NN O O
and NN O O
59 NN O O
in NN O O
the NN O O
standard NN O O
care NN O O
group NN O O
outside NN O O
of NN O O
the NN O O
sessions NN O O
; NN O O
participants NN O O
in NN O O
the NN O O
behavioral NN O O
intervention NN O O
group NN O O
experienced NN O O
30 NN O O
adverse NN O O
events NN O O
during NN O O
the NN O O
sessions NN O O
( NN O O
most NN O O
commonly NN O O
musculoskeletal NN O O
injury/discomfort NN O O
and NN O O
mild NN O O
hypoglycemia NN O O
) NN O O
. NN O O

Among NN O O
patients NN O O
with NN O O
type NN O O
2 NN O O
diabetes NN O O
at NN O O
3 NN O O
diabetes NN O O
clinics NN O O
in NN O O
Rome NN O O
who NN O O
were NN O O
followed NN O O
up NN O O
for NN O O
3 NN O O
years NN O O
, NN O O
a NN O O
behavioral NN O O
intervention NN O O
strategy NN O O
compared NN O O
with NN O O
standard NN O O
care NN O O
resulted NN O O
in NN O O
a NN O O
sustained NN O O
increase NN O O
in NN O O
physical NN O O
activity NN O O
and NN O O
decrease NN O O
in NN O O
sedentary NN O O
time NN O O
. NN O O

Further NN O O
research NN O O
is NN O O
needed NN O O
to NN O O
assess NN O O
the NN O O
generalizability NN O O
of NN O O
these NN O O
findings NN O O
. NN O O

ClinicalTrials.gov NN O O
Identifier NN O O
: NN O O
NCT01600937 NN O O
. NN O O



-DOCSTART- (30994898)

Prior NN O O
observational NN O O
studies NN O O
suggest NN O O
that NN O O
quality NN O O
of NN O O
care NN O O
improvement NN O O
( NN O O
QCI NN O O
) NN O O
initiatives NN O O
can NN O O
improve NN O O
the NN O O
clinical NN O O
outcomes NN O O
of NN O O
acute NN O O
coronary NN O O
syndrome NN O O
( NN O O
ACS NN O O
) NN O O
. NN O O

To NN O O
our NN O O
knowledge NN O O
, NN O O
this NN O O
has NN O O
never NN O O
been NN O O
demonstrated NN O O
in NN O O
a NN O O
well-powered NN O O
randomized NN O O
clinical NN O O
trial NN O O
. NN O O

To NN O O
determine NN O O
whether NN O O
a NN O O
clinical NN O O
pathway-based NN O O
, NN O O
multifaceted NN O O
QCI NN O O
intervention NN O O
could NN O O
improve NN O O
clinical NN O O
outcomes NN O O
among NN O O
patients NN O O
with NN O O
ACS NN O O
in NN O O
resource-constrained NN O O
hospitals NN O O
in NN O O
China NN O O
. NN O O

This NN O O
large NN O O
, NN O O
stepped-wedge NN O O
cluster NN O O
randomized NN O O
clinical NN O O
trial NN O O
was NN O O
conducted NN O O
in NN O O
nonpercutaneous NN O O
coronary NN O O
intervention NN O O
hospitals NN O O
across NN O O
China NN O O
and NN O O
included NN O O
all NN O O
patients NN O O
older NN O O
than NN O O
18 NN O O
years NN O O
and NN O O
with NN O O
a NN O O
final NN O O
diagnosis NN O O
of NN O O
ACS NN O O
who NN O O
were NN O O
recruited NN O O
consecutively NN O O
between NN O O
October NN O O
2011 NN O O
and NN O O
December NN O O
2014 NN O O
. NN O O

We NN O O
excluded NN O O
patients NN O O
who NN O O
died NN O O
before NN O O
or NN O O
within NN O O
10 NN O O
minutes NN O O
of NN O O
hospital NN O O
arrival NN O O
. NN O O

We NN O O
recruited NN O O
5768 NN O O
and NN O O
0 NN O O
eligible NN O O
patients NN O O
for NN O O
the NN O O
control NN O O
and NN O O
intervention NN O O
groups NN O O
, NN O O
respectively NN O O
, NN O O
in NN O O
step NN O O
1 NN O O
, NN O O
4326 NN O O
and NN O O
1365 NN O O
in NN O O
step NN O O
2 NN O O
, NN O O
3278 NN O O
and NN O O
3059 NN O O
in NN O O
step NN O O
3 NN O O
, NN O O
1419 NN O O
and NN O O
4468 NN O O
in NN O O
step NN O O
4 NN O O
, NN O O
and NN O O
0 NN O O
and NN O O
5645 NN O O
in NN O O
step NN O O
5 NN O O
. NN O O

The NN O O
intervention NN O O
included NN O O
establishing NN O O
a NN O O
QCI NN O O
team NN O O
, NN O O
training NN O O
clinical NN O O
staff NN O O
, NN O O
implementing NN O O
ACS NN O O
clinical NN O O
pathways NN O O
, NN O O
sequential NN O O
site NN O O
performance NN O O
assessment NN O O
and NN O O
feedback NN O O
, NN O O
online NN O O
technical NN O O
support NN O O
, NN O O
and NN O O
patient NN O O
education NN O O
. NN O O

The NN O O
usual NN O O
care NN O O
was NN O O
the NN O O
control NN O O
that NN O O
was NN O O
compared NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
was NN O O
the NN O O
incidence NN O O
of NN O O
in-hospital NN O O
major NN O O
adverse NN O O
cardiovascular NN O O
events NN O O
( NN O O
MACE NN O O
) NN O O
, NN O O
comprising NN O O
all-cause NN O O
mortality NN O O
, NN O O
reinfarction/myocardial NN O O
infarction NN O O
, NN O O
and NN O O
nonfatal NN O O
stroke NN O O
. NN O O

Secondary NN O O
outcomes NN O O
included NN O O
16 NN O O
key NN O O
performance NN O O
indicators NN O O
( NN O O
KPIs NN O O
) NN O O
and NN O O
the NN O O
composite NN O O
score NN O O
developed NN O O
from NN O O
these NN O O
KPIs NN O O
. NN O O

Of NN O O
29 NN O O
346 NN O O
patients NN O O
( NN O O
17 NN O O
639 NN O O
men NN O O
[ NN O O
61 NN O O
% NN O O
] NN O O
; NN O O
mean NN O O
[ NN O O
SD NN O O
] NN O O
age NN O O
for NN O O
control NN O O
, NN O O
64.1 NN O O
[ NN O O
11.6 NN O O
] NN O O
years NN O O
; NN O O
mean NN O O
[ NN O O
SD NN O O
] NN O O
age NN O O
for NN O O
intervention NN O O
, NN O O
63.9 NN O O
[ NN O O
11.7 NN O O
] NN O O
years NN O O
) NN O O
who NN O O
were NN O O
recruited NN O O
from NN O O
101 NN O O
hospitals NN O O
, NN O O
14 NN O O
809 NN O O
( NN O O
50.5 NN O O
% NN O O
) NN O O
were NN O O
in NN O O
the NN O O
control NN O O
period NN O O
and NN O O
14 NN O O
537 NN O O
( NN O O
49.5 NN O O
% NN O O
) NN O O
were NN O O
in NN O O
the NN O O
intervention NN O O
period NN O O
. NN O O

There NN O O
was NN O O
no NN O O
significant NN O O
difference NN O O
in NN O O
the NN O O
incidence NN O O
of NN O O
in-hospital NN O O
MACE NN O O
between NN O O
the NN O O
intervention NN O O
and NN O O
control NN O O
periods NN O O
after NN O O
adjusting NN O O
for NN O O
cluster NN O O
and NN O O
time NN O O
effects NN O O
( NN O O
3.9 NN O O
% NN O O
vs NN O O
4.4 NN O O
% NN O O
; NN O O
odds NN O O
ratio NN O O
, NN O O
0.93 NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
0.75 NN O O
- NN O O
1.15 NN O O
; NN O O
P NN O O
= NN O O
.52 NN O O
) NN O O
. NN O O

The NN O O
intervention NN O O
showed NN O O
a NN O O
significant NN O O
improvement NN O O
in NN O O
the NN O O
composite NN O O
KPI NN O O
score NN O O
( NN O O
mean NN O O
[ NN O O
SD NN O O
] NN O O
, NN O O
0.69 NN O O
[ NN O O
0.22 NN O O
] NN O O
vs NN O O
0.61 NN O O
[ NN O O
0.23 NN O O
] NN O O
; NN O O
P NN O O
< NN O O
.01 NN O O
) NN O O
and NN O O
in NN O O
7 NN O O
individual NN O O
KPIs NN O O
, NN O O
including NN O O
the NN O O
early NN O O
use NN O O
of NN O O
antiplatelet NN O O
therapy NN O O
and NN O O
the NN O O
use NN O O
of NN O O
appropriate NN O O
secondary NN O O
prevention NN O O
medicines NN O O
at NN O O
discharge NN O O
. NN O O

No NN O O
unexpected NN O O
adverse NN O O
events NN O O
were NN O O
reported NN O O
. NN O O

Among NN O O
resource-constrained NN O O
Chinese NN O O
hospitals NN O O
, NN O O
introducing NN O O
a NN O O
multifaceted NN O O
QCI NN O O
intervention NN O O
had NN O O
no NN O O
significant NN O O
effect NN O O
on NN O O
in-hospital NN O O
MACE NN O O
, NN O O
although NN O O
it NN O O
improved NN O O
a NN O O
few NN O O
of NN O O
the NN O O
care NN O O
process NN O O
indicators NN O O
of NN O O
evidence-based NN O O
ACS NN O O
management NN O O
. NN O O

ClinicalTrials.gov NN O O
identifier NN O O
: NN O O
NCT01398228 NN O O
. NN O O



-DOCSTART- (31126835)

The NN O O
main NN O O
aim NN O O
of NN O O
this NN O O
study NN O O
was NN O O
to NN O O
evaluate NN O O
the NN O O
effect NN O O
of NN O O
remote NN O O
ischaemic NN O O
preconditioning NN O O
( NN O O
RIPC NN O O
) NN O O
on NN O O
arterial NN O O
stiffness NN O O
in NN O O
patients NN O O
undergoing NN O O
vascular NN O O
surgery NN O O
. NN O O

This NN O O
was NN O O
a NN O O
randomised NN O O
, NN O O
sham NN O O
controlled NN O O
, NN O O
double NN O O
blind NN O O
, NN O O
single NN O O
centre NN O O
study NN O O
. NN O O

Patients NN O O
undergoing NN O O
open NN O O
abdominal NN O O
aortic NN O O
aneurysm NN O O
repair NN O O
, NN O O
surgical NN O O
lower NN O O
limb NN O O
revascularisation NN O O
surgery NN O O
or NN O O
carotid NN O O
endarterectomy NN O O
were NN O O
recruited NN O O
. NN O O

A NN O O
RIPC NN O O
or NN O O
a NN O O
sham NN O O
procedure NN O O
was NN O O
performed NN O O
, NN O O
using NN O O
a NN O O
blood NN O O
pressure NN O O
cuff NN O O
, NN O O
along NN O O
with NN O O
preparation NN O O
for NN O O
anaesthesia NN O O
. NN O O

The NN O O
RIPC NN O O
protocol NN O O
consisting NN O O
of NN O O
four NN O O
cycles NN O O
of NN O O
5 NN O O
min NN O O
of NN O O
ischaemia NN O O
, NN O O
followed NN O O
by NN O O
5 NN O O
min NN O O
of NN O O
reperfusion NN O O
was NN O O
applied NN O O
. NN O O

Arterial NN O O
stiffness NN O O
and NN O O
haemodynamic NN O O
parameters NN O O
were NN O O
measured NN O O
pre-operatively NN O O
and NN O O
20 NN O O
- NN O O
28 NN O O
h NN O O
after NN O O
surgery NN O O
. NN O O

Two NN O O
primary NN O O
outcomes NN O O
were NN O O
selected NN O O
: NN O O
augmentation NN O O
index NN O O
and NN O O
pulse NN O O
wave NN O O
velocity NN O O
. NN O O

Ninety-eight NN O O
patients NN O O
were NN O O
randomised NN O O
. NN O O

After NN O O
dropouts NN O O
44 NN O O
and NN O O
46 NN O O
patients NN O O
were NN O O
included NN O O
in NN O O
the NN O O
RIPC NN O O
and NN O O
sham NN O O
groups NN O O
, NN O O
respectively NN O O
. NN O O

Both NN O O
groups NN O O
were NN O O
comparable NN O O
. NN O O

There NN O O
were NN O O
no NN O O
statistically NN O O
significant NN O O
differences NN O O
in NN O O
augmentation NN O O
index NN O O
( NN O O
p NN O O
= NN O O
.8 NN O O
) NN O O
, NN O O
augmentation NN O O
index NN O O
corrected NN O O
for NN O O
heart NN O O
rate NN O O
of NN O O
75 NN O O
beats NN O O
per NN O O
minute NN O O
( NN O O
p NN O O
= NN O O
.8 NN O O
) NN O O
, NN O O
pulse NN O O
wave NN O O
velocity NN O O
( NN O O
p NN O O
= NN O O
.7 NN O O
) NN O O
, NN O O
large NN O O
artery NN O O
elasticity NN O O
indices NN O O
( NN O O
p NN O O
= NN O O
.8 NN O O
) NN O O
, NN O O
small NN O O
artery NN O O
elasticity NN O O
indices NN O O
( NN O O
p NN O O
= NN O O
.6 NN O O
) NN O O
, NN O O
or NN O O
mean NN O O
arterial NN O O
pressure NN O O
( NN O O
p NN O O
= NN O O
.7 NN O O
) NN O O
changes NN O O
between NN O O
the NN O O
RIPC NN O O
and NN O O
sham NN O O
groups NN O O
. NN O O

There NN O O
occurred NN O O
statistically NN O O
significant NN O O
( NN O O
p NN O O
≤ NN O O
.01 NN O O
) NN O O
improvement NN O O
in NN O O
augmentation NN O O
index NN O O
( NN O O
-5.8 NN O O
% NN O O
vs. NN O O
-5.5 NN O O
% NN O O
) NN O O
, NN O O
augmentation NN O O
index NN O O
corrected NN O O
for NN O O
a NN O O
heart NN O O
rate NN O O
of NN O O
75 NN O O
beats NN O O
per NN O O
minute NN O O
( NN O O
-2.5 NN O O
% NN O O
vs. NN O O
-2 NN O O
% NN O O
) NN O O
, NN O O
small NN O O
artery NN O O
elasticity NN O O
indices NN O O
( NN O O
0.7 NN O O
mL/mmHg NN O O
× NN O O
100 NN O O
vs. NN O O
0.9 NN O O
mL/mmHg NN O O
× NN O O
100 NN O O
) NN O O
, NN O O
and NN O O
mean NN O O
arterial NN O O
pressure NN O O
post-operatively NN O O
in NN O O
both NN O O
the NN O O
RIPC NN O O
and NN O O
the NN O O
sham NN O O
groups NN O O
( NN O O
change NN O O
median NN O O
values NN O O
in NN O O
RIPC NN O O
and NN O O
sham NN O O
groups NN O O
, NN O O
respectively NN O O
) NN O O
. NN O O

RIPC NN O O
had NN O O
no NN O O
significant NN O O
effect NN O O
on NN O O
arterial NN O O
stiffness NN O O
, NN O O
but NN O O
there NN O O
was NN O O
significant NN O O
improvement NN O O
in NN O O
arterial NN O O
stiffness NN O O
after NN O O
surgery NN O O
in NN O O
both NN O O
groups NN O O
. NN O O

Arterial NN O O
stiffness NN O O
and NN O O
haemodynamics NN O O
may NN O O
be NN O O
influenced NN O O
by NN O O
surgery NN O O
or NN O O
anaesthesia NN O O
or NN O O
oxidative NN O O
stress NN O O
or NN O O
all NN O O
factors NN O O
combined NN O O
. NN O O

Further NN O O
studies NN O O
are NN O O
needed NN O O
to NN O O
clarify NN O O
these NN O O
findings NN O O
. NN O O

CLINICALTRIALS.GOV NN O O
: NN O O
NCT02689414 NN O O
. NN O O



-DOCSTART- (31074815)

Health NN O O
risk NN O O
behaviors NN O O
are NN O O
a NN O O
leading NN O O
cause NN O O
of NN O O
morbidity NN O O
during NN O O
adolescence NN O O
. NN O O

Screening NN O O
and NN O O
counseling NN O O
for NN O O
health NN O O
risk NN O O
behaviors NN O O
are NN O O
recommended NN O O
but NN O O
infrequently NN O O
performed NN O O
. NN O O

To NN O O
test NN O O
the NN O O
effect NN O O
of NN O O
an NN O O
electronic NN O O
screening NN O O
and NN O O
feedback NN O O
tool NN O O
on NN O O
clinician NN O O
counseling NN O O
and NN O O
adolescent-reported NN O O
health NN O O
risk NN O O
behaviors NN O O
. NN O O

A NN O O
randomized NN O O
clinical NN O O
trial NN O O
compared NN O O
electronic NN O O
screening NN O O
and NN O O
feedback NN O O
on NN O O
an NN O O
intention-to-treat NN O O
basis NN O O
with NN O O
usual NN O O
care NN O O
among NN O O
300 NN O O
youths NN O O
13 NN O O
to NN O O
18 NN O O
years NN O O
of NN O O
age NN O O
at NN O O
5 NN O O
pediatric NN O O
clinics NN O O
in NN O O
the NN O O
Pacific NN O O
Northwest NN O O
. NN O O

Outcomes NN O O
were NN O O
assessed NN O O
via NN O O
electronic NN O O
survey NN O O
at NN O O
1 NN O O
day NN O O
and NN O O
3 NN O O
months NN O O
after NN O O
the NN O O
initial NN O O
visit NN O O
. NN O O

Study NN O O
data NN O O
collection NN O O
occurred NN O O
from NN O O
March NN O O
13 NN O O
, NN O O
2015 NN O O
, NN O O
to NN O O
November NN O O
29 NN O O
, NN O O
2016 NN O O
, NN O O
and NN O O
statistical NN O O
analysis NN O O
was NN O O
conducted NN O O
between NN O O
February NN O O
6 NN O O
, NN O O
2017 NN O O
, NN O O
and NN O O
June NN O O
20 NN O O
, NN O O
2018 NN O O
. NN O O

Youths NN O O
in NN O O
the NN O O
intervention NN O O
group NN O O
( NN O O
n NN O O
= NN O O
147 NN O O
) NN O O
received NN O O
electronic NN O O
screening NN O O
and NN O O
personalized NN O O
feedback NN O O
with NN O O
clinician NN O O
clinical NN O O
decision NN O O
support NN O O
. NN O O

Youths NN O O
in NN O O
the NN O O
control NN O O
group NN O O
( NN O O
n NN O O
= NN O O
153 NN O O
) NN O O
received NN O O
standard NN O O
screening NN O O
and NN O O
counseling NN O O
as NN O O
provided NN O O
by NN O O
their NN O O
clinic NN O O
. NN O O

Youths NN O O
' NN O O
report NN O O
of NN O O
receipt NN O O
of NN O O
counseling NN O O
during NN O O
the NN O O
visit NN O O
and NN O O
risk NN O O
behaviors NN O O
at NN O O
3 NN O O
months NN O O
. NN O O

In NN O O
the NN O O
final NN O O
study NN O O
sample NN O O
of NN O O
300 NN O O
youths NN O O
( NN O O
intervention NN O O
group NN O O
, NN O O
75 NN O O
girls NN O O
and NN O O
72 NN O O
boys NN O O
; NN O O
mean NN O O
[ NN O O
SD NN O O
] NN O O
age NN O O
, NN O O
14.5 NN O O
[ NN O O
1.4 NN O O
years NN O O
] NN O O
; NN O O
and NN O O
control NN O O
group NN O O
, NN O O
80 NN O O
girls NN O O
and NN O O
73 NN O O
boys NN O O
; NN O O
mean NN O O
[ NN O O
SD NN O O
] NN O O
age NN O O
, NN O O
14.5 NN O O
[ NN O O
1.4 NN O O
] NN O O
years NN O O
) NN O O
, NN O O
234 NN O O
( NN O O
78.0 NN O O
% NN O O
) NN O O
were NN O O
aged NN O O
13 NN O O
to NN O O
15 NN O O
years NN O O
. NN O O

After NN O O
adjusting NN O O
for NN O O
age NN O O
, NN O O
sex NN O O
, NN O O
and NN O O
random NN O O
effect NN O O
of NN O O
clinic NN O O
, NN O O
youths NN O O
in NN O O
the NN O O
intervention NN O O
group NN O O
were NN O O
more NN O O
likely NN O O
to NN O O
receive NN O O
counseling NN O O
for NN O O
each NN O O
of NN O O
their NN O O
reported NN O O
risk NN O O
behaviors NN O O
than NN O O
were NN O O
youths NN O O
in NN O O
the NN O O
control NN O O
group NN O O
( NN O O
adjusted NN O O
rate NN O O
ratio NN O O
, NN O O
1.32 NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
1.07 NN O O
- NN O O
1.63 NN O O
) NN O O
. NN O O

Youths NN O O
in NN O O
the NN O O
intervention NN O O
group NN O O
had NN O O
a NN O O
significantly NN O O
greater NN O O
reduction NN O O
( NN O O
β NN O O
= NN O O
-0.48 NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
-0.89 NN O O
to NN O O
-0.02 NN O O
; NN O O
P NN O O
= NN O O
.02 NN O O
) NN O O
in NN O O
their NN O O
risk NN O O
behavior NN O O
scores NN O O
at NN O O
3 NN O O
months NN O O
when NN O O
compared NN O O
with NN O O
youths NN O O
in NN O O
the NN O O
control NN O O
group NN O O
. NN O O

Electronic NN O O
screening NN O O
of NN O O
health NN O O
risk NN O O
behavior NN O O
with NN O O
clinical NN O O
decision NN O O
support NN O O
and NN O O
motivational NN O O
feedback NN O O
to NN O O
teens NN O O
can NN O O
improve NN O O
care NN O O
delivery NN O O
and NN O O
outcomes NN O O
. NN O O

ClinicalTrials.gov NN O O
identifier NN O O
: NN O O
NCT02360410 NN O O
. NN O O



-DOCSTART- (31021882)

Multimodal NN O O
analgesia NN O O
can NN O O
improve NN O O
postoperative NN O O
pain NN O O
and NN O O
possibly NN O O
accelerate NN O O
functional NN O O
recovery NN O O
after NN O O
surgery NN O O
. NN O O

Serratus NN O O
plane NN O O
block NN O O
( NN O O
SPB NN O O
) NN O O
is NN O O
a NN O O
novel NN O O
, NN O O
ultrasound-guided NN O O
regional NN O O
anaesthetic NN O O
technique NN O O
for NN O O
complete NN O O
analgesia NN O O
of NN O O
the NN O O
anterolateral NN O O
chest NN O O
wall NN O O
. NN O O

But NN O O
, NN O O
the NN O O
effect NN O O
of NN O O
SPB NN O O
on NN O O
the NN O O
quality NN O O
of NN O O
recovery NN O O
after NN O O
breast NN O O
cancer NN O O
surgery NN O O
has NN O O
not NN O O
been NN O O
established NN O O
. NN O O

To NN O O
test NN O O
the NN O O
hypothesis NN O O
that NN O O
pre-operative NN O O
SPB NN O O
would NN O O
enhance NN O O
the NN O O
quality NN O O
of NN O O
recovery NN O O
following NN O O
breast NN O O
cancer NN O O
surgery NN O O
. NN O O

A NN O O
randomised NN O O
, NN O O
double-blind NN O O
, NN O O
parallel-group NN O O
, NN O O
placebo-controlled NN O O
trial NN O O
. NN O O

Single NN O O
university NN O O
teaching NN O O
hospital NN O O
, NN O O
from NN O O
March NN O O
2016 NN O O
to NN O O
June NN O O
2017 NN O O
. NN O O

Seventy-two NN O O
women NN O O
scheduled NN O O
for NN O O
breast NN O O
cancer NN O O
surgery NN O O
. NN O O

Participants NN O O
were NN O O
randomised NN O O
in NN O O
a NN O O
1 NN O O
: NN O O
1 NN O O
ratio NN O O
to NN O O
receive NN O O
SPB NN O O
with NN O O
25 NN O O
ml NN O O
of NN O O
ropivacaine NN O O
0.5 NN O O
% NN O O
or NN O O
physiological NN O O
saline NN O O
. NN O O

The NN O O
primary NN O O
endpoint NN O O
was NN O O
the NN O O
40-item NN O O
Quality NN O O
of NN O O
Recovery NN O O
questionnaire NN O O
score NN O O
24 NN O O
hours NN O O
postoperatively NN O O
hours NN O O
. NN O O

Secondary NN O O
endpoints NN O O
were NN O O
postoperative NN O O
pain NN O O
intensity NN O O
, NN O O
cumulative NN O O
opioid NN O O
consumption NN O O
, NN O O
postoperative NN O O
nausea NN O O
and NN O O
vomiting NN O O
, NN O O
dizziness NN O O
, NN O O
post NN O O
anaesthesia NN O O
care NN O O
unit NN O O
discharge NN O O
time NN O O
and NN O O
patient NN O O
satisfaction NN O O
. NN O O

The NN O O
global NN O O
median NN O O
[ NN O O
IQR NN O O
] NN O O
40-item NN O O
Quality NN O O
of NN O O
Recovery NN O O
questionnaire NN O O
score NN O O
at NN O O
24 NN O O
postoperative NN O O
hours NN O O
was NN O O
significantly NN O O
higher NN O O
in NN O O
the NN O O
SPB NN O O
group NN O O
( NN O O
158 NN O O
[ NN O O
153.8 NN O O
to NN O O
159.3 NN O O
] NN O O
) NN O O
than NN O O
the NN O O
control NN O O
group NN O O
( NN O O
141 NN O O
[ NN O O
139 NN O O
to NN O O
145.3 NN O O
] NN O O
) NN O O
with NN O O
a NN O O
median NN O O
difference NN O O
of NN O O
15 NN O O
( NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
: NN O O
13 NN O O
to NN O O
17 NN O O
, NN O O
P NN O O
< NN O O
0.001 NN O O
) NN O O
. NN O O

Compared NN O O
with NN O O
the NN O O
control NN O O
group NN O O
, NN O O
postoperative NN O O
pain NN O O
scores NN O O
at NN O O
rest NN O O
were NN O O
significantly NN O O
lower NN O O
up NN O O
to NN O O
24 NN O O
h NN O O
in NN O O
the NN O O
SPB NN O O
group NN O O
. NN O O

Pre-operative NN O O
SPB NN O O
reduced NN O O
postoperative NN O O
cumulative NN O O
opioid NN O O
consumption NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
postoperative NN O O
nausea NN O O
and NN O O
vomiting NN O O
and NN O O
the NN O O
post NN O O
anaesthesia NN O O
care NN O O
unit NN O O
discharge NN O O
time NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
patient NN O O
satisfaction NN O O
scores NN O O
were NN O O
higher NN O O
in NN O O
the NN O O
SPB NN O O
group NN O O
. NN O O

Pre-operative NN O O
administration NN O O
of NN O O
SPB NN O O
with NN O O
ropivacaine NN O O
improved NN O O
the NN O O
quality NN O O
of NN O O
recovery NN O O
, NN O O
postoperative NN O O
analgesia NN O O
and NN O O
patient NN O O
satisfaction NN O O
following NN O O
breast NN O O
cancer NN O O
surgery NN O O
. NN O O

ClinicalTrials.gov NN O O
( NN O O
identifier NN O O
: NN O O
NCT02691195 NN O O
) NN O O
. NN O O



-DOCSTART- (30996056)

To NN O O
determine NN O O
the NN O O
effect NN O O
of NN O O
erenumab NN O O
, NN O O
a NN O O
human NN O O
anti-calcitonin NN O O
gene-related NN O O
peptide NN O O
receptor NN O O
monoclonal NN O O
antibody NN O O
, NN O O
in NN O O
patients NN O O
with NN O O
chronic NN O O
migraine NN O O
and NN O O
medication NN O O
overuse NN O O
. NN O O

In NN O O
this NN O O
double-blind NN O O
, NN O O
placebo-controlled NN O O
study NN O O
, NN O O
667 NN O O
adults NN O O
with NN O O
chronic NN O O
migraine NN O O
were NN O O
randomized NN O O
( NN O O
3:2:2 NN O O
) NN O O
to NN O O
placebo NN O O
or NN O O
erenumab NN O O
( NN O O
70 NN O O
or NN O O
140 NN O O
mg NN O O
) NN O O
, NN O O
stratified NN O O
by NN O O
region NN O O
and NN O O
medication NN O O
overuse NN O O
status NN O O
. NN O O

Data NN O O
from NN O O
patients NN O O
with NN O O
baseline NN O O
medication NN O O
overuse NN O O
at NN O O
baseline NN O O
were NN O O
used NN O O
to NN O O
assess NN O O
changes NN O O
in NN O O
monthly NN O O
migraine NN O O
days NN O O
, NN O O
acute NN O O
migraine-specific NN O O
medication NN O O
treatment NN O O
days NN O O
, NN O O
and NN O O
proportion NN O O
of NN O O
patients NN O O
achieving NN O O
≥50 NN O O
% NN O O
reduction NN O O
from NN O O
baseline NN O O
in NN O O
monthly NN O O
migraine NN O O
days NN O O
. NN O O

Of NN O O
667 NN O O
patients NN O O
randomized NN O O
, NN O O
41 NN O O
% NN O O
( NN O O
n NN O O
= NN O O
274 NN O O
) NN O O
met NN O O
medication NN O O
overuse NN O O
criteria NN O O
. NN O O

In NN O O
the NN O O
medication NN O O
overuse NN O O
subgroup NN O O
, NN O O
erenumab NN O O
70 NN O O
or NN O O
140 NN O O
mg NN O O
groups NN O O
had NN O O
greater NN O O
reductions NN O O
than NN O O
the NN O O
placebo NN O O
group NN O O
at NN O O
month NN O O
3 NN O O
in NN O O
monthly NN O O
migraine NN O O
days NN O O
( NN O O
mean NN O O
[ NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
] NN O O
-6.6 NN O O
[ NN O O
-8.0 NN O O
to NN O O
-5.3 NN O O
] NN O O
and NN O O
-6.6 NN O O
[ NN O O
-8.0 NN O O
to NN O O
-5.3 NN O O
] NN O O
vs NN O O
-3.5 NN O O
[ NN O O
-4.6 NN O O
to NN O O
-2.4 NN O O
] NN O O
) NN O O
and NN O O
acute NN O O
migraine-specific NN O O
medication NN O O
treatment NN O O
days NN O O
( NN O O
-5.4 NN O O
[ NN O O
-6.5 NN O O
to NN O O
-4.4 NN O O
] NN O O
and NN O O
-4.9 NN O O
[ NN O O
-6.0 NN O O
to NN O O
-3.8 NN O O
] NN O O
vs NN O O
-2.1 NN O O
[ NN O O
-3.0 NN O O
to NN O O
-1.2 NN O O
] NN O O
) NN O O
. NN O O

In NN O O
the NN O O
placebo NN O O
and NN O O
70 NN O O
and NN O O
140 NN O O
mg NN O O
groups NN O O
, NN O O
≥50 NN O O
% NN O O
reductions NN O O
in NN O O
monthly NN O O
migraine NN O O
days NN O O
were NN O O
achieved NN O O
by NN O O
18 NN O O
% NN O O
, NN O O
36 NN O O
% NN O O
( NN O O
odds NN O O
ratio NN O O
[ NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
] NN O O
2.67 NN O O
[ NN O O
1.36 NN O O
- NN O O
5.22 NN O O
] NN O O
) NN O O
and NN O O
35 NN O O
% NN O O
( NN O O
odds NN O O
ratio NN O O
2.51 NN O O
[ NN O O
1.28 NN O O
- NN O O
4.94 NN O O
] NN O O
) NN O O
. NN O O

These NN O O
clinical NN O O
responses NN O O
paralleled NN O O
improvements NN O O
in NN O O
patient-reported NN O O
outcomes NN O O
with NN O O
a NN O O
consistent NN O O
benefit NN O O
of NN O O
erenumab NN O O
across NN O O
multiple NN O O
measures NN O O
of NN O O
impact NN O O
, NN O O
disability NN O O
, NN O O
and NN O O
health-related NN O O
quality NN O O
of NN O O
life NN O O
. NN O O

The NN O O
observed NN O O
treatment NN O O
effects NN O O
were NN O O
similar NN O O
in NN O O
the NN O O
non-medication NN O O
overuse NN O O
subgroup NN O O
. NN O O

Erenumab NN O O
reduced NN O O
migraine NN O O
frequency NN O O
and NN O O
acute NN O O
migraine-specific NN O O
medication NN O O
treatment NN O O
days NN O O
in NN O O
patients NN O O
with NN O O
chronic NN O O
migraine NN O O
and NN O O
medication NN O O
overuse NN O O
, NN O O
improving NN O O
disability NN O O
and NN O O
quality NN O O
of NN O O
life NN O O
. NN O O

NCT02066415 NN O O
. NN O O

This NN O O
study NN O O
provides NN O O
Class NN O O
II NN O O
evidence NN O O
that NN O O
erenumab NN O O
reduces NN O O
monthly NN O O
migraine NN O O
days NN O O
at NN O O
3 NN O O
months NN O O
in NN O O
patients NN O O
with NN O O
chronic NN O O
migraine NN O O
and NN O O
medication NN O O
overuse NN O O
. NN O O



-DOCSTART- (31270121)

A NN O O
current NN O O
non-pharmacological NN O O
mean NN O O
for NN O O
attaining NN O O
painless NN O O
local NN O O
anaesthesia NN O O
( NN O O
LA NN O O
) NN O O
is NN O O
presented NN O O
by NN O O
vibrotactile NN O O
devices NN O O
. NN O O

Their NN O O
concept NN O O
is NN O O
to NN O O
reduce NN O O
injection NN O O
pain NN O O
due NN O O
to NN O O
distraction NN O O
by NN O O
applying NN O O
physical NN O O
stimuli NN O O
which NN O O
interfere NN O O
with NN O O
pain NN O O
signals NN O O
. NN O O

The NN O O
aim NN O O
of NN O O
this NN O O
study NN O O
is NN O O
to NN O O
determine NN O O
the NN O O
efficacy NN O O
of NN O O
the NN O O
DentalVibe NN O O
( NN O O
DV NN O O
) NN O O
device NN O O
in NN O O
reducing NN O O
pain NN O O
and NN O O
anxiety NN O O
associated NN O O
with NN O O
LA NN O O
in NN O O
paediatric NN O O
patients NN O O
. NN O O

The NN O O
proposed NN O O
study NN O O
is NN O O
a NN O O
randomised NN O O
controlled NN O O
clinical NN O O
trial NN O O
with NN O O
split-mouth NN O O
design NN O O
. NN O O

Included NN O O
are NN O O
positive NN O O
patients NN O O
aged NN O O
8 NN O O
- NN O O
12 NN O O
years NN O O
, NN O O
requiring NN O O
buccal NN O O
infiltration NN O O
for NN O O
extraction NN O O
of NN O O
two NN O O
bilateral NN O O
primary NN O O
maxillary NN O O
molars NN O O
. NN O O

After NN O O
dental NN O O
fear NN O O
measurement NN O O
, NN O O
eligible NN O O
patients NN O O
undergo NN O O
two NN O O
single-visit NN O O
treatments NN O O
with NN O O
DV NN O O
device NN O O
allocated NN O O
to NN O O
either NN O O
first NN O O
or NN O O
second NN O O
LA NN O O
via NN O O
computer-generated NN O O
randomisation NN O O
sequence NN O O
. NN O O

Outcome NN O O
measures NN O O
will NN O O
be NN O O
self-reported NN O O
pain NN O O
felt NN O O
during NN O O
LA NN O O
on NN O O
Visual NN O O
Analogue NN O O
Scale NN O O
; NN O O
self-reported NN O O
anxiety NN O O
on NN O O
Facial NN O O
Image NN O O
Scale NN O O
; NN O O
pain-related NN O O
behaviour NN O O
according NN O O
to NN O O
Faces NN O O
, NN O O
Legs NN O O
, NN O O
Activity NN O O
, NN O O
Cry NN O O
, NN O O
Consolability NN O O
Scale NN O O
; NN O O
heart NN O O
rate NN O O
; NN O O
patient NN O O
preference NN O O
to NN O O
LA NN O O
technique NN O O
. NN O O

Data NN O O
will NN O O
be NN O O
analysed NN O O
with NN O O
intention-to-treat NN O O
concept NN O O
by NN O O
Student NN O O
's NN O O
t-test NN O O
for NN O O
paired NN O O
samples NN O O
, NN O O
Wilcoxon NN O O
signed-rank NN O O
test NN O O
, NN O O
p<0.05 NN O O
. NN O O

Pretest NN O O
on NN O O
20 NN O O
subjects NN O O
resulted NN O O
in NN O O
n=41 NN O O
patients NN O O
sample NN O O
size NN O O
. NN O O

This NN O O
study NN O O
protocol NN O O
has NN O O
been NN O O
approved NN O O
by NN O O
the NN O O
Committee NN O O
for NN O O
Scientific NN O O
Research NN O O
Ethics NN O O
, NN O O
Medical NN O O
University NN O O
- NN O O
Plovdiv NN O O
, NN O O
Bulgaria NN O O
( NN O O
Reference NN O O
number NN O O
P-8604 NN O O
, NN O O
Protocol NN O O
of NN O O
approval NN O O
No. NN O O
6/23.11.2017 NN O O
) NN O O
and NN O O
registered NN O O
on NN O O
a NN O O
publicly NN O O
accessible NN O O
database NN O O
. NN O O

This NN O O
research NN O O
received NN O O
institutional NN O O
funding NN O O
from NN O O
the NN O O
Medical NN O O
University NN O O
- NN O O
Plovdiv NN O O
, NN O O
Bulgaria NN O O
, NN O O
under NN O O
project NN O O
SPD-03/2017 NN O O
. NN O O

Findings NN O O
will NN O O
be NN O O
reported NN O O
in NN O O
scientific NN O O
publications NN O O
and NN O O
at NN O O
research NN O O
conferences NN O O
, NN O O
and NN O O
in NN O O
project NN O O
summary NN O O
papers NN O O
for NN O O
participants NN O O
. NN O O

NCT03445182 NN O O
; NN O O
Pre-results NN O O
. NN O O



-DOCSTART- (30449712)

Post-traumatic NN O O
stress NN O O
disorder NN O O
( NN O O
PTSD NN O O
) NN O O
is NN O O
a NN O O
complex NN O O
and NN O O
difficult-to-treat NN O O
disorder NN O O
, NN O O
affecting NN O O
10 NN O O
- NN O O
20 NN O O
% NN O O
of NN O O
military NN O O
veterans NN O O
. NN O O

Previous NN O O
research NN O O
has NN O O
raised NN O O
the NN O O
question NN O O
of NN O O
whether NN O O
a NN O O
non-trauma-focused NN O O
treatment NN O O
can NN O O
be NN O O
as NN O O
effective NN O O
as NN O O
trauma NN O O
exposure NN O O
therapy NN O O
in NN O O
reducing NN O O
PTSD NN O O
symptoms NN O O
. NN O O

This NN O O
study NN O O
aimed NN O O
to NN O O
compare NN O O
the NN O O
non-trauma-focused NN O O
practice NN O O
of NN O O
Transcendental NN O O
Meditation NN O O
( NN O O
TM NN O O
) NN O O
with NN O O
prolonged NN O O
exposure NN O O
therapy NN O O
( NN O O
PE NN O O
) NN O O
in NN O O
a NN O O
non-inferiority NN O O
clinical NN O O
trial NN O O
, NN O O
and NN O O
to NN O O
compare NN O O
both NN O O
therapies NN O O
with NN O O
a NN O O
control NN O O
of NN O O
PTSD NN O O
health NN O O
education NN O O
( NN O O
HE NN O O
) NN O O
. NN O O

We NN O O
did NN O O
a NN O O
randomised NN O O
controlled NN O O
trial NN O O
at NN O O
the NN O O
Department NN O O
of NN O O
Veterans NN O O
Affairs NN O O
San NN O O
Diego NN O O
Healthcare NN O O
System NN O O
in NN O O
CA NN O O
, NN O O
USA NN O O
. NN O O

We NN O O
included NN O O
203 NN O O
veterans NN O O
with NN O O
a NN O O
current NN O O
diagnosis NN O O
of NN O O
PTSD NN O O
resulting NN O O
from NN O O
active NN O O
military NN O O
service NN O O
randomly NN O O
assigned NN O O
to NN O O
a NN O O
TM NN O O
or NN O O
PE NN O O
group NN O O
, NN O O
or NN O O
an NN O O
active NN O O
control NN O O
group NN O O
of NN O O
HE NN O O
, NN O O
using NN O O
stratified NN O O
block NN O O
randomisation NN O O
. NN O O

Each NN O O
treatment NN O O
provided NN O O
12 NN O O
sessions NN O O
over NN O O
12 NN O O
weeks NN O O
, NN O O
with NN O O
daily NN O O
home NN O O
practice NN O O
. NN O O

TM NN O O
and NN O O
HE NN O O
were NN O O
mainly NN O O
given NN O O
in NN O O
a NN O O
group NN O O
setting NN O O
and NN O O
PE NN O O
was NN O O
given NN O O
individually NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
was NN O O
change NN O O
in NN O O
PTSD NN O O
symptom NN O O
severity NN O O
over NN O O
3 NN O O
months NN O O
, NN O O
assessed NN O O
by NN O O
the NN O O
Clinician-Administered NN O O
PTSD NN O O
Scale NN O O
( NN O O
CAPS NN O O
) NN O O
. NN O O

Analysis NN O O
was NN O O
by NN O O
intention NN O O
to NN O O
treat NN O O
. NN O O

We NN O O
hypothesised NN O O
that NN O O
TM NN O O
would NN O O
show NN O O
non-inferiority NN O O
to NN O O
PE NN O O
in NN O O
improvement NN O O
of NN O O
CAPS NN O O
score NN O O
( NN O O
Δ=10 NN O O
) NN O O
, NN O O
with NN O O
TM NN O O
and NN O O
PE NN O O
superior NN O O
to NN O O
PTSD NN O O
HE NN O O
. NN O O

This NN O O
study NN O O
is NN O O
registered NN O O
with NN O O
ClinicalTrials.gov NN O O
, NN O O
number NN O O
NCT01865123 NN O O
. NN O O

Between NN O O
June NN O O
10 NN O O
, NN O O
2013 NN O O
, NN O O
and NN O O
Oct NN O O
7 NN O O
, NN O O
2016 NN O O
, NN O O
203 NN O O
veterans NN O O
were NN O O
randomly NN O O
assigned NN O O
to NN O O
an NN O O
intervention NN O O
group NN O O
( NN O O
68 NN O O
to NN O O
the NN O O
TM NN O O
group NN O O
, NN O O
68 NN O O
to NN O O
the NN O O
PE NN O O
group NN O O
, NN O O
and NN O O
67 NN O O
to NN O O
the NN O O
PTSD NN O O
HE NN O O
group NN O O
) NN O O
. NN O O

TM NN O O
was NN O O
significantly NN O O
non-inferior NN O O
to NN O O
PE NN O O
on NN O O
change NN O O
in NN O O
CAPS NN O O
score NN O O
from NN O O
baseline NN O O
to NN O O
3-month NN O O
post-test NN O O
( NN O O
difference NN O O
between NN O O
groups NN O O
in NN O O
mean NN O O
change NN O O
-5·9 NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
-14·3 NN O O
to NN O O
2·4 NN O O
, NN O O
p=0·0002 NN O O
) NN O O
. NN O O

In NN O O
standard NN O O
superiority NN O O
comparisons NN O O
, NN O O
significant NN O O
reductions NN O O
in NN O O
CAPS NN O O
scores NN O O
were NN O O
found NN O O
for NN O O
TM NN O O
versus NN O O
PTSD NN O O
HE NN O O
( NN O O
-14·6 NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
-23·3 NN O O
to NN O O
-5·9 NN O O
, NN O O
p=0·0009 NN O O
) NN O O
, NN O O
and NN O O
PE NN O O
versus NN O O
PTSD NN O O
HE NN O O
( NN O O
-8·7 NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
-17·0 NN O O
to NN O O
-0·32 NN O O
, NN O O
p=0·041 NN O O
) NN O O
. NN O O

61 NN O O
% NN O O
of NN O O
those NN O O
receiving NN O O
TM NN O O
, NN O O
42 NN O O
% NN O O
of NN O O
those NN O O
receiving NN O O
PE NN O O
, NN O O
and NN O O
32 NN O O
% NN O O
of NN O O
those NN O O
receiving NN O O
HE NN O O
showed NN O O
clinically NN O O
significant NN O O
improvements NN O O
on NN O O
the NN O O
CAPS NN O O
score NN O O
. NN O O

A NN O O
non-trauma-focused-therapy NN O O
, NN O O
TM NN O O
, NN O O
might NN O O
be NN O O
a NN O O
viable NN O O
option NN O O
for NN O O
decreasing NN O O
the NN O O
severity NN O O
of NN O O
PTSD NN O O
symptoms NN O O
in NN O O
veterans NN O O
and NN O O
represents NN O O
an NN O O
efficacious NN O O
alternative NN O O
for NN O O
veterans NN O O
who NN O O
prefer NN O O
not NN O O
to NN O O
receive NN O O
or NN O O
who NN O O
do NN O O
not NN O O
respond NN O O
to NN O O
traditional NN O O
exposure-based NN O O
treatments NN O O
of NN O O
PTSD NN O O
. NN O O

Department NN O O
of NN O O
Defense NN O O
, NN O O
US NN O O
Army NN O O
Medical NN O O
Research NN O O
. NN O O



-DOCSTART- (31147675)

This NN O O
hypothesis-generating NN O O
trial NN O O
evaluated NN O O
neoadjuvant NN O O
ipatasertib-paclitaxel NN O O
for NN O O
early NN O O
triple-negative NN O O
breast NN O O
cancer NN O O
( NN O O
TNBC NN O O
) NN O O
. NN O O

In NN O O
this NN O O
randomized NN O O
phase NN O O
II NN O O
trial NN O O
, NN O O
patients NN O O
with NN O O
early NN O O
TNBC NN O O
( NN O O
T NN O O
≥ NN O O
1.5 NN O O
cm NN O O
, NN O O
N0 NN O O
- NN O O
2 NN O O
) NN O O
were NN O O
randomized NN O O
1:1 NN O O
to NN O O
receive NN O O
weekly NN O O
paclitaxel NN O O
80 NN O O
mg/m2 NN O O
with NN O O
ipatasertib NN O O
400 NN O O
mg NN O O
or NN O O
placebo NN O O
( NN O O
days NN O O
1 NN O O
- NN O O
21 NN O O
every NN O O
28 NN O O
days NN O O
) NN O O
for NN O O
12 NN O O
weeks NN O O
before NN O O
surgery NN O O
. NN O O

Co-primary NN O O
endpoints NN O O
were NN O O
pathologic NN O O
complete NN O O
response NN O O
( NN O O
pCR NN O O
) NN O O
rate NN O O
( NN O O
ypT0/TisN0 NN O O
) NN O O
in NN O O
the NN O O
intention-to-treat NN O O
( NN O O
ITT NN O O
) NN O O
and NN O O
immunohistochemistry NN O O
PTEN-low NN O O
populations NN O O
. NN O O

Secondary NN O O
endpoints NN O O
included NN O O
pCR NN O O
rate NN O O
in NN O O
patients NN O O
with NN O O
PIK3CA/AKT1/PTEN-altered NN O O
tumors NN O O
and NN O O
pre-surgery NN O O
response NN O O
rates NN O O
by NN O O
magnetic NN O O
resonance NN O O
imaging NN O O
( NN O O
MRI NN O O
) NN O O
. NN O O

pCR NN O O
rates NN O O
with NN O O
ipatasertib NN O O
versus NN O O
placebo NN O O
were NN O O
17 NN O O
% NN O O
versus NN O O
13 NN O O
% NN O O
, NN O O
respectively NN O O
, NN O O
in NN O O
the NN O O
ITT NN O O
population NN O O
( NN O O
N NN O O
= NN O O
151 NN O O
) NN O O
, NN O O
16 NN O O
% NN O O
versus NN O O
13 NN O O
% NN O O
in NN O O
the NN O O
immunohistochemistry NN O O
PTEN-low NN O O
population NN O O
( NN O O
N NN O O
= NN O O
35 NN O O
) NN O O
, NN O O
and NN O O
18 NN O O
% NN O O
versus NN O O
12 NN O O
% NN O O
in NN O O
the NN O O
PIK3CA/AKT1/PTEN-altered NN O O
subgroup NN O O
( NN O O
N NN O O
= NN O O
62 NN O O
) NN O O
. NN O O

Rates NN O O
of NN O O
overall NN O O
and NN O O
complete NN O O
response NN O O
( NN O O
CR NN O O
) NN O O
by NN O O
MRI NN O O
favored NN O O
ipatasertib NN O O
in NN O O
all NN O O
three NN O O
populations NN O O
( NN O O
CR NN O O
rate NN O O
39 NN O O
% NN O O
versus NN O O
9 NN O O
% NN O O
in NN O O
the NN O O
PIK3CA/AKT1/PTEN-altered NN O O
subgroup NN O O
) NN O O
. NN O O

Ipatasertib NN O O
was NN O O
associated NN O O
with NN O O
more NN O O
grade NN O O
≥3 NN O O
adverse NN O O
events NN O O
( NN O O
32 NN O O
% NN O O
versus NN O O
16 NN O O
% NN O O
with NN O O
placebo NN O O
) NN O O
, NN O O
especially NN O O
diarrhea NN O O
( NN O O
17 NN O O
% NN O O
versus NN O O
1 NN O O
% NN O O
) NN O O
. NN O O

Higher NN O O
cycle NN O O
1 NN O O
day NN O O
8 NN O O
( NN O O
C1D8 NN O O
) NN O O
immune NN O O
score NN O O
was NN O O
significantly NN O O
associated NN O O
with NN O O
better NN O O
response NN O O
only NN O O
in NN O O
placebo-treated NN O O
patients NN O O
. NN O O

All NN O O
ipatasertib-treated NN O O
patients NN O O
with NN O O
low NN O O
immune NN O O
scores NN O O
and NN O O
a NN O O
CR NN O O
had NN O O
PIK3CA/AKT1/PTEN-altered NN O O
tumors NN O O
. NN O O

Adding NN O O
ipatasertib NN O O
to NN O O
12 NN O O
weeks NN O O
of NN O O
paclitaxel NN O O
for NN O O
early NN O O
TNBC NN O O
did NN O O
not NN O O
clinically NN O O
or NN O O
statistically NN O O
significantly NN O O
increase NN O O
pCR NN O O
rate NN O O
, NN O O
although NN O O
overall NN O O
response NN O O
rate NN O O
by NN O O
MRI NN O O
was NN O O
numerically NN O O
higher NN O O
with NN O O
ipatasertib NN O O
. NN O O

The NN O O
antitumor NN O O
effect NN O O
of NN O O
ipatasertib NN O O
was NN O O
most NN O O
pronounced NN O O
in NN O O
biomarker-selected NN O O
patients NN O O
. NN O O

Safety NN O O
was NN O O
consistent NN O O
with NN O O
prior NN O O
experience NN O O
of NN O O
ipatasertib-paclitaxel NN O O
. NN O O

A NN O O
T NN O O
cell-rich NN O O
environment NN O O
at NN O O
C1D8 NN O O
had NN O O
a NN O O
stronger NN O O
association NN O O
with NN O O
improved NN O O
outcomes NN O O
in NN O O
paclitaxel-treated NN O O
patients NN O O
than NN O O
seen NN O O
for NN O O
baseline NN O O
TILs NN O O
. NN O O

This NN O O
dependency NN O O
may NN O O
be NN O O
overcome NN O O
with NN O O
the NN O O
addition NN O O
of NN O O
AKT NN O O
inhibition NN O O
, NN O O
especially NN O O
in NN O O
patients NN O O
with NN O O
PIK3CA/AKT1/PTEN-altered NN O O
tumors NN O O
. NN O O

NCT02301988 NN O O
. NN O O



-DOCSTART- (31367958)

Previous NN O O
studies NN O O
have NN O O
demonstrated NN O O
a NN O O
relationship NN O O
between NN O O
cognitive NN O O
impairment NN O O
and NN O O
hypoglycaemia NN O O
( NN O O
<3 NN O O
mmol/l NN O O
) NN O O
. NN O O

This NN O O
study NN O O
hypothesised NN O O
that NN O O
non-severe NN O O
insulin-induced NN O O
hypoglycaemia NN O O
reduces NN O O
cognitive NN O O
function NN O O
in NN O O
individuals NN O O
with NN O O
type NN O O
2 NN O O
diabetes NN O O
. NN O O

In NN O O
this NN O O
randomised NN O O
crossover NN O O
study NN O O
, NN O O
25 NN O O
participants NN O O
with NN O O
type NN O O
2 NN O O
diabetes NN O O
attended NN O O
two NN O O
experimental NN O O
visits NN O O
with NN O O
hyperinsulinaemic NN O O
glucose NN O O
clamping NN O O
: NN O O
one NN O O
hypoglycaemic NN O O
clamp NN O O
( NN O O
plasma NN O O
glucose NN O O
3.0 NN O O
± NN O O
0.2 NN O O
mmol/l NN O O
) NN O O
and NN O O
one NN O O
euglycaemic NN O O
clamp NN O O
( NN O O
plasma NN O O
glucose NN O O
6.0 NN O O
± NN O O
0.2 NN O O
mmol/l NN O O
) NN O O
. NN O O

Participants NN O O
were NN O O
eligible NN O O
if NN O O
their NN O O
diabetes NN O O
was NN O O
treated NN O O
with NN O O
diet NN O O
or NN O O
glucose-lowering NN O O
medications NN O O
( NN O O
except NN O O
sulfonylureas NN O O
or NN O O
insulin NN O O
) NN O O
, NN O O
age NN O O
was NN O O
35 NN O O
- NN O O
70 NN O O
years NN O O
, NN O O
BMI NN O O
was NN O O
23 NN O O
- NN O O
35 NN O O
kg/m NN O O
and NN O O
HbA NN O O
was NN O O
below NN O O
75 NN O O
mmol/mol NN O O
( NN O O
9 NN O O
% NN O O
) NN O O
. NN O O

Cognitive NN O O
function NN O O
was NN O O
assessed NN O O
with NN O O
a NN O O
neurocognitive NN O O
test NN O O
battery NN O O
measuring NN O O
verbal NN O O
memory NN O O
, NN O O
executive NN O O
function NN O O
, NN O O
sustained NN O O
attention NN O O
and NN O O
psychomotor NN O O
speed NN O O
. NN O O

From NN O O
the NN O O
examined NN O O
cognitive NN O O
domains NN O O
, NN O O
a NN O O
global NN O O
cognition NN O O
score NN O O
was NN O O
constructed NN O O
estimating NN O O
global NN O O
cognition NN O O
. NN O O

A NN O O
measurement NN O O
for NN O O
psychomotor NN O O
speed NN O O
was NN O O
selected NN O O
as NN O O
the NN O O
primary NN O O
outcome NN O O
. NN O O

Participants NN O O
and NN O O
people NN O O
assessing NN O O
the NN O O
outcomes NN O O
were NN O O
blinded NN O O
to NN O O
group NN O O
assignment NN O O
. NN O O

Cognitive NN O O
performance NN O O
was NN O O
impaired NN O O
during NN O O
hypoglycaemia NN O O
with NN O O
a NN O O
mean NN O O
score NN O O
in NN O O
the NN O O
primary NN O O
outcome NN O O
test NN O O
, NN O O
Symbol NN O O
Digit NN O O
Modalities NN O O
Test NN O O
measuring NN O O
psychomotor NN O O
speed NN O O
, NN O O
of NN O O
48.7 NN O O
± NN O O
9.8 NN O O
( NN O O
hypoglycaemia NN O O
) NN O O
vs NN O O
56.6 NN O O
± NN O O
12.0 NN O O
( NN O O
euglycaemia NN O O
) NN O O
; NN O O
i.e. NN O O
a NN O O
change NN O O
of NN O O
-7.9 NN O O
points NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
-10.9 NN O O
, NN O O
-4.9 NN O O
; NN O O
p NN O O
< NN O O
0.0001 NN O O
) NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
hypoglycaemia NN O O
reduced NN O O
global NN O O
cognitive NN O O
score NN O O
by NN O O
-0.7 NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
-0.9 NN O O
, NN O O
-0.6 NN O O
; NN O O
p NN O O
< NN O O
0.0001 NN O O
) NN O O
. NN O O

A NN O O
stable NN O O
glucose NN O O
plateau NN O O
was NN O O
achieved NN O O
during NN O O
both NN O O
experimental NN O O
visits NN O O
. NN O O

For NN O O
the NN O O
hypoglycaemic NN O O
clamp NN O O
, NN O O
mean NN O O
plasma NN O O
glucose NN O O
concentration NN O O
( NN O O
± NN O O
SD NN O O
) NN O O
during NN O O
neurocognitive NN O O
testing NN O O
was NN O O
3.1 NN O O
( NN O O
± NN O O
0.3 NN O O
) NN O O
mmol/l NN O O
. NN O O

Age NN O O
, NN O O
sex NN O O
, NN O O
fasting NN O O
C-peptide NN O O
, NN O O
counter-regulatory NN O O
hormones NN O O
and NN O O
the NN O O
severity NN O O
of NN O O
hypoglycaemic NN O O
symptoms NN O O
did NN O O
not NN O O
influence NN O O
cognitive NN O O
function NN O O
. NN O O

Acute NN O O
non-severe NN O O
hypoglycaemia NN O O
( NN O O
mean NN O O
plasma NN O O
glucose NN O O
3.1 NN O O
mmol/l NN O O
) NN O O
has NN O O
a NN O O
substantial NN O O
negative NN O O
impact NN O O
on NN O O
cognitive NN O O
function NN O O
in NN O O
individuals NN O O
with NN O O
type NN O O
2 NN O O
diabetes NN O O
. NN O O

ClinicalTrials.gov NN O O
NCT03014011 NN O O
. NN O O

The NN O O
study NN O O
was NN O O
supported NN O O
in NN O O
part NN O O
by NN O O
a NN O O
research NN O O
grant NN O O
from NN O O
the NN O O
Investigator NN O O
Initiated NN O O
Studies NN O O
Program NN O O
of NN O O
Merck NN O O
Sharp NN O O
& NN O O
Dohme NN O O
Corp NN O O
( NN O O
MSD-MA-NORD-007 NN O O
- NN O O
01 NN O O
) NN O O
. NN O O

The NN O O
opinions NN O O
expressed NN O O
in NN O O
this NN O O
paper NN O O
are NN O O
those NN O O
of NN O O
the NN O O
authors NN O O
and NN O O
do NN O O
not NN O O
necessarily NN O O
represent NN O O
those NN O O
of NN O O
Merck NN O O
Sharp NN O O
& NN O O
Dohme NN O O
Corp. NN O O
Funding NN O O
was NN O O
also NN O O
received NN O O
from NN O O
Skibsreder NN O O
Per NN O O
Henriksen NN O O
, NN O O
R. NN O O
og NN O O
hustrus NN O O
Foundation NN O O
, NN O O
The NN O O
Danish NN O O
Alzheimer NN O O
Foundation NN O O
and NN O O
Savværksejer NN O O
Jeppe NN O O
Juhl NN O O
og NN O O
hustrus NN O O
Foundation NN O O
. NN O O



-DOCSTART- (30992295)

The NN O O
optimal NN O O
duration NN O O
of NN O O
postsurgical NN O O
antibiotic NN O O
therapy NN O O
for NN O O
adult NN O O
native NN O O
joint NN O O
bacterial NN O O
arthritis NN O O
remains NN O O
unknown NN O O
. NN O O

We NN O O
conducted NN O O
a NN O O
prospective NN O O
, NN O O
unblinded NN O O
, NN O O
randomised NN O O
, NN O O
non-inferiority NN O O
study NN O O
comparing NN O O
either NN O O
2 NN O O
or NN O O
4 NN O O
weeks NN O O
of NN O O
antibiotic NN O O
therapy NN O O
after NN O O
surgical NN O O
drainage NN O O
of NN O O
native NN O O
joint NN O O
bacterial NN O O
arthritis NN O O
in NN O O
adults NN O O
. NN O O

Excluded NN O O
were NN O O
implant-related NN O O
infections NN O O
, NN O O
episodes NN O O
without NN O O
surgical NN O O
lavage NN O O
and NN O O
episodes NN O O
with NN O O
a NN O O
follow-up NN O O
of NN O O
less NN O O
than NN O O
2 NN O O
months NN O O
. NN O O

We NN O O
enrolled NN O O
154 NN O O
cases NN O O
: NN O O
77 NN O O
in NN O O
the NN O O
4-week NN O O
arm NN O O
and NN O O
77 NN O O
in NN O O
the NN O O
2-week NN O O
arm NN O O
. NN O O

Median NN O O
length NN O O
of NN O O
intravenous NN O O
antibiotic NN O O
treatment NN O O
was NN O O
1 NN O O
and NN O O
2 NN O O
days NN O O
, NN O O
respectively NN O O
. NN O O

The NN O O
median NN O O
number NN O O
of NN O O
surgical NN O O
lavages NN O O
was NN O O
1 NN O O
in NN O O
both NN O O
arms NN O O
. NN O O

Recurrence NN O O
of NN O O
infection NN O O
was NN O O
noted NN O O
in NN O O
three NN O O
patients NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
: NN O O
1 NN O O
in NN O O
the NN O O
2-week NN O O
arm NN O O
( NN O O
99 NN O O
% NN O O
cure NN O O
rate NN O O
) NN O O
and NN O O
2 NN O O
in NN O O
the NN O O
4-week NN O O
arm NN O O
( NN O O
97 NN O O
% NN O O
cure NN O O
rate NN O O
) NN O O
. NN O O

There NN O O
was NN O O
no NN O O
difference NN O O
in NN O O
the NN O O
number NN O O
of NN O O
adverse NN O O
events NN O O
or NN O O
sequelae NN O O
between NN O O
the NN O O
study NN O O
arms NN O O
. NN O O

Of NN O O
the NN O O
overall NN O O
154 NN O O
arthritis NN O O
cases NN O O
, NN O O
99 NN O O
concerned NN O O
the NN O O
hand NN O O
and NN O O
wrist NN O O
, NN O O
for NN O O
which NN O O
an NN O O
additional NN O O
subgroup NN O O
analysis NN O O
was NN O O
performed NN O O
. NN O O

In NN O O
this NN O O
per-protocol NN O O
subanalysis NN O O
, NN O O
we NN O O
noted NN O O
three NN O O
recurrences NN O O
: NN O O
one NN O O
in NN O O
the NN O O
2-week NN O O
arm NN O O
( NN O O
97 NN O O
% NN O O
cure NN O O
) NN O O
; NN O O
two NN O O
in NN O O
the NN O O
4-week NN O O
arm NN O O
( NN O O
96 NN O O
% NN O O
cure NN O O
) NN O O
and NN O O
witnessed NN O O
sequelae NN O O
in NN O O
50 NN O O
% NN O O
in NN O O
the NN O O
2-week NN O O
arm NN O O
versus NN O O
55 NN O O
% NN O O
in NN O O
the NN O O
4-week NN O O
arm NN O O
, NN O O
of NN O O
which NN O O
five NN O O
( NN O O
13 NN O O
% NN O O
) NN O O
and NN O O
six NN O O
( NN O O
13 NN O O
% NN O O
) NN O O
needed NN O O
further NN O O
interventions NN O O
. NN O O

After NN O O
initial NN O O
surgical NN O O
lavage NN O O
for NN O O
septic NN O O
arthritis NN O O
, NN O O
2 NN O O
weeks NN O O
of NN O O
targeted NN O O
antibiotic NN O O
therapy NN O O
is NN O O
not NN O O
inferior NN O O
to NN O O
4 NN O O
weeks NN O O
regarding NN O O
cure NN O O
rate NN O O
, NN O O
adverse NN O O
events NN O O
or NN O O
sequelae NN O O
and NN O O
leads NN O O
to NN O O
a NN O O
significantly NN O O
shorter NN O O
hospital NN O O
stay NN O O
, NN O O
at NN O O
least NN O O
for NN O O
hand NN O O
and NN O O
wrist NN O O
arthritis NN O O
. NN O O

NCT03615781 NN O O
. NN O O



-DOCSTART- (31248843)

Acute NN O O
graft-versus-host-disease NN O O
( NN O O
GVHD NN O O
) NN O O
after NN O O
non-myeloablative NN O O
human NN O O
leucocyte NN O O
antigen NN O O
(HLA)-matched NN O O
, NN O O
unrelated NN O O
donor NN O O
, NN O O
allogeneic NN O O
haemopoietic NN O O
stem NN O O
cell NN O O
transplantation NN O O
( NN O O
HSCT NN O O
) NN O O
is NN O O
associated NN O O
with NN O O
considerable NN O O
morbidity NN O O
and NN O O
mortality NN O O
. NN O O

This NN O O
trial NN O O
aimed NN O O
to NN O O
evaluate NN O O
the NN O O
efficacy NN O O
of NN O O
adding NN O O
sirolimus NN O O
to NN O O
the NN O O
standard NN O O
cyclosporine NN O O
and NN O O
mycophenolate NN O O
mofetil NN O O
prophylaxis NN O O
therapy NN O O
for NN O O
preventing NN O O
acute NN O O
GVHD NN O O
in NN O O
this NN O O
setting NN O O
. NN O O

This NN O O
multicentre NN O O
, NN O O
randomised NN O O
, NN O O
phase NN O O
3 NN O O
trial NN O O
took NN O O
place NN O O
at NN O O
nine NN O O
HSCT NN O O
centres NN O O
based NN O O
in NN O O
the NN O O
USA NN O O
, NN O O
Denmark NN O O
, NN O O
and NN O O
Germany NN O O
. NN O O

Eligible NN O O
patients NN O O
were NN O O
diagnosed NN O O
with NN O O
advanced NN O O
haematological NN O O
malignancies NN O O
treatable NN O O
by NN O O
allogeneic NN O O
HSCT NN O O
, NN O O
had NN O O
a NN O O
Karnofsky NN O O
score NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
60 NN O O
, NN O O
were NN O O
aged NN O O
older NN O O
than NN O O
50 NN O O
years NN O O
, NN O O
or NN O O
if NN O O
they NN O O
were NN O O
aged NN O O
50 NN O O
years NN O O
or NN O O
younger NN O O
, NN O O
were NN O O
considered NN O O
at NN O O
high NN O O
risk NN O O
of NN O O
regimen-related NN O O
toxicity NN O O
associated NN O O
with NN O O
a NN O O
high-dose NN O O
pre-transplantation NN O O
conditioning NN O O
regimen NN O O
. NN O O

Patients NN O O
were NN O O
randomly NN O O
allocated NN O O
by NN O O
an NN O O
adaptive NN O O
randomisation NN O O
scheme NN O O
stratified NN O O
by NN O O
transplantation NN O O
centre NN O O
to NN O O
receive NN O O
either NN O O
the NN O O
standard NN O O
GVHD NN O O
prophylaxis NN O O
regimen NN O O
( NN O O
cyclosporine NN O O
and NN O O
mycophenolate NN O O
mofetil NN O O
) NN O O
or NN O O
the NN O O
triple-drug NN O O
combination NN O O
regimen NN O O
( NN O O
cyclosporine NN O O
, NN O O
mycophenolate NN O O
mofetil NN O O
, NN O O
and NN O O
sirolimus NN O O
) NN O O
. NN O O

Patients NN O O
and NN O O
physicians NN O O
were NN O O
not NN O O
masked NN O O
to NN O O
treatment NN O O
. NN O O

All NN O O
patients NN O O
were NN O O
prepared NN O O
for NN O O
HSCT NN O O
with NN O O
fludarabine NN O O
( NN O O
30 NN O O
mg/m NN O O
per NN O O
day NN O O
) NN O O
4 NN O O
, NN O O
3 NN O O
, NN O O
and NN O O
2 NN O O
days NN O O
before NN O O
receiving NN O O
2 NN O O
or NN O O
3 NN O O
Gy NN O O
total NN O O
body NN O O
irradiation NN O O
on NN O O
the NN O O
day NN O O
of NN O O
HSCT NN O O
( NN O O
day NN O O
0 NN O O
) NN O O
. NN O O

In NN O O
both NN O O
study NN O O
groups NN O O
, NN O O
5·0 NN O O
mg/kg NN O O
of NN O O
cyclosporine NN O O
was NN O O
administered NN O O
orally NN O O
twice NN O O
daily NN O O
starting NN O O
3 NN O O
days NN O O
before NN O O
HSCT NN O O
, NN O O
and NN O O
( NN O O
in NN O O
the NN O O
absence NN O O
of NN O O
GVHD NN O O
) NN O O
tapered NN O O
from NN O O
day NN O O
96 NN O O
through NN O O
to NN O O
day NN O O
150 NN O O
. NN O O

In NN O O
the NN O O
standard NN O O
GVHD NN O O
prophylaxis NN O O
group NN O O
, NN O O
15 NN O O
mg/kg NN O O
of NN O O
mycophenolate NN O O
mofetil NN O O
was NN O O
given NN O O
orally NN O O
three NN O O
times NN O O
daily NN O O
from NN O O
day NN O O
0 NN O O
until NN O O
day NN O O
30 NN O O
, NN O O
then NN O O
twice NN O O
daily NN O O
until NN O O
day NN O O
150 NN O O
, NN O O
and NN O O
( NN O O
in NN O O
the NN O O
absence NN O O
of NN O O
GVHD NN O O
) NN O O
tapered NN O O
off NN O O
by NN O O
day NN O O
180 NN O O
. NN O O

In NN O O
the NN O O
triple-drug NN O O
group NN O O
, NN O O
mycophenolate NN O O
mofetil NN O O
doses NN O O
were NN O O
the NN O O
same NN O O
as NN O O
in NN O O
the NN O O
standard NN O O
group NN O O
, NN O O
but NN O O
the NN O O
drug NN O O
was NN O O
discontinued NN O O
on NN O O
day NN O O
40 NN O O
. NN O O

Sirolimus NN O O
was NN O O
started NN O O
3 NN O O
days NN O O
before NN O O
HSCT NN O O
, NN O O
taken NN O O
orally NN O O
at NN O O
2 NN O O
mg NN O O
once NN O O
daily NN O O
and NN O O
adjusted NN O O
to NN O O
maintain NN O O
trough NN O O
concentrations NN O O
between NN O O
3 NN O O
- NN O O
12 NN O O
ng/mL NN O O
through NN O O
to NN O O
day NN O O
150 NN O O
, NN O O
and NN O O
( NN O O
in NN O O
the NN O O
absence NN O O
of NN O O
GVHD NN O O
) NN O O
tapered NN O O
off NN O O
by NN O O
day NN O O
180 NN O O
. NN O O

The NN O O
primary NN O O
endpoint NN O O
was NN O O
the NN O O
cumulative NN O O
incidence NN O O
of NN O O
grade NN O O
2 NN O O
- NN O O
4 NN O O
acute NN O O
GVHD NN O O
at NN O O
day NN O O
100 NN O O
post-transplantation NN O O
. NN O O

Secondary NN O O
endpoints NN O O
were NN O O
non-relapse NN O O
mortality NN O O
, NN O O
overall NN O O
survival NN O O
, NN O O
progression-free NN O O
survival NN O O
, NN O O
cumulative NN O O
incidence NN O O
of NN O O
grade NN O O
3 NN O O
- NN O O
4 NN O O
acute NN O O
GVHD NN O O
, NN O O
and NN O O
cumulative NN O O
incidence NN O O
of NN O O
chronic NN O O
GVHD NN O O
. NN O O

Efficacy NN O O
and NN O O
safety NN O O
analyses NN O O
were NN O O
per NN O O
protocol NN O O
, NN O O
including NN O O
all NN O O
patients NN O O
who NN O O
received NN O O
conditioning NN O O
treatment NN O O
and NN O O
underwent NN O O
transplantation NN O O
. NN O O

Toxic NN O O
effects NN O O
were NN O O
measured NN O O
according NN O O
to NN O O
the NN O O
Common NN O O
Terminology NN O O
Criteria NN O O
for NN O O
Adverse NN O O
Events NN O O
( NN O O
CTCAE NN O O
) NN O O
. NN O O

The NN O O
current NN O O
study NN O O
was NN O O
closed NN O O
prematurely NN O O
by NN O O
recommendation NN O O
of NN O O
the NN O O
Data NN O O
and NN O O
Safety NN O O
Monitoring NN O O
Board NN O O
on NN O O
July NN O O
27 NN O O
, NN O O
2016 NN O O
, NN O O
after NN O O
168 NN O O
patients NN O O
received NN O O
the NN O O
allocated NN O O
intervention NN O O
, NN O O
based NN O O
on NN O O
the NN O O
results NN O O
of NN O O
a NN O O
prespecified NN O O
interim NN O O
analysis NN O O
for NN O O
futility NN O O
. NN O O

This NN O O
study NN O O
is NN O O
registered NN O O
with NN O O
ClinicalTrials.gov NN O O
, NN O O
number NN O O
NCT01231412 NN O O
. NN O O

Participants NN O O
were NN O O
recruited NN O O
between NN O O
Nov NN O O
1 NN O O
, NN O O
2010 NN O O
, NN O O
and NN O O
July NN O O
27 NN O O
, NN O O
2016 NN O O
. NN O O

Of NN O O
180 NN O O
patients NN O O
enrolled NN O O
in NN O O
the NN O O
study NN O O
, NN O O
167 NN O O
received NN O O
the NN O O
complete NN O O
study NN O O
intervention NN O O
and NN O O
were NN O O
included NN O O
in NN O O
safety NN O O
and NN O O
efficacy NN O O
analyses NN O O
: NN O O
77 NN O O
patients NN O O
in NN O O
the NN O O
standard NN O O
GVHD NN O O
prophylaxis NN O O
group NN O O
and NN O O
90 NN O O
in NN O O
the NN O O
triple-drug NN O O
group NN O O
. NN O O

At NN O O
the NN O O
time NN O O
of NN O O
analysis NN O O
, NN O O
median NN O O
follow-up NN O O
was NN O O
48 NN O O
months NN O O
( NN O O
IQR NN O O
31 NN O O
- NN O O
60 NN O O
) NN O O
. NN O O

The NN O O
cumulative NN O O
incidence NN O O
of NN O O
grade NN O O
2 NN O O
- NN O O
4 NN O O
acute NN O O
GVHD NN O O
at NN O O
day NN O O
100 NN O O
was NN O O
lower NN O O
in NN O O
the NN O O
triple-drug NN O O
group NN O O
compared NN O O
with NN O O
the NN O O
standard NN O O
GVHD NN O O
prophylaxis NN O O
group NN O O
( NN O O
26 NN O O
% NN O O
[ NN O O
95 NN O O
% NN O O
CI NN O O
17 NN O O
- NN O O
35 NN O O
] NN O O
in NN O O
the NN O O
triple-drug NN O O
group NN O O
vs NN O O
52 NN O O
% NN O O
[ NN O O
41 NN O O
- NN O O
63 NN O O
] NN O O
in NN O O
the NN O O
standard NN O O
group NN O O
; NN O O
HR NN O O
0·45 NN O O
[ NN O O
95 NN O O
% NN O O
CI NN O O
0·28 NN O O
- NN O O
0·73 NN O O
] NN O O
; NN O O
p=0·0013 NN O O
) NN O O
. NN O O

After NN O O
1 NN O O
and NN O O
4 NN O O
years NN O O
, NN O O
non-relapse NN O O
mortality NN O O
increased NN O O
to NN O O
4 NN O O
% NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
0 NN O O
- NN O O
9 NN O O
) NN O O
and NN O O
16 NN O O
% NN O O
( NN O O
8 NN O O
- NN O O
24 NN O O
) NN O O
in NN O O
the NN O O
triple-drug NN O O
group NN O O
and NN O O
16 NN O O
% NN O O
( NN O O
8 NN O O
- NN O O
24 NN O O
) NN O O
and NN O O
32 NN O O
% NN O O
( NN O O
21 NN O O
- NN O O
43 NN O O
) NN O O
in NN O O
the NN O O
standard NN O O
group NN O O
( NN O O
HR NN O O
0·48 NN O O
[ NN O O
0·26 NN O O
- NN O O
0·90 NN O O
] NN O O
; NN O O
p=0·021 NN O O
) NN O O
. NN O O

Overall NN O O
survival NN O O
at NN O O
1 NN O O
year NN O O
was NN O O
86 NN O O
% NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
78 NN O O
- NN O O
93 NN O O
) NN O O
in NN O O
the NN O O
triple-drug NN O O
group NN O O
and NN O O
70 NN O O
% NN O O
in NN O O
the NN O O
standard NN O O
group NN O O
( NN O O
60 NN O O
- NN O O
80 NN O O
) NN O O
and NN O O
at NN O O
4 NN O O
years NN O O
it NN O O
was NN O O
64 NN O O
% NN O O
in NN O O
the NN O O
triple-drug NN O O
group NN O O
( NN O O
54 NN O O
- NN O O
75 NN O O
) NN O O
and NN O O
46 NN O O
% NN O O
in NN O O
the NN O O
standard NN O O
group NN O O
( NN O O
34 NN O O
- NN O O
57 NN O O
% NN O O
; NN O O
HR NN O O
0·62 NN O O
[ NN O O
0·40 NN O O
- NN O O
0·97 NN O O
] NN O O
; NN O O
p=0·035 NN O O
) NN O O
. NN O O

Progression-free NN O O
survival NN O O
at NN O O
1 NN O O
year NN O O
was NN O O
77 NN O O
% NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
68 NN O O
- NN O O
85 NN O O
) NN O O
in NN O O
the NN O O
triple-drug NN O O
group NN O O
and NN O O
64 NN O O
% NN O O
( NN O O
53 NN O O
- NN O O
74 NN O O
) NN O O
in NN O O
the NN O O
standard NN O O
drug NN O O
group NN O O
, NN O O
and NN O O
at NN O O
4 NN O O
years NN O O
it NN O O
was NN O O
59 NN O O
% NN O O
in NN O O
the NN O O
triple-drug NN O O
group NN O O
( NN O O
49 NN O O
- NN O O
70 NN O O
) NN O O
and NN O O
41 NN O O
% NN O O
in NN O O
the NN O O
standard NN O O
group NN O O
( NN O O
30 NN O O
- NN O O
53 NN O O
% NN O O
; NN O O
HR NN O O
0·64 NN O O
[ NN O O
0·42 NN O O
- NN O O
0·99 NN O O
] NN O O
; NN O O
p=0·045 NN O O
) NN O O
. NN O O

We NN O O
observed NN O O
no NN O O
difference NN O O
in NN O O
the NN O O
cumulative NN O O
incidence NN O O
of NN O O
grade NN O O
3 NN O O
- NN O O
4 NN O O
acute NN O O
GVHD NN O O
( NN O O
2 NN O O
% NN O O
[ NN O O
0 NN O O
- NN O O
5 NN O O
] NN O O
in NN O O
the NN O O
triple-drug NN O O
group NN O O
vs NN O O
8 NN O O
% NN O O
[ NN O O
2 NN O O
- NN O O
14 NN O O
] NN O O
in NN O O
the NN O O
standard NN O O
group NN O O
; NN O O
HR NN O O
0·55 NN O O
[ NN O O
0·16 NN O O
- NN O O
1·96 NN O O
] NN O O
; NN O O
p=0·36 NN O O
) NN O O
and NN O O
chronic NN O O
GVHD NN O O
( NN O O
49 NN O O
% NN O O
[ NN O O
39 NN O O
- NN O O
59 NN O O
] NN O O
in NN O O
triple-drug NN O O
group NN O O
vs NN O O
50 NN O O
% NN O O
[ NN O O
39 NN O O
- NN O O
61 NN O O
] NN O O
in NN O O
the NN O O
standard NN O O
group NN O O
; NN O O
HR NN O O
0·94 NN O O
[ NN O O
0·62 NN O O
- NN O O
1·40 NN O O
] NN O O
; NN O O
p=0·74 NN O O
) NN O O
. NN O O

In NN O O
both NN O O
groups NN O O
the NN O O
most NN O O
common NN O O
CTCAE NN O O
grade NN O O
4 NN O O
or NN O O
higher NN O O
toxic NN O O
effects NN O O
were NN O O
pulmonary NN O O
. NN O O

Adding NN O O
sirolimus NN O O
to NN O O
cyclosporine NN O O
and NN O O
mycophenolate NN O O
mofetil NN O O
resulted NN O O
in NN O O
a NN O O
significantly NN O O
lower NN O O
proportion NN O O
of NN O O
patients NN O O
developing NN O O
acute NN O O
GVHD NN O O
compared NN O O
with NN O O
patients NN O O
treated NN O O
with NN O O
cyclosporine NN O O
and NN O O
mycophenolate NN O O
mofetil NN O O
alone NN O O
. NN O O

Based NN O O
on NN O O
these NN O O
results NN O O
, NN O O
the NN O O
combination NN O O
of NN O O
cyclosporine NN O O
, NN O O
mycophenolate NN O O
mofetil NN O O
, NN O O
and NN O O
sirolimus NN O O
has NN O O
become NN O O
the NN O O
new NN O O
standard NN O O
GVHD NN O O
prophylaxis NN O O
regimen NN O O
for NN O O
patients NN O O
treated NN O O
with NN O O
non-myeloablative NN O O
conditioning NN O O
and NN O O
HLA-matched NN O O
unrelated NN O O
HSCT NN O O
at NN O O
the NN O O
Fred NN O O
Hutchinson NN O O
Cancer NN O O
Research NN O O
Center NN O O
. NN O O

National NN O O
Institutes NN O O
of NN O O
Health NN O O
. NN O O



-DOCSTART- (31050949)

The NN O O
purpose NN O O
of NN O O
this NN O O
randomized NN O O
controlled NN O O
clinical NN O O
trial NN O O
is NN O O
to NN O O
evaluate NN O O
the NN O O
efficiency NN O O
of NN O O
erbium-doped NN O O
: NN O O
yttrium-aluminum-garnet NN O O
( NN O O
Er NN O O
: NN O O
YAG NN O O
) NN O O
laser NN O O
adjunct NN O O
to NN O O
nonsurgical NN O O
periodontal NN O O
debridement NN O O
on NN O O
clinical NN O O
periodontal NN O O
parameters NN O O
and NN O O
red NN O O
complex NN O O
periodontopathogens NN O O
. NN O O

Thirty-eight NN O O
systematically NN O O
healthy NN O O
, NN O O
never-smoker NN O O
patients NN O O
with NN O O
chronic NN O O
periodontitis NN O O
were NN O O
randomly NN O O
assigned NN O O
to NN O O
one NN O O
of NN O O
two NN O O
groups NN O O
in NN O O
a NN O O
parallel NN O O
design NN O O
: NN O O
1-scaling NN O O
and NN O O
root NN O O
planing NN O O
( NN O O
SRP NN O O
) NN O O
and NN O O
2-SRP NN O O
+ NN O O
Laser NN O O
( NN O O
SRP NN O O
+ NN O O
L NN O O
) NN O O
. NN O O

SRP NN O O
and NN O O
SRP NN O O
+ NN O O
L NN O O
administration NN O O
were NN O O
completed NN O O
within NN O O
24 NN O O
h. NN O O
Clinical NN O O
attachment NN O O
level NN O O
( NN O O
CAL NN O O
) NN O O
, NN O O
probing NN O O
depth NN O O
( NN O O
PD NN O O
) NN O O
, NN O O
plaque NN O O
index NN O O
( NN O O
PI NN O O
) NN O O
, NN O O
and NN O O
bleeding NN O O
on NN O O
probing NN O O
( NN O O
BOP NN O O
) NN O O
were NN O O
recorded NN O O
at NN O O
baseline NN O O
and NN O O
3 NN O O
and NN O O
6 NN O O
months NN O O
after NN O O
treatment NN O O
. NN O O

Subgingival NN O O
plaque NN O O
samples NN O O
were NN O O
also NN O O
measured NN O O
1 NN O O
month NN O O
after NN O O
treatment NN O O
. NN O O

Microbiological NN O O
evaluation NN O O
was NN O O
performed NN O O
using NN O O
real-time NN O O
polymerase NN O O
chain NN O O
reaction NN O O
. NN O O

All NN O O
clinical NN O O
parameters NN O O
significantly NN O O
improved NN O O
3 NN O O
and NN O O
6 NN O O
months NN O O
after NN O O
treatment NN O O
in NN O O
both NN O O
groups NN O O
. NN O O

In NN O O
the NN O O
deep NN O O
and NN O O
moderately NN O O
deep NN O O
pockets NN O O
, NN O O
PD NN O O
reduction NN O O
and NN O O
CAL NN O O
gain NN O O
between NN O O
baseline NN O O
and NN O O
6 NN O O
months NN O O
were NN O O
significantly NN O O
different NN O O
between NN O O
the NN O O
groups NN O O
( NN O O
< NN O O
0.05 NN O O
) NN O O
. NN O O

There NN O O
were NN O O
no NN O O
statistically NN O O
significant NN O O
differences NN O O
regarding NN O O
BOP NN O O
and NN O O
PI NN O O
between NN O O
the NN O O
groups NN O O
. NN O O

There NN O O
were NN O O
no NN O O
statistically NN O O
significant NN O O
differences NN O O
in NN O O
, NN O O
, NN O O
and NN O O
levels NN O O
between NN O O
the NN O O
SRP NN O O
and NN O O
SRP NN O O
+ NN O O
L NN O O
groups NN O O
at NN O O
any NN O O
time NN O O
point NN O O
( NN O O
> NN O O
0.05 NN O O
) NN O O
. NN O O

Within NN O O
the NN O O
limits NN O O
of NN O O
this NN O O
randomized NN O O
clinical NN O O
trial NN O O
, NN O O
the NN O O
adjunctive NN O O
use NN O O
of NN O O
Er NN O O
: NN O O
YAG NN O O
laser NN O O
with NN O O
SRP NN O O
may NN O O
be NN O O
beneficial NN O O
in NN O O
moderately NN O O
deep NN O O
and NN O O
deep NN O O
pockets NN O O
to NN O O
improve NN O O
CAL NN O O
and NN O O
PD NN O O
. NN O O

However NN O O
, NN O O
Er NN O O
: NN O O
YAG NN O O
laser NN O O
failed NN O O
to NN O O
demonstrate NN O O
additional NN O O
microbiological NN O O
benefits NN O O
in NN O O
nonsurgical NN O O
periodontal NN O O
treatment NN O O
. NN O O

Clinicaltrials.gov NN O O
# NN O O
NCT03387371 NN O O
. NN O O



-DOCSTART- (30541563)

We NN O O
evaluated NN O O
the NN O O
effectiveness NN O O
and NN O O
cost-effectiveness NN O O
of NN O O
a NN O O
loyalty NN O O
scheme NN O O
based NN O O
intervention NN O O
involving NN O O
rewards NN O O
for NN O O
increasing NN O O
physical NN O O
activity NN O O
in NN O O
public NN O O
sector NN O O
employees NN O O
. NN O O

A NN O O
cluster NN O O
randomised NN O O
wait-list NN O O
controlled NN O O
trial NN O O
in NN O O
public NN O O
sector NN O O
organisations NN O O
in NN O O
Northern NN O O
Ireland NN O O
. NN O O

We NN O O
randomly NN O O
assigned NN O O
clusters NN O O
( NN O O
1:1 NN O O
) NN O O
using NN O O
a NN O O
computer NN O O
generated NN O O
random NN O O
sequence NN O O
. NN O O

Researchers NN O O
were NN O O
masked NN O O
to NN O O
allocation NN O O
, NN O O
but NN O O
participants NN O O
were NN O O
not NN O O
. NN O O

Employees NN O O
aged NN O O
18 NN O O
- NN O O
65 NN O O
years NN O O
with NN O O
no NN O O
self-reported NN O O
medical NN O O
contraindications NN O O
to NN O O
physical NN O O
activity NN O O
were NN O O
included NN O O
. NN O O

The NN O O
Physical NN O O
Activity NN O O
Loyalty NN O O
Scheme NN O O
( NN O O
PAL NN O O
) NN O O
intervention NN O O
was NN O O
based NN O O
on NN O O
high-street NN O O
loyalty NN O O
cards NN O O
where NN O O
participants NN O O
earned NN O O
points NN O O
for NN O O
minutes NN O O
of NN O O
activity NN O O
that NN O O
could NN O O
be NN O O
redeemed NN O O
for NN O O
rewards NN O O
, NN O O
complemented NN O O
by NN O O
evidence-based NN O O
behaviour NN O O
change NN O O
techniques NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
was NN O O
objectively NN O O
measured NN O O
mean NN O O
steps/day NN O O
at NN O O
6 NN O O
months NN O O
using NN O O
a NN O O
validated NN O O
pedometer NN O O
( NN O O
Yamax NN O O
Digi-Walker NN O O
CW-701 NN O O
) NN O O
over NN O O
7 NN O O
days NN O O
, NN O O
assessed NN O O
with NN O O
intention NN O O
to NN O O
treat NN O O
analysis NN O O
. NN O O

Secondary NN O O
outcomes NN O O
included NN O O
health NN O O
, NN O O
mental NN O O
wellbeing NN O O
, NN O O
quality NN O O
of NN O O
life NN O O
, NN O O
work NN O O
absenteeism NN O O
and NN O O
presenteeism NN O O
, NN O O
and NN O O
use NN O O
of NN O O
healthcare NN O O
resources NN O O
. NN O O

Cost-effectiveness NN O O
, NN O O
cost-benefit NN O O
and NN O O
mediation NN O O
analyses NN O O
were NN O O
conducted NN O O
. NN O O

Trial NN O O
registered NN O O
with NN O O
Current NN O O
Controlled NN O O
Trials NN O O
, NN O O
number NN O O
ISRCTN17975376 NN O O
. NN O O

Between NN O O
September NN O O
2014 NN O O
and NN O O
October NN O O
2015 NN O O
, NN O O
we NN O O
recruited NN O O
and NN O O
randomly NN O O
assigned NN O O
37 NN O O
clusters NN O O
( NN O O
from NN O O
nine NN O O
organisations NN O O
; NN O O
mean NN O O
clusters NN O O
per NN O O
organisation NN O O
= NN O O
four NN O O
) NN O O
and NN O O
853 NN O O
participants NN O O
to NN O O
the NN O O
intervention NN O O
( NN O O
n NN O O
= NN O O
19 NN O O
with NN O O
457 NN O O
participants NN O O
) NN O O
or NN O O
control NN O O
group NN O O
( NN O O
n NN O O
= NN O O
18 NN O O
with NN O O
396 NN O O
participants NN O O
) NN O O
. NN O O

Primary NN O O
outcome NN O O
data NN O O
were NN O O
available NN O O
for NN O O
249 NN O O
( NN O O
54·4 NN O O
% NN O O
) NN O O
intervention NN O O
and NN O O
236 NN O O
( NN O O
59·6 NN O O
% NN O O
) NN O O
control NN O O
participants NN O O
. NN O O

Mean NN O O
steps/day NN O O
were NN O O
significantly NN O O
lower NN O O
in NN O O
the NN O O
intervention NN O O
vs NN O O
control NN O O
group NN O O
( NN O O
adjusted NN O O
mean NN O O
difference NN O O
= NN O O
- NN O O
336 NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
: NN O O
-612 NN O O
to NN O O
- NN O O
60 NN O O
, NN O O
p NN O O
= NN O O
0·02 NN O O
) NN O O
at NN O O
6 NN O O
months NN O O
. NN O O

Participants NN O O
redeemed NN O O
only NN O O
39 NN O O
% NN O O
( NN O O
SD NN O O
43 NN O O
% NN O O
) NN O O
of NN O O
their NN O O
earned NN O O
points NN O O
. NN O O

Using NN O O
the NN O O
Quality NN O O
Adjusted NN O O
Life NN O O
Year NN O O
outcome NN O O
, NN O O
the NN O O
intervention NN O O
was NN O O
not NN O O
cost NN O O
effective NN O O
from NN O O
an NN O O
NHS/PSS NN O O
perspective NN O O
. NN O O

A NN O O
net NN O O
cost NN O O
analysis NN O O
from NN O O
an NN O O
employer NN O O
perspective NN O O
demonstrated NN O O
the NN O O
intervention NN O O
group NN O O
was NN O O
associated NN O O
with NN O O
a NN O O
mean NN O O
of NN O O
2·97 NN O O
h NN O O
less NN O O
absenteeism NN O O
over NN O O
a NN O O
4 NN O O
week NN O O
period NN O O
( NN O O
p NN O O
= NN O O
0·62 NN O O
) NN O O
, NN O O
which NN O O
could NN O O
result NN O O
in NN O O
net NN O O
savings NN O O
ranging NN O O
from NN O O
£ NN O O
66 NN O O
to NN O O
£ NN O O
735 NN O O
depending NN O O
on NN O O
the NN O O
wage NN O O
rate NN O O
employed NN O O
. NN O O

At NN O O
4-weeks NN O O
post-baseline NN O O
there NN O O
were NN O O
significant NN O O
increases NN O O
in NN O O
identified NN O O
regulation NN O O
, NN O O
integrated NN O O
regulation NN O O
, NN O O
intrinsic NN O O
motivation NN O O
, NN O O
social NN O O
norms NN O O
and NN O O
intentions NN O O
in NN O O
intervention NN O O
compared NN O O
to NN O O
control NN O O
participants NN O O
. NN O O

Our NN O O
mixed NN O O
results NN O O
pose NN O O
challenges NN O O
that NN O O
are NN O O
too NN O O
infrequently NN O O
exposed NN O O
in NN O O
public NN O O
heath NN O O
intervention NN O O
trials NN O O
. NN O O

Although NN O O
the NN O O
intervention NN O O
successfully NN O O
altered NN O O
several NN O O
hypothesised NN O O
mediating NN O O
constructs NN O O
it NN O O
did NN O O
not NN O O
translate NN O O
into NN O O
long-term NN O O
behaviour NN O O
change NN O O
. NN O O

Our NN O O
incentive NN O O
level NN O O
may NN O O
have NN O O
been NN O O
too NN O O
low NN O O
to NN O O
incentivise NN O O
change NN O O
, NN O O
despite NN O O
being NN O O
designed NN O O
a NN O O
priori NN O O
by NN O O
a NN O O
Contingent NN O O
Valuation NN O O
Survey NN O O
. NN O O

There NN O O
were NN O O
also NN O O
major NN O O
re-structuring NN O O
of NN O O
several NN O O
organisations NN O O
which NN O O
presented NN O O
significant NN O O
implementation NN O O
challenges NN O O
, NN O O
and NN O O
technical NN O O
limitations NN O O
. NN O O

ISRCTN17975376 NN O O
( NN O O
Registered NN O O
19/09/2014 NN O O
) NN O O
. NN O O



-DOCSTART- (31196052)

Fun NN O O
For NN O O
Wellness NN O O
( NN O O
FFW NN O O
) NN O O
is NN O O
an NN O O
online NN O O
behavioral NN O O
intervention NN O O
developed NN O O
to NN O O
encourage NN O O
growth NN O O
in NN O O
well-being NN O O
by NN O O
providing NN O O
capability-enhancing NN O O
learning NN O O
opportunities NN O O
to NN O O
participants NN O O
. NN O O

Self-efficacy NN O O
theory NN O O
guides NN O O
the NN O O
conceptual NN O O
model NN O O
underlying NN O O
the NN O O
FFW NN O O
intervention NN O O
. NN O O

Some NN O O
initial NN O O
evidence NN O O
has NN O O
been NN O O
provided NN O O
for NN O O
the NN O O
efficacy NN O O
of NN O O
FFW NN O O
to NN O O
promote NN O O
: NN O O
well-being NN O O
self-efficacy NN O O
; NN O O
interpersonal NN O O
, NN O O
community NN O O
, NN O O
psychological NN O O
and NN O O
economic NN O O
subjective NN O O
well-being NN O O
; NN O O
and NN O O
, NN O O
interpersonal NN O O
and NN O O
physical NN O O
well-being NN O O
actions NN O O
. NN O O

The NN O O
purpose NN O O
of NN O O
this NN O O
paper NN O O
is NN O O
to NN O O
describe NN O O
the NN O O
protocol NN O O
for NN O O
a NN O O
new NN O O
randomized NN O O
controlled NN O O
trial NN O O
( NN O O
RCT NN O O
) NN O O
designed NN O O
to NN O O
provide NN O O
the NN O O
first NN O O
investigation NN O O
of NN O O
the NN O O
effectiveness NN O O
of NN O O
FFW NN O O
to NN O O
increase NN O O
well-being NN O O
and NN O O
physical NN O O
activity NN O O
in NN O O
adults NN O O
with NN O O
obesity NN O O
in NN O O
the NN O O
United NN O O
States NN O O
of NN O O
America NN O O
. NN O O

The NN O O
study NN O O
design NN O O
is NN O O
a NN O O
large-scale NN O O
, NN O O
prospective NN O O
, NN O O
parallel NN O O
group NN O O
RCT NN O O
. NN O O

Approximately NN O O
9 NN O O
hundred NN O O
participants NN O O
will NN O O
be NN O O
randomly NN O O
assigned NN O O
to NN O O
the NN O O
FFW NN O O
or NN O O
Usual NN O O
Care NN O O
( NN O O
UC NN O O
) NN O O
group NN O O
to NN O O
achieve NN O O
a NN O O
1:1 NN O O
group NN O O
( NN O O
i.e. NN O O
UC NN O O
) NN O O
assignment NN O O
. NN O O

Participants NN O O
will NN O O
be NN O O
recruited NN O O
through NN O O
an NN O O
online NN O O
panel NN O O
recruitment NN O O
company NN O O
. NN O O

Data NN O O
collection NN O O
, NN O O
including NN O O
determination NN O O
of NN O O
eligibility NN O O
, NN O O
will NN O O
be NN O O
conducted NN O O
online NN O O
and NN O O
enrollment NN O O
is NN O O
scheduled NN O O
to NN O O
begin NN O O
on NN O O
8 NN O O
August NN O O
2018 NN O O
. NN O O

Data NN O O
collection NN O O
will NN O O
occur NN O O
at NN O O
baseline NN O O
, NN O O
30 NN O O
days NN O O
and NN O O
60 NN O O
days NN O O
after NN O O
baseline NN O O
. NN O O

Instruments NN O O
to NN O O
measure NN O O
demographic NN O O
information NN O O
, NN O O
anthropometric NN O O
characteristics NN O O
, NN O O
self-efficacy NN O O
, NN O O
physical NN O O
activity NN O O
and NN O O
well-being NN O O
will NN O O
be NN O O
included NN O O
in NN O O
the NN O O
battery NN O O
. NN O O

Data NN O O
will NN O O
be NN O O
modeled NN O O
under NN O O
an NN O O
intent NN O O
to NN O O
treat NN O O
approach NN O O
and/or NN O O
a NN O O
complier NN O O
average NN O O
causal NN O O
effect NN O O
approach NN O O
depending NN O O
on NN O O
the NN O O
level NN O O
of NN O O
observed NN O O
engagement NN O O
with NN O O
the NN O O
intervention NN O O
. NN O O

The NN O O
effectiveness NN O O
trial NN O O
described NN O O
in NN O O
this NN O O
paper NN O O
builds NN O O
upon NN O O
the NN O O
2015 NN O O
FFW NN O O
efficacy NN O O
trial NN O O
and NN O O
has NN O O
the NN O O
potential NN O O
to NN O O
be NN O O
important NN O O
for NN O O
at NN O O
least NN O O
three NN O O
reasons NN O O
. NN O O

The NN O O
first NN O O
reason NN O O
is NN O O
based NN O O
upon NN O O
a NN O O
general NN O O
scientific NN O O
approach NN O O
that NN O O
the NN O O
potential NN O O
utility NN O O
of NN O O
interventions NN O O
should NN O O
be NN O O
evaluated NN O O
under NN O O
both NN O O
ideal NN O O
( NN O O
e.g. NN O O
, NN O O
more NN O O
controlled NN O O
) NN O O
and NN O O
real-world NN O O
( NN O O
e.g. NN O O
, NN O O
less NN O O
controlled NN O O
) NN O O
conditions NN O O
. NN O O

The NN O O
second NN O O
reason NN O O
is NN O O
based NN O O
upon NN O O
the NN O O
global NN O O
need NN O O
for NN O O
readily NN O O
scalable NN O O
online NN O O
behavioral NN O O
interventions NN O O
that NN O O
effectively NN O O
promote NN O O
physical NN O O
activity NN O O
in NN O O
adults NN O O
. NN O O

The NN O O
third NN O O
reason NN O O
is NN O O
based NN O O
upon NN O O
the NN O O
troubling NN O O
global NN O O
trend NN O O
toward NN O O
obesity NN O O
along NN O O
with NN O O
evidence NN O O
for NN O O
obesity NN O O
as NN O O
a NN O O
risk NN O O
factor NN O O
for NN O O
several NN O O
major NN O O
non-communicable NN O O
diseases NN O O
. NN O O

ClinicalTrials.gov NN O O
, NN O O
identifier NN O O
: NN O O
NCT03194854 NN O O
, NN O O
registered NN O O
21 NN O O
June NN O O
2017 NN O O
. NN O O



-DOCSTART- (30598384)

Long NN O O
chain NN O O
polyunsaturated NN O O
n-3 NN O O
fatty NN O O
acids NN O O
( NN O O
LC-PUFA NN O O
) NN O O
are NN O O
of NN O O
functional NN O O
and NN O O
structural NN O O
importance NN O O
for NN O O
brain NN O O
development NN O O
. NN O O

Observational NN O O
studies NN O O
have NN O O
shown NN O O
positive NN O O
relations NN O O
between NN O O
fatty NN O O
fish NN O O
consumption NN O O
and NN O O
cognitive NN O O
performance NN O O
in NN O O
children NN O O
, NN O O
but NN O O
Results NN O O
from NN O O
intervention NN O O
studies NN O O
using NN O O
supplementary NN O O
n-3 NN O O
LC-PUFA NN O O
are NN O O
conflicting NN O O
. NN O O

Salmon NN O O
is NN O O
a NN O O
good NN O O
source NN O O
of NN O O
n-3 NN O O
LC-PUFA NN O O
, NN O O
including NN O O
eicosapentaenoic NN O O
acid NN O O
( NN O O
EPA NN O O
) NN O O
and NN O O
docosahexaenoic NN O O
acid NN O O
( NN O O
DHA NN O O
) NN O O
. NN O O

We NN O O
tested NN O O
the NN O O
hypothesis NN O O
that NN O O
an NN O O
increased NN O O
dietary NN O O
salmon NN O O
intake NN O O
results NN O O
in NN O O
better NN O O
cognitive NN O O
outcomes NN O O
than NN O O
a NN O O
meat NN O O
based NN O O
diet NN O O
. NN O O

Children NN O O
( NN O O
n NN O O
= NN O O
205 NN O O
, NN O O
age NN O O
4 NN O O
- NN O O
6 NN O O
years NN O O
) NN O O
in NN O O
this NN O O
trial NN O O
were NN O O
individually NN O O
randomized NN O O
to NN O O
eating NN O O
meals NN O O
containing NN O O
farmed NN O O
Atlantic NN O O
salmon NN O O
or NN O O
meat NN O O
three NN O O
times NN O O
weekly NN O O
for NN O O
16 NN O O
weeks NN O O
. NN O O

Pre- NN O O
and NN O O
post-intervention NN O O
a NN O O
cognitive NN O O
test NN O O
( NN O O
Wechsler NN O O
Preschool NN O O
and NN O O
Primary NN O O
Scale NN O O
of NN O O
Intelligence NN O O
, NN O O
3rd NN O O
edition NN O O
, NN O O
WPPSI-III NN O O
) NN O O
and NN O O
a NN O O
fine-motor NN O O
coordination NN O O
test NN O O
( NN O O
Nine NN O O
Hole NN O O
Peg NN O O
Test NN O O
, NN O O
9-HPT NN O O
) NN O O
were NN O O
performed NN O O
. NN O O

Biochemical NN O O
analyses NN O O
included NN O O
glycerophospholipid NN O O
fatty NN O O
acid NN O O
profiles NN O O
in NN O O
plasma NN O O
and NN O O
cheek NN O O
cells NN O O
, NN O O
serum NN O O
25-hydroxyvitamin NN O O
D NN O O
, NN O O
and NN O O
urinary NN O O
iodine NN O O
concentration NN O O
. NN O O

Dietary NN O O
intake NN O O
before NN O O
and NN O O
during NN O O
the NN O O
study NN O O
were NN O O
determined NN O O
using NN O O
food NN O O
frequency NN O O
questionnaires NN O O
. NN O O

Intakes NN O O
of NN O O
EPA NN O O
, NN O O
DHA NN O O
, NN O O
vitamin NN O O
D NN O O
and NN O O
iodine NN O O
were NN O O
higher NN O O
in NN O O
the NN O O
salmon NN O O
than NN O O
the NN O O
meat NN O O
group NN O O
, NN O O
but NN O O
on NN O O
biomarker NN O O
level NN O O
only NN O O
EPA NN O O
and NN O O
DHA NN O O
increased NN O O
significantly NN O O
in NN O O
the NN O O
salmon NN O O
group NN O O
compared NN O O
to NN O O
the NN O O
meat NN O O
group NN O O
( NN O O
p NN O O
< NN O O
0.001 NN O O
) NN O O
. NN O O

In NN O O
general NN O O
linear NN O O
models NN O O
no NN O O
significant NN O O
differences NN O O
between NN O O
the NN O O
intervention NN O O
groups NN O O
were NN O O
found NN O O
in NN O O
the NN O O
scale NN O O
scores NN O O
of NN O O
the NN O O
WPPSI-III NN O O
tests NN O O
and NN O O
the NN O O
9-HPT NN O O
. NN O O

In NN O O
analyses NN O O
of NN O O
the NN O O
raw NN O O
scores NN O O
, NN O O
the NN O O
salmon NN O O
group NN O O
showed NN O O
significantly NN O O
better NN O O
improvement NN O O
in NN O O
two NN O O
of NN O O
the NN O O
eight NN O O
raw NN O O
scores NN O O
compared NN O O
to NN O O
the NN O O
meat NN O O
group NN O O
( NN O O
symbol NN O O
search NN O O
p NN O O
= NN O O
0.038 NN O O
, NN O O
picture NN O O
concepts NN O O
p NN O O
= NN O O
0.047 NN O O
) NN O O
. NN O O

Intake NN O O
of NN O O
farmed NN O O
Atlantic NN O O
salmon NN O O
led NN O O
to NN O O
a NN O O
greater NN O O
increase NN O O
of NN O O
the NN O O
raw NN O O
scores NN O O
of NN O O
the NN O O
picture NN O O
concept NN O O
and NN O O
symbol NN O O
search NN O O
subtests NN O O
, NN O O
while NN O O
in NN O O
the NN O O
six NN O O
other NN O O
subtests NN O O
raw NN O O
scores NN O O
were NN O O
not NN O O
different NN O O
between NN O O
the NN O O
groups NN O O
. NN O O

This NN O O
might NN O O
indicate NN O O
a NN O O
modest NN O O
positive NN O O
association NN O O
of NN O O
salmon NN O O
intake NN O O
with NN O O
the NN O O
performance NN O O
of NN O O
preschool NN O O
children NN O O
in NN O O
some NN O O
subtests NN O O
evaluating NN O O
fluid NN O O
intelligence NN O O
but NN O O
does NN O O
not NN O O
suggest NN O O
an NN O O
influence NN O O
on NN O O
global NN O O
IQ NN O O
development NN O O
. NN O O

ClinicalTrials.gov NN O O
registration NN O O
number NN O O
: NN O O
NCT01951937 NN O O
. NN O O



-DOCSTART- (31307843)

The NN O O
combination NN O O
of NN O O
prolonged NN O O
essential NN O O
amino NN O O
acid NN O O
( NN O O
EAA NN O O
) NN O O
supplementation NN O O
and NN O O
aerobic NN O O
exercise NN O O
training NN O O
( NN O O
Ex NN O O
) NN O O
improves NN O O
muscle NN O O
protein NN O O
metabolism NN O O
, NN O O
strength NN O O
and NN O O
function NN O O
in NN O O
healthy NN O O
older NN O O
adults NN O O
. NN O O

However NN O O
, NN O O
excess NN O O
EAA NN O O
intake NN O O
may NN O O
worsen NN O O
insulin NN O O
sensitivity NN O O
. NN O O

Here NN O O
we NN O O
report NN O O
the NN O O
effects NN O O
of NN O O
EAA NN O O
supplementation NN O O
( NN O O
EAA NN O O
, NN O O
n NN O O
= NN O O
11 NN O O
) NN O O
, NN O O
placebo NN O O
( NN O O
PLA NN O O
, NN O O
n NN O O
= NN O O
10 NN O O
) NN O O
, NN O O
aerobic NN O O
exercise NN O O
with NN O O
placebo NN O O
( NN O O
Ex NN O O
+ NN O O
PLA NN O O
, NN O O
n NN O O
= NN O O
11 NN O O
) NN O O
or NN O O
Ex NN O O
with NN O O
EAA NN O O
supplementation NN O O
( NN O O
Ex NN O O
+ NN O O
EAA NN O O
, NN O O
n NN O O
= NN O O
10 NN O O
) NN O O
for NN O O
22 NN O O
weeks NN O O
on NN O O
insulin NN O O
sensitivity NN O O
in NN O O
non-diabetic NN O O
older NN O O
adults NN O O
. NN O O

A NN O O
2 NN O O
× NN O O
2 NN O O
design NN O O
with NN O O
block NN O O
randomization NN O O
and NN O O
double NN O O
blinding NN O O
for NN O O
supplement NN O O
or NN O O
placebo NN O O
was NN O O
used NN O O
. NN O O

Subjects NN O O
ingested NN O O
EAA NN O O
( NN O O
15 NN O O
g NN O O
) NN O O
or NN O O
placebo NN O O
daily NN O O
. NN O O

Exercising NN O O
subjects NN O O
participated NN O O
in NN O O
supervised NN O O
progressive NN O O
vigorous NN O O
treadmill NN O O
walking NN O O
3 NN O O
times NN O O
weekly NN O O
. NN O O

Measures NN O O
of NN O O
insulin NN O O
sensitivity NN O O
by NN O O
oral NN O O
glucose NN O O
tolerance NN O O
testing NN O O
were NN O O
collected NN O O
at NN O O
baseline NN O O
and NN O O
22 NN O O
weeks NN O O
. NN O O

Dietary NN O O
intakes NN O O
of NN O O
protein NN O O
and NN O O
specific NN O O
amino NN O O
acids NN O O
were NN O O
determined NN O O
in NN O O
a NN O O
subset NN O O
of NN O O
subjects NN O O
. NN O O

Overall NN O O
, NN O O
exercise NN O O
improved NN O O
insulin NN O O
sensitivity NN O O
, NN O O
while NN O O
EAA NN O O
supplementation NN O O
had NN O O
no NN O O
effect NN O O
. NN O O

In NN O O
the NN O O
dietary NN O O
subset NN O O
, NN O O
post-intervention NN O O
insulin NN O O
sensitivity NN O O
did NN O O
not NN O O
correlate NN O O
significantly NN O O
with NN O O
the NN O O
total NN O O
intake NN O O
of NN O O
EAA NN O O
, NN O O
anti-angiogenic NN O O
amino NN O O
acids NN O O
( NN O O
cysteine NN O O
, NN O O
methionine NN O O
) NN O O
, NN O O
or NN O O
branched-chain NN O O
amino NN O O
acids NN O O
( NN O O
isoleucine NN O O
, NN O O
leucine NN O O
, NN O O
valine NN O O
) NN O O
. NN O O

Overall NN O O
, NN O O
we NN O O
conclude NN O O
that NN O O
in NN O O
healthy NN O O
older NN O O
adults NN O O
with NN O O
moderate NN O O
protein NN O O
intake NN O O
, NN O O
EAA NN O O
supplementation NN O O
is NN O O
metabolically NN O O
safe NN O O
as NN O O
it NN O O
does NN O O
not NN O O
decrease NN O O
insulin NN O O
sensitivity NN O O
regardless NN O O
of NN O O
its NN O O
combination NN O O
with NN O O
aerobic NN O O
exercise NN O O
. NN O O

Thus NN O O
, NN O O
daily NN O O
protein NN O O
intake NN O O
should NN O O
be NN O O
controlled NN O O
for NN O O
when NN O O
modeling NN O O
insulin NN O O
sensitivity NN O O
. NN O O

Future NN O O
studies NN O O
should NN O O
explore NN O O
the NN O O
role NN O O
of NN O O
increased NN O O
blood NN O O
flow NN O O
as NN O O
a NN O O
potential NN O O
explanatory NN O O
factor NN O O
for NN O O
the NN O O
observed NN O O
interaction NN O O
between NN O O
aerobic NN O O
exercise NN O O
and NN O O
supplementation NN O O
. NN O O

NCT00872911 NN O O
. NN O O



-DOCSTART- (30572939)

The NN O O
preliminary NN O O
results NN O O
of NN O O
our NN O O
phase NN O O
II NN O O
randomized NN O O
trial NN O O
reported NN O O
comparable NN O O
functional NN O O
sphincter NN O O
preservation NN O O
rates NN O O
and NN O O
short-term NN O O
survival NN O O
outcomes NN O O
between NN O O
patients NN O O
undergoing NN O O
total NN O O
mesorectal NN O O
excision NN O O
( NN O O
TME NN O O
) NN O O
with NN O O
or NN O O
without NN O O
preoperative NN O O
concurrent NN O O
chemoradiotherapy NN O O
( NN O O
CCRT NN O O
) NN O O
. NN O O

We NN O O
now NN O O
report NN O O
the NN O O
long-term NN O O
results NN O O
after NN O O
a NN O O
median NN O O
follow-up NN O O
of NN O O
71 NN O O
months NN O O
. NN O O

Between NN O O
March NN O O
23 NN O O
, NN O O
2008 NN O O
and NN O O
August NN O O
2 NN O O
, NN O O
2012 NN O O
, NN O O
192 NN O O
patients NN O O
with NN O O
T3-T4 NN O O
or NN O O
node-positive NN O O
, NN O O
resectable NN O O
, NN O O
mid/low NN O O
rectal NN O O
adenocarcinoma NN O O
were NN O O
randomly NN O O
assigned NN O O
to NN O O
receive NN O O
TME NN O O
with NN O O
or NN O O
without NN O O
preoperative NN O O
CCRT NN O O
. NN O O

The NN O O
following NN O O
endpoints NN O O
were NN O O
assessed NN O O
: NN O O
cumulative NN O O
rates NN O O
of NN O O
local NN O O
recurrence NN O O
and NN O O
distant NN O O
metastasis NN O O
, NN O O
disease-free NN O O
survival NN O O
( NN O O
DFS NN O O
) NN O O
, NN O O
and NN O O
overall NN O O
survival NN O O
( NN O O
OS NN O O
) NN O O
. NN O O

The NN O O
data NN O O
of NN O O
184 NN O O
eligible NN O O
patients NN O O
were NN O O
analyzed NN O O
: NN O O
94 NN O O
patients NN O O
in NN O O
the NN O O
TME NN O O
group NN O O
and NN O O
90 NN O O
patients NN O O
in NN O O
the NN O O
CCRT NN O O
+ NN O O
TME NN O O
group NN O O
. NN O O

In NN O O
the NN O O
whole NN O O
cohort NN O O
, NN O O
the NN O O
5-year NN O O
DFS NN O O
and NN O O
OS NN O O
rates NN O O
were NN O O
84.8 NN O O
% NN O O
and NN O O
85.1 NN O O
% NN O O
, NN O O
respectively NN O O
. NN O O

The NN O O
5-year NN O O
DFS NN O O
rates NN O O
were NN O O
85.2 NN O O
% NN O O
in NN O O
the NN O O
CCRT NN O O
+ NN O O
TME NN O O
group NN O O
and NN O O
84.3 NN O O
% NN O O
in NN O O
the NN O O
TME NN O O
group NN O O
( NN O O
P NN O O
= NN O O
0.969 NN O O
) NN O O
, NN O O
and NN O O
the NN O O
5-year NN O O
OS NN O O
rates NN O O
were NN O O
83.5 NN O O
% NN O O
in NN O O
the NN O O
CCRT NN O O
+ NN O O
TME NN O O
group NN O O
and NN O O
86.5 NN O O
% NN O O
in NN O O
the NN O O
TME NN O O
group NN O O
( NN O O
P NN O O
= NN O O
0.719 NN O O
) NN O O
. NN O O

The NN O O
5-year NN O O
cumulative NN O O
rates NN O O
of NN O O
local NN O O
recurrence NN O O
were NN O O
6.3 NN O O
% NN O O
and NN O O
5.0 NN O O
% NN O O
( NN O O
P NN O O
= NN O O
0.681 NN O O
) NN O O
, NN O O
and NN O O
the NN O O
5-year NN O O
cumulative NN O O
rates NN O O
of NN O O
distant NN O O
metastasis NN O O
were NN O O
15.0 NN O O
% NN O O
and NN O O
15.7 NN O O
% NN O O
( NN O O
P NN O O
= NN O O
0.881 NN O O
) NN O O
in NN O O
the NN O O
CCRT NN O O
+ NN O O
TME NN O O
and NN O O
TME NN O O
groups NN O O
, NN O O
respectively NN O O
. NN O O

No NN O O
significant NN O O
improvements NN O O
in NN O O
5-year NN O O
DFS NN O O
and NN O O
OS NN O O
were NN O O
observed NN O O
with NN O O
CCRT NN O O
by NN O O
subgroup NN O O
analyses NN O O
. NN O O

Both NN O O
treatment NN O O
strategies NN O O
yielded NN O O
similar NN O O
long-term NN O O
outcomes NN O O
. NN O O

A NN O O
selective NN O O
policy NN O O
towards NN O O
preoperative NN O O
CCRT NN O O
is NN O O
thus NN O O
recommended NN O O
for NN O O
rectal NN O O
cancer NN O O
patients NN O O
if NN O O
high-quality NN O O
TME NN O O
surgery NN O O
and NN O O
enhanced NN O O
chemotherapy NN O O
can NN O O
be NN O O
performed NN O O
. NN O O

Trial NN O O
registration NN O O
ChiCTR-TRC-08000122 NN O O
. NN O O

Registered NN O O
16 NN O O
July NN O O
2008 NN O O
. NN O O



-DOCSTART- (30788692)

A NN O O
lack NN O O
of NN O O
adequate NN O O
physical NN O O
activity NN O O
among NN O O
young NN O O
African NN O O
American NN O O
women NN O O
remains NN O O
a NN O O
serious NN O O
public NN O O
health NN O O
challenge NN O O
. NN O O

Few NN O O
evidence-based NN O O
interventions NN O O
are NN O O
available NN O O
to NN O O
increase NN O O
physical NN O O
activity NN O O
in NN O O
this NN O O
population NN O O
, NN O O
and NN O O
none NN O O
has NN O O
leveraged NN O O
mobile NN O O
technologies NN O O
, NN O O
even NN O O
though NN O O
African NN O O
Americans NN O O
are NN O O
among NN O O
the NN O O
most NN O O
avid NN O O
users NN O O
of NN O O
mobile NN O O
applications NN O O
( NN O O
apps NN O O
) NN O O
. NN O O

We NN O O
conducted NN O O
a NN O O
pilot NN O O
randomized NN O O
controlled NN O O
trial NN O O
to NN O O
test NN O O
the NN O O
efficacy NN O O
of NN O O
a NN O O
mobile NN O O
app-based NN O O
small-group NN O O
intervention NN O O
in NN O O
increasing NN O O
physical NN O O
activity NN O O
among NN O O
African NN O O
American NN O O
women NN O O
aged NN O O
18 NN O O
to NN O O
35 NN O O
years NN O O
( NN O O
N NN O O
= NN O O
91 NN O O
) NN O O
in NN O O
Philadelphia NN O O
, NN O O
PA NN O O
. NN O O

Cohorts NN O O
of NN O O
eight NN O O
participants NN O O
were NN O O
randomized NN O O
in NN O O
a NN O O
1:1 NN O O
ratio NN O O
to NN O O
a NN O O
4-women NN O O
small-group NN O O
intervention NN O O
or NN O O
an NN O O
individual NN O O
control NN O O
condition NN O O
. NN O O

Control NN O O
participants NN O O
used NN O O
the NN O O
app NN O O
to NN O O
track NN O O
their NN O O
own NN O O
activities NN O O
. NN O O

Small-group NN O O
participants NN O O
could NN O O
track NN O O
their NN O O
own NN O O
activities NN O O
and NN O O
those NN O O
of NN O O
the NN O O
other NN O O
three NN O O
women NN O O
in NN O O
their NN O O
group NN O O
and NN O O
could NN O O
message NN O O
the NN O O
other NN O O
women NN O O
using NN O O
a NN O O
chatting NN O O
tool NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
was NN O O
meeting NN O O
the NN O O
goal NN O O
of NN O O
engaging NN O O
in NN O O
at NN O O
least NN O O
90 NN O O
min/day NN O O
of NN O O
light NN O O
physical NN O O
activity NN O O
during NN O O
the NN O O
3-month NN O O
study NN O O
period NN O O
objectively NN O O
assessed NN O O
by NN O O
a NN O O
Fitbit NN O O
device NN O O
. NN O O

Data NN O O
were NN O O
collected NN O O
in NN O O
2016 NN O O
and NN O O
analyzed NN O O
in NN O O
2017 NN O O
. NN O O

Group NN O O
participants NN O O
had NN O O
higher NN O O
odds NN O O
of NN O O
meeting NN O O
the NN O O
goal NN O O
( NN O O
OR NN O O
= NN O O
1.48 NN O O
, NN O O
p NN O O
= NN O O
.048 NN O O
) NN O O
than NN O O
did NN O O
control NN O O
participants NN O O
, NN O O
an NN O O
effect NN O O
that NN O O
did NN O O
not NN O O
wane NN O O
during NN O O
the NN O O
3-month NN O O
study NN O O
period NN O O
. NN O O

Irrespective NN O O
of NN O O
condition NN O O
, NN O O
participants NN O O
had NN O O
lower NN O O
body-mass NN O O
index NN O O
( NN O O
p NN O O
= NN O O
.01 NN O O
) NN O O
and NN O O
performed NN O O
more NN O O
push-ups NN O O
( NN O O
p NN O O
< NN O O
.0001 NN O O
) NN O O
at NN O O
the NN O O
1-month NN O O
and NN O O
3-month NN O O
assessments NN O O
compared NN O O
with NN O O
the NN O O
baseline NN O O
measures NN O O
. NN O O

Mobile NN O O
apps NN O O
facilitating NN O O
small NN O O
online NN O O
groups NN O O
can NN O O
contribute NN O O
to NN O O
efforts NN O O
to NN O O
increase NN O O
physical NN O O
activity NN O O
among NN O O
young NN O O
African NN O O
American NN O O
women NN O O
. NN O O

This NN O O
study NN O O
is NN O O
registered NN O O
at NN O O
www.clinicaltrials.gov NN O O
NCT02736903 NN O O
. NN O O



-DOCSTART- (30646198)

Interventions NN O O
to NN O O
reduce NN O O
postpartum NN O O
depression NN O O
have NN O O
mainly NN O O
focused NN O O
on NN O O
enhancing NN O O
screening NN O O
to NN O O
increase NN O O
treatment NN O O
rates NN O O
among NN O O
women NN O O
. NN O O

Preventive NN O O
approaches NN O O
are NN O O
timely NN O O
from NN O O
a NN O O
population NN O O
health NN O O
perspective NN O O
, NN O O
particularly NN O O
in NN O O
low- NN O O
and NN O O
middle-income NN O O
countries NN O O
where NN O O
access NN O O
to NN O O
mental NN O O
health NN O O
services NN O O
is NN O O
limited NN O O
. NN O O

To NN O O
assess NN O O
the NN O O
efficacy NN O O
of NN O O
regular NN O O
exercise NN O O
during NN O O
pregnancy NN O O
on NN O O
the NN O O
prevention NN O O
of NN O O
postpartum NN O O
depression NN O O
. NN O O

This NN O O
randomized NN O O
clinical NN O O
trial NN O O
examines NN O O
a NN O O
prespecified NN O O
secondary NN O O
outcome NN O O
of NN O O
the NN O O
Physical NN O O
Activity NN O O
for NN O O
Mothers NN O O
Enrolled NN O O
in NN O O
Longitudinal NN O O
Analysis NN O O
( NN O O
PAMELA NN O O
) NN O O
Study NN O O
, NN O O
a NN O O
parallel-group NN O O
, NN O O
randomized NN O O
clinical NN O O
trial NN O O
. NN O O

This NN O O
trial NN O O
was NN O O
nested NN O O
in NN O O
the NN O O
2015 NN O O
Pelotas NN O O
( NN O O
Brazil NN O O
) NN O O
Birth NN O O
Cohort NN O O
Study NN O O
. NN O O

Between NN O O
August NN O O
27 NN O O
, NN O O
2014 NN O O
, NN O O
and NN O O
March NN O O
14 NN O O
, NN O O
2016 NN O O
, NN O O
pregnant NN O O
women NN O O
between NN O O
16 NN O O
and NN O O
20 NN O O
weeks NN O O
of NN O O
gestation NN O O
with NN O O
no NN O O
contraindications NN O O
to NN O O
exercise NN O O
were NN O O
randomized NN O O
1:2 NN O O
to NN O O
the NN O O
intervention NN O O
group NN O O
or NN O O
control NN O O
group NN O O
via NN O O
computer-generated NN O O
randomization NN O O
using NN O O
a NN O O
block NN O O
size NN O O
of NN O O
9 NN O O
. NN O O

Data NN O O
were NN O O
analyzed NN O O
from NN O O
March NN O O
7 NN O O
to NN O O
May NN O O
2 NN O O
, NN O O
2018 NN O O
. NN O O

Participants NN O O
assigned NN O O
to NN O O
the NN O O
intervention NN O O
were NN O O
engaged NN O O
in NN O O
a NN O O
16-week NN O O
supervised NN O O
exercise NN O O
program NN O O
including NN O O
aerobic NN O O
and NN O O
resistance NN O O
training NN O O
delivered NN O O
in NN O O
60-minute NN O O
sessions NN O O
3 NN O O
times NN O O
per NN O O
week NN O O
. NN O O

Postpartum NN O O
depressive NN O O
symptoms NN O O
were NN O O
assessed NN O O
with NN O O
the NN O O
Edinburgh NN O O
Postnatal NN O O
Depression NN O O
Scale NN O O
3 NN O O
months NN O O
after NN O O
birth NN O O
. NN O O

A NN O O
score NN O O
of NN O O
12 NN O O
or NN O O
greater NN O O
was NN O O
defined NN O O
as NN O O
screening NN O O
positive NN O O
for NN O O
postpartum NN O O
depression NN O O
. NN O O

Primary NN O O
analysis NN O O
was NN O O
performed NN O O
on NN O O
a NN O O
complete NN O O
case NN O O
basis NN O O
( NN O O
90 NN O O
% NN O O
of NN O O
participants NN O O
who NN O O
had NN O O
the NN O O
primary NN O O
end NN O O
point NN O O
ascertained NN O O
) NN O O
. NN O O

A NN O O
total NN O O
of NN O O
639 NN O O
participants NN O O
( NN O O
mean NN O O
[ NN O O
SD NN O O
] NN O O
age NN O O
, NN O O
27.1 NN O O
[ NN O O
5.1 NN O O
] NN O O
years NN O O
; NN O O
mean NN O O
gestational NN O O
age NN O O
, NN O O
16.5 NN O O
[ NN O O
1.5 NN O O
] NN O O
weeks NN O O
) NN O O
were NN O O
randomly NN O O
assigned NN O O
to NN O O
the NN O O
intervention NN O O
group NN O O
( NN O O
n NN O O
= NN O O
213 NN O O
) NN O O
or NN O O
control NN O O
group NN O O
( NN O O
n NN O O
= NN O O
426 NN O O
) NN O O
. NN O O

Compliance NN O O
with NN O O
the NN O O
protocol NN O O
, NN O O
defined NN O O
as NN O O
having NN O O
engaged NN O O
in NN O O
at NN O O
least NN O O
70 NN O O
% NN O O
of NN O O
exercise NN O O
sessions NN O O
, NN O O
was NN O O
low NN O O
( NN O O
40.4 NN O O
% NN O O
) NN O O
. NN O O

There NN O O
was NN O O
no NN O O
significant NN O O
difference NN O O
in NN O O
mean NN O O
( NN O O
SD NN O O
) NN O O
scores NN O O
for NN O O
postpartum NN O O
depression NN O O
between NN O O
the NN O O
intervention NN O O
group NN O O
( NN O O
4.8 NN O O
[ NN O O
3.7 NN O O
] NN O O
) NN O O
and NN O O
the NN O O
control NN O O
group NN O O
( NN O O
5.4 NN O O
[ NN O O
4.1 NN O O
] NN O O
) NN O O
( NN O O
mean NN O O
difference NN O O
, NN O O
-0.6 NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
-1.3 NN O O
to NN O O
0.1 NN O O
) NN O O
. NN O O

There NN O O
was NN O O
also NN O O
no NN O O
significant NN O O
difference NN O O
in NN O O
rates NN O O
of NN O O
postpartum NN O O
depression NN O O
between NN O O
the NN O O
intervention NN O O
group NN O O
( NN O O
12 NN O O
of NN O O
192 NN O O
[ NN O O
6.3 NN O O
% NN O O
] NN O O
) NN O O
and NN O O
the NN O O
control NN O O
group NN O O
( NN O O
36 NN O O
of NN O O
387 NN O O
[ NN O O
9.3 NN O O
% NN O O
] NN O O
) NN O O
( NN O O
odds NN O O
ratio NN O O
, NN O O
0.65 NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
0.33 NN O O
- NN O O
1.28 NN O O
) NN O O
. NN O O

Instrumental NN O O
variable NN O O
analysis NN O O
indicated NN O O
that NN O O
noncompliance NN O O
may NN O O
have NN O O
attenuated NN O O
the NN O O
effect NN O O
estimates NN O O
obtained NN O O
in NN O O
the NN O O
primary NN O O
analysis NN O O
. NN O O

Moderate-intensity NN O O
exercise NN O O
during NN O O
pregnancy NN O O
did NN O O
not NN O O
lead NN O O
to NN O O
significant NN O O
reductions NN O O
in NN O O
postpartum NN O O
depression NN O O
. NN O O

However NN O O
, NN O O
noncompliance NN O O
to NN O O
the NN O O
intervention NN O O
protocol NN O O
was NN O O
substantial NN O O
and NN O O
may NN O O
have NN O O
led NN O O
to NN O O
underestimations NN O O
of NN O O
the NN O O
possible NN O O
benefits NN O O
of NN O O
exercise NN O O
. NN O O

The NN O O
point NN O O
estimates NN O O
for NN O O
this NN O O
study NN O O
are NN O O
in NN O O
the NN O O
same NN O O
direction NN O O
as NN O O
the NN O O
previous NN O O
randomized NN O O
clinical NN O O
trial NN O O
on NN O O
this NN O O
topic NN O O
. NN O O

Future NN O O
studies NN O O
on NN O O
how NN O O
to NN O O
promote NN O O
regular NN O O
exercise NN O O
during NN O O
pregnancy NN O O
to NN O O
improve NN O O
compliance NN O O
, NN O O
particularly NN O O
targeting NN O O
young NN O O
and NN O O
less NN O O
educated NN O O
women NN O O
, NN O O
are NN O O
warranted NN O O
before NN O O
further NN O O
trials NN O O
are NN O O
undertaken NN O O
. NN O O

ClinicalTrials.gov NN O O
Identifier NN O O
: NN O O
NCT02148965 NN O O
. NN O O



-DOCSTART- (30409212)

The NN O O
lymphatic NN O O
spread NN O O
from NN O O
the NN O O
cancers NN O O
of NN O O
the NN O O
oral NN O O
cavity NN O O
follows NN O O
an NN O O
orderly NN O O
progression NN O O
and NN O O
involvement NN O O
of NN O O
lower NN O O
nodes NN O O
without NN O O
involvement NN O O
of NN O O
upper NN O O
nodes NN O O
and NN O O
skip NN O O
metastasis NN O O
is NN O O
rare NN O O
. NN O O

Selective NN O O
neck NN O O
dissections NN O O
are NN O O
increasingly NN O O
being NN O O
performed NN O O
for NN O O
node-positive NN O O
patients NN O O
; NN O O
however NN O O
, NN O O
in NN O O
node-negative NN O O
patients NN O O
the NN O O
options NN O O
of NN O O
wait NN O O
and NN O O
watch NN O O
, NN O O
prophylactic NN O O
radiotherapy NN O O
, NN O O
and NN O O
prophylactic NN O O
elective NN O O
node NN O O
dissections NN O O
are NN O O
debated NN O O
. NN O O

Quality NN O O
of NN O O
life NN O O
and NN O O
shoulder NN O O
functions NN O O
are NN O O
important NN O O
to NN O O
choose NN O O
the NN O O
appropriate NN O O
therapeutic NN O O
modality NN O O
. NN O O

Patients NN O O
with NN O O
oral NN O O
squamous NN O O
carcinoma NN O O
with NN O O
clinically NN O O
and NN O O
radiologically NN O O
negative NN O O
neck NN O O
were NN O O
randomized NN O O
to NN O O
IIb NN O O
preserving NN O O
superselective NN O O
neck NN O O
dissection NN O O
or NN O O
conventional NN O O
supraomohyoid NN O O
neck NN O O
dissection NN O O
. NN O O

The NN O O
primary NN O O
end NN O O
point NN O O
of NN O O
the NN O O
study NN O O
was NN O O
recurrence NN O O
of NN O O
disease NN O O
( NN O O
clinical NN O O
or NN O O
radiological NN O O
) NN O O
and NN O O
shoulder NN O O
function NN O O
as NN O O
demonstrated NN O O
by NN O O
the NN O O
clinical NN O O
examination NN O O
and NN O O
electromyography NN O O
. NN O O

The NN O O
secondary NN O O
end NN O O
point NN O O
was NN O O
quality NN O O
of NN O O
life NN O O
as NN O O
measured NN O O
by NN O O
the NN O O
FACT-HN NN O O
version NN O O
4 NN O O
questionnaire NN O O
at NN O O
the NN O O
end NN O O
of NN O O
1 NN O O
year NN O O
follow-up NN O O
. NN O O

The NN O O
mean NN O O
number NN O O
of NN O O
lymph NN O O
node NN O O
harvested NN O O
per NN O O
patient NN O O
was NN O O
25.6 NN O O
( NN O O
range NN O O
8 NN O O
- NN O O
85 NN O O
) NN O O
. NN O O

Of NN O O
the NN O O
32 NN O O
patients NN O O
, NN O O
3 NN O O
had NN O O
histologically NN O O
positive NN O O
node NN O O
in NN O O
level NN O O
Ib NN O O
, NN O O
one NN O O
of NN O O
these NN O O
patients NN O O
had NN O O
single NN O O
positive NN O O
node NN O O
while NN O O
the NN O O
remaining NN O O
two NN O O
had NN O O
three NN O O
positive NN O O
nodes NN O O
in NN O O
level NN O O
Ib NN O O
. NN O O

At NN O O
median NN O O
follow-up NN O O
of NN O O
36 NN O O
months NN O O
disease-free NN O O
survival NN O O
in NN O O
IIb NN O O
, NN O O
sparing NN O O
group NN O O
was NN O O
83 NN O O
% NN O O
compared NN O O
to NN O O
91 NN O O
% NN O O
in NN O O
control NN O O
arm NN O O
, NN O O
the NN O O
difference NN O O
in NN O O
survival NN O O
between NN O O
two NN O O
groups NN O O
was NN O O
statistically NN O O
not NN O O
significant NN O O
( NN O O
p NN O O
= NN O O
0.694 NN O O
) NN O O
. NN O O

EMG NN O O
of NN O O
the NN O O
shoulder NN O O
showed NN O O
denervation NN O O
pattern NN O O
in NN O O
45 NN O O
% NN O O
patients NN O O
undergoing NN O O
IIb NN O O
preserving NN O O
surgery NN O O
at NN O O
1 NN O O
month NN O O
follow-up NN O O
compared NN O O
to NN O O
95 NN O O
% NN O O
in NN O O
conventional NN O O
surgery NN O O
group NN O O
, NN O O
this NN O O
recovered NN O O
in NN O O
all NN O O
patients NN O O
but NN O O
one NN O O
at NN O O
3 NN O O
months NN O O
and NN O O
100 NN O O
% NN O O
recovery NN O O
was NN O O
seen NN O O
at NN O O
6 NN O O
months NN O O
. NN O O

The NN O O
results NN O O
of NN O O
the NN O O
present NN O O
study NN O O
indicate NN O O
that NN O O
superselective NN O O
IIb NN O O
preserving NN O O
neck NN O O
dissections NN O O
are NN O O
technically NN O O
feasible NN O O
and NN O O
appear NN O O
to NN O O
be NN O O
oncologically NN O O
safe NN O O
procedures NN O O
when NN O O
performed NN O O
as NN O O
elective NN O O
prophylactic NN O O
procedures NN O O
in NN O O
highly NN O O
select NN O O
group NN O O
of NN O O
patients NN O O
. NN O O

A NN O O
significant NN O O
number NN O O
of NN O O
occult NN O O
metastasis NN O O
seen NN O O
in NN O O
the NN O O
present NN O O
study NN O O
suggests NN O O
prophylactic NN O O
dissection NN O O
to NN O O
be NN O O
better NN O O
than NN O O
wait NN O O
and NN O O
watch NN O O
policy NN O O
. NN O O

Results NN O O
also NN O O
show NN O O
initial NN O O
higher NN O O
shoulder NN O O
morbidity NN O O
at NN O O
1 NN O O
month NN O O
in NN O O
patients NN O O
undergoing NN O O
IIb NN O O
preserving NN O O
dissections NN O O
; NN O O
however NN O O
, NN O O
at NN O O
the NN O O
end NN O O
of NN O O
1 NN O O
year NN O O
recovery NN O O
is NN O O
complete NN O O
and NN O O
both NN O O
procedures NN O O
are NN O O
comparable NN O O
. NN O O

The NN O O
trial NN O O
is NN O O
registered NN O O
at NN O O
clinicaltrials.gov NN O O
with NN O O
registration NN O O
no NN O O
NCT00847717 NN O O
; NN O O
registered NN O O
on NN O O
February NN O O
19 NN O O
, NN O O
2009 NN O O
. NN O O



-DOCSTART- (30805607)

Case NN O O
reports NN O O
suggest NN O O
a NN O O
link NN O O
between NN O O
energy NN O O
drinks NN O O
( NN O O
EDs NN O O
) NN O O
and NN O O
adverse NN O O
events NN O O
, NN O O
including NN O O
deaths NN O O
. NN O O

We NN O O
examined NN O O
cardiovascular NN O O
and NN O O
metabolic NN O O
effects NN O O
of NN O O
EDs NN O O
and NN O O
mixtures NN O O
providing NN O O
relevant NN O O
ingredients NN O O
of NN O O
EDs NN O O
compared NN O O
to NN O O
a NN O O
similarly NN O O
composed NN O O
control NN O O
product NN O O
( NN O O
CP NN O O
) NN O O
without NN O O
these NN O O
components NN O O
. NN O O

This NN O O
randomized NN O O
, NN O O
crossover NN O O
trial NN O O
comprised NN O O
38 NN O O
adults NN O O
( NN O O
19 NN O O
women NN O O
, NN O O
mean NN O O
BMI NN O O
23 NN O O
kg/m2 NN O O
, NN O O
mean NN O O
age NN O O
22 NN O O
y NN O O
) NN O O
. NN O O

We NN O O
examined NN O O
effects NN O O
of NN O O
a NN O O
single NN O O
administration NN O O
of NN O O
a NN O O
commercial NN O O
ED NN O O
, NN O O
the NN O O
CP NN O O
, NN O O
and NN O O
the NN O O
CP NN O O
supplemented NN O O
with NN O O
major NN O O
ED-ingredients NN O O
at NN O O
the NN O O
same NN O O
concentrations NN O O
as NN O O
in NN O O
the NN O O
ED NN O O
. NN O O

The NN O O
study NN O O
products NN O O
were NN O O
administered NN O O
at NN O O
2 NN O O
volumes NN O O
, NN O O
750 NN O O
or NN O O
1000 NN O O
mL. NN O O
Both NN O O
volumes NN O O
of NN O O
the NN O O
study NN O O
products NN O O
were NN O O
acceptably NN O O
tolerated NN O O
with NN O O
no NN O O
dose-dependent NN O O
effects NN O O
on NN O O
blood NN O O
pressure NN O O
( NN O O
BP NN O O
, NN O O
primary NN O O
outcome NN O O
) NN O O
, NN O O
heart NN O O
rate NN O O
, NN O O
heart NN O O
rate NN O O
corrected NN O O
duration NN O O
of NN O O
QT-segment NN O O
in NN O O
electrocardiography NN O O
( NN O O
QTc NN O O
interval NN O O
) NN O O
, NN O O
and NN O O
glucose NN O O
metabolism NN O O
. NN O O

After NN O O
ED NN O O
consumption NN O O
, NN O O
11 NN O O
% NN O O
of NN O O
the NN O O
participants NN O O
reported NN O O
symptoms NN O O
, NN O O
in NN O O
contrast NN O O
to NN O O
0 NN O O
- NN O O
3 NN O O
% NN O O
caused NN O O
by NN O O
other NN O O
study NN O O
products NN O O
. NN O O

After NN O O
1 NN O O
h NN O O
, NN O O
administration NN O O
of NN O O
an NN O O
ED NN O O
caused NN O O
an NN O O
increase NN O O
in NN O O
systolic NN O O
BP NN O O
( NN O O
116.9 NN O O
± NN O O
10.4 NN O O
to NN O O
120.7 NN O O
± NN O O
10.7 NN O O
mmHg NN O O
, NN O O
mean NN O O
± NN O O
SD NN O O
, NN O O
P NN O O
< NN O O
0.01 NN O O
) NN O O
and NN O O
a NN O O
QTc NN O O
prolongation NN O O
( NN O O
393.3 NN O O
± NN O O
20.6 NN O O
to NN O O
400.8 NN O O
± NN O O
24.1 NN O O
ms NN O O
, NN O O
P NN O O
< NN O O
0.01 NN O O
) NN O O
. NN O O

Also NN O O
caffeine NN O O
, NN O O
but NN O O
not NN O O
taurine NN O O
or NN O O
glucuronolactone NN O O
, NN O O
caused NN O O
an NN O O
increase NN O O
in NN O O
BP NN O O
, NN O O
but NN O O
no NN O O
QTc NN O O
prolongation NN O O
. NN O O

The NN O O
BP NN O O
effects NN O O
were NN O O
most NN O O
pronounced NN O O
after NN O O
1 NN O O
h NN O O
and NN O O
returned NN O O
to NN O O
normal NN O O
after NN O O
a NN O O
few NN O O
hours NN O O
. NN O O

All NN O O
study NN O O
products NN O O
caused NN O O
a NN O O
decrease NN O O
in NN O O
serum NN O O
glucose NN O O
and NN O O
an NN O O
increase NN O O
in NN O O
insulin NN O O
concentrations NN O O
after NN O O
1 NN O O
h NN O O
compared NN O O
to NN O O
baseline NN O O
values NN O O
, NN O O
corresponding NN O O
to NN O O
an NN O O
elevation NN O O
in NN O O
the NN O O
HOMA-IR NN O O
( NN O O
ED NN O O
+ NN O O
4.0 NN O O
, NN O O
other NN O O
products NN O O
+ NN O O
1.0 NN O O
- NN O O
2.8 NN O O
, NN O O
all NN O O
P NN O O
< NN O O
0.001 NN O O
) NN O O
. NN O O

A NN O O
single NN O O
high-volume NN O O
intake NN O O
of NN O O
ED NN O O
caused NN O O
adverse NN O O
changes NN O O
in NN O O
BP NN O O
, NN O O
QTc NN O O
, NN O O
and NN O O
insulin NN O O
sensitivity NN O O
in NN O O
young NN O O
, NN O O
healthy NN O O
individuals NN O O
. NN O O

These NN O O
effects NN O O
of NN O O
EDs NN O O
can NN O O
not NN O O
be NN O O
easily NN O O
attributed NN O O
to NN O O
the NN O O
single NN O O
components NN O O
caffeine NN O O
, NN O O
taurine NN O O
, NN O O
or NN O O
glucuronolactone NN O O
. NN O O

This NN O O
trial NN O O
was NN O O
registered NN O O
at NN O O
clinicaltrials.gov NN O O
as NN O O
NCT01421979 NN O O
. NN O O



-DOCSTART- (30689494)

Human NN O O
papillomavirus NN O O
( NN O O
HPV NN O O
) NN O O
causes NN O O
a NN O O
number NN O O
of NN O O
cancers NN O O
that NN O O
disproportionally NN O O
affect NN O O
Latinos NN O O
yet NN O O
there NN O O
is NN O O
a NN O O
paucity NN O O
of NN O O
research NN O O
on NN O O
interventions NN O O
to NN O O
increase NN O O
HPV NN O O
vaccination NN O O
among NN O O
this NN O O
population NN O O
. NN O O

We NN O O
sought NN O O
to NN O O
evaluate NN O O
the NN O O
efficacy NN O O
of NN O O
a NN O O
web-based NN O O
, NN O O
individually NN O O
customizable NN O O
intervention NN O O
, NN O O
called NN O O
CHICOs NN O O
( NN O O
ombatting NN O O
PV NN O O
nfection NN O O
and NN O O
ancer NN O O
tailored NN O O
intervention NN O O
) NN O O
for NN O O
its NN O O
impact NN O O
on NN O O
HPV NN O O
vaccine NN O O
utilization NN O O
. NN O O

We NN O O
conducted NN O O
a NN O O
three-armed NN O O
, NN O O
randomized NN O O
, NN O O
controlled NN O O
trial NN O O
in NN O O
the NN O O
waiting NN O O
rooms NN O O
of NN O O
five NN O O
family NN O O
medicine NN O O
practices NN O O
from NN O O
June NN O O
2014-February NN O O
2016 NN O O
where NN O O
CHICOS NN O O
was NN O O
compared NN O O
to NN O O
an NN O O
iPad-based NN O O
version NN O O
of NN O O
the NN O O
Vaccine NN O O
Information NN O O
Sheet NN O O
from NN O O
the NN O O
Centers NN O O
for NN O O
Disease NN O O
Control NN O O
and NN O O
Prevention NN O O
( NN O O
untailored NN O O
intervention NN O O
) NN O O
, NN O O
and NN O O
usual NN O O
care NN O O
. NN O O

Pair-wise NN O O
comparisons NN O O
between NN O O
study NN O O
arms NN O O
of NN O O
6 NN O O
different NN O O
measures NN O O
of NN O O
HPV NN O O
vaccine NN O O
uptake NN O O
were NN O O
assessed NN O O
, NN O O
with NN O O
analyses NN O O
stratified NN O O
by NN O O
adolescents NN O O
versus NN O O
young NN O O
adults NN O O
. NN O O

Of NN O O
the NN O O
1,294 NN O O
participants NN O O
enrolled NN O O
in NN O O
the NN O O
study NN O O
, NN O O
1,013 NN O O
individuals NN O O
could NN O O
be NN O O
assessed NN O O
for NN O O
vaccination NN O O
. NN O O

Across NN O O
study NN O O
arms NN O O
, NN O O
265 NN O O
adolescents NN O O
, NN O O
but NN O O
only NN O O
18 NN O O
young NN O O
adults NN O O
, NN O O
received NN O O
an NN O O
HPV NN O O
vaccine NN O O
dose NN O O
during NN O O
the NN O O
study NN O O
period NN O O
. NN O O

In NN O O
both NN O O
intention-to-treat NN O O
and NN O O
per-protocol NN O O
analyses NN O O
there NN O O
were NN O O
essentially NN O O
no NN O O
differences NN O O
between NN O O
the NN O O
CHICOS NN O O
and NN O O
untailored NN O O
arms NN O O
in NN O O
any NN O O
vaccination NN O O
measure NN O O
, NN O O
or NN O O
between NN O O
the NN O O
untailored NN O O
or NN O O
CHICOS NN O O
arms NN O O
and NN O O
usual NN O O
care NN O O
. NN O O

Our NN O O
study NN O O
suggests NN O O
that NN O O
a NN O O
tailored NN O O
educational NN O O
intervention NN O O
may NN O O
not NN O O
be NN O O
effective NN O O
for NN O O
increasing NN O O
HPV NN O O
vaccine NN O O
uptake NN O O
among NN O O
Latino NN O O
adolescents NN O O
or NN O O
young NN O O
adults NN O O
. NN O O

However NN O O
, NN O O
the NN O O
higher NN O O
than NN O O
expected NN O O
baseline NN O O
levels NN O O
of NN O O
positive NN O O
vaccination NN O O
attitudes NN O O
of NN O O
study NN O O
participants NN O O
could NN O O
have NN O O
diminished NN O O
the NN O O
statistical NN O O
power NN O O
of NN O O
the NN O O
study NN O O
. NN O O

Trial NN O O
Registration NN O O
Number NN O O
: NN O O
ClinicalTrials.gov NN O O
( NN O O
NCT02145156 NN O O
) NN O O
. NN O O



-DOCSTART- (31337414)

Surgical NN O O
male NN O O
circumcision NN O O
( NN O O
MC NN O O
) NN O O
safely NN O O
reduces NN O O
risk NN O O
of NN O O
female-to-male NN O O
HIV-1 NN O O
transmission NN O O
by NN O O
up NN O O
to NN O O
60 NN O O
% NN O O
. NN O O

The NN O O
average NN O O
rate NN O O
of NN O O
global NN O O
moderate NN O O
and NN O O
severe NN O O
adverse NN O O
events NN O O
( NN O O
AEs NN O O
) NN O O
is NN O O
0.8 NN O O
% NN O O
: NN O O
99 NN O O
% NN O O
of NN O O
men NN O O
heal NN O O
from NN O O
MC NN O O
without NN O O
incident NN O O
. NN O O

To NN O O
reach NN O O
the NN O O
2016 NN O O
global NN O O
MC NN O O
target NN O O
of NN O O
20 NN O O
million NN O O
, NN O O
productivity NN O O
must NN O O
double NN O O
in NN O O
countries NN O O
plagued NN O O
by NN O O
severe NN O O
healthcare NN O O
worker NN O O
shortages NN O O
like NN O O
Zimbabwe NN O O
. NN O O

The NN O O
ZAZIC NN O O
consortium NN O O
partners NN O O
with NN O O
the NN O O
Zimbabwe NN O O
Ministry NN O O
of NN O O
Health NN O O
and NN O O
Child NN O O
Care NN O O
and NN O O
has NN O O
performed NN O O
over NN O O
120,000 NN O O
MCs NN O O
. NN O O

MC NN O O
care NN O O
in NN O O
Zimbabwe NN O O
requires NN O O
in-person NN O O
, NN O O
follow-up NN O O
visits NN O O
at NN O O
post-operative NN O O
days NN O O
2,7 NN O O
, NN O O
and NN O O
42 NN O O
. NN O O

The NN O O
ZAZIC NN O O
program NN O O
AE NN O O
rate NN O O
is NN O O
0.4 NN O O
% NN O O
; NN O O
therefore NN O O
, NN O O
overstretched NN O O
clinic NN O O
have NN O O
staff NN O O
conducted NN O O
more NN O O
than NN O O
200,000 NN O O
unnecessary NN O O
reviews NN O O
of NN O O
MC NN O O
clients NN O O
without NN O O
complications NN O O
. NN O O

Through NN O O
an NN O O
un-blinded NN O O
, NN O O
prospective NN O O
, NN O O
randomized NN O O
, NN O O
controlled NN O O
trial NN O O
in NN O O
two NN O O
high-volume NN O O
MC NN O O
facilities NN O O
, NN O O
we NN O O
will NN O O
compare NN O O
two NN O O
groups NN O O
of NN O O
adult NN O O
MC NN O O
clients NN O O
with NN O O
cell NN O O
phones NN O O
, NN O O
randomized NN O O
1:1 NN O O
into NN O O
two NN O O
groups NN O O
: NN O O
( NN O O
1 NN O O
) NN O O
routine NN O O
care NN O O
( NN O O
control NN O O
group NN O O
, NN O O
N NN O O
= NN O O
361 NN O O
) NN O O
and NN O O
( NN O O
2 NN O O
) NN O O
clients NN O O
who NN O O
receive NN O O
and NN O O
respond NN O O
to NN O O
a NN O O
daily NN O O
text NN O O
with NN O O
in-person NN O O
follow NN O O
up NN O O
only NN O O
if NN O O
desired NN O O
or NN O O
if NN O O
a NN O O
complication NN O O
is NN O O
suspected NN O O
( NN O O
intervention NN O O
group NN O O
, NN O O
N NN O O
= NN O O
361 NN O O
) NN O O
. NN O O

If NN O O
an NN O O
intervention NN O O
client NN O O
responds NN O O
affirmatively NN O O
to NN O O
any NN O O
automated NN O O
daily NN O O
text NN O O
with NN O O
a NN O O
suspected NN O O
AE NN O O
, NN O O
an NN O O
MC NN O O
nurse NN O O
will NN O O
exchange NN O O
manual NN O O
, NN O O
modifiable NN O O
, NN O O
scripted NN O O
texts NN O O
with NN O O
the NN O O
client NN O O
to NN O O
determine NN O O
symptoms NN O O
and NN O O
severity NN O O
, NN O O
requesting NN O O
an NN O O
in-person NN O O
visit NN O O
if NN O O
desired NN O O
or NN O O
warranted NN O O
. NN O O

Both NN O O
arms NN O O
will NN O O
complete NN O O
a NN O O
study-specific NN O O
, NN O O
day NN O O
14 NN O O
, NN O O
in-person NN O O
, NN O O
follow-up NN O O
review NN O O
for NN O O
verification NN O O
of NN O O
self-reports NN O O
( NN O O
intervention NN O O
) NN O O
and NN O O
comparison NN O O
( NN O O
control NN O O
) NN O O
. NN O O

Data NN O O
collection NN O O
includes NN O O
extraction NN O O
of NN O O
routine NN O O
client NN O O
MC NN O O
records NN O O
, NN O O
study-specific NN O O
database NN O O
reports NN O O
, NN O O
and NN O O
participant NN O O
usability NN O O
surveys NN O O
. NN O O

Intent-to-treat NN O O
( NN O O
ITT NN O O
) NN O O
analysis NN O O
will NN O O
be NN O O
used NN O O
to NN O O
explore NN O O
differences NN O O
between NN O O
groups NN O O
to NN O O
determine NN O O
if NN O O
two-way NN O O
texting NN O O
( NN O O
2wT NN O O
) NN O O
can NN O O
safely NN O O
reduce NN O O
MC NN O O
follow-up NN O O
visits NN O O
, NN O O
estimate NN O O
the NN O O
cost NN O O
savings NN O O
associated NN O O
with NN O O
2wT NN O O
over NN O O
routine NN O O
MC NN O O
follow NN O O
up NN O O
, NN O O
and NN O O
assess NN O O
the NN O O
acceptability NN O O
and NN O O
feasibility NN O O
of NN O O
2wT NN O O
for NN O O
scale NN O O
up NN O O
. NN O O

It NN O O
is NN O O
expected NN O O
that NN O O
this NN O O
mobile NN O O
health NN O O
intervention NN O O
will NN O O
be NN O O
as NN O O
safe NN O O
as NN O O
routine NN O O
care NN O O
while NN O O
providing NN O O
distinct NN O O
advantages NN O O
in NN O O
efficiency NN O O
, NN O O
costs NN O O
, NN O O
and NN O O
reduced NN O O
healthcare NN O O
worker NN O O
burden NN O O
. NN O O

The NN O O
success NN O O
of NN O O
this NN O O
intervention NN O O
could NN O O
lead NN O O
to NN O O
adaptation NN O O
and NN O O
adoption NN O O
of NN O O
this NN O O
intervention NN O O
at NN O O
the NN O O
national NN O O
level NN O O
, NN O O
increasing NN O O
the NN O O
efficiency NN O O
of NN O O
MC NN O O
scale NN O O
up NN O O
, NN O O
and NN O O
reducing NN O O
burdens NN O O
on NN O O
providers NN O O
and NN O O
patients NN O O
. NN O O

ClinicalTrials.gov NN O O
, NN O O
NCT03119337 NN O O
. NN O O

Registered NN O O
on NN O O
18 NN O O
April NN O O
2017 NN O O
. NN O O



-DOCSTART- (30419040)

Mass NN O O
azithromycin NN O O
distribution NN O O
reduces NN O O
under-5 NN O O
child NN O O
mortality NN O O
. NN O O

Trachoma NN O O
control NN O O
programs NN O O
currently NN O O
treat NN O O
infants NN O O
aged NN O O
6 NN O O
months NN O O
and NN O O
older NN O O
. NN O O

Here NN O O
, NN O O
we NN O O
report NN O O
findings NN O O
from NN O O
an NN O O
infant NN O O
adverse NN O O
event NN O O
survey NN O O
in NN O O
1 NN O O
- NN O O
5 NN O O
month NN O O
olds NN O O
who NN O O
received NN O O
azithromycin NN O O
as NN O O
part NN O O
of NN O O
a NN O O
large NN O O
community-randomized NN O O
trial NN O O
in NN O O
Niger NN O O
. NN O O

Active NN O O
surveillance NN O O
of NN O O
infants NN O O
aged NN O O
1 NN O O
- NN O O
5 NN O O
months NN O O
at NN O O
the NN O O
time NN O O
of NN O O
treatment NN O O
was NN O O
conducted NN O O
in NN O O
30 NN O O
randomly NN O O
selected NN O O
communities NN O O
from NN O O
within NN O O
a NN O O
large NN O O
cluster NN O O
randomized NN O O
trial NN O O
of NN O O
biannual NN O O
mass NN O O
azithromycin NN O O
distribution NN O O
compared NN O O
to NN O O
placebo NN O O
to NN O O
assess NN O O
the NN O O
potential NN O O
impact NN O O
on NN O O
child NN O O
mortality NN O O
. NN O O

We NN O O
compared NN O O
the NN O O
distribution NN O O
of NN O O
adverse NN O O
events NN O O
reported NN O O
after NN O O
treatment NN O O
among NN O O
azithromycin-treated NN O O
versus NN O O
placebo-treated NN O O
infants NN O O
. NN O O

From NN O O
January NN O O
2015 NN O O
to NN O O
February NN O O
2018 NN O O
, NN O O
the NN O O
caregivers NN O O
of NN O O
1,712 NN O O
infants NN O O
were NN O O
surveyed NN O O
. NN O O

Approximately NN O O
one-third NN O O
of NN O O
caregivers NN O O
reported NN O O
at NN O O
least NN O O
one NN O O
adverse NN O O
event NN O O
( NN O O
azithromycin NN O O
: NN O O
29.6 NN O O
% NN O O
, NN O O
placebo NN O O
: NN O O
34.3 NN O O
% NN O O
, NN O O
risk NN O O
ratio NN O O
[ NN O O
RR NN O O
] NN O O
0.86 NN O O
, NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
[ NN O O
CI NN O O
] NN O O
0.68 NN O O
to NN O O
1.10 NN O O
, NN O O
P NN O O
= NN O O
0.23 NN O O
) NN O O
. NN O O

The NN O O
most NN O O
commonly NN O O
reported NN O O
adverse NN O O
events NN O O
included NN O O
diarrhea NN O O
( NN O O
azithromycin NN O O
: NN O O
19.3 NN O O
% NN O O
, NN O O
placebo NN O O
: NN O O
28.1 NN O O
% NN O O
, NN O O
RR NN O O
0.68 NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
0.49 NN O O
to NN O O
0.96 NN O O
, NN O O
P NN O O
= NN O O
0.03 NN O O
) NN O O
, NN O O
vomiting NN O O
( NN O O
azithromycin NN O O
: NN O O
15.9 NN O O
% NN O O
, NN O O
placebo NN O O
: NN O O
21.0 NN O O
% NN O O
, NN O O
RR NN O O
0.76 NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
0.56 NN O O
to NN O O
1.02 NN O O
, NN O O
P NN O O
= NN O O
0.07 NN O O
) NN O O
, NN O O
and NN O O
skin NN O O
rash NN O O
( NN O O
azithromycin NN O O
: NN O O
12.3 NN O O
% NN O O
, NN O O
placebo NN O O
: NN O O
13.6 NN O O
% NN O O
, NN O O
RR NN O O
0.90 NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
0.59 NN O O
to NN O O
1.37 NN O O
, NN O O
P NN O O
= NN O O
0.63 NN O O
) NN O O
. NN O O

No NN O O
cases NN O O
of NN O O
infantile NN O O
hypertrophic NN O O
pyloric NN O O
stenosis NN O O
were NN O O
reported NN O O
. NN O O

Azithromycin NN O O
given NN O O
to NN O O
infants NN O O
aged NN O O
1 NN O O
- NN O O
5 NN O O
months NN O O
appeared NN O O
to NN O O
be NN O O
safe NN O O
. NN O O

Inclusion NN O O
of NN O O
younger NN O O
infants NN O O
in NN O O
larger NN O O
azithromycin-based NN O O
child NN O O
mortality NN O O
or NN O O
trachoma NN O O
control NN O O
programs NN O O
could NN O O
be NN O O
considered NN O O
if NN O O
deemed NN O O
effective NN O O
. NN O O

ClinicalTrials.gov NN O O
NCT02048007 NN O O
. NN O O



-DOCSTART- (30399035)

Retention NN O O
of NN O O
mothers NN O O
and NN O O
infants NN O O
across NN O O
the NN O O
prevention NN O O
of NN O O
mother-to-child NN O O
HIV NN O O
transmission NN O O
( NN O O
PMTCT NN O O
) NN O O
continuum NN O O
remains NN O O
challenging NN O O
. NN O O

We NN O O
assessed NN O O
the NN O O
effectiveness NN O O
of NN O O
a NN O O
lay NN O O
worker NN O O
administered NN O O
combination NN O O
intervention NN O O
compared NN O O
with NN O O
the NN O O
standard NN O O
of NN O O
care NN O O
( NN O O
SOC NN O O
) NN O O
on NN O O
mother-infant NN O O
attrition NN O O
. NN O O

HIV-positive NN O O
pregnant NN O O
women NN O O
starting NN O O
antenatal NN O O
care NN O O
at NN O O
10 NN O O
facilities NN O O
in NN O O
western NN O O
Kenya NN O O
were NN O O
randomized NN O O
using NN O O
simple NN O O
randomization NN O O
to NN O O
receive NN O O
individualized NN O O
health NN O O
education NN O O
, NN O O
retention/adherence NN O O
support NN O O
, NN O O
appointment NN O O
reminders NN O O
, NN O O
and NN O O
missed NN O O
visit NN O O
tracking NN O O
vs. NN O O
routine NN O O
care NN O O
per NN O O
guidelines NN O O
. NN O O

The NN O O
primary NN O O
endpoint NN O O
was NN O O
attrition NN O O
of NN O O
mother-infant NN O O
pairs NN O O
at NN O O
6 NN O O
months NN O O
postpartum NN O O
. NN O O

Attrition NN O O
was NN O O
defined NN O O
as NN O O
the NN O O
proportion NN O O
of NN O O
mother-infant NN O O
pairs NN O O
not NN O O
retained NN O O
in NN O O
the NN O O
clinic NN O O
at NN O O
6 NN O O
months NN O O
postpartum NN O O
because NN O O
of NN O O
mother NN O O
or NN O O
infant NN O O
death NN O O
or NN O O
lost NN O O
to NN O O
follow-up NN O O
. NN O O

Intent-to-treat NN O O
analysis NN O O
was NN O O
used NN O O
to NN O O
assess NN O O
the NN O O
difference NN O O
in NN O O
attrition NN O O
. NN O O

This NN O O
trial NN O O
is NN O O
registered NN O O
with NN O O
ClinicalTrials.gov NN O O
; NN O O
NCT01962220 NN O O
. NN O O

From NN O O
September NN O O
2013 NN O O
to NN O O
June NN O O
2014 NN O O
, NN O O
361 NN O O
HIV-positive NN O O
pregnant NN O O
women NN O O
were NN O O
screened NN O O
, NN O O
and NN O O
340 NN O O
were NN O O
randomized NN O O
to NN O O
the NN O O
intervention NN O O
( NN O O
n NN O O
= NN O O
170 NN O O
) NN O O
or NN O O
SOC NN O O
( NN O O
n NN O O
= NN O O
170 NN O O
) NN O O
. NN O O

Median NN O O
age NN O O
at NN O O
enrollment NN O O
was NN O O
26 NN O O
years NN O O
( NN O O
interquartile NN O O
range NN O O
22 NN O O
- NN O O
30 NN O O
) NN O O
; NN O O
median NN O O
gestational NN O O
age NN O O
was NN O O
24 NN O O
weeks NN O O
( NN O O
interquartile NN O O
range NN O O
17 NN O O
- NN O O
28 NN O O
) NN O O
. NN O O

Overall NN O O
attrition NN O O
of NN O O
mother-infant NN O O
pairs NN O O
was NN O O
23.5 NN O O
% NN O O
at NN O O
6 NN O O
months NN O O
postpartum NN O O
. NN O O

Attrition NN O O
was NN O O
significantly NN O O
lower NN O O
in NN O O
the NN O O
intervention NN O O
arm NN O O
compared NN O O
with NN O O
SOC NN O O
( NN O O
18.8 NN O O
% NN O O
vs. NN O O
28.2 NN O O
% NN O O
, NN O O
relative NN O O
risk NN O O
( NN O O
RR NN O O
) NN O O
= NN O O
0.67 NN O O
, NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
: NN O O
0.45 NN O O
to NN O O
0.99 NN O O
, NN O O
P NN O O
= NN O O
0.04 NN O O
) NN O O
. NN O O

Overall NN O O
, NN O O
the NN O O
proportion NN O O
of NN O O
mothers NN O O
who NN O O
were NN O O
retained NN O O
and NN O O
virally NN O O
suppressed NN O O
( NN O O
< NN O O
1000 NN O O
copies/mL NN O O
) NN O O
at NN O O
6 NN O O
months NN O O
postpartum NN O O
was NN O O
54.4 NN O O
% NN O O
, NN O O
with NN O O
no NN O O
difference NN O O
between NN O O
study NN O O
arms NN O O
. NN O O

Provision NN O O
of NN O O
a NN O O
combination NN O O
intervention NN O O
by NN O O
lay NN O O
counselors NN O O
can NN O O
decrease NN O O
attrition NN O O
along NN O O
the NN O O
PMTCT NN O O
cascade NN O O
in NN O O
low-resource NN O O
settings NN O O
. NN O O



-DOCSTART- (30703190)

Androgen-deprivation NN O O
therapy NN O O
( NN O O
ADT NN O O
) NN O O
plus NN O O
docetaxel NN O O
is NN O O
the NN O O
standard NN O O
of NN O O
care NN O O
in NN O O
hormone-naive NN O O
metastatic NN O O
prostate NN O O
cancer NN O O
but NN O O
is NN O O
of NN O O
uncertain NN O O
benefit NN O O
in NN O O
a NN O O
nonmetastatic NN O O
, NN O O
high-risk NN O O
prostate NN O O
cancer NN O O
setting NN O O
. NN O O

To NN O O
assess NN O O
the NN O O
benefit NN O O
of NN O O
ADT NN O O
plus NN O O
docetaxel NN O O
in NN O O
patients NN O O
presenting NN O O
with NN O O
rising NN O O
prostate-specific NN O O
antigen NN O O
( NN O O
PSA NN O O
) NN O O
levels NN O O
after NN O O
primary NN O O
local NN O O
therapy NN O O
and NN O O
high-risk NN O O
factors NN O O
but NN O O
no NN O O
evidence NN O O
of NN O O
metastatic NN O O
disease NN O O
. NN O O

This NN O O
open-label NN O O
, NN O O
phase NN O O
3 NN O O
, NN O O
randomized NN O O
superiority NN O O
trial NN O O
comparing NN O O
ADT NN O O
plus NN O O
docetaxel NN O O
vs NN O O
ADT NN O O
alone NN O O
enrolled NN O O
patients NN O O
from NN O O
28 NN O O
centers NN O O
in NN O O
France NN O O
between NN O O
June NN O O
4 NN O O
, NN O O
2003 NN O O
, NN O O
and NN O O
September NN O O
25 NN O O
, NN O O
2007 NN O O
; NN O O
final NN O O
follow-up NN O O
was NN O O
conducted NN O O
April NN O O
12 NN O O
, NN O O
2017 NN O O
, NN O O
and NN O O
analysis NN O O
was NN O O
performed NN O O
May NN O O
2 NN O O
to NN O O
July NN O O
31 NN O O
, NN O O
2017 NN O O
. NN O O

Patients NN O O
had NN O O
undergone NN O O
primary NN O O
local NN O O
therapy NN O O
for NN O O
prostate NN O O
cancer NN O O
, NN O O
were NN O O
experiencing NN O O
rising NN O O
PSA NN O O
levels NN O O
, NN O O
and NN O O
were NN O O
considered NN O O
to NN O O
be NN O O
at NN O O
high NN O O
risk NN O O
of NN O O
metastatic NN O O
disease NN O O
. NN O O

Stratification NN O O
was NN O O
by NN O O
prior NN O O
local NN O O
therapy NN O O
and NN O O
PSA-level NN O O
doubling NN O O
time NN O O
( NN O O
≤6 NN O O
vs NN O O
> NN O O
6 NN O O
months NN O O
) NN O O
, NN O O
and NN O O
intention-to-treat NN O O
analysis NN O O
was NN O O
used NN O O
. NN O O

Patients NN O O
were NN O O
randomly NN O O
assigned NN O O
to NN O O
receive NN O O
ADT NN O O
( NN O O
1 NN O O
year NN O O
) NN O O
plus NN O O
docetaxel NN O O
, NN O O
70 NN O O
mg/m2 NN O O
( NN O O
every NN O O
3 NN O O
weeks NN O O
[ NN O O
6 NN O O
cycles NN O O
] NN O O
) NN O O
, NN O O
or NN O O
ADT NN O O
alone NN O O
( NN O O
1 NN O O
year NN O O
) NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
was NN O O
PSA NN O O
progression-free NN O O
survival NN O O
( NN O O
PSA-PFS NN O O
) NN O O
. NN O O

Secondary NN O O
end NN O O
points NN O O
were NN O O
PSA NN O O
response NN O O
, NN O O
radiologic NN O O
PFS NN O O
, NN O O
overall NN O O
survival NN O O
, NN O O
safety NN O O
, NN O O
and NN O O
quality NN O O
of NN O O
life NN O O
. NN O O

Overall NN O O
, NN O O
254 NN O O
patients NN O O
were NN O O
randomized NN O O
( NN O O
1:1 NN O O
) NN O O
to NN O O
the NN O O
trial NN O O
; NN O O
median NN O O
age NN O O
, NN O O
64 NN O O
years NN O O
in NN O O
the NN O O
ADT NN O O
plus NN O O
docetaxel NN O O
arm NN O O
, NN O O
66 NN O O
years NN O O
in NN O O
the NN O O
ADT NN O O
alone NN O O
arm NN O O
. NN O O

At NN O O
a NN O O
median NN O O
follow-up NN O O
of NN O O
30.0 NN O O
months NN O O
, NN O O
the NN O O
median NN O O
PSA-PFS NN O O
was NN O O
20.3 NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
19.0 NN O O
- NN O O
21.6 NN O O
) NN O O
months NN O O
in NN O O
the NN O O
ADT NN O O
plus NN O O
docetaxel NN O O
arm NN O O
vs NN O O
19.3 NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
18.2 NN O O
- NN O O
20.8 NN O O
) NN O O
months NN O O
in NN O O
the NN O O
ADT NN O O
alone NN O O
arm NN O O
( NN O O
hazard NN O O
ratio NN O O
[ NN O O
HR NN O O
] NN O O
, NN O O
0.85 NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
0.62 NN O O
- NN O O
1.16 NN O O
; NN O O
P NN O O
= NN O O
.31 NN O O
) NN O O
. NN O O

At NN O O
a NN O O
median NN O O
follow-up NN O O
of NN O O
10.5 NN O O
years NN O O
, NN O O
there NN O O
was NN O O
no NN O O
significant NN O O
between-arm NN O O
difference NN O O
in NN O O
radiologic NN O O
PFS NN O O
( NN O O
HR NN O O
, NN O O
1.03 NN O O
; NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
0.74 NN O O
- NN O O
1.43 NN O O
; NN O O
P NN O O
= NN O O
.88 NN O O
) NN O O
. NN O O

Overall NN O O
survival NN O O
data NN O O
were NN O O
not NN O O
mature NN O O
. NN O O

The NN O O
most NN O O
common NN O O
grade NN O O
3 NN O O
or NN O O
4 NN O O
hematologic NN O O
toxic NN O O
effects NN O O
in NN O O
the NN O O
ADT NN O O
plus NN O O
docetaxel NN O O
arm NN O O
were NN O O
neutropenia NN O O
( NN O O
60 NN O O
of NN O O
125 NN O O
patients NN O O
[ NN O O
48.0 NN O O
% NN O O
] NN O O
) NN O O
, NN O O
febrile NN O O
neutropenia NN O O
( NN O O
10 NN O O
[ NN O O
8.0 NN O O
% NN O O
] NN O O
) NN O O
, NN O O
and NN O O
thrombocytopenia NN O O
( NN O O
4 NN O O
[ NN O O
3.0 NN O O
% NN O O
] NN O O
) NN O O
. NN O O

There NN O O
was NN O O
no NN O O
significant NN O O
between-arm NN O O
difference NN O O
in NN O O
overall NN O O
quality NN O O
of NN O O
life NN O O
. NN O O

Compared NN O O
with NN O O
ADT NN O O
alone NN O O
, NN O O
combined NN O O
ADT NN O O
plus NN O O
docetaxel NN O O
therapy NN O O
with NN O O
curative NN O O
intent NN O O
did NN O O
not NN O O
significantly NN O O
improve NN O O
PSA-PFS NN O O
in NN O O
patients NN O O
with NN O O
high-risk NN O O
prostate NN O O
cancer NN O O
and NN O O
rising NN O O
PSA NN O O
levels NN O O
and NN O O
no NN O O
evidence NN O O
of NN O O
metastatic NN O O
disease NN O O
. NN O O

French NN O O
Health NN O O
Products NN O O
Safety NN O O
Agency NN O O
identifier NN O O
: NN O O
030591 NN O O
; NN O O
ClinicalTrials.gov NN O O
identifier NN O O
: NN O O
NCT00764166 NN O O
. NN O O



-DOCSTART- (30482460)

The NN O O
fear NN O O
of NN O O
falling NN O O
has NN O O
a NN O O
high NN O O
prevalence NN O O
in NN O O
the NN O O
community NN O O
, NN O O
and NN O O
intervention NN O O
programs NN O O
for NN O O
this NN O O
condition NN O O
are NN O O
scarce NN O O
, NN O O
making NN O O
it NN O O
is NN O O
necessary NN O O
to NN O O
strengthen NN O O
this NN O O
type NN O O
of NN O O
therapy NN O O
in NN O O
order NN O O
to NN O O
prevent NN O O
adverse NN O O
consequences NN O O
in NN O O
the NN O O
elderly NN O O
population NN O O
. NN O O

To NN O O
establish NN O O
the NN O O
effectiveness NN O O
of NN O O
three NN O O
intervention NN O O
programs NN O O
in NN O O
reducing NN O O
the NN O O
fear NN O O
of NN O O
falling NN O O
and NN O O
increasing NN O O
functionality NN O O
in NN O O
elderly NN O O
people NN O O
in NN O O
the NN O O
city NN O O
of NN O O
Manizales NN O O
. NN O O

A NN O O
randomised NN O O
trial NN O O
was NN O O
conducted NN O O
on NN O O
ambulatory NN O O
elderly NN O O
patients NN O O
with NN O O
fear NN O O
of NN O O
falling NN O O
and NN O O
functional NN O O
limitation NN O O
of NN O O
the NN O O
city NN O O
of NN O O
Manizales NN O O
. NN O O

A NN O O
total NN O O
of NN O O
125 NN O O
individuals NN O O
were NN O O
randomised NN O O
to NN O O
one NN O O
of NN O O
three NN O O
interventions NN O O
: NN O O
Tai NN O O
Chi NN O O
( NN O O
TCh NN O O
) NN O O
, NN O O
cognitive NN O O
behavioural NN O O
therapy NN O O
( NN O O
CBT NN O O
) NN O O
, NN O O
and NN O O
postural NN O O
control NN O O
( NN O O
CP NN O O
) NN O O
exercises NN O O
. NN O O

The NN O O
primary NN O O
outcomes NN O O
were NN O O
: NN O O
fear NN O O
of NN O O
falling NN O O
( NN O O
evaluated NN O O
by NN O O
the NN O O
Falls NN O O
Efficacy NN O O
Scale NN O O
[ NN O O
FES-I NN O O
] NN O O
) NN O O
, NN O O
and NN O O
functionality NN O O
using NN O O
the NN O O
Short NN O O
Physical NN O O
Performance NN O O
Battery NN O O
( NN O O
SPPB NN O O
) NN O O
. NN O O

The NN O O
data NN O O
was NN O O
collected NN O O
before NN O O
initiating NN O O
the NN O O
interventions NN O O
and NN O O
after NN O O
the NN O O
8 NN O O
weeks NN O O
intervention NN O O
. NN O O

An NN O O
intention-to-treat NN O O
analysis NN O O
was NN O O
conducted NN O O
on NN O O
119 NN O O
elderly NN O O
patients NN O O
. NN O O

The NN O O
three NN O O
interventions NN O O
reduced NN O O
the NN O O
fear NN O O
of NN O O
falling NN O O
and NN O O
increased NN O O
physical NN O O
performance NN O O
, NN O O
with NN O O
no NN O O
significant NN O O
differences NN O O
observed NN O O
between NN O O
them NN O O
( NN O O
P=.13 NN O O
) NN O O
. NN O O

As NN O O
regards NN O O
gait NN O O
speed NN O O
, NN O O
differences NN O O
were NN O O
only NN O O
found NN O O
between NN O O
the NN O O
pre- NN O O
and NN O O
post-intervention NN O O
with NN O O
CP NN O O
( NN O O
P<.001 NN O O
) NN O O
. NN O O

The NN O O
results NN O O
suggest NN O O
that NN O O
the NN O O
TCh NN O O
, NN O O
CBT NN O O
and NN O O
CP NN O O
interventions NN O O
helped NN O O
the NN O O
elderly NN O O
to NN O O
reduce NN O O
their NN O O
fear NN O O
of NN O O
falling NN O O
. NN O O

Only NN O O
CP NN O O
demonstrated NN O O
an NN O O
improvement NN O O
in NN O O
the NN O O
speed NN O O
of NN O O
walking NN O O
at NN O O
the NN O O
end NN O O
of NN O O
the NN O O
eight NN O O
weeks NN O O
of NN O O
intervention NN O O
( NN O O
identifier NN O O
NCT03211429 NN O O
) NN O O
. NN O O



-DOCSTART- (30919948)

Transverse NN O O
abdominis NN O O
plane NN O O
( NN O O
TAP NN O O
) NN O O
block NN O O
is NN O O
considered NN O O
an NN O O
effective NN O O
alternative NN O O
to NN O O
neuraxial NN O O
analgesia NN O O
for NN O O
abdominal NN O O
surgery NN O O
. NN O O

However NN O O
, NN O O
limited NN O O
evidence NN O O
supports NN O O
its NN O O
use NN O O
over NN O O
traditional NN O O
analgesic NN O O
modalities NN O O
in NN O O
colorectal NN O O
surgery NN O O
. NN O O

This NN O O
study NN O O
compared NN O O
the NN O O
analgesic NN O O
efficacy NN O O
of NN O O
liposomal NN O O
bupivacaine NN O O
TAP NN O O
block NN O O
with NN O O
intrathecal NN O O
( NN O O
IT NN O O
) NN O O
opioid NN O O
administration NN O O
in NN O O
a NN O O
multicentre NN O O
RCT NN O O
. NN O O

Patients NN O O
undergoing NN O O
elective NN O O
small NN O O
bowel NN O O
or NN O O
colorectal NN O O
resection NN O O
were NN O O
randomized NN O O
to NN O O
receive NN O O
TAP NN O O
block NN O O
or NN O O
a NN O O
single NN O O
injection NN O O
of NN O O
IT NN O O
analgesia NN O O
with NN O O
hydromorphone NN O O
. NN O O

Patients NN O O
were NN O O
assessed NN O O
at NN O O
4 NN O O
, NN O O
8 NN O O
, NN O O
16 NN O O
, NN O O
24 NN O O
and NN O O
48 NN O O
h NN O O
after NN O O
surgery NN O O
. NN O O

Primary NN O O
outcomes NN O O
were NN O O
mean NN O O
pain NN O O
scores NN O O
and NN O O
morphine NN O O
milligram NN O O
equivalents NN O O
( NN O O
MMEs NN O O
) NN O O
administered NN O O
within NN O O
48 NN O O
h NN O O
after NN O O
surgery NN O O
. NN O O

Secondary NN O O
outcomes NN O O
included NN O O
duration NN O O
of NN O O
hospital NN O O
stay NN O O
, NN O O
incidence NN O O
of NN O O
postoperative NN O O
ileus NN O O
and NN O O
use NN O O
of NN O O
intravenous NN O O
patient-controlled NN O O
analgesia NN O O
. NN O O

In NN O O
total NN O O
, NN O O
209 NN O O
patients NN O O
were NN O O
recruited NN O O
and NN O O
200 NN O O
completed NN O O
the NN O O
trial NN O O
( NN O O
TAP NN O O
102 NN O O
, NN O O
IT NN O O
98 NN O O
) NN O O
. NN O O

The NN O O
TAP NN O O
group NN O O
had NN O O
a NN O O
1·6-point NN O O
greater NN O O
mean NN O O
pain NN O O
score NN O O
than NN O O
the NN O O
IT NN O O
group NN O O
at NN O O
4 NN O O
h NN O O
after NN O O
surgery NN O O
, NN O O
and NN O O
this NN O O
difference NN O O
lasted NN O O
for NN O O
16 NN O O
h NN O O
after NN O O
operation NN O O
. NN O O

The NN O O
TAP NN O O
group NN O O
received NN O O
more NN O O
MMEs NN O O
within NN O O
the NN O O
first NN O O
24 NN O O
h NN O O
after NN O O
surgery NN O O
than NN O O
the NN O O
IT NN O O
group NN O O
( NN O O
median NN O O
difference NN O O
in NN O O
MMEs NN O O
10·0 NN O O
, NN O O
95 NN O O
per NN O O
cent NN O O
c.i NN O O
. NN O O

3·0 NN O O
to NN O O
20·5 NN O O
) NN O O
. NN O O

There NN O O
were NN O O
no NN O O
differences NN O O
in NN O O
MME NN O O
use NN O O
at NN O O
24 NN O O
and NN O O
48 NN O O
h NN O O
, NN O O
or NN O O
with NN O O
respect NN O O
to NN O O
secondary NN O O
outcomes NN O O
. NN O O

IT NN O O
opioid NN O O
administration NN O O
provided NN O O
better NN O O
immediate NN O O
postoperative NN O O
pain NN O O
control NN O O
than NN O O
TAP NN O O
block NN O O
. NN O O

Both NN O O
modalities NN O O
resulted NN O O
in NN O O
low NN O O
pain NN O O
scores NN O O
in NN O O
patients NN O O
undergoing NN O O
elective NN O O
colorectal NN O O
surgery NN O O
and NN O O
should NN O O
be NN O O
considered NN O O
in NN O O
multimodal NN O O
postoperative NN O O
analgesic NN O O
plans NN O O
. NN O O

Registration NN O O
number NN O O
: NN O O
NCT02356198 NN O O
( NN O O
http://www.clinicaltrials.gov NN O O
) NN O O
. NN O O



-DOCSTART- (30901755)

OBJECTIVE NN O O
: NN O O
Information NN O O
about NN O O
postoperative NN O O
rehabilitation NN O O
for NN O O
cervical NN O O
radiculopathy NN O O
( NN O O
CR NN O O
) NN O O
is NN O O
scarce NN O O
. NN O O

The NN O O
aim NN O O
of NN O O
this NN O O
study NN O O
was NN O O
to NN O O
investigate NN O O
the NN O O
additional NN O O
benefits NN O O
of NN O O
structured NN O O
postoperative NN O O
rehabilitation NN O O
( NN O O
SPT NN O O
) NN O O
, NN O O
which NN O O
was NN O O
performed NN O O
in NN O O
all NN O O
patients NN O O
, NN O O
compared NN O O
with NN O O
a NN O O
pragmatic NN O O
standard NN O O
postoperative NN O O
approach NN O O
( NN O O
SA NN O O
) NN O O
, NN O O
in NN O O
which NN O O
rehabilitation NN O O
was NN O O
used NN O O
as NN O O
needed NN O O
and NN O O
patients NN O O
sought NN O O
physiotherapy NN O O
on NN O O
their NN O O
own NN O O
without NN O O
a NN O O
referral NN O O
, NN O O
in NN O O
patients NN O O
with NN O O
MRI NN O O
evidence NN O O
of NN O O
disc NN O O
herniation NN O O
and NN O O
concomitant NN O O
clinical NN O O
signs NN O O
who NN O O
underwent NN O O
surgery NN O O
for NN O O
CR NN O O
. NN O O

METHODS NN O O
: NN O O
Patients NN O O
( NN O O
n NN O O
= NN O O
202 NN O O
) NN O O
were NN O O
randomized NN O O
to NN O O
receive NN O O
SPT NN O O
or NN O O
SA NN O O
. NN O O

Included NN O O
key NN O O
variables NN O O
in NN O O
the NN O O
present NN O O
study NN O O
were NN O O
primary NN O O
and NN O O
selected NN O O
secondary NN O O
outcomes NN O O
of NN O O
a NN O O
prospective NN O O
randomized NN O O
controlled NN O O
multicenter NN O O
study NN O O
. NN O O

The NN O O
main NN O O
outcome NN O O
was NN O O
the NN O O
Neck NN O O
Disability NN O O
Index NN O O
( NN O O
NDI NN O O
) NN O O
score NN O O
. NN O O

The NN O O
NDI NN O O
score NN O O
, NN O O
pain NN O O
variables NN O O
, NN O O
self-efficacy NN O O
, NN O O
and NN O O
health-related NN O O
quality NN O O
of NN O O
life NN O O
were NN O O
investigated NN O O
at NN O O
baseline NN O O
and NN O O
3 NN O O
, NN O O
6 NN O O
, NN O O
12 NN O O
, NN O O
and NN O O
24 NN O O
months NN O O
postoperatively NN O O
. NN O O

RESULTS NN O O
: NN O O
SPT NN O O
provided NN O O
no NN O O
additional NN O O
benefits NN O O
over NN O O
SA NN O O
( NN O O
p NN O O
= NN O O
0.08 NN O O
to NN O O
p NN O O
= NN O O
0.99 NN O O
) NN O O
at NN O O
the NN O O
postoperative NN O O
2-year NN O O
follow-up NN O O
. NN O O

Both NN O O
groups NN O O
improved NN O O
over NN O O
time NN O O
( NN O O
p NN O O
< NN O O
0.0001 NN O O
) NN O O
, NN O O
with NN O O
no NN O O
reported NN O O
adverse NN O O
effects NN O O
. NN O O

CONCLUSIONS NN O O
: NN O O
One NN O O
can NN O O
conclude NN O O
that NN O O
SPT NN O O
offered NN O O
no NN O O
additional NN O O
benefits NN O O
over NN O O
SA NN O O
; NN O O
however NN O O
, NN O O
patients NN O O
tolerated NN O O
postoperative NN O O
neck NN O O
exercises NN O O
without NN O O
any NN O O
negative NN O O
side NN O O
effects NN O O
. NN O O

These NN O O
findings NN O O
are NN O O
important NN O O
for NN O O
the NN O O
development NN O O
of NN O O
future NN O O
active NN O O
and NN O O
neck-specific NN O O
postoperative NN O O
rehabilitation NN O O
interventions NN O O
for NN O O
patients NN O O
with NN O O
CR.Clinical NN O O
trial NN O O
registration NN O O
no. NN O O
: NN O O
NCT01547611 NN O O
( NN O O
clinicaltrials.gov NN O O
) NN O O
. NN O O



-DOCSTART- (30885591)

Infections NN O O
with NN O O
Clostridium NN O O
difficile NN O O
are NN O O
a NN O O
health NN O O
threat NN O O
, NN O O
yet NN O O
no NN O O
products NN O O
are NN O O
currently NN O O
licensed NN O O
for NN O O
prevention NN O O
of NN O O
primary NN O O
C NN O O
difficile NN O O
infections NN O O
. NN O O

Intravenous NN O O
β-lactam NN O O
antibiotics NN O O
are NN O O
considered NN O O
to NN O O
confer NN O O
a NN O O
high NN O O
risk NN O O
of NN O O
C NN O O
difficile NN O O
infection NN O O
because NN O O
of NN O O
their NN O O
biliary NN O O
excretion NN O O
into NN O O
the NN O O
gastrointestinal NN O O
tract NN O O
and NN O O
disruption NN O O
of NN O O
the NN O O
gut NN O O
microbiome NN O O
. NN O O

ribaxamase NN O O
( NN O O
SYN-004 NN O O
) NN O O
is NN O O
an NN O O
orally NN O O
administered NN O O
β-lactamase NN O O
that NN O O
was NN O O
designed NN O O
to NN O O
be NN O O
given NN O O
with NN O O
intravenous NN O O
β-lactam NN O O
antibiotics NN O O
to NN O O
degrade NN O O
excess NN O O
antibiotics NN O O
in NN O O
the NN O O
upper NN O O
gastrointestinal NN O O
tract NN O O
before NN O O
they NN O O
disrupt NN O O
the NN O O
gut NN O O
microbiome NN O O
and NN O O
lead NN O O
to NN O O
C NN O O
difficile NN O O
infection NN O O
. NN O O

We NN O O
therefore NN O O
aimed NN O O
to NN O O
determine NN O O
whether NN O O
administration NN O O
of NN O O
ribaxamase NN O O
could NN O O
prevent NN O O
C NN O O
difficile NN O O
infection NN O O
in NN O O
patients NN O O
being NN O O
treated NN O O
with NN O O
intravenous NN O O
ceftriaxone NN O O
for NN O O
a NN O O
lower NN O O
respiratory NN O O
tract NN O O
infection NN O O
, NN O O
thereby NN O O
supporting NN O O
continued NN O O
clinical NN O O
development NN O O
. NN O O

In NN O O
this NN O O
parallel-group NN O O
, NN O O
double-blind NN O O
, NN O O
multicentre NN O O
, NN O O
phase NN O O
2b NN O O
, NN O O
randomised NN O O
placebo-controlled NN O O
trial NN O O
, NN O O
we NN O O
recruited NN O O
patients NN O O
who NN O O
had NN O O
been NN O O
admitted NN O O
to NN O O
a NN O O
hospital NN O O
with NN O O
a NN O O
lower NN O O
respiratory NN O O
tract NN O O
infection NN O O
with NN O O
a NN O O
pneumonia NN O O
index NN O O
score NN O O
of NN O O
90 NN O O
- NN O O
130 NN O O
and NN O O
who NN O O
were NN O O
expected NN O O
to NN O O
be NN O O
treated NN O O
with NN O O
ceftriaxone NN O O
for NN O O
at NN O O
least NN O O
5 NN O O
days NN O O
. NN O O

Patients NN O O
were NN O O
recruited NN O O
from NN O O
54 NN O O
clinical NN O O
sites NN O O
in NN O O
the NN O O
USA NN O O
, NN O O
Canada NN O O
, NN O O
Bulgaria NN O O
, NN O O
Hungary NN O O
, NN O O
Poland NN O O
, NN O O
Romania NN O O
, NN O O
and NN O O
Serbia NN O O
. NN O O

We NN O O
randomly NN O O
assigned NN O O
patients NN O O
older NN O O
than NN O O
50 NN O O
years NN O O
to NN O O
groups NN O O
( NN O O
1:1 NN O O
) NN O O
in NN O O
blocks NN O O
of NN O O
four NN O O
by NN O O
use NN O O
of NN O O
an NN O O
interactive NN O O
web NN O O
portal NN O O
; NN O O
these NN O O
groups NN O O
were NN O O
assigned NN O O
to NN O O
receive NN O O
either NN O O
150 NN O O
mg NN O O
ribaxamase NN O O
or NN O O
placebo NN O O
four NN O O
times NN O O
per NN O O
day NN O O
during NN O O
, NN O O
and NN O O
for NN O O
72 NN O O
h NN O O
after NN O O
, NN O O
treatment NN O O
with NN O O
ceftriaxone NN O O
. NN O O

All NN O O
patients NN O O
, NN O O
clinical NN O O
investigators NN O O
, NN O O
study NN O O
staff NN O O
, NN O O
and NN O O
sponsor NN O O
personnel NN O O
were NN O O
masked NN O O
to NN O O
the NN O O
study NN O O
drug NN O O
assignments NN O O
. NN O O

The NN O O
primary NN O O
endpoint NN O O
was NN O O
the NN O O
incidence NN O O
of NN O O
C NN O O
difficile NN O O
infection NN O O
, NN O O
as NN O O
diagnosed NN O O
by NN O O
the NN O O
local NN O O
laboratory NN O O
, NN O O
in NN O O
patients NN O O
who NN O O
received NN O O
at NN O O
least NN O O
one NN O O
treatment NN O O
dose NN O O
, NN O O
and NN O O
this NN O O
outcome NN O O
was NN O O
assessed NN O O
during NN O O
treatment NN O O
and NN O O
for NN O O
4 NN O O
weeks NN O O
after NN O O
treatment NN O O
. NN O O

This NN O O
study NN O O
is NN O O
registered NN O O
with NN O O
ClinicalTrials.gov NN O O
, NN O O
number NN O O
NCT02563106 NN O O
. NN O O

Between NN O O
Nov NN O O
16 NN O O
, NN O O
2015 NN O O
, NN O O
and NN O O
Nov NN O O
10 NN O O
, NN O O
2016 NN O O
, NN O O
we NN O O
screened NN O O
433 NN O O
patients NN O O
for NN O O
inclusion NN O O
in NN O O
the NN O O
study NN O O
. NN O O

Of NN O O
these NN O O
patients NN O O
, NN O O
20 NN O O
( NN O O
5 NN O O
% NN O O
) NN O O
patients NN O O
were NN O O
excluded NN O O
from NN O O
the NN O O
study NN O O
( NN O O
16 NN O O
[ NN O O
4 NN O O
% NN O O
] NN O O
patients NN O O
did NN O O
not NN O O
meet NN O O
inclusion NN O O
criteria NN O O
; NN O O
four NN O O
[ NN O O
1 NN O O
% NN O O
] NN O O
patients NN O O
because NN O O
of NN O O
dosing NN O O
restrictions NN O O
) NN O O
. NN O O

We NN O O
enrolled NN O O
and NN O O
randomly NN O O
assigned NN O O
413 NN O O
patients NN O O
to NN O O
groups NN O O
, NN O O
of NN O O
whom NN O O
207 NN O O
patients NN O O
were NN O O
assigned NN O O
to NN O O
receive NN O O
ceftriaxone NN O O
plus NN O O
ribaxamase NN O O
and NN O O
206 NN O O
patients NN O O
were NN O O
assigned NN O O
to NN O O
receive NN O O
ceftriaxone NN O O
plus NN O O
placebo NN O O
. NN O O

However NN O O
, NN O O
one NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
patient NN O O
in NN O O
the NN O O
ribaxamase NN O O
group NN O O
withdrew NN O O
consent NN O O
and NN O O
was NN O O
not NN O O
treated NN O O
with NN O O
ribaxamase NN O O
. NN O O

During NN O O
the NN O O
study NN O O
and NN O O
within NN O O
the NN O O
4 NN O O
weeks NN O O
after NN O O
antibiotic NN O O
treatment NN O O
, NN O O
two NN O O
( NN O O
1·0 NN O O
% NN O O
) NN O O
patients NN O O
in NN O O
the NN O O
ribaxamase NN O O
group NN O O
and NN O O
seven NN O O
( NN O O
3·4 NN O O
% NN O O
) NN O O
patients NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
were NN O O
diagnosed NN O O
with NN O O
an NN O O
infection NN O O
with NN O O
C NN O O
difficile NN O O
( NN O O
risk NN O O
reduction NN O O
2·4 NN O O
% NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
-0·6 NN O O
to NN O O
5·9 NN O O
; NN O O
one-sided NN O O
p=0·045 NN O O
) NN O O
. NN O O

Adverse NN O O
events NN O O
were NN O O
similar NN O O
between NN O O
groups NN O O
but NN O O
more NN O O
deaths NN O O
were NN O O
reported NN O O
in NN O O
the NN O O
ribaxamase NN O O
group NN O O
( NN O O
11 NN O O
deaths NN O O
vs NN O O
five NN O O
deaths NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
) NN O O
. NN O O

This NN O O
disparity NN O O
was NN O O
due NN O O
to NN O O
the NN O O
higher NN O O
incidence NN O O
of NN O O
deaths NN O O
attributed NN O O
to NN O O
cardiac-associated NN O O
causes NN O O
in NN O O
the NN O O
ribaxamase NN O O
group NN O O
( NN O O
six NN O O
deaths NN O O
vs NN O O
one NN O O
death NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
) NN O O
. NN O O

In NN O O
patients NN O O
treated NN O O
with NN O O
intravenous NN O O
ceftriaxone NN O O
for NN O O
lower NN O O
respiratory NN O O
tract NN O O
infections NN O O
, NN O O
oral NN O O
ribaxamase NN O O
reduced NN O O
the NN O O
incidence NN O O
of NN O O
C NN O O
difficile NN O O
infections NN O O
compared NN O O
with NN O O
placebo NN O O
. NN O O

The NN O O
imbalance NN O O
in NN O O
deaths NN O O
between NN O O
the NN O O
groups NN O O
appeared NN O O
to NN O O
be NN O O
related NN O O
to NN O O
the NN O O
underlying NN O O
health NN O O
of NN O O
the NN O O
patients NN O O
. NN O O

Ribaxamase NN O O
has NN O O
the NN O O
potential NN O O
to NN O O
prevent NN O O
C NN O O
difficile NN O O
infection NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
intravenous NN O O
β-lactam NN O O
antibiotics NN O O
, NN O O
and NN O O
our NN O O
findings NN O O
support NN O O
continued NN O O
clinical NN O O
development NN O O
of NN O O
ribaxamase NN O O
to NN O O
prevent NN O O
C NN O O
difficile NN O O
infection NN O O
. NN O O

Synthetic NN O O
Biologics NN O O
. NN O O



-DOCSTART- (30522663)

The NN O O
aim NN O O
of NN O O
this NN O O
study NN O O
was NN O O
to NN O O
assess NN O O
the NN O O
safety NN O O
and NN O O
effectiveness NN O O
of NN O O
a NN O O
next-generation NN O O
low-dose NN O O
drug-coated NN O O
balloon NN O O
( NN O O
DCB NN O O
) NN O O
designed NN O O
to NN O O
optimize NN O O
the NN O O
amount NN O O
of NN O O
drug NN O O
transferred NN O O
into NN O O
the NN O O
vessel NN O O
wall NN O O
and NN O O
to NN O O
maximize NN O O
the NN O O
amount NN O O
of NN O O
time NN O O
the NN O O
drug NN O O
resides NN O O
in NN O O
the NN O O
vessel NN O O
wall NN O O
. NN O O

Several NN O O
randomized NN O O
controlled NN O O
studies NN O O
evaluating NN O O
various NN O O
DCBs NN O O
have NN O O
demonstrated NN O O
a NN O O
significantly NN O O
higher NN O O
patency NN O O
rate NN O O
compared NN O O
with NN O O
noncoated NN O O
percutaneous NN O O
transluminal NN O O
angioplasty NN O O
balloons NN O O
at NN O O
1 NN O O
year NN O O
. NN O O

However NN O O
, NN O O
the NN O O
data NN O O
are NN O O
limited NN O O
and NN O O
vary NN O O
by NN O O
DCB NN O O
at NN O O
longer NN O O
follow-up NN O O
time NN O O
points NN O O
. NN O O

An NN O O
earlier NN O O
generation NN O O
low-dose NN O O
DCB NN O O
failed NN O O
to NN O O
demonstrate NN O O
significant NN O O
treatment NN O O
effect NN O O
at NN O O
2 NN O O
years NN O O
, NN O O
raising NN O O
questions NN O O
regarding NN O O
the NN O O
durability NN O O
of NN O O
low-dose NN O O
DCBs NN O O
. NN O O

In NN O O
this NN O O
prospective NN O O
, NN O O
multicenter NN O O
trial NN O O
, NN O O
294 NN O O
patients NN O O
were NN O O
randomized NN O O
( NN O O
3:1 NN O O
) NN O O
to NN O O
treatment NN O O
with NN O O
a NN O O
DCB NN O O
or NN O O
an NN O O
uncoated NN O O
percutaneous NN O O
transluminal NN O O
angioplasty NN O O
balloon NN O O
. NN O O

Assessments NN O O
at NN O O
2 NN O O
years NN O O
included NN O O
primary NN O O
patency NN O O
with NN O O
duplex NN O O
ultrasonography NN O O
, NN O O
clinically NN O O
driven NN O O
target NN O O
lesion NN O O
revascularization NN O O
, NN O O
and NN O O
functional NN O O
outcomes NN O O
. NN O O

Primary NN O O
patency NN O O
at NN O O
2 NN O O
years NN O O
was NN O O
significantly NN O O
higher NN O O
in NN O O
the NN O O
DCB NN O O
cohort NN O O
( NN O O
75.9 NN O O
% NN O O
vs. NN O O
61.0 NN O O
% NN O O
; NN O O
p NN O O
= NN O O
0.025 NN O O
) NN O O
, NN O O
and NN O O
the NN O O
rate NN O O
of NN O O
clinically NN O O
driven NN O O
target NN O O
lesion NN O O
revascularization NN O O
was NN O O
significantly NN O O
lower NN O O
( NN O O
12.1 NN O O
% NN O O
vs. NN O O
30.5 NN O O
% NN O O
; NN O O
p NN O O
< NN O O
0.001 NN O O
) NN O O
. NN O O

There NN O O
were NN O O
no NN O O
major NN O O
limb NN O O
amputations NN O O
in NN O O
either NN O O
group NN O O
. NN O O

The NN O O
rates NN O O
of NN O O
all-cause NN O O
( NN O O
6.5 NN O O
% NN O O
vs. NN O O
5.1 NN O O
% NN O O
; NN O O
p NN O O
= NN O O
1.00 NN O O
) NN O O
and NN O O
cardiovascular-related NN O O
( NN O O
1.6 NN O O
% NN O O
vs. NN O O
1.7 NN O O
% NN O O
; NN O O
p NN O O
= NN O O
1.00 NN O O
) NN O O
mortality NN O O
were NN O O
similar NN O O
between NN O O
groups NN O O
. NN O O

Functional NN O O
improvements NN O O
over NN O O
baseline NN O O
were NN O O
sustained NN O O
in NN O O
both NN O O
groups NN O O
, NN O O
with NN O O
60 NN O O
% NN O O
fewer NN O O
reinterventions NN O O
in NN O O
the NN O O
DCB NN O O
group NN O O
. NN O O

A NN O O
sustained NN O O
treatment NN O O
effect NN O O
is NN O O
achievable NN O O
with NN O O
a NN O O
low-dose NN O O
DCB NN O O
with NN O O
an NN O O
optimized NN O O
coating NN O O
formulation NN O O
. NN O O

This NN O O
trial NN O O
demonstrated NN O O
for NN O O
the NN O O
first NN O O
time NN O O
a NN O O
statistically NN O O
significantly NN O O
higher NN O O
primary NN O O
patency NN O O
rate NN O O
for NN O O
a NN O O
low-dose NN O O
DCB NN O O
versus NN O O
PTA NN O O
at NN O O
2 NN O O
years NN O O
. NN O O

( NN O O
CVI NN O O
Drug NN O O
Coated NN O O
Balloon NN O O
European NN O O
Randomized NN O O
Clinical NN O O
Trial NN O O
; NN O O
NCT01858363 NN O O
) NN O O
. NN O O



-DOCSTART- (30622733)

Rotator NN O O
cuff NN O O
tendinopathies NN O O
are NN O O
the NN O O
most NN O O
common NN O O
shoulder NN O O
disorders NN O O
. NN O O

As NN O O
persistent NN O O
symptoms NN O O
lasting NN O O
more NN O O
than NN O O
3 NN O O
months NN O O
have NN O O
been NN O O
shown NN O O
to NN O O
be NN O O
a NN O O
strong NN O O
indicator NN O O
of NN O O
poor NN O O
outcomes NN O O
, NN O O
it NN O O
is NN O O
important NN O O
to NN O O
have NN O O
successful NN O O
interventions NN O O
in NN O O
the NN O O
acute NN O O
stage NN O O
. NN O O

However NN O O
, NN O O
there NN O O
is NN O O
no NN O O
evidence NN O O
yet NN O O
to NN O O
guide NN O O
clinical NN O O
interventions NN O O
in NN O O
an NN O O
acute NN O O
pain NN O O
context NN O O
. NN O O

The NN O O
objective NN O O
of NN O O
this NN O O
study NN O O
was NN O O
to NN O O
compare NN O O
the NN O O
short-term NN O O
effect NN O O
of NN O O
a NN O O
2-week NN O O
gradual NN O O
reloading NN O O
exercises NN O O
programme NN O O
with NN O O
the NN O O
use NN O O
of NN O O
cryotherapy NN O O
on NN O O
symptoms NN O O
and NN O O
function NN O O
for NN O O
acute NN O O
rotator NN O O
cuff NN O O
tendinopathy NN O O
. NN O O

This NN O O
simple-blind NN O O
, NN O O
randomised NN O O
controlled NN O O
trial NN O O
included NN O O
44 NN O O
participants NN O O
with NN O O
acute NN O O
rotator NN O O
cuff NN O O
tendinopathy NN O O
who NN O O
were NN O O
randomly NN O O
allocated NN O O
to NN O O
either NN O O
the NN O O
exercises NN O O
or NN O O
cryotherapy NN O O
group NN O O
. NN O O

Symptoms NN O O
and NN O O
functional NN O O
limitations NN O O
were NN O O
evaluated NN O O
at NN O O
weeks NN O O
0 NN O O
, NN O O
2 NN O O
and NN O O
6 NN O O
using NN O O
self-reported NN O O
questionnaires NN O O
( NN O O
Disabilities NN O O
of NN O O
the NN O O
Arm NN O O
, NN O O
Shoulder NN O O
and NN O O
Hand NN O O
, NN O O
Western NN O O
Ontario NN O O
Rotator NN O O
Cuff NN O O
, NN O O
and NN O O
Brief NN O O
Pain NN O O
Inventory NN O O
) NN O O
, NN O O
while NN O O
acromiohumeral NN O O
distance NN O O
, NN O O
shoulder NN O O
strength NN O O
and NN O O
active NN O O
range NN O O
of NN O O
motion NN O O
were NN O O
evaluated NN O O
at NN O O
weeks NN O O
0 NN O O
and NN O O
2 NN O O
. NN O O

Following NN O O
interventions NN O O
, NN O O
both NN O O
groups NN O O
showed NN O O
statistically NN O O
significant NN O O
improvements NN O O
on NN O O
symptoms NN O O
and NN O O
function NN O O
at NN O O
week NN O O
2 NN O O
and NN O O
week NN O O
6 NN O O
compared NN O O
with NN O O
baseline NN O O
. NN O O

However NN O O
, NN O O
there NN O O
was NN O O
no NN O O
significant NN O O
group NN O O
× NN O O
time NN O O
interaction NN O O
. NN O O

There NN O O
was NN O O
no NN O O
time NN O O
effect NN O O
on NN O O
acromiohumeral NN O O
distance NN O O
, NN O O
shoulder NN O O
strength NN O O
and NN O O
active NN O O
range NN O O
of NN O O
motion NN O O
, NN O O
as NN O O
well NN O O
as NN O O
no NN O O
time NN O O
× NN O O
group NN O O
interaction NN O O
. NN O O

The NN O O
results NN O O
showed NN O O
a NN O O
statistically NN O O
significant NN O O
improvement NN O O
in NN O O
symptoms NN O O
and NN O O
function NN O O
in NN O O
both NN O O
groups NN O O
, NN O O
but NN O O
there NN O O
was NN O O
no NN O O
difference NN O O
between NN O O
the NN O O
short-term NN O O
effect NN O O
of NN O O
a NN O O
cryotherapy NN O O
based-approach NN O O
and NN O O
a NN O O
gradual NN O O
reloading NN O O
exercises NN O O
programme NN O O
. NN O O

NCT02813304 NN O O
. NN O O



-DOCSTART- (30458805)

Difference NN O O
between NN O O
combined NN O O
inspiratory NN O O
and NN O O
expiratory NN O O
muscle NN O O
training NN O O
in NN O O
same NN O O
respiratory NN O O
cycle NN O O
or NN O O
different NN O O
cycles NN O O
remained NN O O
unclarified NN O O
. NN O O

We NN O O
explored NN O O
the NN O O
difference NN O O
between NN O O
both NN O O
patterns NN O O
of NN O O
combined NN O O
trainings NN O O
in NN O O
patients NN O O
with NN O O
COPD NN O O
. NN O O

In NN O O
this NN O O
randomized NN O O
, NN O O
open-label NN O O
, NN O O
controlled NN O O
trial NN O O
, NN O O
stable NN O O
COPD NN O O
subjects NN O O
trained NN O O
for NN O O
48 NN O O
minutes NN O O
daily NN O O
, NN O O
for NN O O
8 NN O O
weeks NN O O
, NN O O
using NN O O
a NN O O
monitoring NN O O
device NN O O
for NN O O
quality NN O O
control NN O O
. NN O O

Ninety-two NN O O
subjects NN O O
were NN O O
randomly NN O O
and NN O O
equally NN O O
assigned NN O O
for NN O O
sham NN O O
training NN O O
, NN O O
inspiratory NN O O
muscle NN O O
training(IMT NN O O
) NN O O
, NN O O
combined NN O O
inspiratory NN O O
and NN O O
expiratory NN O O
muscle NN O O
training NN O O
in NN O O
same NN O O
cycle(CTSC NN O O
) NN O O
or NN O O
combined NN O O
inspiratory NN O O
and NN O O
expiratory NN O O
muscle NN O O
training NN O O
in NN O O
different NN O O
cycles(CTDC NN O O
) NN O O
. NN O O

Respiratory NN O O
muscle NN O O
strength NN O O
, NN O O
as NN O O
the NN O O
primary NN O O
endpoint NN O O
, NN O O
was NN O O
measured NN O O
before NN O O
and NN O O
after NN O O
training NN O O
. NN O O

Registry NN O O
: NN O O
ClinicalTrials.gov NN O O
( NN O O
identifier NN O O
: NN O O
NCT02326181 NN O O
) NN O O
. NN O O

Respiratory NN O O
muscle NN O O
training NN O O
improved NN O O
maximal NN O O
inspiratory NN O O
pressure(PImax NN O O
) NN O O
, NN O O
while NN O O
no NN O O
significant NN O O
difference NN O O
was NN O O
found NN O O
in NN O O
PImax NN O O
among NN O O
IMT NN O O
, NN O O
CTSC NN O O
and NN O O
CTDC NN O O
. NN O O

Maximal NN O O
expiratory NN O O
pressure(PEmax NN O O
) NN O O
in NN O O
CTSC NN O O
and NN O O
CTDC NN O O
was NN O O
greater NN O O
than NN O O
IMT(P NN O O
= NN O O
0.026 NN O O
, NN O O
and NN O O
P=0.04 NN O O
, NN O O
respectively NN O O
) NN O O
and NN O O
sham NN O O
training NN O O
( NN O O
P NN O O
= NN O O
0.001 NN O O
) NN O O
. NN O O

IMT NN O O
, NN O O
CTSC NN O O
, NN O O
and NN O O
CTDC NN O O
shortened NN O O
inhalation NN O O
and NN O O
prolonged NN O O
exhalation(P NN O O
< NN O O
0.01 NN O O
) NN O O
. NN O O

Subjects NN O O
with NN O O
respiratory NN O O
muscle NN O O
weakness NN O O
in NN O O
IMT NN O O
and NN O O
CTDC NN O O
exhibited NN O O
greater NN O O
increase NN O O
in NN O O
PImax NN O O
than NN O O
those NN O O
without NN O O
. NN O O

IMT NN O O
, NN O O
CTSC NN O O
and NN O O
CTDC NN O O
showed NN O O
no NN O O
difference NN O O
in NN O O
symptoms NN O O
and NN O O
quality NN O O
of NN O O
life NN O O
scales NN O O
among NN O O
themselves(P NN O O
> NN O O
0.05 NN O O
) NN O O
. NN O O

Both NN O O
patterns NN O O
of NN O O
CTSC NN O O
and NN O O
CTDC NN O O
improved NN O O
inspiratory NN O O
and NN O O
expiratory NN O O
muscle NN O O
strength NN O O
, NN O O
while NN O O
IMT NN O O
alone NN O O
only NN O O
raised NN O O
PImax NN O O
. NN O O

Respiratory NN O O
muscle NN O O
training NN O O
might NN O O
change NN O O
the NN O O
respiratory NN O O
cycles NN O O
, NN O O
and NN O O
be NN O O
more NN O O
beneficial NN O O
for NN O O
COPD NN O O
patients NN O O
with NN O O
inspiratory NN O O
muscle NN O O
weakness NN O O
. NN O O



-DOCSTART- (30415593)

Upper NN O O
extremity NN O O
( NN O O
UE NN O O
) NN O O
impairment NN O O
is NN O O
common NN O O
with NN O O
primary NN O O
progressive NN O O
multiple NN O O
sclerosis NN O O
( NN O O
PPMS NN O O
) NN O O
. NN O O

This NN O O
exploratory NN O O
analysis NN O O
examined NN O O
the NN O O
effects NN O O
of NN O O
ocrelizumab NN O O
on NN O O
confirmed NN O O
progression NN O O
( NN O O
CP NN O O
) NN O O
and NN O O
confirmed NN O O
improvement NN O O
( NN O O
CI NN O O
) NN O O
in NN O O
UE NN O O
impairment NN O O
in NN O O
patients NN O O
from NN O O
ORATORIO NN O O
. NN O O

Patients NN O O
with NN O O
PPMS NN O O
received NN O O
ocrelizumab NN O O
600 NN O O
mg NN O O
or NN O O
placebo NN O O
every NN O O
24 NN O O
weeks NN O O
for NN O O
⩾120 NN O O
weeks NN O O
. NN O O

The NN O O
Nine-Hole NN O O
Peg NN O O
Test NN O O
( NN O O
9HPT NN O O
) NN O O
was NN O O
administered NN O O
at NN O O
baseline NN O O
( NN O O
BL NN O O
) NN O O
and NN O O
every NN O O
12 NN O O
weeks NN O O
thereafter NN O O
. NN O O

Prespecified NN O O
exploratory NN O O
endpoints NN O O
included NN O O
change NN O O
in NN O O
9HPT NN O O
time NN O O
and NN O O
proportion NN O O
of NN O O
patients NN O O
with NN O O
CP NN O O
of NN O O
⩾20 NN O O
% NN O O
in NN O O
9HPT NN O O
. NN O O

Analysis NN O O
populations NN O O
included NN O O
intention-to-treat NN O O
( NN O O
ITT NN O O
) NN O O
patients NN O O
and NN O O
subgroups NN O O
stratified NN O O
by NN O O
BL NN O O
9HPT NN O O
time NN O O
and NN O O
Expanded NN O O
Disability NN O O
Status NN O O
Scale NN O O
. NN O O

Post NN O O
hoc NN O O
analyses NN O O
included NN O O
the NN O O
proportion NN O O
of NN O O
patients NN O O
achieving NN O O
more NN O O
severe NN O O
thresholds NN O O
of NN O O
CP NN O O
and NN O O
the NN O O
proportion NN O O
achieving NN O O
CI NN O O
in NN O O
9HPT NN O O
. NN O O

Among NN O O
ITT NN O O
patients NN O O
, NN O O
ocrelizumab NN O O
significantly NN O O
reduced NN O O
the NN O O
change NN O O
in NN O O
9HPT NN O O
time NN O O
over NN O O
120 NN O O
weeks NN O O
, NN O O
the NN O O
risk NN O O
of NN O O
CP NN O O
of NN O O
⩾20 NN O O
% NN O O
in NN O O
9HPT NN O O
time NN O O
for NN O O
both NN O O
hands NN O O
and NN O O
the NN O O
risk NN O O
of NN O O
more NN O O
severe NN O O
9HPT NN O O
progression NN O O
versus NN O O
placebo NN O O
. NN O O

Numerical NN O O
trends NN O O
also NN O O
favoured NN O O
ocrelizumab NN O O
versus NN O O
placebo NN O O
with NN O O
respect NN O O
to NN O O
achieving NN O O
CI NN O O
. NN O O

Consistent NN O O
directional NN O O
trends NN O O
were NN O O
observed NN O O
in NN O O
subgroup NN O O
analyses NN O O
. NN O O

Ocrelizumab NN O O
reduces NN O O
the NN O O
risk NN O O
of NN O O
UE NN O O
disability NN O O
progression NN O O
and NN O O
may NN O O
increase NN O O
the NN O O
possibility NN O O
of NN O O
improvement NN O O
versus NN O O
placebo NN O O
in NN O O
PPMS NN O O
. NN O O



-DOCSTART- (30931720)

School NN O O
screening NN O O
and NN O O
the NN O O
note NN O O
home NN O O
( NN O O
pinned NN O O
to NN O O
a NN O O
backpack NN O O
) NN O O
informing NN O O
parents/caregivers NN O O
that NN O O
their NN O O
child NN O O
needs NN O O
to NN O O
see NN O O
a NN O O
dentist NN O O
have NN O O
not NN O O
been NN O O
effective NN O O
. NN O O

The NN O O
Family NN O O
Access NN O O
to NN O O
a NN O O
Dentist NN O O
Study NN O O
( NN O O
FADS NN O O
) NN O O
evaluated NN O O
the NN O O
effectiveness NN O O
of NN O O
school NN O O
interventions NN O O
based NN O O
on NN O O
the NN O O
common-sense NN O O
model NN O O
of NN O O
self-regulation NN O O
( NN O O
CSM NN O O
) NN O O
among NN O O
K-4 NN O O
children NN O O
needing NN O O
restorative NN O O
treatment NN O O
. NN O O

FADS NN O O
was NN O O
a NN O O
multisite NN O O
double-blind NN O O
randomized NN O O
controlled NN O O
trial NN O O
with NN O O
5 NN O O
arms NN O O
. NN O O

FADS NN O O
tested NN O O
a NN O O
CSM-driven NN O O
referral NN O O
letter NN O O
and NN O O
dental NN O O
information NN O O
guide NN O O
( NN O O
DIG NN O O
) NN O O
to NN O O
move NN O O
caregivers NN O O
from NN O O
inaccurate NN O O
to NN O O
accurate NN O O
perceptions NN O O
of NN O O
dental NN O O
caries NN O O
. NN O O

Six NN O O
school NN O O
districts NN O O
from NN O O
Ohio NN O O
and NN O O
Washington NN O O
( NN O O
14 NN O O
schools NN O O
) NN O O
participated NN O O
in NN O O
school NN O O
years NN O O
2015 NN O O
to NN O O
2016 NN O O
and NN O O
2016 NN O O
to NN O O
2017 NN O O
. NN O O

A NN O O
total NN O O
of NN O O
611 NN O O
caregivers NN O O
were NN O O
randomized NN O O
, NN O O
and NN O O
86 NN O O
% NN O O
( NN O O
n NN O O
= NN O O
597 NN O O
children NN O O
) NN O O
completed NN O O
the NN O O
exit NN O O
examination NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
was NN O O
receipt NN O O
of NN O O
care NN O O
based NN O O
on NN O O
a NN O O
change NN O O
in NN O O
oral NN O O
health NN O O
status NN O O
determined NN O O
clinically NN O O
within NN O O
1 NN O O
school NN O O
year NN O O
. NN O O

In NN O O
accordance NN O O
with NN O O
our NN O O
primary NN O O
aims NN O O
, NN O O
5 NN O O
arms NN O O
were NN O O
collapsed NN O O
into NN O O
3 NN O O
: NN O O
CSM NN O O
letter NN O O
and NN O O
reduced NN O O
CSM NN O O
letter NN O O
( NN O O
combined NN O O
) NN O O
, NN O O
CSM NN O O
letter NN O O
+ NN O O
DIG NN O O
and NN O O
reduced NN O O
CSM NN O O
letter NN O O
+ NN O O
reduced NN O O
DIG NN O O
( NN O O
combined NN O O
) NN O O
, NN O O
and NN O O
standard NN O O
letter NN O O
. NN O O

Among NN O O
all NN O O
sites NN O O
, NN O O
39.7 NN O O
% NN O O
received NN O O
restorative NN O O
care NN O O
( NN O O
237 NN O O
of NN O O
597 NN O O
) NN O O
. NN O O

Combined NN O O
analysis NN O O
of NN O O
sites NN O O
revealed NN O O
that NN O O
the NN O O
CSM NN O O
referral NN O O
letter NN O O
( NN O O
with NN O O
and NN O O
without NN O O
the NN O O
DIG NN O O
) NN O O
did NN O O
not NN O O
increase NN O O
dental NN O O
visits NN O O
when NN O O
compared NN O O
with NN O O
the NN O O
standard NN O O
letter NN O O
. NN O O

However NN O O
, NN O O
for NN O O
combined NN O O
sites NN O O
( NN O O
East NN O O
Cleveland NN O O
, NN O O
Ohio NN O O
; NN O O
Washington NN O O
) NN O O
, NN O O
the NN O O
CSM NN O O
+ NN O O
DIG NN O O
increased NN O O
dental NN O O
visits NN O O
when NN O O
compared NN O O
with NN O O
standard NN O O
letter NN O O
in NN O O
univariate NN O O
analysis NN O O
( NN O O
51.3 NN O O
% NN O O
vs. NN O O
40.9 NN O O
% NN O O
) NN O O
, NN O O
indicating NN O O
1.6-times NN O O
increased NN O O
odds NN O O
of NN O O
a NN O O
dental NN O O
visit NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
0.97 NN O O
to NN O O
2.58 NN O O
) NN O O
after NN O O
imputation NN O O
and NN O O
adjustment NN O O
for NN O O
covariates NN O O
. NN O O

The NN O O
CSM NN O O
+ NN O O
DIG NN O O
group NN O O
had NN O O
1.9-times NN O O
increased NN O O
odds NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
1.21 NN O O
to NN O O
3.08 NN O O
) NN O O
of NN O O
care NN O O
when NN O O
compared NN O O
the NN O O
CSM NN O O
letter NN O O
alone NN O O
. NN O O

A NN O O
CSM-driven NN O O
approach NN O O
to NN O O
informing NN O O
caregivers NN O O
of NN O O
the NN O O
chronic NN O O
nature NN O O
of NN O O
caries NN O O
with NN O O
resources NN O O
in NN O O
an NN O O
illustrative NN O O
manner NN O O
can NN O O
increase NN O O
the NN O O
benefit NN O O
of NN O O
school NN O O
oral NN O O
health NN O O
screening NN O O
( NN O O
Clinicaltrials.gov NN O O
NCT02395120 NN O O
) NN O O
. NN O O

A NN O O
school NN O O
dental NN O O
referral NN O O
( NN O O
note NN O O
home NN O O
) NN O O
that NN O O
tells NN O O
a NN O O
parent NN O O
that NN O O
the NN O O
child NN O O
has NN O O
cavities NN O O
has NN O O
not NN O O
been NN O O
effective NN O O
. NN O O

In NN O O
this NN O O
trial NN O O
, NN O O
a NN O O
referral NN O O
based NN O O
on NN O O
the NN O O
common-sense NN O O
model NN O O
of NN O O
self-regulation NN O O
increased NN O O
follow-up NN O O
care NN O O
for NN O O
children NN O O
with NN O O
restorative NN O O
needs NN O O
. NN O O



-DOCSTART- (31074236)

To NN O O
compare NN O O
response NN O O
rate NN O O
and NN O O
survivals NN O O
of NN O O
locally NN O O
advanced NN O O
stage NN O O
cervical NN O O
cancer NN O O
patients NN O O
who NN O O
had NN O O
standard NN O O
concurrent NN O O
chemoradiation NN O O
therapy NN O O
( NN O O
CCRT NN O O
) NN O O
alone NN O O
to NN O O
those NN O O
who NN O O
had NN O O
adjuvant NN O O
chemotherapy NN O O
( NN O O
ACT NN O O
) NN O O
after NN O O
CCRT NN O O
. NN O O

Patients NN O O
aged NN O O
18 NN O O
- NN O O
70 NN O O
years NN O O
who NN O O
had NN O O
International NN O O
Federation NN O O
of NN O O
Gynecology NN O O
and NN O O
Obstetrics NN O O
stage NN O O
IIB-IVA NN O O
without NN O O
para-aortic NN O O
lymph NN O O
node NN O O
enlargement NN O O
, NN O O
Eastern NN O O
Cooperative NN O O
Oncology NN O O
Group NN O O
scores NN O O
0 NN O O
- NN O O
2 NN O O
, NN O O
and NN O O
non-aggressive NN O O
histopathology NN O O
were NN O O
randomized NN O O
to NN O O
have NN O O
CCRT NN O O
with NN O O
weekly NN O O
cisplatin NN O O
followed NN O O
by NN O O
observation NN O O
( NN O O
arm NN O O
A NN O O
) NN O O
or NN O O
by NN O O
ACT NN O O
with NN O O
paclitaxel NN O O
plus NN O O
carboplatin NN O O
every NN O O
4 NN O O
weeks NN O O
for NN O O
3 NN O O
cycles NN O O
( NN O O
arm NN O O
B NN O O
) NN O O
. NN O O

Data NN O O
analysis NN O O
of NN O O
259 NN O O
patients NN O O
showed NN O O
no NN O O
significant NN O O
difference NN O O
in NN O O
complete NN O O
responses NN O O
at NN O O
4 NN O O
months NN O O
after NN O O
treatment NN O O
between NN O O
arm NN O O
A NN O O
( NN O O
n=129 NN O O
) NN O O
and NN O O
arm NN O O
B NN O O
( NN O O
n=130 NN O O
) NN O O
: NN O O
94.1 NN O O
% NN O O
vs. NN O O
87.0 NN O O
% NN O O
( NN O O
p=0.154 NN O O
) NN O O
respectively NN O O
. NN O O

With NN O O
the NN O O
median NN O O
follow-up NN O O
of NN O O
27.4 NN O O
months NN O O
, NN O O
15.5 NN O O
% NN O O
of NN O O
patients NN O O
in NN O O
arm NN O O
A NN O O
and NN O O
10.8 NN O O
% NN O O
in NN O O
arm NN O O
B NN O O
experienced NN O O
recurrences NN O O
( NN O O
p=0.123 NN O O
) NN O O
. NN O O

There NN O O
were NN O O
no NN O O
significant NN O O
differences NN O O
of NN O O
overall NN O O
or NN O O
loco-regional NN O O
failure NN O O
. NN O O

However NN O O
, NN O O
systemic NN O O
recurrences NN O O
were NN O O
significantly NN O O
lower NN O O
in NN O O
arm NN O O
B NN O O
than NN O O
arm NN O O
A NN O O
: NN O O
5.4 NN O O
% NN O O
vs. NN O O
10.1 NN O O
% NN O O
( NN O O
p=0.029 NN O O
) NN O O
. NN O O

The NN O O
3-year NN O O
progression-free NN O O
survival NN O O
( NN O O
PFS NN O O
) NN O O
and NN O O
3-year NN O O
overall NN O O
survival NN O O
( NN O O
OS NN O O
) NN O O
of NN O O
the NN O O
patients NN O O
in NN O O
both NN O O
arms NN O O
were NN O O
not NN O O
significantly NN O O
different NN O O
. NN O O

The NN O O
hazard NN O O
ratio NN O O
of NN O O
PFS NN O O
and NN O O
OS NN O O
of NN O O
arm NN O O
B NN O O
compared NN O O
to NN O O
arm NN O O
A NN O O
were NN O O
1.26 NN O O
( NN O O
95 NN O O
% NN O O
CI=0.82 NN O O
- NN O O
1.96 NN O O
; NN O O
p=0.293 NN O O
) NN O O
and NN O O
1.42 NN O O
( NN O O
95 NN O O
% NN O O
CI=0.81 NN O O
- NN O O
2.49 NN O O
; NN O O
p=0.221 NN O O
) NN O O
respectively NN O O
. NN O O

ACT NN O O
with NN O O
paclitaxel NN O O
plus NN O O
carboplatin NN O O
after NN O O
CCRT NN O O
did NN O O
not NN O O
improve NN O O
response NN O O
rate NN O O
and NN O O
survival NN O O
compared NN O O
to NN O O
CCRT NN O O
alone NN O O
. NN O O

Only NN O O
significant NN O O
decrease NN O O
of NN O O
systemic NN O O
recurrences NN O O
with NN O O
ACT NN O O
was NN O O
observed NN O O
, NN O O
but NN O O
not NN O O
overall NN O O
or NN O O
loco-regional NN O O
failure NN O O
. NN O O

ClinicalTrials.gov NN O O
Identifier NN O O
: NN O O
NCT02036164 NN O O
, NN O O
Thai NN O O
Clinical NN O O
Trials NN O O
Registry NN O O
Identifier NN O O
: NN O O
TCTR NN O O
20140106001 NN O O
. NN O O



-DOCSTART- (30686385)

The NN O O
Thinking NN O O
Healthy NN O O
Programme NN O O
( NN O O
THP NN O O
) NN O O
is NN O O
a NN O O
psychological NN O O
intervention NN O O
recommended NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
perinatal NN O O
depression NN O O
. NN O O

However NN O O
, NN O O
efforts NN O O
to NN O O
integrate NN O O
the NN O O
intervention NN O O
at NN O O
scale NN O O
into NN O O
the NN O O
routines NN O O
of NN O O
community NN O O
health NN O O
workers NN O O
who NN O O
delivered NN O O
the NN O O
THP NN O O
when NN O O
it NN O O
was NN O O
first NN O O
evaluated NN O O
were NN O O
compromised NN O O
by NN O O
the NN O O
competing NN O O
responsibilities NN O O
of NN O O
community NN O O
health NN O O
workers NN O O
. NN O O

We NN O O
aimed NN O O
to NN O O
assess NN O O
the NN O O
effectiveness NN O O
and NN O O
cost-effectiveness NN O O
of NN O O
THP NN O O
peer-delivered NN O O
( NN O O
THPP NN O O
) NN O O
in NN O O
Goa NN O O
, NN O O
India NN O O
. NN O O

In NN O O
this NN O O
single-blind NN O O
, NN O O
individually NN O O
randomised NN O O
controlled NN O O
trial NN O O
, NN O O
we NN O O
recruited NN O O
pregnant NN O O
women NN O O
aged NN O O
18 NN O O
years NN O O
or NN O O
older NN O O
who NN O O
scored NN O O
at NN O O
least NN O O
10 NN O O
on NN O O
the NN O O
Patient NN O O
Health NN O O
Questionnaire-9 NN O O
( NN O O
PHQ-9 NN O O
) NN O O
from NN O O
antenatal NN O O
clinics NN O O
in NN O O
Goa NN O O
. NN O O

Participants NN O O
were NN O O
randomly NN O O
allocated NN O O
( NN O O
1:1 NN O O
) NN O O
to NN O O
receive NN O O
enhanced NN O O
usual NN O O
care NN O O
( NN O O
EUC NN O O
; NN O O
so-called NN O O
because NN O O
, NN O O
in NN O O
India NN O O
, NN O O
perinatal NN O O
depression NN O O
is NN O O
not NN O O
typically NN O O
treated NN O O
) NN O O
only NN O O
( NN O O
control NN O O
group NN O O
) NN O O
or NN O O
THPP NN O O
in NN O O
addition NN O O
to NN O O
EUC NN O O
( NN O O
intervention NN O O
group NN O O
) NN O O
in NN O O
randomly NN O O
sized NN O O
blocks NN O O
that NN O O
were NN O O
stratified NN O O
by NN O O
area NN O O
of NN O O
residence NN O O
( NN O O
urban NN O O
or NN O O
rural NN O O
) NN O O
. NN O O

Group NN O O
allocations NN O O
were NN O O
concealed NN O O
from NN O O
participants NN O O
and NN O O
researchers NN O O
before NN O O
assignments NN O O
were NN O O
made NN O O
by NN O O
use NN O O
of NN O O
sequentially NN O O
numbered NN O O
opaque NN O O
envelopes NN O O
. NN O O

The NN O O
primary NN O O
outcomes NN O O
were NN O O
the NN O O
severity NN O O
of NN O O
depressive NN O O
symptoms NN O O
( NN O O
assessed NN O O
by NN O O
PHQ-9 NN O O
score NN O O
) NN O O
and NN O O
the NN O O
prevalence NN O O
of NN O O
remission NN O O
( NN O O
defined NN O O
as NN O O
a NN O O
PHQ-9 NN O O
score NN O O
of NN O O
less NN O O
than NN O O
5 NN O O
) NN O O
in NN O O
participants NN O O
with NN O O
available NN O O
data NN O O
6 NN O O
months NN O O
after NN O O
childbirth NN O O
, NN O O
which NN O O
was NN O O
assessed NN O O
by NN O O
researchers NN O O
who NN O O
were NN O O
masked NN O O
to NN O O
treatment NN O O
allocations NN O O
. NN O O

We NN O O
analysed NN O O
outcomes NN O O
by NN O O
intention NN O O
to NN O O
treat NN O O
, NN O O
adjusting NN O O
for NN O O
covariates NN O O
that NN O O
were NN O O
defined NN O O
a NN O O
priori NN O O
or NN O O
that NN O O
showed NN O O
imbalance NN O O
at NN O O
baseline NN O O
. NN O O

The NN O O
trial NN O O
is NN O O
registered NN O O
with NN O O
ClinicalTrials.gov NN O O
, NN O O
number NN O O
NCT02104232 NN O O
. NN O O

Between NN O O
Oct NN O O
24 NN O O
, NN O O
2014 NN O O
, NN O O
and NN O O
June NN O O
24 NN O O
, NN O O
2016 NN O O
, NN O O
we NN O O
assessed NN O O
118 NN O O
260 NN O O
women NN O O
for NN O O
their NN O O
eligibility NN O O
for NN O O
screening NN O O
, NN O O
of NN O O
whom NN O O
111 NN O O
851 NN O O
( NN O O
94·6 NN O O
% NN O O
) NN O O
women NN O O
were NN O O
ineligible NN O O
. NN O O

6409 NN O O
( NN O O
5·4 NN O O
% NN O O
) NN O O
women NN O O
were NN O O
eligible NN O O
for NN O O
screening NN O O
and NN O O
6369 NN O O
( NN O O
99·4 NN O O
% NN O O
) NN O O
of NN O O
these NN O O
women NN O O
consented NN O O
to NN O O
be NN O O
screened NN O O
with NN O O
the NN O O
PHQ-9 NN O O
( NN O O
40 NN O O
women NN O O
did NN O O
not NN O O
consent NN O O
) NN O O
, NN O O
of NN O O
whom NN O O
333 NN O O
( NN O O
5·2 NN O O
% NN O O
) NN O O
screened NN O O
positive NN O O
for NN O O
depression NN O O
( NN O O
defined NN O O
as NN O O
a NN O O
PHQ-9 NN O O
score NN O O
of NN O O
at NN O O
least NN O O
10 NN O O
) NN O O
. NN O O

We NN O O
enrolled NN O O
280 NN O O
( NN O O
84·1 NN O O
% NN O O
) NN O O
women NN O O
with NN O O
perinatal NN O O
depression NN O O
; NN O O
140 NN O O
women NN O O
were NN O O
assigned NN O O
to NN O O
the NN O O
THPP NN O O
and NN O O
EUC NN O O
group NN O O
and NN O O
140 NN O O
women NN O O
to NN O O
the NN O O
EUC NN O O
only NN O O
group NN O O
. NN O O

The NN O O
final NN O O
treatment NN O O
was NN O O
given NN O O
on NN O O
May NN O O
27 NN O O
, NN O O
2017 NN O O
. NN O O

The NN O O
final NN O O
6-month NN O O
outcome NN O O
assessment NN O O
was NN O O
completed NN O O
on NN O O
June NN O O
9 NN O O
, NN O O
2017 NN O O
. NN O O

At NN O O
6 NN O O
months NN O O
after NN O O
birth NN O O
, NN O O
122 NN O O
( NN O O
87 NN O O
% NN O O
) NN O O
women NN O O
in NN O O
the NN O O
THPP NN O O
and NN O O
EUC NN O O
group NN O O
and NN O O
129 NN O O
( NN O O
92 NN O O
% NN O O
) NN O O
women NN O O
in NN O O
the NN O O
EUC NN O O
only NN O O
group NN O O
were NN O O
assessed NN O O
for NN O O
the NN O O
primary NN O O
outcome NN O O
. NN O O

There NN O O
was NN O O
a NN O O
higher NN O O
prevalence NN O O
of NN O O
remission NN O O
at NN O O
6 NN O O
months NN O O
after NN O O
birth NN O O
in NN O O
the NN O O
THPP NN O O
and NN O O
EUC NN O O
group NN O O
compared NN O O
with NN O O
the NN O O
EUC NN O O
only NN O O
group NN O O
( NN O O
89 NN O O
[ NN O O
73 NN O O
% NN O O
] NN O O
women NN O O
in NN O O
the NN O O
intervention NN O O
group NN O O
vs NN O O
77 NN O O
[ NN O O
60 NN O O
% NN O O
] NN O O
women NN O O
in NN O O
the NN O O
control NN O O
group NN O O
; NN O O
prevalence NN O O
ratio NN O O
1·21 NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
1·01 NN O O
to NN O O
1·45 NN O O
; NN O O
p=0·04 NN O O
) NN O O
, NN O O
but NN O O
there NN O O
was NN O O
no NN O O
evidence NN O O
of NN O O
a NN O O
difference NN O O
in NN O O
symptom NN O O
severity NN O O
between NN O O
the NN O O
groups NN O O
( NN O O
mean NN O O
PHQ-9 NN O O
score NN O O
3·47 NN O O
[ NN O O
SD NN O O
4·49 NN O O
] NN O O
in NN O O
the NN O O
intervention NN O O
group NN O O
vs NN O O
4·48 NN O O
[ NN O O
5·11 NN O O
] NN O O
in NN O O
the NN O O
control NN O O
group NN O O
; NN O O
standardised NN O O
mean NN O O
difference NN O O
-0·18 NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
-0·43 NN O O
to NN O O
0·07 NN O O
; NN O O
p=0·16 NN O O
) NN O O
. NN O O

There NN O O
was NN O O
no NN O O
evidence NN O O
of NN O O
significant NN O O
differences NN O O
in NN O O
serious NN O O
adverse NN O O
events NN O O
between NN O O
the NN O O
groups NN O O
. NN O O

THPP NN O O
had NN O O
a NN O O
moderate NN O O
effect NN O O
on NN O O
remission NN O O
from NN O O
perinatal NN O O
depression NN O O
over NN O O
the NN O O
6-month NN O O
postnatal NN O O
period NN O O
. NN O O

THPP NN O O
is NN O O
relatively NN O O
cheap NN O O
to NN O O
deliver NN O O
and NN O O
is NN O O
cost-saving NN O O
through NN O O
reduced NN O O
health-care NN O O
, NN O O
time NN O O
and NN O O
productivity NN O O
costs NN O O
. NN O O

National NN O O
Institute NN O O
of NN O O
Mental NN O O
Health NN O O
( NN O O
USA NN O O
) NN O O
. NN O O



-DOCSTART- (30808668)

Evidence NN O O
indicates NN O O
e-cigarettes NN O O
can NN O O
help NN O O
people NN O O
quit NN O O
smoking NN O O
; NN O O
however NN O O
, NN O O
more NN O O
confirmatory NN O O
trials NN O O
are NN O O
needed NN O O
. NN O O

To NN O O
date NN O O
, NN O O
no NN O O
trials NN O O
have NN O O
evaluated NN O O
the NN O O
effectiveness NN O O
and NN O O
safety NN O O
of NN O O
combining NN O O
nicotine NN O O
patches NN O O
with NN O O
e-cigarettes NN O O
( NN O O
with NN O O
and NN O O
without NN O O
nicotine NN O O
) NN O O
for NN O O
smoking NN O O
cessation NN O O
. NN O O

This NN O O
study NN O O
is NN O O
a NN O O
pragmatic NN O O
, NN O O
three-arm NN O O
, NN O O
community-based NN O O
, NN O O
single-blind NN O O
, NN O O
randomised NN O O
trial NN O O
undertaken NN O O
in NN O O
New NN O O
Zealand NN O O
. NN O O

Eligible NN O O
participants NN O O
are NN O O
daily/non-daily NN O O
smokers NN O O
, NN O O
aged NN O O
≥18 NN O O
years NN O O
, NN O O
naive NN O O
e-cigarette NN O O
users NN O O
and NN O O
motivated NN O O
to NN O O
quit NN O O
smoking NN O O
in NN O O
the NN O O
next NN O O
2 NN O O
weeks NN O O
. NN O O

Participants NN O O
( NN O O
n=1809 NN O O
) NN O O
, NN O O
recruited NN O O
using NN O O
multi-media NN O O
advertising NN O O
, NN O O
are NN O O
randomised NN O O
to NN O O
14 NN O O
weeks NN O O
of NN O O
( NN O O
1 NN O O
) NN O O
21 NN O O
mg NN O O
nicotine NN O O
patches NN O O
( NN O O
n=201 NN O O
) NN O O
; NN O O
( NN O O
2 NN O O
) NN O O
21 NN O O
mg NN O O
nicotine NN O O
patches+18 NN O O
mg/mL NN O O
nicotine NN O O
e-cigarette NN O O
( NN O O
n=804 NN O O
) NN O O
; NN O O
or NN O O
( NN O O
3 NN O O
) NN O O
21 NN O O
mg NN O O
nicotine NN O O
patches+nicotine NN O O
free NN O O
e-cigarette NN O O
( NN O O
n=804 NN O O
) NN O O
. NN O O

Participants NN O O
receive NN O O
weekly NN O O
withdrawal-oriented NN O O
behavioural NN O O
support NN O O
calls NN O O
for NN O O
6 NN O O
weeks NN O O
post-randomisation NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
is NN O O
self-reported NN O O
biochemically NN O O
verified NN O O
continuous NN O O
abstinence NN O O
( NN O O
CA NN O O
) NN O O
at NN O O
6 NN O O
months NN O O
post NN O O
quit-date NN O O
. NN O O

The NN O O
primary NN O O
comparison NN O O
is NN O O
nicotine NN O O
patch NN O O
+ NN O O
nicotine NN O O
e-cigarette NN O O
versus NN O O
nicotine NN O O
patch NN O O
+ NN O O
nicotine NN O O
free NN O O
e-cigarette NN O O
, NN O O
and NN O O
the NN O O
secondary NN O O
comparison NN O O
is NN O O
nicotine NN O O
patch NN O O
versus NN O O
nicotine NN O O
patch NN O O
+ NN O O
nicotine NN O O
e-cigarette NN O O
( NN O O
90 NN O O
% NN O O
power NN O O
, NN O O
p=0.05 NN O O
, NN O O
to NN O O
detect NN O O
an NN O O
absolute NN O O
difference NN O O
in NN O O
6 NN O O
month NN O O
CA NN O O
rates NN O O
of NN O O
8 NN O O
% NN O O
and NN O O
15 NN O O
% NN O O
respectively NN O O
) NN O O
. NN O O

Secondary NN O O
outcomes NN O O
, NN O O
collected NN O O
by NN O O
phone NN O O
interview NN O O
at NN O O
quit NN O O
date NN O O
, NN O O
then NN O O
1 NN O O
, NN O O
3 NN O O
, NN O O
6 NN O O
and NN O O
12 NN O O
months NN O O
post-quit NN O O
date NN O O
, NN O O
include NN O O
self-reported NN O O
CA NN O O
, NN O O
7 NN O O
day NN O O
point NN O O
prevalence NN O O
abstinence NN O O
, NN O O
cigarettes NN O O
per NN O O
day NN O O
( NN O O
if NN O O
smoking NN O O
, NN O O
or NN O O
when NN O O
smoking NN O O
for NN O O
non-daily NN O O
smokers NN O O
) NN O O
, NN O O
time NN O O
to NN O O
relapse NN O O
( NN O O
if NN O O
returned NN O O
to NN O O
smoking NN O O
) NN O O
, NN O O
belief NN O O
in NN O O
ability NN O O
to NN O O
quit NN O O
, NN O O
use NN O O
of NN O O
other NN O O
cessation NN O O
support NN O O
, NN O O
side NN O O
effects/serious NN O O
adverse NN O O
events NN O O
, NN O O
treatment NN O O
compliance NN O O
, NN O O
seeking NN O O
additional NN O O
support NN O O
around NN O O
e-cigarette NN O O
use NN O O
, NN O O
daily NN O O
use NN O O
of NN O O
both NN O O
e-cigarettes NN O O
and NN O O
cigarettes NN O O
, NN O O
use NN O O
of NN O O
treatment NN O O
past NN O O
14 NN O O
weeks NN O O
, NN O O
views NN O O
on NN O O
treatment NN O O
and NN O O
recommendation NN O O
to NN O O
others NN O O
, NN O O
weight NN O O
and NN O O
cost-per-quitter NN O O
. NN O O

The NN O O
Northern NN O O
A NN O O
Health NN O O
and NN O O
Disability NN O O
Ethics NN O O
Committee NN O O
approved NN O O
the NN O O
trial NN O O
. NN O O

Findings NN O O
will NN O O
be NN O O
disseminated NN O O
through NN O O
publication NN O O
, NN O O
conference/meeting NN O O
presentations NN O O
, NN O O
and NN O O
media NN O O
. NN O O

NCT02521662 NN O O
; NN O O
Pre-results NN O O
. NN O O



-DOCSTART- (30392872)

To NN O O
compare NN O O
the NN O O
efficacy NN O O
of NN O O
a NN O O
breath-enhanced NN O O
and NN O O
a NN O O
conventional NN O O
jet NN O O
nebulizer NN O O
in NN O O
the NN O O
treatment NN O O
of NN O O
children NN O O
with NN O O
moderate NN O O
to NN O O
severe NN O O
acute NN O O
asthma NN O O
. NN O O

We NN O O
enrolled NN O O
subjects NN O O
between NN O O
6 NN O O
and NN O O
18 NN O O
years NN O O
of NN O O
age NN O O
presenting NN O O
to NN O O
the NN O O
emergency NN O O
department NN O O
( NN O O
ED NN O O
) NN O O
with NN O O
acute NN O O
asthma NN O O
and NN O O
an NN O O
initial NN O O
forced NN O O
expiratory NN O O
volume NN O O
in NN O O
1 NN O O
second NN O O
( NN O O
FEV NN O O
) NN O O
< NN O O
70 NN O O
% NN O O
of NN O O
predicted NN O O
. NN O O

We NN O O
excluded NN O O
patients NN O O
with NN O O
chronic NN O O
disease NN O O
, NN O O
who NN O O
required NN O O
immediate NN O O
resuscitation NN O O
, NN O O
or NN O O
failed NN O O
spirometry NN O O
. NN O O

Subjects NN O O
were NN O O
randomized NN O O
to NN O O
breath-enhanced NN O O
or NN O O
conventional NN O O
jet NN O O
delivery NN O O
of NN O O
a NN O O
5-mg NN O O
albuterol NN O O
treatment NN O O
. NN O O

Our NN O O
primary NN O O
outcome NN O O
was NN O O
change NN O O
in NN O O
FEV NN O O
, NN O O
and NN O O
secondary NN O O
outcomes NN O O
included NN O O
change NN O O
in NN O O
clinical NN O O
asthma NN O O
scores NN O O
, NN O O
ED NN O O
length NN O O
of NN O O
stay NN O O
, NN O O
disposition NN O O
, NN O O
and NN O O
side NN O O
effects NN O O
. NN O O

Student NN O O
t NN O O
test NN O O
and NN O O
multivariable NN O O
linear NN O O
regression NN O O
were NN O O
used NN O O
to NN O O
evaluate NN O O
the NN O O
primary NN O O
outcome NN O O
. NN O O

In NN O O
total NN O O
, NN O O
497 NN O O
patients NN O O
were NN O O
assessed NN O O
for NN O O
eligibility NN O O
with NN O O
118 NN O O
enrolled NN O O
and NN O O
107 NN O O
subjects NN O O
available NN O O
for NN O O
analysis NN O O
of NN O O
the NN O O
primary NN O O
outcome NN O O
. NN O O

Improvement NN O O
in NN O O
FEV NN O O
was NN O O
significantly NN O O
greater NN O O
with NN O O
conventional NN O O
jet NN O O
nebulizer NN O O
( NN O O
mean NN O O
ΔFEV NN O O
+ NN O O
13.8 NN O O
% NN O O
vs NN O O
+ NN O O
9.1 NN O O
% NN O O
, NN O O
P NN O O
= NN O O
.04 NN O O
) NN O O
. NN O O

This NN O O
difference NN O O
remained NN O O
significant NN O O
after NN O O
adjustment NN O O
for NN O O
baseline NN O O
differences NN O O
. NN O O

Subgroup NN O O
analysis NN O O
of NN O O
57 NN O O
subjects NN O O
with NN O O
spirometry NN O O
meeting NN O O
American NN O O
Thoracic NN O O
Society/European NN O O
Respiratory NN O O
Society NN O O
guidelines NN O O
yielded NN O O
similar NN O O
results NN O O
( NN O O
mean NN O O
ΔFEV NN O O
+ NN O O
14.5 NN O O
% NN O O
vs NN O O
+ NN O O
8.5 NN O O
% NN O O
, NN O O
P=.03 NN O O
) NN O O
. NN O O

There NN O O
were NN O O
no NN O O
significant NN O O
differences NN O O
in NN O O
clinical NN O O
asthma NN O O
scores NN O O
, NN O O
ED NN O O
length NN O O
of NN O O
stay NN O O
, NN O O
disposition NN O O
, NN O O
or NN O O
side NN O O
effects NN O O
. NN O O

Albuterol NN O O
delivered NN O O
via NN O O
conventional NN O O
jet NN O O
nebulizer NN O O
resulted NN O O
in NN O O
significantly NN O O
greater NN O O
improvement NN O O
in NN O O
FEV NN O O
than NN O O
albuterol NN O O
delivered NN O O
by NN O O
breath-enhanced NN O O
nebulizer NN O O
, NN O O
without NN O O
significant NN O O
differences NN O O
in NN O O
clinical NN O O
measures NN O O
. NN O O

Conventional NN O O
jet NN O O
nebulizers NN O O
may NN O O
deliver NN O O
albuterol NN O O
to NN O O
children NN O O
with NN O O
acute NN O O
asthma NN O O
more NN O O
effectively NN O O
than NN O O
breath-enhanced NN O O
nebulizers NN O O
. NN O O

ClinicalTrials.gov NN O O
: NN O O
NCT02566902 NN O O
. NN O O



-DOCSTART- (30398602)

There NN O O
are NN O O
few NN O O
effective NN O O
treatments NN O O
for NN O O
heart NN O O
failure NN O O
with NN O O
preserved NN O O
ejection NN O O
fraction NN O O
( NN O O
HFpEF NN O O
) NN O O
. NN O O

Short-term NN O O
administration NN O O
of NN O O
inorganic NN O O
nitrite NN O O
or NN O O
nitrate NN O O
preparations NN O O
has NN O O
been NN O O
shown NN O O
to NN O O
enhance NN O O
nitric NN O O
oxide NN O O
signaling NN O O
, NN O O
which NN O O
may NN O O
improve NN O O
aerobic NN O O
capacity NN O O
in NN O O
HFpEF NN O O
. NN O O

To NN O O
determine NN O O
the NN O O
effect NN O O
of NN O O
4 NN O O
weeks NN O O
' NN O O
administration NN O O
of NN O O
inhaled NN O O
, NN O O
nebulized NN O O
inorganic NN O O
nitrite NN O O
on NN O O
exercise NN O O
capacity NN O O
in NN O O
HFpEF NN O O
. NN O O

Multicenter NN O O
, NN O O
double-blind NN O O
, NN O O
placebo-controlled NN O O
, NN O O
2-treatment NN O O
, NN O O
crossover NN O O
trial NN O O
of NN O O
105 NN O O
patients NN O O
with NN O O
HFpEF NN O O
. NN O O

Participants NN O O
were NN O O
enrolled NN O O
from NN O O
July NN O O
22 NN O O
, NN O O
2016 NN O O
, NN O O
to NN O O
September NN O O
12 NN O O
, NN O O
2017 NN O O
, NN O O
at NN O O
17 NN O O
US NN O O
sites NN O O
, NN O O
with NN O O
final NN O O
date NN O O
of NN O O
follow-up NN O O
of NN O O
January NN O O
2 NN O O
, NN O O
2018 NN O O
. NN O O

Inorganic NN O O
nitrite NN O O
or NN O O
placebo NN O O
administered NN O O
via NN O O
micronebulizer NN O O
device NN O O
. NN O O

During NN O O
each NN O O
6-week NN O O
phase NN O O
of NN O O
the NN O O
crossover NN O O
study NN O O
, NN O O
participants NN O O
received NN O O
no NN O O
study NN O O
drug NN O O
for NN O O
2 NN O O
weeks NN O O
( NN O O
baseline/washout NN O O
) NN O O
followed NN O O
by NN O O
study NN O O
drug NN O O
( NN O O
nitrite NN O O
or NN O O
placebo NN O O
) NN O O
at NN O O
46 NN O O
mg NN O O
3 NN O O
times NN O O
a NN O O
day NN O O
for NN O O
1 NN O O
week NN O O
followed NN O O
by NN O O
80 NN O O
mg NN O O
3 NN O O
times NN O O
a NN O O
day NN O O
for NN O O
3 NN O O
weeks NN O O
. NN O O

The NN O O
primary NN O O
end NN O O
point NN O O
was NN O O
peak NN O O
oxygen NN O O
consumption NN O O
( NN O O
mL/kg/min NN O O
) NN O O
. NN O O

Secondary NN O O
end NN O O
points NN O O
included NN O O
daily NN O O
activity NN O O
levels NN O O
assessed NN O O
by NN O O
accelerometry NN O O
, NN O O
health NN O O
status NN O O
as NN O O
assessed NN O O
by NN O O
the NN O O
Kansas NN O O
City NN O O
Cardiomyopathy NN O O
Questionnaire NN O O
( NN O O
score NN O O
range NN O O
, NN O O
0 NN O O
- NN O O
100 NN O O
, NN O O
with NN O O
higher NN O O
scores NN O O
reflecting NN O O
better NN O O
quality NN O O
of NN O O
life NN O O
) NN O O
, NN O O
functional NN O O
class NN O O
, NN O O
cardiac NN O O
filling NN O O
pressures NN O O
assessed NN O O
by NN O O
echocardiography NN O O
, NN O O
N-terminal NN O O
fragment NN O O
of NN O O
the NN O O
prohormone NN O O
brain NN O O
natriuretic NN O O
peptide NN O O
levels NN O O
, NN O O
other NN O O
exercise NN O O
indices NN O O
, NN O O
adverse NN O O
events NN O O
, NN O O
and NN O O
tolerability NN O O
. NN O O

Outcomes NN O O
were NN O O
assessed NN O O
after NN O O
treatment NN O O
for NN O O
4 NN O O
weeks NN O O
. NN O O

Among NN O O
105 NN O O
patients NN O O
who NN O O
were NN O O
randomized NN O O
( NN O O
median NN O O
age NN O O
, NN O O
68 NN O O
years NN O O
; NN O O
56 NN O O
% NN O O
women NN O O
) NN O O
, NN O O
98 NN O O
( NN O O
93 NN O O
% NN O O
) NN O O
completed NN O O
the NN O O
trial NN O O
. NN O O

During NN O O
the NN O O
nitrite NN O O
phase NN O O
, NN O O
there NN O O
was NN O O
no NN O O
significant NN O O
difference NN O O
in NN O O
mean NN O O
peak NN O O
oxygen NN O O
consumption NN O O
as NN O O
compared NN O O
with NN O O
the NN O O
placebo NN O O
phase NN O O
( NN O O
13.5 NN O O
vs NN O O
13.7 NN O O
mL/kg/min NN O O
; NN O O
difference NN O O
, NN O O
-0.20 NN O O
[ NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
-0.56 NN O O
to NN O O
0.16 NN O O
] NN O O
; NN O O
P NN O O
= NN O O
.27 NN O O
) NN O O
. NN O O

There NN O O
were NN O O
no NN O O
significant NN O O
between-treatment NN O O
phase NN O O
differences NN O O
in NN O O
daily NN O O
activity NN O O
levels NN O O
( NN O O
5497 NN O O
vs NN O O
5503 NN O O
accelerometry NN O O
units NN O O
; NN O O
difference NN O O
, NN O O
-15 NN O O
[ NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
-264 NN O O
to NN O O
234 NN O O
] NN O O
; NN O O
P NN O O
= NN O O
.91 NN O O
) NN O O
, NN O O
Kansas NN O O
City NN O O
Cardiomyopathy NN O O
Questionnaire NN O O
Clinical NN O O
Summary NN O O
Score NN O O
( NN O O
62.6 NN O O
vs NN O O
61.9 NN O O
; NN O O
difference NN O O
, NN O O
1.1 NN O O
[ NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
-1.4 NN O O
to NN O O
3.5 NN O O
] NN O O
; NN O O
P NN O O
= NN O O
.39 NN O O
) NN O O
, NN O O
functional NN O O
class NN O O
( NN O O
2.5 NN O O
vs NN O O
2.5 NN O O
; NN O O
difference NN O O
, NN O O
0.1 NN O O
[ NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
-0.1 NN O O
to NN O O
0.2 NN O O
] NN O O
; NN O O
P NN O O
= NN O O
.43 NN O O
) NN O O
, NN O O
echocardiographic NN O O
E/e NN O O
' NN O O
ratio NN O O
( NN O O
16.4 NN O O
vs NN O O
16.6 NN O O
; NN O O
difference NN O O
, NN O O
0.1 NN O O
[ NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
-1.2 NN O O
to NN O O
1.3 NN O O
] NN O O
; NN O O
P NN O O
= NN O O
.93 NN O O
) NN O O
, NN O O
or NN O O
N-terminal NN O O
fragment NN O O
of NN O O
the NN O O
prohormone NN O O
brain NN O O
natriuretic NN O O
peptide NN O O
levels NN O O
( NN O O
520 NN O O
vs NN O O
533 NN O O
pg/mL NN O O
; NN O O
difference NN O O
, NN O O
11 NN O O
[ NN O O
95 NN O O
% NN O O
CI NN O O
, NN O O
-53 NN O O
to NN O O
75 NN O O
] NN O O
; NN O O
P NN O O
= NN O O
.74 NN O O
) NN O O
. NN O O

Worsening NN O O
heart NN O O
failure NN O O
occurred NN O O
in NN O O
3 NN O O
participants NN O O
( NN O O
2.9 NN O O
% NN O O
) NN O O
during NN O O
the NN O O
nitrite NN O O
phase NN O O
and NN O O
8 NN O O
( NN O O
7.6 NN O O
% NN O O
) NN O O
during NN O O
the NN O O
placebo NN O O
phase NN O O
. NN O O

Among NN O O
patients NN O O
with NN O O
HFpEF NN O O
, NN O O
administration NN O O
of NN O O
inhaled NN O O
inorganic NN O O
nitrite NN O O
for NN O O
4 NN O O
weeks NN O O
, NN O O
compared NN O O
with NN O O
placebo NN O O
, NN O O
did NN O O
not NN O O
result NN O O
in NN O O
significant NN O O
improvement NN O O
in NN O O
exercise NN O O
capacity NN O O
. NN O O

ClinicalTrials.gov NN O O
Identifier NN O O
: NN O O
NCT02742129 NN O O
. NN O O



-DOCSTART- (30832678)

The NN O O
World NN O O
Health NN O O
Organization NN O O
( NN O O
WHO NN O O
) NN O O
revised NN O O
its NN O O
clinical NN O O
guidelines NN O O
for NN O O
management NN O O
of NN O O
childhood NN O O
pneumonia NN O O
in NN O O
2013 NN O O
. NN O O

Significant NN O O
delays NN O O
have NN O O
occurred NN O O
during NN O O
previous NN O O
introductions NN O O
of NN O O
new NN O O
guidelines NN O O
into NN O O
routine NN O O
clinical NN O O
practice NN O O
in NN O O
low- NN O O
and NN O O
middle-income NN O O
countries NN O O
( NN O O
LMIC NN O O
) NN O O
. NN O O

We NN O O
therefore NN O O
examined NN O O
whether NN O O
providing NN O O
enhanced NN O O
audit NN O O
and NN O O
feedback NN O O
as NN O O
opposed NN O O
to NN O O
routine NN O O
standard NN O O
feedback NN O O
might NN O O
accelerate NN O O
adoption NN O O
of NN O O
the NN O O
new NN O O
pneumonia NN O O
guidelines NN O O
by NN O O
clinical NN O O
teams NN O O
within NN O O
hospitals NN O O
in NN O O
a NN O O
low-income NN O O
setting NN O O
. NN O O

In NN O O
this NN O O
parallel NN O O
group NN O O
cluster NN O O
randomized NN O O
controlled NN O O
trial NN O O
, NN O O
12 NN O O
hospitals NN O O
were NN O O
assigned NN O O
to NN O O
either NN O O
enhanced NN O O
feedback NN O O
( NN O O
n NN O O
= NN O O
6 NN O O
hospitals NN O O
) NN O O
or NN O O
standard NN O O
feedback NN O O
( NN O O
n NN O O
= NN O O
6 NN O O
hospitals NN O O
) NN O O
using NN O O
restricted NN O O
randomization NN O O
. NN O O

The NN O O
standard NN O O
( NN O O
network NN O O
) NN O O
intervention NN O O
delivered NN O O
in NN O O
both NN O O
trial NN O O
arms NN O O
included NN O O
support NN O O
to NN O O
improve NN O O
collection NN O O
and NN O O
quality NN O O
of NN O O
patient NN O O
data NN O O
, NN O O
provision NN O O
of NN O O
mentorship NN O O
and NN O O
team NN O O
management NN O O
training NN O O
for NN O O
pediatricians NN O O
, NN O O
peer-to-peer NN O O
networking NN O O
( NN O O
meetings NN O O
and NN O O
social NN O O
media NN O O
) NN O O
, NN O O
and NN O O
multimodal NN O O
( NN O O
print NN O O
, NN O O
electronic NN O O
) NN O O
bimonthly NN O O
hospital NN O O
specific NN O O
feedback NN O O
reports NN O O
on NN O O
multiple NN O O
indicators NN O O
of NN O O
evidence NN O O
guideline NN O O
adherence NN O O
. NN O O

In NN O O
addition NN O O
to NN O O
this NN O O
network NN O O
intervention NN O O
, NN O O
the NN O O
enhanced NN O O
feedback NN O O
group NN O O
received NN O O
a NN O O
monthly NN O O
hospital-specific NN O O
feedback NN O O
sheet NN O O
targeting NN O O
pneumonia NN O O
indicators NN O O
presented NN O O
in NN O O
multiple NN O O
formats NN O O
( NN O O
graphical NN O O
and NN O O
text NN O O
) NN O O
linked NN O O
to NN O O
explicit NN O O
performance NN O O
goals NN O O
and NN O O
action NN O O
plans NN O O
and NN O O
specific NN O O
email NN O O
follow NN O O
up NN O O
from NN O O
a NN O O
network NN O O
coordinator NN O O
. NN O O

At NN O O
the NN O O
start NN O O
of NN O O
the NN O O
trial NN O O
, NN O O
all NN O O
hospitals NN O O
received NN O O
a NN O O
standardized NN O O
training NN O O
on NN O O
the NN O O
new NN O O
guidelines NN O O
and NN O O
printed NN O O
booklets NN O O
containing NN O O
pneumonia NN O O
treatment NN O O
protocols NN O O
. NN O O

The NN O O
primary NN O O
outcome NN O O
was NN O O
the NN O O
proportion NN O O
of NN O O
children NN O O
admitted NN O O
with NN O O
indrawing NN O O
and/or NN O O
fast-breathing NN O O
pneumonia NN O O
who NN O O
were NN O O
correctly NN O O
classified NN O O
using NN O O
new NN O O
guidelines NN O O
and NN O O
received NN O O
correct NN O O
antibiotic NN O O
treatment NN O O
( NN O O
oral NN O O
amoxicillin NN O O
) NN O O
in NN O O
the NN O O
first NN O O
24 NN O O
h. NN O O

The NN O O
secondary NN O O
outcome NN O O
was NN O O
the NN O O
proportion NN O O
of NN O O
correctly NN O O
classified NN O O
and NN O O
treated NN O O
children NN O O
for NN O O
whom NN O O
clinicians NN O O
changed NN O O
treatment NN O O
from NN O O
oral NN O O
amoxicillin NN O O
to NN O O
injectable NN O O
antibiotics NN O O
. NN O O

The NN O O
trial NN O O
included NN O O
2299 NN O O
childhood NN O O
pneumonia NN O O
admissions NN O O
, NN O O
1087 NN O O
within NN O O
the NN O O
hospitals NN O O
randomized NN O O
to NN O O
enhanced NN O O
feedback NN O O
intervention NN O O
, NN O O
and NN O O
1212 NN O O
to NN O O
standard NN O O
feedback NN O O
. NN O O

The NN O O
proportion NN O O
of NN O O
children NN O O
who NN O O
were NN O O
correctly NN O O
classified NN O O
and NN O O
treated NN O O
in NN O O
the NN O O
first NN O O
24 NN O O
h NN O O
during NN O O
the NN O O
entire NN O O
9-month NN O O
period NN O O
was NN O O
38.2 NN O O
% NN O O
( NN O O
393 NN O O
out NN O O
of NN O O
1030 NN O O
) NN O O
and NN O O
38.4 NN O O
% NN O O
( NN O O
410 NN O O
out NN O O
of NN O O
1068 NN O O
) NN O O
in NN O O
the NN O O
enhanced NN O O
feedback NN O O
and NN O O
standard NN O O
feedback NN O O
groups NN O O
, NN O O
respectively NN O O
( NN O O
odds NN O O
ratio NN O O
1.11 NN O O
; NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
[ NN O O
CI NN O O
] NN O O
0.37 NN O O
- NN O O
3.34 NN O O
; NN O O
P NN O O
= NN O O
0.855 NN O O
) NN O O
. NN O O

However NN O O
, NN O O
in NN O O
exploratory NN O O
analyses NN O O
, NN O O
there NN O O
was NN O O
evidence NN O O
of NN O O
an NN O O
interaction NN O O
between NN O O
type NN O O
of NN O O
feedback NN O O
and NN O O
duration NN O O
( NN O O
in NN O O
months NN O O
) NN O O
since NN O O
commencement NN O O
of NN O O
intervention NN O O
, NN O O
suggesting NN O O
a NN O O
difference NN O O
in NN O O
adoption NN O O
of NN O O
pneumonia NN O O
policy NN O O
over NN O O
time NN O O
in NN O O
the NN O O
enhanced NN O O
compared NN O O
to NN O O
standard NN O O
feedback NN O O
arm NN O O
( NN O O
OR NN O O
= NN O O
1.25 NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
1.14 NN O O
to NN O O
1.36 NN O O
, NN O O
P NN O O
< NN O O
0.001 NN O O
) NN O O
. NN O O

Enhanced NN O O
feedback NN O O
comprising NN O O
increased NN O O
frequency NN O O
, NN O O
clear NN O O
messaging NN O O
aligned NN O O
with NN O O
goal NN O O
setting NN O O
, NN O O
and NN O O
outreach NN O O
from NN O O
a NN O O
coordinator NN O O
did NN O O
not NN O O
lead NN O O
to NN O O
a NN O O
significant NN O O
overall NN O O
effect NN O O
on NN O O
correct NN O O
pneumonia NN O O
classification NN O O
and NN O O
treatment NN O O
during NN O O
the NN O O
9-month NN O O
trial NN O O
. NN O O

There NN O O
appeared NN O O
to NN O O
be NN O O
a NN O O
significant NN O O
effect NN O O
of NN O O
time NN O O
( NN O O
representing NN O O
cumulative NN O O
effect NN O O
of NN O O
feedback NN O O
cycles NN O O
) NN O O
on NN O O
adoption NN O O
of NN O O
the NN O O
new NN O O
policy NN O O
in NN O O
the NN O O
enhanced NN O O
feedback NN O O
compared NN O O
to NN O O
standard NN O O
feedback NN O O
group NN O O
. NN O O

Future NN O O
studies NN O O
should NN O O
plan NN O O
for NN O O
longer NN O O
follow-up NN O O
periods NN O O
to NN O O
confirm NN O O
these NN O O
findings NN O O
. NN O O

US NN O O
National NN O O
Institutes NN O O
of NN O O
Health-ClinicalTrials.gov NN O O
identifier NN O O
( NN O O
NCT NN O O
number NN O O
) NN O O
NCT02817971 NN O O
. NN O O

Registered NN O O
September NN O O
28 NN O O
, NN O O
2016-retrospectively NN O O
registered NN O O
. NN O O



